WO2008050821A1 - Indole compound - Google Patents

Indole compound Download PDF

Info

Publication number
WO2008050821A1
WO2008050821A1 PCT/JP2007/070772 JP2007070772W WO2008050821A1 WO 2008050821 A1 WO2008050821 A1 WO 2008050821A1 JP 2007070772 W JP2007070772 W JP 2007070772W WO 2008050821 A1 WO2008050821 A1 WO 2008050821A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
optionally substituted
methyl
hydrogen atom
Prior art date
Application number
PCT/JP2007/070772
Other languages
French (fr)
Inventor
Tsuneo Yasuma
Osamu Ujikawa
Masahiro Itoh
Kazuko Aoki
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39010108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008050821(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0717722-4A priority Critical patent/BRPI0717722A2/en
Priority to CA2666973A priority patent/CA2666973C/en
Priority to UAA200904957A priority patent/UA97257C2/en
Priority to MEP-118/09A priority patent/MEP11809A/en
Priority to CN2007800470664A priority patent/CN101573357B/en
Priority to GEAP200711259A priority patent/GEP20115241B/en
Priority to NZ576570A priority patent/NZ576570A/en
Priority to JP2009515658A priority patent/JP5260507B2/en
Priority to AU2007310064A priority patent/AU2007310064B2/en
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Priority to RU2009118602/04A priority patent/RU2454415C9/en
Priority to US12/311,893 priority patent/US8410087B2/en
Priority to EP07830506A priority patent/EP2074119A1/en
Priority to KR1020097010151A priority patent/KR101444486B1/en
Priority to MX2009003972A priority patent/MX2009003972A/en
Priority to CL2008001017A priority patent/CL2008001017A1/en
Priority to ARP080101557A priority patent/AR080058A1/en
Priority to PE2008000659A priority patent/PE20090884A1/en
Publication of WO2008050821A1 publication Critical patent/WO2008050821A1/en
Priority to TNP2009000129A priority patent/TN2009000129A1/en
Priority to IL198154A priority patent/IL198154A/en
Priority to NO20091948A priority patent/NO20091948L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a indole compound having a glucokinase activating action and useful as a therapeutic agent for diabetes and the like.
  • Glucokinase (sometimes to be abbreviated to as GK in the present specification) (EC2.7.1.1) is one of the four kinds of hexokinases found in mammals, and is also called hexokinase IV.
  • GK is an enzyme that catalyzes the conversion of glucose to glucose-6-phosphate, which is the first step of glycolysis.
  • GK is mainly present in the pancreatic ⁇ cell and the liver, and acts in the pancreatic ⁇ cell as a sensor of extracellular glucose concentration that defines the glucose-stimulated insulin secretion. In the liver, the enzyme reaction of GK becomes a rate determining factor and regulates glycogen synthesis and glycolysis.
  • the three hexokinases (I, II, III) other than GK reach the maximum enzyme activity at a glucose concentration of 1 rriM or below.
  • GK shows low affinity for glucose and has a Km value of 8-15 mM which is close to a physiological blood glucose level. Accordingly, GK- mediated promotion of intracellular glucose metabolism occurs, which corresponds to blood glucose changes from normal blood glucose (5 mM) to postprandial- hyperglycemia (10-15 mM) .
  • GK heterozygous deficient mouse showed a hyperglycemic condition, and further, a disordered glucose-stimulated insulin secretion response.
  • GK homozygous deficient mouse dies shortly after birth with manifestations of marked hyperglycemia and urinary sugar.
  • GK overexpressed mouse (hetero type) showed decreased blood glucose level, increased blood glucose clearance rate, increased liver glycogen content and the like. From these findings, it has been clarified that GK plays an important role in the systemic glucose homeostasis. In other words, decreased GK activity causes insulin secretion failure and lower liver glucose metabolism, which develops impaired glucose tolerance and diabetes. Conversely, GK activation or increased GK activity due to overexpression causes promoted insulin secretion and promoted liver glucose metabolism, which in turn increases the systemic use of glucose to improve glucose tolerance.
  • GK gene abnormality due to the decreased affinity of GK for glucose (increased Km value) and decreased Vmax, the blood glucose threshold value of insulin secretion increases and the insulin secretory capacity decreases.
  • the liver due to the decreased GK activity, decreased glucose uptake, promoted gluconeogenesis, decreased glycogen synthesis and liver insulin resistance are observed.
  • a family with a mutation increasing the GK activity has also been found. In such family, fasting hypoglycemia associated with increased plasma insulin concentration is observed (see New England Journal Medicine, 1998, vol. 338, page 226-230) .
  • GK acts as a glucose sensor in mammals including human, and 'plays an important role in blood glucose regulation.
  • control of blood glucose utilizing the glucose sensor system of GK is considered to open a new way to treat diabetes in many type 2 diabetes patients.
  • a GK activating substance is expected to show insulin secretagogue action in the pancreatic ⁇ cell and glucose uptake promotion and glucose release suppressive action in the liver, it will be useful as a prophylactic or therapeutic drug for type 2 diabetes.
  • VMH Ventromedial Hypothalamus
  • a subset of nerve cell present in VMH is called glucose responsive neuron, and plays an important role in the body weight control. From electrophysiological experiments, the neuron is activated in response to physiological changes in the glucose concentration (5-20 ⁇ M) .
  • a pharmaceutical agent capable of activating glucokinase of VHM has a possibility of providing not only a blood glucose corrective effect but also improvement of obesity.
  • a pharmaceutical agent capable of activating GK is useful as a prophylactic or therapeutic drug for diabetes, diabetic complications, and obesity.
  • ring A is an optionally substituted monocyclic or bicyclic aromatic ring
  • ring B is an optionally substituted 6-membered unsaturated hydrocarbon ring or an optionally substituted 6-membered unsaturated heterocycle containing one nitrogen atom
  • ring C is an optionally substituted 5-membered heterocycle containing one or two nitrogen atoms
  • X is -N(R 1 )- or an oxygen atom;
  • Y is a carbon atom or a nitrogen atom
  • Z is -N(R 2 )- or a nitrogen atom
  • R 1 and R 2 are the same or different and each is a hydrogen atom or lower alkyl is useful as an antitumor agent or an angiogenesis inhibitor
  • R 1 , R 2 , R 3 , R 4 , R 6 and R 7 are each independently a hydrogen atom, a halogen atom, a nitro group, -CN, -OH, -COOH, -CF 3 , -NR 10 R 11 (wherein R 10 and R 11 are each independently a hydrogen atom, a Ci-6 alkyl group, -SO2CH3 etc.), a Ci- 6 alkyl group, a C 3 -S cycloalkyl group, a heteroaryl group and the like; R 5 is a Ci_6 alkyl group and the like; and A is an optionally substituted thiazolyl and the like, is useful as a glucokinase activator (see WO2005/049019) .
  • A is an optionally substituted thiazolyl and the like, is useful as a glucokinase activator (see WO2005/049019) .
  • the purpose of the present invention is to provide a glucokinase activator which is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, obesity and the like, and the like.
  • R 1 is a hydrogen atom or a halogen atom
  • R 2 is a group represented by
  • A is CH or N
  • R 4 and R 5 are each independently an optionally substituted Ci_6 alkyl group or an optionally substituted C3- 1 0 cycloalkyl group, or R 4 and R 5 in combination form an optionally substituted ring wherein the ring should not be morpholine;
  • R 6 R 1 , R 21 and R 22 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, a cyano group or an acyl group, or R ⁇ and R 7 in combination form an optionally substituted ring;
  • W is 0 or NR 8 wherein R 8 is a hydrogen atom, an optionally substituted Ci_6 alkyl group or an optionally substituted C 3 - I0 cycloalkyl group;
  • R 3 is an optionally substituted heterocyclic group or an optionally substituted C 6 -i4 aryl group; and R 9 , R 10 and R 11 are each independently a hydrogen atom, a halogen atom, an optionally substituted Ci- ⁇ alkyl group or an optionally substituted Ci_ 6 alkoxy group, provided that a compound wherein R 21 is a hydrogen atom or a Ci- ⁇ alkoxy- carbonyl group, R 22 is a hydrogen atom, and R 6 and R 7 are both hydrogen atoms, and a compound wherein R 21 is a hydrogen atom or a Ci-6 alkoxy- carbonyl groug, R 22 is a hydrogen atom, and R 6 and R 7 are both methyl groups are excluded, or a salt thereof [hereinafter to be abbreviated as compound
  • the present invention relates to [1] compound (I) ;
  • R 1 is a hydrogen atom or a halogen atom
  • R 2 is a group represented by
  • R 4 and R 5 are each independently an optionally substituted Ci_6 alkyl group or an optionally substituted C 3 - I0 cycloalkyl group, or R 4 and R 5 in combination form an optionally substituted ring wherein the ring should not be morpholine; and R 6 and R 7 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, a cyano group or an acyl group, or R 6 and R 7 in combination form an optionally substituted ring;
  • W is 0 or NR 8 wherein R 8 is a hydrogen atom or an optionally substituted Ci-6 alkyl group;
  • R 3 is an optionally substituted heterocyclic group
  • R 9 , R 10 and R 11 are each independently a hydrogen atom, a halogen atom, an optionally substituted Ci_ s alkyl group or an optionally substituted Ci- 6 alkoxy group, provided that a compound wherein R 6 and R 1 are both hydrogen atoms, and a compound wherein R s and R 7 are both methyl groups are excluded, or a salt thereof; [3] the compound of the above-mentioned [1], wherein R 2 is a group represented by
  • R 6 and R 7 are as defined in the above-mentioned [I];
  • glucokinase activator comprising compound (I) or a prodrug thereof
  • a pharmaceutical agent comprising compound (I) or a prodrug thereof
  • compound (I) Since compound (I) has a superior glucokinase activating action, compound (I) is useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the- like.
  • ⁇ halogen atom fluorine atom, chlorine atom, bromine ' atom or iodine atom can be mentioned.
  • Ci_ 3 alkylenedioxy group in the present specification, methylenedioxy, ethylenedioxy or the like.
  • Ci_6 alkyl group methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1, 1-dimethylbutyl, 2,2-dimethylbutyl, 3, 3-dimethylbutyl, 2-ethylbutyl or the like.
  • Ci-6 alkoxy group in the present specification, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy or the like.
  • Ci- 6 alkyl-carbonyl group acetyl, propanoyl, butanoyl, isobutanoyl, pentanoyl, isopentanoyl, hexanoyl or the like.
  • R 1 is a hydrogen atom or a halogen atom.
  • R 1 is preferably a hydrogen atom or a fluorine atom, more preferably a hydrogen atom.
  • R 2 is a group represented by
  • R 2 is preferably a group represented by
  • R 2 is a group represented by
  • R 6 , R 7 , R 21 and R 22 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, a cyano group or an acyl group, or R 6 and R 7 in combination form an optionally substituted ring.
  • C 1 -Io alkyl group for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3- dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, decyl ' and the like can be mentioned.
  • C2-10 alkenyl group for example, ethenyl, 1- propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3- hexenyl, 5-hexenyl, 1-heptenyl, 1-octenyl and the like can be mentioned.
  • C2- 1 0 alkynyl group for example, ethynyl, 1- propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1- pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2- hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-heptynyl, 1- octynyl and the like can be mentioned.
  • cycloalkyl group for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like can be mentioned.
  • C3- 1 0 cycloalkenyl group for example, 2- cyclopenten-1-yl, 3-cyclopenten-l-yl, 2-cyclohexen-l-yl, 3- cyclohexen-1-yl and the like can be mentioned.
  • C4-10 cycloalkadienyl group for example, 2,4- cyclopentadien-1-yl, 2, 4-cyclohexadien-l-yl, 2,5- cyclohexadien-1-yl and the like can be mentioned.
  • C 3 - I0 cycloalkyl group, C 3 - 10 cycloalkenyl group and C4- 10 cycloalkadienyl are each optionally condensed with a benzene ring to form a fused cyclic group, and as the fused cyclic group, for example, indanyl, dihydronaphthyl, tetrahydronaphthyl, fluorenyl and the like can be mentioned.
  • a cross-linked hydrocarbon group such as bicyclo[2.2.1]heptyl, bicyclo [2.2.2] octyl, bicyclo [3.2.
  • aryl group for example, phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, .biphenylyl and the like can be mentioned. Of these, phenyl, 1-naphthyl, 2-naphthyl and the like are preferable.
  • C7-13 aralkyl group for example, benzyl, phenethyl, naphthylmethyl, biphenylylmethyl and the like can be mentioned.
  • Ce-13 arylalkenyl group for example, styryl and the like can be mentioned.
  • C3-10 cycloalkyl-Ci-6 alkyl group for example, cyclohexylmethyl and the like can be mentioned.
  • Ci-10 alkyl group, C 2 -io alkenyl group and C 2 -io alkynyl group exemplified as the aforementioned "hydrocarbon group” optionally have 1 to 3 substituents at substitutable positions.
  • substituents for example,
  • a C 3 - I0 cycloalkyl group e.g., cyclopropyl, cyclohexyl
  • a C 6 -i 4 aryl group e.g., phenyl, naphthyl
  • a Ci_ 6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci- 6 alkoxy-carbonyl group optionally substituted by 1 to 3 Ce ⁇ A aryl groups (e.g., phenyl),
  • a C 7 - I3 aralkyl-carbonyl group e.g., benzylcarbonyl, phenethylcarbonyl
  • a C ⁇ - G alkylsulfonyl group' e.g., methylsulfonyl, ethylsulfonyl, isopropylsulfonyl
  • a C 6 - I4 arylsulfonyl group e.g., benzenesulfonyl, 1- naphthalenesulfonyl, 2-naphthalenesulfonyl
  • Ci_ 6 alkyl groups e.g., benzenesulfonyl, 1- naphthalenesulfonyl, 2-naphthalenesulfonyl
  • a Cv- 13 aralkylsulfonyl group e.g., benzylsulfonyl
  • a C 3 - X0 cycloalkyl group e.g., cyclohexyl
  • an aromatic heterocyclic group e.g., triazolyl
  • a non-aromatic heterocyclic group e.g., tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl, 1,1- dioxidotetrahydrothiopyranyl
  • Ci_ 6 alkoxy-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • an aromatic heterocyclyl-carbonyl group e.g., thienylcarbonyl, indolylcarbonyl
  • the amino groups are each optionally mono- or di-substituted by substituent (s) selected from a Ci_ 6 alkyl group and an aromatic heterocyclyl-sulfonyl group (e.g., thienylsulfonyl) ]
  • substituent (s) selected from a Ci_ 6 alkyl group and an aromatic heterocyclyl-sulfonyl group e.g., thienylsulfonyl
  • a non-aromatic heterocyclyl-carbonyl group e.g., piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1-oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl
  • a non-aromatic heterocyclyl-carbonyl group e.g., piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1-oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl
  • Ci_ 6 alkyl group optionally substituted by 1 to 3 hydroxy groups, (c) a halogen atom, and (d) a carboxy group;
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl, ethylsulfonyl
  • a Ci-6 alkylsulfonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a Ci-6 alkoxy group, a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl) and an aromatic heterocyclic group (e.g., furyl) ,
  • a C 6 - I4 aryl group e.g., phenyl
  • a C 3 - 10 cycloalkyl group e.g., cyclopropyl
  • Ci- 6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., triazolyl, tetrazolyl
  • a non-aromatic heterocyclic group e.g., tetrahydropyranyl
  • Ci-6 alkoxy group optionally substituted by 1 to 3 substituents selected from
  • a C2-6 alkenyloxy group e.g., ethenyloxy
  • a C3- 1 0 cycloalkyloxy group e.g., cyclohexyloxy
  • aryloxy group e.g., phenyloxy, naphthyloxy
  • Ci- 6 alkyl-carbonyloxy group e.g., acetyloxy, tert- butylcarbonyloxy
  • Ci- ⁇ alkylthio group e.g., methylthio, ethylthio
  • a C ⁇ -14 arylthio group e.g., phenylthio, naphthylthio
  • Ci-6 alkylsulfinyl group e.g., methylsulfinyl
  • a C3-10 cycloalkyl-Ci-6 alkyloxy group e.g., cyclopropylmethyloxy
  • an aromatic heterocyclyl-carbonylthio group e.g., indolylcarbonylthio
  • substituent (s) selected from a Ci-6 alkyl group and an aromatic heterocyclyl-sulfonyl group e.g., thienylsulfonyl
  • an aromatic heterocyclyl-oxy group e.g., pyrimidyloxy, pyrazinyloxy
  • Ci-6 alkylsulfonyloxy group e.g., methylsulfonyloxy
  • a non-aromatic heterocyclyl-carbonyloxy group e.g., morpholinylcarbonyloxy
  • Ci_ 6 alkyl groups optionally substituted by 1 to 3 Ci_ 6 alkyl groups; and the like
  • the C3-10 cycloalkyl group, C 3 - X0 cycloalkenyl group, C4_i 0 cycloalkadienyl group, Ce-u aryl group, C 7 - I3 aralkyl group, Cs- I3 arylalkenyl group and C3-10 cycloalkyl-Ci-6 alkyl group exemplified as the aforementioned "hydrocarbon group” optionally have 1 to 3 substituents at substitutable positions, as such substituents, for example,
  • a C3-10 cycloalkyl group e.g., cyclopropyl, cyclohexyl
  • a C3-10 cycloalkyl group e.g., cyclopropyl, cyclohexyl
  • a C ⁇ -xi aryl group e.g., phenyl, naphthyl
  • a Ci_ 6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • an aromatic heterocyclic group e.g., thienyl, furyl, pyridyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, tetrazolyl, oxadiazolyl, pyrazinyl, quinolyl, indolyl
  • an aromatic heterocyclic group e.g., thienyl, furyl, pyridyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, tetrazolyl, oxadiazolyl, pyrazinyl, quinolyl, indolyl
  • substituents selected from (a) a Ci- ⁇ alkyl group optionally substituted by 1 to 3 halogen atoms,
  • a halogen atom (d) a halogen atom; (4) a non-aromatic heterocyclic group (e.g., tetrahydrofuryl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, dioxolyl, dioxolanyl, 1, 3-dihydro-2-benzofuranyl, thiazolidinyl, thiazolinyl) optionally substituted by 1 to 3 substituents selected from (a) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
  • a non-aromatic heterocyclic group e.g., tetrahydrofuryl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, dioxolyl, dioxolanyl, 1, 3-dihydro-2-benzofuranyl
  • substituent (s) selected from (a) a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C 1 - ⁇ alkylsulfonyl group (e.g., methylsulfonyl),
  • Ci_ 6 alkoxy-carbonyl group optionally substituted by 1 to 3 C 6 - I4 aryl groups (e.g., phenyl),
  • a C ⁇ - 14 aryl-carbonyl group e.g., benzoyl
  • a C 7 - I3 aralkyl-carbonyl group e.g., benzylcarbonyl, phenethylcarbonyl
  • Ci- 6 alkylsulfonyl group e.g., methylsulfonyl, ethylsulfonyl, isopropylsulfonyl
  • a C 6 - H arylsulfonyl group e.g., benzenesulfonyl, 1- naphthalenesulfonyl, 2-naphthalenesulfonyl
  • a C 7 - I3 aralkylsulfonyl group e.g., benzylsulfonyl
  • a C 3 - I0 cycloalkyl group e.g., cyclohexyl
  • an aromatic heterocyclic group e.g., triazolyl
  • a non-aromatic heterocyclic group e.g., tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl, 1,1- dioxidotetrahydrothiopyranyl
  • Ci-s alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • a Q . - 6 alkoxy-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • an aromatic heterocyclyl-carbonyl group e.g., thienylcarbonyl, indolylcarbonyl
  • the amino groups are each optionally mono- or di-substituted by substituent (s) selected from a C x - 6 alkyl group and an aromatic heterocyclyl-sulfonyl group (e.g., thienylsulfonyl) ] ;
  • a non-aromatic heterocyclyl-carbonyl group e.g., piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1-oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl
  • a non-aromatic heterocyclyl-carbonyl group e.g., piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1-oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl
  • Ci_6 alkylsulfonyl group e.g., methylsulfonyl, ethylsulfonyl
  • a Ci_6 alkylsulfonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci_ 6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a Ci-6 alkoxy group, a C ⁇ - ⁇ alkylsulfonyl group (e.g., methylsulfonyl) and an aromatic heterocyclic group (e.g., furyl) ,
  • a Ce-i4 aryl group e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopropyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., triazolyl, tetrazolyl
  • a non-aromatic heterocyclic group e.g., tetrahydropyranyl
  • Ci-6 alkoxy group optionally substituted by 1 to 3 substituents selected from
  • a C 2 -6 alkenyloxy group e.g., ethenyloxy
  • a C3-10 cycloalkyloxy group e.g., cyclohexyloxy
  • (21) a C ⁇ - 1 4 aryloxy group (e.g., phe ⁇ yloxy, naphthyloxy) ;
  • Ci-6 alkyl-carbonyloxy group e.g., acetyloxy, tert- butylcarbonyloxy
  • Ci-6 alkylthio group e.g., methylthio, ethylthio
  • substituents selected from
  • a C 6 - I4 arylthio group e.g., phenylthio, naphthylthio
  • Ci-6 alkylsulfinyl group e.g., methylsulfinyl
  • a C3-10 cycloalkyl-Ci_6 alkyloxy group e.g., cyclopropylmethyloxy
  • an aromatic heterocyclyl-carbonylthio group e.g., indolylcarbonylthio
  • substituent (s) selected from a C 1 -S alkyl group and an aromatic heterocyclyl-sulfonyl group (e . g . , thienylsulfonyl) ] ;
  • an aromatic heterocyclyl-oxy group e.g., pyrimidyloxy, pyrazinyloxy
  • Ci_6 alkylsulfonyloxy group e.g., methylsulfonyloxy
  • a non-aromatic heterocyclyl-carbonyloxy group e.g., morpholinylcarbonyloxy
  • optionally substituted by 1 to 3 C ⁇ _ 6 alkyl groups e.g., morpholinylcarbonyloxy
  • Ci_ 6 alkoxy group optionally substituted by 1 to 3 substituents selected from a carboxy group and a Ci_ 6 alkoxy-carbonyl group,
  • Ci-6 alkyl-carbonylox-y group e.g., acetyloxy, tert- butylcarbonyloxy
  • an aromatic heterocyclic group e.g., thienyl, tetrazolyl, imidazolyl, furyl, pyridyl
  • a non-aromatic heterocyclic group e.g., tetrahydrofuranyl, piperidino, piperazinyl, morpholinyl, dihydrooxadiazolyl, hexahydropyrazinooxazinyl (e.g., hexahydropyrazino[2, 1-c] [1, 4]oxazinyl)
  • substituents selected from a Ci_6 alkyl-carbonyl group and an oxo group e.g., hexahydropyrazino[2, 1-c] [1, 4]oxazinyl
  • an amino group optionally mono- or di-substituted by Ci- 6 alkyl group (s) (the Ci_ 6 alkyl group is optionally substituted by 1 to 3 substituents selected from
  • Ci- S alkylthio group optionally substituted by 1 to 3 substituents selected from a carboxy group, a Ci-e alkoxy- carbonyl group, a hydroxy group and a carbamoyl group,
  • a phosphono group optionally mono- or di-substituted by Ci-6 alkyl group (s)
  • a non-aromatic heterocyclyl-carbonyl group e.g., raorpholinylcarbonyl
  • a C2-6 alkenyl group e.g., ethenyl, 1-propenyl
  • substituents selected from (a) a halogen atom
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • acyl group for R 5 , R 7 , R 21 or R 22 , for example, groups represented by the formulas: -C0R a / -CO-OR a , -S ⁇ 2R a / - SOR a , -CO-NR a 'R b/ , -CS-NR a 'R b ' and -SO 2 -NR a 'R b ' wherein R a is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R a ' and R b ' are the same or different and each is ' a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R a ' and R b ' form, together with the adjacent nitrogen atom, an optionally substituted nitrogen-containing heterocycle, and the like can be mentioned.
  • nitrogen-containing heterocycle of the "optionally substituted nitrogen-containing heterocycle” formed by R a ' and R b ' together with the adjacent nitrogen atom
  • a 5- to 7-membered nitrogen-containing heterocycle containing, as a ring-constituting atom besides carbon atoms, at least one nitrogen atom and optionally further containing one or two heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom
  • pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, morpholine, thiomorpholine, oxopiperazine and the like can be mentioned.
  • the nitrogen-containing heterocycle optionally has 1 to 3 (preferably 1 or 2) substituents at substitutable positions.
  • substituents those exemplified as the substituents which the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group” for R 6 , R 7 , R 21 or R 22 optionally has, can be mentioned.
  • acyl group As preferable examples of the "acyl group",
  • a C 6 -i 4 aryl-carbonyl group e.g., benzoyl, l ⁇ naphthoyl, 2- naphthoyl
  • substituents selected from (a) a halogen atom
  • Ci- 6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • benzyloxycarbonyl e.g., benzyloxycarbonyl, phenethyloxycarbonyl; carboxybenzyloxycarbonyl; methoxycarbonylbenzyloxycarbonyl; biphenylylmethoxycarbonyl
  • benzyloxycarbonyl e.g., benzyloxycarbonyl, phenethyloxycarbonyl; carboxybenzyloxycarbonyl; methoxycarbonylbenzyloxycarbonyl; biphenylylmethoxycarbonyl
  • a carbamoyl group mono- or di-substituted by C ⁇ - ⁇ alkyl group (s) optionally substituted by 1 to 3 substituents selected from a halogen atom and a Ci_ 6 alkoxy group e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, propylcarbamoyl, isopropylcarbamoyl, butylcarbamoyl, isobutylcarbamoyl, trifluoroethylcarbamoyl, N-methoxyethyl-N-methylcarbamoyl) ;
  • Ci-6 alkylsulfonyl group optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkylsulfinyl group e.g., methylsulfinyl
  • a C7-13 aralkyl-carbonyl group e.g., benzylcarbonyl, phenethylcarbonyl
  • an aromatic heterocyclyl-carbonyl group e.g., furylcarbonyl, thienylcarbonyl, thiazolylcarbonyl, pyrazolylcarbonyl, pyridylcarbonyl, pyrazinylcarbonyl, benzofurylcarbonyl, benzothienylcarbonyl, quinoxalinylcarbonyl
  • an aromatic heterocyclyl-carbonyl group e.g., furylcarbonyl, thienylcarbonyl, thiazolylcarbonyl, pyrazolylcarbonyl, pyridylcarbonyl, pyrazinylcarbonyl, benzofurylcarbonyl, benzothienylcarbonyl, quinoxalinylcarbonyl
  • a non-aromatic heterocyclyl-carbonyl group e.g., tetrahydrofurylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, piperidinylcarbonyl, pyrrolidinylcarbonyl, piperazinylcarbonyl, dioxolylcarbonyl, dioxolanylcarbonyl, 1, 3-dihydro-2-benzofuranylcarbonyl, thiazolidinylcarbonyl) optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci_ 6 alkyl group a sulfamoyl group mono- or di-substituted by Ci_ 6 alkyl group (s) optionally substituted by 1 to 3 substituents selected from a halogen atom and a Ci- 6 alkoxy group (e.g., methylsulfamoyl, ethylsulfamoyl, dimethylsulfamoyl) ; and the like can be mentioned.
  • R 6 is preferably an optionally substituted Ci_ 6 alkyl group, a cyano group or an acyl group, more preferably a Ci- ⁇ alkyl group substituted by an optionally substituted heterocyclic group.
  • Ci-6 alkyl group preferably methyl, ethyl, isopropyl
  • a non-aromatic heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl
  • a hydroxy group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • halogen atom preferably fluorine atom
  • Ci_ 6 alkoxy group preferably methoxy
  • cyano group
  • Ci-s alkoxy-carbonyl group (preferably methoxycarbonyl)
  • a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl) ;
  • Ci_ s alkyl group preferably methyl, ethyl, isopropyl substituted by 1 to 3 substituents selected from (a) a non-aromatic heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group,
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci_6 alkylsulfonyl group preferably methylsulfonyl
  • a halogen atom ' preferably fluorine atom
  • R 5 As another preferable specific examples for R 5 , (1) a Ci- 6 alkyl group (preferably methyl, ethyl, isopropyl, isobutyl) optionally substituted by 1 to 3 substituents selected from
  • a heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl
  • a heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkylsulfonyl group preferably methy1sulfony1
  • Ci-6 alkyl group preferably methyl, ethyl
  • a Ci-3 alkylenedioxy group preferably ethylenedioxy
  • Ci-6 alkyl group preferably methyl, ethyl, isobutyl
  • a Ci- ⁇ alkylsulfonyl group preferably methylsulfonyl
  • Ci-6 alkoxy-carbonyl group preferably methoxycarbonyl
  • aryl groups preferably phenyl
  • a non-aromatic heterocyclic group preferably tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl, 1, 1-dioxidotetrahydrothiopyranyl
  • Ci-6 alkoxy group preferably methoxy
  • Ci- 6 alkylsulfonyloxy group preferably methylsulfonyloxy
  • Ci_ 6 alkyl-carbonyl group preferably acetyl
  • a non-aromatic heterocyclyl-carbonyl group preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl
  • a non-aromatic heterocyclyl-carbonyl group preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl
  • Ci-e alkyl group preferably methyl, ethyl
  • a halogen atom preferably fluorine atom
  • Ci-6 alkyl group preferably methyl, ethyl
  • a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a C ⁇ - 6 alkoxy group (preferably methoxy) and a Ci-6 alkylsulfonyl group (preferably methylsulfonyl )
  • Ci-e alkoxy group preferably methoxy
  • C3-10 cycloalkyl group preferably cyclopropyl
  • Ci-e alkylsulfonyl group preferably methylsulfonyl
  • an aromatic heterocyclic group preferably triazolyl, tetrazolyl
  • Ci- 6 alkoxy-carbonyl group preferably methoxycarbonyl
  • carbamoyl group optionally mono- or di-substituted by Ci_ 6 alkyl group (s) (preferably ethyl)
  • a non-aromatic heterocyclyl-carbonyl group preferably pyrrolidinylcarbonyl, morpholinylcarbonyl, piperazinylcarbonyl
  • Ci-6 alkyl groups preferably methyl
  • Ci_ 6 alkyl group preferably methyl, ethyl, isopropyl, isobutyl substituted by 1 to 3 substituents selected from
  • a heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl
  • a heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl
  • Ci_s alkyl-carbonyl group preferably acetyl
  • Ci_6 alkylsulfonyl group preferably methylsulfonyl
  • R 7 is preferably a hydrogen atom or an optionally substituted Ci- ⁇ alkyl group, more preferably a hydrogen atom.
  • R 7 As preferable specific examples for R 7 , (1) a hydrogen atom; and (2) a Ci-6 alkyl group (preferably methyl) ; can be mentioned.
  • R 6 and R 7 in combination form an optionally substituted ring as the "ring" of the “optionally substituted ring", for example, a C3-10 cycloalkane, a C3-10 cycloalkene, a C 3 - 10 cycloalkadiene, a monocyclic non-aromatic heterocycle and the like can be mentioned.
  • C3-10 cycloalkane C 3 -I 0 cycloalkene and C4-10 cycloalkadiene
  • rings corresponding to the C3-10 cycloalkyl group, C3-10 cycloalkenyl group and C4- 1 0 cycloalkadienyl group exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R 6 , R 7 , R 21 or R 22 can be mentioned.
  • the monocyclic non-aromatic heterocycle a ring corresponding to the monocyclic non-aromatic heterocyclic group exemplified as the below-mentioned "optionally substituted heterocyclic group" for R 3 , can be mentioned.
  • the "ring" of the “optionally substituted ring” optionally has 1 to 3 substituents at substitutable positions.
  • substituents those exemplified as the substituents which the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group” for R 6 , R 7 , R 21 or R 22 optionally has, can be mentioned.
  • the "optionally substituted ring” is preferably an optionally substituted monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran, 1- oxidotetrahydrothiopyran) or an optionally substituted C3- 1 0 cycloalkane (preferably cyclohexane) , more preferably an optionally substituted monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran, 1- oxidotetrahydrothiopyran) .
  • an optionally substituted monocyclic non-aromatic heterocycle preferably piperidine, tetrahydropyran, 1- oxidotetrahydrothiopyran
  • a monocyclic non- aromatic heterocycle preferably piperidine, tetrahydropyran
  • 1 to 3 substituents selected from (a) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by aromatic heterocyclic group (s) (preferably imidazolyl) optionally substituted by 1 to 3 Ci_ 6 alkyl groups (preferably methyl)
  • a Ci-6 alkyl group preferably methyl, ethyl
  • aromatic heterocyclic group s
  • s preferably imidazolyl
  • Ci_ 6 alkyl groups preferably methyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • a monocyclic non-aromatic heterocycle preferably piperidine, tetrahydropyran, 1-oxidotetrahydrothiopyran
  • 1 to 3 substituents selected from (a) a C 1 -( S alkyl group (preferably methyl, ethyl, isobutyl) optionally substituted by 1 to 3 substituents selected from (i) an aromatic heterocyclic group (preferably imidazolyl, furyl, pyridyl) optionally substituted by 1 to 3 Ci_6 alkyl groups (preferably methyl) , (ii) a cyano group,
  • Ci_6 alkoxy group preferably methoxy
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkoxy-carbonyl group preferably methoxycarbonyl
  • a carbamoyl group optionally mono- or di- substituted by Ci-6 alkyl group (s) (preferably ethyl), (b) a C 7 - X3 aralkyl group (preferably benzyl) , (c) a Ci_6 alkyl-carbonyl group .(preferably acetyl) ,
  • Ci_6 alkylsulfonyl group preferably methylsulfonyl
  • Ci_6 alkyl group preferably methyl
  • R 21 is preferably a hydrogen atom or an optionally substituted C ⁇ - ⁇ alkyl group.
  • R 21 As preferable specific examples for R 21 ,
  • Ci-6 alkyl group (preferably methyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a non-aromatic heterocyclic group (preferably morpholinyl) ; can be mentioned.
  • R 22 is preferably a hydrogen atom.
  • R 2 is a group represented by
  • A is. CH or N;
  • R 4 and R 5 are each independently an optionally substituted C ⁇ - 6 alkyl group or an optionally substituted C 3 - 1 0 cycloalkyl group, or R 4 and R 5 in combination form an optionally substituted ring (the ring should not be morpholine) .
  • A is preferably CH.
  • the "Ci-6 alkyl group" of the "optionally substituted Ci- ' 6 alkyl group” for R 4 or R 5 optionally has 1 to 3 substituents at substitutable positions.
  • substituents those exemplified as the substituents which the Ci-10 alkyl group and the like exemplified as the "hydrocarbon group” of the "optionally substituted hydrocarbon group” for R 5 , R 7 , R 21 or R 22 optionally has, can be mentioned.
  • the "C3- 1 0 cycloalkyl group” optionally has 1 to 3 substituents at substitutable positions.
  • substituents those exemplified as the substituents which the C3- 1 0 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group” for R 6 , R 7 , R 21 or R 22 optionally has, can be mentioned.
  • R 4 and R 5 are preferably each independently (1) a Ci_6 alkyl group (preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, neopentyl) optionally substituted by 1 to 3 substituents selected from
  • Ci_s alkoxy group preferably methoxy, ethoxy
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl, ethylsulfonyl
  • Ci-6 alkoxy-carbonyl group preferably methoxycarbonyl, ethoxycarbonyl
  • an aromatic heterocyclic group preferably pyridyl
  • a C3- 1 0 cycloalkyl group preferably cyclopropyl
  • nitrogen- containing non-aromatic heterocycle of the "optionally substituted nitrogen-containing non-aromatic heterocycle"
  • a monocyclic nitrogen-containing non-aromatic heterocycle the ring should not be morpholine
  • a fused nitrogen-containing non-aromatic heterocycle a nitrogen- containing spiro ring and the like
  • a 5- to 7-meit ⁇ bered monocyclic nitrogen-containing non-aromatic heterocycle (the ring should not be morpholine) containing, as a ring-constituting atom besides carbon atoms, at least one nitrogen atom and optionally further containing 1 to 3 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom can be mentioned.
  • pyrrolidine oxopyrrolidine
  • dioxopyrrolidine piperidine
  • thiomorpholine 1, 1-dioxidothiomorpholine
  • piperazine oxopiperazine and the like
  • fused nitrogen-containing non-aromatic heterocycle for example, a ring wherein the above-mentioned 5 ⁇ to 7-membered monocyclic nitrogen-containing non-aromatic heterocycle and 1 or 2 rings selected from a 5 or 6-membered aromatic heterocycle, a 5 or ⁇ -membered non-aromatic heterocycle and a benzene ring are condensed, and a ring wherein the above-mentioned ring is partially saturated, can be mentioned.
  • the 5 or 6-membered aromatic heterocycle and 5 or 6-membered non-aromatic heterocycle for example, a ring corresponding to a 5- or 6-membered ring group, from among the aromatic heterocyclic group and non-aromatic heterocyclic group exemplified, as the "heterocyclic group" of the below- mentioned “optionally substituted heterocyclic group” for R 3 , can be mentioned.
  • fused nitrogen- containing non-aromatic heterocycle tetrahydropyrrole [3, 4- c]pyrrole-l,3 (2H, 3aH) -dione, hexahydropyrazino [2, 1- c] [1, 4] oxazin-4 (3H) -one, hexahydro [1, 3] oxazolo [3, 4-a]pyrazin- 3-one, 5, 6, 7, 8-tetrahydro [1,2, 4] triazolo [4, 3-a]pyrazine and the like can be mentioned.
  • nitrogen-containing spiro heterocycle for example, a ring formed by the above-mentioned 5- to 7-membered monocyclic nitrogen-containing non-aromatic heterocycle and 1 or 2 rings selected from a C 3 - 1 0 cycloalkane, a C3-10 cycloalkene, a C4-10 cycloalkadiene and a 5 or 6-membered non-aromatic heterocycle can be mentioned.
  • C3-10 cycloalkane, C3-10 cycloalkene and C4-10 cycloalkadiene a ring corresponding to the C 3 - 10 cycloalkyl group, C3- 1 0 cycloalkenyl group and C 4 - 10 cycloalkadienyl 1 group exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R 6 , R 7 , R 21 or R 22 can be mentioned.
  • the hydrocarbon group of the "optionally substituted hydrocarbon group" for R 6 , R 7 , R 21 or R 22
  • the 5 or 6-membered non-aromatic heterocycle a ring corresponding to a 5- or ⁇ -membered ring group, from among the monocyclic non-aromatic heterocyclic group exemplified as the "heterocyclic group" of the below-mentioned "optionally substituted heterocyclic group” for R 3 , can be mentioned.
  • nitrogen- containing spiro heterocycle l-oxa-3, 8-diazaspiro [4.5]decan- 2-one and the like can be mentioned.
  • the "ring" of the “optionally substituted ring” optionally has 1 to 3 substituents at substitutable positions.
  • substituents those exemplified as the substituents which the C 3 -Io cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group” for R 6 , R 7 , R 21 or R 22 optionally has, can be mentioned.
  • the "optionally substituted ring” is preferably an "optionally substituted nitrogen-containing non- aromatic heterocycle (the ring should not be morpholine) ", more preferably a nitrogen-containing non-aromatic heterocycle (the ring should not be morpholine) [preferably a monocyclic nitrogen-containing non-aromatic heterocycle (the ring should not be morpholine) (preferably pyrrolidine, oxopyrrolidine, piperidine, thiomorpholine, 1,1- dioxidothiomorpholine, piperazine, oxopiperazine) ; a fused nitrogen-containing non-aromatic heterocycle (preferably tetrahydropyrrole [3, 4-c]pyrrole-l, 3 (2H, 3aH) -dione, hexahydropyrazino [2, 1-c] [1, 4]oxazin-4 (3H) -one, hexahydro [ 1, 3
  • Ci- 6 alkoxy group preferably methoxy, ethoxy
  • Ci- 6 alkoxy-carbonyl group preferably methoxycarbonyl, ethoxycarbonyl
  • carbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) (preferably methyl)
  • a non-aromatic heterocyclic group preferably tetrahydrofuranyl
  • Ci- 6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkoxy-carbonyl group preferably methoxycarbonyl, ethoxycarbonyl
  • a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl) ;
  • a Q L -6 alkylsulfonyl group (preferably methylsulfonyl, ethylsulfonyl) ; (8) a carbamoyl group;
  • an aromatic heterocyclyl-oxy group (preferably pyrimidyloxy, pyrazinyloxy) .
  • R 4 and R 5 in combination form an optionally substituted ring (the ring should not be morpholine) .
  • W is O or NR 8 wherein R 8 is a hydrogen atom, an optionally substituted Ci_ 6 alkyl group or an optionally substituted C3-10 cycloalkyl group. W is preferably NR 8 wherein R 8 is defined above.
  • the "Ci-6 alkyl group" of the "optionally substituted C ⁇ - 6 alkyl group” for R 8 optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the Ci-io alkyl group and the like exemplified as the "hydrocarbon group" of the
  • R 6 , R 7 , R 21 or R 22 optionally has, can be mentioned.
  • Ci- 6 alkyl group preferably methyl, ethyl, propyl, isopropyl
  • substituents selected from
  • R 8 (1) a hydrogen atom
  • Ci- 6 alkoxy-carbonyl group (preferably ethoxycarbonyl) ; can be mentioned.
  • R 3 is an optionally substituted heterocyclic group or an optionally substituted C ⁇ -u aryl group.
  • heterocyclic group of the "optionally substituted heterocyclic group” for R 3
  • aromatic heterocyclic group and a non-aromatic heterocyclic group can be mentioned.
  • aromatic heterocyclic group for example, a 4- to 7-membered (preferably 5- or 6-membered) monocyclic aromatic heterocyclic group containing, as a ring- constituting atom besides carbon atoms, 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom, and a fused aromatic heterocyclic group can be mentioned.
  • fused aromatic heterocyclic group for example, a group derived from a fused ring wherein a ring corresponding to the 4- to 7-membered monocyclic aromatic heterocyclic group and 1 or 2 rings selected from a 5- or 6-membered aromatic heterocycle containing 1 or 2 nitrogen atoms (e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine) , a 5- membered aromatic heterocycle containing one sulfur atom (e.g., thiophene) and a benzene ring are fused, and the like can be mentioned.
  • a 5- or 6-membered aromatic heterocycle containing 1 or 2 nitrogen atoms e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine
  • a 5- membered aromatic heterocycle containing one sulfur atom e.g., thiophene
  • a benzene ring
  • aromatic heterocyclic group monocyclic aromatic heterocyclic groups such as furyl (e.g., 2-furyl, 3-furyl) , thienyl (e.g., 2-thienyl, 3-thienyl) , pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl) , pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl) , pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl) , pyrazinyl (e.g., 2-pyrazinyl) , pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl) , imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4- imidazolyl,
  • furyl e
  • tetrazolyl e.g., tetrazol-1-yl, tetrazol-5-yl
  • triazinyl e.g., 1, 2, 4-triazin-l-yl, 1, 2, 4-triazin-3-yl
  • fused heterocyclic group such as quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl, 6-quinolyl) , isoquinolyl (e.g., 3- isoquinolyl) , quinazolyl (e.g., 2-quinazolyl, 4-quinazolyl) , quinoxalyl (e.g., 2-quinoxalyl, ⁇ -quinoxalyl) , benzofuryl (e.g., 2-benzofuryl, 3-benzofuryl) , benzothienyl (e.g., 2- benzothienyl, 3-benzothienyl) , benzoxazolyl (e.g., 2- be
  • non-aromatic heterocyclic group for example, a 4- to 7-membered (preferably 5- or 6-membered) monocyclic non- aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atoms, 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom, and a fused non-aromatic heterocyclic group can be mentioned.
  • the fused non-aromatic heterocyclic group for example, a group derived from a fused ring wherein a ring corresponding to the 4- to 7- membered monocyclic non-aromatic heterocyclic group and 1 or 2 rings selected from a 5- or 6-membered aromatic or non- aromatic heterpcycle containing 1 or 2 nitrogen atoms (e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine) , a 5-membered aromatic or non-aromatic heterocycle containing one sulfur atom (e.g., thiophene, tetrahydrothiophene) and a benzene ring are fused, a group wherein the above-mentioned group is partially saturated, and the like can be mentioned.
  • non-aromatic heterocyclic group monocyclic non-aromatic heterocyclic groups such as tetrahydrofuranyl (e.g., 2-tetrahydrofuranyl) , pyrrolidinyl (e.g., 1-pyrrolidinyl) , piperidinyl (e.g., piperidino, 2- piperidinyl, 3-piperidinyl, 4-piperidinyl) , morpholinyl (e.g., morpholino) , thiomorpholinyl (e.g., thiomorpholino) , piperazinyl (e.g., 1-piperazinyl, 2-piperazinyl, 3- piperazinyl) , hexamethyleniminyl (e.g., hexamethylenimin-1-yl) oxazolidinyl (e.g., oxazolidin-2-yl) , thiazolidinyl (e.g.
  • heterocyclic group of the aforementioned “optionally substituted heterocyclic group” optionally has 1 to 3 substituents at substitutable positions.
  • substituents those exemplified as the substituents which the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group” for R ⁇ , R 7 , R 21 or R 22 optionally has, can be mentioned.
  • the "C 6 -i4 aryl group” optionally has 1 to 3 substituents at substitutable positions.
  • substituents those exemplified as the substituents which the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group” for R 6 , R 7 , R 21 or R 22 optionally has, can be mentioned.
  • R 3 is preferably an optionally substituted 5- or 6- membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, furyI 7 thiazolyl / imidazolyl) or an optionally substituted C 3 -i 4 aryl group (e.g., phenyl), more preferably an optionally substituted 5- or 6-membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, furyl, thiazolyl, imidazolyl) , particularly preferably a 5- or 6-membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, furyl, thiazolyl, imidazolyl) .
  • an optionally substituted 5- or 6- membered monocyclic aromatic heterocyclic group preferably thienyl, pyridyl, furyI 7 thiazolyl / imidazolyl
  • C 3 -i 4 aryl group e
  • a 5- or ⁇ -membered monocyclic aromatic heterocyclic group preferably thienyl, pyridyl, furyl, thiazolyl, imidazolyl
  • a 5- or ⁇ -membered monocyclic aromatic heterocyclic group preferably thienyl, pyridyl, furyl, thiazolyl, imidazolyl
  • Ci- 6 alkyl group preferably methyl
  • a C ⁇ - 1 4 aryl group e.g., phenyl
  • substituents selected from (a) a C ⁇ -s alkyl group (preferably methyl) optionally substituted by 1 to 3 halogen atoms (preferably fluorine atom)
  • a C ⁇ -s alkyl group preferably methyl
  • halogen atoms preferably fluorine atom
  • Ci_6 alkoxy group (preferably methoxy) ; can be mentioned.
  • R 9 , R 10 and R 11 are each independently a hydrogen atom, a halogen atom, an optionally substituted Ci-e alkyl group or an optionally substituted Ci-6 alkoxy group.
  • the "Ci-e alkyl group" of the "optionally substituted Ci_ 6 alkyl group” for R 9 , R 10 or R 11 optionally has 1 to 3 substituents at substitutable positions.
  • substituents those exemplified as the substituents which the Ci-io alkyl group and the like exemplified as the "hydrocarbon group” of the "optionally substituted hydrocarbon group” for R 6 , R 7 , R 21 or R 22 optionally has, can be mentioned.
  • the "Ci-6 alkoxy group” of the "optionally substituted Ci_ 5 alkoxy group" for R 9 , R 10 or R 11 optionally has 1 to 3 substituents at substitutable positions.
  • R 9 is preferably a hydrogen atom or a halogen atom (preferably chlorine atom) .
  • R 10 is preferably a hydrogen atom, a halogen atom, a Ci_6 alkyl group or an optionally substituted Ci-6 alkoxy group, more preferably a hydrogen atom, a C ⁇ - ⁇ alkyl group or an optionally substituted C ⁇ -6 alkoxy group.
  • R 10 is preferably a hydrogen atom, a halogen atom, a Ci_6 alkyl group or an optionally substituted Ci-6 alkoxy group, more preferably a hydrogen atom, a C ⁇ - ⁇ alkyl group or an optionally substituted C ⁇ -6 alkoxy group.
  • halogen atom preferably bromine atom
  • Ci- 6 alkoxy group preferably methoxy, ethoxy, propoxy, isopropoxy
  • 1 to 3 substituents selected from
  • Ci-6 alkoxy group preferably methoxy
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkoxy-carbonyl group preferably ethoxycarbonyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • R 11 is preferably a hydrogen atom, a halogen atom (preferably chlorine atom) or a C ⁇ - 6 alkyl group (preferably methyl) .
  • Compound (I) does not contain a compound wherein R 21 is a hydrogen atom or a C ⁇ -6 alkoxy- carbonyl group, R 22 is a hydrogen atom, and R 6 and R 7 are both hydrogen atoms, and a compound wherein R 21 is a hydrogen atom or a Ci_6 alkoxy- carbonyl groug, R 22 is a hydrogen atom, and R 6 and R 7 are both methyl groups .
  • R 1 is a hydrogen atom
  • R 2 is a group represented by
  • A is CH or N
  • R 4 and R 5 are each independently
  • Ci-6 alkyl group preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, neopentyl
  • a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkoxy group preferably methoxy, ethoxy
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl, ethylsulfonyl
  • Ci_6 alkoxy-carbonyl group preferably methoxycarbonyl, ethoxycarbonyl
  • a nitrogen-containing non- aromatic heterocycle (the ring should not be morpholine) [preferably a monocyclic nitrogen-containing non-aromatic heterocycle (the ring should not be morpholine) (preferably pyrrolidine, oxopyrrolidine, piperidine, thiomorpholine, 1,1- dioxidothiomorpholine, piperazine, oxopiperazine) ; a fused nitrogen-containing non-aromatic heterocycle (preferably tetrahydropyrrole [3, 4-c]pyrrole-l, 3 (2H, 3aH) -dione, hexahydropyrazino [2, 1-c] [1,4] oxazin-4 (3H) -one, hexahydro [1, 3] oxazolo [3, 4-a]pyrazin-3-one, 5,6,1, 8- tetrahydro [1,2, 4] triazolo[4, 3-a]pyrazine) ; or
  • Ci- 6 alkyl group preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl
  • a Ci- 6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • Ci- 6 alkoxy-carbonyl group preferably methoxycarbonyl, ethoxycarbonyl
  • Ci_ e alkyl-carbonyl group (s) preferably acetylamino
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkoxy-carbonyl group preferably methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl, ethylsulfonyl
  • a hydrogen atom or (2) a Ci-6 alkyl group (preferably methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkoxy group preferably methoxy, ethoxy
  • R 3 is a 5- or 6-i ⁇ embered monocyclic aromatic heterocyclic group (preferably thienyl) ;
  • R 9 is a hydrogen atom or a halogen atom (preferably chlorine atom) ;
  • R 10 is a hydrogen atom; and R 11 is a hydrogen atom, halogen atom (preferably chlorine atom) or a Ci_ 6 alkyl group (preferably methyl) .
  • R 6 is (1) a Ci_6 alkyl group (preferably methyl, ethyl, isopropyl) optionally substituted by 1 to 3 substituents selected from (a) a non-aromatic heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl) optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-s alkylsulfonyl group preferably methylsulfonyl
  • halogen atom preferably fluorine atom
  • Ci-6 alkoxy-carbonyl group preferably methoxycarbonyl
  • a carbamoyl group or (6) a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl) ,
  • Ci_ 6 alkyl group preferably methyl, ethyl, isopropyl substituted by 1 to 3 substituents selected from
  • a non-aromatic heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl
  • a non-aromatic heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl
  • substituents selected from (i) a hydroxy group
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • Ci-6 alkyl group preferably methyl
  • R 6 and R 7 in combination form a monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran) optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group preferably methyl, ethyl
  • aromatic heterocyclic group preferably imidazolyl
  • 1 to 3 C ⁇ - 6 alkyl groups preferably methyl
  • Ci-s a.lkyl-carbonyl group preferably acetyl
  • Ci_6 alkylsulfonyl group preferably methylsulfonyl
  • Ci_6 alkyl group preferably methyl
  • W is NR 8 ;
  • R 8 is (1) a hydrogen atom, or
  • Ci-6 alkyl group preferably methyl, ethyl, propyl, isopropyl
  • R 3 is a 5- or 6-membered monocyclic aromatic heterocyclic group (preferably thienyl) ;
  • R 9 is a hydrogen atom or a halogen atom (preferably chlorine atom) ;
  • R 10 is a hydrogen atom;
  • R 11 is a hydrogen atom, halogen atom (preferably chlorine atom) or a Ci_ 6 alkyl group (preferably methyl) .
  • R 1 is a hydrogen atom or a halogen atom (preferably fluorine atom) ;
  • R 2 is a group represented by
  • Ci-6 alkyl group preferably methyl, , ethyl, isopropyl, isobutyl
  • 1 to 3 substituents selected from
  • a heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl
  • a heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • Ci- 6 alkyl-carbonyl group preferably acetyl
  • Ci- 6 alkoxy-carbonyl group preferably methoxycarbonyl
  • Ce- ⁇ u aryl groups preferably phenyl
  • a non-aromatic heterocyclic group preferably tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl, 1 , 1-dioxidotetrahydrothiopyranyl
  • Ci-6 alkoxy group preferably methoxy
  • Ci-6 alkylsulfonyloxy group preferably methylsulfonyloxy
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • a C 2 -S alkenyl-carbonyl group preferably vinylcarbonyl
  • a Ci-6 alkoxy-carbonyl group preferably ethoxycarbonyl
  • a carboxy group preferably a non-aromatic heterocyclyl-carbonyl group (preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1, 1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group,
  • Ci-6 alkyl group preferably methyl, ethyl
  • a halogen atom preferably fluorine atom
  • Ci-6 alkyl group preferably methyl, ethyl
  • a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a Ci_ 6 alkoxy group (preferably methoxy) and a Ci-6 alkylsulfonyl group (preferably methylsulfonyl)
  • a Ci-6 alkyl group preferably methyl, ethyl
  • substituents selected from a hydroxy group, a Ci_ 6 alkoxy group (preferably methoxy) and a Ci-6 alkylsulfonyl group (preferably methylsulfonyl)
  • Ci-6 alkoxy group preferably methoxy
  • C3- 1 0 cycloalkyl group preferably cyclopropyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • an aromatic heterocyclic group preferably triazolyl, tetrazolyl
  • a non-aromatic heterocyclic group preferably tetrahydropyranyl
  • a Ci-6 alkylthio group preferably methylthio
  • a formyl group a non-aromatic heterocyclic group (preferably tetrahydropyranyl)
  • a Ci-6 alkylthio group preferably methylthio
  • a formyl group a non-aromatic heterocyclic group (preferably tetrahydropyranyl)
  • a Ci-6 alkylthio group preferably methylthio
  • Ci_ 5 alkyl group preferably ethyl
  • a non-aromatic heterocyclyl-carbonyl group preferably pyrrolidinylcarbonyl, morpholinylcarbonyl, piperazinylcarbonyl
  • Ci-6 alkyl groups preferably methyl
  • Ci_ 6 alkyl group preferably methyl, ethyl, isopropyl, isobutyl
  • 1 to 3 substituents selected from (a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl,- piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothioit ⁇ orpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, ⁇ triazolyl) optionally substituted by 1 to 3 substituents selected from (a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl,- piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothioit ⁇ orpholinyl, pyrazolinyl, pyrazolidinyl,
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci_ 6 alkylsulfonyl group preferably methylsulfonyl
  • a halogen atom preferably fluorine atom
  • Ci_6 alkyl group preferably methyl, ethyl
  • Ci- 3 alkylenedioxy group preferably ethylenedioxy
  • Ci-6 alkyl group preferably methyl
  • R 6 and R 7 in combination form (1) a monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran, 1-oxidotetrahydrothiopyran) optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group preferably methyl, ethyl, isobutyl
  • substituents selected from (i) an aromatic heterocyclic group (preferably imidazolyl, furyl, pyridyl) optionally substituted by 1 to 3 C ⁇ - 6 alkyl groups (preferably methyl) , (ii) a cyano group, (iii) a hydroxy group, (iv) a carboxy group,
  • Ci-6 alkoxy group preferably methoxy
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci- 6 alkoxy-carbonyl group preferably methoxycarbonyl
  • carbamoyl group optionally mono- or di- substituted by Ci- 6 alkyl group (s) (preferably ethyl)
  • Ci_6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • a carbamoyl group optionally mono- or di-substituted by
  • Ci-6 alkyl group (s) (preferably methyl), and (f) a non-aromatic heterocyclic group (preferably tetrahydropyranyl) , or
  • Ci-s alkyl group (preferably methyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a non-aromatic heterocyclic group (preferably morpholinyl) ;
  • R 22 is a hydrogen atom; W is NR 8 ; R 8 is
  • Ci-6 alkyl group preferably methyl, ethyl, ' propyl, isopropyl, isobutyl
  • 1 to 3 substituents selected from (a) a C 3 -1 0 cycloalkyl group (preferably cyclopropyl) ,
  • Ci-6 alkoxy group preferably methoxy, ethoxy
  • Ci-6 alkoxy-carbonyl group preferably ethoxycarbonyl
  • R 3 is (1) a 5- or 6-membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, ⁇ furyl, thiazolyl, imidazolyl) optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group preferably methyl
  • C ⁇ -14 aryl group e.g., phenyl
  • Ci-6 alkyl group preferably methyl
  • halogen atoms preferably fluorine atom
  • Ci-6 alkoxy group preferably methoxy
  • R 9 is a hydrogen atom or a halogen atom (preferably chlorine atom) ;
  • a hydrogen atom (2) a halogen atom (preferably bromine atom) , (3) a Ci-6 alkyl group (preferably methyl) , or
  • Ci-6 alkoxy group preferably methoxy, ethoxy, propoxy, isopropoxy
  • 1 to 3 substituents selected from (a) a halogen atom (preferably fluorine atom) ,
  • Ci-6 alkoxy group preferably methoxy
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • R 11 is a hydrogen atom, a halogen atom (preferably chlorine atom) or a Ci - ⁇ alkyl group (preferably methyl ) .
  • R 1 is a hydrogen atom or a halogen atom (preferably fluorine atom) ;
  • R 2 is a group represented by
  • R 6 is (1) a Ci-6 alkyl group (preferably methyl, ethyl, isopropyl, isobutyl) optionally substituted by 1 to 3 substituents selected from
  • a heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl
  • a heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • Ci-6 alkyl group preferably methyl, ethyl
  • a Ci-3 alkylenedioxy group preferably ethylenedioxy
  • Ci-6 alkyl group preferably methyl, ethyl, isobutyl
  • a Ci- 6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Ci- 6 alkylsulfonyl group (preferably methylsulfonyl)
  • Ci_6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkoxy-carbonyl group preferably methoxycarbonyl
  • aryl groups preferably phenyl
  • a non-aromatic heterocyclic group preferably tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl, 1, 1-dioxidotetrahydrothiopyranyl
  • Ci-6 alkoxy group preferably methoxy
  • Ci_ 6 alkylsulfonyloxy group preferably methylsulfonyloxy
  • Ci_ 6 alkyl-carbonyl group preferably acetyl
  • a C 2 - 6 alkenyl-carbonyl group preferably vinylcarbonyl
  • a Ci- 6 alkoxy-carbonyl group preferably ethoxycarbonyl
  • a non-aromatic heterocyclyl-carbonyl group preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1, 1- dioxidothiomorpholinylcarbonyL, pyrrolidinylcarbonyl, azetidinylcarbonyl
  • a non-aromatic heterocyclyl-carbonyl group preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1, 1- dioxidothiomorpholinylcarbonyL, pyrrolidinylcarbonyl, azetidinylcarbonyl
  • Ci- 6 alkyl group preferably methyl, ethyl
  • a halogen atom preferably fluorine atom
  • Ci-6 alkyl group preferably methyl, ethyl
  • a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a C3.-6 alkoxy group (preferably methoxy) and a Ci-6 alkylsulfonyl group (preferably methylsulfonyl)
  • a Ci-6 alkyl group preferably methyl, ethyl
  • Ci-e alkoxy group preferably methoxy
  • C3- 1 0 cycloalkyl group preferably cyclopropyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • an aromatic heterocyclic group preferably triazolyl, tetrazolyl
  • Ci-6 alkylthio group preferably, methylthio
  • Ci-6 alkoxy-carbonyl group preferably methoxycarbonyl
  • carbamoyl group optionally mono- or di-substituted by Ci- 6 alkyl group (s) (preferably ethyl)
  • a non-aromatic heterocyclyl-carbonyl group preferably pyrrolidinylcarbonyl, morpholinylcarbonyl, piperazinylcarbonyl
  • 1 to 3 Ci- 6 alkyl groups preferably methyl
  • Ci- 6 alkyl group preferably methyl, ethyl, isopropyl, isobutyl substituted by 1 to 3 substituents selected from
  • a heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl
  • a heterocyclic group preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl
  • Ci- 6 alkyl-carbonyl group preferably acetyl
  • Ci- 6 alkylsulfonyl group preferably methylsulfonyl
  • Ci_ 6 alkyl group preferably methyl, ethyl
  • a Ci- 3 alkylenedioxy group preferably ethylenedioxy
  • Ci_6 alkyl group (preferably methyl)
  • a monocyclic non-aromatic heterocycle preferably piperidine, tetrahydropyran, 1-oxidotetrahydrothiopyran
  • a monocyclic non-aromatic heterocycle preferably piperidine, tetrahydropyran, 1-oxidotetrahydrothiopyran
  • Ci-6 alkyl group preferably methyl, ethyl, isobutyl
  • an aromatic heterocyclic group preferably imidazolyl, furyl, pyridyl
  • Ci-6 alkyl groups preferably methyl
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci- 6 alkoxy-carbonyl group preferably methoxycarbonyl
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkylsulfonyl group preferably methylsulfonyl
  • a non-aromatic heterocyclic group preferably tetrahydropyranyl
  • Ci- 6 alkyl group preferably methyl, ethyl, propyl, isopropyl, isobutyl
  • 1 to 3 substituents selected from
  • Ci-6 alkoxy group preferably methoxy, ethoxy
  • a 5- or 6-membered monocyclic aromatic heterocyclic group preferably thienyl, pyridyl, furyl, ' thiazolyl, imidazolyl
  • substituents selected from (a) a halogen atom (preferably chlorine atom) , and (b) a Q L -6 alkyl group (preferably methyl) , or
  • Ci-6 alkyl group preferably methyl
  • halogen atoms preferably fluorine atom
  • Ci-6 alkoxy group preferably methoxy
  • R 9 is a hydrogen atom or a halogen atom (preferably chlorine atom) ;
  • R 10 is
  • Ci-6 alkyl group preferably methyl
  • Ci- 6 alkoxy group preferably methoxy, ethoxy, propoxy, isopropoxy
  • 1 to 3 substituents selected from
  • Ci-6 alkoxy group preferably methoxy
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkoxy-carbonyl group preferably ethoxycarbonyl
  • Ci-s alkylsulfonyl group preferably methylsulfonyl
  • R 11 is a hydrogen atom, a halogen atom (preferably chlorine atom) or a Ci_ 6 alkyl group (preferably methyl) .
  • R 1 is a hydrogen atom or a halogen atom (preferably fluorine atom) ;
  • R 2 is a group represented by
  • Ci-6 alkyl group preferably methyl, ethyl, isopropyl, isobutyl
  • substituents selected from (a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl) optionally substituted by 1 to 3 substituents selected from (a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, tri
  • Ci- 6 alkyl-carbonyl group preferably acetyl
  • Ci- 6 alkylsulfonyl group preferably methylsulfonyl
  • a halogen atom preferably fluorine atom
  • Ci-6 alkyl group preferably methyl, ethyl
  • a Ci_ 3 alkylenedioxy group preferably ethylenedioxy
  • Ci-6 alkoxy-carbonyl group preferably methoxycarbonyl
  • aryl groups preferably phenyl
  • an aromatic heterocyclic group preferably triazolyl
  • a non-aromatic heterocyclic group preferably tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl
  • Ci-6 alkoxy group preferably methoxy
  • a C ⁇ - ⁇ alkylsulfonyloxy group preferably methylsulfonyloxy
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • a non-aromatic heterocyclyl-carbonyl group preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, _ pyrrolidinylcarbonyl, azetidinylcarbonyl
  • a non-aromatic heterocyclyl-carbonyl group preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, _ pyrrolidinylcarbonyl, azetidinylcarbonyl
  • Ci-6 alkyl group preferably methyl, ethyl
  • a halogen atom preferably fluorine atom
  • a non-aromatic heterocyclyl-carbonyloxy group preferably morpholinylcarbonyloxy
  • Ci-6 alkyl groups preferably methyl
  • Ci-6 alkyl group preferably methyl, ethyl
  • a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a C ⁇ - 6 alkoxy group (preferably methoxy) and a Ci_6 alkylsulfonyl group (preferably methylsulfonyl)
  • a Ci-6 alkyl group preferably methyl, ethyl
  • substituents selected from a hydroxy group, a C ⁇ - 6 alkoxy group (preferably methoxy) and a Ci_6 alkylsulfonyl group (preferably methylsulfonyl)
  • Ci-6 alkoxy group preferably methoxy
  • a C3- 1 0 cycloalkyl group preferably cyclopropyl
  • a Ci_6 alkylsulfonyl group preferably methylsulfonyl
  • Ci-6 alkylthio group preferably methylthio
  • a formyl group preferably methylthio
  • a cyano group optionally substituted by 1 to 3 carboxy groups
  • Ci- 6 alkoxy-carbonyl group (preferably methoxycarbonyl)
  • Ci_ 6 alkyl group preferably ethyl
  • a non-aromatic heterocyclyl-carbonyl group preferably pyrrolidinylcarbonyl, morpholinylcarbonyl, piperazinylcarbonyl
  • Ci- ⁇ alkyl groups preferably methyl
  • Ci- 6 alkyl group preferably methyl, ethyl, isopropyl, isobutyl substituted by 1 to 3 substituents selected from (a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothioi ⁇ o . rpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl) optionally substituted by 1 to 3 substituents selected from (a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothioi ⁇ o . rpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazo
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci- 6 alkylsulfonyl group preferably methylsulfonyl
  • Ci-6 alkyl group preferably methyl, ethyl
  • a Ci- 3 alkylenedioxy group preferably ethylenedioxy
  • a monocyclic non-aromatic heterocycle preferably piperidine, tetrahydropyran, 1-oxidotetrahydrothiopyran
  • a monocyclic non-aromatic heterocycle preferably piperidine, tetrahydropyran, 1-oxidotetrahydrothiopyran
  • Ci-6 alkyl group preferably methyl, ethyl, isobutyl
  • substituents selected from (i) an aromatic heterocyclic group (preferably imidazolyl, furyl, pyridyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (preferably methyl) , (ii) a cyano group, (iii) a hydroxy group, (iv) a carboxy group,
  • Ci-6 alkoxy group preferably methoxy
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci-6 alkoxy-carbonyl group preferably methoxycarbonyl
  • a carbamoyl group optionally mono- or di- substituted by Ci- 6 alkyl group (s) (preferably ethyl)
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci- 6 alkylsulfonyl group preferably methylsulfonyl
  • a non-aromatic heterocyclic group preferably tetrahydropyranyl
  • a C3-10 cycloalkane preferably cyclohexane
  • 1 to 3 substituents selected from an oxo group ' and a C 1 - 3 alkylenedioxy group (preferably ethylenedioxy) ;
  • R 21 is a Ci-6 alkyl group (preferably methyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a non-aromatic heterocyclic group (preferably morpholinyl) ;
  • R 22 is a hydrogen atom; W is NR 8 ; R 8 is (1) a hydrogen atom, or
  • Ci-6 alkyl group preferably methyl, ethyl, propyl, isopropyl, isobutyl
  • a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkoxy-carbonyl group preferably ethoxycarbonyl
  • Ci-6 alkyl group preferably methyl
  • halogen atoms preferably fluorine atom
  • Ci-6 alkoxy group preferably methoxy
  • R 9 is a hydrogen atom or a halogen atom, (preferably chlorine atom)
  • R 10 is
  • halogen atom preferably bromine atom
  • Ci- 6 alkyl group preferably methyl
  • Ci- 6 alkoxy group preferably methoxy, ethoxy, propoxy, isopropoxy
  • 1 to 3 substituents selected from
  • Ci_6 alkoxy group preferably methoxy
  • Ci-6 alkyl-carbonyl group preferably acetyl
  • Ci- 6 alkoxy-carbonyl group preferably ethoxycarbonyl
  • Ci- 6 alkylsulfonyl group preferably methylsulfonyl
  • R 11 is a hydrogen atom, a halogen atom (preferably chlorine atom) or a C ⁇ -6 alkyl group (preferably methyl) .
  • compound (I) is in the form of a salt
  • a salt with inorganic base for example, a salt with organic base, a salt with inorganic acid, a salt with organic acid, a salt with basic or acidic amino acid and the like can be mentioned.
  • alkali metal salts such as sodium salt, potassium salt and the like
  • alkaline earth metal salts such as calcium salt, magnesium salt and the like
  • aluminum salts ammonium salts and the like
  • salts with organic base salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N-dibenzylethylenediamine and the like can be mentioned.
  • salt with inorganic acid salt with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like can be mentioned.
  • salts with organic acid salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like can be mentioned.
  • salts with basic amino acid salts with arginine, lysine, ornithine and the like can be mentioned.
  • salts with acidic amino acid salts with aspartic acid, glutamic acid and the like can be mentioned.
  • a prodrug of the compound (I) means a compound which is converted to the compound (I) with a reaction due to an enzyme, an gastric acid, etc. under the physiological condition in the living body, that is, a compound which is converted to the compound (I) with enzymatic oxidation, reduction, hydrolysis and the like; a compound which is converted to the compound (I) by hydrolysis and the like due to gastric acid and the like.
  • a prodrug of the compound (I) may be a compound obtained by subjecting an amino group in the compound (I) to an acylation, alkylation or phosphorylation (e.g., a compound obtained by subjecting an amino group in the compound (I) to an eicosanoylation, alanylation, pentylaminocarbonylation, (5- methyl-2-oxo-l, 3-dioxolen-4-yl)methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, pivaloyloxymethylation or tert-butylation) ; a compound obtained by subjecting a hydroxy group in the compound (I) to an acylation, alkylation, phosphorylation or boration (e.g., a compound obtained by subjecting an hydroxy group in the compound (I) to an acetylation, palmitoylation, propanoylation, pivaloylation, succinylation, fumarylation, al
  • a prodrug of the compound (I) may also be one which is ' converted into the compound (I) under a physiological condition, such as those described in IYAKUHIN NO KZVIHATSU (Development of Pharmaceuticals) , Vol. 7, Design of Molecules, p.163-198, Published by HIROKAWA SHOTEN (1990).
  • the compound (I) may be labeled with an isotope (e.g., 3 H, 14 C, 35 S, 125 I etc.) and the like.
  • an isotope e.g., 3 H, 14 C, 35 S, 125 I etc.
  • the compound (I) may be a non-hydrate or hydrate.
  • Deuterium-converted compound wherein 1 H has been converted to 2 H(D) are also encompassed in the compound (I).
  • the compound (I) or a prodrug thereof shows low toxicity and can be used as an agent for the prophylaxis or treatment of various diseases to be mentioned later for mammals (e.g., humans, mice, rats, rabbits, dogs, cats, bovines, horses, pigs, monkeys etc.) as they are or by admixing with a pharmacologically acceptable carrier and the like to give a pharmaceutical composition.
  • organic or inorganic carriers conventionally used as materials for pharmaceutical preparations are used as a pharmacologically acceptable carrier, which are added as excipient, lubricant, binder and disintegrant for solid preparations; or solvent, solubilizing agent, suspending agent, isotonicity agent, buffer and soothing agent for liquid preparations, and the like.
  • an additive for pharmaceutical preparations such as preservative, antioxidant, coloring agent, sweetening agent and the . like can be used.
  • excipient examples include lactose, sucrose, D-mannitol, D-sorbitol, starch, ⁇ -starch, dextrin, crystalline cellulose, low-substituted hydroxypropylcellulose, sodium carboxymethylcellulose, gum acacia, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminate metasilicate and the like.
  • Preferred examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
  • binder examples include ⁇ -starch, saccharose, gelatin, gum acacia, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and the like.
  • disintegrant examples include lactose, sucrose, starch, carboxymethylcellulose, calcium carboxymethylcellulose, sodium croscarmellose, sodium carboxymethylstarch, light anhydrous silicic acid, low- substituted hydroxypropylcellulose and the like.
  • the solvent include water for injection, physiological brine, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil and the like.
  • solubilizing agent examples include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, sodium acetate and the like.
  • suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, lauryl aminopropionate, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate and the like; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and the like; polysorbates, polyoxyethylene hydrogenated castor oil and the like.
  • surfactants such as stearyltriethanolamine, sodium lauryl sulfate, lauryl aminopropionate, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate and the like
  • hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyeth
  • Preferred examples of the isotonicity agent include sodium chloride, glycerol, D-mannitol, D-sorbitol, glucose and the like.
  • buffers such as phosphate, acetate, carbonate, citrate and the like.
  • Preferred examples of the soothing agent include benzyl alcohol and the like.
  • Preferred examples of the preservative include p- oxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
  • Preferred examples of the antioxidant include sulfite, ascorbate and the like.
  • the coloring agent include water- soluble edible tar pigments (e.g., foodcolors such as Food Color Red Nos. 2 and 3, Food Color Yellow Nos. 4 and 5, Food Color Blue Nos. 1 and 2 and the like), water insoluble lake pigments (e.g., aluminum ' salt of the aforementioned water- soluble edible tar pigment), natural pigments (e.g., beta carotene, chlorophil, red iron oxide) and the like.
  • the sweetening agent include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like.
  • the dosage form of the aforementioned pharmaceutical composition is, for example, an oral agent such as tablets (inclusive of sugar-coated tablets, film-coated tablets, sublingual tablets and orally disintegrable tablets) , capsules (inclusive of soft capsules and microcapsules) , granules, powders, troches, syrups, emulsions, suspensions, films (e.g., orally disintegrable film) and the like; a parenteral agent such as injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, drip infusions), external agents (e.g., transdermal preparations, ointments), suppositories (e.g., rectal suppositories, vaginal suppositories) , pellets, nasal preparations, pulmonary preparations (inhalations) , ophthalmic preparations and the like, and the like.
  • an oral agent such as tablets (inclusive of sugar-co
  • agents may be controlled-release preparations such as rapid-release preparations and sustained-release preparations (e.g., sustained-release microcapsules).
  • the pharmaceutical composition can be produced according to a method conventionally used in the field of pharmaceutical preparation, such as the method described in Japan Pharmacopoeia and the like. Concrete production methods of preparations are described in detail in the following. While the content of the compound of the present invention in the pharmaceutical composition varies depending on the dosage form, dose of the compound of the present invention and the like, it is, for example, about 0.1 to 100 wt%.
  • the compound of the present invention has a superior GK activating action, and can be used as an agent for the prophylaxis or treatment of various diseases for mammals (e.g., human, bovine, horse, dog, cat, monkey, mouse, rat, specifically human) .
  • mammals e.g., human, bovine, horse, dog, cat, monkey, mouse, rat, specifically human
  • the compound of the present invention has a selective GK activating action, it shows low toxicity (e.g., acute toxicity, chronic toxicity, cardiotoxicity, carcinogenic, genetic toxicity) , which causes fewer side effects.
  • the compound of the present invention can be used as an agent for the prophylaxis or treatment of diabetes (e.g., type-1 diabetes, type-2 diabetes, gestational diabetes, obese diabetes etc.); an agent for the prophylaxis or treatment of obesity; an agent for the prophylaxis or treatment of hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, hypo-HDL-emia, postprandial hyperlipidemia etc.); an agent for the prophylaxis or treatment of arteriosclerosis; an agent for the prophylaxis or treatment of impaired glucose tolerance (IGT) ; and an agent for preventing progression of impaired glucose tolerance into diabetes.
  • diabetes e.g., type-1 diabetes, type-2 diabetes, gestational diabetes, obese diabetes etc.
  • hyperlipidemia e.g., hypertriglyceridemia, hypercholesterolemia, hypo-HDL-emia, postprandial hyperlipidemia etc.
  • arteriosclerosis e.g., arteriosclerosis
  • diabetes is a condition showing any of a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 126 mg/dl, a 75 g oral glucose tolerance test (75 g OGTT) 2 h level (glucose concentration of intravenous plasma) of not less than 200 mg/dl, and a non-fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 200 mg/dl.
  • a condition not falling under the above-mentioned diabetes and different from ⁇ a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of less than 110 mg/dl or a 75 g oral glucose tolerance test (75 g OGTT) 2 h level (glucose concentration of intravenous plasma) of less than 140 mg/dl" (normal type) is called a "borderline type".
  • ADA American Diabetes Association
  • diabetes is a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 126 mg/dl, or a 75 g oral glucose tolerance test 2 h level (glucose concentration of intravenous plasma) of not less than 200 mg/dl.
  • impaired glucose tolerance is a condition showing a 75 g oral glucose tolerance test 2 h level (glucose concentration of intravenous plasma) of not less than 140 mg/dl and less than 200 mg/dl.
  • IFG Impaired. Fasting Glucose
  • IFG a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 100 mg/dl and less than 126 mg/dl
  • IFG a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 100 mg/dl and less than 126 mg/dl
  • IFG a condition showing a 75 g oral glucose tolerance test 2 h level (glucose concentration of intravenous plasma) of not less than 110 mg/dl and less than 126 mg/dl.
  • the compound of the present invention can also be used as an agent for the prophylaxis or treatment of diabetes, borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) and IFG (Impaired Fasting Glycemia) , as determined according to the above-mentioned new diagnostic criteria. Moreover, the compound of the present invention can prevent progress of borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) or IFG (Impaired Fasting Glycemia) into diabetes.
  • the compound of the present invention can also be used as an agent for the prophylaxis or treatment of, for example, diabetic complications [e.g., neuropathy, nephropathy, retinopathy, cataract, macroangiopathy, osteopenia, hyperosmolar diabetic coma, infectious disease (e.g., respiratory infection, urinary tract infection, gastrointestinal infection, dermal soft tissue infections, inferior limb infection), diabetic foot lesion (e.g., gangrene, ulcer) , xerostomia, hypacusis, cerebrovascular disorder, peripheral blood circulation disorder, diabetic diarrhea] , obesity, osteoporosis, cachexia (e.g., cancerous cachexia, tuberculous cachexia, diabetic cachexia, blood disease cachexia, endocrine disease cachexia, infectious disease cachexia or cachexia due to acquired immunodeficiency syndrome) , fatty liver, hypertension, polycystic ovary syndrome, kidney disease (e.g., diabetic nephropathy, glomerular
  • the compound of the present invention can also be used for improvement of insulin resistance, promotion or increase of insulin secretion, decrease of visceral fat, suppression of accumulation of visceral fat, improvement of sugar metabolism, improvement of lipid metabolism (including suppression of oxidative LDL production, improvement of lipoprotein metabolism, lowering of blood remnant) , improvement of coronary metabolism, prophylaxis or treatment of cardiovascular complication, prophylaxis or treatment of heart failure complication, prophylaxis or treatment of anovulation, prophylaxis or treatment of hirsutism, prophylaxis or treatment of hyperandrogenism, improvement of pancreatic ( ⁇ cell) function, regeneration of pancreas ( ⁇ cell) , promotion of regeneration of pancreas ( ⁇ cell) and the like.
  • the compound of the present invention can also be used for the secondary prevention and suppression of progression of various diseases mentioned above (e.g., cardiovascular event such as myocardial infarction etc.).
  • cardiovascular event such as myocardial infarction etc.
  • the compound of the present invention is particularly useful as an agent for the prophylaxis or treatment of type-2 diabetes, obese diabetes and the like.
  • the dose of the compound of the present invention varies depending on the administration subject, administration route, target disease, condition and the like, the compound of the present invention is generally given in a single dose of about 0.01-100 mg/kg body weight, preferably 0.05-30 mg/kg body weight, more preferably 0.1-10 mg/kg body weight, in the case of, for example, oral administration to adult diabetic patients. This dose is desirably given 1 to 3 times a day.
  • the compound of the present invention can be used in combination with drugs such as a therapeutic agent for diabetes, a therapeutic agent for diabetic complications, a therapeutic agent for hyperlipidemia, an antihypertensive agent, an antiobestic agent, a diuretic, a chemotherapeutic agent, an immunotherapeutic agent, an antithrombotic agent, a therapeutic agent for osteoporosis, a antidementia agent, an erectile dysfunction improver, a therapeutic agent for pollakiuria or urinary incontinence, a therapeutic agent for dysuria and the like (hereinafter to be referred to as a combination drug) .
  • drugs such as a therapeutic agent for diabetes, a therapeutic agent for diabetic complications, a therapeutic agent for hyperlipidemia, an antihypertensive agent, an antiobestic agent, a diuretic, a chemotherapeutic agent, an immunotherapeutic agent, an antithrombotic agent, a therapeutic agent for osteoporosis, a antidementia agent, an
  • the compound of the present invention and a combination drug may be administered as two kinds of preparations each containing an active ingredient, or may be administered as a single preparation containing both active ingredients .
  • the dose of the combination drug can be determined as appropriate based on the dose clinically employed.
  • the proportion of the compound of the.present invention and the combination drug can be appropriately determined depending on the administration subject, administration route, target disease, condition, combination and the like.
  • the combination drug is used in an amount of 0.01-100 parts by weight per 1 part by weight of the compound of the present invention.
  • insulin preparations e.g., animal insulin preparations extracted from pancreas of bovine or swine; human insulin preparations genetically synthesized using Escherichia coli or yeast; zinc insulin; protamine zinc insulin; fragment or derivative of insulin (e.g., INS-I), oral insulin preparation
  • insulin sensitizers e.g., pioglitazone or a salt thereof (preferably hydrochloride) , rosiglitazone or a salt thereof (preferably maleate) , Tesaglitazar, Ragaglitazar, Muraglitazar, Edaglitazone, Metaglidasen, Naveglitazar, AMG-131, THR-0921
  • ⁇ -glucosidase inhibitors e.g., voglibose, acarbose, miglitol, emiglitate
  • biguanides e.g., metformin, buformin or a
  • ⁇ 3 agonists e.g., AJ-9677
  • GPR40 agonists GLP-I receptor agonists [e.g., GLP-I, GLP-IMR agent, NN-2211, AC-2993 (exendin-4), BIM-51077, Mb(S 7 SS)IiGLP-I(V 7 SV)NH 2 / CJC-1131]
  • amylin agonists e.g., pramlintide
  • phosphotyrosine phosphatase inhibitors e.g., sodium vanadate
  • gluconeogenesis inhibitors e.g., glycogen phosphorylase inhibitors, glucose-6-phosphatase inhibitors, glucagon antagonists
  • SGLT sodium-glucose cotransporter
  • ll ⁇ -hydroxysteroid dehydrogenase inhibitors e.g., BVT-3498
  • adiponectin or agonists thereof IKK inhibitors (e.g., AS-2868) , leptin resistance improving drugs, somatostatin receptor agonists, glucokinase activators (e.g., Ro-28-1675) , GIP (Glucose-dependent insulinotropic peptide) and the like.
  • IKK inhibitors e.g., AS-2868
  • leptin resistance improving drugs e.g., somatostatin receptor agonists
  • glucokinase activators e.g., Ro-28-1675
  • GIP Glucose-dependent insulinotropic peptide
  • Examples of the therapeutic agents for diabetic complications include aldose reductase inhibitors (e.g., Tolrestat, Epalrestat, Zenarestat, Zopolrestat, Minalrestat, Fidarestat, CT-112, ranirestat (AS-3201) ) , neurotrophic factors and increasing drugs thereof (e.g., NGF, NT-3, BDNF, neurotrophin production-secretion promoters described in WO01/14372 (e.g., 4- (4-chlorophenyl) -2- (2-methyl-l- imidazolyl) -5- [3- (2-methylphenoxy) propyl] oxazole) ) , stimulators (e.g., Y-128), PKC inhibitors (e.g., ruboxistaurin mesylate), AGE inhibitors (e.g., ALT-946, pimagedine, N- phenacylthiazolium bromide (ALT-766) , ALT-711, EXO-226,
  • HMG-CoA reductase inhibitors e.g., pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, pitavastatin, rosuvastatin and salts thereof (e.g., sodium salt, calcium salt)
  • squalene synthase inhibitors e.g., compounds described in WO97/10224, such as N- [ [ (3R, 5S) -1- (3- acetoxy-2, 2-dimethylpropyl) -7-chloro-5- (2, 3-dimethoxyphenyl) - 2-oxo-l, 2, 3, 5-tetrahydro-4, l-benzoxazepin-3- yl] acetyl]piperidine-4-acetic acid), fibrate compounds (e.g., bezafibrate, clofibrate, simfibrate, clinofibrate) , ACAT inhibitors (e.g., pravastat
  • soysterol e.g., soysterol, ⁇ -oryzanol
  • ⁇ -oryzanol e.g., soysterol, ⁇ -oryzanol
  • antihypertensive agents examples include angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, delapril), angiotensin II antagonists (e.g., candesartan cilexetil, losartan, eprosartan, valsartan, telmisartan, irbesartan, tasosartan, 1- [ [2' - (2, 5-dihydro-5- oxo-4H-l,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-2-ethoxy-lH- benzimidazole-7-carboxylic acid), calcium antagonists (e.g., manidipine, nifedipine, amlodipine, efonidipine, nicardipine) , potassium channel openers (e.g., levcromakalim, L-27152, AL 0671, NIP-
  • antiobesity agents examples include antiobesity agents acting on the central nervous system (e.g., dexfenfluramine, fenfluramine, phentermine, sibutramine, amfepramone, dexamphetamine, mazindol, phenylpropanolamine, clobenzorex; MCH receptor antagonists (e.g., SB-568849; SNAP- 7941; compounds described in WO01/82925 and WO01/87834) ; neuropeptide Y antagonists (e.g., CP-422935) ; cannabinoid receptor antagonists (e.g., SR-141716, SR-147778); ghrelin antagonists), pancreatic lipase inhibitors (e.g., orlistat,
  • MCH receptor antagonists e.g., SB-568849; SNAP- 7941; compounds described in WO01/82925 and WO01/87834
  • ATL-962 ATL-962
  • ⁇ 3 agonists e.g., AJ-9677
  • peptide anorexiants e.g., leptin, CNTF (Ciliary Neurotropic Factor)
  • cholecystokinin agonists e.g., lintitript, FPL-15849
  • feeding deterrents e.g., P-57
  • P-57 feeding deterrents
  • diuretics examples include xanthine derivatives (e.g., sodium salicylate and theobromine, calcium salicylate and theobromine), thiazide preparations (e.g., ethiazide, cyclopenthiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penflutizide, polythiazide, methyclothiazide) , antialdosterone preparations (e.g., spironolactone, triamterene), carbonate dehydratase inhibitors (e.g., acetazolamide) , chlorobenzenesulfonamide preparations (e.g., chlortalidone, mefruside, indapamide) , azosemide, isosorbide, etacrynic acid, piretanide, bumetanide, furose
  • chemotherapeutic agents examples include alkylating agents (e.g., cyclophosphamide, ifosfamide), metabolic antagonists (e.g., methotrexate, 5-fluorouracil and derivatives thereof), antitumor antibiotics (e.g., mitomycin, adriamycin) , plant-derived antitumor agents (e.g., vincristine, vindesine, Taxol) , cisplatin, carboplatin, etoposide and the like.
  • alkylating agents e.g., cyclophosphamide, ifosfamide
  • metabolic antagonists e.g., methotrexate, 5-fluorouracil and derivatives thereof
  • antitumor antibiotics e.g., mitomycin, adriamycin
  • plant-derived antitumor agents e.g., vincristine, vindesine, Taxol
  • cisplatin carbop
  • immunotherapeutic agents examples include microorganism or bacterial components (e.g., muramyl dipeptide derivatives, Picibanil), polysaccharides having immunity potentiating activity (e.g., lentinan, schizophyllan, krestin) , cytokines obtained by genetic engineering techniques (e.g., interferon, interleukin (IL) ) , colony stimulating factors
  • microorganism or bacterial components e.g., muramyl dipeptide derivatives, Picibanil
  • polysaccharides having immunity potentiating activity e.g., lentinan, schizophyllan, krestin
  • cytokines obtained by genetic engineering techniques (e.g., interferon, interleukin (IL) )
  • colony stimulating factors e.g., interferon, interleukin (IL)
  • granulocyte colony stimulating factor erythropoietin
  • interleukins such as IL-I, IL-2, IL-12 and the like.
  • antithrombotic agents examples include heparin (e.g., heparin sodium, heparin calcium, dalteparin sodium), warfarins (e.g., warfarin potassium), anti-thrombin drugs (e.g., aragatroban) , thrombolytic agents (e.g., urokinase, tisokinase,reteplase, nateplase, monteplase, pamiteplase) , platelet aggregation inhibitors (e.g., ticlopidine hydrochloride, cilostazol, ethyl icosapentate, beraprost sodium, sarpogrelate hydrochloride) and the like.
  • heparin e.g., heparin sodium, heparin calcium, dalteparin sodium
  • warfarins e.g., warfarin potassium
  • anti-thrombin drugs e.g., ara
  • Examples of the therapeutic agents for osteoporosis include alfacalcidol, calcitriol, elcatonin, calcitonin salmon, estriol, ipriflavone, risedronate disodium, pamidronate disodium, alendronate sodium hydrate, reminderonate disodium and the like.
  • antidementia agents examples include tacrine, donepezil, rivastigmine, galanthamine and the like.
  • erectile dysfunction improvers examples include apomorphine, sildenafil citrate and the like.
  • Examples of the therapeutic agents for pollakiuria or urinary incontinence include flavoxate hydrochloride, oxybutynin hydrochloride, propiverine hydrochloride and the like.
  • Examples of the therapeutic agents for dysuria include acetylcholine esterase inhibitors (e.g., distigmine) and the like.
  • drugs having a cachexia-improving action established in animal models and clinical situations such as "cyclooxygenase inhibitors (e.g., indomethacin) , progesterone derivatives (e.g., megestrol acetate), glucosteroids (e.g., dexamethasone) , metoclopramide agents, tetrahydrocannabinol agents, fat metabolism improving agents (e.g., eicosapentanoic acid), growth hormones, IGF-I, or antibodies to a cachexia- inducing factor such as TNF- ⁇ , LIF, IL-6, oncostatin M and the like, can be used in combination with the compound of the present invention.
  • cyclooxygenase inhibitors e.g., indomethacin
  • progesterone derivatives e.g., megestrol acetate
  • glucosteroids e.g., dexamethasone
  • the combination drug is preferably insulin preparation, insulin sensitizer, ⁇ -glucosidase inhibitor, biguanide, insulin secretagogue (preferably sulfonylurea) and the like.
  • Two or more kinds of the above-mentioned combination drugs may be used in an appropriate combination.
  • the amount thereof can be reduced within a safe range in consideration of counteraction of these agents.
  • the dose of an insulin sensitizer, an insulin secretagogue (preferably a sulfonylurea) and a biguanide can be reduced as compared with the normal dose. Therefore, an adverse effect which may be caused by these agents can be prevented safely.
  • the dose of the therapeutic agent for diabetic complications, therapeutic agent for hyperlipidemia and antihypertensive agent can be reduced whereby an adverse effect which may be caused by these agents can be prevented effectively.
  • compound (I) can be produced by reacting compound (II) with compound (III) or a reactive derivative thereof.
  • reactive derivative of compound (III) for example, a reactive derivative generally used such as a sulfonyl halide, a sulfonic anhydride, N-sulfonylimidazolide and the like can be mentioned, and a sulfonyl halide is particularly preferable.
  • This reaction can be carried out in the presence of a base.
  • a base for example, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; alkaline earth metal hydroxides such as magnesium hydroxide, calcium hydroxide and the like; alkali metal carbonates such as sodium carbonate,, potassium carbonate and the like; alkali metal hydrogencarbonates such as sodium hydrogencarbonate, potassium hydrogencarbonate and the like; alkali metal Ci-6 alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like; organic bases such as trimethylamine, triethylamine, diisopropylethylamine, pyridine, picoline, N-methylpyrrolidine, N-methylmorpholine, 1, 5-diazabicyclo [4.3.0] -5-nonene, 1, 4- diazabicyclo[2.2.2] octane, 1, 8-diazabicyclo [5.4.0]-7-
  • This reaction is preferably carried out in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, tert-butylalcohol and the like; ethers such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert- butyl methyl ether, diisopropyl ether, 1, 2-dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, trichloroethylene and the like; hydrocarbons such as n-hexane, benzene, toluene and the like; amides such as formamide, N,
  • the amount of compound (III) or a reactive derivative thereof to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (II) .
  • the amount of the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (III) or a reactive derivative thereof.
  • the reaction temperature is generally -30°C to 100 0 C.
  • the reaction time is generally 0.5 _ to 20 hr.
  • Ci-e alkyl group for R 15 or R 15 ' , those similar to the “optionally substituted Ci-6 alkyl group” for R 4 or R 5 can be mentioned, and methyl group and ethyl group are preferable.
  • substituents those exemplified as the substituents which the C 3 - I0 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group” for R ⁇ , R 7 , R 21 or R 22 optionally has, can be mentioned.
  • the "optionally substituted C 6 - 14 aryl group” is preferably a phenyl group or a 4-methoxyphenyl group.
  • a halogen atom for example, a halogen atom; an optionally halogenated Ci- 6 alkylsulfonyloxy group (e.g., methanesulfonyloxy, ethanesulfonyloxy, trichloromethanesulfonyloxy, trifluoromethanesulfonyloxy) ; a C ⁇ -io arylsulfonyloxy group optionally substituted by 1 to 3 substituents selected from a Ci- ⁇ alkyl group, a Ci_6 alkoxy group and a nitro group (e.g., phenylsulfonyloxy, m- nitrophenylsulfonyloxy, p-toluenesulfonyloxy) ; a Ci- 6 alkoxysulfonyloxy group; a C 6 -io aryloxysulfonyloxy group; a Ci_
  • Compound (I-A) can be produced ' by reacting compound (IV) with compound (V) in the presence of a base.
  • the amount of compound (V) to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (IV) .
  • This reaction is preferably carried out in a solvent inert to the reaction.
  • a solvent inert those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned.
  • the amount of the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (IV) .
  • reaction temperature is generally -100°C to 100°C.
  • reaction time is generally 0.5 to 20 hr.
  • Compound (I-B) can be produced from compound (VI) according to methods described in Angew. Chei ⁇ ., Int. Ed., 2003, vol. 42, page 83, Tetrahedron, 1999, vol. 55, page 10271, and the like.
  • compound (VI) is reacted with triphenylphosphine oxide and trifluoromethanesulfonic anhydride or phosphorus pentachloride.
  • This reaction is carried out without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; nitriles such as acetonitrile, propionitrile and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
  • the amount of the triphenylpho ' sphine oxide and trifluoromethanesulfonic anhydride or phosphorus pentachloride to be used is generally 1 to 10 mol, preferably 1 to 6 mol, per 1 mol of compound (VI) , respectively.
  • the reaction temperature is generally -70°C to 100°C.
  • the reaction time is generally 0.5 to 20 hr.
  • Compound (VIII) can be produced by subjecting compound (VII) to a reduction reaction.
  • the reduction reaction is carried out, for example, using a reducing agent.
  • a reducing agent for example, metal hydrides such as aluminum hydride, diisobutylaluminum hydride, tributyltin hydride and the like; metal hydrogen complex compounds such as lithium aluminum hydride, sodium borohydride and the like; borane complexes such as borane-tetrahydrofuran complex, borane-dimethylsulfide complex and the like; alkylboranes such as thexylborane, disiamylborane and the like; diborane; metals such as zinc, aluminum, tin, iron and the like; alkali metal (e.g., sodium, lithium etc.) /liquid ammonia (Birch reduction) and the.
  • metal hydrides such as aluminum hydride, diisobutylaluminum hydride, tributyltin hydride and the like
  • metal hydrogen complex compounds such as lithium aluminum
  • the amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent.
  • the amount of the metal hydride or metal hydrogen complex compound to be used is generally about 0.25 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (VII)
  • the amount of the borane complex, alkylborane or diborane to be used is generally about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (VII)
  • the amount of the metal (containing alkali metal used for Birch reduction) to be used is generally about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 equivalent of compound (VII) .
  • the reduction reaction is preferably carried out in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1- propanol, 2-propanol, terf-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N- dimethylacetamide, hexamethylphosphoramide and the like; organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, methanesulfonic acid and the like,
  • reaction time varies depending on the kind and amount of the reducing agent to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
  • Compound (IV) can be produced by converting the hydroxy group of compound (VIII) to a leaving group for L 1 according to a method known per se.
  • Compound (VI) can be produced by reacting compound (IX) or a reactive derivative of the carboxy group or a salt thereof with compound (X) .
  • a mixed acid anhydride with an acid e.g., substituted phosphates such as dialkylphosphate, phenylphosphate, diphenylphosphate, dibenzylphosphate, halogenated phosphate and the like; dialkylphosphorous acid; sulfurous acid; thiosulfuric acid; sulfuric acid; sulfonic acids such as methanesulfonic acid and the like; aliphatic carboxylic acids such as formic acid, acetic acid, ' propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, trichloroacetic acid and the like; aromatic carboxylic acids such as benzoic acid and the like) ;
  • substituted phosphates such as dialkylphosphate, phenylphosphate, diphenylphosphate, dibenzylphosphate, halogenated phosphate and the like
  • dialkylphosphorous acid sulfurous acid
  • an activated ester such as cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl ester, vinyl ester, propargyl ester, p-nitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenylthioester, p-nitrophenyl ester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolylthio ester and the like; 7) a ester with a N-hydroxy compound (e.g., N, N- dimethylhydroxyamine, l-hydroxy-2- (IH) -pyridone, N- hydroxysuccinir ⁇ ide, N-hydroxyphthalimide 7 1-hydroxy-lH- benzotriazole) ; and the like can be
  • salts with a base such as alkali metal salts (e.g., sodium salt, potassium salt and the like), alkaline earth metal salts (e.g., calcium salt, magnesium salt and the like) , ammonium salts, organic base salts (e.g. , trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N 7 N- dibenzylethylenediamine salt and the like) and the like can be mentioned.
  • alkali metal salts e.g., sodium salt, potassium salt and the like
  • alkaline earth metal salts e.g., calcium salt, magnesium salt and the like
  • ammonium salts e.g., organic base salts (e.g. , trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N 7 N- dibenzylethylenediamine salt and the like) and the like
  • This reaction is preferably carried out in a solvent inert to the reaction.
  • a solvent inert those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned.
  • reaction when compound (IX) is used in the form of a free acid or a salt thereof, the reaction is preferably carried out in the presence of a conventional condensing agent such as a carbodiimide (e.g., N,N' -dicyclohexylcarbodiimide, N-cyclohexyl-N' -morpholinoethylcarbodiimide, N-cyclohexyl-N' - (4-diethylaminocyclohexyl) carbodiimide, N,N' - diethylcarbodiimide, N 7 N' -diisopropylcarbodiimide, N-ethyl-N'- (3-dimethylaminopropyl) carbodiimide and the like), N 7 N'- carbonylbis (2-methylimidazole) , a trialkyl phosphate, a polyphosphate (e.g., ethyl polyphosphate, iso
  • This reaction can be carried out in the presence of a base, as necessary.
  • a base those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned.
  • the amount of compound (X) to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (IX) .
  • the amount of the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (IX) .
  • the reaction temperature is generally -30°C to 100°C.
  • the reaction time is generally 0.5 to 20 hr.
  • compound (IX) When an mixed acid anhydride is used as a reactive derivative of compound (IX) , compound (IX) can be reacted with a chloroformate (e.g., methyl chloroformate, ethyl chloroformate, isobutyl chloroformate) in the presence of a base (e.g., triethylamine, N-methylmorpholine, N, N- dimethylaniline, sodium hydrogencarbonate, sodium carbonate, potassium carbonate) , and then reacted with compound (X) .
  • a chloroformate e.g., methyl chloroformate, ethyl chloroformate, isobutyl chloroformate
  • a base e.g., triethylamine, N-methylmorpholine, N, N- dimethylaniline, sodium hydrogencarbonate, sodium carbonate, potassium carbonate
  • This reaction is preferably carried out in a solvent inert to the reaction.
  • solvent such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether, 1,2- dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1,2- dichloroethane, carbon tetrachloride, trichloroethylene and the like; hydrocarbons such as n-hexane, benzene, toluene and the like; amides such as formamide, N,N-dimethylformamide, N, N-dimethylacetamide and the like; nitriles such as.
  • the amount of compound (X) to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (IX) .
  • the reaction temperature is generally -30°C to 100°C.
  • the reaction time is generally 0.5 to 20 hr.
  • R 17 is a C X - 6 alkyl group
  • L 2 is a leaving group
  • P 1 is a hydrogen atom or a protecting group
  • protecting group for P 1 , for example, a formyl group; a Ci-6 alkyl-carbonyl group, a phenylcarbonyl group, a Ci- 6 alkoxy-carbonyl group, an allyloxycarbonyl group, a phenyloxycarbonyl group, a fluorenylmethyloxycarbonyl group, a C 7 -io aralkyl-carbonyl group (e.g., benzylcarbonyl) , a C7- 1 0 aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl) , a C7-20 aralkyl group (e.g., benzyl, trityl) and a methoxymethyl group, each of which has optionally substituent (s) , and the like can be mentioned.
  • substituents for example, a phenyl group, a halogen atom, a Ci-6 alkyl-carbonyl group, a Ci_ 6 alkoxy group optionally substituted by halogen atom(s), a nitro group and the like can be mentioned.
  • the number of the substituents is 1 to 3.
  • Compound (XI) can be produced by reacting compound (IX-A) or a reactive derivative of the carboxy group or a salt thereof with ammonia or a salt thereof.
  • salt of compound (IX-A) or a reactive derivative of the carboxy group those exemplified as the preferable salt of compound (IX) or a reactive derivative of the carboxy group in Scheme 3 can be mentioned.
  • ammonia or a salt thereof aqueous ammonia, ammonium acetate, ammonium choloride and the like can be mentioned.
  • the protecting gro ⁇ p can be removed according to a conventional deprotection such as an acid treatment, an alkali treatment, a catalytic reduction and the like, as necessary.
  • Compound (XII) wherein P 1 is a hydrogen atom can be produced by reacting compound (XI) with diphosphorus pentasulfide or a Lawesson's reagent.
  • This reaction is carried out without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
  • the amount of the diphosphorus pentasulfide or Lawesson' s reagent to be used is generally 0.5 to 10 r ⁇ ol, preferably 0.5 to 3 mol, per 1 mol of compound (XI) .
  • the reaction temperature is generally -30°C to 200°C.
  • the reaction time ' is generally 0.5 to 20 hr.
  • Compound (VII-A) can be produced by reacting compound (XII) with compound (XIII) .
  • This reaction is carried out in the presence of a acid catalyst or a base, as necessary.
  • the acid catalyst for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; Lewis acids such as a boron trihalide (e.g., boron trichloride, boron trifluoride) , a titanium tetrahalide (e.g., titanium tetrachloride, titanium tetrabromide) , an aluminum halide (e.g., aluminum chloride, aluminum bromide) and the like; organic acids such as acetic acid, formic acid, trifluoroacetic acid and the like, and the like can be mentioned.
  • boron trihalide e.g., boron trichloride, boron trifluoride
  • titanium tetrahalide e.g., titanium tetrachloride, titanium tetrabromide
  • aluminum halide e.g., aluminum chloride, aluminum bromide
  • organic acids such as acetic acid, formic acid, trifluoroacetic acid
  • organic bases such as triethylamine, pyridine, 4-dimethylaminopyridine, diisopropylethylamine and the like
  • inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and the like, and the like can be mentioned.
  • This reaction is carried out without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated ' hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoramide and the like, and the like can be mentioned.
  • the amount of compound (XIII) and the acid catalyst to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XII) , respectively.
  • reaction time varies depending on the kind and amount of compound (XII), compound (XIII) and the acid catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
  • the amount of the compound (XIII) and the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XII) , respectively.
  • reaction time varies depending on the kind and amount of compound (XII), compound (XIII) and the base to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120 0 C, preferably about 0 to about 80°C.
  • Compound (XIII) can be produced according to a method known per se.
  • Compound (XV) can be produced by reacting compound (IX) or a reactive derivative of the carboxy group or a salt thereof with compound (XIV) .
  • Compound (XV) can also be produced from compound (IX) or a reactive derivative of the carboxy group or a salt thereof in two steps.
  • compound (XVI) can be produced by reacting compound (IX) or a reactive derivative of the carboxy group or a salt thereof with hydrazine.
  • compound (XV) can be produced by reacting compound (XVI) with compound (XVII) .
  • This reaction can be carried out in the presence of a base, as necessary.
  • a base for example, organic bases such as triethylamine, pyridine, 4-dimethylaminopyridine, diisopropylethylamine and the like; inorganic bases such' as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and the like, and the like can be mentioned.
  • the amount of compound (XVII) and the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 r ⁇ ol of compound (XVI) , respectively.
  • the reaction temperature is generally -30°C to 200°C.
  • the reaction time is generally 0.5 to 20 hr.
  • Compound (VII-B) can be produced by reacting compound (XV) with diphosphorus pentasulfide or a Lawesson' s reagent. This reaction is carried out without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like, and the like can be mentioned. These -solvents may be used in a mixture at an appropriate ratio .
  • the amount of the diphosphorus pentasulfide or Lawesson' s reagent to be used is generally 0.5 to 10 mol, preferably 0.5 to 3 mol, per 1 mol of compound (XV) .
  • the reaction temperature is generally -30 0 C to 200°C.
  • the reaction time is generally 0.5 to 20 hr.
  • Compound (XIX) can be produced by reacting compound (XVIII) with compound (III) or a reactive derivative thereof.
  • Compound (IX-A) can be produced by subjecting compound (XIX) to a hydrolysis.
  • the hydrolysis is carried out using an acid or a base according to a conventional method.
  • the acid for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; Lewis acids such as boron trichloride, boron tribromide and the like; organic acids such as trifluoroacetic acid, p-toluenesulfonic acid and the like, and the like can be mentioned.
  • the Lewis acid can be used together with a thiol or a sulfide.
  • alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide and the like
  • alkali metal carbonates such as sodium carbonate, potassium carbonate and the like
  • alkali metal Ci_ 6 alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like
  • organic bases such as triethylamine, imidazole, formamidine and the like, and the like can be mentioned.
  • the amount of the acid or base to be used is generally about 0.5 to 10 mol, preferably about 0.5 to 6 mol, per 1 mol of compound (XIX) .
  • the hydrolysis is carried out without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, propanol and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; organic acids such as formic acid, acetic acid and the like; ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane and the like; nitriles such as acetonitrile, propionitrile and the like; ketones such as acetone, methyl ethyl ketone and the like; sulfoxides
  • the reaction time is generally 10 min to 60 hr, preferably 10 min to 12 hr.
  • the reaction temperature is generally -10 to 200°C, preferably 0 to 120°C.
  • the protecting group can be removed according to a conventional deprotection such as an acid treatment, an alkali treatment, a catalytic reduction and the like, as necessary.
  • Compound (XVIII) can be produced, for example, according to the following method.
  • E is a nitro group, an optionally protected amino group or an optionally protected hydroxy group
  • H-X is a mineral acid such as hydrochloric acid, sulfuric acid and the like; or a organic acid such as acetic acid, formic acid, trifluoroacetic acid and the like, and the other symbols are as defined above.
  • amino-protecting group for example, a formyl group; a C ⁇ -6 alkyl-carbonyl group, a phenylcarbonyl group, a Ci_ 6 alkoxy- carbonyl group, an allyloxycarbonyl group, a phenyloxycarbonyl group, a fluorenylmethyloxycarbonyl group, a C7-10 aralkyl- carbonyl group (e.g., benzylcarbonyl) , a C 7 _ 10 aralkyloxy- carbonyl group (e.g., benzyloxycarbonyl) , a C 7 _2o aralkyl group (e.g., benzyl, .
  • substituents for example, a phenyl group, a halogen atom, a Ci- ⁇ alkyl-carbonyl group, a C ⁇ - ⁇ alkoxy group optionally substituted by halogen atom(s) , a nitro group and the like can be mentioned.
  • the number of the substituents is 1 to 3.
  • hydroxy-protecting group for example, a Ci_ 6 alkyl group, a C 7 - 2 o aralkyl group (e.g., benzyl, trityl), a formyl group, a Ci-6 alkyl-carbonyl group, a benzoyl group, a C 7 _io aralkyl-carbonyl group (e.g., benzylcarbonyl), a 2-tetrahydropyranyl group, a tetrahydrofuranyl group and a trialkylsilyl group (e.g., trimethylsilyl, tert-butyldimethylsilyl, diisopropylethylsilyl) , each of which optionally has substituent (s) , and the like can be mentioned.
  • a Ci_ 6 alkyl group e.g., benzyl, trityl
  • a formyl group e.g., benzyl,
  • substituents for example, a halogen atom, a Ci-6 alkyl group, a phenyl group, a C7- 1 0 aralkyl group (e.g., benzyl etc.), a Ci-s alkoxy group, a nitro group and the like can be mentioned.
  • the number of the substituents is 1 to 4.
  • Compound (XXII) can be produced by reacting compound (XX) with compound (XXI) .
  • This reaction is carried out without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, tert-butylalcohol and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoramide and the like, and the like can be mentioned.
  • the reaction can generally be promoted using an acid catalyst.
  • the acid catalyst for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; Lewis acids such as a boron trihalide (e.g., boron trichloride, boron trifluoride) , a titanium tetrahalide (e.g., titanium tetrachloride, titanium tetrabromide) , an aluminum halide (e.g., aluminum chloride, aluminum bromide) and the like; organic acids such as acetic acid, formic acid, trifluoroacetic acid and the like, and the like can be mentioned.
  • mineral acids such as hydrochloric acid, sulfuric acid and the like
  • Lewis acids such as a boron trihalide (e.g., boron trichloride, boron trifluoride) , a titanium tetrahalide (e.g., titanium tetrachloride, titanium tetrabromide)
  • the amount of compound (XXI) and the acid catalyst to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XX) , respectively.
  • reaction time varies depending on the kind and amount of compound (XX) , compound (XXI) and the acid catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 8O 0 C.
  • Compound (XXII) can also be produced by subjecting compound (XXIII) to the Japp-Klingemann reaction [Org. Reactions, 1959, vol. 10, page 143; J. Chem. Soc, 1927, page 1] .
  • compound (XXIV) which is produced using compound (XXIII) , an acid (H-X) and sodium nitrite according to a method known per se, is reacted with compound (XXV) in the presence of a base.
  • a base for example, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; alkaline earth metal hydroxides such as magnesium hydroxide, calcium hydroxide and the like; alkali metal carbonates such as sodium carbonate, potassium carbonate and the like; alkali metal hydrogencarbonates such as sodium hydrogencarbonate, potassium hydrogencarbonate and the like; organic bases such as trimethylamine, triethylamine, diisopropylethylamine, pyridine, picoline, N-methylpyrrolidine, N-methylmorpholine, 1, 5-diazabicyclo [4.3.0] -5-nonene, 1,4- diazabicyclo[2.2.2] octane, 1, 8-diaza
  • This reaction is preferably carried out in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, tert-butylalcohol and the like; ethers such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert- butyl methyl ether, diisopropyl ether, 1, 2-dimethoxyethane and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, trichloroethylene and the like; hydrocarbons such as n-hexane, benzene, toluene and the like; amides such as formamide, N,N-dimethylformamide, N, N- dimethylacetamide and the like; nitriles such as acetonitrile
  • the amount of compound (XXV) to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXIV) .
  • the amount of the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per ' 1 mol of compound (XXIV) .
  • the reaction time is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
  • Compound (XVIII-A) can be produced by subjecting compound (XXII) to the Fischer method [Berichte, 1883, vol. 16, page 2241] . In this reaction, compound (XXII) is reacted with an acidic catalyst under heating.
  • the acidic catalyst for example, zinc chloride (without a solvent or in a solvent such as naphthalene, ethanol and the like) , hydrogen chloride/ethanol, sulfuric acid/ethanol, concentrated sulfuric acid, hydrogen chloride/acetic acid, acetic acid, boron fluoride, polyphosphoric acid, methanesulfonic acid, phosphorous pentoxide and the like can be mentioned.
  • These acidic catalysts may be used in ' a mixture at an appropriate ratio.
  • the amount of the acidic catalyst to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXII) . While the reaction time varies depending on the kind and amount of the acidic catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about 0 to about
  • Compound (XVIII-A) can also be produced by subjecting compound (XXVI) to the Reissert method [Berichte, 1897, vol.
  • compound (XXVIII) can be produced by reacting compound (XXVI) with compound (XXVII) in the presence of a base.
  • compound (XVIII-A) can be produced by subjecting compound (XXVIII) to a reduction reaction.
  • alkali metal Ci- S alkoxides such as sodium methoxide, sodium ethoxide, potassium ethoxide, potassium tert-butoxide and the like, and the like can be mentioned.
  • the amount of compound (XXVII) and the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXVI), respectively.
  • the reaction temperature is generally -30°C to 100 0 C.
  • the reaction time is generally 0.5 to 20 hr.
  • the reduction reaction in the second step is carried out, for example, using a reducing agent.
  • a reducing agent for example, metals such as iron, zinc, tin and the like; sulfides such as sodium dithionite and the like; and the like can be mentioned.
  • the amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent.
  • the amount of the metal to be used is generally about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 equivalent of compound (XXVIII)
  • the amount of the sulfide to be used is generally about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 equivalent of compound (XXVIII).
  • the reduction reaction can also be carried out by a hydrogenation reaction.
  • catalysts such as palladium carbon, palladium black, platinum dioxide, Raney-nickel, Raney-cobalt, iron trichloride and the like can be used.
  • the amount of the catalyst to be used is generally about 5 to 1000 wt%, preferably about 10 to 300 wt%, relative ' to compound (XXVIII) .
  • the hydrogenation reaction can also be carried out using various hydrogen sources instead of hydrogen gas.
  • hydrogen source for example, formic acid, ammonium formate, triethylammonium formate, sodium phosphinate, hydrazine and the like can be mentioned.
  • the amount of the hydrogen source to be used is generally about 1 to 100 mol, preferably about 1 to 5 mol, per 1 mol of compound (XXVIII) .
  • the reduction reaction is preferably carried out in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1- propanol, 2-propanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N, N- dimethylacetamide, hexamethylphosphoramide and
  • reaction time varies depending on the kind and amount of the reducing agent to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
  • Compound (XVIII-B) can be produced by subjecting compound (XVIII-A) to a protection reaction known per se, as necessary.
  • Compound (XVIII) can be produced by subjecting compound (XVIII-B) wherein E is a protected amino group or a protected hydroxy group to a conventional deprotection reaction such as an acid treatment, an alkali treatment, a catalytic reduction and the like, as necessary.
  • Compound (XVIII) wherein W is an amino group can be produced by subjecting compound (XVIII-B) wherein E is a nitro group to a reduction reaction.
  • the reduction reaction is carried out, for example, using a reducing agent.
  • a reducing agent for example, metals such as iron, zinc, tin and the like; sulfides such as sodium dithionite and the like can be mentioned.
  • the amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent.
  • the amount of the metal to be used is generally about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 equivalent of compound (XVIII-B)
  • the amount of the sulfide to be used is generally about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 equivalent of compound (XVIII-B) .
  • the reduction reaction can also be carried out by a hydrogenation reaction.
  • catalysts such as palladium carbon, palladium black, platinum dioxide, Raney-nickel, Raney-cobalt, iron trichloride and the like can be used.
  • the amount of the catalyst to be used is generally about 5 to 1000 wt%, preferably about 10 to 300 wt%, per 1 mol of compound (XVIII-B) .
  • the hydrogenation reaction can also be carried out using various hydrogen sources instead of hydrogen gas.
  • hydrogen source for example, formic acid, ammonium formate, triethylammonium formate, sodium phosphinate, hydrazine and the like can be mentioned.
  • the amount of the hydrogen source to be used is generally about 1 to 10 mol, preferably about 1 to 5 mol, per 1 mol of compound (XVIII-B) .
  • This reaction is preferably carried out in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, tert-butylalcohol and the like; ethers such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert- butyl methyl ether, diisopropyl ether, 1, 2-dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; hydrocarbons such as n-hexane, benzene, toluene and the like; amides such as formamide, N, N- dimethylformamide, N,N-dimethylacetamide and the like; organic acids such as formic acid, acetic acid, propionic acid
  • reaction time varies depending on the kind and amount of the reducing agent to be used and the activity and amount of the catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
  • Compound (XXXVI) can be produced from compound (XXXIV) according to a known method [J. Org. Chem. Soc, 1963, vol. 28, page 1240; Tetrahedron, 2003, vol. 59, page 4979].
  • This reaction is carried out without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoramide and the like; nitriles such as acetonitrile, propionitrile and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1,2- dichloroethane, carbon tetrachloride, trichloroethylene and the like, and the like can
  • amines such as pyrrolidine, piperazine, morpholine, ethylenediamine and the like, and the like can be mentioned.
  • the amount of the base to be used is generally 0.01 to 10 mol, preferably 0.05 to 2 mol, per 1 mol of compound (XXXIV) .
  • the amount of compound (XXXV) to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXXIV) .
  • the amount of the nitromethane to be used is generally 1 to 50 mol, preferably 1 to 10 mol, per 1 mol of compound (XXXIV) .
  • reaction time varies depending on the kind and amount of compound (XXXIV) , compound (XXXV) , the nitromethane and base to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about 0 to about 200°C, preferably about 25 to about 100°C.
  • Compound (XXXVI) can also be produced from compound (XXXIV) in three steps.
  • compound (XXXVII) can be produced by subjecting compound (XXXIV) and nitromethane to the Henry reaction [J. Org. Chem. Soc, 1963, vol. 28, page 1240; Synthesis, 1994, page 190; J. Am. Chem. Soc, 2003, vol. 125, page 3700] in the presence of a base. This reaction is carried out without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N, N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoramide and the like; nitriles such as acetonitrile, propionitrile and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1,2- dichloroethane, carbon tetrachloride, trichloroethylene and the like,
  • alkali metal Ci_ 6 alkoxides such as sodium methoxide, sodium ethoxide, potassium ethoxide, potassium tert-butoxide and the like, and the like can be mentioned.
  • the amount of the base to be used is generally 0.01 to 10 mol, preferably 0.05 to 2 mol, per 1 mol of compound (XXXIV) .
  • the amount of the nitromethane to be used is generally 1 to 50 mol, preferably 1 to 10 mol, per 1 mol of compound (XXXIV) . While the reaction time varies depending on the kind and amount of compound (XXXIV) , the nitromethane and base to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about 0 to about 200 0 C, preferably about 25 to about 100°C.
  • compound (XXXVIII) can be produced by subjecting compound (XXXVII) to a dehydration reaction.
  • This reaction is carried out without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N, N-dimethylformamide, N,N-dimethylacetam.ide, hexamethylphosphoramide and the like; nitriles such as acetonitrile, propionitrile and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1,2- . dichloroethane, carbon tetrachloride, trichloroethylene and the like;
  • the dehydration reaction is generally carried out using a dehydrating agent.
  • a dehydrating agent chlorinating agents such as thionyl chloride, phosphoryl chloride and the like; sulfonylating agents such as methanesulfonyl chloride, methanesulfonic anhydride and the like; acylating agents such as acetyl chloride, acetic anhydride, trifluoroacetic anhydride and the like, and the like can be mentioned.
  • the amount of the dehydrating agent to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXXVII) .
  • This reaction can be carried out in the presence of a base, as necessary.
  • a base those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned.
  • the amount of the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXXVII) .
  • the reaction temperature is generally -30°C to 200°C.
  • the reaction time is generally 0.5 to 20 hr.
  • compound (XXXVI) can be produced by reacting compound (XXXVIII) with compound (XXXV) in the presence of a base.
  • This reaction is carried out without a solvent or in a solvent inert to the reaction.
  • a solvent those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned.
  • the base to be used in this reaction those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned.
  • the amount of compound (XXXV) to be used is generally 1 to 10 mol, preferably 1 to 2 mol, per 1 mol of compound (XXXVIII) .
  • the amount of the base to be used is generally 0.05 to 10 mol, preferably 0.1 to 3 mol, per 1 mol of compound (XXXVIII) .
  • the reaction temperature is generally -30°C to 100 0 C.
  • the reaction time is generally 0.5 to 20 hr.
  • Compound (X-I) can be produced by subjecting compound (XXXVI) to a reduction reaction.
  • the reduction reaction is carried out, for example, using a reducing agent.
  • a reducing agent for example, metal hydrides such as aluminum hydride, diisobutylaluminum hydride, tributyltin hydride and the like; metal hydrogen complex compounds such as lithium aluminum hydride, sodium borohydride and the like; borane complexes such as borane-tetrahydrofuran complex, borane-dimethylsulfide complex and the like; alkylboranes such as thexylborane, disiamylborane and the like; diborane; metals such as zinc, aluminum, tin, iron and the like, and the like can be mentioned.
  • the amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent.
  • the amount of the metal hydride or metal hydrogen complex compound to be used is generally about 0.25 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (XXXVI), and the amount of the borane complex, alkylborane or diborane to be used , is generally about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (XXXVI) .
  • the reduction reaction is preferably carried out in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1- propanol, 2-propanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N- dimethylacetamide, hexamethylphosphoramide and the like; organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, methanesulfonic acid and the like,
  • reaction time varies depending on the kind and amount of the reducing agent to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
  • Compound (X) can be produced by reacting compound (XXXIX) with compound (XL) in the presence of an acid catalyst or a base, as necessary.
  • the acid catalyst for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; organic acids such as acetic acid, formic acid, trifluoroacetic acid and the like, and the like can be mentioned.
  • organic bases such as triethylamine, pyridine, 4-dimethylaminopyridine, diisopropylethylamine and the like; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and the like, and the like can be mentioned.
  • This reaction is carried out without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1,2-dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N, N- dimethylacetamide, hexamethylphosphoramide and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
  • the amount of the compound (XL) and the acid catalyst to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXXIX) , respectively.
  • reaction time varies depending on the kind and amount of compound (XXXIX) , compound (XL) and the acid catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
  • the amount of compound (XL) and the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXXIX) , respectively.
  • reaction time varies depending on the kind and amount of compound (XXXIX) , compound (XL) and the base to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr/
  • the reaction temperature is generally about -20 to about 120°C, preferably about 0 to about
  • the amount of compound (XLII) to be used is generally 0.1 to 10 mol, preferably 0.1 to 2 mol, per 1 mol of compound
  • reaction temperature is generally -30°C to 200°C.
  • the reaction time is generally 0.5 to 20 hr.
  • R 32 is a hydrogen atom, an optionally substituted hydroxy group, an optionally mono- or di-substituted amino group, an optionally substituted acyl group, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, X and R 32 in combination optionally form an optionally substituted ring, R 33 and R 34 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally mono- or di-substituted amino group or an optionally substituted acyl group, R 33 and R 34 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally mono- or di-substituted amino group or an optionally substituted acyl group, R 33 and R 34
  • metal hydrides such as aluminum hydride, diisobutylaluminum hydride, tributyltin hydride and the like
  • metal hydrogen complex compounds such as lithium aluminum hydride, sodium borohydride, lithium borohydride, calcium borohydride and the like
  • borane complexes such as borane- tetrahydrofuran complex, borane-dimethylsulfide complex and the like
  • alkylboranes such as thexylborane, disiamylborane and the like; diborane and the like can be mentioned.
  • the amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent.
  • the amount of the metal hydride or metal hydrogen complex compound to be used is about 0.25 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (I-Bl), and the amount of the borane complex, alkylborane or diborane to be used is about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (I- Bl) .
  • the reduction reaction is advantageously carried out using a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1-propanol, 2-propanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N- dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoric triamide and the like; organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, r ⁇ ethanesulfonic acid and the like, and the like can be mentioned. These solvents may be used in
  • reaction time varies depending on the kind and amount of the reducing agent to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120 0 C, preferably about 0 to about 80°C.
  • Compound (I-B3) can be produced by subjecting compound (I-B2) to a substituent-conversion reaction known per se.
  • compound (I-B3) can be produced by introducing the leaving group for L 1 to compound (I-B2) according to the method shown in Scheme 3, and by subjecting the resulting compound to a nucleophilic substitution reaction known per se.
  • compound (I-B3) can also be produced by subjecting compound (I-B2) to the Mitsunobu reaction known per se.
  • Compound (I-B3) wherein X is a optionally mono- substituted amino group can also be produced from compound (I- B4) .
  • compound (I-B3) can be produced by subjecting compound (I-B4) to a reductive amination reaction known per se.
  • This reaction can be carried out by a catalytic reduction, or using, as a reducing agent, a metal hydrogen complex compound such as sodium borohydride, sodium tri (acetoxy)borohydride, sodium cyanoborohydride and the like.
  • a metal hydrogen complex compound such as sodium borohydride, sodium tri (acetoxy)borohydride, sodium cyanoborohydride and the like.
  • the amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent.
  • the amount of the metal hydride or metal hydrogen complex compound to be used is about 0.25 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (I-B4) .
  • the reduction reaction is advantageously carried out using a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1-propanol, 2-propanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1, 2-dichloroethane, carbon tetrachloride, trichloroethylene and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoric triamide and the like, and the like can • be mentioned
  • reaction time varies depending on the kind and amount of the reducing agent to be used and the activity and amount of the catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
  • Compound (I-B4) can be produced by subjecting compound (I-B2) to an oxidization reaction.
  • the oxidation reaction is carried out using an oxidant according to a conventional method.
  • the oxidant activated manganese dioxide, pyridinium chlorochromate (PCC) , pyridinium dichromate (PDC), 1, 1, 1-tris (acetyloxy) -1, 1-dihydro-l, 2- benziodoxol-3- (IH) -one (Dess-Martin Periodinane) , dimethyl sulfoxide-acid anhydride (acetic anhydride, trifluoroacetic anhydride and the like) , dimethyl sulfoxide-thionyl chloride, dimethyl sulfoxide-sulfuryl chloride, dimethyl sulfoxide- oxalyl chloride, dimethyl sulfoxide-chlorine, and dimethylsulfoxide-dicyclohexylcarbodi
  • the amount of the oxidant to be used is about 0.25 to about 10 mo1, preferably about 0.5 to about 5 mol, per 1 mol of compound (I-B2) .
  • the oxidation reaction is advantageously carried out using a solvent inert to the reaction.
  • solvent such as ethers such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether, 1, 2-dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, trichloroethylene and the like; aromatic hydrocarbons such as benzene, toluene and the like ; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as formamide, N,N-dimethylforr ⁇ amide, N,N-dimethylacetamide and the
  • reaction time varies depending on the kind and amount of the oxidant to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
  • the reaction temperature is generally about -70 to about 120°C, preferably about -70 to about 80 0 C.
  • Compound (I-B5) can be produced by subjecting compound (I-Bl) to a hydrolysis.
  • Compound (I-B6) can be produced by reacting compound (I- B5) or a reactive derivative of the carboxy group or a salt thereof with compound (XLI) .
  • organic lithiums such as methyllithium, n-butyllithium, vinyllithium, phenyllithium and the like;
  • Grignard reagents such as methylmagnesium bromide, methylmagnesium chloride, vinylmagnesium bromide, phenylmagnesium bromide and the like can be mentioned.
  • the reaction of compound (I-B6) with compound (XLII) is advantageously carried out using a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, ethers .such as dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether, ethylene glycol dimethyl ether and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
  • the amount of compound (XLII) to be used is 1 to 10 mol equivalents, preferably 1 to 3 mol equivalents, relative to compound (I-B6) .
  • the reaction temperature is generally -30°C to 100°C.
  • the reaction time is generally 0.5 to 20 hr.
  • the acid catalyst to be used in this reaction for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; Lewis acids such as a boron trihalide (e.g., boron trichloride, boron trifluoride and the like) , a titanium tetrahalide (e.g., titanium tetrachloride, titanium tetrabromide and the like), an aluminum halide (e.g., aluminum chloride, aluminum bromide and the like) and the like; organic acids such as acetic acid, formic acid, trifluoroacetic acid and the like can be mentioned.
  • mineral acids such as hydrochloric acid, sulfuric acid and the like
  • Lewis acids such as a boron trihalide (e.g., boron trichloride, boron trifluoride and the like) , a titanium tetrahalide (e.g., titanium tetrachloride, titanium tetrabromide and the like
  • This reaction is advantageously without a solvent or in a solvent inert to the reaction.
  • solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such- as methanol, ethanol, 1- propanol, 2-propanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1, 2-dimethoxyethane and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1, 2-dichloroethane, carbon tetrachloride, trichloroethylene and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N- dimethylformamide, N,N-dir ⁇ ethylace
  • the amount of compound (XLIII) to be used is 1 to 10 mol equivalents, preferably 1 to 3 mol equivalents, relative to compound (I-B7) .
  • the reaction temperature is generally -30°C to 100°C.
  • the reaction time is generally 0.5 to 20 hr.
  • a protecting group generally used in peptide chemistry and the- like may be introduced into these groups.
  • the protecting group can be removed according to a conventional method in any step in each scheme.
  • Compound (I) can also be produced by subjecting the compound obtained in each of the above-mentioned production methods to a substituent-conversion reaction.
  • the compound of the present invention obtained according to the above-mentioned production method can be isolated and purified by a known means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like.
  • various starting material compounds used in each of the above-mentioned production methods can be isolated and purified by a known means such as those mentioned above and the like.
  • the starting material compounds may be directly used in the form of a reaction mixture without isolation as the starting materials of the next step.
  • the compound of the present invention when the starting material compound can form a salt, the compound may also be used in the form of a salt.
  • a salt those similar to the salts of the aforementioned compound of the present invention can be mentioned.
  • the compound of the present invention contains an optical isomer, a stereoisomer, a positional isomer or a rotational isomer, these are encompassed in the compound of the present invention, and obtained as a single product according to a synthetic method and separation method known per se.
  • an optical isomer and an optical isomer resolved from this compound are also encompassed in the compound of the present invention.
  • the compound of the present invention may be in the form of a crystal.
  • the crystal of the compound of the present invention (hereinafter sometimes to be abbreviated as the crystal of the present invention) can be produced by crystallization of the compound of the present invention according to a crystallization method known per se.
  • the melting point refers to that measured using, for example, micromelting point measuring apparatus (Yanako, MP-500D or Buchi, B-545) or DSC (differential scanning calorimetry) device (SEIKO, EXSTAR6000) and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The purpose of the present invention is to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I):wherein R1 is a hydrogen atom or a halogen atom; R2 is a group represented by wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.

Description

DESCRIPTION INDOLE COMPOUND
Technical Field The present invention relates to a indole compound having a glucokinase activating action and useful as a therapeutic agent for diabetes and the like.
Background Art Glucokinase (sometimes to be abbreviated to as GK in the present specification) (EC2.7.1.1) is one of the four kinds of hexokinases found in mammals, and is also called hexokinase IV. GK is an enzyme that catalyzes the conversion of glucose to glucose-6-phosphate, which is the first step of glycolysis. GK is mainly present in the pancreatic β cell and the liver, and acts in the pancreatic β cell as a sensor of extracellular glucose concentration that defines the glucose-stimulated insulin secretion. In the liver, the enzyme reaction of GK becomes a rate determining factor and regulates glycogen synthesis and glycolysis. The three hexokinases (I, II, III) other than GK reach the maximum enzyme activity at a glucose concentration of 1 rriM or below. In contrast, GK shows low affinity for glucose and has a Km value of 8-15 mM which is close to a physiological blood glucose level. Accordingly, GK- mediated promotion of intracellular glucose metabolism occurs, which corresponds to blood glucose changes from normal blood glucose (5 mM) to postprandial- hyperglycemia (10-15 mM) .
The hypothesis proposed by Matschinsky et al. in 1984 that GK acts as a glucose sensor in the pancreatic β cell and hepatocytes has been demonstrated by the analysis of glucokinase transgenic mouse in recent years (see The Journal of Biological Chemistry (J. Biol. Chem. ) , 1995, vol. 270, page 30253-30256; The Journal of Biological Chemistry (J. Biol. Chem.), 1997, vol. 272, page 22564-22569; The Journal of Biological Chemistry (J. Biol. Chem.), 1997, vol. 272, page 22570-22575; NIHONRINSHO, 2002, vol. 60, page 523-534; and Cell, 1995, vol. 83, page 69-78) . That is, GK heterozygous deficient mouse showed a hyperglycemic condition, and further, a disordered glucose-stimulated insulin secretion response. GK homozygous deficient mouse dies shortly after birth with manifestations of marked hyperglycemia and urinary sugar. On the other hand, GK overexpressed mouse (hetero type) showed decreased blood glucose level, increased blood glucose clearance rate, increased liver glycogen content and the like. From these findings, it has been clarified that GK plays an important role in the systemic glucose homeostasis. In other words, decreased GK activity causes insulin secretion failure and lower liver glucose metabolism, which develops impaired glucose tolerance and diabetes. Conversely, GK activation or increased GK activity due to overexpression causes promoted insulin secretion and promoted liver glucose metabolism, which in turn increases the systemic use of glucose to improve glucose tolerance.
In addition, it has been clarified from the analysis of a report on GK gene abnormality mainly in the family of M0DY2 (Maturity Onset Diabetes of the Young) that GK also acts as a glucose sensor in human, and plays a key role in glucose homeostasis (see Nature, 1992, vol. 356, page 721-722) . In GK gene abnormality, due to the decreased affinity of GK for glucose (increased Km value) and decreased Vmax, the blood glucose threshold value of insulin secretion increases and the insulin secretory capacity decreases. In the liver, due to the decreased GK activity, decreased glucose uptake, promoted gluconeogenesis, decreased glycogen synthesis and liver insulin resistance are observed. On the other hand, a family with a mutation increasing the GK activity has also been found. In such family, fasting hypoglycemia associated with increased plasma insulin concentration is observed (see New England Journal Medicine, 1998, vol. 338, page 226-230) .
As mentioned above, GK acts as a glucose sensor in mammals including human, and 'plays an important role in blood glucose regulation. On the other hand, control of blood glucose utilizing the glucose sensor system of GK is considered to open a new way to treat diabetes in many type 2 diabetes patients. Particularly, since a GK activating substance is expected to show insulin secretagogue action in the pancreatic β cell and glucose uptake promotion and glucose release suppressive action in the liver, it will be useful as a prophylactic or therapeutic drug for type 2 diabetes.
In recent years, it has been clarified that pancreatic β cell type glucokinase expresses locally in the feeding center (Ventromedial Hypothalamus: VMH) of rat brain. A subset of nerve cell present in VMH is called glucose responsive neuron, and plays an important role in the body weight control. From electrophysiological experiments, the neuron is activated in response to physiological changes in the glucose concentration (5-20 ΠM) . However, since the glucose concentration sensor system of VHM is assumed to have a mechanism mediated by glucokinase as in the case of insulin secretion in the pancreatic β cell, different from pancreatic β cell and the liver, a pharmaceutical agent capable of activating glucokinase of VHM has a possibility of providing not only a blood glucose corrective effect but also improvement of obesity.
As mentioned above, a pharmaceutical agent capable of activating GK is useful as a prophylactic or therapeutic drug for diabetes, diabetic complications, and obesity.
As the indole compound, the following compound has been reported.
(1) It has been reported that a compound represented by the formula:
Figure imgf000004_0001
wherein ring A is an optionally substituted monocyclic or bicyclic aromatic ring; . ring B is an optionally substituted 6-membered unsaturated hydrocarbon ring or an optionally substituted 6-membered unsaturated heterocycle containing one nitrogen atom; ring C is an optionally substituted 5-membered heterocycle containing one or two nitrogen atoms;
W is a single bond or -CH=CH-; X is -N(R1)- or an oxygen atom;
Y is a carbon atom or a nitrogen atom;
Z is -N(R2)- or a nitrogen atom; and
R1 and R2 are the same or different and each is a hydrogen atom or lower alkyl is useful as an antitumor agent or an angiogenesis inhibitor
(see WO 95/07276 and JP-A-2000-309534) .
(2) It has been reported that a compound represented by the formula:
Figure imgf000005_0001
wherein
R1, R2, R3, R4, R6 and R7 are each independently a hydrogen atom, a halogen atom, a nitro group, -CN, -OH, -COOH, -CF3, -NR10R11 (wherein R10 and R11 are each independently a hydrogen atom, a Ci-6 alkyl group, -SO2CH3 etc.), a Ci-6 alkyl group, a C3-S cycloalkyl group, a heteroaryl group and the like; R5 is a Ci_6 alkyl group and the like; and A is an optionally substituted thiazolyl and the like, is useful as a glucokinase activator (see WO2005/049019) . However, none of the above-mentioned prior articles discloses the following formula (I) . Disclosure of the Invention
The purpose of the present invention is to provide a glucokinase activator which is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, obesity and the like, and the like.
The present inventors have conducted intensive studies and found that a compound represented by the formula (I) :
Figure imgf000006_0001
wherein
R1 is a hydrogen atom or a halogen atom; R2 is a group represented by
Figure imgf000006_0002
wherein A is CH or N;
R4 and R5 are each independently an optionally substituted Ci_6 alkyl group or an optionally substituted C3-10 cycloalkyl group, or R4 and R5 in combination form an optionally substituted ring wherein the ring should not be morpholine; and
R6( R1, R21 and R22 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, a cyano group or an acyl group, or Rδ and R7 in combination form an optionally substituted ring; W is 0 or NR8 wherein R8 is a hydrogen atom, an optionally substituted Ci_6 alkyl group or an optionally substituted C3-I0 cycloalkyl group;
R3 is an optionally substituted heterocyclic group or an optionally substituted C6-i4 aryl group; and R9, R10 and R11 are each independently a hydrogen atom, a halogen atom, an optionally substituted Ci-β alkyl group or an optionally substituted Ci_6 alkoxy group, provided that a compound wherein R21 is a hydrogen atom or a Ci-β alkoxy- carbonyl group, R22 is a hydrogen atom, and R6 and R7 are both hydrogen atoms, and a compound wherein R21 is a hydrogen atom or a Ci-6 alkoxy- carbonyl groug, R22 is a hydrogen atom, and R6 and R7 are both methyl groups are excluded, or a salt thereof [hereinafter to be abbreviated as compound
(I)] unexpectedly has a superior glucokinase activating action as well as superior properties as a pharmaceutical product such as stability and the like, and can be a safe and useful as a pharmaceutical agent, which resulted in the completion of the present invention.
Accordingly, the present invention relates to [1] compound (I) ;
[2] the compound of the above-mentioned [1], which is a compound represented by the formula (I) :
Figure imgf000007_0001
wherein R1 is a hydrogen atom or a halogen atom; R2 is a group represented by
Figure imgf000007_0002
wherein A is CH or N; R4 and R5 are each independently an optionally substituted Ci_6 alkyl group or an optionally substituted C3-I0 cycloalkyl group, or R4 and R5 in combination form an optionally substituted ring wherein the ring should not be morpholine; and R6 and R7 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, a cyano group or an acyl group, or R6 and R7 in combination form an optionally substituted ring;
W is 0 or NR8 wherein R8 is a hydrogen atom or an optionally substituted Ci-6 alkyl group;
R3 is an optionally substituted heterocyclic group; and
R9, R10 and R11 are each independently a hydrogen atom, a halogen atom, an optionally substituted Ci_s alkyl group or an optionally substituted Ci-6 alkoxy group, provided that a compound wherein R6 and R1 are both hydrogen atoms, and a compound wherein Rs and R7 are both methyl groups are excluded, or a salt thereof; [3] the compound of the above-mentioned [1], wherein R2 is a group represented by
Figure imgf000008_0001
wherein R6 and R7 are as defined in the above-mentioned [I];
[4] the compound of the above-mentioned [3], wherein R6 is a Ci- 6 alkyl group substituted by an optionally substituted heterocyclic group;
[5] the compound of the above-mentioned [3], wherein R7 is a hydrogen atom;
[6] the compound of the above-mentioned [3], wherein R6 and R7 in combination form an optionally substituted ring;
[7] the compound of the above-mentioned [3], wherein W is NR8 wherein R8 is as defined in the above-mentioned [I];
[8] the compound of the above-mentioned [3], wherein R3 is a 5- or 6-meiαbered monocyclic aromatic heterocyclic group;
[9] the compound of the above-mentioned [3], wherein R9 is a hydrogen atom or a halogen atom;
[10] the compound of the above-mentioned [3], wherein R10 is a hydrogen atom, a halogen atom, a Ci-6 alkyl group or an optionally substituted Ci_6 alkoxy group;
[11] the compound of the above-mentioned [3], wherein R11 is a hydrogen atom, a halogen atom or a Cα-6 alkyl group;
[12] N,N-dimethyl-2-{4-[ (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl }-l, 3-thiazol-5- yl) methyl]piperazin-l-yl}acetamide;
N-methyl-N- [2- (8-oxa-l-thia-3-azaspiro [4.5] dec-2-en-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide;
N- [2- [4- (hydroxymethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -5- (2- methoxyethoxy) -lH-indol-7-yl] -N-methylpyridine-2-sulfonamide;
N-methyl-N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2- yl] -lH-indol-7-yl} thiophene-2-sulfonamide;
2- (2-{7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl}-
4, 5-dihydro~l, 3-thiazol-5-yl) acetamide; N- (difluoromethyl) -N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide;
2- {2- [7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) - lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5-yl} acetamide;
N- (5- (2-methoxyethoxy) -2- {5- [ (1-oxidothiomorpholino) methyl] - 4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylpyridine-
2-sulfonamide;
2- (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}-l- thia-3, 8-diazaspiro [4.5] dec-2-en-8-yl) acetamide; or
N- [2-{5- [ (1, 1-dioxidothiomorpholino) methyl] -4, 5-dihydro-l, 3- thiazol-2-yl}-5- (2-methoxyethoxy) -lH-indol-7-yl] -N- methylpyridine-2-sulfonamide; or a salt thereof;
[13] a prodrug of compound (I) ;
[14] a glucokinase activator comprising compound (I) or a prodrug thereof; [15] a pharmaceutical agent comprising compound (I) or a prodrug thereof;
[16] the pharmaceutical agent of the above-mentioned [15], which is an agent for the prophylaxis or treatment of diabetes or obesity;
[17] a method of activating a glucokinase in a mammal, which comprises administering compound (I) or a prodrug thereof to the mammal;
[18] a method for the prophylaxis or treatment of diabetes or obesity in a mammal, which comprises administering compound
(I) or a prodrug thereof to the mammal;
[19] use of compound (I) or a prodrug thereof for the production of a glucokinase activator;
[20] use of compound (I) or a prodrug thereof for the production of an agent for the prophylaxis or treatment of diabetes or obesity; and the like.
Since compound (I) has a superior glucokinase activating action, compound (I) is useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the- like.
[Detailed Description of the Invention]
Unless otherwise specified, as the ^halogen atom" in the present specification, fluorine atom, chlorine atom, bromine ' atom or iodine atom can be mentioned.
Unless otherwise specified, as the wCi_3 alkylenedioxy group" in the present specification, methylenedioxy, ethylenedioxy or the like. Unless otherwise specified, as the "Ci_6 alkyl group" in the present specification, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1, 1-dimethylbutyl, 2,2-dimethylbutyl, 3, 3-dimethylbutyl, 2-ethylbutyl or the like. Unless otherwise specified, as the "Ci-6 alkoxy group" in the present specification, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy or the like.
Unless otherwise specified/ as the "Ci-6 alkoxy-carbonyl group" in the present specification, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl or the like.
Unless otherwise specified, as' the XΛCi-6 alkyl-carbonyl group" in the present specification, acetyl, propanoyl, butanoyl, isobutanoyl, pentanoyl, isopentanoyl, hexanoyl or the like.
Each symbol in the formulas is described in detail in the following. R1 is a hydrogen atom or a halogen atom.
R1 is preferably a hydrogen atom or a fluorine atom, more preferably a hydrogen atom.
R2 is a group represented by
Figure imgf000011_0001
wherein each symbol is as defined above .
R2 is preferably a group represented by
Figure imgf000011_0002
wherein each symbol is as defined above, more preferably a group represented by
Figure imgf000011_0003
wherein each symbol is as defined above.
In the embodiment wherein R2 is a group represented by
Figure imgf000012_0001
R6, R7, R21 and R22 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, a cyano group or an acyl group, or R6 and R7 in combination form an optionally substituted ring.
As the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22, for example, a Ci-io alkyl group, a C2-io alkenyl group, a C2-io alkynyl group, a C3-I0 cycloalkyl group, a C3-10 cycloalkenyl group, a C4-I0 cycloalkadienyl group, a Cβ-i4 aryl group, a C7-13 aralkyl group, a Cs-13 arylalkenyl group, a C3-I0 cycloalkyl-Ci-6 alkyl group and the like can be mentioned.
As used herein, as the C1-Io alkyl group, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3- dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, decyl ' and the like can be mentioned.
As the C2-10 alkenyl group, for example, ethenyl, 1- propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3- hexenyl, 5-hexenyl, 1-heptenyl, 1-octenyl and the like can be mentioned. As the C2-10 alkynyl group, for example, ethynyl, 1- propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1- pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2- hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-heptynyl, 1- octynyl and the like can be mentioned. • As the C3-10 cycloalkyl group, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like can be mentioned. As the C3-10 cycloalkenyl group, for example, 2- cyclopenten-1-yl, 3-cyclopenten-l-yl, 2-cyclohexen-l-yl, 3- cyclohexen-1-yl and the like can be mentioned.
As the C4-10 cycloalkadienyl group, for example, 2,4- cyclopentadien-1-yl, 2, 4-cyclohexadien-l-yl, 2,5- cyclohexadien-1-yl and the like can be mentioned.
The above-mentioned C3-I0 cycloalkyl group, C3-10 cycloalkenyl group and C4-10 cycloalkadienyl are each optionally condensed with a benzene ring to form a fused cyclic group, and as the fused cyclic group, for example, indanyl, dihydronaphthyl, tetrahydronaphthyl, fluorenyl and the like can be mentioned. In addition, as the aforementioned hydrocarbon group, a cross-linked hydrocarbon group such as bicyclo[2.2.1]heptyl, bicyclo [2.2.2] octyl, bicyclo [3.2. l]octyl, bicyclo[3.2.2]nonyl, bicyclo [3.3. l]nonyl, bicyclo [4.2.1] nonyl, bicyclo [4.3.1] decyl, adamantyl, norbornanyl and the like, and the like can also be mentioned.
As the Cδ-14 aryl group, for example, phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, .biphenylyl and the like can be mentioned. Of these, phenyl, 1-naphthyl, 2-naphthyl and the like are preferable.
As the C7-13 aralkyl group, for example, benzyl, phenethyl, naphthylmethyl, biphenylylmethyl and the like can be mentioned.
As the Ce-13 arylalkenyl group, for example, styryl and the like can be mentioned.'
As the C3-10 cycloalkyl-Ci-6 alkyl group, for example, cyclohexylmethyl and the like can be mentioned.
The Ci-10 alkyl group, C2-io alkenyl group and C2-io alkynyl group exemplified as the aforementioned "hydrocarbon group" optionally have 1 to 3 substituents at substitutable positions. As such substituents, for example,
(1) a C3-I0 cycloalkyl group (e.g., cyclopropyl, cyclohexyl) ;
(2) a C6-i4 aryl group (e.g., phenyl, naphthyl) optionally substituted by 1 to 3 substituents selected from (a) a Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a hydroxy group,
(c) a Ci-6 alkoxy group, and
(d) a halogen atom; (3) an optionally substituted heterocyclic group (those similar to the below-mentioned "optionally substituted heterocyclic group" for R3 can be mentioned) ; (4) an amino group optionally mono- or di-substituted by substituent (s) selected from (a) a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl),
(b) a QL-6 alkyl-carbonyl group,
(c) a Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 Ce~χA aryl groups (e.g., phenyl),
(d) a C6-i4 aryl-carbonyl group (e.g., benzoyl),
(e) a C7-I3 aralkyl-carbonyl group (e.g., benzylcarbonyl, phenethylcarbonyl) ,
(f) a carbamoyl group optionally mono- or di-substituted by substituent (s) selected from a Ci-6 alkyl group, a Ce-ύ aryl group (e.g., phenyl) and a C7_i3 aralkyl group (e.g., benzyl),
(g) a Cχ-G alkylsulfonyl group' (e.g., methylsulfonyl, ethylsulfonyl, isopropylsulfonyl) ,
(h) a C6-I4 arylsulfonyl group (e.g., benzenesulfonyl, 1- naphthalenesulfonyl, 2-naphthalenesulfonyl) optionally substituted by 1 to 3 Ci_6 alkyl groups, (i) a Cv-13 aralkylsulfonyl group (e.g., benzylsulfonyl) (j) a C3-X0 cycloalkyl group (e.g., cyclohexyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Ci_δ alkyl group,
(k) an aromatic heterocyclic group (e.g., triazolyl) , and (1) a non-aromatic heterocyclic group (e.g., tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl, 1,1- dioxidotetrahydrothiopyranyl) ; (5) an amidino group/ (6) a Ci_6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms;
(7) a Ci_6 alkoxy-carbonyl group optionally substituted by 1 to 3 halogen atoms; (8) an aromatic heterocyclyl-carbonyl group (e.g., thienylcarbonyl, indolylcarbonyl) optionally substituted by 1 to 3 amino groups [the amino groups are each optionally mono- or di-substituted by substituent (s) selected from a Ci_6 alkyl group and an aromatic heterocyclyl-sulfonyl group (e.g., thienylsulfonyl) ] ;
(9) a non-aromatic heterocyclyl-carbonyl group (e.g., piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1-oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl) optionally substituted by 1 to 3 substituents selected from
(a) a hydroxy group,
(b) a Ci_6 alkyl group optionally substituted by 1 to 3 hydroxy groups, (c) a halogen atom, and (d) a carboxy group;
(10) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl, ethylsulfonyl) optionally substituted by 1 to 3 halogen atoms;
(11) a carbamoyl group optionally mono- or di-substituted by substituent (s) selected from
(a) a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a Ci-6 alkoxy group, a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl) and an aromatic heterocyclic group (e.g., furyl) , (b) a C6-I4 aryl group (e.g., phenyl),
(c) a C7-I3 aralkyl group (e.g., benzyl),
(d) a QL_6 alkoxy group,
(e) a C3-10 cycloalkyl group (e.g., cyclopropyl) ,
(f) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl), (g) an aromatic heterocyclic group (e.g., triazolyl, tetrazolyl) , and
(h) a non-aromatic heterocyclic group (e.g., tetrahydropyranyl) ;
(12) a thiocarbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms;
(13) a sulfamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms; (14) a carboxy group;
(15) a hydroxy group;
(16) a Ci-6 alkoxy group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom, (b) a carboxy group,
(c) a Ci-6 alkoxy group, and
(d) a Ci-6 alkoxy-carbonyl group;
(17) a C2-6 alkenyloxy group (e.g., ethenyloxy) optionally substituted by 1 to 3 halogen atoms; (18) a C3-10 cycloalkyloxy group (e.g., cyclohexyloxy) ;
(19) a C7-13 aralkyloxy group (e.g., benzyloxy) optionally substituted by 1 to 3 halogen atoms;
(20) a Cβ-14 aryloxy group (e.g., phenyloxy, naphthyloxy) ;
(21) a Ci-6 alkyl-carbonyloxy group (e.g., acetyloxy, tert- butylcarbonyloxy) ;
(22) a mercapto group;
(23) a Ci-β alkylthio group (e.g., methylthio, ethylthio) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom, (b) a C6-I4 aryl group, and (c) a carboxy group;
(24) a Cβ-14 arylthio group (e.g., phenylthio, naphthylthio) ;
(25) an aromatic heterocyclyl-thio group (e.g., tetrazolylthio) optionally substituted by 1 to 3 Ci_5 alkyl groups; (26) a sulfo group;
(27 ) a cyano group;
(28) an azido group;
C
(29) a nitro group; (30) a nitroso group;
(31) a halogen atom;
(32) a Ci-6 alkylsulfinyl group (e.g., methylsulfinyl) ;
(33) an oxo group;
(34) a C3-10 cycloalkyl-Ci-6 alkyloxy group (e.g., cyclopropylmethyloxy) ;
(35) a Ci-3 alkylenedioxy group;
(36) an aromatic heterocyclyl-carbonylthio group (e.g., indolylcarbonylthio) optionally substituted by 1 to 3 amino groups [the amino groups are each optionally mono- or di- substituted by substituent (s) selected from a Ci-6 alkyl group and an aromatic heterocyclyl-sulfonyl group (e.g., thienylsulfonyl) ] ;
(37) a formyl group;
(38) an aromatic heterocyclyl-oxy group (e.g., pyrimidyloxy, pyrazinyloxy) ;
(39) a Ci-6 alkylsulfonyloxy group (e.g., methylsulfonyloxy) ;
(40) a C2-6 alkenyl-carbonyl group (e.g., vinylcarbonyl) ;
(41) a non-aromatic heterocyclyl-carbonyloxy group (e.g., morpholinylcarbonyloxy) optionally substituted by 1 to 3 Ci_6 alkyl groups; and the like can be mentioned.
The C3-10 cycloalkyl group, C3-X0 cycloalkenyl group, C4_i0 cycloalkadienyl group, Ce-u aryl group, C7-I3 aralkyl group, Cs-I3 arylalkenyl group and C3-10 cycloalkyl-Ci-6 alkyl group exemplified as the aforementioned "hydrocarbon group" optionally have 1 to 3 substituents at substitutable positions, As such substituents, for example,
(1) a C3-10 cycloalkyl group (e.g., cyclopropyl, cyclohexyl) ;
(2) a Cβ-xi aryl group (e.g., phenyl, naphthyl) optionally substituted by 1 to 3 substituents selected from (a) a Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a hydroxy group,
(c) a Ci-6 alkoxy group, and (d) a halogen atom;
(3) an aromatic heterocyclic group (e.g., thienyl, furyl, pyridyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, tetrazolyl, oxadiazolyl, pyrazinyl, quinolyl, indolyl) optionally substituted by 1 to 3 substituents selected from (a) a Ci-β alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a hydroxy group,
(c) a Ci-6 alkoxy group, and
(d) a halogen atom; (4) a non-aromatic heterocyclic group (e.g., tetrahydrofuryl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, dioxolyl, dioxolanyl, 1, 3-dihydro-2-benzofuranyl, thiazolidinyl, thiazolinyl) optionally substituted by 1 to 3 substituents selected from (a) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a hydroxy group,
(c) a Ci_6 alkoxy group,
(d) a Ci-6 alkyl-carbonyl group, (e) a Ci-6 alkylsulfonyl group,
(f) an oxo group, and
(g) a halogen atom;
(5) an amino group optionally mono- or di-substituted by substituent (s) selected from (a) a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C1-^ alkylsulfonyl group (e.g., methylsulfonyl),
(b) a Ci_6 alkyl-carbonyl group,
(c) a Ci_6 alkoxy-carbonyl group optionally substituted by 1 to 3 C6-I4 aryl groups (e.g., phenyl), (d) a Cβ-14 aryl-carbonyl group (e.g., benzoyl),
(e) a C7-I3 aralkyl-carbonyl group (e.g., benzylcarbonyl, phenethylcarbonyl) ,
(f) a carbamoyl group optionally mono- or di-substituted by substituent (s) selected from a Ci-6 alkyl group, a C6_14 aryl group (e.g., phenyl) and a C7-I3 aralkyl group (e.g., benzyl),
(g) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl, ethylsulfonyl, isopropylsulfonyl)',
(h) a C6-H arylsulfonyl group (e.g., benzenesulfonyl, 1- naphthalenesulfonyl, 2-naphthalenesulfonyl) optionally substituted by 1 to 3 Cχ-6 alkyl groups, (i) a C7-I3 aralkylsulfonyl group (e.g., benzylsulfonyl) (j) a C3-I0 cycloalkyl group (e.g., cyclohexyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Ci-e alkyl group,
(k) an aromatic heterocyclic group (e.g., triazolyl) , and (1) a non-aromatic heterocyclic group (e.g., tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl, 1,1- dioxidotetrahydrothiopyranyl) ; (6) an amidino group;
(7) a Ci-s alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms;
(8) a Q.-6 alkoxy-carbonyl group optionally substituted by 1 to 3 halogen atoms; (9) an aromatic heterocyclyl-carbonyl group (e.g., thienylcarbonyl, indolylcarbonyl) optionally substituted by 1 to 3 amino groups [the amino groups are each optionally mono- or di-substituted by substituent (s) selected from a Cx-6 alkyl group and an aromatic heterocyclyl-sulfonyl group (e.g., thienylsulfonyl) ] ;
(10) a non-aromatic heterocyclyl-carbonyl group (e.g., piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1-oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl) optionally substituted by 1 to 3 substituents selected from
(a) a hydroxy group,
(b) a CjL-6 alkyl group optionally substituted by 1 to 3 hydroxy groups, (c) a halogen atom, and (d) a carboxy group;
(11) a Ci_6 alkylsulfonyl group (e.g., methylsulfonyl, ethylsulfonyl) optionally substituted by 1 to 3 halogen atoms;
(12) a carbamoyl group optionally mono- or di-substituted by substituent (s) selected from
(a) a Ci_6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a Ci-6 alkoxy group, a Cχ-β alkylsulfonyl group (e.g., methylsulfonyl) and an aromatic heterocyclic group (e.g., furyl) , (b) a Ce-i4 aryl group (e.g., phenyl),
(c) a C7-13 aralkyl group (e.g., benzyl),
(d) a Ci_6 alkoxy group,
(e) a C3-10 cycloalkyl group (e.g., cyclopropyl) ,
(f) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl), (g) an aromatic heterocyclic group (e.g., triazolyl, tetrazolyl), and
(h) a non-aromatic heterocyclic group (e.g., tetrahydropyranyl) ;
(13) a thiocarbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms;
(14) a sulfamoyl group optionally mono- or di-substituted by Ci_6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms; (15) a carboxy group;
(16) a hydroxy group;
(17) a Ci-6 alkoxy group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom, (b) a carboxy group, (c) a Cχ_6 alkoxy group, and
(d) a Ci-6 alkoxy-carbonyl group;
(18) a C2-6 alkenyloxy group (e.g., ethenyloxy) optionally substituted by 1 to 3 halogen atoms; (19) a C3-10 cycloalkyloxy group (e.g., cyclohexyloxy) ;
(20) a C7-13 aralkyloxy group (e.g., benzyloxy) optionally substituted by 1 to 3 halogen atoms;
(21) a Cβ-14 aryloxy group (e.g., pheήyloxy, naphthyloxy) ;
(22) a Ci-6 alkyl-carbonyloxy group (e.g., acetyloxy, tert- butylcarbonyloxy) ;
(23) a mercapto group;
(24) a Ci-6 alkylthio group (e.g., methylthio, ethylthio) optionally substituted by 1 to 3' substituents selected from
(a) a halogen atom, (b) a Cs_i4 aryl group, and (c) a carboxy group;
(25) a C6-I4 arylthio group (e.g., phenylthio, naphthylthio) ;
(26) an aromatic heterocyclyl-thio group (e.g., tetrazolylthio) optionally substituted by 1 to 3 Ci_6 alkyl groups ;
(27) a sulfo group;
(28) a cyano group;
(29) an azido group;
(30) a nitro group; (31) a nitroso group;
(33) a halogen atom;
(33) a Ci-6 alkylsulfinyl group (e.g., methylsulfinyl) ;
(34) an oxo group;
(35) a C3-10 cycloalkyl-Ci_6 alkyloxy group (e.g., cyclopropylmethyloxy) ;
(36) a Ci-3 alkylenedioxy group;
(37) an aromatic heterocyclyl-carbonylthio group (e.g., indolylcarbonylthio) optionally substituted by 1 to 3 amino groups [the amino groups are each optionally mono- or di- substituted by substituent (s) selected from a C1-S alkyl group and an aromatic heterocyclyl-sulfonyl group (e . g . , thienylsulfonyl) ] ;
(38) a formyl group;
(39) an aromatic heterocyclyl-oxy group (e.g., pyrimidyloxy, pyrazinyloxy) ;
(40) a Ci_6 alkylsulfonyloxy group (e.g., methylsulfonyloxy) ;
(41) a C2-6 alkenyl-carbonyl group (e.g., vinylcarbonyl) ;
(42) a non-aromatic heterocyclyl-carbonyloxy group (e.g., morpholinylcarbonyloxy) optionally substituted by 1 to 3 Cχ_6 alkyl groups;
(43) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a carboxy group, (c) a hydroxy group,
(d) a Ci_6 alkoxy group optionally substituted by 1 to 3 substituents selected from a carboxy group and a Ci_6 alkoxy-carbonyl group,
(e) a C1_6 alkyl-carbonyl group, (f) a Ci_6 alkoxy-carbonyl group,
(g) a Ci-6 alkyl-carbonylox-y group (e.g., acetyloxy, tert- butylcarbonyloxy) ,
(h) a carbamoyl group optionally mono- or di-substituted by substituent (s) selected from a Ci_6 alkyl, a Ci-e alkylsulfonyl group and an amino group,
(i) an aromatic heterocyclic group (e.g., thienyl, tetrazolyl, imidazolyl, furyl, pyridyl) optionally substituted by 1 to 3 Ci-6 alkyl groups, (j ) a non-aromatic heterocyclic group (e.g., tetrahydrofuranyl, piperidino, piperazinyl, morpholinyl, dihydrooxadiazolyl, hexahydropyrazinooxazinyl (e.g., hexahydropyrazino[2, 1-c] [1, 4]oxazinyl) ) optionally substituted by 1 to 3 substituents selected from a Ci_6 alkyl-carbonyl group and an oxo group, (k) an amino group optionally mono- or di-substituted by Ci- 6 alkyl group (s) (the Ci_6 alkyl group is optionally substituted by 1 to 3 substituents selected from a non- aromatic heterocyclic group (e.g., morpholinyl) , a Cχ-β alkoxy group and a Ci_6 alkylsulfonyl group) , (1) a Ci-6 alkylsulfonyl group optionally substituted by 1 to 3 carboxy groups, .
(m) a Ci-S alkylthio group optionally substituted by 1 to 3 substituents selected from a carboxy group, a Ci-e alkoxy- carbonyl group, a hydroxy group and a carbamoyl group, (n) a phosphono group optionally mono- or di-substituted by Ci-6 alkyl group (s),
(o) a non-aromatic heterocyclyl-carbonyl group (e.g., raorpholinylcarbonyl) ,
(p) a 'cyano group, and (q) a CΘ-14 aryloxy group optionally substituted by 1 to 3 substituents selected from a carboxy group and a Ci-6 alkoxy-carbonyl group;
(44) a C2-6 alkenyl group (e.g., ethenyl, 1-propenyl) optionally substituted by 1 to 3 substituents selected from (a) a halogen atom,
(b) a carboxy group,
(c) a Ci-6 alkoxy-carbonyl group, and
(d) a carbamoyl group;
(45) a C7-13 aralkyl group (e.g., benzyl) optionally substituted by L to 3 substituents selected from
(a) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a hydroxy group,
(c) a Ci-6 alkoxy group, and (d) a halogen atom; and the like can be mentioned.
As the "acyl group" for R5, R7, R21 or R22, for example, groups represented by the formulas: -C0Ra/ -CO-ORa, -Sθ2Ra/ - SORa, -CO-NRa'Rb/, -CS-NRa'Rb' and -SO2-NRa'Rb' wherein Ra is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and Ra' and Rb' are the same or different and each is' a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or Ra' and Rb' form, together with the adjacent nitrogen atom, an optionally substituted nitrogen-containing heterocycle, and the like can be mentioned.
As the "optionally substituted hydrocarbon group" for Ra, Ra' or Rbf , those similar to the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 can be mentioned. As the "optionally substituted heterocyclic group" for R% Ra' or Rb' , those similar to the below-mentioned "optionally substituted heterocyclic group" for R3 can be mentioned.
As the "nitrogen-containing heterocycle" of the "optionally substituted nitrogen-containing heterocycle" formed by Ra' and Rb' together with the adjacent nitrogen atom, for example, a 5- to 7-membered nitrogen-containing heterocycle containing, as a ring-constituting atom besides carbon atoms, at least one nitrogen atom and optionally further containing one or two heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom can be mentioned. As preferable examples of the nitrogen-containing heterocycle, pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, morpholine, thiomorpholine, oxopiperazine and the like can be mentioned. The nitrogen-containing heterocycle optionally has 1 to 3 (preferably 1 or 2) substituents at substitutable positions. As such substituents, those exemplified as the substituents which the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 optionally has, can be mentioned. As preferable examples of the "acyl group",
(1) a formyl group;
(2) a carboxy group;
(3) a carbamoyl group; ( 4 ) a C1-(S alkyl-carbonyl group; (5) a Ci_6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
(a) a carbqxy group,
(b) a carbamoyl group, (c) a thiocarbamoyl group,
(d) a Ci-6 alkoxy-carbonyl group, and
(e) a Ci_6 alkyl-carbonyloxy group
(e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert- butoxycarbonyl ; carboxymethoxycarbonyl, carboxyethoxycarbonyl, carboxybutoxycarbonyl; carbarαoylmethoxycarbonyl; thiocarbamoylmethoxycarbonyl; ethoxycarbonylmethoxycarbonyl, ethoxycarbonylethoxycarbonyl, methoxycarbonylbutoxycarbonyl, ethoxycarbonylbutoxycarbonyl; tert- butylcarbonyloxymethoxycarbonyl) ; (6) a C3-10 cycloalkyl-carbonyl group (e.g., cyclopentylcarbonyl, cyclohexylcarbonyl) ;
(7) a C6-i4 aryl-carbonyl group (e.g., benzoyl, l~naphthoyl, 2- naphthoyl) optionally substituted by 1 to 3 substituents selected from (a) a halogen atom,
(b) a cyano group,
(c) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(d) a Ci_6 alkoxy group, (e) a carboxy group,
(f) a Ci_6 alkoxy-carbonyl group, and
(g) a carbamoyl group;
(8) a C6-i4 aryloxy-carbonyl group (e.g., phenyloxycarbonyl, naphthyloxycarbonyl) optionally substituted by 1 to 3 substituents selected from
(a) a carboxy group,
(b) a Ci-6 alkoxy-carbonyl group, and
(c) a carbamoyl group;
(9) a C7-I3 aralkyloxy-carbonyl group optionally substituted by 1 to 3 substituents selected from (a) a carboxy group,
(b) a carbamoyl group,
(c) a thiocarbamoyl group,
(d) a Ci-6 alkoxy-carbonyl group, (e) a halogen atom,
(f) a cyano group,
(g) a nitro group,
(h) a Ci_6 alkoxy group, (i) a Ci-6 alkylsulfonyl group, and (j ) a Ci-6 alkyl group
(e.g., benzyloxycarbonyl, phenethyloxycarbonyl; carboxybenzyloxycarbonyl; methoxycarbonylbenzyloxycarbonyl; biphenylylmethoxycarbonyl) ;
(10) a carbamoyl group mono- or di-substituted by Cχ-β alkyl group (s) optionally substituted by 1 to 3 substituents selected from a halogen atom and a Ci_6 alkoxy group (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, propylcarbamoyl, isopropylcarbamoyl, butylcarbamoyl, isobutylcarbamoyl, trifluoroethylcarbamoyl, N-methoxyethyl-N-methylcarbamoyl) ;
(11) a Ci-6 alkylsulfonyl group optionally substituted by 1 to 3 substituents selected from
(a) a carboxy group,
(b) a carbamoyl group, and (c) a C1-G alkoxy-carboήyl group
(e.g., methylsulfonyl, carboxymethylsulfonyl) ;
(12) a Ci-6 alkylsulfinyl group (e.g., methylsulfinyl) ;
(13) a thiocarbamoyl group;
(14) a C7-13 aralkyl-carbonyl group (e.g., benzylcarbonyl, phenethylcarbonyl) ;
(15) an aromatic heterocyclyl-carbonyl group (e.g., furylcarbonyl, thienylcarbonyl, thiazolylcarbonyl, pyrazolylcarbonyl, pyridylcarbonyl, pyrazinylcarbonyl, benzofurylcarbonyl, benzothienylcarbonyl, quinoxalinylcarbonyl) optionally substituted by 1 to 3 substituents selected from
(a) a Ci_6 alkyl group,
(b) a C5-I4 aryl group,
(c) a C7-I3 aralkyl group, (d) a Ci-6 alkoxy group,
(e) a carboxy group,
(f) a Ci-6 alkoxy-carbonyl group, and
(g) a carbamoyl group;
(16) a non-aromatic heterocyclyl-carbonyl group (e.g., tetrahydrofurylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, piperidinylcarbonyl, pyrrolidinylcarbonyl, piperazinylcarbonyl, dioxolylcarbonyl, dioxolanylcarbonyl, 1, 3-dihydro-2-benzofuranylcarbonyl, thiazolidinylcarbonyl) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a hydroxy group,
(c) a Ci-6 alkoxy group, and (d) a halogen atom;
(17) a sulfamoyl group;
(18) a sulfamoyl group mono- or di-substituted by Ci_6 alkyl group (s) optionally substituted by 1 to 3 substituents selected from a halogen atom and a Ci-6 alkoxy group (e.g., methylsulfamoyl, ethylsulfamoyl, dimethylsulfamoyl) ; and the like can be mentioned.
When R6 and R7 are independent, R6 is preferably an optionally substituted Ci_6 alkyl group, a cyano group or an acyl group, more preferably a Ci-β alkyl group substituted by an optionally substituted heterocyclic group.
As preferable specific examples for R6,
(1) a Ci-6 alkyl group (preferably methyl, ethyl, isopropyl) optionally substituted by 1 to 3 substituents selected from
(a) a non-aromatic heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl), (iii) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) , and
(iv) a halogen atom (preferably fluorine atom) ,
(b) an amino group,
(c) a hydroxy group, and
(d) a Ci_6 alkoxy group (preferably methoxy) ; (2) a cyano group;
(3) a carboxy group;
(4) a Ci-s alkoxy-carbonyl group (preferably methoxycarbonyl) ;
(5) a carbamoyl group; and
(6) a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl) ;
[preferably a Ci_s alkyl group (preferably methyl, ethyl, isopropyl) substituted by 1 to 3 substituents selected from (a) a non-aromatic heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl), (iii) a Ci_6 alkylsulfonyl group (preferably methylsulfonyl) , and (iv) a halogen atom' (preferably fluorine atom) ] can be mentioned.
As another preferable specific examples for R5, (1) a Ci-6 alkyl group (preferably methyl, ethyl, isopropyl, isobutyl) optionally substituted by 1 to 3 substituents selected from
(a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl) optionally substituted by 1 to 3 substituents selected from
(i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (iii) a Ci-6 alkylsulfonyl group (preferably methy1sulfony1) ,
(iv) a halogen atom (preferably fluorine atom), (v) an oxo group,
(vi) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, and (vii) a Ci-3 alkylenedioxy group (preferably ethylenedioxy) ,
(b) an amino group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (preferably methyl, ethyl, isobutyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Ci-β alkylsulfonyl group (preferably methylsulfonyl) ,
(ii) a QL-6 alkyl-carbonyl group (preferably acetyl) ,
(iii) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) optionally substituted by 1 to 3 C6-i4 aryl groups (preferably phenyl),
(iv) a C3-.10 cycloalkyl group (preferably cyclohexyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Ci_6 alkyl group (preferably methyl ) ,
(v) an aromatic heterocyclic group (preferably triazolyl) , and
(vi) a non-aromatic heterocyclic group (preferably tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl, 1, 1-dioxidotetrahydrothiopyranyl) ,
(c) a hydroxy group,
(d) a Ci-6 alkoxy group (preferably methoxy) ,
(e) a Ci-6 alkylsulfonyloxy group (preferably methylsulfonyloxy) , (f) a Ci_6 alkyl-carbonyl group (preferably acetyl),
O Q (g) a C2-S alkenyl-carbonyl group (preferably vinylcarbonyl) , (h) .a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl ) , (i) a carboxy group,
(j) a non-aromatic heterocyclyl-carbonyl group (preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group,
(ii) a Ci-e alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, (iii) a halogen atom (preferably fluorine atom) , and (iv) a carboxy group,
(k) a non-aromatic heterocyclyl-carbonyloxy group (preferably morpholinylcarbonyloxy) optionally substituted by 1 to 3 Ci-6 alkyl groups (preferably methyl) , (1) a carbamoyl group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group, a Cχ-6 alkoxy group (preferably methoxy) and a Ci-6 alkylsulfonyl group (preferably methylsulfonyl ),
(ii) a Ci-e alkoxy group (preferably methoxy) , (iii) a C3-10 cycloalkyl group (preferably cyclopropyl ) , (iv) a Ci-e alkylsulfonyl group (preferably methylsulfonyl) , (v) an aromatic heterocyclic group (preferably triazolyl, tetrazolyl), and
(vi) a non-aromatic heterocyclic group (preferably tetrahydropyranyl) ,
(m) a Ci-e alkylthio group (preferably, methylthio) optionally substituted by 1 to 3 carboxy groups, and (n) a formyl group;
(2) a cyano group;
(3) a carboxy group;
(4) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) ; (5) a carbamoyl group optionally mono- or di-substituted by Ci_6 alkyl group (s) (preferably ethyl); and
(6) a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl, morpholinylcarbonyl, piperazinylcarbonyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (preferably methyl) ;
[preferably a Ci_6 alkyl group (preferably methyl, ethyl, isopropyl, isobutyl) substituted by 1 to 3 substituents selected from
(a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group,
(ii) a Ci_s alkyl-carbonyl group (preferably acetyl) , (iii) a Ci_6 alkylsulfonyl group (preferably methylsulfonyl) ,
(iv) a halogen atom (preferably fluorine atom) , (v) an oxo group,
(vi) a C1S alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, and (vii) a Ci_3 alkylenedioxy group (preferably ethylenedioxy) ] can be mentioned.
When R5 and R7 are independent, R7 is preferably a hydrogen atom or an optionally substituted Ci-β alkyl group, more preferably a hydrogen atom.
As preferable specific examples for R7, (1) a hydrogen atom; and (2) a Ci-6 alkyl group (preferably methyl) ; can be mentioned.
When R6 and R7 in combination form an optionally substituted ring, as the "ring" of the "optionally substituted ring", for example, a C3-10 cycloalkane, a C3-10 cycloalkene, a C3-10 cycloalkadiene, a monocyclic non-aromatic heterocycle and the like can be mentioned.
As the C3-10 cycloalkane, C3-I0 cycloalkene and C4-10 cycloalkadiene, rings corresponding to the C3-10 cycloalkyl group, C3-10 cycloalkenyl group and C4-10 cycloalkadienyl group exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 can be mentioned. As the monocyclic non-aromatic heterocycle, a ring corresponding to the monocyclic non-aromatic heterocyclic group exemplified as the below-mentioned "optionally substituted heterocyclic group" for R3, can be mentioned.
The "ring" of the "optionally substituted ring" optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 optionally has, can be mentioned.
When R6 and R7 in combination form an optionally substituted ring, the "optionally substituted ring" is preferably an optionally substituted monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran, 1- oxidotetrahydrothiopyran) or an optionally substituted C3-10 cycloalkane (preferably cyclohexane) , more preferably an optionally substituted monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran, 1- oxidotetrahydrothiopyran) .
As preferable specific examples, a monocyclic non- aromatic heterocycle (preferably piperidine, tetrahydropyran) optionally substituted by 1 to 3 substituents selected from (a) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by aromatic heterocyclic group (s) (preferably imidazolyl) optionally substituted by 1 to 3 Ci_6 alkyl groups (preferably methyl) ,
(b) a C7-13 aralkyl group (preferably benzyl) , (c) a Ci-6 alkyl-carbonyl group (preferably acetyl) ,
(d) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) , and
(e) a carbamoyl group optionally mono- or di-substituted by • Ci-6 alkyl group (s) (preferably methyl) ; can be mentioned.
As another preferable specific examples, (1) a monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran, 1-oxidotetrahydrothiopyran) optionally substituted by 1 to 3 substituents selected from (a) a C1-(S alkyl group (preferably methyl, ethyl, isobutyl) optionally substituted by 1 to 3 substituents selected from (i) an aromatic heterocyclic group (preferably imidazolyl, furyl, pyridyl) optionally substituted by 1 to 3 Ci_6 alkyl groups (preferably methyl) , (ii) a cyano group,
(iii) a hydroxy group, - (iv) a carboxy group,
(v) a Ci_6 alkoxy group (preferably methoxy) , (vi) a Ci-6 alkyl-carbonyl group (preferably acetyl), (vii) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) , and
(viii) a carbamoyl group optionally mono- or di- substituted by Ci-6 alkyl group (s) (preferably ethyl), (b) a C7-X3 aralkyl group (preferably benzyl) , (c) a Ci_6 alkyl-carbonyl group .(preferably acetyl) ,
(d) a Ci_6 alkylsulfonyl group (preferably methylsulfonyl) ,
(e) a carbamoyl group optionally mono- or di-substituted by Ci_6 alkyl group (s) (preferably methyl), and
(f) a non-aromatic heterocyclic group (preferably tetrahydropyranyl) ; and (2) a C3-10 cycloalkane (preferably cyclohexane) optionally substituted by 1 to 3 substituents selected from an oxo group and a Ci_3 alkylenedioxy group (preferably ethylenedioxy) / can be mentioned. R21 is preferably a hydrogen atom or an optionally substituted Cχ-β alkyl group.
As preferable specific examples for R21,
(1) a hydrogen atom; and
(2) a Ci-6 alkyl group (preferably methyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a non-aromatic heterocyclic group (preferably morpholinyl) ; can be mentioned.
R22 is preferably a hydrogen atom. In the embodiment wherein R2 is a group represented by
Figure imgf000034_0001
A is. CH or N;
R4 and R5 are each independently an optionally substituted Cχ-6 alkyl group or an optionally substituted C3-10 cycloalkyl group, or R4 and R5 in combination form an optionally substituted ring (the ring should not be morpholine) .
In this embodiment, A is preferably CH.
The "Ci-6 alkyl group" of the "optionally substituted Ci-' 6 alkyl group" for R4 or R5 optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the Ci-10 alkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R5, R7, R21 or R22 optionally has, can be mentioned. As the λΛC3-10 cycloalkyl group" of the "optionally substituted C3-I0 cycloalkyl group" for R4 or R5, those similar to the "C3-I0 cycloalkyl group" exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 can be mentioned.
The "C3-10 cycloalkyl group" optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 optionally has, can be mentioned.
When R4 and R5 are independent, R4 and. R5 are preferably each independently (1) a Ci_6 alkyl group (preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, neopentyl) optionally substituted by 1 to 3 substituents selected from
(a) a Ci_s alkoxy group (preferably methoxy, ethoxy) ,
(b) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl, ethylsulfonyl) ,
(c) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl, ethoxycarbonyl) , and
(d) an aromatic heterocyclic group (preferably pyridyl) ; or (2) a C3-10 cycloalkyl group (preferably cyclopropyl) . When R4 and R5 in combination form an optionally substituted ring, as the "ring" of the "optionally substituted ring", an optionally substituted nitrogen-containing non- aromatic heterocycle can be mentioned. As the "nitrogen- containing non-aromatic heterocycle" of the "optionally substituted nitrogen-containing non-aromatic heterocycle", for example, a monocyclic nitrogen-containing non-aromatic heterocycle (the ring should not be morpholine) , a fused nitrogen-containing non-aromatic heterocycle, a nitrogen- containing spiro ring and the like can be mentioned. As the "monocyclic nitrogen-containing non-aromatic heterocycle", for example, a 5- to 7-meitιbered monocyclic nitrogen-containing non-aromatic heterocycle (the ring should not be morpholine) containing, as a ring-constituting atom besides carbon atoms, at least one nitrogen atom and optionally further containing 1 to 3 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom can be mentioned. As preferable specific examples of the 5- to 7- membered monocyclic nitrogen-containing non-aromatic heterocycle, pyrrolidine, oxopyrrolidine, dioxopyrrolidine, piperidine, thiomorpholine, 1, 1-dioxidothiomorpholine, piperazine, oxopiperazine and the like can be mentioned.
As the "fused nitrogen-containing non-aromatic heterocycle", for example, a ring wherein the above-mentioned 5^ to 7-membered monocyclic nitrogen-containing non-aromatic heterocycle and 1 or 2 rings selected from a 5 or 6-membered aromatic heterocycle, a 5 or β-membered non-aromatic heterocycle and a benzene ring are condensed, and a ring wherein the above-mentioned ring is partially saturated, can be mentioned. As the 5 or 6-membered aromatic heterocycle and 5 or 6-membered non-aromatic heterocycle, for example, a ring corresponding to a 5- or 6-membered ring group, from among the aromatic heterocyclic group and non-aromatic heterocyclic group exemplified, as the "heterocyclic group" of the below- mentioned "optionally substituted heterocyclic group" for R3, can be mentioned.
As preferable specific examples of the fused nitrogen- containing non-aromatic heterocycle, tetrahydropyrrole [3, 4- c]pyrrole-l,3 (2H, 3aH) -dione, hexahydropyrazino [2, 1- c] [1, 4] oxazin-4 (3H) -one, hexahydro [1, 3] oxazolo [3, 4-a]pyrazin- 3-one, 5, 6, 7, 8-tetrahydro [1,2, 4] triazolo [4, 3-a]pyrazine and the like can be mentioned.
As the "nitrogen-containing spiro heterocycle", for example, a ring formed by the above-mentioned 5- to 7-membered monocyclic nitrogen-containing non-aromatic heterocycle and 1 or 2 rings selected from a C3-10 cycloalkane, a C3-10 cycloalkene, a C4-10 cycloalkadiene and a 5 or 6-membered non-aromatic heterocycle can be mentioned.
As the C3-10 cycloalkane, C3-10 cycloalkene and C4-10 cycloalkadiene, a ring corresponding to the C3-10 cycloalkyl group, C3-10 cycloalkenyl group and C4-10 cycloalkadienyl 1 group exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 can be mentioned. As. the 5 or 6-membered non-aromatic heterocycle, a ring corresponding to a 5- or β-membered ring group, from among the monocyclic non-aromatic heterocyclic group exemplified as the "heterocyclic group" of the below-mentioned "optionally substituted heterocyclic group" for R3, can be mentioned.
As preferable specific examples of the nitrogen- containing spiro heterocycle, l-oxa-3, 8-diazaspiro [4.5]decan- 2-one and the like can be mentioned.
The "ring" of the "optionally substituted ring" optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the C3-Io cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 optionally has, can be mentioned.
When R4 and R5 in combination form an optionally substituted ring, the "optionally substituted ring" is preferably an "optionally substituted nitrogen-containing non- aromatic heterocycle (the ring should not be morpholine) ", more preferably a nitrogen-containing non-aromatic heterocycle (the ring should not be morpholine) [preferably a monocyclic nitrogen-containing non-aromatic heterocycle (the ring should not be morpholine) (preferably pyrrolidine, oxopyrrolidine, piperidine, thiomorpholine, 1,1- dioxidothiomorpholine, piperazine, oxopiperazine) ; a fused nitrogen-containing non-aromatic heterocycle (preferably tetrahydropyrrole [3, 4-c]pyrrole-l, 3 (2H, 3aH) -dione, hexahydropyrazino [2, 1-c] [1, 4]oxazin-4 (3H) -one, hexahydro [ 1, 3] oxazolo [3, 4-a]pyrazin-3-one, 5,6,1,8- tetrahydro [1,2, 4] triazolo [4, 3-a]pyrazine) ; or a nitrogen-containing spiro heterocycle (preferably l-oxa-3, 8- diazaspiro [4.5]decan-2-one) ] optionally substituted by 1 to 3 substituents selected from (1) a Ci-6 alkyl group (preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (preferably fluorine- atom) , (b) a carboxy group,
(c) a hydroxy group,
(d) a Ci-6 alkoxy group (preferably methoxy, ethoxy) ,
(e) a Ci-6 alkoxy-carbonyl group "(preferably methoxycarbonyl, ethoxycarbonyl ) , (f) a carbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) (preferably methyl) , and (g) a non-aromatic heterocyclic group (preferably tetrahydrofuranyl) ;
(2) an aromatic heterocyclic group (preferably pyridyl, pyrimidinyl) optionally substituted by 1 to 3 Ci-e alkyl groups;
(3) an amino group optionally mono- or di-substituted by Ci-6 alkyl-carbonyl group (s) (preferably acetylamino) ;
(4) a Ci-6 alkyl-carbonyl group (preferably acetyl);
(5) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl, ethoxycarbonyl) ;
(6) a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl) ;
(7) a QL-6 alkylsulfonyl group (preferably methylsulfonyl, ethylsulfonyl) ; (8) a carbamoyl group;
(9) a hydroxy group; and
(10) an aromatic heterocyclyl-oxy group (preferably pyrimidyloxy, pyrazinyloxy) .
Preferably, R4 and R5 in combination form an optionally substituted ring (the ring should not be morpholine) .
W is O or NR8 wherein R8 is a hydrogen atom, an optionally substituted Ci_6 alkyl group or an optionally substituted C3-10 cycloalkyl group. W is preferably NR8 wherein R8 is defined above. The "Ci-6 alkyl group" of the "optionally substituted Cχ-6 alkyl group" for R8 optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the Ci-io alkyl group and the like exemplified as the "hydrocarbon group" of the
"optionally substituted hydrocarbon group" for R6, R7, R21 or R22 optionally has, can be mentioned.
As the "optionally substituted C3-10 cycloalkyl" for R8, those similar to the "optionally substituted C3_io cycloalkyl" for R4 or R5 can be mentioned.
As preferable specific examples for R8
(1) a hydrogen atom; and
(2) a Ci-6 alkyl group (preferably methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 substituents selected from
(a) a C3-10 cycloalkyl group (preferably cyclopropyl) , and
(b) a Cχ-6 alkoxy group (preferably methoxy, ethoxy) ; can be mentioned.
As another preferable specific examples for R8 (1) a hydrogen atom; and
(2) a C1-6 alkyl group (preferably methyl, ethyl, propyl, isopropyl, isobutyl) optionally substituted by 1 to 3 substituents selected from
(a) a C3-10 cycloalkyl group (preferably cyclopropyl) , (b) a Ci_s alkoxy group ' (preferably methoxy, ethoxy) ,
(c) a halogen atom (preferably fluorine atom) , / (d) a cyano group,
(e) a hydroxy group,
(f) a carboxy group, (g) a carbamoyl group, and
(h) a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl) ; can be mentioned.
R3 is an optionally substituted heterocyclic group or an optionally substituted Cβ-u aryl group.
As the "heterocyclic group" of the "optionally substituted heterocyclic group" for R3, an aromatic heterocyclic group and a non-aromatic heterocyclic group can be mentioned.
As used herein, as the aromatic heterocyclic group, for example, a 4- to 7-membered (preferably 5- or 6-membered) monocyclic aromatic heterocyclic group containing, as a ring- constituting atom besides carbon atoms, 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom, and a fused aromatic heterocyclic group can be mentioned. As the fused aromatic heterocyclic group, for example, a group derived from a fused ring wherein a ring corresponding to the 4- to 7-membered monocyclic aromatic heterocyclic group and 1 or 2 rings selected from a 5- or 6-membered aromatic heterocycle containing 1 or 2 nitrogen atoms (e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine) , a 5- membered aromatic heterocycle containing one sulfur atom (e.g., thiophene) and a benzene ring are fused, and the like can be mentioned.
As preferable examples of the aromatic heterocyclic group, monocyclic aromatic heterocyclic groups such as furyl (e.g., 2-furyl, 3-furyl) , thienyl (e.g., 2-thienyl, 3-thienyl) , pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl) , pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl) , pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl) , pyrazinyl (e.g., 2-pyrazinyl) , pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl) , imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4- imidazolyl, 5-imidazolyl) , pyrazolyl (e.g., 1-pyrazolyl, 3- pyrazolyl, 4-pyrazolyl) , thiazolyl . (e.g. , 2-thiazolyl, 4- thiazolyl, 5-thiazolyl) , isothiazolyl (e.g., 4-isothiazolyl) , oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl/ 5-oxazolyl), isoxazolyl, oxadiazolyl (e.g., 1, 2, 4-oxadiazol-3-yl, 1,2,4- oxadiazol-5-yl, 1, 3, 4-oxadiazol-2-yl) , thiadiazolyl (e.g., l,3,4-thiadiazol-2-yl, 1, 2, 4-thiadiazol-3-yl, 1,2,4- thiadiazol-5-yl) , triazolyl (e.g., 1, 2, 4-triazol-l-yl, 1,2,4- triazol-3-yl, 1, 2, 3-triazol-l-yl, 1, 2, 3-triazol-2-yl, 1,2,3- triazol-4-yl) , . tetrazolyl (e.g., tetrazol-1-yl, tetrazol-5-yl) , triazinyl (e.g., 1, 2, 4-triazin-l-yl, 1, 2, 4-triazin-3-yl) and the like; fused heterocyclic group such as quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl, 6-quinolyl) , isoquinolyl (e.g., 3- isoquinolyl) , quinazolyl (e.g., 2-quinazolyl, 4-quinazolyl) , quinoxalyl (e.g., 2-quinoxalyl, β-quinoxalyl) , benzofuryl (e.g., 2-benzofuryl, 3-benzofuryl) , benzothienyl (e.g., 2- benzothienyl, 3-benzothienyl) , benzoxazolyl (e.g., 2- benzoxazolyl) , benzisoxazolyl (e.g., 7-benzisoxazolyl) , benzothiazolyl (e.g., 2-benzothiazolyl) , benzimidazolyl (e.g., benzimidazol-1-yl, benzimidazol-2-yl, benzimidazol-5-yl) , benzotriazolyl (e.g., IH-I, 2, 3-benzotriazol-5-yl) , indolyl (e.g., indol-1-yl, indol-2-yl, indol-3-yl, indol-5-yl), indazolyl (e.g., lH-indazol-3-yl) , pyrrolopyrazinyl (e.g., IH- pyrrolo [2, 3-b]pyrazin-2-yl, IH-pyrrolo [2, 3-b]pyrazin-6-yl) , imidazopyridinyl (e.g., lH-imidazo [4, 5-b]pyridin-2-yl, IH- imidazo [4, 5-c]pyridin-2-yl, 2H-imidazo[l, 2-a]pyridin-3-yl) , imidazopyrazinyl (e.g., IH-imidazo [4, 5-b]pyrazin-2-yl) , irαidazothiazolyl (e.g., imidazo [2, 1-b] thiazol-5- yl)pyrazolopyridinyl (e.g., lH-pyrazolo [4, 3-c]pyridin-3-yl) , pyrazolothienyl (e.g., 2H-pyrazolo [3, 4-b] thiophen-2-yl) , pyrazolotriazinyl (e.g., pyrazolo [5, 1-c] [1, 2, 4] triazin-3-yl) and the like; and the like can be mentioned.
As the non-aromatic heterocyclic group, for example, a 4- to 7-membered (preferably 5- or 6-membered) monocyclic non- aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atoms, 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom, and a fused non-aromatic heterocyclic group can be mentioned. As the fused non-aromatic heterocyclic group, for example, a group derived from a fused ring wherein a ring corresponding to the 4- to 7- membered monocyclic non-aromatic heterocyclic group and 1 or 2 rings selected from a 5- or 6-membered aromatic or non- aromatic heterpcycle containing 1 or 2 nitrogen atoms (e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine) , a 5-membered aromatic or non-aromatic heterocycle containing one sulfur atom (e.g., thiophene, tetrahydrothiophene) and a benzene ring are fused, a group wherein the above-mentioned group is partially saturated, and the like can be mentioned.
As preferable examples of the non-aromatic heterocyclic group, monocyclic non-aromatic heterocyclic groups such as tetrahydrofuranyl (e.g., 2-tetrahydrofuranyl) , pyrrolidinyl (e.g., 1-pyrrolidinyl) , piperidinyl (e.g., piperidino, 2- piperidinyl, 3-piperidinyl, 4-piperidinyl) , morpholinyl (e.g., morpholino) , thiomorpholinyl (e.g., thiomorpholino) , piperazinyl (e.g., 1-piperazinyl, 2-piperazinyl, 3- piperazinyl) , hexamethyleniminyl (e.g., hexamethylenimin-1-yl) oxazolidinyl (e.g., oxazolidin-2-yl) , thiazolidinyl (e.g., thiazolidin-2-yl) , imidazolidinyl (e.g., imidazolidin-2-yl, imidazolidin-3-yl) , oxazolinyl (e.g., oxazolin-2-yl) , thiazolinyl (e.g., thiazolin-2-yl) , imidazolinyl (e.g., imidazolin-2-yl, imidazolin-3-yl) , dioxolyl (e.g., 1,3-dioxol- 4-yl) , dioxolanyl (e.g., 1, 3-dioxolan-4-yl) , dihydrooxadiazolyl (e.g., 4, 5-dihydro-l, 2, 4-oxadiazol-3-yl) , thioxooxazolidinyl (e.g., 2-thioxo-l, 3-oxazolidin-5-yl) , pyranyl (e.g., 4-pyranyl) , tetrahydropyranyl (e.g., 4- tetrahydropyranyl) , thiopyranyl (e.g., 4-thiopyranyl) , tetrahydrothiopyranyl (e.g., 4-tetrahydrothiopyranyl) , 1- oxidotetrahydrothiopyranyl (e.g., 1-oxidotetrahydrothiopyran- 4-yl) , 1, 1-dioxidotetrahydrothiopyranyl (e.g., 1,1- dioxidotetrahydrothiopyran-4-yl) , pyrazolidinyl (e.g., pyrazolidin-1-yl) , tetrahydropyrimidinyl, dioxanyl (e.g., 1,3- dioxan-2-yl, 1, 3-dioxan-4-yl, 1, 3-dioxan-5-yl, 1, 4-dioxan-2- yl), dioxenyl (e.g., 4H-1, 3-dioxin-2-yl, 4H-1, 3-dioxin-4-yl, 4H-l,3-dioxin-5-yl, 4H-1, 3-dioxin -6-yl, 2, 3-dihydro-l, 4- dioxin-2-yl, 2, 3-dihydro-l, 4-dioxin-5-yl) and the like; fused non-aromatic heterocyclic groups such as dihydroindolyl (e.g., 2,3-dihydro-lH-isoindol-l-yl) , dihydroisoindolyl (e.g., 1, 3-dihydro~2H-isoindol-2-yl) , dihydrobenzofuranyl (e.g., 2,3- dihydro-l-benzofuran-5-yl) , dihydrobenzodioxinyl (e.g., 2,3- dihydro-1, 4-benzodioxinyl) , dihydrobenzodioxepinyl (e.g., 3,4- dihydro-2H-l, 5-benzodioxepinyl) , tetrahydrobenzofuranyl (e.g., 4, 5, 6, 7-tetrahydro-l-benzofuran-3-yl) , chromenyl (e.g., 4H- chromen-2-yl, 2H-chromen-3-yl) , dihydroquinolinyl (e.g., 1,2- dihydroquinolin-4-yl) , tetrahydroquinolinyl (e.g., 1,2,3,4- tetrahydroquinolin-4-yl) , dihydroisoquinolinyl (e.g., 1,2- dihydroisoquinolin-4-yl) , tetrahydroisoquinolinyl (e.g., 1, 2, 3, 4-tetrahydroisoquinolin-4-yl) , dihydrophthalazinyl (e.g., 1, 4-dihydrophthalazin-4-yl) , hexahydropyrazinooxazinyl (e.g., hexahydropyrazino [2, 1-c] [1, 4]oxazinyl) and the like; and the like can be mentioned.
The "heterocyclic group" of the aforementioned "optionally substituted heterocyclic group" optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for Rδ, R7, R21 or R22 optionally has, can be mentioned. As the "C6-i4 aryl group" of the "optionally substituted C6-i4 aryl group" for R3, those similar to the "Cδ-i4 aryl group" exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 can be mentioned.
The "C6-i4 aryl group" optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 optionally has, can be mentioned.
R3 is preferably an optionally substituted 5- or 6- membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, furyI7 thiazolyl/ imidazolyl) or an optionally substituted C3-i4 aryl group (e.g., phenyl), more preferably an optionally substituted 5- or 6-membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, furyl, thiazolyl, imidazolyl) , particularly preferably a 5- or 6-membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, furyl, thiazolyl, imidazolyl) .
As preferable specific examples for R3,
(1) a 5- or β-membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, furyl, thiazolyl, imidazolyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (preferably chlorine atom), and
(b) a Ci-6 alkyl group (preferably methyl) ; and
(2) a Cδ-14 aryl group (e.g., phenyl) optionally substituted by 1 to 3 substituents selected from (a) a Cχ-s alkyl group (preferably methyl) optionally substituted by 1 to 3 halogen atoms (preferably fluorine atom) , and
(b) a Ci_6 alkoxy group (preferably methoxy) ; can be mentioned. R9, R10 and R11 are each independently a hydrogen atom, a halogen atom, an optionally substituted Ci-e alkyl group or an optionally substituted Ci-6 alkoxy group.
The "Ci-e alkyl group" of the "optionally substituted Ci_6 alkyl group" for R9, R10 or R11 optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the Ci-io alkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 optionally has, can be mentioned. The "Ci-6 alkoxy group" of the "optionally substituted Ci_5 alkoxy group" for R9, R10 or R11 optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the Cx-I0 alkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 optionally has, can be mentioned.
R9 is preferably a hydrogen atom or a halogen atom (preferably chlorine atom) .
R10 is preferably a hydrogen atom, a halogen atom, a Ci_6 alkyl group or an optionally substituted Ci-6 alkoxy group, more preferably a hydrogen atom, a Cχ-β alkyl group or an optionally substituted Cχ-6 alkoxy group. As preferable specific examples for R10,
(1) a hydrogen atom;
(2) a halogen atom (preferably bromine atom) ;
(3) a C1S alkyl group (preferably methyl) ; and
(4) a Ci-6 alkoxy group (preferably methoxy, ethoxy, propoxy, isopropoxy) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (preferably fluorine atom) ,
(b) a hydroxy group,
(c) a carboxy group, (d) a carbamoyl group,
(e) a Ci-6 alkoxy group (preferably methoxy) ,
(f) a Ci-6 alkyl-carbonyl group (preferably acetyl) ,
(g) a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl ) , and (h) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ; can be mentioned.
R11 is preferably a hydrogen atom, a halogen atom (preferably chlorine atom) or a Cχ-6 alkyl group (preferably methyl) . Compound (I) does not contain a compound wherein R21 is a hydrogen atom or a Cχ-6 alkoxy- carbonyl group, R22 is a hydrogen atom, and R6 and R7 are both hydrogen atoms, and a compound wherein R21 is a hydrogen atom or a Ci_6 alkoxy- carbonyl groug, R22 is a hydrogen atom, and R6 and R7 are both methyl groups .
Preferable examples of compound (I) is as follow. [Compound (A) ]
Compound (I) wherein
R1 is a hydrogen atom;
R2 is a group represented by
Figure imgf000046_0001
A is CH or N;
R4 and R5 are each independently
(1) a Ci-6 alkyl group (preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, neopentyl) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkoxy group (preferably methoxy, ethoxy) ,
(b) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl, ethylsulfonyl) ,
(c) a Ci_6 alkoxy-carbonyl group (preferably methoxycarbonyl, ethoxycarbonyl ) , and
(d) an aromatic heterocyclic group (preferably pyridyl) / or
(2) a C3-.10 cycloalkyl group (preferably cyclopropyl) ; or
R4 and R5 in combination form, a nitrogen-containing non- aromatic heterocycle (the ring should not be morpholine) [preferably a monocyclic nitrogen-containing non-aromatic heterocycle (the ring should not be morpholine) (preferably pyrrolidine, oxopyrrolidine, piperidine, thiomorpholine, 1,1- dioxidothiomorpholine, piperazine, oxopiperazine) ; a fused nitrogen-containing non-aromatic heterocycle (preferably tetrahydropyrrole [3, 4-c]pyrrole-l, 3 (2H, 3aH) -dione, hexahydropyrazino [2, 1-c] [1,4] oxazin-4 (3H) -one, hexahydro [1, 3] oxazolo [3, 4-a]pyrazin-3-one, 5,6,1, 8- tetrahydro [1,2, 4] triazolo[4, 3-a]pyrazine) ; or a nitrogen-containing spiro heterocycle (preferably l-oxa-3,8- diazaspiro [4.5] decan-2-one) ] optionally substituted by 1 to 3 substituents selected from
(1) a Ci-6 alkyl group (preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (preferably fluorine atom) ,
(b) a carboxy group,
(c) a hydroxy group, (d) a Ci-6 alkoxy group (preferably methoxy, ethoxy) ,
(e) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl, ethoxycarbonyl) ,
(f) a carbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) (preferably methyl) , and (g) a non-aromatic heterocyclic group (preferably tetrahydrofuranyl) ,
(2) an aromatic heterocyclic group (preferably pyridyl, pyrimidinyl) optionally substituted by 1 to 3 Ci-6 alkyl groups,
(3) an amino group optionally mono- or di-substituted by Ci_e alkyl-carbonyl group (s) (preferably acetylamino) ,
(4) a Ci-6 alkyl-carbonyl group (preferably acetyl),
(5) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl, ethoxycarbonyl) ,
(6) a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl) ,
(7) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl, ethylsulfonyl) ,
(8) a carbamoyl group,
(9) a hydroxy group, and (10) an aromatic heterocyclyl-oxy group (preferably pyrimidyloxy, pyrazinyloxy) , W is NR8; R8 is
(1) a hydrogen atom, or (2) a Ci-6 alkyl group (preferably methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 substituents selected from
(a) a C3-I0 cycloalkyl group (preferably cyclopropyl) , and
(b) a Ci-6 alkoxy group (preferably methoxy, ethoxy) ; R3 is a 5- or 6-iαembered monocyclic aromatic heterocyclic group (preferably thienyl) ;
R9 is a hydrogen atom or a halogen atom (preferably chlorine atom) ;
R10 is a hydrogen atom; and R11 is a hydrogen atom, halogen atom (preferably chlorine atom) or a Ci_6 alkyl group (preferably methyl) .
[Compound (Al) ]
Compound (A) wherein A is N.
[Compound (A2) ]
Compound (A) wherein A is CH.
[Compound (B) ] Compound (I) wherein R1 is a hydrogen atom; R2 is a group represented by
Figure imgf000048_0001
R6 is (1) a Ci_6 alkyl group (preferably methyl, ethyl, isopropyl) optionally substituted by 1 to 3 substituents selected from (a) a non-aromatic heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl) optionally substituted by 1 to 3 substituents selected from
(i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl), (iii) a Ci-s alkylsulfonyl group (preferably methylsulfonyl) , and
(iv) a halogen atom (preferably fluorine atom) ,
(b) an amino group,
(c) a hydroxy group, and (d) a Ci-6 alkoxy group (preferably methoxy) ,
(2) a cyano group,
(3) a carboxy group,
(4) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) ,
(5) a carbamoyl group, or (6) a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl) ,
[preferably a Ci_6 alkyl group (preferably methyl, ethyl, isopropyl) substituted by 1 to 3 substituents selected from
(a) a non-aromatic heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl) optionally substituted by -1 to 3 substituents selected from (i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (iii) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) , and
(iv) a halogen atom (preferably fluorine atom)], and R7 is
(1) a hydrogen atom, or
(2) a Ci-6 alkyl group (preferably methyl) ; or R6 and R7 in combination form, a monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by aromatic heterocyclic group (s) (preferably imidazolyl) optionally substituted by 1 to 3 Cχ-6 alkyl groups (preferably methyl) ,
(b) a C7-i3 aralkyl group (preferably benzyl) ,
(c) a Ci-s a.lkyl-carbonyl group (preferably acetyl),
(d) a Ci_6 alkylsulfonyl group (preferably methylsulfonyl) , and
(e) a carbamoyl group optionally mono- or di-substituted by Ci_6 alkyl group (s) (preferably methyl) ;
W is NR8; R8 is (1) a hydrogen atom, or
(2) a Ci-6 alkyl group (preferably methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 substituents selected from
(a) a C3-IO cycloalkyl group (preferably cyclopropyl) , and (b) a Ci-6 alkoxy group (preferably methoxy, ethoxy) ;
R3 is a 5- or 6-membered monocyclic aromatic heterocyclic group (preferably thienyl) ;
R9 is a hydrogen atom or a halogen atom (preferably chlorine atom) ; R10 is a hydrogen atom; and
R11 is a hydrogen atom, halogen atom (preferably chlorine atom) or a Ci_6 alkyl group (preferably methyl) .
[Compound (C) ] Compound (I) wherein
R1 is a hydrogen atom or a halogen atom (preferably fluorine atom) ;
R2 is a group represented by
Figure imgf000050_0001
R6 is
(1) a Ci-6 alkyl group (preferably methyl,, ethyl, isopropyl, isobutyl) optionally substituted by 1 to 3 substituents selected from
(a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl) optionally substituted by 1 to 3 substituents selected from
(i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (iϋ) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ,
(iv) a halogen atom (preferably fluorine atom) , (v) an oxo group,
(vi) a Cχ-6 alkyl group (preferably methyl, ethyl) . optionally substituted by 1 to 3 hydroxy groups, and (vii) a Ca-3 alkylenedioxy group (preferably ethylenedioxy) ,
(b) an amino group optionally mono- or di-substituted by substituent (s) selected from (i) a Ci-6 alkyl group (preferably methyl, ethyl, isobutyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Ci-β alkylsulfonyl group (preferably methylsulfonyl),
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl), (iii) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) optionally substituted by 1 to 3 Ce-÷u aryl groups (preferably phenyl) ,
(iv) a C3-10 cycloalkyl group (preferably cyclohexyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Qi_6 alkyl group (preferably methyl) ,
(v) an aromatic heterocyclic group (preferably triazolyl) , and
(vi) a non-aromatic heterocyclic group (preferably tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl, 1 , 1-dioxidotetrahydrothiopyranyl) ,
(c) a hydroxy group,
(d) a Ci-6 alkoxy group (preferably methoxy) ,
(e) a Ci-6 alkylsulfonyloxy group (preferably methylsulfonyloxy) ,
(f) a Ci-6 alkyl-carbonyl group (preferably acetyl),
(g) a C2-S alkenyl-carbonyl group (preferably vinylcarbonyl) , (h) a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl) , (i) a carboxy group, (j) a non-aromatic heterocyclyl-carbonyl group (preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1, 1- dioxidothiomorpholinylcarbonyl, pyrrolidinylcarbonyl, azetidinylcarbonyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group,
(ii) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, (iii) a halogen atom (preferably fluorine atom) , and
(iv) a carboxy group,
(k) a non-aromatic heterocyclyl-carbonyloxy group (preferably morpholinylcarbonyloxy) optionally substituted by 1 to 3 Ci-6 alkyl groups (preferably methyl) , (1) a carbamoyl group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group, a Ci_6 alkoxy group (preferably methoxy) and a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ,
(ii) a Ci-6 alkoxy group (preferably methoxy) , (iii) a C3-10 cycloalkyl group (preferably cyclopropyl) , (iv) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) , (v) an aromatic heterocyclic group (preferably triazolyl, tetrazolyl) , and
(vi) a non-aromatic heterocyclic group (preferably tetrahydropyranyl) , (m) a Ci-6 alkylthio group (preferably methylthio) optionally substituted by 1 to 3 carboxy groups, and (n) a formyl group,
(2) a cyano group,
(3) a carboxy group, (4) a QL-6 alkoxy-carbonyl group (preferably methoxycarbonyl) ,
(5) a carbamoyl group optionally mono- or di-substituted by Ci_5 alkyl group (s) (preferably ethyl), or
(6) a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl, morpholinylcarbonyl, piperazinylcarbonyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (preferably methyl) ,
[preferably a Ci_6 alkyl group (preferably methyl, ethyl, isopropyl, isobutyl) .substituted by 1 to 3 substituents selected from (a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl,- piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothioitιorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, ■triazolyl) optionally substituted by 1 to 3 substituents selected from
(i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (iii) a Ci_6 alkylsulfonyl group (preferably methylsulfonyl) , (iv) a halogen atom (preferably fluorine atom) , (v) an oxo group,
(vi) a Ci_6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, and (vii) a Ci-3 alkylenedioxy group (preferably ethylenedioxy) ] , and R7 is
(1) a hydrogen atom, or
(2) a Ci-6 alkyl group (preferably methyl) ; or
R6 and R7 in combination form (1) a monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran, 1-oxidotetrahydrothiopyran) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group (preferably methyl, ethyl, isobutyl)
■ optionally substituted by 1 to 3 substituents selected from (i) an aromatic heterocyclic group (preferably imidazolyl, furyl, pyridyl) optionally substituted by 1 to 3 Cχ-6 alkyl groups (preferably methyl) , (ii) a cyano group, (iii) a hydroxy group, (iv) a carboxy group,
(v) a Ci-6 alkoxy group (preferably methoxy) , (vi) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (vii) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) , and (viii) a carbamoyl group optionally mono- or di- substituted by Ci-6 alkyl group (s) (preferably ethyl),
(b) a C7-i3 aralkyl group (preferably benzyl) ,
(c) a Ci_6 alkyl-carbonyl group (preferably acetyl) ,
(d) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) , (e) a carbamoyl group optionally mono- or di-substituted by
Ci-6 alkyl group (s) (preferably methyl), and (f) a non-aromatic heterocyclic group (preferably tetrahydropyranyl) , or
(2) a C3-10 cycloalkane (preferably cyclohexane) optionally substituted by 1 to 3 substituents , selected from an oxo group and a Ci_3 alkylenedioxy group (preferably ethylenedioxy) ; R21 is
(1) a hydrogen atom, or
(2) a Ci-s alkyl group (preferably methyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a non-aromatic heterocyclic group (preferably morpholinyl) ;
R22 is a hydrogen atom; W is NR8; R8 is
(1) a hydrogen atom, or
(2) a Ci-6 alkyl group (preferably methyl, ethyl, ' propyl, isopropyl, isobutyl) optionally substituted by 1 to 3 substituents selected from (a) a C3-10 cycloalkyl group (preferably cyclopropyl) ,
(b) a Ci-6 alkoxy group (preferably methoxy, ethoxy) ,
(c) a halogen atom (preferably fluorine atom) ,
(d) a cyano group,
(e) a hydroxy group, (f) a carboxy group,
(g) a carbamoyl group, and
(h) a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl) ;
R3 is (1) a 5- or 6-membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, ■ furyl, thiazolyl, imidazolyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (preferably chlorine atom) , and
(b) a Ci-6 alkyl group (preferably methyl) , or (2) a Cβ-14 aryl group (e.g., phenyl) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group (preferably methyl) optionally substituted by 1 to 3 halogen atoms (preferably fluorine atom) , and (b) a Ci-6 alkoxy group (preferably methoxy) ;
R9 is a hydrogen atom or a halogen atom (preferably chlorine atom) ;
R10 is
(1) a hydrogen atom, (2) a halogen atom (preferably bromine atom) , (3) a Ci-6 alkyl group (preferably methyl) , or
(4) a Ci-6 alkoxy group (preferably methoxy, ethoxy, propoxy, isopropoxy) optionally substituted by 1 to 3 substituents selected from (a) a halogen atom (preferably fluorine atom) ,
(b) a hydroxy group,
(c) a carboxy group,
(d) a carbamoyl group,
(e) a Ci-6 alkoxy group (preferably methoxy) , (f) a Ci-6 alkyl-carbonyl group (preferably acetyl),
(g) a Ci-6 alkoxy-carbonyl group "(preferably ethoxycarbonyl) , and
(h) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ; and R11 is a hydrogen atom, a halogen atom (preferably chlorine atom) or a Ci -β alkyl group (preferably methyl ) .
[Compound (D) ]
Compound (I) wherein R1 is a hydrogen atom or a halogen atom (preferably fluorine atom) ;
R2 is a group represented by
Figure imgf000056_0001
R6 is (1) a Ci-6 alkyl group (preferably methyl, ethyl, isopropyl, isobutyl) optionally substituted by 1 to 3 substituents selected from
(a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl) optionally substituted by 1 to 3 substituents selected from
(i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (iii) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ,
(iv) a halogen atom (preferably fluorine atom) , (y) an oxo group,
(vi) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, and (vii) a Ci-3 alkylenedioxy group (preferably ethylenedioxy) ,
(b) an amino group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (preferably methyl, ethyl, isobutyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Ci-6 alkylsulfonyl group (preferably methylsulfonyl),
(ii) a Ci_6 alkyl-carbonyl group (preferably acetyl) ,
(iii) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) optionally substituted by 1 to 3 Cβ-i4 aryl groups (preferably phenyl) ,
(iv) a C3-10 cycloalkyl group (preferably cyclohexyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Ci-S alkyl group (preferably methyl) ,
(v) an aromatic heterocyclic group (preferably triazolyl) , and
(vi) a non-aromatic heterocyclic group (preferably tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl, 1, 1-dioxidotetrahydrothiopyranyl) ,
(c) a hydroxy group,
(d) a Ci-6 alkoxy group (preferably methoxy) ,
(e) a Ci_6 alkylsulfonyloxy group (preferably methylsulfonyloxy) , (f) a Ci_6 alkyl-carbonyl group (preferably acetyl), (g) a C2-6 alkenyl-carbonyl group (preferably vinylcarbonyl) , (h) a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl ) , (i) a carbo.xy group,
(j) a non-aromatic heterocyclyl-carbonyl group (preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1, 1- dioxidothiomorpholinylcarbonyL, pyrrolidinylcarbonyl, azetidinylcarbonyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group,
(ii) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, (iii) a halogen atom (preferably fluorine atom) , and (iv) a carboxy group,
(k) a non-aromatic heterocyclyl-carbonyloxy group (preferably morpholinylcarbonyloxy) optionally substituted by 1 to 3 Ci-6 alkyl groups (preferably methyl), (1) a carbamoyl group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group, a C3.-6 alkoxy group (preferably methoxy) and a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ,
(ii) a Ci-e alkoxy group (preferably methoxy) , (iii) a C3-10 cycloalkyl group (preferably cyclopropyl) , (iv) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl), (v) an aromatic heterocyclic group (preferably triazolyl, tetrazolyl) , and
(vi) a non-aromatic heterocyclic group (preferably tetrahydropyranyl) ,
(m) a Ci-6 alkylthio group (preferably, methylthio) . optionally substituted by 1 to 3 carboxy groups, and (n) a forrayl group,
(2) a cyano group,
(3) a carboxy group,
(4) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) , (5) a carbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) (preferably ethyl), or
(6) a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl, morpholinylcarbonyl, piperazinylcarbonyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (preferably methyl) ,
[preferably a Ci-6 alkyl group (preferably methyl, ethyl, isopropyl, isobutyl) substituted by 1 to 3 substituents selected from
(a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (iii) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ,
(iv) a halogen atom (preferably fluorine atom) , (v) an oxo group,
(vi) a Ci_6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, and (vii) a Ci-3 alkylenedioxy group (preferably ethylenedioxy) ] , and R7 is
(1) a hydrogen atom, or
(2) a Ci_6 alkyl group (preferably methyl) ; or
R6 and R7 in combination form
(1) a monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran, 1-oxidotetrahydrothiopyran) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group (preferably methyl, ethyl, isobutyl) optionally .substituted by 1 to 3 substituents selected from
(i) an aromatic heterocyclic group (preferably imidazolyl, furyl, pyridyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (preferably methyl) ,
(ii) a cyano group,
(iii) a hydroxy group,
(iv) a carboxy group, (v) a Ci-6 alkoxy group (preferably methoxy) ,
(vi) a Ci-6 alkyl-carbonyl group (preferably acetyl) ,
(vii) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) , and
(viii) a carbamoyl group optionally mono- or di- substituted by Ci_6 alkyl group (s) (preferably ethyl),
(b) a C7-i3 aralkyl group (preferably benzyl) ,
(c) a Ci-6 alkyl-carbonyl group (preferably acetyl),
(d) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ,
(e) a carbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) (preferably methyl), and
(f) a non-aromatic heterocyclic group (preferably tetrahydropyranyl) , or
(2) a C3-10 cycloalkane (preferably cyclohexane) optionally substituted by 1 to 3 substituents selected from an oxo group and a C1-3 alkylenedioxy group (preferably ethylenedioxy) ; W is NR8; R8 is
(1) a hydrogen atom, or
(2) a Ci-6 alkyl group (preferably methyl, ethyl, propyl, isopropyl, isobutyl) optionally substituted by 1 to 3 substituents selected from
(a) a C3-10 cycloalkyl group (preferably cyclopropyl) ,
(b) a Ci-6 alkoxy group (preferably methoxy, ethoxy) ,
(c) a halogen atom (preferably fluorine atom) , - (d) a cyano group, (e) a hydroxy group,
(f) a carboxy group,
(g) a carbamoyl group, and
(h) a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl) ; R3 is
(1) a 5- or 6-membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, furyl,' thiazolyl, imidazolyl) optionally substituted by 1 to 3 substituents selected from (a) a halogen atom (preferably chlorine atom) , and (b) a QL-6 alkyl group (preferably methyl) , or
(2) a Cβ-14 aryl group (e.g., phenyl) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group (preferably methyl) optionally substituted by 1 to 3 halogen atoms (preferably fluorine atom) , and
(b) a Ci-6 alkoxy group (preferably methoxy) ;
R9 is a hydrogen atom or a halogen atom (preferably chlorine atom) ; R10 is
(1) a hydrogen atom,
(2) a halogen atom (preferably bromine atom) ,
(3) a Ci-6 alkyl group (preferably methyl) , or
(4) a Ci-6 alkoxy group (preferably methoxy, ethoxy, propoxy, isopropoxy) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (preferably fluorine atom) ,
(b) a hydroxy group,
(c) a carboxy group, (d) a carbamoyl group,
(e) a Ci-6 alkoxy group (preferably methoxy) ,
(f) a Ci-6 alkyl-carbonyl group (preferably acetyl),
(g) a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl), and (h) a Ci-s alkylsulfonyl group (preferably methylsulfonyl) ; and
R11 is a hydrogen atom, a halogen atom (preferably chlorine atom) or a Ci_6 alkyl group (preferably methyl) .
[Compound (E) ]
Compound (I) wherein
R1 is a hydrogen atom or a halogen atom (preferably fluorine atom) ;
R2 is a group represented by
Figure imgf000062_0001
R6 is
(1) a Ci-6 alkyl group (preferably methyl, ethyl, isopropyl, isobutyl) optionally substituted by 1 to 3 substituents selected from (a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothiomorpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl) optionally substituted by 1 to 3 substituents selected from
(i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (iii) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) , (iv) a halogen atom (preferably fluorine atom) , (v) an oxo group,
(vi) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, and (vii) a Ci_3 alkylenedioxy group (preferably ethylenedioxy) ,
(b) an amino group optionally mono- or di-substituted by substituent (s) selected from (i) a Ci-6 alkyl group (preferably methyl, ethyl, isobutyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Ci-s alkylsulfonyl group (preferably methylsulfonyl) , (ii) a Ci-6 alkyl-carbonyl group (preferably acetyl) ,
(iii) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) optionally substituted by 1 to 3 C6-i4 aryl groups (preferably phenyl) ,
(iv) a C3-10 cycloalkyl group (preferably cyclohexyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a Cχ-6 alkyl group (preferably methyl) ,
(v) an aromatic heterocyclic group (preferably triazolyl) , and (vi)' a non-aromatic heterocyclic group (preferably tetrahydrothiopyranyl, 1-oxidotetrahydrothiopyranyl,
1, 1-dioxidotetrahydrothiopyranyl) ,
(c) a hydroxy group,
(d) a Ci-6 alkoxy group (preferably methoxy) , (e) a Cχ-β alkylsulfonyloxy group (preferably methylsulfonyloxy) ,
(f) a Ci-6 alkyl-carbonyl group (preferably acetyl),
(g) a C2-6 alkenyl-carbonyl group (preferably vinylcarbonyl) , (h) a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl) , (i) a carboxy group,
(j) a non-aromatic heterocyclyl-carbonyl group (preferably piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, 1- oxidothiomorpholinylcarbonyl, 1,1- dioxidothiomorpholinylcarbonyl, _ pyrrolidinylcarbonyl, azetidinylcarbonyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group,
(ii) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, (iii) a halogen atom (preferably fluorine atom) , and (iv) a carboxy group,
(k) a non-aromatic heterocyclyl-carbonyloxy group (preferably morpholinylcarbonyloxy) optionally substituted by 1 to 3 Ci-6 alkyl groups (preferably methyl) ,
(1) a carbamoyl group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group, a Cχ-6 alkoxy group (preferably methoxy) and a Ci_6 alkylsulfonyl group (preferably methylsulfonyl) ,
(ii) a Ci-6 alkoxy group (preferably methoxy) , (iii) a C3-10 cycloalkyl group (preferably cyclopropyl) , (iv) a Ci_6 alkylsulfonyl group (preferably methylsulfonyl) ,
(v) an aromatic heterocyclic group (preferably triazolyl, tetrazolyl) , and
(vi) a non-aromatic heterocyclic group (preferably tetrahydropyranyl) ,
(m) a Ci-6 alkylthio group (preferably methylthio) optionally substituted by 1 to 3 carboxy groups, and (n) a formyl group, (2) a cyano group, (3) a carboxy group,
(4) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) ,
(5) a carbamoyl group optionally mono- or di-substituted by Ci_6 alkyl group (s) (preferably ethyl), or
(6) a non-aromatic heterocyclyl-carbonyl group (preferably pyrrolidinylcarbonyl, morpholinylcarbonyl, piperazinylcarbonyl) optionally substituted by 1 to 3 Ci-β alkyl groups (preferably methyl) ,
[preferably a Ci-6 alkyl group (preferably methyl, ethyl, isopropyl, isobutyl) substituted by 1 to 3 substituents selected from (a) a heterocyclic group (preferably piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1- oxidothioiαo.rpholinyl, 1, 1-dioxidothiomorpholinyl, pyrazolinyl, pyrazolidinyl, azetidinyl, imidazolyl, triazolyl) optionally substituted by 1 to 3 substituents selected from
(i) a hydroxy group,
(ii) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (iii) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ,
(iv) a halogen atom (preferably fluorine atom) , (v) an oxo group,
(vi) a Ci-6 alkyl group (preferably methyl, ethyl) optionally substituted by 1 to 3 hydroxy groups, and (vii) a Ci-3 alkylenedioxy group (preferably ethylenedioxy) ] , and R7 is
(1) a hydrogen atom, or
(2) a Ci-6 alkyl group (preferably methyl) ; or R6 and R7 in combination form •
(1) a monocyclic non-aromatic heterocycle (preferably piperidine, tetrahydropyran, 1-oxidotetrahydrothiopyran) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group (preferably methyl, ethyl, isobutyl) optionally substituted by 1 to 3 substituents selected from (i) an aromatic heterocyclic group (preferably imidazolyl, furyl, pyridyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (preferably methyl) , (ii) a cyano group, (iii) a hydroxy group, (iv) a carboxy group,
(v) a Ci-6 alkoxy group (preferably methoxy) , (vi) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (vii) a Ci-6 alkoxy-carbonyl group (preferably methoxycarbonyl) , and (viii) a carbamoyl group optionally mono- or di- substituted by Ci-6 alkyl group (s) (preferably ethyl),
(b) a C7-13 aralkyl group (preferably benzyl) ,
(c) a Ci-6 alkyl-carbonyl group (preferably acetyl) , (d) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ,
(e) a carbamoyl group optionally mono- or di-substituted by C1S alkyl group (s) (preferably methyl), and
(f) a non-aromatic heterocyclic group (preferably tetrahydropyranyl) , or (2) a C3-10 cycloalkane (preferably cyclohexane) optionally substituted by 1 to 3 substituents selected from an oxo group ' and a C1-3 alkylenedioxy group (preferably ethylenedioxy) ;
R21 is a Ci-6 alkyl group (preferably methyl) optionally substituted by 1 to 3 substituents selected from a hydroxy group and a non-aromatic heterocyclic group (preferably morpholinyl) ;
R22 is a hydrogen atom; W is NR8; R8 is (1) a hydrogen atom, or
(2) a Ci-6 alkyl group (preferably methyl, ethyl, propyl, isopropyl, isobutyl) optionally substituted by 1 to 3 substituents selected from
(a) a C3-10 cycloalkyl group (preferably cyclopropyl) , (b) a Ci-6 alkoxy group ' (preferably methoxy, ethoxy) ,
(c) a halogen atom (preferably fluorine atom) ,
(d) a cyano group,
(e) a hydroxy group,
(f) a carboxy group, (g) a carbamoyl group, and
(h) a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl) ;
R3 is
( 1 ) a 5- or β-membered monocyclic aromatic heterocyclic group (preferably thienyl, pyridyl, furyl, thiazolyl, imidazolyl ) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (preferably chlorine atom) , and
(b) a Ci-6 a.lkyl group (preferably methyl) , or
(2) a C6-I4 aryl group (e.g., phenyl) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group (preferably methyl) optionally substituted by 1 to 3 halogen atoms (preferably fluorine atom) , and
(b) a Ci-6 alkoxy group (preferably methoxy) ; R9 is a hydrogen atom or a halogen atom, (preferably chlorine atom) ; R10 is
(1) a hydrogen atom,
(2) a halogen atom (preferably bromine atom) , (3) a Ci-6 alkyl group (preferably methyl) , or
(4) a Ci-6 alkoxy group (preferably methoxy, ethoxy, propoxy, isopropoxy) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (preferably fluorine atom) , (b) a hydroxy group,
(c) a carboxy group,
(d) a carbamoyl group,
(e) a Ci_6 alkoxy group (preferably methoxy) ,
(f) a Ci-6 alkyl-carbonyl group (preferably acetyl), (g) a Ci-6 alkoxy-carbonyl group (preferably ethoxycarbonyl) , and
(h) a Ci-6 alkylsulfonyl group (preferably methylsulfonyl) ; and
R11 is a hydrogen atom, a halogen atom (preferably chlorine atom) or a Cχ-6 alkyl group (preferably methyl) .
[Compound (F) ]
N,N-dimethyl-2-{4-[ (2- {7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-l, 3-thiazol-5-yl)methyl]piperazin-l-yl}acetamide; N-methyl-N-[2- (8-oxa-l-thia-3-azaspiro [4.5] dec-2-en-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide;
N- [2- [4- (hydroxymethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -5- (2- methoxyethoxy) -IH-indol-7-yl] -N-methylpyridine-2-sulfonamide; N-methyl-N-{2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2- yl] -IH-indol-7-yl} thiophene-2-sulfonamide;
2- (2- { 7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl } - 4, 5-dihydro-l, 3-thiazol-5-yl) acetamide;
N- (difluoromethyl) -N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide; 2-{2- [7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) - lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5-yl} acetamide; N- (5- (2-methoxyethoxy) -2- {5- [ (1-oxidothiomorpholino) methyl] - 4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylpyridine- 2-sulfonamide; 2- (2- {7- [methyl (2-thienylsulfonyl) amino] -IH-indol-2-yl}-l- thia-3, 8-diazaspiro [4.5] dec-2-en-8-yl) acetamide; or N- [2-{5- [ (1, 1-dioxidothiomorpholino) methyl] -4, 5-dihydro-l, 3- thiazol-2-yl}-5- (2-methoxyethoxy) -IH-indol-7-yl] -N- methylpyridine-2-sulfonamide; or a salt thereof.
When compound (I) is in the form of a salt, as such salts, for example, a salt with inorganic base, a salt with organic base, a salt with inorganic acid, a salt with organic acid, a salt with basic or acidic amino acid and the like can be mentioned.
As preferable examples of the salt with inorganic base, alkali metal salts such as sodium salt, potassium salt and the like; alkaline earth metal salts such as calcium salt, magnesium salt and the like; and aluminum salts; ammonium salts and the like can be mentioned.
As preferable examples of the salt with organic base, salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N-dibenzylethylenediamine and the like can be mentioned.
As preferable examples of the salt with inorganic acid, salt with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like can be mentioned. As preferable examples of the salt with organic acid, salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like can be mentioned.
As preferable examples of the salt with basic amino acid, salts with arginine, lysine, ornithine and the like can be mentioned.
As preferable examples of the salt with acidic amino acid, salts with aspartic acid, glutamic acid and the like can be mentioned.
A prodrug of the compound (I) means a compound which is converted to the compound (I) with a reaction due to an enzyme, an gastric acid, etc. under the physiological condition in the living body, that is, a compound which is converted to the compound (I) with enzymatic oxidation, reduction, hydrolysis and the like; a compound which is converted to the compound (I) by hydrolysis and the like due to gastric acid and the like. A prodrug of the compound (I) may be a compound obtained by subjecting an amino group in the compound (I) to an acylation, alkylation or phosphorylation (e.g., a compound obtained by subjecting an amino group in the compound (I) to an eicosanoylation, alanylation, pentylaminocarbonylation, (5- methyl-2-oxo-l, 3-dioxolen-4-yl)methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, pivaloyloxymethylation or tert-butylation) ; a compound obtained by subjecting a hydroxy group in the compound (I) to an acylation, alkylation, phosphorylation or boration (e.g., a compound obtained by subjecting an hydroxy group in the compound (I) to an acetylation, palmitoylation, propanoylation, pivaloylation, succinylation, fumarylation, alanylation or dimethylaminomethylcarbonylation) ; a compound obtained by subjecting a carboxyl group in the compound (I) to an esterification or amidation (e.g., a compound obtained by subjecting a carboxyl group in the compound (I) to an ethyl esterification, phenyl esterification, carboxymethyl esterification, dimethylaminomethyl esterification, pivaloyloxymethyl esterification, ethoxycarbonyloxyethyl esterification, phthalidyl esterification, (5-methyl-2-oxo- 1, 3-dioxolen~4-yl) methyl esterification, cyclohexyloxycarbonylethyl esterification or methylamidation) and the like. These compounds can be produced from the compound (I) according to a method known per se.
A prodrug of the compound (I) may also be one which is ' converted into the compound (I) under a physiological condition, such as those described in IYAKUHIN NO KZVIHATSU (Development of Pharmaceuticals) , Vol. 7, Design of Molecules, p.163-198, Published by HIROKAWA SHOTEN (1990).
The compound (I) may be labeled with an isotope (e.g., 3H, 14C, 35S, 125I etc.) and the like.
Furthermore, the compound (I) may be a non-hydrate or hydrate.
Deuterium-converted compound wherein 1H has been converted to 2H(D) are also encompassed in the compound (I). The compound (I) or a prodrug thereof (hereinafter sometimes to be abbreviated as the compound of the present invention) shows low toxicity and can be used as an agent for the prophylaxis or treatment of various diseases to be mentioned later for mammals (e.g., humans, mice, rats, rabbits, dogs, cats, bovines, horses, pigs, monkeys etc.) as they are or by admixing with a pharmacologically acceptable carrier and the like to give a pharmaceutical composition.
Here, various organic or inorganic carriers conventionally used as materials for pharmaceutical preparations are used as a pharmacologically acceptable carrier, which are added as excipient, lubricant, binder and disintegrant for solid preparations; or solvent, solubilizing agent, suspending agent, isotonicity agent, buffer and soothing agent for liquid preparations, and the like. Where necessary, an additive for pharmaceutical preparations such as preservative, antioxidant, coloring agent, sweetening agent and the. like can be used.
Preferable examples of the excipient include lactose, sucrose, D-mannitol, D-sorbitol, starch, α-starch, dextrin, crystalline cellulose, low-substituted hydroxypropylcellulose, sodium carboxymethylcellulose, gum acacia, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminate metasilicate and the like.
Preferred examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
Preferable examples of the binder include α-starch, saccharose, gelatin, gum acacia, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and the like.
Preferable examples of the disintegrant include lactose, sucrose, starch, carboxymethylcellulose, calcium carboxymethylcellulose, sodium croscarmellose, sodium carboxymethylstarch, light anhydrous silicic acid, low- substituted hydroxypropylcellulose and the like.
Preferable examples of the solvent include water for injection, physiological brine, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil and the like.
Preferred examples of the solubilizing agent include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, sodium acetate and the like.
Preferred examples of the suspending agent include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, lauryl aminopropionate, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate and the like; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and the like; polysorbates, polyoxyethylene hydrogenated castor oil and the like.
Preferred examples of the isotonicity agent include sodium chloride, glycerol, D-mannitol, D-sorbitol, glucose and the like.
Preferred examples of the buffer include buffers such as phosphate, acetate, carbonate, citrate and the like.
Preferred examples of the soothing agent include benzyl alcohol and the like.
Preferred examples of the preservative include p- oxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like..
Preferred examples of the antioxidant include sulfite, ascorbate and the like.
Preferable examples of the coloring agent include water- soluble edible tar pigments (e.g., foodcolors such as Food Color Red Nos. 2 and 3, Food Color Yellow Nos. 4 and 5, Food Color Blue Nos. 1 and 2 and the like), water insoluble lake pigments (e.g., aluminum' salt of the aforementioned water- soluble edible tar pigment), natural pigments (e.g., beta carotene, chlorophil, red iron oxide) and the like. Preferable examples of the sweetening agent include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like.
The dosage form of the aforementioned pharmaceutical composition is, for example, an oral agent such as tablets (inclusive of sugar-coated tablets, film-coated tablets, sublingual tablets and orally disintegrable tablets) , capsules (inclusive of soft capsules and microcapsules) , granules, powders, troches, syrups, emulsions, suspensions, films (e.g., orally disintegrable film) and the like; a parenteral agent such as injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, drip infusions), external agents (e.g., transdermal preparations, ointments), suppositories (e.g., rectal suppositories, vaginal suppositories) , pellets, nasal preparations, pulmonary preparations (inhalations) , ophthalmic preparations and the like, and the like. These may be administered safely via an oral or parenteral (e.g., topical, rectal, intravenous administrations etc.) route.
These agents may be controlled-release preparations such as rapid-release preparations and sustained-release preparations (e.g., sustained-release microcapsules).
The pharmaceutical composition can be produced according to a method conventionally used in the field of pharmaceutical preparation, such as the method described in Japan Pharmacopoeia and the like. Concrete production methods of preparations are described in detail in the following. While the content of the compound of the present invention in the pharmaceutical composition varies depending on the dosage form, dose of the compound of the present invention and the like, it is, for example, about 0.1 to 100 wt%.
The compound of the present invention has a superior GK activating action, and can be used as an agent for the prophylaxis or treatment of various diseases for mammals (e.g., human, bovine, horse, dog, cat, monkey, mouse, rat, specifically human) . In addition, as the compound of the present invention has a selective GK activating action, it shows low toxicity (e.g., acute toxicity, chronic toxicity, cardiotoxicity, carcinogenic, genetic toxicity) , which causes fewer side effects. The compound of the present invention can be used as an agent for the prophylaxis or treatment of diabetes (e.g., type-1 diabetes, type-2 diabetes, gestational diabetes, obese diabetes etc.); an agent for the prophylaxis or treatment of obesity; an agent for the prophylaxis or treatment of hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, hypo-HDL-emia, postprandial hyperlipidemia etc.); an agent for the prophylaxis or treatment of arteriosclerosis; an agent for the prophylaxis or treatment of impaired glucose tolerance (IGT) ; and an agent for preventing progression of impaired glucose tolerance into diabetes.
For diagnostic criteria of diabetes, Japan Diabetes Society reported new diagnostic criteria in 1999. According to this report, diabetes is a condition showing any of a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 126 mg/dl, a 75 g oral glucose tolerance test (75 g OGTT) 2 h level (glucose concentration of intravenous plasma) of not less than 200 mg/dl, and a non-fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 200 mg/dl. A condition not falling under the above-mentioned diabetes and different from λΛa condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of less than 110 mg/dl or a 75 g oral glucose tolerance test (75 g OGTT) 2 h level (glucose concentration of intravenous plasma) of less than 140 mg/dl" (normal type) is called a "borderline type".
In addition, ADA (American Diabetes Association) reported new diagnostic criteria of diabetes and WHO.
According to these reports, diabetes is a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 126 mg/dl, or a 75 g oral glucose tolerance test 2 h level (glucose concentration of intravenous plasma) of not less than 200 mg/dl. According to the above-mentioned reports by ADA and WHO, . impaired glucose tolerance is a condition showing a 75 g oral glucose tolerance test 2 h level (glucose concentration of intravenous plasma) of not less than 140 mg/dl and less than 200 mg/dl. According to the report of ADA, a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 100 mg/dl and less than 126 mg/dl is called IFG (Impaired. Fasting Glucose). According to the report of WHO, among the IFG (Impaired Fasting Glucose) , a condition showing a 75 g oral glucose tolerance test 2 h level (glucose concentration of intravenous plasma) of not less than 110 mg/dl and less than 126 mg/dl is called IFG (Impaired Fasting Glycemia) .
The compound of the present invention can also be used as an agent for the prophylaxis or treatment of diabetes, borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) and IFG (Impaired Fasting Glycemia) , as determined according to the above-mentioned new diagnostic criteria. Moreover, the compound of the present invention can prevent progress of borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) or IFG (Impaired Fasting Glycemia) into diabetes.
The compound of the present invention can also be used as an agent for the prophylaxis or treatment of, for example, diabetic complications [e.g., neuropathy, nephropathy, retinopathy, cataract, macroangiopathy, osteopenia, hyperosmolar diabetic coma, infectious disease (e.g., respiratory infection, urinary tract infection, gastrointestinal infection, dermal soft tissue infections, inferior limb infection), diabetic foot lesion (e.g., gangrene, ulcer) , xerostomia, hypacusis, cerebrovascular disorder, peripheral blood circulation disorder, diabetic diarrhea] , obesity, osteoporosis, cachexia (e.g., cancerous cachexia, tuberculous cachexia, diabetic cachexia, blood disease cachexia, endocrine disease cachexia, infectious disease cachexia or cachexia due to acquired immunodeficiency syndrome) , fatty liver, hypertension, polycystic ovary syndrome, kidney disease (e.g., diabetic nephropathy, glomerular nephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end stage kidney disease, pyelonephritis, hydronephrosis) , muscular dystrophy, myocardial infarction, angina pectoris, cerebrovascular accident (e.g., cerebral infarction, cerebral apoplexy), abnormal sugar metabolism, abnormal lipid metabolism, insulin resistance syndrome, Syndrome X, metabolic syndrome (according to the above-mentioned report by WHO, state concurrently associated with at least one of type 2 diabetes, impaired glucose tolerance and insulin resistance, and at least two from obesity, abnormal lipid metabolism, hypertension and trace albumin urine) , Gushing' s syndrome, hyperinsulinemia, hyperinsulinemia-induced sensory disorder, tumor (e.g., leukemia, breast cancer, prostate cancer, skin cancer) , irritable bowel syndrome, acute or chronic diarrhea, inflammatory diseases (e.g., chronic rheumatoid arthritis, spondylitis deformans, osteoarthritis, lumbago, gout, postoperative or traumatic inflammation, swelling, neuralgia, pharyngolaryngitis, cystitis, hepatitis (inclusive of nonalcoholic steatohepatitis) , pneumonia, pancreatitis, inflammatory bowel disease, ulcerative colitis, stomach mucous membrane injury (including stomach mucous membrane injury caused by aspirin)), visceral fat syndrome, Alzheimer's disease, cerebrovascular dementia, depression and the like.
The compound of the present invention can also be used for improvement of insulin resistance, promotion or increase of insulin secretion, decrease of visceral fat, suppression of accumulation of visceral fat, improvement of sugar metabolism, improvement of lipid metabolism (including suppression of oxidative LDL production, improvement of lipoprotein metabolism, lowering of blood remnant) , improvement of coronary metabolism, prophylaxis or treatment of cardiovascular complication, prophylaxis or treatment of heart failure complication, prophylaxis or treatment of anovulation, prophylaxis or treatment of hirsutism, prophylaxis or treatment of hyperandrogenism, improvement of pancreatic (β cell) function, regeneration of pancreas (β cell) , promotion of regeneration of pancreas (β cell) and the like.
The compound of the present invention can also be used for the secondary prevention and suppression of progression of various diseases mentioned above (e.g., cardiovascular event such as myocardial infarction etc.).
The compound of the present invention is particularly useful as an agent for the prophylaxis or treatment of type-2 diabetes, obese diabetes and the like.
While the dose of the compound of the present invention varies depending on the administration subject, administration route, target disease, condition and the like, the compound of the present invention is generally given in a single dose of about 0.01-100 mg/kg body weight, preferably 0.05-30 mg/kg body weight, more preferably 0.1-10 mg/kg body weight, in the case of, for example, oral administration to adult diabetic patients. This dose is desirably given 1 to 3 times a day. The compound of the present invention can be used in combination with drugs such as a therapeutic agent for diabetes, a therapeutic agent for diabetic complications, a therapeutic agent for hyperlipidemia, an antihypertensive agent, an antiobestic agent, a diuretic, a chemotherapeutic agent, an immunotherapeutic agent, an antithrombotic agent, a therapeutic agent for osteoporosis, a antidementia agent, an erectile dysfunction improver, a therapeutic agent for pollakiuria or urinary incontinence, a therapeutic agent for dysuria and the like (hereinafter to be referred to as a combination drug) . In this case, the timing of administration of the compound of the present invention and a combination drug is not limited. These may be simultaneously administered to an administration subject or administered in a staggered manner. Moreover, the compound of the present invention and a combination drug may be administered as two kinds of preparations each containing an active ingredient, or may be administered as a single preparation containing both active ingredients .
The dose of the combination drug can be determined as appropriate based on the dose clinically employed. The proportion of the compound of the.present invention and the combination drug can be appropriately determined depending on the administration subject, administration route, target disease, condition, combination and the like. When, for example, the administration subject is human, the combination drug is used in an amount of 0.01-100 parts by weight per 1 part by weight of the compound of the present invention. Examples of the therapeutic agents for diabetes include insulin preparations (e.g., animal insulin preparations extracted from pancreas of bovine or swine; human insulin preparations genetically synthesized using Escherichia coli or yeast; zinc insulin; protamine zinc insulin; fragment or derivative of insulin (e.g., INS-I), oral insulin preparation), insulin sensitizers (e.g., pioglitazone or a salt thereof (preferably hydrochloride) , rosiglitazone or a salt thereof (preferably maleate) , Tesaglitazar, Ragaglitazar, Muraglitazar, Edaglitazone, Metaglidasen, Naveglitazar, AMG-131, THR-0921) , α-glucosidase inhibitors (e.g., voglibose, acarbose, miglitol, emiglitate) , biguanides (e.g., metformin, buformin or a salt thereof (e.g., hydrochloride, fumarate, succinate)), insulin secretagogues [sulfonylurea (e.g., tolbutamide, glibenclamide, gliclazide, chlorpropamide, tolazamide, acetohexamide, glyclopyramide, glimepiride, glipizide, glybuzole) , repaglinide, nateglinide, mitiglinide or calcium salt hydrate thereof], dipeptidyl-peptidase IV inhibitors (e.g.,
Vildagliptin, Sitagliptin, Saxagliptin, T-6666, TS-021), β3 agonists (e.g., AJ-9677), GPR40 agonists, GLP-I receptor agonists [e.g., GLP-I, GLP-IMR agent, NN-2211, AC-2993 (exendin-4), BIM-51077, Mb(S7SS)IiGLP-I(V7SV)NH2/ CJC-1131] , amylin agonists (e.g., pramlintide) , phosphotyrosine phosphatase inhibitors (e.g., sodium vanadate), gluconeogenesis inhibitors (e.g., glycogen phosphorylase inhibitors, glucose-6-phosphatase inhibitors, glucagon antagonists), SGLT (sodium-glucose cotransporter) inhibitors
(e.g., T-1095), llβ-hydroxysteroid dehydrogenase inhibitors (e.g., BVT-3498), adiponectin or agonists thereof, IKK inhibitors (e.g., AS-2868) , leptin resistance improving drugs, somatostatin receptor agonists, glucokinase activators (e.g., Ro-28-1675) , GIP (Glucose-dependent insulinotropic peptide) and the like.
Examples of the therapeutic agents for diabetic complications include aldose reductase inhibitors (e.g., Tolrestat, Epalrestat, Zenarestat, Zopolrestat, Minalrestat, Fidarestat, CT-112, ranirestat (AS-3201) ) , neurotrophic factors and increasing drugs thereof (e.g., NGF, NT-3, BDNF, neurotrophin production-secretion promoters described in WO01/14372 (e.g., 4- (4-chlorophenyl) -2- (2-methyl-l- imidazolyl) -5- [3- (2-methylphenoxy) propyl] oxazole) ) , stimulators (e.g., Y-128), PKC inhibitors (e.g., ruboxistaurin mesylate), AGE inhibitors (e.g., ALT-946, pimagedine, N- phenacylthiazolium bromide (ALT-766) , ALT-711, EXO-226, Pyridorin, Pyridoxamine) , active oxygen scavengers (e.g., thioctic acid), cerebral vasodilators (e.g., tiapuride, mexiletine) , somatostatin receptor agonists (BIM23190) , apoptosis signal regulating kinase-1 (ASK-I) inhibitors and the like.
Examples of the therapeutic agents for hyperlipidemia include HMG-CoA reductase inhibitors (e.g., pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, pitavastatin, rosuvastatin and salts thereof (e.g., sodium salt, calcium salt)), squalene synthase inhibitors (e.g., compounds described in WO97/10224, such as N- [ [ (3R, 5S) -1- (3- acetoxy-2, 2-dimethylpropyl) -7-chloro-5- (2, 3-dimethoxyphenyl) - 2-oxo-l, 2, 3, 5-tetrahydro-4, l-benzoxazepin-3- yl] acetyl]piperidine-4-acetic acid), fibrate compounds (e.g., bezafibrate, clofibrate, simfibrate, clinofibrate) , ACAT inhibitors (e.g., Avasimibe, Eflucimibe) , anion exchange resins (e.g., colestyramine) , probucol, nicotinic acid drugs (e.g., nicomol, niceritrol) , ethyl icosapentate, phytosterols
(e.g., soysterol, γ-oryzanol) and the like.
Examples of the antihypertensive agents include angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, delapril), angiotensin II antagonists (e.g., candesartan cilexetil, losartan, eprosartan, valsartan, telmisartan, irbesartan, tasosartan, 1- [ [2' - (2, 5-dihydro-5- oxo-4H-l,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-2-ethoxy-lH- benzimidazole-7-carboxylic acid), calcium antagonists (e.g., manidipine, nifedipine, amlodipine, efonidipine, nicardipine) , potassium channel openers (e.g., levcromakalim, L-27152, AL 0671, NIP-121), clonidine and the like.
Examples of the antiobesity agents include antiobesity agents acting on the central nervous system (e.g., dexfenfluramine, fenfluramine, phentermine, sibutramine, amfepramone, dexamphetamine, mazindol, phenylpropanolamine, clobenzorex; MCH receptor antagonists (e.g., SB-568849; SNAP- 7941; compounds described in WO01/82925 and WO01/87834) ; neuropeptide Y antagonists (e.g., CP-422935) ; cannabinoid receptor antagonists (e.g., SR-141716, SR-147778); ghrelin antagonists), pancreatic lipase inhibitors (e.g., orlistat,
ATL-962), β3 agonists (e.g., AJ-9677) , peptide anorexiants (e.g., leptin, CNTF (Ciliary Neurotropic Factor)), cholecystokinin agonists (e.g., lintitript, FPL-15849) , feeding deterrents (e.g., P-57) and the like.
Examples of the diuretics include xanthine derivatives (e.g., sodium salicylate and theobromine, calcium salicylate and theobromine), thiazide preparations (e.g., ethiazide, cyclopenthiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penflutizide, polythiazide, methyclothiazide) , antialdosterone preparations (e.g., spironolactone, triamterene), carbonate dehydratase inhibitors (e.g., acetazolamide) , chlorobenzenesulfonamide preparations (e.g., chlortalidone, mefruside, indapamide) , azosemide, isosorbide, etacrynic acid, piretanide, bumetanide, furosemide and the like.
Examples of the chemotherapeutic agents include alkylating agents (e.g., cyclophosphamide, ifosfamide), metabolic antagonists (e.g., methotrexate, 5-fluorouracil and derivatives thereof), antitumor antibiotics (e.g., mitomycin, adriamycin) , plant-derived antitumor agents (e.g., vincristine, vindesine, Taxol) , cisplatin, carboplatin, etoposide and the like. Of these, Furtulon or NeoFurtulon, which are 5- fluorouracil derivatives, and the like are preferable. Examples of the immunotherapeutic agents include microorganism or bacterial components (e.g., muramyl dipeptide derivatives, Picibanil), polysaccharides having immunity potentiating activity (e.g., lentinan, schizophyllan, krestin) , cytokines obtained by genetic engineering techniques (e.g., interferon, interleukin (IL) ) , colony stimulating factors
(e.g., granulocyte colony stimulating factor, erythropoietin) and the like, with preference given to interleukins such as IL-I, IL-2, IL-12 and the like.
Examples of the antithrombotic agents include heparin (e.g., heparin sodium, heparin calcium, dalteparin sodium), warfarins (e.g., warfarin potassium), anti-thrombin drugs (e.g., aragatroban) , thrombolytic agents (e.g., urokinase, tisokinase, alteplase, nateplase, monteplase, pamiteplase) , platelet aggregation inhibitors (e.g., ticlopidine hydrochloride, cilostazol, ethyl icosapentate, beraprost sodium, sarpogrelate hydrochloride) and the like.
Examples of the therapeutic agents for osteoporosis include alfacalcidol, calcitriol, elcatonin, calcitonin salmon, estriol, ipriflavone, risedronate disodium, pamidronate disodium, alendronate sodium hydrate, incadronate disodium and the like.
Examples of the antidementia agents include tacrine, donepezil, rivastigmine, galanthamine and the like.
Examples of the erectile dysfunction improvers include apomorphine, sildenafil citrate and the like.
Examples of the therapeutic agents for pollakiuria or urinary incontinence include flavoxate hydrochloride, oxybutynin hydrochloride, propiverine hydrochloride and the like. Examples of the therapeutic agents for dysuria include acetylcholine esterase inhibitors (e.g., distigmine) and the like.
Furthermore, drugs having a cachexia-improving action established in animal models and clinical situations, such as" cyclooxygenase inhibitors (e.g., indomethacin) , progesterone derivatives (e.g., megestrol acetate), glucosteroids (e.g., dexamethasone) , metoclopramide agents, tetrahydrocannabinol agents, fat metabolism improving agents (e.g., eicosapentanoic acid), growth hormones, IGF-I, or antibodies to a cachexia- inducing factor such as TNF-α, LIF, IL-6, oncostatin M and the like, can be used in combination with the compound of the present invention.
The combination drug is preferably insulin preparation, insulin sensitizer, α-glucosidase inhibitor, biguanide, insulin secretagogue (preferably sulfonylurea) and the like.
Two or more kinds of the above-mentioned combination drugs may be used in an appropriate combination.
When the compound of the present invention is used in combination with a combination drug, the amount thereof can be reduced within a safe range in consideration of counteraction of these agents. Particularly, the dose of an insulin sensitizer, an insulin secretagogue (preferably a sulfonylurea) and a biguanide can be reduced as compared with the normal dose. Therefore, an adverse effect which may be caused by these agents can be prevented safely. In addition, the dose of the therapeutic agent for diabetic complications, therapeutic agent for hyperlipidemia and antihypertensive agent can be reduced whereby an adverse effect which may be caused by these agents can be prevented effectively.
Compound (I) can be produced, for example, according to mentods shown in the following Schemes 1 and 2.
Scheme 1
Figure imgf000083_0001
(H) (I) wherein each symbol is as defined above.
In this scheme, compound (I) can be produced by reacting compound (II) with compound (III) or a reactive derivative thereof.
As preferable reactive derivative of compound (III) , for example, a reactive derivative generally used such as a sulfonyl halide, a sulfonic anhydride, N-sulfonylimidazolide and the like can be mentioned, and a sulfonyl halide is particularly preferable.
This reaction can be carried out in the presence of a base. As the base, for example, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; alkaline earth metal hydroxides such as magnesium hydroxide, calcium hydroxide and the like; alkali metal carbonates such as sodium carbonate,, potassium carbonate and the like; alkali metal hydrogencarbonates such as sodium hydrogencarbonate, potassium hydrogencarbonate and the like; alkali metal Ci-6 alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like; organic bases such as trimethylamine, triethylamine, diisopropylethylamine, pyridine, picoline, N-methylpyrrolidine, N-methylmorpholine, 1, 5-diazabicyclo [4.3.0] -5-nonene, 1, 4- diazabicyclo[2.2.2] octane, 1, 8-diazabicyclo [5.4.0]-7-undecene and the like; organic lithiums such as methyllithium, n- butyllithium, sec-butyllithium, tert-butyllithium and the like; lithium amides such as lithium diisopropylamide and the like, and the like can be mentioned.
This reaction is preferably carried out in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, tert-butylalcohol and the like; ethers such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert- butyl methyl ether, diisopropyl ether, 1, 2-dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, trichloroethylene and the like; hydrocarbons such as n-hexane, benzene, toluene and the like; amides such as formamide, N, N- dimethylformamide, N,N-dimethylacetamide and the like; nitriles such as acetonitrile, propionitrile and the like; sulfoxides such as dimethylsulfoxide and the like; sulfolane; hexamethylphosphoramide; water and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio .
The amount of compound (III) or a reactive derivative thereof to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (II) . The amount of the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (III) or a reactive derivative thereof.
The reaction temperature is generally -30°C to 1000C. The reaction time is generally 0.5 _ to 20 hr.
Compound (III) can be produced according to a method known per se. Scheme 2
Figure imgf000085_0001
(IV) (I-A) cyclization
Figure imgf000085_0002
Figure imgf000085_0003
(VI) (I-B) wherein L1 is a leaving group, R15 and R15' are each independently a hydrogen atom, an optionally substituted Ci-e alkyl group or an optionally substituted C6-i4 aryl group, Ar is a phenyl group or a 4-methoxyphenyl group, and the other symbols are as defined above.
As the "optionally substituted Ci-e alkyl group" for R15 or R15' , those similar to the "optionally substituted Ci-6 alkyl group" for R4 or R5 can be mentioned, and methyl group and ethyl group are preferable.
As the "C6-i4 aryl group" of "optionally substituted C6-i4 aryl group" for R15 or R15' , those similar to the "C6-H aryl group" exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for R6, R7, R21 or R22 can be mentioned. The Cβ-u aryl group optionally has 1 to 3 substituents at substitutable positions. As such substituents, those exemplified as the substituents which the C3-I0 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group" for Rδ, R7, R21 or R22 optionally has, can be mentioned. The "optionally substituted C6-14 aryl group" is preferably a phenyl group or a 4-methoxyphenyl group.
As the "leaving group" for L1, for example, a halogen atom; an optionally halogenated Ci-6 alkylsulfonyloxy group (e.g., methanesulfonyloxy, ethanesulfonyloxy, trichloromethanesulfonyloxy, trifluoromethanesulfonyloxy) ; a Cβ-io arylsulfonyloxy group optionally substituted by 1 to 3 substituents selected from a Ci-β alkyl group, a Ci_6 alkoxy group and a nitro group (e.g., phenylsulfonyloxy, m- nitrophenylsulfonyloxy, p-toluenesulfonyloxy) ; a Ci-6 alkoxysulfonyloxy group; a C6-io aryloxysulfonyloxy group; a Ci_6 alkoxy group; a di-Ci_s alkylamino group and the like can be mentioned.
Compound (I-A) can be produced' by reacting compound (IV) with compound (V) in the presence of a base.
The amount of compound (V) to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (IV) .
As the base, those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned.
This reaction is preferably carried out in a solvent inert to the reaction. As such solvent, those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned.
The amount of the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (IV) .
The reaction temperature is generally -100°C to 100°C. The reaction time is generally 0.5 to 20 hr. Compound (I-B) can be produced from compound (VI) according to methods described in Angew. Cheiα., Int. Ed., 2003, vol. 42, page 83, Tetrahedron, 1999, vol. 55, page 10271, and the like.
In this reaction, compound (VI) is reacted with triphenylphosphine oxide and trifluoromethanesulfonic anhydride or phosphorus pentachloride.
This reaction is carried out without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; nitriles such as acetonitrile, propionitrile and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
The amount of the triphenylpho'sphine oxide and trifluoromethanesulfonic anhydride or phosphorus pentachloride to be used is generally 1 to 10 mol, preferably 1 to 6 mol, per 1 mol of compound (VI) , respectively.
The reaction temperature is generally -70°C to 100°C. The reaction time is generally 0.5 to 20 hr.
Compound (II) , (IV) and (VI) used as starting materials in the aforementioned Schemes 1 and 2 can be produced, for example, according to the following Scheme 3 to 7 or a method analogous thereto. Scheme 3
(VII) (VIII) (IV)
Figure imgf000087_0002
wherein R16 is a hydrogen atom or a Ci_6 alkoxy group, and the other symbols are as defined above.
Compound (VIII) can be produced by subjecting compound (VII) to a reduction reaction.
The reduction reaction is carried out, for example, using a reducing agent. As the reducing agent, for example, metal hydrides such as aluminum hydride, diisobutylaluminum hydride, tributyltin hydride and the like; metal hydrogen complex compounds such as lithium aluminum hydride, sodium borohydride and the like; borane complexes such as borane-tetrahydrofuran complex, borane-dimethylsulfide complex and the like; alkylboranes such as thexylborane, disiamylborane and the like; diborane; metals such as zinc, aluminum, tin, iron and the like; alkali metal (e.g., sodium, lithium etc.) /liquid ammonia (Birch reduction) and the. like can be mentioned. The amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent. For example, the amount of the metal hydride or metal hydrogen complex compound to be used is generally about 0.25 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (VII) , the amount of the borane complex, alkylborane or diborane to be used is generally about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (VII) , and the amount of the metal (containing alkali metal used for Birch reduction) to be used is generally about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 equivalent of compound (VII) .
The reduction reaction is preferably carried out in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1- propanol, 2-propanol, terf-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N- dimethylacetamide, hexamethylphosphoramide and the like; organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, methanesulfonic acid and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio. While the reaction time varies depending on the kind and amount of the reducing agent to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
Compound (IV) can be produced by converting the hydroxy group of compound (VIII) to a leaving group for L1 according to a method known per se.
Compound (VI) can be produced by reacting compound (IX) or a reactive derivative of the carboxy group or a salt thereof with compound (X) .
As the reactive derivative of the carboxy group of compound (IX), for example, 1) an acid chloride / 2) an acid azide;
3) a mixed acid anhydride with an acid (e.g., substituted phosphates such as dialkylphosphate, phenylphosphate, diphenylphosphate, dibenzylphosphate, halogenated phosphate and the like; dialkylphosphorous acid; sulfurous acid; thiosulfuric acid; sulfuric acid; sulfonic acids such as methanesulfonic acid and the like; aliphatic carboxylic acids such as formic acid, acetic acid, ' propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, trichloroacetic acid and the like; aromatic carboxylic acids such as benzoic acid and the like) ;
4) a symmetric acid anhydride;
5) an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole;
6) an activated ester such as cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl ester, vinyl ester, propargyl ester, p-nitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenylthioester, p-nitrophenyl ester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolylthio ester and the like; 7) a ester with a N-hydroxy compound (e.g., N, N- dimethylhydroxyamine, l-hydroxy-2- (IH) -pyridone, N- hydroxysuccinirαide, N-hydroxyphthalimide7 1-hydroxy-lH- benzotriazole) ; and the like can be mentioned. These reactive derivatives are appropriately determined according to the kind of compound (IX) to.be used.
As preferable salt of compound (IX) or a reactive derivative of the carboxy group, for example, salts with a base, such as alkali metal salts (e.g., sodium salt, potassium salt and the like), alkaline earth metal salts (e.g., calcium salt, magnesium salt and the like) , ammonium salts, organic base salts (e.g. , trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N7N- dibenzylethylenediamine salt and the like) and the like can be mentioned.
This reaction is preferably carried out in a solvent inert to the reaction. As such solvent, those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned.
In this reaction, when compound (IX) is used in the form of a free acid or a salt thereof, the reaction is preferably carried out in the presence of a conventional condensing agent such as a carbodiimide (e.g., N,N' -dicyclohexylcarbodiimide, N-cyclohexyl-N' -morpholinoethylcarbodiimide, N-cyclohexyl-N' - (4-diethylaminocyclohexyl) carbodiimide, N,N' - diethylcarbodiimide, N7N' -diisopropylcarbodiimide, N-ethyl-N'- (3-dimethylaminopropyl) carbodiimide and the like), N7N'- carbonylbis (2-methylimidazole) , a trialkyl phosphate, a polyphosphate (e.g., ethyl polyphosphate, isopropyl polyphosphate and the like) , phosphorus oxychloride, diphenylphosphorylazide, thionyl chloride, oxalyl chloride, a lower alkyl haloformate (e.g., ethyl chloroformate, isopropyl chloroformate and the like) , triphenylphosphine, N- hydroxybenzotriazole, 1- (p-chlorobenzenesulfonyloxy) -6-chloro- lH-benzotriazole, Vilsmeier-reagent (prepared by the reaction of N, N'-dimethylformamide and thionyl chloride, phosgene, chloroformic acid trichloromethyl, phosphorus oxychloride and the like), and the like.
This reaction can be carried out in the presence of a base, as necessary. As such base, those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned. The amount of compound (X) to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (IX) . The amount of the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (IX) .
The reaction temperature is generally -30°C to 100°C. The reaction time is generally 0.5 to 20 hr.
When an mixed acid anhydride is used as a reactive derivative of compound (IX) , compound (IX) can be reacted with a chloroformate (e.g., methyl chloroformate, ethyl chloroformate, isobutyl chloroformate) in the presence of a base (e.g., triethylamine, N-methylmorpholine, N, N- dimethylaniline, sodium hydrogencarbonate, sodium carbonate, potassium carbonate) , and then reacted with compound (X) .
This reaction is preferably carried out in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether, 1,2- dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1,2- dichloroethane, carbon tetrachloride, trichloroethylene and the like; hydrocarbons such as n-hexane, benzene, toluene and the like; amides such as formamide, N,N-dimethylformamide, N, N-dimethylacetamide and the like; nitriles such as. acetonitrile, propionitrile and the like; sulfoxides such as dimethylsulfoxide and the like; sulfolane; hexamethylphosphoramide and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
The amount of compound (X) to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (IX) .
The reaction temperature is generally -30°C to 100°C. The reaction time is generally 0.5 to 20 hr.
Compound (VII) can be produced, for example, according to the following method. Scheme 4
Figure imgf000092_0001
(VII-A)
(XII)
Figure imgf000092_0002
wherein R17 is a CX-6 alkyl group, L2 is a leaving group, P1 is a hydrogen atom or a protecting group, and the other symbols are as defined above.
As the "leaving group" for L2, those exemplified as the aforementioned L1 can be mentioned.
As the "protecting group" for P1, for example, a formyl group; a Ci-6 alkyl-carbonyl group, a phenylcarbonyl group, a Ci-6 alkoxy-carbonyl group, an allyloxycarbonyl group, a phenyloxycarbonyl group, a fluorenylmethyloxycarbonyl group, a C7-io aralkyl-carbonyl group (e.g., benzylcarbonyl) , a C7-10 aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl) , a C7-20 aralkyl group (e.g., benzyl, trityl) and a methoxymethyl group, each of which has optionally substituent (s) , and the like can be mentioned. As the substituents, for example, a phenyl group, a halogen atom, a Ci-6 alkyl-carbonyl group, a Ci_6 alkoxy group optionally substituted by halogen atom(s), a nitro group and the like can be mentioned. The number of the substituents is 1 to 3.
Compound (XI) can be produced by reacting compound (IX-A) or a reactive derivative of the carboxy group or a salt thereof with ammonia or a salt thereof.
As the reactive derivative of the carboxy group of compound (IX-A), those exemplified as the reactive derivative of the carboxy group of compound (IX) in Scheme 3 can be mentioned.
As the salt of compound (IX-A) or a reactive derivative of the carboxy group, those exemplified as the preferable salt of compound (IX) or a reactive derivative of the carboxy group in Scheme 3 can be mentioned. As the ammonia or a salt thereof, aqueous ammonia, ammonium acetate, ammonium choloride and the like can be mentioned.
This reaction is carried out in the same manner as in the reaction of compound (IX) or a reactive derivative of the carboxy group or a salt thereof with compound (X) in Scheme 3, and using ammonia or a salt thereof instead of compound (X) . •
In compound (IX-A) , when P1 is a protecting group, the protecting groμp can be removed according to a conventional deprotection such as an acid treatment, an alkali treatment, a catalytic reduction and the like, as necessary.
Compound (XII) wherein P1 is a hydrogen atom can be produced by reacting compound (XI) with diphosphorus pentasulfide or a Lawesson's reagent.
This reaction is carried out without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
The amount of the diphosphorus pentasulfide or Lawesson' s reagent to be used is generally 0.5 to 10 rαol, preferably 0.5 to 3 mol, per 1 mol of compound (XI) .
The reaction temperature is generally -30°C to 200°C. The reaction time 'is generally 0.5 to 20 hr.
Compound (VII-A) can be produced by reacting compound (XII) with compound (XIII) .
This reaction is carried out in the presence of a acid catalyst or a base, as necessary.
As the acid catalyst, for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; Lewis acids such as a boron trihalide (e.g., boron trichloride, boron trifluoride) , a titanium tetrahalide (e.g., titanium tetrachloride, titanium tetrabromide) , an aluminum halide (e.g., aluminum chloride, aluminum bromide) and the like; organic acids such as acetic acid, formic acid, trifluoroacetic acid and the like, and the like can be mentioned.
As the base, for example, organic bases such as triethylamine, pyridine, 4-dimethylaminopyridine, diisopropylethylamine and the like; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and the like, and the like can be mentioned.
This reaction is carried out without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated' hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoramide and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio . When an acid catalyst is used, the amount of compound (XIII) and the acid catalyst to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XII) , respectively.
While the reaction time varies depending on the kind and amount of compound (XII), compound (XIII) and the acid catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C. When a base is used, the amount of the compound (XIII) and the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XII) , respectively.
While the reaction time varies depending on the kind and amount of compound (XII), compound (XIII) and the base to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -20 to about 1200C, preferably about 0 to about 80°C.
Compound (XIII) can be produced according to a method known per se.
Compound (XV) can be produced by reacting compound (IX) or a reactive derivative of the carboxy group or a salt thereof with compound (XIV) .
As the reactive derivative of the carboxy group of compound (IX) or a salt thereof, those exemplified in Scheme 3 can be mentioned.
This reaction is carried out in the same manner as in the reaction of compound (IX) or a reactive derivative of the carboxy group or a salt thereof with compound (X) in Scheme 3, and using compound (XIV) instead of compound (X) .
Compound (XV) can also be produced from compound (IX) or a reactive derivative of the carboxy group or a salt thereof in two steps.
In the first step, compound (XVI) can be produced by reacting compound (IX) or a reactive derivative of the carboxy group or a salt thereof with hydrazine.
As the solvent to be used in this reaction, those exemplified for the aforementioned reaction of compound (IX) with compound (XIV) can be mentioned. This reaction is carried out in the same manner as in the reaction of compound (IX) or a reactive derivative of the carboxy group or a salt thereof with compound (X) in Scheme 3, and using hydrazine instead of compound (X) .
In the second step, compound (XV) can be produced by reacting compound (XVI) with compound (XVII) .
As the solvent to be used in this reaction, those exemplified for the aforementioned reaction of compound (IX) with compound (XIV) can be mentioned.
This reaction can be carried out in the presence of a base, as necessary. As such base, for example, organic bases such as triethylamine, pyridine, 4-dimethylaminopyridine, diisopropylethylamine and the like; inorganic bases such' as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and the like, and the like can be mentioned.
The amount of compound (XVII) and the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 rαol of compound (XVI) , respectively.
The reaction temperature is generally -30°C to 200°C. The reaction time is generally 0.5 to 20 hr.
Compound (VII-B) can be produced by reacting compound (XV) with diphosphorus pentasulfide or a Lawesson' s reagent. This reaction is carried out without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like, and the like can be mentioned. These -solvents may be used in a mixture at an appropriate ratio .
The amount of the diphosphorus pentasulfide or Lawesson' s reagent to be used is generally 0.5 to 10 mol, preferably 0.5 to 3 mol, per 1 mol of compound (XV) .
The reaction temperature is generally -300C to 200°C. The reaction time is generally 0.5 to 20 hr.
Compounds (XIII) , (XIV) and (XVII) can be produced according to a method known per se. Compound (IX) can be produced, for example, according to the following method. Scheme 5
Figure imgf000098_0001
(IX-A) wherein R18 is a Cχ-6 alkyl group, and the other symbols are as defined above.
Compound (XIX) can be produced by reacting compound (XVIII) with compound (III) or a reactive derivative thereof.
This reaction is carried out in the same manner as in the reaction of the compound (II) with compound (III) or a reactive derivative thereof in Scheme 1.
Compound (IX-A) can be produced by subjecting compound (XIX) to a hydrolysis. The hydrolysis is carried out using an acid or a base according to a conventional method.
As the acid, for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; Lewis acids such as boron trichloride, boron tribromide and the like; organic acids such as trifluoroacetic acid, p-toluenesulfonic acid and the like, and the like can be mentioned. The Lewis acid can be used together with a thiol or a sulfide.
As the base, for example, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide and the like; alkali metal carbonates such as sodium carbonate, potassium carbonate and the like; alkali metal Ci_6 alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like; organic bases such as triethylamine, imidazole, formamidine and the like, and the like can be mentioned.
The amount of the acid or base to be used is generally about 0.5 to 10 mol, preferably about 0.5 to 6 mol, per 1 mol of compound (XIX) . The hydrolysis is carried out without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, propanol and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; organic acids such as formic acid, acetic acid and the like; ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane and the like; nitriles such as acetonitrile, propionitrile and the like; ketones such as acetone, methyl ethyl ketone and the like; sulfoxides such as dimethylsulfoxide and the like; water and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio .
The reaction time is generally 10 min to 60 hr, preferably 10 min to 12 hr. The reaction temperature is generally -10 to 200°C, preferably 0 to 120°C. In compound (XVIII),- compound (XIX) and compound (IX-A), when P1 is a protecting group, the protecting group can be removed according to a conventional deprotection such as an acid treatment, an alkali treatment, a catalytic reduction and the like, as necessary. Compound (XVIII) can be produced, for example, according to the following method.
Scheme 6
Figure imgf000100_0001
protection
Figure imgf000100_0002
wherein E is a nitro group, an optionally protected amino group or an optionally protected hydroxy group, H-X is a mineral acid such as hydrochloric acid, sulfuric acid and the like; or a organic acid such as acetic acid, formic acid, trifluoroacetic acid and the like, and the other symbols are as defined above.
In the "optionally protected amino group" for E, as the amino-protecting group, for example, a formyl group; a Cχ-6 alkyl-carbonyl group, a phenylcarbonyl group, a Ci_6 alkoxy- carbonyl group, an allyloxycarbonyl group, a phenyloxycarbonyl group, a fluorenylmethyloxycarbonyl group, a C7-10 aralkyl- carbonyl group (e.g., benzylcarbonyl) , a C7_10 aralkyloxy- carbonyl group (e.g., benzyloxycarbonyl) , a C7_2o aralkyl group (e.g., benzyl, . trityl) , a phthaloyl group, a dithiasuccinoyl group and a N, N-dimethylaiαinomethylene group, each of which optionally has substituent (s) , and the like can be mentioned. As the substituents, for example, a phenyl group, a halogen atom, a Ci-β alkyl-carbonyl group, a Cι-β alkoxy group optionally substituted by halogen atom(s) , a nitro group and the like can be mentioned. The number of the substituents is 1 to 3. In the "optionally protected hydroxy group" for E, As the hydroxy-protecting group, for example, a Ci_6 alkyl group, a C7- 2o aralkyl group (e.g., benzyl, trityl), a formyl group, a Ci-6 alkyl-carbonyl group, a benzoyl group, a C7_io aralkyl-carbonyl group (e.g., benzylcarbonyl), a 2-tetrahydropyranyl group, a tetrahydrofuranyl group and a trialkylsilyl group (e.g., trimethylsilyl, tert-butyldimethylsilyl, diisopropylethylsilyl) , each of which optionally has substituent (s) , and the like can be mentioned. As the substituents, for example, a halogen atom, a Ci-6 alkyl group, a phenyl group, a C7-10 aralkyl group (e.g., benzyl etc.), a Ci-s alkoxy group, a nitro group and the like can be mentioned. The number of the substituents is 1 to 4.
Compound (XXII) can be produced by reacting compound (XX) with compound (XXI) . This reaction is carried out without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, tert-butylalcohol and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoramide and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
In this reaction, the reaction can generally be promoted using an acid catalyst. As the acid catalyst, for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; Lewis acids such as a boron trihalide (e.g., boron trichloride, boron trifluoride) , a titanium tetrahalide (e.g., titanium tetrachloride, titanium tetrabromide) , an aluminum halide (e.g., aluminum chloride, aluminum bromide) and the like; organic acids such as acetic acid, formic acid, trifluoroacetic acid and the like, and the like can be mentioned.
The amount of compound (XXI) and the acid catalyst to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XX) , respectively.
While the reaction time varies depending on the kind and amount of compound (XX) , compound (XXI) and the acid catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 8O0C.
Compound (XXII) can also be produced by subjecting compound (XXIII) to the Japp-Klingemann reaction [Org. Reactions, 1959, vol. 10, page 143; J. Chem. Soc, 1927, page 1] .
In this reaction, compound (XXIV) which is produced using compound (XXIII) , an acid (H-X) and sodium nitrite according to a method known per se, is reacted with compound (XXV) in the presence of a base. As the base, for example, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; alkaline earth metal hydroxides such as magnesium hydroxide, calcium hydroxide and the like; alkali metal carbonates such as sodium carbonate, potassium carbonate and the like; alkali metal hydrogencarbonates such as sodium hydrogencarbonate, potassium hydrogencarbonate and the like; organic bases such as trimethylamine, triethylamine, diisopropylethylamine, pyridine, picoline, N-methylpyrrolidine, N-methylmorpholine, 1, 5-diazabicyclo [4.3.0] -5-nonene, 1,4- diazabicyclo[2.2.2] octane, 1, 8-diazabicyclo [5.4.0] -7-undecene and the like, and the like can be mentioned.
This reaction is preferably carried out in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, tert-butylalcohol and the like; ethers such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert- butyl methyl ether, diisopropyl ether, 1, 2-dimethoxyethane and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, trichloroethylene and the like; hydrocarbons such as n-hexane, benzene, toluene and the like; amides such as formamide, N,N-dimethylformamide, N, N- dimethylacetamide and the like; nitriles such as acetonitrile, propionitrile and the like; water and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
The amount of compound (XXV) to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXIV) . The amount of the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per' 1 mol of compound (XXIV) .
The reaction time is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C. Compound (XVIII-A) can be produced by subjecting compound (XXII) to the Fischer method [Berichte, 1883, vol. 16, page 2241] . In this reaction, compound (XXII) is reacted with an acidic catalyst under heating.
As the acidic catalyst, for example, zinc chloride (without a solvent or in a solvent such as naphthalene, ethanol and the like) , hydrogen chloride/ethanol, sulfuric acid/ethanol, concentrated sulfuric acid, hydrogen chloride/acetic acid, acetic acid, boron fluoride, polyphosphoric acid, methanesulfonic acid, phosphorous pentoxide and the like can be mentioned. These acidic catalysts may be used in' a mixture at an appropriate ratio.
The amount of the acidic catalyst to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXII) . While the reaction time varies depending on the kind and amount of the acidic catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about 0 to about
200°C, preferably about 80 to about 1900C. Compound (XVIII-A) can also be produced by subjecting compound (XXVI) to the Reissert method [Berichte, 1897, vol.
30, page 1030] in two steps.
In the first step, compound (XXVIII) can be produced by reacting compound (XXVI) with compound (XXVII) in the presence of a base. In the second step, compound (XVIII-A) can be produced by subjecting compound (XXVIII) to a reduction reaction.
As the base to be used in the first step, for example, alkali metal Ci-S alkoxides such as sodium methoxide, sodium ethoxide, potassium ethoxide, potassium tert-butoxide and the like, and the like can be mentioned.
The amount of compound (XXVII) and the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXVI), respectively. The reaction temperature is generally -30°C to 1000C. The reaction time is generally 0.5 to 20 hr.
The reduction reaction in the second step is carried out, for example, using a reducing agent. As the reducing agent, for example, metals such as iron, zinc, tin and the like; sulfides such as sodium dithionite and the like; and the like can be mentioned. The amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent. For example, the amount of the metal to be used is generally about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 equivalent of compound (XXVIII), and the amount of the sulfide to be used is generally about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 equivalent of compound (XXVIII). The reduction reaction can also be carried out by a hydrogenation reaction. In this case, for example, catalysts such as palladium carbon, palladium black, platinum dioxide, Raney-nickel, Raney-cobalt, iron trichloride and the like can be used. The amount of the catalyst to be used is generally about 5 to 1000 wt%, preferably about 10 to 300 wt%, relative' to compound (XXVIII) . The hydrogenation reaction can also be carried out using various hydrogen sources instead of hydrogen gas. As such hydrogen source, for example, formic acid, ammonium formate, triethylammonium formate, sodium phosphinate, hydrazine and the like can be mentioned. The amount of the hydrogen source to be used is generally about 1 to 100 mol, preferably about 1 to 5 mol, per 1 mol of compound (XXVIII) . The reduction reaction is preferably carried out in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1- propanol, 2-propanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N, N- dimethylacetamide, hexamethylphosphoramide and the like; organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, methanesulfonic acid and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
While the reaction time varies depending on the kind and amount of the reducing agent to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
Compound (XVIII-B) can be produced by subjecting compound (XVIII-A) to a protection reaction known per se, as necessary. Compound (XVIII) can be produced by subjecting compound (XVIII-B) wherein E is a protected amino group or a protected hydroxy group to a conventional deprotection reaction such as an acid treatment, an alkali treatment, a catalytic reduction and the like, as necessary.
Compound (XVIII) wherein W is an amino group can be produced by subjecting compound (XVIII-B) wherein E is a nitro group to a reduction reaction.
The reduction reaction is carried out, for example, using a reducing agent. As the reducing agent, for example, metals such as iron, zinc, tin and the like; sulfides such as sodium dithionite and the like can be mentioned. The amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent. For example, the amount of the metal to be used is generally about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 equivalent of compound (XVIII-B) , and the amount of the sulfide to be used is generally about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 equivalent of compound (XVIII-B) .
The reduction reaction can also be carried out by a hydrogenation reaction. In this case, for example, catalysts such as palladium carbon, palladium black, platinum dioxide, Raney-nickel, Raney-cobalt, iron trichloride and the like can be used. The amount of the catalyst to be used is generally about 5 to 1000 wt%, preferably about 10 to 300 wt%, per 1 mol of compound (XVIII-B) . The hydrogenation reaction can also be carried out using various hydrogen sources instead of hydrogen gas. As such hydrogen source, for example, formic acid, ammonium formate, triethylammonium formate, sodium phosphinate, hydrazine and the like can be mentioned. The amount of the hydrogen source to be used is generally about 1 to 10 mol, preferably about 1 to 5 mol, per 1 mol of compound (XVIII-B) .
This reaction is preferably carried out in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, tert-butylalcohol and the like; ethers such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert- butyl methyl ether, diisopropyl ether, 1, 2-dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; hydrocarbons such as n-hexane, benzene, toluene and the like; amides such as formamide, N, N- dimethylformamide, N,N-dimethylacetamide and the like; organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, methanesulfonic acid and the like; water and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
While the reaction time varies depending on the kind and amount of the reducing agent to be used and the activity and amount of the catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
Compounds (XX), (XXI), (XXIII), (XXV), (XXVI) and (XXVII) used as starting materials in Scheme 6 can be produced according to a method known per se.
Compound (X) used as a starting material in Scheme 3 can be produced, for example, according to the following method. Scheme 7
Figure imgf000108_0001
(XXXIV)
(XXXVI) (X-I)
Figure imgf000108_0002
(XXXVII) (XXXVIII)
Figure imgf000108_0003
(XXXIX) (X)
wherein each symbol is as defined above.
Compound (XXXVI) can be produced from compound (XXXIV) according to a known method [J. Org. Chem. Soc, 1963, vol. 28, page 1240; Tetrahedron, 2003, vol. 59, page 4979].
In this reaction, compound (XXXIV) is reacted with compound (XXXV) , nitromethane and a base .
This reaction is carried out without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoramide and the like; nitriles such as acetonitrile, propionitrile and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1,2- dichloroethane, carbon tetrachloride, trichloroethylene and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
As the base, for example, amines such as pyrrolidine, piperazine, morpholine, ethylenediamine and the like, and the like can be mentioned.
The amount of the base to be used is generally 0.01 to 10 mol, preferably 0.05 to 2 mol, per 1 mol of compound (XXXIV) . The amount of compound (XXXV) to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXXIV) .
The amount of the nitromethane to be used is generally 1 to 50 mol, preferably 1 to 10 mol, per 1 mol of compound (XXXIV) .
While the reaction time varies depending on the kind and amount of compound (XXXIV) , compound (XXXV) , the nitromethane and base to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about 0 to about 200°C, preferably about 25 to about 100°C.
Compound (XXXVI) can also be produced from compound (XXXIV) in three steps. In the first step, compound (XXXVII) can be produced by subjecting compound (XXXIV) and nitromethane to the Henry reaction [J. Org. Chem. Soc, 1963, vol. 28, page 1240; Synthesis, 1994, page 190; J. Am. Chem. Soc, 2003, vol. 125, page 3700] in the presence of a base. This reaction is carried out without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N, N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoramide and the like; nitriles such as acetonitrile, propionitrile and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1,2- dichloroethane, carbon tetrachloride, trichloroethylene and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
As the base to be used in the first step, for example, alkali metal Ci_6 alkoxides such as sodium methoxide, sodium ethoxide, potassium ethoxide, potassium tert-butoxide and the like, and the like can be mentioned. The amount of the base to be used is generally 0.01 to 10 mol, preferably 0.05 to 2 mol, per 1 mol of compound (XXXIV) .
The amount of the nitromethane to be used is generally 1 to 50 mol, preferably 1 to 10 mol, per 1 mol of compound (XXXIV) . While the reaction time varies depending on the kind and amount of compound (XXXIV) , the nitromethane and base to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about 0 to about 2000C, preferably about 25 to about 100°C.
In the second step, compound (XXXVIII) can be produced by subjecting compound (XXXVII) to a dehydration reaction.
This reaction is carried out without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N, N-dimethylformamide, N,N-dimethylacetam.ide, hexamethylphosphoramide and the like; nitriles such as acetonitrile, propionitrile and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1,2- . dichloroethane, carbon tetrachloride, trichloroethylene and the like; pyridine and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
The dehydration reaction is generally carried out using a dehydrating agent. As the dehydrating agent, chlorinating agents such as thionyl chloride, phosphoryl chloride and the like; sulfonylating agents such as methanesulfonyl chloride, methanesulfonic anhydride and the like; acylating agents such as acetyl chloride, acetic anhydride, trifluoroacetic anhydride and the like, and the like can be mentioned.
The amount of the dehydrating agent to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXXVII) .
This reaction can be carried out in the presence of a base, as necessary. As such base, those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned.
When a base is used, the amount of the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXXVII) .
The reaction temperature is generally -30°C to 200°C. The reaction time is generally 0.5 to 20 hr.
In the third step, compound (XXXVI) can be produced by reacting compound (XXXVIII) with compound (XXXV) in the presence of a base.
This reaction is carried out without a solvent or in a solvent inert to the reaction. As such' solvent, those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned. The base to be used in this reaction, those exemplified for the reaction of compound (II) with compound (III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned. The amount of compound (XXXV) to be used is generally 1 to 10 mol, preferably 1 to 2 mol, per 1 mol of compound (XXXVIII) .
The amount of the base to be used is generally 0.05 to 10 mol, preferably 0.1 to 3 mol, per 1 mol of compound (XXXVIII) . The reaction temperature is generally -30°C to 1000C. The reaction time is generally 0.5 to 20 hr.
Compound (X-I) can be produced by subjecting compound (XXXVI) to a reduction reaction.
The reduction reaction is carried out, for example, using a reducing agent. As the reducing agent, for example, metal hydrides such as aluminum hydride, diisobutylaluminum hydride, tributyltin hydride and the like; metal hydrogen complex compounds such as lithium aluminum hydride, sodium borohydride and the like; borane complexes such as borane-tetrahydrofuran complex, borane-dimethylsulfide complex and the like; alkylboranes such as thexylborane, disiamylborane and the like; diborane; metals such as zinc, aluminum, tin, iron and the like, and the like can be mentioned.
The amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent. For example, the amount of the metal hydride or metal hydrogen complex compound to be used is generally about 0.25 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (XXXVI), and the amount of the borane complex, alkylborane or diborane to be used,is generally about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (XXXVI) .
The reduction reaction is preferably carried out in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1- propanol, 2-propanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1, 2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N- dimethylacetamide, hexamethylphosphoramide and the like; organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, methanesulfonic acid and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
While the reaction time varies depending on the kind and amount of the reducing agent to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr.
The reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
Compound (X) can be produced by reacting compound (XXXIX) with compound (XL) in the presence of an acid catalyst or a base, as necessary.
As the acid catalyst, for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; organic acids such as acetic acid, formic acid, trifluoroacetic acid and the like, and the like can be mentioned. As the base, for example, organic bases such as triethylamine, pyridine, 4-dimethylaminopyridine, diisopropylethylamine and the like; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and the like, and the like can be mentioned.
This reaction is carried out without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4- dioxane, 1,2-dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N, N- dimethylacetamide, hexamethylphosphoramide and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
When an acid catalyst is used, the amount of the compound (XL) and the acid catalyst to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXXIX) , respectively.
While the reaction time varies depending on the kind and amount of compound (XXXIX) , compound (XL) and the acid catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
When a base is used, the amount of compound (XL) and the base to be used is generally 1 to 10 mol, preferably 1 to 3 mol, per 1 mol of compound (XXXIX) , respectively.
While the reaction time varies depending on the kind and amount of compound (XXXIX) , compound (XL) and the base to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr/ The reaction temperature is generally about -20 to about 120°C, preferably about 0 to about
80°C.
Compound (I) can also be produced, for example, according to methods shown in the following Schemes 8 and 9. Scheme 8 "~~
Figure imgf000114_0001
(XH) (XLO CI-Bl) wherein R30 is an optionally substituted Ci-6 alkyl group, R31 is an optionally substituted Ci_6 alkyl group or an optionally substituted aryl group, and the other symbols are as defined above . Compound (I-Bl) can be produced from compound (XII) according to a method described in J. Org. Chem., 2002, vol.
67, page 4595.
In this reaction, compound (XΪI) and compound (XLI) are reacted with in the presence of compound (XLII) . This reaction is carried out without a solvent or in a solvent inert to the reaction. As such solvent, those exemplified for the reaction of compound (II) with compound
(III) or a reactive derivative thereof as shown in Scheme 1 can be mentioned. The amount of compound (XLI) to be used is generally 1 to
10 mol, preferably 1 to 4 mol, per 1 mol of compound (XII) .
The amount of compound (XLII) to be used is generally 0.1 to 10 mol, preferably 0.1 to 2 mol, per 1 mol of compound
(XII) • The reaction temperature is generally -30°C to 200°C.
The reaction time is generally 0.5 to 20 hr.
Scheme 9
Figure imgf000116_0001
(I-B5) (I-B6) (I-B7)
Figure imgf000116_0002
wherein X is an oxygen atom, an optionally oxidized sulfur atom or an optionally mono-substituted amino group, M is a metal (e.g., potassium, sodium, lithium, magnesium, copper, mercury, zinc, thallium, boron, tin and the like, each of which is optionally complexed) , R32 is a hydrogen atom, an optionally substituted hydroxy group, an optionally mono- or di-substituted amino group, an optionally substituted acyl group, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, X and R32 in combination optionally form an optionally substituted ring, R33 and R34 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally mono- or di-substituted amino group or an optionally substituted acyl group, R33 and R34 in combination optionally form an optionally substituted ring, R35 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R35, R37 and R38 are each independently, a hydrogen atom or an optionally substituted hydrocarbon group, R39 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and the other symbols are as defined above. Compound (I-B2) can be produced by subjecting compound (I-Bl) to a reduction reaction.
As the reducing agent to be used in this reaction, for example, metal hydrides such as aluminum hydride, diisobutylaluminum hydride, tributyltin hydride and the like; metal hydrogen complex compounds such as lithium aluminum hydride, sodium borohydride, lithium borohydride, calcium borohydride and the like; borane complexes such as borane- tetrahydrofuran complex, borane-dimethylsulfide complex and the like; alkylboranes such as thexylborane, disiamylborane and the like; diborane and the like can be mentioned. The amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent. For example, the amount of the metal hydride or metal hydrogen complex compound to be used is about 0.25 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (I-Bl), and the amount of the borane complex, alkylborane or diborane to be used is about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (I- Bl) . The reduction reaction is advantageously carried out using a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1-propanol, 2-propanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N- dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoric triamide and the like; organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, rαethanesulfonic acid and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
While the reaction time varies depending on the kind and amount of the reducing agent to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -20 to about 1200C, preferably about 0 to about 80°C.
Compound (I-B3) can be produced by subjecting compound (I-B2) to a substituent-conversion reaction known per se.
For example, compound (I-B3) can be produced by introducing the leaving group for L1 to compound (I-B2) according to the method shown in Scheme 3, and by subjecting the resulting compound to a nucleophilic substitution reaction known per se. Alternatively, compound (I-B3) can also be produced by subjecting compound (I-B2) to the Mitsunobu reaction known per se. Compound (I-B3) wherein X is a optionally mono- substituted amino group can also be produced from compound (I- B4) .
For example, compound (I-B3) can be produced by subjecting compound (I-B4) to a reductive amination reaction known per se.
This reaction can be carried out by a catalytic reduction, or using, as a reducing agent, a metal hydrogen complex compound such as sodium borohydride, sodium tri (acetoxy)borohydride, sodium cyanoborohydride and the like. The amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent. For example, the amount of the metal hydride or metal hydrogen complex compound to be used is about 0.25 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (I-B4) . The reduction reaction is advantageously carried out using a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1-propanol, 2-propanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1, 2-dichloroethane, carbon tetrachloride, trichloroethylene and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoric triamide and the like, and the like can • be mentioned. These solvents may be used in a mixture at an appropriate ratio.
While the reaction time varies depending on the kind and amount of the reducing agent to be used and the activity and amount of the catalyst to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -20 to about 120°C, preferably about 0 to about 80°C.
Compound (I-B4) can be produced by subjecting compound (I-B2) to an oxidization reaction. The oxidation reaction is carried out using an oxidant according to a conventional method. As the oxidant, activated manganese dioxide, pyridinium chlorochromate (PCC) , pyridinium dichromate (PDC), 1, 1, 1-tris (acetyloxy) -1, 1-dihydro-l, 2- benziodoxol-3- (IH) -one (Dess-Martin Periodinane) , dimethyl sulfoxide-acid anhydride (acetic anhydride, trifluoroacetic anhydride and the like) , dimethyl sulfoxide-thionyl chloride, dimethyl sulfoxide-sulfuryl chloride, dimethyl sulfoxide- oxalyl chloride, dimethyl sulfoxide-chlorine, and dimethylsulfoxide-dicyclohexylcarbodiimide (DCC) in the presence of an acid (phosphoric acid, trifluoroacetic acid, dichloroacetic acid and the like) , and the like can be mentioned.
The amount of the oxidant to be used is about 0.25 to about 10 mo1, preferably about 0.5 to about 5 mol, per 1 mol of compound (I-B2) .
The oxidation reaction is advantageously carried out using a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether, 1, 2-dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, trichloroethylene and the like; aromatic hydrocarbons such as benzene, toluene and the like ; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as formamide, N,N-dimethylforrαamide, N,N-dimethylacetamide and the like; nitriles such as acetonitrile, propionitrile and the like; sulfoxides such as dimethylsulfoxide and the like; sulfolane; hexamethylphosphoramide; organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, methanesulfonic acid and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
While the reaction time varies depending on the kind and amount of the oxidant to be used, it is generally about 1 hr to about 100 hr, preferably about 1 hr to about 50 hr. The reaction temperature is generally about -70 to about 120°C, preferably about -70 to about 800C.
Compound (I-B5) can be produced by subjecting compound (I-Bl) to a hydrolysis.
This reaction is carried out in the same manner as in the hydrolysis of compound (XIX) in Scheme 5. Compound (I-B6) can be produced by reacting compound (I- B5) or a reactive derivative of the carboxy group or a salt thereof with compound (XLI) .
This reaction is carried out in the same manner as in the reaction of compound (IX) or a reactive derivative of the carboxy group or a salt thereof with compound (X) in Scheme 3. Compound (I-B7) can be produced by reacting compound (I- B6) with compound (XLII) .
As preferable of compound (XLII) , organic lithiums such as methyllithium, n-butyllithium, vinyllithium, phenyllithium and the like; Grignard reagents such as methylmagnesium bromide, methylmagnesium chloride, vinylmagnesium bromide, phenylmagnesium bromide and the like can be mentioned.
The reaction of compound (I-B6) with compound (XLII) is advantageously carried out using a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, ethers .such as dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether, ethylene glycol dimethyl ether and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
The amount of compound (XLII) to be used is 1 to 10 mol equivalents, preferably 1 to 3 mol equivalents, relative to compound (I-B6) .
The reaction temperature is generally -30°C to 100°C. The reaction time is generally 0.5 to 20 hr.
Compound (I-B8) can be produced by reacting compound (I- Bl) wherein R35 is [-CR36=CR37R38] with compound (XLIII) in the presence of an acid catalyst, as necessary.
As the acid catalyst to be used in this reaction, for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; Lewis acids such as a boron trihalide (e.g., boron trichloride, boron trifluoride and the like) , a titanium tetrahalide (e.g., titanium tetrachloride, titanium tetrabromide and the like), an aluminum halide (e.g., aluminum chloride, aluminum bromide and the like) and the like; organic acids such as acetic acid, formic acid, trifluoroacetic acid and the like can be mentioned.
This reaction is advantageously without a solvent or in a solvent inert to the reaction. As such solvent, while the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such- as methanol, ethanol, 1- propanol, 2-propanol, tert-butylalcohol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1, 2-dimethoxyethane and the like; halogenated hydrocarbons such as dichloromethane, chloroform, 1, 2-dichloroethane, carbon tetrachloride, trichloroethylene and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N- dimethylformamide, N,N-dirαethylacetamide, hexamethylphosphoric triamide and the like, and the like can be mentioned. These solvents may be used in a mixture at an appropriate ratio.
The amount of compound (XLIII) to be used is 1 to 10 mol equivalents, preferably 1 to 3 mol equivalents, relative to compound (I-B7) .
The reaction temperature is generally -30°C to 100°C. The reaction time is generally 0.5 to 20 hr.
In the above-mentioned production method, when the starting compound or the compound of the present invention has an amino group, a carboxyl group, a hydroxy group or a carbonyl group as a substituent, a protecting group generally used in peptide chemistry and the- like may be introduced into these groups. The protecting group can be removed according to a conventional method in any step in each scheme.
Compound (I) can also be produced by subjecting the compound obtained in each of the above-mentioned production methods to a substituent-conversion reaction.
The compound of the present invention obtained according to the above-mentioned production method can be isolated and purified by a known means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. In addition, various starting material compounds used in each of the above-mentioned production methods can be isolated and purified by a known means such as those mentioned above and the like.
Alternatively, the starting material compounds may be directly used in the form of a reaction mixture without isolation as the starting materials of the next step.
For the production of the compound of the present invention, when the starting material compound can form a salt, the compound may also be used in the form of a salt. As such salt, those similar to the salts of the aforementioned compound of the present invention can be mentioned.
When the compound of the present invention contains an optical isomer, a stereoisomer, a positional isomer or a rotational isomer, these are encompassed in the compound of the present invention, and obtained as a single product according to a synthetic method and separation method known per se. For example, an optical isomer and an optical isomer resolved from this compound are also encompassed in the compound of the present invention.
The compound of the present invention may be in the form of a crystal.
The crystal of the compound of the present invention (hereinafter sometimes to be abbreviated as the crystal of the present invention) can be produced by crystallization of the compound of the present invention according to a crystallization method known per se.
In the present specification, the melting point refers to that measured using, for example, micromelting point measuring apparatus (Yanako, MP-500D or Buchi, B-545) or DSC (differential scanning calorimetry) device (SEIKO, EXSTAR6000) and the like.
In general, melting points vary depending on measurement apparatuses, measurement conditions and the like. The crystal in the present specification may show a different melting point described in the present specification, as long as it is within general error range.
The crystal of the present invention is superior in physicochemical properties (e.g., melting point, solubility, stability and the like) and biological properties (e.g., pharmacokinetics (absorption, distribution, metabolism, excretion) , efficacy expression and the like) , and is extremely useful as a pharmaceutical agent.
Examples
The present invention is explained in detail in the following by referring to the following Reference Examples, Examples, Experimental Examples and Formulation Examples, which are not to be construed as limitative. In addition, the present invention may be modified without departing from the scope of invention.
The term "room temperature" in the following Reference Examples and Examples indicates the range of generally from about 100C to about 35°C. As for "%", the yield is in mol/mol%, the solvent used for chromatography is in % by volume and other λΛ%" is in % by weight. OH proton, NH proton etc. on proton NMR spectrum that could not be confirmed due to broad peak are not included in the data. The other symbols used herein mean the following: s : singlet d : doublet t : triplet q : quartet m : multiplet br : broad
J : coupling constant
Hz : Hertz
CDCl3 : deuterated chloroform DMSOd6: dimethyl sulfoxide-d6
1H-NMR : proton nuclear magnetic resonance
TFA : trifluoroacetic acid
In the following Reference Examples and Examples, nuclear magnetic resonance spectrum (NMR) were measured under the following conditions.
NMR measurement tools: Varian Inc. Varian Gemini 200 (200 MHz),
Varian Gemini 300 (300 MHz), Bruker BioSpin Corp. AVANCE 300. In the following Examples, high performance liquid chromatography (HPLC) - mass spectrum (LC-MS) was measured under the following conditions . measurement tools: Micromass Ltd., Quattro Micro and Agilent
Technologies, Inc. HPIlOO, or Waters Corporation, MUX system
(Micromass Ltd., ZQ)
Column: Shiseido Co., Ltd., Capcelpak Cl8 UG-120, 1.5 X 35 mm solvent: SOLUTION A; 5 mM ammonium acetate/2% acetonitrile/water, SOLUTION B; 5 mM ammonium acetate/95% acetonitrile/water gradient cycle: 0.00 min (SOLUTIONA 100%), 2.00 min (SOLUTION
B 100%), 3.00 min (SOLUTION B 100%), 3.01 min (SOLUTION A 100%), 3.80 min (SOLUTION A 100%) flow rate: 0.5 ml/min, detection: UV 220 nm ionization method: Electron Spray Ionization: ESI
In the following Reference Examples and Examples, purification by preparative high performance liquid chromatography (HPLC) was performed, under the following conditions. In the case of a compound having a basic functional group, however, when trifluoroacetic acid is used in this operation, neutralization and the like may be necessary to obtain a free compound. tools: Gilson, Inc., high through-put purification system Column: Shiseido Co., Ltd., Capcelpak C18 UG-120, S-5 uM, 20 x 50 mm solvent: SOLUTION A; 0.1% trifluoroacetic acid-containing water, SOLUTION B; 0.1% trifluoroacetic acid-containing acetonitrile gradient cycle: 0.00 min (SOLUTION A/SOLUTION B = 95/5), 1.10 min (SOLUTION A/SOLUTION B=95/5) , 5.00 min (SOLUTION A/SOLUTION B=0/100), 6.40 min (SOLUTION A/SOLUTION B = 0/100), 6.50 min (SOLUTION A/SOLUTION B = 95/5) . flow rate: 20 ml/min, detection: UV 220 nm Alternatively, tools: Waters mass preparative system (UV Purification System) Column: Develosil ODS-UG-10 solvent: SOLUTION A; 0.1% trifluoroacetic acid-containing water, SOLUTION B; 0.1% trifluoroacetic acid-containing acetonitrile gradient cycle: 0.00 min (SOLUTION A/SOLUTION B = 95/5), 1.00 min (SOLUTION A/SOLUTION B = 95/5), 2.00 min (SOLUTION A/SOLUTION B = 80/20), 5.00 min (SOLUTION A/SOLUTION B = 5/95), 5.10 min (SOLUTION A/SOLUTION B = 0/100), 7.00 min (SOLUTION A/SOLUTION B 100/0) flow rate: 150 ml/min^ detection: UV 220 nm
In the following Reference Examples and Examples, preparative high performance liquid chromatography (HPLC) for chiral resolution was performed using K-Prep manufactured by YMC Co., Ltd. and preparative supercritical fluid chromatography (SFC) was performed using Multigram II manufactured by METTLER-TOLEDO K.K.
Reference Example 1 ethyl 1- (methoxymethyl) -7-nitro-lH-indole-2- carboxylate
Figure imgf000126_0001
To a suspension of sodium hydride (60%, in oil, 0.51 g) in N,N-dimethylformamide (15 ml) was slowly added ethyl 7-nitro-lH- indole-2-carboxylate (2.50 g) at 0°C, and the mixture was stirred for 30 min. Chloromethyl methyl ether (1.00 ml) was added to the reaction mixture over 20 min at 0°C, and the mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (2.29 g, yield 77%) as pale-yellow crystals from a fraction eluted with ethyl acetate-hexane (1:3, volume ratio), melting point 62 - 63°C.
Reference Example 2 ethyl 7-amino-l- (methoxymethyl) -lH-indole-2- carboxylate
Figure imgf000127_0001
A mixture of ethyl 1- (methoxymethyl) -7-nitro-lH-indole-2- carboxylate (2.35 g) , 10% palladium-carbon (0.24 g) , ethanol (4 ml) and tetrahydrofuran (10 ml) was stirred overnight at room temperature under hydrogen atmosphere. The palladium-carbon was removed by filtration, and the filtrate was concentrated. The residue was subjected to silica gel column chromatography to give the title compound (1.92 g, yield 91%) as a yellow oil from a fraction eluted with ethyl acetate-hexane (1:3, volume ratio). 1H-NMR (CDCl3) δ: 1.41 (3H, t, J=7.2 Hz), 3.44 (3H, s) , 4.36 (2H, q, J=7.2 Hz), 4.53 (2H, brs) , 6.16 (2H, s) , 6.61 (IH, dd, J=7.7, 0.9 Hz), 6.97 (IH, t, J=7.7 Hz), 7.10 (IH, dd, 3-1.1, 0.9 Hz), 7.28 (IH, s) . Reference Example 3 ethyl 1- (methoxymethyl) -7- [ (2- thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000128_0001
To a mixture of ethyl 7-amino-l- (methoxymethyl) -lH-indole- 2-carboxylate (0.70 g) and pyridine (8 ml) was added thiophene-
2-sulfonyl chloride (0.57 g) at 0°C, and the mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated, 10% aqueous citric acid solution was added, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed with saturated brine, dried (MgSU4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (1.03 g, yield 93%) as a yellow oil from a fraction eluted with ethyl acetate- hexane (1:2, volume ratio).
1H-NMR(CDCI3)OII^O (3H, t, J=7.2 Hz), 3.45 (3H, s) , 4.35 (2H, q, J=7.2 Hz), 5.70 (2H, s) , 7.00 (IH, dd, J=5.1, 3.7 Hz), 7.19 (IH, t, J=7.8 Hz), 7.32 (IH, s) , 7.46-7.64 (4H, m) , 8.87 (IH, brs) . Reference Example 4 ethyl 1- (methoxymethyl) -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000128_0002
A mixture of ethyl 1- (methoxymethyl) -7- [ (2- thienylsulfonyl) amino] -lH-indole-2-carboxylate (1.03 g) , methyl iodide (0.24 ml), potassium carbonate (0.36 g) and N,N- dimethylformamide (10 ml) was stirred overnight at room temperature. Water was added to the reaction mixture, and the resulting crystals were collected by filtration, washed with water, and dried to give the title compound (1.06 g, yield 99%) as colorless crystals, melting point 143 - 145°C. Reference Example 5 ethyl 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxylate
Figure imgf000129_0001
A mixture of ethyl 1- (methoxymethyl) -7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxylate (1.06 g) , concentrated hydrochloric acid (1 ml) and ethanol (5 ml) was heated overnight under reflux. Water was added to the reaction mixture, and the resulting crystals were collected by filtration, washed with water, and dried. The obtained crystals were subjected to silica gel column chromatography to give the title- compound (0.43 g, yield 46%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (2:1, volume ratio) . The crystals were recrystallized from ethyl acetate-hexane. melting point 164 - 165°C. Reference Example 6 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxylic acid
Figure imgf000129_0002
A mixture of ethyl 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxylate (0.40 g) , 8N aqueous sodium hydroxide solution (0.40 ml), tetrahydrofuran (5 ml) and methanol (5 ml) was stirred at 60°C for 1 hr. The reaction mixture was concentrated, and water was added to the residue. The mixture was acidified with 10% aqueous citric acid solution, and the resulting crystals were collected by filtration, washed with water, and dried to give the title compound (0.35 g, yield 91%) as colorless crystals, melting point >240°C (decomposition). Reference Example 7 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxamide
Figure imgf000130_0001
To a mixture of 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxylic acid (17.20 g) , IH-1, 2, 3-benzotriazol-l-ol (8.29 g) and N,N-dimethylformamide (150 ml) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (11.8 g) at room temperature, and the mixture was stirred at 50°C for 20 min. The mixture was allowed to cool to room temperature, and 28% aqueous ammonia (3.4 ml) was added. The reaction mixture was stirred at room temperature for 2 hr, and water was added. The mixture was acidified with 10% aqueous citric acid solution, and the resulting crystals were filtrated, washed with water, washed with cooled ethyl acetate, and dried to give the title compound (11.47 g, yield 67%) as colorless crystals, melting point 244 -
245°C.
Reference Example 8 1- (methoxymethyl ) -7- [ (2- thienylsulfonyl ) amino] -lH-indole-2-carboxamide
Figure imgf000130_0002
In the same manner as in Reference Example 7, the title compound (26.9 g, yield 88%) was obtained as colorless crystals from 1- (methoxymethyl) -7- [ (2-thienylsulfonyl) amino] -lH-indole-2- carboxylic acid (29.4 g) . melting point 142-1440C. Reference Example 9 7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -1- (methoxymethyl) -lH-indole-2-carboxamide
Figure imgf000131_0001
A mixture of 1- (methoxymethyl) -7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (1.0 g) , (bromomethyl) cyclopropane (456 mg) , potassium carbonate (1.13 g) and N, N-dimethylformamide (5 ml) was stirred at 85°C for 20 hr. The reaction mixture was diluted with ethyl acetate and saturated brine. The organic layer was washed with aqueous sodium bicarbonate and saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated. The residue was subjected to basic silica gel column chromatography, and eluted with ethyl acetate-hexane mixture (2:1) to give the title compound (820 mg, yield 72%) as an amorphous form.
1H-NMR (CDCl3) δ: 0.16-0.05 (IH, m) , 0.08-0.19 (IH, m) , 0.37-0.47 (IH, m) , 0.86-1.08 (IH, m) , 3.43 (IH, dd, J=13.5, 7.3 Hz), 3.45 (3H, s), 3.79 (IH, dd, J = 13.5, 7.3 Hz), 6.20 (2H, s), 6.68 (IH, d, J = 7.7 Hz), 7.01 (IH, t, J-= 7.7 Hz), 7.08-7.18 (2H, m) , 7.44-7.51 (IH, m) , 7.59-7.72 (2H, m) . Reference Example 10 7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000131_0002
A mixture of 1- (methoxymethyl) -7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (390 mg) , oxalic acid dihydrate (351 mg) , methanol (15 ml) and water (15 ml) was stirred at 70°C for 1 hr, and then at 90°C for 14 hr. The reaction mixture was allowed to cool to room temperature, and the resulting crystals were collected by filtration, washed successively with water and diethyl ether-hexane mixture, and dried to give the title compound (286 mg, yield 81%) as crystals. melting point 229 - 231°C Reference Example 11 7- [isopropyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxamide
Figure imgf000132_0001
A mixture of 1- (methoxymethyl) -7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (1.0 g) , 2- iodopropane (574 mg) , potassium carbonate (1.13 g) and N,N- dimethylacetamide (5 ml) was stirred at room temperature for a week. The reaction mixture was diluted with ethyl acetate and saturated brine, and the organic layer was washed with aqueous sodium bicarbonate and saturated brine, dried over magnesium sulfate, and filtrated. The filtrate was concentrated, and the residue was subjected to basic silica gel column chromatography, and eluted with ethyl acetate-hexane (2:1) mixture to give a solid. A mixture of this solid, oxalic acid dihydrate (605 mg) , methanol (15 ml) and water (15 ml) was stirred at 100°C for 3.5 days . The reaction mixture was allowed to cool to room temperature, and the obtained solid was collected by filtration, washed successively with water, hexane-diisopropyl ether mixture and hexane. The obtained solid was subjected to basic silica gel column chromatography, and eluted with ethyl acetate-hexane mixture (2:1) to give the title compound (340 nag, yield 34%) as an amorphous solid.
1H-NMR (CDCl3) δ: 1.04-1.21 (6H, m) , 4.79-4.96 (IH, m) , 6.79-6.94 (2H, m), 7.01-7.11 (2H, m) , 7.47-7.55 (IH, m) , 7.59 (IH, dd, J=5.1, 1.3 Hz), 7.66 (IH, d, J=7.9 Hz), 9.98 (IH, s) . Reference Example 12 7- [ (2-ethoxyethyl) (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide
Figure imgf000133_0001
A mixture of 1- (methoxymethyl) -7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (6.25 g) , 1- bromo-2-ethoxyethane (3.41 g) , potassium carbonate (7.09 g) and N,N-dimethylformamide (30 ml) was stirred at 75°C for 6 hr. The reaction mixture was diluted with ethyl acetate and saturated brine. The organic layer was washed with aqueous sodium bicarbonate and saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated. The obtained residue was subjected to basic silica gel column chromatography, and eluted with ethyl acetate-hexane (2:1) mixture to give a solid. A mixture of this solid (5.50 g) , oxalic acid dihydrate
(4.77 g) , methanol (50 ml) and water (50 ml) was stirred at 90°C for 14 hr. The reaction mixture was allowed to cool to room temperature, and diluted with water, and the obtained solid was crystallized, and washed with water to give the title compound
(4.70 g, yield 95%) as crystals, melting point 1350C. Reference Example 13 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carbothioamide
Figure imgf000133_0002
A mixture of 7- [methyl (2-thienylsulfonyl) amino] -IH-indole- 2-carboxamide (11.47 g) , Lawesson' s reagent (15.2 g) and tetrahydrofuran (150 ml) was stirred at 50°C for 4 hr. The reaction mixture was concentrated, and the resulting crystals were filtrated, washed with toluene, and dried to give the title compound (11.16 g, yield 93%) as yellow crystals, melting point
239 - 240°C.
Reference Example 14 7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -lH-indole-2-carbothioamide
Figure imgf000134_0001
A mixture of 7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (264 mg) , Lawesson' s reagent (339 mg) and tetrahydrofuran (5 ml) was stirred at 60°C for 2 hr. The reaction mixture was concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography, and eluted with a mixed solvent of ethyl acetate-hexane (1:1) to give the title compound (243 mg, yield 88%) as an amorphous solid. MS m/z 392 (M+H+) . Reference Example 15 7- [ethyl (2-thienylsulfonyl) amino] -IH- indole-2-carbothioamide
Figure imgf000134_0002
A mixture of 1- (methoxymethyl) -7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (6.0 g) , ethyl iodide (1.6 ml), potassium carbonate (6.78 g) and N,N- dimethylformamide (30 ml) was stirred at room temperature for 20 hr. The reaction mixture was diluted with ethyl acetate and saturated brine, and the organic layer was washed with aqueous sodium bicarbonate and saturated brine, dried over magnesium sulfate, and filtrated. The filtrate was concentrated, and the residue was subjected to basic silica gel column chromatography, and eluted with, ethyl acetate-hexane (1:1) mixture to give a solid. A mixture of this solid, oxalic acid dihydrate (5.84 g) , methanol (50 ml) and water (50 ml) was stirred at 950C for 7 hr. The reaction mixture was concentrated, diluted with ethyl acetate-tetrahydrofuran mixture, and washed with water, and the aqueous layer was extracted with ethyl acetate-tetrahydrofuran mixture. The combined organic layer was dried over magnesium sulfate, and filtrated. The filtrate was concentrated, and the obtained solid was washed with water. A mixture of this solid, Lawesson' s reagent (3.76 g) and tetrahydrofuran (50 ml) was stirred at 65°C for 2.5 hr. The reaction mixture was concentrated, and the residue was crystallized from methylene chloride-toluene mixture to give the title compound (3.5 g, yield 62%) as crystals, melting point 163°C. Reference Example 16 7- [isopropyl (2-thienylsulfonyl) amino] -IH- indole-2-carbothioamide
Figure imgf000135_0001
A mixture of 7- [isopropyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxamide (320 mg) , Lawesson' s reagent (213 mg) and tetrahydrofuran (5 ml) was stirred at 700C for 1 hr. The reaction mixture was concentrated under reduced pressure, and the residue was crystallized from methylene chloride-toluene mixture, and washed with hexane to give the title compound (148 mg, yield 44%) as crystals, melting point 204-2050C. Reference Example 17 7- [ (2-ethoxyethyl) (2- thienylsulfonyl) amino] -lH-indole-2-carbothioamide
Figure imgf000136_0001
A mixture of 7- [ (2-ethoxyethyl) (2-thienylsulfonyl) amino] - lH-indole-2-carboxamide (4.70 g) , Lawesson' s reagent (3.06 g) and tetrahydrofuran (30 ml) was stirred at 70°C for 3 hr. The reaction mixture was concentrated, and toluene was added to the residue. The obtained solid was washed with toluene to give the title compound (2.99 g, yield 58%) as crystals, melting point
182°C.
Reference Example 18 N-{2- [5- (hydroxymethyl) -1, 3-thiazol-2-yl]- IH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000136_0002
A mixture of 7- [methyl (2-thienylsulfonyl) amino] -IH-indole- 2-carbothioamide (1.00 g) , bromomalonaldehyde (0.86 g) and N,N- dimethylacetamide (8 ml) was stirred at 80°C for 3 hr. Water was added to the reaction mixture, and the resulting crystals were collected by filtration, washed with water, and dried. The obtained crystals were dissolved in tetrahydrofuran (8 ml) and methanol (8 ml) , sodium borohydride (63 mg) was added at 0°C, and the mixture was stirred at 00C for 1 hr. The reaction mixture was concentrated, 10% aqueous citric acid solution was added, and the resulting crystals were collected by filtration, washed with water, and dried. The crystals were subjected to silica gel column chromatography to give the title compound (0.43 g, yield 39%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (3:1, volume ratio), melting point 201-2020C. Reference Example 19 N-ethyl-N-{2- [5- (hydroxymethyl) -1,3- thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000137_0001
A mixture of 7- [ethyl (2-thienylsulfonyl) amino] -lH-indole- 2-carbothioamide (4.10 g) , bromomalonaldehyde (3.55 g) and N,N- dimethylacetamide (30 ml) was stirred at 950C for 1.5 hr. Water was added to the reaction mixture, and the obtained precipitate was collected by filtration and dissolved in tetrahydrofuran (30 ml) and methanol (30 ml) . After cooling with an ice bath, sodium borohydride (508 mg) was added, and the mixture was stirred at ■ room temperature for 16 hr. The reaction mixture was concentrated, and diluted with ethyl acetate-tetrahydrofuran mixture. The organic layer was washed successively with aqueous sodium bicarbonate and saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-hexane (2:1) mixture to give the title compound (800 mg, yield 17%) as a solid. MS m/z 420(M+H+) . Reference Example 20 N- (cyclopropylmethyl) -N- {2- [5-
(hydroxymethyl) -1, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000137_0002
In the same manner as in Reference Example 19, the title compound (100 mg, yield 50%) was obtained as crystals from 7- t (cyclopropylmethyl) (2-thienylsulfonyl) amino] -IH-indole-2- carbothioamide (225 mg) and bromomalonaldehyde (182 mg) . melting point 174°C.
Reference Example 21 N- (2- [5- (hydroxymethyl) -1, 3-thiazol-2-yl] - lH-indol-7-yl) -N-isopropylthiophene-2-sulfonamide
Figure imgf000138_0001
In the same manner as in Reference Example 19, the title compound (124 mg, yield 88%) was obtained as crystals from 7- [isopropyl (2-thienylsulfonyl) amino] -lH-indole-2-carbothioamide
(123 mg) and bromomalonaldehyde (103 mg) . melting point 209°C.o Reference Example 22 N- (2-ethoxyethyl) -N- {2- [5- (hydroxymethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000138_0002
In the same manner as in Reference Example 19, the title compound (1.00 g, yield 29%) was obtained as a amorphous form5 from 7- [ (2-ethoxyethyl) (2-thienylsulfonyl) amino] -IH-indole-2- carbothioamide (3.00 g) and bromomalonaldehyde (2.32 g) . MS m/z 464 (M+H+) .
Reference Example 23 N-{2- [5- (chloromethyl) -1, 3-thiazol-2-yl] - IH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000138_0003
A mixture of N- {2- [5- (hydroxymethyl) -1, 3-thiazol-2-yl] -IH- indol-7-yl}-N-methylthiophene-2-sulfonainide (0.10 g) , thionyl chloride (0.03 ml), N,N-dimethylformamide (one drop) and tetrahydrofuran (6 ml) was stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed successively with saturated brine, aqueous sodium bicarbonate and saturated brine, dried (MgSO4) , and concentrated to give the title compound (0.08 g, yield 76%) as yellow crystals, melting point 204 - 2050C.
Reference Example 24 N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] - lH~indol-7-yl}~N-isopropylthiophene-2-sulfonamide
Figure imgf000139_0001
A mixture of N- {2- [5- (hydroxymethyl) -1, 3-thiazol-2-yl] -IH- indol-7-yl}-N-isopropylthiophene-2-sulfonamide (2.12 g) , thionyl chloride (0.70 ml), N,N-dimethylformamide (two drop) and tetrahydrofuran (30 ml) was stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with saturated brine, aqueous sodium bicarbonate and saturated brine, dried (MgSO4) , and concentrated. The residue was crystallized from diethyl ether, and the crystals were collected by filtration, washed with diethyl ether, and dried to give the title compound (2.00 g, yield 90%) as yellow crystals, melting point 184 - 185°C.
Reference Example 25 N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] - lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide
Figure imgf000140_0001
To a mixture of N-ethyl-N-{2- [5- (hydroxyrαethyl) -1, 3- thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide (3.43 g) , N,N-dimethylformamide (0.05 ml) and tetrahydrofuran (50 ml) was added thionyl chloride (1.56 g) , and the mixture was stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate and saturated brine, and the organic layer was washed with saturated brine, and dried over magnesium sulfate, and filtrated. The filtrate was concentrated, and the obtained solid was washed with ether-hexane (1:1) to give the title compound (3.27 g, yield 91%) as s pale-yellow solid.
1H-ISlMR(CDCl3)O: 1.12 (3H, t, J = 7.1 Hz), 3.77 (2H, q, J = 7.1 Hz), 4.85 (2H, d, J = 0.8 Hz), 6.57 (IH, dd, J = 7.6, 0.9 Hz), 6.96-7.03 (2H, m) , 7.09 (IH, dd, J = 4.9, 3.8 Hz), 7.39 (IH, dd, J = 3.8, 1.3 Hz), 7.56-7.64 (2H, m) , 7.74 (IH, s) , 9.48 (IH, s) . Reference Example 26 N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] - lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene-2-sulfonamide
Figure imgf000140_0002
In the same manner as in Reference Example 25, the title compound (2.05 g, yield 97%) was obtained as a pale-yellow solid from N- (cyclopropylmethyl) -N- {2- [5- (hydroxymethyl) -1, 3-thiazol- 2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide (2.15 g) . melting point 135°C.
Reference Example 27 N- { 2- [ 5- (chloromethyl) -1 , 3-thiazol-2-yl] - lH-indol-7-yl }-N- (2-ethoxyethyl) thiophene- 2 -sulfonamide
Figure imgf000141_0001
In the same manner as in Reference Example 25, the title compound (970 mg, yield 93%) was obtained as a pale-yellow solid from N- (2-ethoxyethyl) -N- {2- [5- (hydroxymethyl) -1, 3-thiazol-2- yl]-lH-indol-7-yl}thiophene-2-sulfonamide (1.00 g).
1H-NMR(CDCl3)B: 1.14 (3H, t, J = 7.0 Hz), 3.38-3.55 (4H, m) , 3.91 (2H, s), 4.85 (2H, s) , 6.69 (IH, d, J = 7.5 Hz), 6.95-7.03 (2H, m) , 7.05-7.10 (IH, m) , 7.42-7.46 ' (IH, m) , 7.57-7.62 (2H, m) , 7.73 (IH, s), 9.75 (IH, s) . Reference Example 28 ethyl [2- ( {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2- yl}carbonyl)hydrazino] (oxo) acetate
Figure imgf000141_0002
To a mixture of 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxylic acid (0.50 g) , 1H-1,2, 3-benzotriazol-l-ol (0.24 g) and N, N-dimethylformamide (10 ml) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.30 g) at room temperature, and the mixture was stirred for 10 min. Ethyl hydrazino (oxo) acetate (0.33 g) was added, and the reaction mixture was stirred at room temperature for 2 hr. Water was added, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (0.43 g, yield 63%) as colorless crystals from a fraction eluted with ethyl acetate, melting point 133 - 134°C. Reference Example 29 ethyl 5-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-!, 3, 4-thiadiazole-2- carboxylate
Figure imgf000142_0001
A mixture of ethyl [2- ( {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2- yl}carbonyl)hydrazino] (oxo) acetate (0.43 g) , Lawesson' s reagent (0.42 g) and tetrahydrofuran (10 ml) was stirred overnight at
5O0C. The reaction mixture was concentrated, and the residue was subjected to silica gel column chromatography to give the title compound (0.29 g, yield 68%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (2:3, volume ratio). The crystals were recrystallized from ethyl acetate-hexane. melting point 176 - 177°C.
Reference Example 30 N-{2- [5- (hydroxymethyl) -1, 3, 4-thiadiazol-2- yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000142_0002
To a mixture of ethyl 5- {7- [methyl (2- thienylsulfonyl) amino] -IH-indol-2-yl}-l, 3, 4-thiadiazole-2- carboxylate (1.38 g) , tetrahydrofuran (20 ml) and methanol (4 ml) was added sodium borohydride (0.26 g) , and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, and water was added to the residue. The resulting crystals were collected by filtration, washed with water, and dried to give the title compound (1.18 g, yield 94%) as colorless crystals, melting point 259-2600C (decomposition). Reference Example 31 3- (benzylthio) -3-methyl-4-nitrobutan-l-ol
Figure imgf000143_0001
A mixture of 4-hydroxy-2-butanone (5.00 g) , benzylmercaptan (6.65 ml), nitromethane (30.7 ml), ethylenediamine (3.80 ml) and acetonitrile (30 ml) was stirred at room temperature for 4 hr. The reaction mixture was concentrated, and the obtained residue was subjected to silica gel column chromatography to give the title compound (5.70 g, yield 39%) as a colorless oil from a fraction eluted with ethyl' acetate-hexane (1:1, volume ratio).
1H-NMR(CDCI3)OJLSS (3H, s) , 1.77 (IH, t, J=5.6 Hz), 1.94-2.12 (4H, m), 3.78-4.01 (4H, m) , 4.52 (IH, d, J=ILl Hz), 4.61 (IH, d, J=ILl Hz), 7.22-7.35 (5H, m) .
Reference Example 32 4-amino-3- (benzylthio) -3-methylbutan-l-ol
Figure imgf000143_0002
To a mixture of lithium aluminum hydride (1.67 g) and tetrahydrofuran (30 ml) was added a solution of 3- (benzylthio) - 3-methyl-4-nitrobutan-l-ol (3.00 g) in tetrahydrofuran (10 ml) over 1 hr at room temperature. The reaction mixture was stirred at room temperature for l'hr, ethanol (10 ml) and water (6.4 ml) were added in this order, and the resulting inorganic salt was removed by filtration. The filtrate was concentrated, and the residue was dissolved in ethyl acetate, dried (MgSCi) / and concentrated to give the title compound (2.62 g, yield 99%) as a yellow oil.
1H-NMR (CDCl3) δ: 1.37 (3H, s), 1.78-1.98 (2H, m) , 2.66 (IH, d, J=12.6 Hz), 2.78 (IH, d, J=12.6 Hz), 3.55-3.86 (4H, m) , 7.20- 7.38 (5H, m) . Reference Example 33 N- [2- (benzylthio) -4-hydroxy-2-methylbutyl] - 7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000144_0001
To a mixture of 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxylic acid (2.00 g) , 4-amino-3- (benzylthio) -3- methylbutan-1-ol (1.61 g) , IH-I, 2, 3-benzotriazol-l-ol (0.96 g) and N, N-dimethylformamide (20 ml) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (1.37 g) at room temperature, and the mixture was stirred at room temperature for 5 hr. Water was added to the reaction mixture,' and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (2.10 g, yield 65%) as colorless crystals from a fraction eluted with ethyl acetate, melting point 132-133°C.
Reference Example 34 4- [3- (benzylthio) -3-methyl-4- nitrobutyl]morpholine
Figure imgf000144_0002
A mixture of 3-buten-2-one (2.00 ml) and morpholine (2.35 ml) was stirred at room temperature for 30 min (exothermic reaction). Benzylmercaptan (3.20 ml), nitromethane (13.2 ml), ethylenediamine (1.8 ml) and acetonitrile (10 ml) were added to the reaction mixture, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated, and the obtained residue was subjected to silica gel column chromatography to give the title compound (3.27 g, yield 41%) as a yellow oil from a fraction eluted with ethyl acetate. 1H-NMR (CDCl3) δ: 1.50 (3H, s) , 1.82-2.20 (2H, m) , 2.38-2.70 (6H, m) , 3.69 (4H7 t, J=4.7 Hz), 3.75 (IH, d, J=12.2 Hz), 3.80 (IH, d, J=12.2 Hz) , 4.48 (IH, d, J=Il.1 Hz) , 4.61 (IH, d, J=Il.1 Hz), 7.22-7.35 (5H, m) . Reference Example 35 2- (benzylthio) -2-methyl-4- (morpholino) butan-1-amine
Figure imgf000145_0001
In the same manner as in Reference Example 32, the title compound (2.90 g, yield 98%) was obtained as a yellow oil from 4- [3- (benzylthio) -3-methyl-4-nitrobutyl]morpholine (3.27 g) .
Figure imgf000145_0002
(3H, s) , 1.58-1.82 (2H, m) , 2.37-2.59 (6H, m) , 2.62 (IH, d, J=13.8 Hz), 2.68 (IH, d, J=13.8 Hz), 3.60-3.80 (6H, m), 7.18-7.38 (5H, m) . Reference Example 36 N- [2- (benzylthio) -2-methyl-4- (morpholino) butyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole- 2-carboxamide
Figure imgf000145_0003
In the same manner as in Reference Example 33, the title compound (1.39 g, yield 76%) was obtained as yellow amorphous crystals from 7- [methyl (2-thienylsulfonyl) amino] -IH-indole-2- carboxylic acid (1.00 g) and 2- (benzylthio) -2-methyl-4- (morpholino)butan-l-amine (1.00 g) . MS: 613 (MH+) . Reference Example 37 ( { [2,2-dimethoxy-l-methyl-l- (nitromethyl) ethyl] thio}methyl) benzene •
Figure imgf000146_0001
A mixture of 1, 1-dimethoxyacetone (5.00 ml), benzylmercaptan (5.50 ml)1, nitromethane (23 ml), ethylenediamine (3.00 ml) and acetonitrile (15 ml) was stirred at room temperature, and then overnight at 80°C. The reaction mixture was concentrated, and the obtained residue was subjected to silica gel column chromatography to give the title compound (5.81 g, yield 48%) as a colorless oil from a fraction eluted with ethyl acetate-hexane (1:6, volume ratio). 1H-NMR (CDCl3) δ: 1.46 (3H, s) , 3.57 (3H, s) , 3.58 (3H, s) , 3.91 (IH, d, J=Il.4 Hz), 3.96 (IH, d, J=Il.4 Hz), 4.39 (IH, s) , 4.64 (IH,- d, J=Il.4 Hz), 4.69 (IH, d, J=Il.4 Hz), 7.19-7.35 (5H, m) . Reference Example 38 2- (benzylthio) -3, 3-dimethoxy—2- methylpropan-1-amine
Figure imgf000146_0002
In the same manner as in Reference Example 32, the title compound (4.69 g, yield 90%) was obtained as a yellow oil from ( { [2, 2-dimethoxy-1-methyl-1- (nitromethyl) ethyl] thio}methyl) benzene (5.81 g) .
Figure imgf000146_0003
(3H, s) , 2.77 (IH, d, J=13.6 Hz), 2.88 (IH, d, J=13.6 Hz), 3.54 (3H, s) , 3.56 (3H, s) , 3.80 (IH, d, J=12.2 Hz), 3.85 (IH, d, J=12.2 Hz), 4.27 (IH, s) , 7.18-7.37 (5H, m) . Reference Example 39 N- [2- (benzylthio) -3-, 3-dimethoxy-2- methylpropyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carboxamide
Figure imgf000147_0001
In the same manner as in Reference Example 33, the title compound (3.87 g, yield 76%) was obtained as a yellow oil from 7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxylic acid (3.00 g) and 2- (benzylthio) -3, 3-dimethoxy-2-methylpropan-l-amine (2.73 g) .
1H-NMR(CDCl3)0: 1.35 (3H, s) , 3.33 (3H, s) , 3.60 (3H, s) , 3.61 (3H, s), 3.69 (IH, dd, J= 13.8, 5.4 Hz), 3.79 (IH, dd, J= 13.8, 5.4 Hz)/ 3.86 (IH, d, J=12.3 Hz), 4.25 (IH, s) , 6.61 (IH, d, J=7.8 Hz), 6.74 (IH, d, J=2.1 Hz), 6.89 (IH, t, J=5.4 Hz), 6.99 (IH, t, J=7.8 Hz), 7.11 (IH, dd, J= 5.1, 3.9 Hz), 7.18-7.43 (6H, m) , 7.59 (IH, d, J=7.8 Hz), 7.63 (IH, dd, J= 5.1, 1.5 Hz), 9.49 (IH, brs) . Reference Example 40 N- [2- (benzylthio) -2-methyl-3-oxopropyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000147_0002
A mixture of N- [2- (benzylthio) -3, 3-dimethoxy-2- methylpropyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carboxamide (1.00 g) , Amberlyst (registered trade mark) 15 ion exchange resin (0.20 g) , water (0.1 ml) and acetone (10 ml) was stirred overnight at room temperature. The insoluble substance was removed by filtration, and the filtrate was concentrated to give the title compound (0.83 g, yield 92%) as colorless crystals, melting point 149 - 15O0C. Reference Example 41 N- [2- (benzylthio) -2-methyl-3- morpholinopropyl] -7- [methyl (2-thienylsulfonyl) amino] -IH-indole- 2-carboxamide
Figure imgf000148_0001
To a mixture of N- [2- (benzylthio) -2-methyl-3-oxopropyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (0.40 g) , morpholine (0.13 ml) and 1,2-dichloroethane (4 ml) was added sodium triacetoxyborohydride (0.36 g) at 00C, and the mixture was stirred at room temperature for 4 hr. Saturated aqueous sodium hydrogencarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO,)) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.25 g, yield 55%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (2:1, volume ratio), melting point 150-152°C. Reference Example 42 tert-butyl 4- {2- (benzylthio) ^-methyl-S[ ( {7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2- yl}carbonyl) amino] propyl}piperazine-l-carboxylate
Figure imgf000148_0002
In the same manner as in Reference Example 41, the title compound (1.55 g, yield 64%) was obtained as colorless crystals from N- [2- (benzylthio) -2-methyl-3-oxopropyl] -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide (1.83 g) and tert-butyl piperazine-1-carboxylate (1.30 g) . melting point 180- 181°C. Reference Example 43 N- [2- (benzyl thio) -3- (hydroxyimino) -2- methylpropyl ] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carboxamide
Figure imgf000149_0001
A mixture of .N- [2- (benzylthio) -2-methyl-3-oxopropyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (1.00 g) , hydroxylamine hydrochloride (0.26 g) , potassium carbonate (0.52 g) and methanol (8 ml) was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCU) , and concentrated to give the title compound (0.25 g, yield 55%) as colorless amorphous crystals. MS: 543 (MH+). Reference Example 44 N- [2- (benzylthio) -2-cyanopropyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000149_0002
To a mixture of N- [2- (benzylthio) -3- (hydroxyimino) -2- methylpropyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carboxamide (1.00 g) and pyridine (6 ml) was added trifluoromethanesulfonic anhydride (0.40 ml) at 00C, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated, 10% aqueous citric acid solution was added to the residue, and the mixture.was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.43 g, yield 45%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (1:2, volume ratio) . melting point 181-182°C.
Reference Example 45 N- [ (l-benzyl-4-hydroxypiperidin-4- yl) methyl] -7- [methyl (2-thienylsulfonyl) amino] -IH-indole-2- carboxamide
Figure imgf000150_0001
To a solution of 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxylic acid in N, N-dimethylformamide (30 ml) were added 1H-1,2, 3-benzotriazol-l-ol (0.738 g) , N- [3-
(dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride ( 0.520 g) and 4- (aminomethy1) -l-benzylpiperidin-4-ol (1.06 g) , and the mixture was stirred at room temperature for 24 hr. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:methanol = 100:0 - 95:5) to give the title compound (1.32 g, yield 76%) as a colorless amorphous solid.
MS m/z 539(M+H+) .
Reference Example 46 ( { [2, 2-dimethoxy-l- (nitromethyl) ethyl] thio}methyl) benzene
Figure imgf000150_0002
A solution of (IE) -3, 3-dimethoxy-l-nitroprop-l-ene (3.03 g, prepared according to Terahedron 2002, 58, 5773-5778), benzylmercaptan (2.54 ml) and piperidine (0.25 ml) in toluene (20 ml) was stirred at room temperature for 48 hr. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate : hexane = 0:100 - 20:80) to give the title compound (4.78 g, yield 86%) as a yellow oil.
1H-NMR (CDCl3) δ: 3.27 (3 H, s) , 3.37 (3 H, s) , 3.39 - 3.47 (1 H, m) , 3.74 - 3.87 (2 H, m) , 4.19 (1 H, d, J=3.8 Hz), 4.38 (1 H, dd, J=13.8, 7.9 Hz), 4.68 (1 H, dd, J=13.8, 5.7 Hz), 7.24 - 7.37 (5 H, m) Reference Example 47 2- (benzylthio) -3, 3-dimethoxypropan-l-amine
Figure imgf000151_0001
To a suspension of lithium aluminum hydride (13.0 g) in tetrahydrofuran (60 ml) was added dropwise a solution (76 ml) of ( { [2, 2-dimethoxy-l- (nitromethyl) ethyl] thio}methyl) benzene (18.6 g) in tetrahydrofuran at O0C. The reaction mixture was allowed to warm to room temperature, and stirred at room temperature for 1 hr. Water and 2N aqueous sodium hydroxide solution were added to the reaction solution, and the mixture was diluted with ethyl acetate. The mixture was filtrated through celite, and the filtrate was concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (ethyl acetate: hexane = 30:70 - 100:0) to give the title compound (12.6 g, yield 76%) as a yellow oil.
1H-NMR(CDCl3)O^.63 - 2.78 (2 H, m),.2.86 - 2.94 (1 H, m) , 3.37 (3 H, s) , 3.38 (3 H, s) , 3.75 - 3.87 (2 H, m) , 4.31 (1 H, d, J=5.5 Hz), 7.20 - 7.40 (5 H, m) . Reference Example 48 N- [2- (benzylthio) -3, 3-dimethoxypropyl]-7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000152_0001
To a solution of 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxylic acid (0.662 g) in N,N-dimethylformamide (20 ml) were added IH-1, 2,3-benzotriazol-l-ol (0.414 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.292 g) and 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (0.500 g) , and the mixture was stirred at room temperature for 15 hr. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 10:90 - 60:40) to give the title compound (0.776 g, yield 70%) as a colorless amorphous solid. 1H-NMR (CDCl3) δ: 2.87 - 2.97 (1 H, m) , 3.33 (3 H, s) , 3.39 (3 H, s), 3.47 (3 H, s), 3.54 - 3.64 (1 H, m) , 3.78 - 3.89 (3 H, m) , 4.35 (1 H, d, J=4.3 Hz), 6.59 - 6.64 (1 H, m) , 6.72 - 6.82 (2 H, m), 6.96 - 7.03 (1 H, m) , 7.09 - 7.14 (1 H, m) , 7.16 - 7.22 (1 H, m), 7.24 - 7.31 (2 H, m) , 7.32 - 7.38 (2 H, m) , 7.39 - 7.42 (1 H, m), 7.56 - 7.67 (2 H, m) , 9.48 (I H, s) .
Reference Example 49 N-[2-'(benzylthio) -3-oxopropyl]-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000152_0002
In the same manner as in Reference Example 40, the title compound (0.490 g, yield 95%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3, 3-dimethoxypropyl] -7- [methyl (2-thienylsulfonγl) amino] -lH-indole-2-carboxamide (0.560 g).
MS m/z 514 (M+H+) .
Reference Example 50 N- [2- (benzylthio) -3- (morpholino) propyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000153_0001
In the same manner as in Reference Example 41, the title compound (0.218 g, yield 81%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide (0.235 g) and morpholine (0.08 ml) . MS m/z 585(M+H+) .
Reference Example 51 N- [2- (benzylthio) -3- (3, 3- difluoropiperidino) propyl] -7- [methyl (2-thienylsulfonyl) amino] - lH-indole-2-carboxamide
Figure imgf000153_0002
the same manner Reference Example 41, the title • compound (0.160 g, yield 66%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide (0.200 g) and 3,3-difluoropiperidine (0.122 g) . MS m/z 619(M+H+) .
Reference Example 52 tert-butyl 4-{2- (benzylthio) -3- [( {7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2- yl}carbonyl) amino] propyl}piperazine-l-carboxylate
Figure imgf000154_0001
In the same manner as in Reference Example 41, the title compound (0.330 g, yield 100%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (2- thienylsulfonyl).amino]-lH-indole-2-carboxamide (0.250 g) and tert-butyl piperazine-1-carboxylate (0.181 g) . MS m/z 684 (M+H+) . Reference Example 53 N- [2- (benzylthio) -2-cyanoethyl] -7-
[methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000154_0002
In the same manners as in Reference Example 43 and
Reference Example 44, the title compound (3.60 g, yield in two steps 48%) was obtained as a colorless amorphous solid from N-
[2- (benzylthio) -3-oxopropyl] -1- [methyl (2-thienylsulfonyl) amino] - lH-indole-2-carboxamide (7.50 g) and hydroxylamine hydrochloride
(2.08 g) . MS m/z 511 (MH-H+) .
Reference Example 54 8-benzylhexahydropyrazino [2, 1- c] [l,4]oxazin-4(3H)-one
Figure imgf000155_0001
To a mixture of (4-benzylpiperazin-2-yl) methanol (6.4 g, 30 mmol) prepared according to J. Med. Chem. 1993, 36, 2075-2083, water (100 ml) and tetrahydrofuran (100 ml) were successively added potassium carbonate (8.3 g, 60 mmol) with chloroacetyl chloride (3.6 mL, 45 mmol), and the mixture was stirred at room temperature for 12 hr. The reaction mixture was concentrated under reduced pressure, and the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was dissolved in ethanol (100 ml) , potassium hydroxide (2 g) was added, and the mixture was stirred at 50°C for 3 hr. The reaction mixture was concentrated under reduced pressure, and the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound (2.6 g, yield 35%) as a yellow oil. MS 247 (M+l) . Reference Example 55 hexahydropyrazino [2, 1-c] [1, 4] oxazin-4 (3H) - one hydrochloride
Figure imgf000155_0002
To a solution of 8-benzylhexahydropyrazino [2, 1- c] [1,4] oxazin-4 (3H) -one (2.6 g, 10.5 mmol) in methanol (50 ml) were added ammonium formate (3.0 g) and 10% palladium-carbon (50% containing water, 1.5 g) , and the mixture was stirred at 80°C for 15 min. The reaction mixture was allowed to cool to room temperature, and the palladium-carbon was removed by filtration. The filtrate was concentrated under reduced pressure, and 4N hydrogen chloride-ethyl acetate solution was added to the s residue. The precipitated crystals were collected by filtration, washed with ethyl acetate, and dried under reduced pressure to give the title compound (1.8 g, yield 93%) as a pale-yellow powder. MS 157 (M+l).
Reference Example 56 7-benzylhexahydro [1, 3] oxazolo [3, 4-0 a]pyrazin-3-one
Figure imgf000156_0001
A mixture of (4-benzylpiperazin-2-yl)methanol (2.8 g, 10 mmol) prepared according to J. Med. Chem. 1993, 36, 2075-2083 and 1, 1' -carbonylbis (IH-imidazole) (3.2 g) , triethylamine (2.85 ml) and tetrahydrofuran (30 ml) was stirred at 80°C for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column 0 chromatography to give the title compound (1.5 g, yield 65%) as a colorless oil from a fraction eluted with ethyl acetate. MS 233 (M+l) .
Reference Example 57 hexahydro [1, 3] oxazolo [3, 4-a]pyrazin-3-one hydrochloride
Figure imgf000156_0002
To a solution of 7-benzylhexahydro [1, 3] oxazolo [3, 4- a]ρyrazin-3-one (1.5 g) in methanol (25 ml) were added ammonium formate (2.0 g) and 10% palladium-carbon (50% containing water,
1.0 g) , and the mixture was stirred at 80°C for 10 min. The reaction mixture was allowed to cool to room temperature, and the palladium-carbon was removed by filtration. The filtrate was concentrated under reduced pressure, and 4N hydrogen chloride- ethyl acetate solution was added to the residue. The precipitated crystals were collected by filtration, washed with ethyl acetate, and dried under reduced pressure to give the title compound (1.0 g, yield 87%) as a pale-yellow powder. MS 143 (M+l) .
Reference Example 58 4- (benzylthio) -4- (nitromethyl) tetrahydro- 2H-pyran
Figure imgf000157_0001
A mixture of tetrahydro-4H-pyran-4-one (10.3 g) , benzylmercaptan (25.6 g) , nitromethane (62.8 g) , ethylenediamine (6.18 g) and acetonitrile (150 ml) was heated overnight under reflux. The reaction mixture was concentrated, and the obtained residue was subjected to silica gel column chromatography to give the title compound (17.6 g, yield 67%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (3:1, volume ratio) . 1H-NMR (CDCl3) 6:1.63-2.05 (4H, m) , 3.70-4.03 (6H, m) , 4.51 (2H, s) , 7.20-7.45 (5H, m) .
Reference Example 59 tert-butyl 4- (benzylthio) -4- (nitromethyl) piperidine-1-carboxylate
Figure imgf000157_0002
In the same manner as in Reference Example 58, the title compound (1.3 g, yield 71%) was obtained as colorless crystals from tert-butyl 4-oxopiperidine-l-carboxylate (1.00 g) , benzylmercaptan (2.48 g) , nitromethane (3.05 g) and ethylenediamine (0.3 g) .
1H-NMR(CDCl3)OrI^S (9H7 s) , 1.79 (4H, q, J=3.7 Hz), 3.13-3.37 (2H, m) , 3.72 (2H, m) , 3.80-4.00 (2H, m) , 4.51 (2H, s) , 7.20- 7.45 (5H, m) .
Reference Example 60 1- [4- (benzylthio) tetrahydro-2H-pyran-4- yl] methanamine
Figure imgf000158_0001
To a mixture of lithium aluminum hydride (2.23 g) and diethyl ether (120 ml) was added a solution of 4- (benzylthio) -4- (nitromethyl) tetrahydro-2H-pyran (5.35 g) in diethyl ether (30 ml) and tetrahydrofuran (15 ml) at 0°C, and the reaction mixture was stirred at 50°C for 2 hr. The reaction mixture was ice- cooled, sodium sulfate 10 hydrate (19.33 g) was added, and the mixture was stirred overnight at room temperature. The reaction mixture was dried (MgSCU) , and the inorganic salt was removed by filtration. The filtrate was concentrated, and the obtained residue was subjected to silica gel column chromatography to give the title compound (3.20 g, yield 67%) as a yellow oil from a fraction eluted with ethyl acetate-methanol (3:1, volume ratio) . 1H-NMR (CDCl3) 5:1.40-1.80 (4H, m) , 2.68 (2H, s) , 3.60 (2H, s) , 3.66-4.00 (4H, m) , 7.18-7.45 (5H, m) . Reference Example 61 tert-butyl 4- (aminomethyl) -4- (benzylthio)piperidine-l-carboxylate
Figure imgf000158_0002
To a mixture of lithium aluminum hydride (0.4 g) and diethyl ether (20 ml) was added a solution of tert-butyl 4- (benzylthio) -4- (nitromethyl)piperidine-l-carboxylate (1.28 g) in diethyl ether (5 ml) at 0°C. The reaction mixture was heated under reflux for 1 hr. The excess lithium aluminum hydride was decomposed with ethyl acetate, and water was added. The reaction mixture was diluted with a mixed solvent of tetrahydrofuran and ethyl acetate; and the inorganic salt was removed by filtration. The filtrate was washed with saturated brine, dried (MgS(Xi) / and concentrated, and the obtained residue was subjected to silica gel column chromatography to give the title compound (0.33 g, yield 28%) as a colorless oil from a fraction eluted with ethyl acetate-methanol (2:1, volume ratio).
1H-My[R(CDCI3)OiLSS-LSO (13H, s) , 2.66 (2H, s) , 3.17-3.37 (2H, m), 3.60 (2H, s) , 3.65-3.92 (2H, m) , 7.16-7.45 (5H, m) .
Reference Example 62 N- { [4- (benzylthio) tetrahydro-2H-pyran-4- yl] methyl} -7- [methyl (2-thienylsulfonyl) amino] -IH-indole-2- carboxamide
Figure imgf000159_0001
A mixture of 7- [methyl (2-thienylsulfonyl) amino] -lH-indole- 2-carboxylic acid (0.50 g) , 1- [4- (benzylthio) tetrahydro-2H- pyran-4-yl]methanamine (0.39 g) , IH-I, 2, 3-benzotriazol-l-ol (0.20 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.34 g) , tetrahydrofuran (10 ml) and acetonitrile (3 ml) was stirred overnight at room temperature. Saturated aqueous sodium hydrogencarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (NaSCU), and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (764 mg, yield 92%) as colorless crystals from a fraction eluted with ethyl acetate.
1H-NMR (CDCl3) 5:1.73-1.86 (4H, m) , 3.33 (3H, s) , 3.56 (2H, d, J=5.9 Hz), 3.71-3.81 (4H, s) , 3.83-3.92 (2H, m) , 6.55-6.63 (2H, m), 6.80 (IH, d, J=2.0 Hz), 7.01 (IH, t, J=7.78 Hz), 7.10-7.14
(IH, m), 7.23-7.43 (6H, m) , 7.61 (IH, d, J=7.8 Hz), 7.64 (IH, d,
J=4.9 Hz) , 9.50 (IH, s) .
Reference Example 63 tert-butyl 4- (benzylthio) -4-{ [ ( {7-
[methyl (2-thienylsulfonyl) amino] -lH-indol-2- yl}carbonyl) amino] methyl}piperidine-l-carboxylate
Figure imgf000160_0001
A mixture of 7- [methyl (2-thienylsulfonyl) amino] -IH-indole- 2-carboxylic acid (0.30 g) , tert-butyl 4- (aminomethyl) -4- (benzylthio)piperidine-l-carboxylate (0.33 g) , IH-I, 2,3- benzotriazol-1-ol (0.13 g) , N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (0.22 g) and tetrahydrofuran (6 ml) was stirred overnight at room temperature. Saturated aqueous sodium hydrogencarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (NaSO4), and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.44 g, yield 75%) as colorless crystals from a fraction eluted with ethyl acetate- hexane (1:1, volume ratio), melting, point 195 - 197°C. Reference Example 64 ethyl 1- (methoxymethyl) -4-methyl-7-nitro- lH-indole-2-carboxylate e
Figure imgf000161_0001
A mixture of ethyl 4-methyl-7-nitro-lH-indole-2- carboxylate (7.0 g) , 60% sodium hydride (1.35 g) and N,N- dimethylformamide (40 ml) was stirred at room temperature for 30 min. This solution was ice-cooled, and a solution of chloromethyl methyl ether (2.6 ml) in tetrahydrofuran (15 ml) was added dropwise. The mixture was stirred at 4°C for 4 hr, and the reaction solution was diluted with ethyl acetate, washed with saturated brine, aqueous citric acid solution and water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate : hexane =5:95 - 1:5) to give the title compound (5.6 g, yield 68%) as pale-yellow needle crystals . 1H-NMR(CDCl3)0: 1.44 (3H, t, J=7.2 Hz), 2.65 (3H, s) , 2.92 (3H, s) , 4.42 (2H, q, J=7.2 Hz), 6.04 (2H, s), 7.05 (IH, dd, J= 8.0, 0.8 Hz), 7.49 (IH, s), 7.82 (IH, d, J=8.0 Hz).
Reference Example 65 ethyl 1- (methoxymethyl) -4-methyl-7- [ (2- thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000161_0002
Ethyl 1- (methoxymethyl) -4-methyl-7-nitro-lH-indole-2- carboxylate (5.6 g) and 10% palladium-carbon (50% containing water, 1.25 g) were added to a mixed solvent of tetrahydrofuran (70 ml) and ethanol (70 ml) , and the mixture was stirred at room temperature for 5 hr under hydrogen atmosphere. The catalyst was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in pyridine (50 ml) , and thiophene-2-sulfonyl chloride (4.0 g) was added under ice- cooling, and the mixture was stirred at room temperature for 18 hr. The reaction solution was concentrated under reduced pressure, and the residue was diluted with ethyl acetate. The mixture was washed with aqueous citric acid solution and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate:hexane=l: 9 - 1:3) to give the title compound (8.4 g, yield 100%) as a pale-yellow oil.
1H-NMR(CDCI3)OII^I (3H, t, J=7.0 Hz), 2.52 (3H, s) , 3.41 (3H, s) , 4.35 (2H, q, J=7.0 Hz), 5.69 (2H, s) , 6.92-7.02 (2H, m) , 7.34 (IH, s), 7.44-7.52 (3H, m) , 8.65 (IH, brs) . Reference Example 66 ethyl 1- (methoxymethyl) -4-methyl-7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000162_0001
A mixture of ethyl 1- (methoxymethyl) -4-methyl-7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxylate (7.8 g) , methyl iodide (1.7 ml), potassium carbonate (2.9 g) and N,N- dimethylformamide (14 ml) was stirred at room temperature for 18 hr. The reaction solution was concentrated under reduced pressure, and the obtained residue was diluted with ethyl acetate. The mixture was washed with aqueous citric acid solution, water and saturated brine, ' dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained colorless crystals were washed with diethyl ether- hexane to give the title compound (6.85 g, yield 85%) as colorless needle crystals.
1H-ISlMR(CDCl3)0: 1.42 (3H, t, J=7.0 Hz), 2.54 (3H, s) , 3.29 (3H, s) , 3.35 (3H, s), 4.40 (2H, q, J=7.0 Hz), 6.33 (IH, d, J=9.8 Hz),
6.43 (IH, d, J=9.8 Hz), 6.45 (IH, d, J=7.8 Hz), 6.78 (IH, dd, J= 7.8, 0.8 Hz), 7.16 (IH, dd, J= 5.0, 4.0 Hz), 7.40 (IH, s) , 7.47 (IH, dd, J= 4.0, 1.4 Hz), 7.67 (IH, dd, J= 5.0, 1.4 Hz) . Reference Example 67 4 -methyl- 7- [methyl (2- thienylsulf onyl ) amino] -lH-indole-2-carboxylic acid
Figure imgf000163_0001
A solution of ethyl 1- (methoxymethyl) -4-methyl-7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxylate (4.0 g) , 6N hydrochloric acid (20 ml) , tetrahydrofuran (20 ml) and ethanol (60 ml) was stirred at 800C for 4 hr. The reaction solution was concentrated under reduced pressure, and the obtained residue was diluted with ethyl acetate. The mixture was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained solid was dissolved in a mixed solvent of tetrahydrofuran (40 ml) and methanol (40 ml), an aqueous solution (20 ml) of 85% potassium hydroxide (2.2 g) was added to this solution, and the mixture was stirred at room temperature for 18 hr. The reaction solution was concentrated under reduced pressure, and the obtained residue was acidified with aqueous citric acid solution. The precipitated crystals were collected by filtration, washed ■ with water, and dried to give the title compound (3.3 g, yield 99%) as colorless crystals. MS: 351 (MH+). melting point 223 - 225°C. Reference Example 68 4-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000164_0001
A mixture of 4-methyl-7- [methyl (2-thienylsulfonyl) amino] - lH-indole-2-carboxylic acid (2.2 g) , IH-I, 2, 3-benzotriazol-l-ol (1.2 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (1.5 g) and N,N-dimethylformamide (30 ml) was stirred at room temperature for 1 hr, and then at 60°C for 1 hr. 28% Aqueous ammonia (2.0 ml) was added to the reaction solution, and the mixture was stirred at room temperature for 3 hr. The reaction solution was concentrated under reduced pressure, and the obtained residue was diluted with ethyl acetate. The mixture was washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained oil was crystallized from ethyl acetate-hexane to give the title compound (1.84 g, yield 84%) as colorless prism crystals. melting point 221 - 222°C.
Reference Example 69 4-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carbothioamide
Figure imgf000164_0002
A mixture of 4-methyl-7- [methyl (2-thienylsulfonyl) amino] - lH-indole-2-carboxamide (1.78 g) , Lawesson' s reagent (2.26 g) and tetrahydrofuran (120 ml) was stirred at 600C for 2 hr. The reaction solution was concentrated under reduced pressure, and the obtained oil was crystallized from dichloromethane-toluene to give the title compound (1.56 g, yield 84%) as pale-yellow crystals . MS : 366 (MH+) . Reference Example 70 N-{2- [5- (hydroxymethyl)-l, 3-thiazol-2-yl]- 4-methyl-lH-indol-7-yl}-N-πιethylthiophene-2-sulfonamide
Figure imgf000165_0001
A solution of 4-methyl-7- [methyl (2-thienylsulfonyl) amino] - lH-indole-2-carbothioamide (0.95 g) , bromomalonaldehyde (0.78 g) and N,N-dimethylacetamide (15 ml) was stirred at 80°C for 3 hr. The reaction solution was diluted with ethyl acetate, washed twice with water, and concentrated under reduced pressure. The obtained residue was washed with toluene to give yellow crystals (857 mg) . The mother liquor was concentrated, and the residue was subjected to silica gel column chromatography (ethyl acetate:hexane=l: 2 - 1:1) to give yellow crystals (80 mg) . The above-mentioned crystals were combined, dissolved in a mixed solvent of tetrahydrofuran (20 ml) and methanol (20 ml) , and the solution was ice-cooled. Sodium borohydride (0.10 g) was added to this solution, and the mixture was stirred under ice-cooling for 2 hr. Aqueous citric acid solution was added to the reaction solution, and the organic solvent was evaporated under reduced pressure. The obtained residue was extracted with ethyl acetate, and the extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate:hexane=l: 2 - 2:1 - 1:0), and washed with ethyl acetate-hexane to give the title compound (0.56 g, yield 60%) as pale-yellow crystals, melting point 184 -
185°C.
MS: 420 (MH+) .
Reference Example 71 N-{2- [5- (chloromethyl) -1, 3-thiazol-2-yl]-4- methyl-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000166_0001
N- {2- [5- (Hydroxymethyl) -1, 3-thiazol-2-yl] -4-methy1-IH- indol-7-yl}-N-methylthiophene-2-sulfonamide (0.55 g) was dissolved in absolute tetrahydrofuran (25 ml) , and this solution was ice-cooled. Thionyl chloride (0.15 ml) and N,N- dimethylformamide (one drop) were added, and the mixture was stirred for 1 hr under ice-cooling, and then at room temperature for 7 hr. The reaction solution was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate : hexane=l : 1) , and the obtained crystals were washed with ethyl acetate-hexane to give the title compound (0.427 g, yield 74%) as pale-yellow crystals, melting point 194-195°C.
Reference Example 72 ethyl 7- [ethyl (2-thienylsulfonyl) amino] -4- methyl-lH-indole-2-carboxylate
Figure imgf000166_0002
To a mixture of ethyl 7- [ (2-thienylsulfonyl) amino] -4- methyl-lH-indole-2-carboxylate (2.89 g) , potassium carbonate (1.2 g) and N,N-dimethylformamide (25 ml) was added dropwise a solution of ethyl iodide (0.67 ml) in N,N-dimethylformamide (2 ml) under ice-cooling. The mixture was stirred at room temperature for 2 days. The reaction solution was diluted with ethyl acetate, washed successively with aqueous citric acid solution, water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained yellow oil was crystallized from ethyl acetate-hexane, and the obtained crystals were washed with ethyl acetate-hexane to give the title compound (2.16 g, yield 70%) as colorless prism crystals, melting point 148 - 149°C.
MS: 393 (MH+) .
Reference Example 73 7- [ethyl (2-thienylsulfonyl) amino] -4-methyl- lH-indole-2-carboxamide
Figure imgf000167_0001
To a solution of ethyl 7- [ethyl (2-thienylsulfonyl) amino] - 4-methyl-lH-indole-2-carboxylate (2.12 g) in tetrahydrofuran (15 ml) -methanol (15 ml) was added an aqueous solution (5 ml) of 85% potassium hydroxide (1.0 g) , and the mixture was stirred at room temperature for 15 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 7- [ethyl (2-thienylsulfonyl) amino] -4-methyl-lH- indole-2-carboxylic acid (2.0 g, yield quantitative) as a colorless amorphous solid. To a mixture of the obtained solid (2.0 g) , IH-1, 2, 3-benzotriazol-l-ol-ammonia complex (1.0 g) and N,N-dimethylformamide (20 ml) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (1.3 g) under ice-cooling, and the mixture was stirred at room temperature for 2 days. The reaction solution was diluted with ethyl acetate, and washed successively with aqueous sodium hydrogencarbonate solution, water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate:hexane=l : 1 - 3:1) to give the title compound (2.0 g, yield quantitative) as a colorless amorphous solid. MS: 364 (MH+) . Reference Example 74 .N-ethyl-N- [2- (5-formyl-l, 3-thiazol-2-yl) -4- methyl-lH-indol-7-yl] thiophene-2-sulfonamide
Figure imgf000168_0001
of 7- [ethyl (2-thienylsulfonyl) amino] -4-methyl- lH-indole-2-carboxamide (1.9 g) , Lawesson' s reagent (2.1 g) and tetrahydrofuran (100 ml) was stirred at 40°C for 4 hr. The reaction solution was concentrated under reduced pressure, and the obtained oil was crystallized from dichloromethane-toluene, and washed with toluene to give 7- [ethyl (2- thienylsulfonyl) amino] -4-methyl-lH-indole-2-carbothioamide (2.0 g, yield quantitative) as pale-yellow crystals. A solution of the obtained crystals (2.0 g) and bromomalonaldehyde (2.4 g) in
N,N-dimethylacetamide (50 ml) was stirred at 70°C for 3 hr. The reaction solution was diluted with ethyl acetate, washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained oil was crystallized from dichloromethane-toluene to give the title compound (1.6 g, yield 70%) as pale-yellow crystals. MS: 432 (MH+). Reference Example 75 N-ethyl-N- {2- [5- (hydroxymethyl) -1, 3- thiazol-2-yl] -4-methyl-lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000169_0001
To a solution of N-ethyl-N- [2- (5-formyl-l, 3-thiazol-2-yl) - 4-methyl-lH-indol-7~yl] thiophene-2-sulfonamide (1.3 g) in a mixed solvent of methanol (15 ml) and tetrahydrofuran (40 ml) was added sodium borohydride (0.14 g) under ice-cooling, and the mixture was stirred at the same temperature for 2 hr. Aqueous citric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained crystals were washed with ethyl acetate-hexane to give the title compound (0.74 g) as pale-yellow crystals. The mother liquor was concentrated, and the residue was subjected to silica gel column chromatography (ethyl acetate :hexane=3: 7 - 6:4) to give the title compound (0.20 g) as pale-yellow crystals, total yield
0.94 g (yield 72%). melting point 166 - 167°C.
MS: 434 (MH+).
Reference Example 76 N-ethyl-N- {2- [5- (chloromethyl) -1, 3-thiazol-
2-yl] -4-methyl-lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000169_0002
N-Ethyl-N- {2- [5- (hydroxymethyl) -1, 3-thiazol-2-yl] -4- methyl-lH-indol-7-yl}thiophene-2-sulfonamide (0.27 g) was dissolved in absolute tetrahydrofuran (10 ml) . This solution was ice-cooled, thionyl chloride (0.080 ml) and N, N- dimethylformamide (one drop) were added, and the mixture was stirred for 1 hr under ice-cooling, and then at room temperature for 2 hr. The reaction solution was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained yellow oil was crystallized from ethyl acetate-hexane to give the title compound (0.26 g, yield 93%) as pale-yellow prism crystals, melting point 177-178°C.
Reference Example 77 ethyl 7-amino-4-chloro-l- (methoxymethyl) - lH-indole-2-carboxylate
Figure imgf000170_0001
A mixture of ethyl 7-amino-l- (methoxymethyl) -lH-indole-2- carboxylate (3.18 g) , N-chlorosuccinimide (1.74 g) and N,N- dimethylformamide (20 ml) was stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The residue was ■ subj ected to silica gel column chromatography to give the title compound (0.91 g, yield 25%) as a yellow oil from a fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
1H-NMR(CDCl3)S: 1.42 (3H, t, J=7.2 Hz), 3.44 (3H, s) , 4.37 (2H, q, J=7.2 Hz), 4.51 (2H, brs) , 6.16 (2H, s) , 6.50 (IH, d, J=8.1 Hz), 6.94 (IH, d, J=8.1 Hz), 7.36 (IH, s) .
Reference Example 78 ethyl 4-chloro-l- (methoxymethyl) -7- [ (2- thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000170_0002
To a mixture of ethyl 7-amino-4-chloro-l- (methoxymethyl) - . lH-indole-2-carboxylate (0.91 g) and pyridine (10 ml) was added thiophene-2-sulfonyl chloride (0.50 g) at 0°C, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated, 10% aqueous citric acid solution was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (1.14 g, yield 83%) as a yellow oil from a fraction eluted with ethyl acetate- hexane (1:2, volume ratio).
1H-NMR(CDCl3)S: 1.41 (3H, t, J=7.1 Hz), 3.44 (3H, s) , 4.36 (2H, q, J=7.1 Hz), 5.69 (2H, s) , 6.99-7.03 (IH, m) , 7.18 (IH, t, J=8.4 Hz), 7.40 (IH, s), 7.48-7.54 (3H," m) , 8.77 (IH, brs) . Reference Example 79 ethyl 4-chloro-l- (methoxymethyl) -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000171_0001
A mixture of ethyl 4-chloro-l- (methoxymethyl) -7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxylate (1.14 g) , methyl iodide (0.33 ml), potassium carbonate (0.37 g) and N,N- dimethylformamide (10 ml) was stirred overnight at room temperature. Water was added to the reaction mixture, and the resulting crystals were collected by filtration, washed with water, and dried to give the title compound (1.10 g, yield 93%) as colorless crystals, melting point 137 - 138°C. Reference Example 80 4-chloro-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000172_0001
A mixture of ethyl 4-chloro-l- (methoxymethyl) -7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxylate (1.10 g) , 6N hydrochloric acid (5 ml) , tetrahydrofuran (20 ml) and ethanol (10 ml) was heated overnight under reflux. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, and concentrated. A mixture of the obtained residue, 4N aqueous sodium hydroxide solution (1.2 ml), tetrahydrofuran (10 ml) and methanol (10 ml) was stirred at 60°C for 1 hr. The reaction mixture was acidified with 10% aqueous citric acid solution, and extracted with ethyl acetate . The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. To a mixture of the obtained residue, 1H-1,2, 3-benzotriazol-l-ol (0.40 g) and N,N-dimethylformamide (10 ml) was added N- [3-
(dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.57 g) at room temperature, and the mixture was stirred at 50°C for 30 rain. The mixture was allowed to cool to room temperature, and 28% aqueous ammonia (0.75 ml) was added. The reaction mixture was stirred at room temperature for 2 hr, followed by an addition of water. The mixture was acidified with 10% aqueous citric acid solution, and" extracted with ethyl acetate, and the ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.25 g, yield 78%) as pale-yellow crystals from a fraction eluted with tetrahydrofuran-hexane (2:1, volume ratio), melting point 252 -
254°C.
Reference Example 81 4-chloro-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carbothioamide
Figure imgf000173_0001
A mixture of 4-chloro-7- [methyl (2-thienylsulfonyl) amino] - lH-indole-2-carboxamide (0.54 g) , Lawesson' s reagent (0.59 g) and tetrahydrofuran (20 ml) was stirred at 60°C for 3 hr. The reaction mixture was concentrated, toluene was added, and the resulting crystals were filtrated, washed with toluene, and dried to give the title compound (0.51 g, yield 87%) as yellow crystals, melting point >248°C (decomposition). Reference Example 82 N-{4-chloro-2- [5- (hydroxymethyl) -1, 3- thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000173_0002
A mixture of 4-chloro-7- [methyl (2-thienylsulfonyl) amino] - lH-indole-2-carbothioamide (0.51 g) , bromomalonaldehyde (0.30 g) and N, N-dimethylacetamide (15 ml) was stirred at 90°C for 4 hr. Water was added to the reaction mixture, and the resulting crystals were collected by filtration, washed with water, and dried. To a mixture of the obtained crystals, tetrahydrofuran (5 ml) and methanol (5 ml) was added sodium borohydride (55 mg) at
00C, and the mixture was stirred at the same temperature for 1 hr. 10% Aqueous citric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.30 g, yield 52%) as pale-yellow crystals from a fraction eluted with tetrahydrofuran-hexane (2:1, volume ratio) . melting point 225 -
226°C.
Reference Example 83 ethyl 7-amino-6-chloro-lH-indole-2- carboxylate
Figure imgf000174_0001
A mixture of ethyl 7-amino-lH-indole-2-carboxylate (2.30 g) , N-chlorosuccinimide (1.40 g) and N, N-dimethylformamide (10 ml) was stirred overnight at room temperature. Water was added to the reaction mixture, and the resulting crystals were collected by filtration, washed with water, and dried. The obtained crystals were subjected to silica gel column chromatography to give the title compound (1.59 g, yield 63%) as pale-yellow crystals from a fraction eluted with ethyl acetate- hexane (2:3, volume ratio), melting point 217 - 218°C (decomposition) .
Reference Example 84 ethyl 6-chloro-7- [ (2- thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000174_0002
To a mixture of ethyl 7-amino-6-chloro-lH-indole-2- carboxylate (1.59 g) and pyridine (10 ml) was added thiophene-2- sulfonyl chloride (1.46 g) , and the mixture was stirred at 50°C for 3 hr. The reaction mixture was concentrated, 10% aqueous citric acid solution was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (2.17 g, yield 85%) as colorless crystals from a fraction eluted with tetrahydrofuran-hexane (1:2, volume ratio) . The crystals were recrystallized from ethyl acetate, melting point 191 - 192°C.
Reference Example 85 6-chloro-7- [ (2-thienylsulfonyl) amino] -IH- indole-2-carboxylic acid
Figure imgf000175_0001
A mixture of ethyl 6-chloro-7- [ (2-thienylsulfonyl) amino] - lH-indole-2-carboxylate (1.00 g) , 4N aqueous sodium hydroxide solution (2.3 ml), tetrahydrofuran (5 ml) and methanol (5 ml) was stirred at 500C for 2 hr. The reaction mixture was concentrated, and acidified with 10% aqueous citric acid solution, and the resulting crystals were collected by filtration, washed with water, and dried to give the title compound (0.88 g, yield 95%) as colorless crystals, melting point >290°C (decomposition) . Reference Example 86 6-chloro-7- [ (2-thienylsulfonyl) amino] -IH- indole-2-carboxamide
Figure imgf000175_0002
To a mixture of 6-chloro-7- [ (2-thienylsulfonyl) amino] -IH- indole-2-carboxylic acid (0.83 g) , 1H-1,2, 3-benzotriazol-l-ol (0.38 g) and N,N-dimethylformamide (10 ml) was added N- [3-
(dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.54 g) at room temperature, and the mixture was stirred at 50°C for 20 min, and allowed to cool to room temperature. 28% Aqueous ammonia (0.30 ml) was added, and the reaction mixture was stirred at room temperature for 1 hr, and acidified with 10% aqueous citric acid solution. The resulting crystals were filtrated, washed with water, and dried to give the title compound ( 0.80 g, yield 96%) as colorless crystals , melting point >300°C (decomposition) .
Reference Example 87 6-chloro-7- [ (2-thienylsulfonyl) amino] -IH- indole-2-carbothioamide
Figure imgf000176_0001
A mixture of 6-chloro-7- [ (2-thienylsulfonyl) amino] -IH- indole-2-carboxamide (0.80 g) , Lawesson' s reagent (0.90 g) and tetrahydrofuran (15 ml) was stirred at 60°C for 3 hr. The reaction mixture was concentrated, toluene was added, and the resulting crystals were filtrated, washed with toluene, and dried to give the title compound (0.75 g, yield 91%) as yellow crystals, melting point 228 - 230°C (decomposition) . Reference Example 88 ethyl 6-chloro-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000176_0002
A mixture of ethyl 6-chloro-7- [ (2-thienylsulfonyl) amino] - lH-indole-2-carboxylate (1.00 g) , methyl iodide (0.17 ml), potassium carbonate (0.36 g) and N, N-dimethylformamide (10 ml) was stirred overnight at room temperature. Water was added to the reaction mixture, and the resulting crystals were collected by filtration, washed with water, and dried. The obtained crystals were subjected to basic silica gel column chromatography to give the title compound (0.80 g, yield 77%) as colorless crystals from a fraction eluted with ethyl acetate- hexane (1:2, volume ratio) . melting point 156 - 157°C. Reference Example 89 6-chloro-7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxylic acid
Figure imgf000177_0001
A mixture of ethyl 6-chloro-7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxylate (0.74 g) , 4N aqueous sodium hydroxide solution (1.2 ml), tetrahydrofuran (6 ml) and methanol (4 ml) was stirred at 60°C for 2 hr. The reaction mixture was concentrated, and acidified with 10% aqueous citric acid solution, and the resulting crystals were collected by filtration, washed with water, and dried to give the title compound (0.69 g, quantitative) as colorless crystals. melting point 286 - 288°C.
Reference Example 90 6-chloro-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000177_0002
To a mixture of 6-chloro-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxylic acid (0.69 g) , IH- 1,2,3-benzotriazol-l-ol (0.31 g) and N, N-dimethylformamide (10 ml) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiirrd.de hydrochloride (0.44 g) at room temperature, and the mixture was stirred at 50°C for 20 min, and allowed to cool to room temperature. 28% Aqueous ammonia (0.30 ml) was added, and the reaction mixture was stirred at room temperature for 2 hr, and acidified with 10% aqueous citric acid solution. The resulting crystals were filtrated, washed with water, and dried to give the title compound (0.70 g, quantitative) as colorless crystals. melting point 225 - 226°C (decomposition) . Reference Example 91 6-chloro-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carbothioamide
Figure imgf000178_0001
A mixture of at 6-chloro-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide (0.70 g) , Lawesson' s reagent (0.77 g) and tetrahydrofuran (20 ml) was stirred at 60°C for 2 hr. The reaction mixture was concentrated, toluene was added, and the resulting crystals were filtrated, washed with toluene, and dried to give the title compound (0.60 g, yield 84%) as yellow crystals, melting point 200 - 201°C. Reference Example 92 N-{β-chloro-2- [5- (hydroxymethyl) -1, 3- thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000178_0002
A mixture of 6-chloro-7- [methyl (2-thienylsulfonyl) amino] - lH-indole-2-carbothioamide (0.60 g) , bromomalonaldehyde (0.38 g) and N, N-dimethylacetamide (10 ml) was stirred at 9O0C for 3 hr. Water was added to the reaction mixture, and the resulting crystals were collected by filtration, washed with water, and dried. To a mixture of the- obtained crystals, tetrahydrofuran (10 ml) and methanol (5 ml) was added sodium borohydride (70 mg) at 0°C, and the mixture was stirred at the same temperature for 30 min. 10% Aqueous citric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.38 g, yield 54%) as pale-yellow crystals from a fraction eluted with tetrahydrofuran-hexane (2:1, volume ratio), melting point 214 - 215°C. Reference Example 93 N- (2- { [ (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l, 3-thiazol-5- yl) methyl] amino}ethyl) acetamide
Figure imgf000179_0001
In the same manner as in Example 186 to be mentioned later, the title compound (0.41 g, yield 49%) was obtained as colorless crystals from N-{2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -IH-indol- 7-yl}-N-methylthiophene-2-sulfonamide (0.70 g) and N- (2- aminoethyl) acetamide (0.41 g) . melting point 154-155°C.
Example 1 N-methyl-N- [2- (5- { [methyl (pyridin-2- ylmethyl) amino]methyl }-1, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000179_0002
A solution (1 ml) of N- {2- [5- (chloromethyl) -1, 3-thiazol-2- yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) , triethylamine (28 mg) and N-methyl-l-pyridin-2-ylmethanamine hydrochloride (19 mg) in N,N-dimethylformamide was stirred at room temperature for 18 hr. The reaction mixture was diluted with water, and extracted with ethyl acetate. The extract was concentrated, and the residue was purified by preparative HPLC to give the title compound (14.6 mg, yield 37%). HPLC purity 100%. MS m/z 510 (M+H+) . 1H-NMR (400 MHz, CDCl3) δ:2.78 (3 H, s), 3.34 (3 H, s) , 4.32 (2 H, s), 4.63 (2 H, s), 6.55 (1 H, d, J=7.7 Hz), 6.98 (1 H, t, J=7.7 Hz), 7.06 (1 H, d, J=2.1 Hz), 7.12 (1 H, dd, J=4.9, 3.8 Hz), 7.39 (1 H, dd, J=3.8, 1.3 Hz), 7.45 (1 H, dd, J=7.0, 5.1 Hz), 7.56 - 7.66 (3 H, m) , 7.77 - 7.97 (2 H, m) , 8.74 (1 H, dd, J=5.0, 0.8 Hz) , 9.65 (1 H, s) . Example 2 N-methyl-N- [2- (5-{ [methyl (2-pyridin-2- ylethyl) amino] methyl }-l, 3-thiazol-2-yl) -lH-indol-7-yl] thiophene- 2-sulfonamide ditrifluoroacetate
Figure imgf000180_0001
In the same manner as in Example 1, the title compound (12.6 mg, yield 31%) was obtained from N- {2- [5- (chloromethyl) -
1, 3~thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
(23 mg) and N-methyl-2- (pyridin-2-yl) ethanamine (16 mg) .
HPLC purity 100%.
MS m/z 524 (M+H+) . Example 3 N-methyl-N- (2- {5- [ (2- (pyridin-2-yl) pyrrolidin-1- yl) methyl] -I13-thiazol-2~yl}-lH-indol-7-yl) thiophene-2- sulfonamide ditrifluoroacetate
Figure imgf000180_0002
In the same manner as in Example 1, the title compound (15.6 mg, yield 38%) was obtained from N- {2- [5- (chloromethyl) l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 2- (pyrrolidin-2-yl) pyridine (18 mg) . HPLC purity 100%. MS m/z 536(M+H+) . Example 4 N-methyl-N- [2- (5-{ [methyl (pyridin-3- ylmethyl) amino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000181_0001
In the same manner as in Example 1, the title compound ( 11 .0 mg, yield 28% ) was obtained from N- { 2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl} -N-methylthiophene-2-sulfonamide (23 mg) and N-methyl-1- (pyridin-3-yl) methanamine hydrochloride ( 19 mg) . HPLC purity 100% . MS m/z 510 (M+H+) .
Example 5 N-methyl-N- [2- (5- { [ 3- (me th yl sul f o ny 1 ) pyrrol idin-1- yl] methyl } -l, 3-thiazol-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide trifluoroacetate
Figure imgf000181_0002
In the same manner as in Example 1, the title compound
( 9. 5 mg, yield 27% ) was obtained from N- {2- [5- (chloromethyl) - l, 3-thiazol-2-yl] -lH-indol-7-yl }-N-methylthiophene-2-sulfonamide (23 mg) and 3- (methylsulfonyl) pyrrolidine ( 18 mg) . HPLC purity 96% . MS m/z 537 (MH-H+) . Example 6 N-methyl-N- { 2- [ 5- ( {methyl [2-
(methylsulfonyl) ethyl] amino}methyl) -l,3-thiazol-2-yl] -lH-indol- 7-yl}thiophene-2-sulfonamide trifluoroacetate
Figure imgf000182_0001
In the same manner as in Example 1, the title compound (6.0 ing, yield 17%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and N-methyl-2- (methylsulfonyl) ethanamine (16 mg) . HPLC purity 100%. MS m/z 525 (M+H+) .
1H-NMR (400 MHz, CDCl3) δ:2.68 (3 H, s) , 3.05 (3 H, s) , 3.34 (3 H, s), 3.43 (2 H, t), 3.54 (2 H, t, J=7.1 Hz), 4.31 (2 H, s) , 6.56 (I H, d, J=7.5 Hz), 6.99 (1 H, t, J=7.8 Hz), 7.05 (1 H, d, J=2.1 Hz), 7.13 (1 H, dd, J=4.9, 3.8 Hz), 7.41 (1 H, dd, J=3.7, 1.2 Hz), 7.59 (1 H, d, J=7.9 Hz), 7.65 (1 H, dd, J=5.0, 1.2 Hz), 7.78 (1 H, s), 9.76 (1 H, brs) , Example 7 N-methyl-N- [2- (5-{ [4- (pyrimidin-2- yloxy) piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000182_0002
In the same manner as in Example 1, the title compound (20.2 mg, yield 55%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 2- (piperidin-4-yloxy)pyrimidine dihydrochloride (30 mg) .
HPLC purity 94%. MS m/z 567 (M+H+) .
Example 8 N-methyl-N- [2- (5- { [ 4- (pyrazin-2- yloxy) piperidino] methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000183_0001
In the same manner as in Example 1, the title compound (20.1 mg, yield 55%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 2- (piperidin-4-yloxy)pyrazine dihydrochloride (30 mg) .
HPLC purity 100%.
MS m/z 567 (M+H+) .
Example 9 N-methyl-N- [2- (5-{ [4- (tetrahydrofuran-2- ylmethyl) piperazin-1-yl]methyl}-1, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000183_0002
In the same manner as in Example 1, the title compound (18.5 mg, yield 43%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 1- (tetrahydrofuran-2-ylmethyl)piperazine (20 mg) . HPLC purity 92%. MS m/z 558 (M+H+) .
Example 10 N,N-dimethyl-2-{4- [ (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l, 3-thiazol-5- yl)methyl]piperazin-l-yl}acetamide ditrifluoroacetate
Figure imgf000184_0001
In the same manner as in Example 1, the title compound (10.7 mg, yield 25%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]~lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and N,N-dimethyl-2- (piperazin-1-yl) acetamide (21 mg) . HPLC purity 92%. MS m/z 559(M+H+) .
Example 11 N-methyl-N- [2- (5-{ [4- (6-methylpyridin-2-yl)piperazin- 1-yl]methyl}-l, 3-thiazol-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide tritrifluoroacetate
Figure imgf000184_0002
In the same manner as in Example 1, the title compound (11.4 mg, yield 23%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 1- (6-methylpyridin-2-yl)piperazine (21 mg) . HPLC purity 100%. MS m/z 565(M+H+) .
Example 12 N-methyl-N- (2-{5- [ (3- (pyrimidin-2-yl) pyrrolidin-1- yl) methyl] -1, 3-thiazol-2-yl}-lH-indol-7-yl) thiophene-2- sulfonamide trifluoroacetate
Figure imgf000184_0003
In the same manner as in Example 1, the title compound (11.5 mg, yield 33%) was obtained from N- {2- [5- (chloromethyl) - l , 3-thiazol-2-yl] -lH-indol-7-yl } -N-methylthiophene-2-sulfonamide (23 itig) and 2- (pyrrolidin-3-yl ) pyrimidine trihydrochloride (31 mg) .
HPLC purity 94% . MS m/z 537 (M+H+) .
Example 13 N-methyl-N- (2- { 5- [ ( 3- (pyridin-2- yl)piperidino) methyl] -1, 3-thiazol~2-yl}-lH-indol-7-yl) thiophene-
2-sulfonamide-sulfonamide ditrifluoroacetate
Figure imgf000185_0001
In the same manner as in Example 1, the title compound
(21.3 mg, yield 51%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7~yl}-N-methylthiophene-2-sulfonamide
(23 mg) and 2- (piperidin-3-yl) pyridine (19 mg) .
HPLC purity 97%. MS m/z 550(M+H+) .
Example 14 N-methyl-N- (2-{5- [ (4- (pyridin-2- yl) piperidino)methyl] -1, 3-thiazol-2-yl}-lH~indol-7-yl) thiophene-
2-sulfonamide ditrifluoroacetate
Figure imgf000185_0002
In the same manner as in Example 1, the title compound
(17.8 mg, yield 42%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 2- (piperidin-4-yl) pyridine (19 mg) . HPLC purity 100%. MS m/z 550 (M+H+) . Example 15 N-methyl-N- (2-{5- [ (5-methyl-4, 6- dioxohexahydropyrrolo [3, 4-c]pyrrol-2 (IH) -yl) methyl] -1, 3-thiazol- 2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000186_0001
In the same manner as in Example 1, the title compound
(7.8 mg, yield 22%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH- indol-7-yl}-N-methyl thiophene-2-sulfonamide (23 mg) and 2 -methyl tetrahydropyrrole [3, 4-c]pyrrole-l, 3 (2H, 3aH) - dione hydrochloride (23 mg) . HPLC purity 100%. MS m/z 542 (M+H+) .
Example 16 N- (2-{5- [ (4 -hydroxy- 4-methylpiperidino) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) -N-methyl thiophene-2-sulfonamide trifluoroacetate
Figure imgf000186_0002
In the same manner as in Example 1, the title compound (9.9 mg, yield 30%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH- indol-7-yl}-N-methyl thiophene-2-sulfonamide (23 mg) and 4-methylpiperidin-4-ol hydrochloride (18 mg) . HPLC purity 96%. MS m/z 503 (M+H+) .
Example 17 N- [2- (5-{ [cyclopropyl (isobutyl) amino] methyl }-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000187_0001
In the same manner as in Example 1, the title compound (4.0 mg, yield 12%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and N-isobutyl-cyclopropanamine hydrochloride (18 mg) . HPLC purity 98%. MS m/z 501 (M+H+) .'
Example 18 N-(2-{5-[ (4-tert-butylpiperidino) methyl] -1, 3-thiazol- 2-yl}-lH~indol-7-yl) -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000187_0002
In the same manner as in Example 1, the title compound ( 12 . 6 mg, yield 36%) was obtained from N- { 2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl } -N-methylthiophene-2-sulfonamide (23 mg) and 4-tert-butylpiperidine hydrochloride (21 mg) . HPLC purity 95% . MS m/z 529 (M+ H+) .
Example 19 N-methyl-N- [2- (5- { [3- (pyrrolidin-1- ylcarbonyl) piperidino] methyl } -l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000188_0001
In the same manner as in Example 1, the title compound (13.4 mg, yield 36%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 3- (pyrrolidin-l-ylcarbonyl)piperidine (22 mg) . HPLC purity 100%. MS m/z 570 (M+H+) .
Example 20 N-methyl-N-{2- [5- (pyrrolidin-1-ylmethyl) -1, 3-thiazol- 2-yl] -lH-indol-7-yl} thiophene-2-sulfonamide trifluoroacetate
Figure imgf000188_0002
In the same manner as in Example 1, the title compound (3.8 mg, yield 12%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonaiαide (23 mg) and pyrrolidine (9 mg) . HPLC purity 100%. MS m/z 459(M+H+) .
Example 21 N- (2-{5- [ (diethylamino) methyl] -1, 3-thiazol-2-yl}-lH- indol-7-yl) -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000188_0003
In the same manner as in Example 1, the title compound (3.7 mg, yield 12%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N~methylthiophene-2-sulfonamide (23 mg) and diethylamine (8 mg) . HPLC purity 95%. MS m/z 461 (M+H+) .
Example 22 N-methyl-N-{2- [5- (piperidinomethyl) -1, 3-thiazol-2- yl] -lH-indol-7-yl}thiophene-2-sulfonamide trifluoroacetate
Figure imgf000189_0001
In the same manner as in Example 1, the title compound (11.1 mg, yield 35%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and piperidine (10 mg) . HPLC purity 95%. MS m/z 473 (M+H+) .
Example 23 N- (2-{5- [ (4-hydroxypiperidino) methyl] -1, 3-thiazol-2- yl}-lH-indol-7-yl) -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000189_0002
In the same manner as in Example 1, the title compound (8.7 mg, yield 27%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 4-hydroxypiperidine (12 mg) .• HPLC purity 100%. MS m/z 489(M+H+) . 1H-NMR (400 MHz, CDCl3) δ:1.94 (2 H, brs) , 2.20 (2 H, brs) , 3.19 (2 H, brs) , 3.35 (3 H, s) , 3.41 (2 H, brs) , 4.24 (1 H, brs) , 4.47 (2 H, s), 6.56 (1 H, d, J=7.5 Hz), 6.99 (1 H, t, J=7.8 Hz), 7.05 (1 H, d, J=2.1 Hz), 7.12 (1 H, dd, J=5.0, 3.9 Hz) , 7.40 (1 H, dd, J=3.8, 1.3 Hz), 7.59 (1 H, d, J=8.1 Hz) , 7.64 (1 H, dd, J=4.9, 1.3 Hz), 7.80 (1 H, s) , 9.69 (1 H, brs) .
Example 24 N- (2-{5- [ (3-hydroxypiperidino) methyl] -1, 3-thiazol-2- yl}-lH-indol-7-yl) -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000190_0001
In the same manner as in Example 1, the title compound (14.3 mg, yield 44%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl]-lH~indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 3-hydroxypiperidine (12 mg) . HPLC purity 97%. MS m/z 489(M+H+) .
Example 25 N- [2- (5-{ [ (2-methoxyethyl) (methyl) amino]methyl}-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000190_0002
In the same manner as in Example 1, the title compound (10.3 mg, yield 32%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and N- (2-methoxyethyl)methylamine (11 mg) . HPLC purity 100%. MS m/z 477 (M+H+) . Example 26 N- [2- (5-{ [ (2S) -2- (methoxymethyl) pyrrolidin-1- yl]methyl}-l,3-thiazol-2-yl)-lH-indol-7-yl]-N-methylthiophene-2- sulfonamide trifluoroacetate
Figure imgf000191_0001
In the same manner as in Example 1, the title compound (11.7 mg, yield 35%) was obtained from N-{2- [5- (chloromethyl) - l/3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and (S) -2- (methoxymethyl) pyrrolidine (14 mg) . HPLC purity 100%. MS m/z 503 (M+H+) . Example 27 N- { 1- [ (2-{7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl }-1, 3-thiazol-5-yl) methyl] pyrrolidin-3-yl } acetamide trifluoroacetate
Figure imgf000191_0002
In the same manner as in Example 1, the title compound (11.0 mg, yield 32%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 3-acetamidopyrrolidine (15 mg) .
HPLC purity 100%.
MS m/z 516(M+H+) . Example 28 1- [ (2- {7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2- yl } -1 , 3- thiazol-5-yl ) methyl ] piperidine-4-carboxamide trifluoroacetate
Figure imgf000192_0001
In the same manner as in Example 1, the title compound
(7.0 mg, yield 21%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol~7~yl}~N-methylthiophene-2-sulfonaruide (23 mg) and isonipecotamide (15 mg) . HPLC purity 94%. MS m/z 516 (M+H+) .
Example 29 N- [2- (5-{ [4- (2-hydroxyethyl)piperidino] methyl }-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000192_0002
In the same manner as in Example 1, the title compound
(13.2 mg, yield 39%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonarnide (23 mg) and 2- (piperidin-4-yl) ethanol (16 mg) . HPLC purity 95%. MS m/z 517 (M+H+) .
Example 30 N- [2- (5-{ [bis (2-methoxyethyl) amino]methyl}-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000193_0001
In the same manner as in Example 1, the title compound (8.4 mg, yield 24%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and bis (2-methoxyethyl) amine (16 mg) . HPLC purity 100%. MS m/z 521 (M+H+) .
1H-NMR (400 MHz, CDCl3) δ:3.32 - 3.39 (7 H, m) , 3.42 (6 H, s) , 3.84 - 3.89 (4 H, m) , 4.83 (2 H, s) , 6.56 (1 H, d, J=7.7 Hz), ■ 6.99 (1 H, t, J=7.7 Hz), 7.07 (1 H, d, J=I.7 Hz), 7.10 - 7.14 (1 H, m) , 7.39 (1 H, dd, J=3.8, 1.3 Hz), 7.58 (1 H, d, J=8.1 Hz), 7.64 (1 H, dd, J=5.0, 1.2 Hz), 7.93 (1 H, s) , 9.66 (1 H, brs) . Example 31 ethyl 1- [ (2- {7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl } -1 , 3-thiazol-5-yl ) methyl ] piperidine-4-carboxylate trifluoroacetate
Figure imgf000193_0002
In the same manner as in Example 1, the title compound (13.9 mg, yield 39%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and ethyl isonipecotate (19 mg) . HPLC purity 100%. MS m/z 545(M+H+) .
Example 32 ethyl 1- [ (2-{7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-1, 3-thiazol-5-yl)methyl]piperidine-3-carboxylate trifluoroacetate
Figure imgf000194_0001
In the same manner as in Example 1, the title compound (13.0 mg, yield 36%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and ethyl nipecotate (19 mg) . HPLC purity 100%. MS m/z 545(M+H+) .
Example 33 N- (2-{5- [ (3-hydroxypyrrolidin-l-yl)methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000194_0002
In the same manner as in Example 1, the title compound (10.7 mg, yield 34%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and DL-3-pyrrolidinol (10 mg) . HPLC purity 100%. MS m/z 475(M+H+) .
Example 34 N- [2- (5-{ [2- (hydroxymethyl) piperidino]methyl }-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000194_0003
In the same manner as in Example 1, the title compound (7.8 mg, yield 23%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and piperidin-2-ylmethanol (14 mg) . HPLC purity 100%. MS m/z 503 (MH-H+) .
Example .35 ethyl N-methyl-N- [ (2-{7- [methyl (2- thienylsulfonyl) amino] ~lH-indol-2-yl}-l, 3-thiazol-5- yl) methyl] glycinate trifluoroacetate
Figure imgf000195_0001
In the same manner as in Example 1, the title compound
(14.5 mg, yield 43%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and sarcosine ethyl ester hydrochloride (18 mg) . HPLC purity 100%. MS m/z 505(M+H+) .
Example 36 ethyl 4- [ (2-{7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl }-1, 3-thiazol-5-yl)methyl] piperazine-1-carboxylate trifluoroacetate
Figure imgf000195_0002
In the same manner as in Example 1, the title compound (12.4 mg, yield 35%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 1-ethoxycarbonylpiperazine (19 mg) . HPLC purity 100%. MS m/z 546 (M+H+) .
Example 37 N- [2- ( 5- { [4- (ethylsulfonyl) piperazin-1-yl] methyl } - 1 , 3-thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000196_0001
In the same manner as in Example 1, the title compound (10.0 mg, yield 27%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (23 mg) and 1-ethylsulfonylpiperazine (21 mg) . HPLC purity 100%. MS m/z 566(M+H+) .
Example 38 N-ethyl-N- [2- (5-{ [methyl (pyridin-2- ylmethyl) amino] methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000196_0002
In the same manner as in Example 1, the title compound ( 14 .4 mg, yield 40%) was obtained from N- { 2- [5- (chloromethyl) - l, 3-thiazol-2-yl] -lH-indoi-7-yl } -N-ethyl thiophene-2-sulfonamide (20 mg) and N-methyl-1- (pyridin-2-yl) methanamine hydrochloride ( 19 mg) .
HPLC purity 100%.
MS m/z 524 (M+H+) .
Example 39 N-ethyl-N- [2- (5- { [methyl (2- (pyridin-2- yl) ethyl ) amino] methyl }-l, 3-thiazol-2-yl ) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000197_0001
In the same manner as in Example 1, the title compound ( 11 . 0 mg, yield 30%) was obtained from N- { 2- [5- (chloromethyl) - l , 3-thiazol-2-yl] -lH-indol-7-yl } -N-ethylthiophene-2-sulfonamide (20 mg) and N-methyl-2- (pyridin-2-yl) ethanamine ( 16 mg) . HPLC purity 100% . MS m/z 538 (M+H+) .
Example 40 N-ethyl-N- (2- { 5- [ (2-pyridin-2-ylpyrrolidin-l- yl) methyl] -1, 3-thiazol-2-yl } -lH-indol-7-yl) thiophene-2- sulfonamide ditrifluoroacetate
Figure imgf000197_0002
In the same manner as in Example 1, the title compound (10.7 mg, yield 29%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 2- (pyrrolidin-2-yl) pyridine (18 mg) . HPLC purity 100%. MS m/z 550(M+H+) .
Example 41 N-ethyl-N- [2- (5- { [methyl (pyridin-3- ylmethyl) amino]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000198_0001
In the same manner as in Example 1, the title compound (7.9 mg, yield 22%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and N-methyl-1- (pyridin-3-yl)methanamine hydrochloride (19 mg) .
HPLC purity 100%. MS m/z 524 (M+H+) .
Example 42 N-ethyl-N~ [2- (5- { [3- (methylsulfonyl) pyrrolidin-1- yl]methyl}-l, 3-thiazol-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide trifluoroacetate
Figure imgf000198_0002
In the same manner as in Example 1, the title compound (6.2 mg, yield 20%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 3- (methylsulfonyl) pyrrolidine (18 mg) . HPLC purity 100%. MS m/z 551 (M+H+) .
Example 43 N-ethyl-N-{2- [5- ( {methyl [2- (methylsulfonyl) ethyl] amino}methyl) -1, 3-thiazol-2-yl] -lH-indol- 7-yl}thiophene-2-sulfonamide trifluoroacetate
Figure imgf000199_0001
In the same manner as in Example I7 the title compound (5.4 mg, yield 18%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and N-methyl-2- (methylsulfonyl) ethanamine (16 mg) . HPLC purity 100%. MS m/z 539 (M+H+) .
Example 44 N-ethyl-N- [2- (5-{ [4- (pyrimidin-2- yloxy)piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000199_0002
In the same manner as in Example 1, the title compound (12.8 mg, yield 39%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 2- (piperidin-4-yloxy)pyrimidine dihydrochloride (30 mg) .
HPLC purity 100%. MS m/z 581 (M+H+) .
1H-NMR (400 MHz, CDCl3) 6:1.11 (3 H, t, J=7.2 Hz) , 2.32 (4 H, brs), 3.27 (2 H, brs) , 3.54 (2 H, brs) , 3.77 (2 H, d, J=7.3 Hz), 4.52 (2 H, s), 5.47 (1 H, brs), 6.58 (1 H, d, J=7.3 Hz), 6.96 - 7.13 (4 H, m), 7.39 (1 H, dd, J=3.7, 1.2 Hz) , 7.61 (2 H, dd, J=4.7, 3.4 Hz), 7.80 (1 H, s) , 8.56 (2 H, d, J=4.7 Hz) , 9.56 (1 H, brs) . Example 45 N-ethyl-N- [2- (5- { [4- (pyrazin-2- yloxy) piperidino] methyl } -l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene- 2 -sulfonamide trifluoroacetate
Figure imgf000200_0001
' In the same manner as in Example 1, the title compound (10.3 mg, yield 31%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl] -lH-indol-7-yll-N-ethylthiophene-2-sulfonaird.de (20 mg) and 2- (piperidin-4-yloxy)pyrazine dihydrochloride (30 mg) . HPLC purity 100%. MS m/z 581 (M+H+) .
Example 46 N-ethyl-N- [2- (5-{ [4- (tetrahydrofuran-2- ylmethyl)piperazin-l-yl]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000200_0002
In the same manner as in Example 1, the title compound (12.9 mg, yield 34%) was obtained from N- {2- [5- (chloromethyl) - ' 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 1- (tetrahydrofuran-2-ylmethyl)piperazine (20 mg) . HPLC purity 95%. MS m/z 572 (M+H+) .
Example 47 2-{4-[ (2-{7- [ethyl (2-thi.enylsulfonyl) amino] -IH-indol- 2-yl}-l, 3-thiazol-5-yl)methyl]piperazin-l-yl}-N,N- dimethylacetamide ditrifluoroacetate
Figure imgf000201_0001
In the same manner as in Example 1, the title compound (16.7 mg, yield 44%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and N,N-dimethyl-2- (piperazin-1-yl) acetamide (20 mg) . HPLC purity 100%. MS m/z 573 (M+H+) .
Example 48 N-ethyl-N- [2- (5-{ [4- (6-methylpyridin-2-yl)piperazin- l-yl]methyl}-l,3-thiazol-2-yl)-lH-indol-7-yl]thiophene-2- sulfonamide tritrifluoroacetate
Figure imgf000201_0002
In the same manner as in Example 1, the title compound (16.3 mg, yield 37%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 1- (6-methylpyridin-2-yl)piperazine (21 mg) . HPLC purity 100%. MS m/z 579 (M+H+) .
Example 49 N-ethyl-N- (2-{5- [ (3- (pyrimidin-2-yl)pyrrolidin-l- yl)methyl]-l,3-thiazol-2-yl}-lH-indol-7-yl)thiophene-2- sulfonamide trifluoroacetate
Figure imgf000201_0003
In the same manner as in Example 1, the title compound (11.0 mg, yield 35%) was obtained from N- {2- [5- (chloromethyl) - l, 3-thiazol-2-yl] -lH-indol-7-yl } -N-ethylthiophene-2-sulfonamide (20 mg) and 2- (pyrrolidin-3-yl) pyrimidine trihydrochloride (31 mg) .
HPLC purity 100% . MS m/z 551 (M+H+) .
Example 50 N-ethyl-N- (2- { 5- [ (3- (pyridin-2-yl) piperidino) methyl] 1 , 3-thiazol-2-yl }-lH-indol-7-yl) thiophene-2-sulfonamide ditrif luoroacetate
Figure imgf000202_0001
In the same manner as in Example 1, the title compound (16.6 mg, yield 44%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] ~lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 2- (piperidin-3-yl) pyridine (19 mg) . HPLC purity 100%. MS m/z 564 (M+H+) .
Example 51 N-ethyl-N- (2- { 5- [ ( 4- (pyridin-2-yl) piperidino) methyl] 1, 3-thiazol-2-yl }-lH-indol-7-yl) thiophene-2-sulfonamide ditrif luoroacetate
Figure imgf000202_0002
In the same manner as in Example 1, the title compound
(13.1 mg, yield 35%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide
(20 mg) and 2- (piperidin-4-yl) pyridine (19 mg) . HPLC purity 100%. MS m/z 564 (M+H+) . Example 52 N-ethyl-N- (2-{5- [ (5-methyl-4, 6- dioxohexahydropyrrolo [3, 4-c]pyrrol-2 (IH) -yl)methyl] -1, 3-thiazol- 2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000203_0001
In the same manner as in Example 1, the title compound (7.4 mg, yield 23%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 2-methyltetrahydropyrrole [3, 4-c]pyrrole-l, 3 (2H, 3aH) - dione hydrochloride (23 mg) . HPLC purity 100%. MS m/z 556(M+H+) .
1H-NMR (400 MHz, CDCl3) δ:1.09 (3 H, t, J=7.1 Hz), 2.85 (2 H, brs), 3.02 (3 H, s), 3.37 (2 H, d, J=7.2 Hz), 3.59 (2 H, d,
J=IO.5 Hz), 3.76 (2 H, d, J=7.2 Hz), 4.13 (2 H, s), 6.58 (1 H, d, J=7.5 Hz), 7.00 (1 H, t, J=7.8 Hz), 7.03 (1 H, d, J=2.3 Hz), 7.09 (1 H, dd, J=4.9, 3.8 Hz), 7.39 (I H, dd, J=3.8, 1.3 Hz), 7.58 - 7.63 (2 H, m) , 7.69 (1 H, s) , 9.74 (1 H, brs) . Example 53 N-ethyl-N- (2- {5- [( 4-hydroxy-4- me thy lpiperidino) methyl ] -1, 3-thiazol-2-yl} -IH- indol-7- yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000203_0002
In the same manner as in Example 1, the title compound (9.6 mg, yield 32%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 4-methylpiperidin-4-ol hydrochloride (18 mg) . HPLC purity 100%. MS m/z 517 (M+H+) . Example 54 N- [2- (5-{ [cyclopropyl (isobutyl) amino]methyl }-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-ethylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000204_0001
In the same manner as in Example 1, the title compound (3.9 mg, yield 13%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and N-isobutyl-cyclopropanamine hydrochloride (18 mg) . HPLC purity 100%. MS m/z 515(M+H+) .
Example 55 N-(2-{5-[ (4-tert-butylpiperidino)methyl] -1, 3-thiazol- 2-yl}-lH-indol-7-yl) -N-ethylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000204_0002
In the same manner as in Example 1, the title compound (9.8 mg, yield 32%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl} -N-ethylthiophene-2-sulfonamide (20 mg) and 4-tert-butylpiperidine hydrochloride (21 mg) . HPLC purity 98%. MS m/z 543 (M+H+) .
Example 56 N-ethyl-N- [2- (5-{ [3- (pyrrolidin-1- ylcarbonyl) piperidino]methyl }-1, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000205_0001
In the same manner as in Example 1, the title compound (14.0 rag, yield 43%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 3- (pyrrolidin-1-ylcarbonyl) piperidine (22 mg) . HPLC purity 100%. MS m/z 584 (M+H+) .
Example 57 N-ethyl-N-{2- [5- (pyrrolidin-1-ylmethyl) -1, 3-thiazol- 2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide trifluoroacetate
Figure imgf000205_0002
In the same manner as in' Example 1, the title compound (7.1 mg, yield 26%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and pyrrolidine (9 mg) . HPLC purity 100%. MS m/z 473 (M+H+) .
Example 58 N- (2-{5- [ (diethylamino)methyl] -1, 3-thiazol-2-yl}-lH- indol-7-yl) -N-ethylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000205_0003
In the same manner as in Example 1/ the title compound (2.5 mg, yield 9%) was obtained from N-{2- [5- (chloromethyl) -1, 3- thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and diethylamine (8 mg) . HPLC purity 94%. MS m/z 475(M+H+) .
Example 59 N-ethyl-N-{2- [5- (piperidinomethyl) -1, 3-thiazol-2-yl] - lH-indol-7-yl }thiophene-2-sulfonamide trifluoroacetate
Figure imgf000206_0001
In the same manner as in Example 1, the title compound (8.6 mg, yield 30%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and piperidine (10 mg) . HPLC purity 100%. MS m/z 487 (M+H+) .
Example 60 N-ethyl-N- (2- {5- [ (4-hydroxypiperidino) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000206_0002
In the same manner as in Example 1, the title compound (10.4 mg, yield 36%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 4-hydroxypiperidine (12 mg) . HPLC purity 100%. MS m/z 503 (M+H+) . Example 61 N-ethyl-N- (2- { 5- [ ( 3-hydroxγpiperidino) methyl] -1 , 3- thiazol-2-yl } -lH-indol-7-yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000207_0001
In the same manner as in Example 1, the title compound (12.4 mg, yield 43%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 ing) and 3-hydroxypiperidine (12 mg) . HPLC purity 100%. MS m/z 503 (M+H+) .
Example 62 N-ethyl-N- [2- (5-{ [ (2- methoxyethyl) (methyl) amino]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000207_0002
In the same manner as in Example 1, the title compound (7.1 mg, yield 25%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and N- (2-methoxyethyl)methylamine (11 mg) . HPLC purity 100%. MS m/z 491 (M+H4') .
Example 63 N-ethyl-N- [2- (5-{ [ (2S) -2- (methoxymethyl)pyrrolidin-l- yl]methyl}-l,3-thiazol-2-yl)-lH-indol-7-yl]thiophene-2- sulfonamide trifluoroacetate
Figure imgf000208_0001
In the same manner as in Example 1, the title compound (10.1 mg, yield 34%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and (S) -2- (methoxymethyl) pyrrolidine (14 mg) . HPLC purity 100%. MS m/z 517 (M+H+) .
Example 64 N-{1- [ (2-{7- [ethyl (2-thienylsulfonyl) amino] -lH-indol- 2-yl}-l, 3-thiazol-5-yl)methyl]pyrrolidin-3-yl}acetamide trifluoroacetate
Figure imgf000208_0002
In the same manner as in Example 1, the title compound (9.6 mg, yield 32%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 3-acetamidopyrrolidine (15 mg) . HPLC purity 100%. MS m/z 530 (M+H+) .
Example 65 1- [ (2- {7- [ethyl (2-thienylsulfonyl) amino] -IH-indol-2- yl} -1, 3-thiazol-5-yl) methyl] piperidine-4-carboxamide trifluoroacetate
Figure imgf000208_0003
In the same manner as in Example 1, the title compound (8.0 ing, yield 26%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and isonipecotamide (15 mg) . HPLC purity 100%. MS m/z 530 (M+H+) .
Example 66 N-ethyl-N- [2- (5-{ [4- (2- hydroxyethyl) piperidino]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000209_0001
In the same manner as in Example 1, the title compound (11.7 mg, yield 38%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl] -lH-indol-7-ylJ-N-ethylthiophene-2-sulfonaird.de (20 mg) and 2- (piperidin-4-yl) ethanol (15 mg) . HPLC purity 100%. MS m/z 531 (M+H+) .
Example 67 N- [2- (5-{ [bis (2-methoxyethyl) amino]methyl}-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-ethylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000209_0002
In the same manner as in Example 1, the title compound (6.6 mg, yield 22%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and bis (2-methoxyethyl) amine (16 mg) . HPLC purity 100%. MS m/z 535(M+H+) . Example 68 ethyl 1- [ (2- { 7- [ethyl (2-thienylsulfonyl) amino] -IH- indol-2-yl } -1 , 3-thiazol-5-yl ) methyl ] piperidine-4-carboxylate trifluoroacetate
Figure imgf000210_0001
In the same manner as in Example 1, the title compound (12.3 mg, yield 39%) was obtained from N-{2- [5- (chloromethyl) - l,3~thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2~sulfonamide (20 mg) and ethyl isonipecotate (19 mg) . HPLC purity 97%. MS m/z 559 (M+H+) .
Example 69 ethyl 1- [ (2-{7- [ethyl (2-thienylsulfonyl) amino] -IH- indol-2-yl }-1, 3-thiazol-5-yl) methyl] piperidine-3-carboxylate trifluoroacetate
Figure imgf000210_0002
In the same manner as in Example I1 the title compound (12.8 mg, yield 40%) was obtained from N-{2- [5- (chloromethyl) - ■ 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and ethyl nipecotate (19 mg) . HPLC purity 97%. MS m/z 559 (M+H+) .
Example 70 N-ethyl-N- (2-{5- [ (3-hydrpxypyrrolidin-l-yl) methyl] - 1, 3-thiazol-2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000211_0001
In the same manner as in Example 1, the title compound (10.0 mg, yield 35%) was obtained from N-{2- [5- (chloromethyl) - l/3-thiazol-2-yl]-IH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and DL-3-pyrrolidinol (10 mg) . HPLC purity 95%. MS m/z 489(MH-H+) . Example 71 N-ethyl-N- [2- (5-{ [2-
(hydroxymethyl) piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7-' yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000211_0002
In the same manner as in Example 1, the title compound (6.9 mg, yield 23%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -IH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and piperidin-2-ylmethanol (14 mg) . HPLC purity 100%. MS m/z 517 (MH-H+) .
Example 72 ethyl N- [ (2-{7- [ethyl (2-thienylsulfonyl) amino] -IH- indol-2-yl }-1, 3-thiazol-5-yl) methyl] -N-methylglycinate trifluoroacetate
Figure imgf000212_0001
In the same manner as in Example 1, the title compound (12.7 mg, yield 43%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and sarcosine ethyl ester hydrochloride (18 mg) . HPLC purity 97%. MS m/z 519(M+H+) .
Example 73 ethyl 4- [ (2-{7- [ethyl (2-thienylsulfonyl) amino] -IH- indol-2-yl }-1, 3-thiazol-5-yl) methyl] piperazine-1-carboxylate trifluoroacetate
Figure imgf000212_0002
In the same manner as in Example 1, the title compound (10.4 mg, yield 33%) was obtained from N-{2- [5- (chloromethyl) - l/3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 1-ethoxycarbonylpiperazine (19 mg) . HPLC purity 100%. MS m/z 560 (M+H+) .
Example 74 N-ethyl-N- [2- (5-{ [4- (ethylsulfonyl)piperazin-l- yl]methyl}-l,3-thiazol-2-yl)-lH-indol-7-yl]thiophene-2- sulfonamide trifluoroacetate
Figure imgf000213_0001
In the same manner as in Example 1, the title compound (10.6 mg, yield 32%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (20 mg) and 1-ethylsulfonylpiperazine (21 mg) . HPLC purity 100%. MS m/z 580 (M+H+) .
Example 75. N- (cyclopropylmethyl) -N- [2- (5- { [methyl (pyridin-2- ylrαethyl) amino]methyl}-!, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000213_0002
In the same manner as in Example 1, the title compound
(17.1 mg, yield 50%) was obtained from N-{2- [5- (chloromethyl) -
1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and N-methyl-1- (pyridin-2-yl)methanamine hydrochloride (19 mg) .
HPLC purity 96%.
MS m/z 550(M+H+) .
Example 76 N- (cyclopropylmethyl) -N- [2- (5- { [methyl (2- (pyridin-2- yl) ethyl) amino]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000214_0001
In the same manner as in Example 1, the title compound (11.4 mg, yield 33%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and N-methyl-2- (pyridin-2-yl) ethanamine (16 mg) .
HPLC purity 100%. MS m/z 564 (M+H+) .
Example 77 N- (cyclopropylmethyl) -N- (2- {5- [ (2- (pyridin-2- yl) pyrrolidin-1-yl)methyl] -1, 3-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000214_0002
In the same manner as in Example 1, the title compound (13.3 mg, yield 38%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 2- (pyrrolidin-2-yl)pyridine (18 mg) . HPLC purity 97%. MS m/z 576(M+H+) . Example 78 N- (cyclopropylmethyl) -N- [2- (5- { [methyl (pyridin-3- ylmethyl) amino]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000215_0001
In the same manner as in Example 1, the title compound (14.0 mg, yield 41%) was obtained from N-{2- [5- (chloromethyl) - l/3-thiazol-2-yl] -lH-indol-7-ylJ-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and N-methyl-1- (pyridin-3-yl)methanamine hydrochloride (19 mg) . HPLC purity 100%. MS m/z 550 (M+H+) .
Example 79 N- (cyclopropylmethyl) -N- [2- (5- { [3- (methylsulfonyl)pyrrolidin-l-yl]methyl}-l, 3-thiazol-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000215_0002
In the same manner as in Example 1, the title compound (10.5 mg, yield 34%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl]-lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 3- (methylsulfonyl) pyrrolidine (18 mg) . HPLC purity 100%. MS m/z 577 (M+H÷) . Example 80 N- (cyclopropylmethyl) -N-{2- [5- ( {methyl [2- (methylsulfonyl) ethyl] amino}methyl) -1, 3-thiazol-2-yl]-lH-indol- 7-yl}thiophene-2-sulfonamide trifluoroacetate
Figure imgf000216_0001
In the same manner as in Example 1, the title compound (8.0 mg, yield 26.8%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and N-methyl-2- (methylsulfonyl) ethanamine (16 mg) .
HPLC purity 100%. MS m/z 565 (M+H+) .
Example 81 N- (cyclopropylmethyl) -N- [2- (5- { [4- (pyrimidin-2- yloxy) piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000216_0002
In the same manner as in Example 1, the title compound
(13.9 mg, yield 44%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene-
2-sulfonamide (20 mg) and' 2- (piperidin-4-yloxy)pyrimidine dihydrochloride (30 mg) .
HPLC purity 100%.
MS m/z 607 (M+H+) . Example 82 N- (cyclopropylmethyl) -N- [2- (5- { [4~ (pyrazin-2- yloxy) piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000217_0001
In the same manner as in Example 1, the title compound (13.0 mg, yield 41%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl]-lH-indol-7-yl}-N- (cyclopropylrαethyl) thiophene- 2-sulfonamide (20 mg) and 2- (piperidin-4-yloxy)pyrazine dihydrochloride (30 mg) . HPLC purity 95%. MS m/z 607 (M+H+) .
Example 83 N- (cyclopropylmethyl) -N- [2- (5-{ [4- (tetrahydrofuran-2- ylmethyl)piperazin-l-yl]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000217_0002
In the same manner as in Example 1, the title compound
(18.6 mg, yield 51%) was obtained from N- {2- [5- (chloromethyl) - I13-thiazol-2-yl]-lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene-
2-sulfonamide (20 mg) and 1- (tetrahydrofuran-2- ylmethyl)piperazine (20 mg) .
HPLC purity 95%.
MS m/z 598 (M+H+) . Example 84 2- { 4- [ (2- {7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl} -1, 3-thiazol-5- yl) methyl] piperazin-1-yl }-N,N-dimethylacetamide ditrifluoroacetate
Figure imgf000218_0001
In the same manner as in Example 1, the title compound
(24.6 mg, yield 68%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and N,N-dimethyl-2- (piperazin-1- yl)acetamide (21 mg) . HPLC purity 100%. MS m/z 599 (M+H+) .
Example 85 N- (cyclopropylmethyl) -N- [2- (5- { [4- (6-methylpyridin-2- yl)piperazin-l-yl]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide tritrifluoroacetate
Figure imgf000218_0002
In the same manner as in Example 1, the title compound (22.6 mg, yield 54%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 1- (6-methylpyridin-2-yl)piperazine (21 mg) .
HPLC purity 97%. MS m/z 605(M+H+) . Example 86 N- (cyclopropylmethyl) -N- (2- {5- [ (3- (pyrimidin-2- yl) pyrrolidin-1-yl)methyl] -1, 3-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide tritrifluoroacetate 007/070772
Figure imgf000219_0001
In the same manner as in Example 1, the title compound (12.3 mg, yield 40%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 2- (pyrrolidin-3-yl)pyrimidine trihydrochloride (31 mg) . HPLC purity 100%. MS m/z 577 (M+H+) .
Example 87 N- (cyclopropylmethyl) -N- (2- {5- [ (3- (pyridin-2- yl)piperidino)methyl]-l,3-thiazol-2-yl}-lH-indol-7-yl) thiophene- 2-sulfonamide ditrifluoroacetate
Figure imgf000219_0002
In the same manner as in Example 1, the title compound
(12.2 mg, yield 34%) was obtained 'from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene-
2-sulfonamide (20 mg) and 2- (piperidin-3-yl)pyridine (19 mg) .
HPLC purity 100%.
MS m/z 590 (M+H"1") .
Example 88 N- (cyclopropylmethyl) -N- (2-{5- [ (4- (pyridin-2- yl) piperidino)methyl] -1, 3-thiazol-2-yl}-lH-indol-7-yl) thiophene-
2-sulfonamide ditrifluoroacetate •
Figure imgf000220_0001
In the same manner as in Example 1, the title compound (18.0 mg, yield 50%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 2- (piperidin-4-yl) pyridine (19 mg) . HPLC purity 100%. MS m/z 590 (M+H+) .
Example 89 N- (cyclopropylmethyl) -N- (2-{5- [ (5-methyl-4, 6- dioxohexahydropyrrolo [3, 4-c]pyrrol-2 (IH) -yl) methyl] -1, 3-thiazol- 2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000220_0002
In the same manner as in Example 1, the title compound
(9.9 mg, yield 32%) was obtained from N- {2- [5- (chloromethyl) -
1, 3-t'hiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 2-methyltetrahydropyrrolo [3, 4- c]pyrrole-l,3 (2H,3aH) -dione hydrochloride (23 mg) .
HPLC purity 95%.
MS m/z 582 (M+H+) .
Example 90 N- (cyclopropylmethyl) -N- (2-{5- [ (4-hydroxy-4- methylpiperidino) methyl] -I13-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000220_0003
In the same manner as in Example 1, the title compound (11.3 mg, yield 39%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-ylJ-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 4-methylpiperidin-4-ol hydrochloride (18 mg) .
HPLC purity 100%. MS m/z 543 (M+H+) .
Example 91 N- [2- (5-{ [cyclopropyl (isobutyl) amino]methyl}-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N- (cyclopropylmethyl) thiophene-2- sulfonamide trifluoroacetate
Figure imgf000221_0001
In the same manner as in Example 1, the title compound
(3.1 mg, yield 11%) was obtained from N-{2- [5- (chloromethyl) -
1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and N-isobutyl-cyclopropanamine hydrochloride (18 mg) .
HPLC purity 100%.
MS m/z 541 (M+H4") .
Example 92 N-(2-{5-[ (4-tert-butylpiperidino)methyl] -1, 3-thiazol- 2-yl}-lH-indol-7-yl) -N- (cyclopropylmethyl) thiophene-2- sulfonamide trifluoroacetate
Figure imgf000221_0002
In the same manner as in Example 1, the title compound (10.6 mg, yield 35%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 4-tert-butylpiperidine hydrochloπαe (21 mg) .
HPLC purity 100.%. MS m/z 569 (M+H+) . Example 93 N- (cyclopropylmethyl) -N- [2- (5- { [3- (pyrrolidin-1- ylcarbonyl) piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiop.hene-2-sulfonamide trifluoroacetate
Figure imgf000222_0001
In the same manner as in Example 1, the title compound (18.5 mg, yield 58%) was obtained from N-{2- [5- (chloromethyl) -
1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene-
2-sulfonamide (20 mg) and 3- (pyrrolidin-l-ylcarbonyl)piperidine
(22 mg) .
HPLC purity 97%. MS m/z 610 (M+H+) .
Example 94 N- (cyclopropylmethyl) -N- {2- [5- (pyrrolidin-1- ylmethyl)-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide trifluoroacetate
Figure imgf000222_0002
In the same manner as in Example 1, the title compound (7.9 mg, yield 29%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and pyrrolidine (8 mg) . HPLC purity 100%. MS m/z 499(M+H+) . Example 95 N- (cyclopropylmethyl) -N- (2- {5- [ (diethyl amino) methyl] ■ 1 , 3-thiazol-2-yl }-lH-indol-7-yl) thiophene-2-sulfonamide tri f luoroacetat e
Figure imgf000223_0001
In the same manner as in Example 1, the title compound (3.5 mg, yield 13%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl]-lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and diethylamine (8 mg) . HPLC purity 92%. MS m/z 501 (M+H4) .
Example 96 N- (cyclopropylmethyl) -N- {2- [5- (piperidinomethyl) -1, 3- thiazol-2-yl] -lH-indol-7-yl} thiophene-2-sulfonamide trifluoroacetate
Figure imgf000223_0002
In the same manner as in Example 1, the title compound (11.2 mg, yield 41%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and piperidine (10 mg) . HPLC purity 100%. MS m/z 513 (M+H+) .
Example 97 N- (cyclopropylmethyl) -N- (2- {5- [( 4- hydroxypiperidino) methyl] -1, 3-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000224_0001
In the same manner as in Example 1, the title compound
(13.5 mg, yield 48%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 4-hydroxypiperidine (12 mg) . HPLC purity 100%. MS m/z 529(M+H+) .
Example 98 N- (cyclopropylmethyl) -N- (2- {5- [ (3- hydroxypiperidino) methyl] -1, 3-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000224_0002
In the same manner as in Example 1, the title compound (14.9 mg, yield 53%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 3-hydroxypiperidine (12 mg) . HPLC purity 100%. MS m/z 529 (M+H+) .
Example 99 N- (cyclopropylmethyl) -N- [2- (5- { [ (2- methoxyethyl) (methyl) amino]methyl }-1, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000225_0001
In the same manner as in Example 1, the title compound (9.5 mg, yield 34%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-ylJ-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and N- (2-methoxyethyl)methylamine (11 mg) . HPLC purity 100%. MS m/z 517 (IYH-H+) .
1H-NMR (400 MHz, CDCl3) δ:0.15 (2 H, d, J=4.3 Hz), 0.37 (2 H, d,
J=7.7 Hz), 0.87 - 0.94 (1 H, m) , 2.86 (3 H, s) , 3.31 (2 H, brs) , 3.44 (3 H, s), 3.57 (2 H, brs), 3.83 (2 H, t, J=4.2 Hz), 4.66 (2
H, s), 6.62 (1 H, d, J=7.7 Hz), 6.96 - 7.04 (1 H, m) , 7.06 -
7.11 (2 H, m) , 7.38 - 7.42 (1 H, m) , 7.58 - 7.64 (2 H, m) , 7.87
(1 H, s) , 9.61 (1 H, brs) .
Example 100 N- (cyclopropylmethyl) -N- [2- (5- {[ (2S) -2- (methoxymethyl)pyrrolidin-l-yl]methyl }-l, 3-thiazol-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000225_0002
In the same manner as in Example 1, the title compound (14.6 mg, yield 50%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and (S) -2- (methoxymethyl) pyrrolidine (14 mg) . HPLC purity 100%. MS m/z 543 (M+H+) .
Example 101 N- {1- [ (2-{7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl}-1, 3-thiazol-5- yl) methyl]pyrrolidin-3-yl}acetamide trifluoroacetate
Figure imgf000226_0001
In the same manner as in Example 1, the title compound
(13.8 mg, yield 47%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 3-acetamidopyrrolidine (15 mg) . HPLC purity 100%. MS m/z 556 (M+H+) .
Example 102 1- [ (2- {7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -lH~indol-2-yl}-l, 3-thiazol-5- yl) methyl] piperidine-4-carboxamide trifluoroacetate
Figure imgf000226_0002
In the same manner as in Example 1, the title compound (13.2 mg, yield 45%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-ylJ-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and isonipecotamide (15 mg) . HPLC purity 97%. MS m/z 556(MH-H+) .
Example 103 N- (cyclopropylmethyl) -N- [2- (5- { [4- (2- hydroxyethyl) piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000227_0001
In the same manner as in Example 1, the title compound (14.2 mg, yield 48%) was obtained from N-{2- [5- (chloromethyl) - l,-3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 2- (piperidin-4-yl) ethanol (16 mg) . HPLC purity 100%. MS m/z 557 (M+H+) .
Example 104 N- [2- (5-{ [bis (2-methoxyethyl) amino]methyl }-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N- (cyclopropylmethyl) thiophene-2- sulfonamide trifluoroacetate
Figure imgf000227_0002
In the same manner as in Example 1, the title compound (7.9 mg, yield 27%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and bis (2-methoxyethyl) amine (16 mg) . HPLC purity 96%. MS m/z 561 (M+H+) .
Example 105 ethyl 1- [ (2-{7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl}-1, 3-thiazol-5- yl)methyl]piperidine-4-carboxylate trifluoroacetate
Figure imgf000227_0003
In the same manner as in Example 1, the title compound (13.6 mg, yield 44%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and ethyl isonipecotate (19 mg) . HPLC purity 97%. MS m/z 585(M+H+) .
Example 106 ethyl 1- [ (2- {7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l, 3-thiazol-5- yl)methyl] piperidine-3-carboxylate trifluoroacetate
Figure imgf000228_0001
In the same manner as in Example 1, the title compound (13.4 mg, yield 44%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and ethyl nipecotate (19 mg) . HPLC purity 100%. MS m/z 585 (M+H+) .
Example 107 N- (cyclopropylmethyl) -N- (2-{5- [ (3-hydroxypyrrolidin- l-yl)methyl]-l,3-thiazol-2-yl}-lH-indol-7-yl)thiophene-2- sulfonamide trifluoroacetate
Figure imgf000228_0002
In the same manner as in Example 1, the title compound (13.0 mg, yield 47%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and DL-3-pyrrolidinol (10 mg) . HPLC purity 100%. MS m/z 515 (M+H+) .
Example 108 N- (cyclopropylmethyl) -N- [2- (5- { [2- (hydroxymethyl) piperidino J methyl }-l , 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trif luoroacetate
Figure imgf000229_0001
In the same manner as in Example 1, the title compound (10.2 mg, yield 35%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yll-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and piperidin-2-ylmethanol (14 mg) . HPLC purity 100%. MS m/z 543(M+H+) .
Example 109 N- [ (2- {7- [ (cyclopropylmethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l, 3-thiazol-5-yl)methyl] - N-methylglycine ethyl ester trifluoroacetate
Figure imgf000229_0002
In the same manner as in Example 1, the title compound (14.9 mg, yield 51%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and sarcosine ethyl ester hydrochloride (18 mg) .
HPLC purity 96%. MS m/z 545(M+H+) . Example 110 ethyl 4- [ (2- { 7- [ (cyclopropylmethyl) ( 2- thienylsulfonyl) amino] -lH-indol~2-yl } -l, 3-thiazol-5- yl) methyl] piperazine-1-carboxylate trif luoroacetate
Figure imgf000230_0001
In the same manner as in Example 1, the title compound (15.2 mg, yield 49%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-ylJ-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 1-ethoxycarbonylpiperazine (19 mg) . HPLC purity 97%. MS m/z 586(M+H+) .
Example 111 N- (cyclopropylmethyl) -N- [2- (5- { [4- (ethylsulfonyl) piperazin-1-yl] methyl }-l, 3-thiazol-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000230_0002
In the same manner as in Example 1, the title compound
(12.0 mg, yield 38%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (cyclopropylmethyl) thiophene- 2-sulfonamide (20 mg) and 1-ethylsulfonylpiperazine (21 mg) . HPLC purity 96%. MS m/z 606^+H+) .
Example 112 N-isopropyl-N- [2- (5-{ [methyl (pyridin-2- ylmethyl) amino] methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000231_0001
In the same manner as in Example 1, the title compound (18.1 mg, yield 49%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide and (21 mg) and N-methyl-1- (pyridin-2-yl)methanamine hydrochloride (19 mg) . HPLC purity 100%. MS m/z 538 (M+H+) .
Example 113 N-isopropyl-N- [2- (5-{ [methyl (2-pyridin-2- ylethyl) amino]methyl }-1, 3-thiazol-2-yl) -lH-indol-7-yl] thiophene- 2-sulfonamide ditrifluoroacetate
Figure imgf000231_0002
In the same manner as in Example 1, the title compound
(14.2 mg, yield 38%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl} -N-isopropylthiophene-2- sulfonamide (21 mg) and N-methyl-2- (pyridin-2-yl) ethanamine (16 mg) .
HPLC purity 100%.
MS m/z 552 (M+H+) . Example 114 N-isopropyl-N- (2- {5- [ (2- (pyridin-2-yl) pyrrolidin-1- yl) methyl] -1, 3-thiazol-2-yl}-lH-indol-7-yl) thiophene-2- sulfonamide ditrifluoroacetate
Figure imgf000232_0001
In the same manner as in Example 1, the title compound (18.6 mg, yield 49%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol~7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 2- (pyrrolidin-2-yl) pyridine (18 mg) . HPLC purity 100%. MS m/z 564 (M+H+) .
Example 115 N-isopropyl-N- [2- (5-{ [methyl (pyridin-3- ylmethyl) amino]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000232_0002
In the same manner as in Example 1, the title compound
(13.0 mg, yield 35%) was obtained from N- {2- [5- (chloromethyl) -
1, 3-thiazol-2-yl] -lH-indoi-T-yll-N-isopropylthiophene-^- sulfonamide (21 mg) and N-methyl-1- (pyridin-3-yl)methanamine hydrochloride (19 mg) .
HPLC purity 100%.
MS m/z 538 (M+H+) .
Example 116 N-isopropyl-N- [2- (5- { [3- (methylsulfonyl) pyrrolidin- l-yl]methyl}-l,3-thiazol-2-yl)-lH-indol-7-yl]thiophene-2- sulfonamide trifluoroacetate
Figure imgf000233_0001
In the same manner as in Example 1, the title compound (12.3 mg, yield 38%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 3- (methylsulfonyl) pyrrolidine (18 mg) . HPLC purity 100%. MS m/z 565(M+H+) .
Example 117 N-isopropyl-N-{2- [5- ( {methyl [2-
(methylsulfonyl) ethyl] amino}methyl)-!, 3-thiazol-2-yl] -IH-indol- 7-yl}thiophene-2~sulfonamide trifluoroacetate
Figure imgf000233_0002
In the same manner as in Example 1, the title compound
(8.4 mg, yield 26%) was obtained from N- {2- [5- (chloromethyl) -
1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and N-methyl-2- (methylsulfonyl) ethanamine
(16 mg) .
HPLC purity 100%.
MS m/z 553 (M+H+) .
Example 118 N-isopropyl-N- [2- (5-{ [4- (pyrimidin-2- yloxy)piperidino]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000234_0001
In the same manner as in Example 1, the title compound (14.1 mg, yield 41%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 2- (piperidin-4-yloxy)pyrimidine dihydrochloride (30 mg) . HPLC purity 100%. MS m/z 595 (M+H+) .
Example 119 N-isopropyl-N- [2- (5-{ [4- (pyrazin-2- yloxy) piperidino]methyl }-1, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000234_0002
In the same manner as in Example 1, the title compound
(16.1 mg, yield 47%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 2- (piperidin-4-yloxy)pyrazine dihydrochloride (30 mg) .
HPLC purity 100%.
MS m/z 595 (M+H+) . Example 120 N-isopropyl-N- [2- (5- { [4- (tetrahydrofuran-2- ylmethyl) piperazin-1-yl]methyl }-1, 37thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000235_0001
In the same manner as in Example 1, the title compound (22.7 mg, yield 58%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 1- (tetrahydrofuran-2-ylmethyl)piperazine (20 mg) .
HPLC purity 94%. MS m/z 586(M+H+) .
Example 121 2-{4- [ (2-{7- [isopropyl (2-thienylsulfonyl) amino] -IH- indol-2-yl }-1, 3-thiazol-5-yl)methyl]piperazin-1-yl}-N,N- dimethylacetamide ditrifluoroacetate
Figure imgf000235_0002
In the same manner as in Example 1, the title compound
(26.2 mg, yield 67%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- .,, sulfonamide (21 mg) and N,N-dimethyl-2-piperazin-l-ylacetamide
(20 mg) .
HPLC purity 91%.
MS m/z 587 (M+H+) . Example 122 N-isopropyl-N- [2- (5-{ [4- (6-methylpyridin-2- yl)piperazin-l-yl]methyl}-l,3-thiazol-2-yl)-lH-indol-7- yl] thiophene-2-sulfonamide tritrifluoroacetate
Figure imgf000236_0001
In the same manner as in Example 1, the title compound (23.4 mg, yield 52%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 1- (6-methylpyridin-2-yl)piperazine (21 mg) .
HPLC purity 98%. MS m/z 593 (M+H+) .
Example 123 N-isopropyl-N- (2- {5- [ (3- (pyrimidin-2-yl)pyrrolidin- l-yl)methyl]-l,3-thiazol-2-yl}-lH-indol-7-yl)thiophene-2- sulfonamide tritrifluoroacetate
Figure imgf000236_0002
In the same manner as in Example 1, the title compound
(15.1 mg, yield 46%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 2- (pyrrolidin-3-yl)pyrimidine trihydrochloride (31 mg) .
HPLC purity 100%.
MS m/z 565 (M+H+) . Example 124 N-isopropyl-N- (2- {5- [ (3- (pyridin-2- yl)piperidino)methyl]-l,3-thiazol-2-yl}-lH-indol-7-yl) thiophene-
2-sulfonamide ditrifluoroacetate
Figure imgf000237_0001
In the same manner as in Example 1, the title compound (7.5 mg, yield 19%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 2- (piperidin-3-yl) pyridine (19 mg) . HPLC purity 100%. MS m/z 578 (M+H+) .
Example 125 N-isopropyl-N- (2-{5- [ (4- (pyridin-2- yl)piperidino)methyl]-l/3-thiazol-2-yl}-lH-indol-7-yl) thiophene- 2-sulfonamide ditrifluoroacetate
Figure imgf000237_0002
In the same manner as in Example 1, the title compound (21.8 mg, yield 56%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 2- (piperidin-4-yl) pyridine (19 mg) . HPLC purity 100%. MS m/z 578 (M+H+) .
Example 126 N-isopropyl-N- (2-{5- [ (5-methyl-4, 6- dioxohexahydropyrrolo [3, 4-c]pyrrol-2 (IH) -yl) methyl] -1, 3-thiazol- 2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000238_0001
In the same manner as in Example 1, the title compound ( 9. 9 mg, yield 30%) was obtained from N- {2- [5- (chloromethyl) - l ,-3-thiazol-2-yl] -lH-indol-7-yl } -N-isopropylthiophene-2- sulfonamide (21 mg) and 2-me thyl tetrahydropyrrole [3, 4-c] pyrrole- 1, 3 (2H, 3aH) -dione hydrochloride (23 mg) . HPLC purity 96% . MS m/z 570 (M+H+) .
Example 127 N- (2- { 5- [ (4-hydroxy-4-methylpiperidino) methyl] -1 , 3- thiazol-2-yl } -lH-indol-7-yl) -N-isopropylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000238_0002
In the same manner as in Example 1, the title compound
(15.6 mg, yield 50%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 4-methylpiperidin-4-ol hydrochloride (18 mg) .
HPLC purity 100%.
MS m/z 531(M+H+) . Example 128 N- [2- (5-{ [cyclopropyl (isobutyl) amino]methyl }-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-isopropylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000239_0001
In the same manner as in Example 1, the title compound (5.3 mg, yield 17%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and N-isobutyl-cyclopropanamine hydrochloride (18 mg) . HPLC purity 100%. MS m/z 529(M+H+) .
Example 129 N- (2-{5- [ (4-tert-butylpiperidino) methyl] -I13- thiazol-2-yl}-lH-indol-7-yl) -N-isopropylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000239_0002
In the same manner as in Example I1 the title compound
(13.1 mg, yield 41%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-'7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 4-tert-butylpiperidine hydrochloride (21 mg) .
HPLC purity 100%.
MS m/z 557 (M+H+) . Example 130 N-isopropyl-N- [2- (5-{ [3- (pyrrolidin-1- ylcarbonyl)piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000240_0001
In the same manner as in Example 1, the title compound (22.0 mg, yield 64%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 3- (pyrrolidin-l-ylcarbonyl)piperidine (22 mg) .
HPLC purity 100%. MS m/z 598 (M+H+) .
Example 131 N-isopropyl-N-{2- [5- (pyrrolidin-1-ylmethyl) -1, 3- thiazol-2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide trifluoroacetate
Figure imgf000240_0002
In the same manner as in Example 1, the title compound (10.9 mg, yield 38%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and pyrrolidine (8 mg) . HPLC purity 100%. MS m/z 487 (M+H+) .
1H-NMR (400 MHz, CDCl3) δ:1.14 (6 H, d, J=12.1 Hz), 2.10 (4 H, d, J=Il.7 Hz), 2.79 - 3.06 (2 H, m) , 3..72 (2 H, brs) , 4.50 (2 H, s) , 4.69 - 4.95 (1 H, m) , 6.79 (1 H, d, J=7.7 Hz), 7.02 - 7.09 (3 H, m) , 7.47 (I H, dd, J=3.7, 1.4 Hz), 7.60 (1 H, dd, J=5.1, 1.3 Hz), 7.67 (1 H, d, J=7.9 Hz), 7.81 (1 H, s) , 9.54 (1 H, brs). Example 132 N- (2-{5- [ (diethylamino)methyl] -I13-thiazol-2-yl}-lH- indol-7-yl) -N-isopropylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000241_0001
In the same manner as in Example 1, the title compound
(3. 0 mg, yield 10% ) was obtained from N- {2- [5- (chloromethyl) - l , 3-thiazol-2-yl] -lH-indol-7-yl} -N-isopropylthiophene-2~ sulfonamide (21 mg) and diethylamine (9 mg) . HPLC purity 100% . MS m/z 489 (M+H+) .
Example 133 N-isopropyl-N- { 2- [5- (piperidinomethyl) ~1, 3-thiazol- 2-yl] -lH-indol-7-yl} thiophene-2-sulfonamide trifluoroacetate
Figure imgf000241_0002
In the same manner as in Example 1, the title compound (11.7 mg, yield 40%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl} -N-isopropylthiophene-2- sulfonamide (21 mg) and piperidine (10 mg) . HPLC purity 100%. MS m/z 501 (M+H+) .
Example 134 N- (2-{5- [ (4-hydroxypiperidino)methyl] -1, 3-thiazol-2- yl}-LH-indol-7-yl) -N-isopropylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000241_0003
In the same manner as in Example 1-, the title compound (15.2 mg, yield 50%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 4-hydroxypiperidine (12 mg) . HPLC purity 100%. MS m/z 517 (M+H+) .
Example 135 N- (2-{5- [ (3-hydroxypiperidino) methyl] -1, 3-thiazol-2- yl}-lH-indol-7-yl) -N-isopropylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000242_0001
In the same manner as in Example 1, the title compound (8.0 mg, yield 26%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol~7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 3-hydroxypiperidine (12 mg) . HPLC purity 100%. MS m/z 517 (M+H+) .
Example 136 N-isopropyl-N- [2- (5-{ [ (2- methoxyethyl) (methyl) amino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000242_0002
In the same manner as in Example 1, the title compound ;i2.0 mg, yield 40%) was obtained from N- {2- [5- (chloromethyl) l,3-thiazol-2-yl]-lH-indol-7-yl}-N-isopropylthiophene-2- sulfonaiαide (21 mg) and N- (2-methoxyethyl)methylamine (11 mg) . HPLC purity 100%. MS m/z 505 (MH-H+) . Example 137 N-isopropyl-N- [2- (5-{ [ (2S) -2-
(methoxymethyl)pyrrolidin-l-yl] methyl }-l, 3-thiazol-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide trif luoroacetate
Figure imgf000243_0001
In the same manner as in Example 1, the title compound (14.1 mg, yield 46%) was obtained from N-{2- [5- (chloromethyl) - ■
1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and (S) -2- (methoxymethyl) pyrrolidine (14 mg)
HPLC purity 100%.
MS m/z 531 (M+H+) . Example 138 N- {1- [ (2-{7- [isopropyl (2-thienylsulfonyl) amino] -IH- indol-2-yl } -1 , 3-thiazol-5-yl ) methyl ] pyrrolidin-3-yl } acetamide trif luoroacetate
Figure imgf000243_0002
In the same manner as in Example 1, the title compound (15.3 mg, yield 48%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 3-acetamidopyrrolidine (15 mg) . HPLC purity 100%. MS m/z 544 (M+H+) . Example 139 1- [ (2- { 7- [isopropyl (2-thienylsulfonyl) amino] -IH- ■ indol-2-yl } -1 , 3-thiazol-5-yl ) methyl ] piperidine-4-carboxamide trifluoroacetate
Figure imgf000244_0001
In the same manner as in Example 1, the title compound (15.0 mg, yield 47%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and isonipecotamide (15 mg) . HPLC purity 100%. MS m/z 544 (M+H+) .
Example 140 N- [2- (5-{ [4- (2-hydroxyethyl)piperidino]methyl}-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-isopropylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000244_0002
In the same manner as in Example 1, the title compound (15.0 mg, yield 47%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 2- (piperidin-4-yl) ethanol (16 mg) . HPLC purity 100%. MS m/z 545(M+H+) .
Example 141 N- [2- (5-{ [bis (2-methoxyethyl) amino]methyl}-1,3- thiazol-2-yl) -lH-indol-7-yl] -N-isopropylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000245_0001
In the same manner as in Example 1, the title compound (8.7 mg, yield 28%) was obtained from N-{2- [5- (chloromethyl) - 1, 3~thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and bis (2-methoxyethyl) amine (16 mg) . HPLC purity 100%. MS m/z 549(MH-H+) .
Example 142 ethyl 1- [ (2- {7- [isopropyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-l, 3-thiazol-5-yl) methyl] piperidine-4-carboxylate' trifluoroacetate
Figure imgf000245_0002
In the same manner as in- Example 1, the title compound (17.9 mg, yield 54%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and ethyl isonipecotate (19 mg) . HPLC purity 100%. MS m/z 573 (M+H+) .
Example 143 ethyl 1- [ (2- {7- [isopropyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-l,3-thiazol-5-yl) methyl] piperidine-3-carboxylate trifluoroacetate
Figure imgf000245_0003
In the same manner as in Example 1, the title compound (16.6 mg, yield 50%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and ethyl nipecotate (19 mg) . HPLC purity 100%. MS m/z 573 (M+H+) .
Example 144 N- (2-{5- [ (3-hydroxypyrrolidin-l-yl) methyl] -I13- thiazol-2-yl}-lH-indol-7-yl) -N-isopropylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000246_0001
In the same manner as in Example 1, the title compound (13.7 mg, yield 46%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl } -N-isopropylthiophene-2- sulfonamide (21 mg) and DL-3-pyrrolidinol (10 mg) . HPLC purity 100%. MS m/z 503 (M+H+) .
Example 145 N- [2- (5-{ [2- (hydroxymethyl)piperidino] methyl}-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-isopropylthiophene-2-sulfonamide trifluoroacetate
Figure imgf000246_0002
In the same manner as in Example 1, the title compound (11.1 mg, yield 36%) was obtained from N- {2- [5- (chloromethyl) l,3-thiazol-2-yl]-lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and piperidin-2-ylmethanol (14 mg) .. HPLC purity 100%. MS m/z 531 (M+H+) .
Example 146 N- [ (2-{ 7- [isopropyl (2-thienylsulfonyl) amino] -IH- indol-2-yl } -1 , 3-thiazol-5-yl ) methyl ] -N-methylglycine ethyl ester trifluoroacetate
Figure imgf000247_0001
In the same manner as in Example 1, the title compound (16.2 mg, yield 52%) was obtained from N-{2- [5- (chloromethyl) - ' 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and sarcosine ethyl ester hydrochloride (18 mg) .
HPLC purity 100%. MS m/z 533 (M+H+) .
1H-NMR (400 MHz, CDCl3) δ:1.09 (3 H, d, J=5.6 Hz), 1.16 (3 H, d, J=5.6 Hz), 1.32 (3 H, t, J=I .2 Hz), 2.98 (3 H, s) , 3.82 (2 H, s) , 4.29 (2 H, q, J=7.3 Hz), 4.72 (2 H, s), 4.75 - 4.86 (1 H, m) , 6.77 (1 H, d, J=7.0 Hz), 7.00 - 7.08 (3 H, m) , 7.45 (1 H, dd, J=3.8, 1.3 Hz), 7.59 (1 H, dd, J=5.1, 1.3 Hz), 7.66 (1 H, d, J=7.9 Hz)/ 7.77 (I H, s) , 9.62 (1 H, brs) . Example 147 ethyl 4- [ (2- {7- [isopropyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-l, 3-thiazol-5-yl) methyl]piperazine-l-carboxylate trifluoroacetate
Figure imgf000247_0002
In the same manner as in Example 1, the title compound ;i4.1 mg, yield 43%) was obtained from N-{2- [5- (chloromethyl) l,3-thiazol-2-yl]-lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 1-ethoxycarbonylpiperazine (19 mg) . HPLC purity 100%. MS m/z 574 (M+H+) . Example 148 N- [2- (5-{ [4- (ethylsulfonyl) piperazin-1-yl]methyl }- 1, 3-thiazol-2-yl) -lH-indol-7-yl] -N-isopropylthiophene-2- sulfonamide trifluoroacetate
Figure imgf000248_0001
In the same manner as in Example 1, the title compound (10.6 mg, yield 31%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N-isopropylthiophene-2- sulfonamide (21 mg) and 1-ethylsulfonylpiperazine (21 mg) .
HPLC purity 100% .
MS m/z 594 (K+ϊt) . Example 149 N- (2-ethoxyethyl) -N- [2- ( 5- { [methyl (pyridin-2- ylmethyl) amino] methyl } -l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene- 2 -sulfonamide ditrifluoroacetate
Figure imgf000248_0002
In the same manner as in Example 1, the title compound (15.5 mg, yield 51%) was obtained from N- { 2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and N-methyl-1- (pyridin-2-yl)methanamine hydrochloride (19 mg) .
HPLC purity 100%. MS m/z 568 (M+H+) . Example 150 N- (2-ethoxyethyl) -N- [2- ( 5- { [methyl (2-pyridin-2- ylethyl) amino ] methyl } -1 , 3-thiazol-2-yl) -lH-indol-7-yl] thiophene- 2-sulfonamide ditrifluoroacetate
Figure imgf000249_0001
In the same manner as in Example 1, the title compound (9.8 mg, yield 32%) was obtained from N- {2- [5- (chloromethyl) - ' 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and N-methyl-2- (pyridin-2-yl) ethanamine (16 mg) . HPLC purity 100%. MS m/z 582 (M+H+) .
Example 151 N- (2-ethoxyethyl) -N- (2- {5- [ (2- (pyridin-2- yl)pyrrolidin-l-yl) methyl] -l,3~thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000249_0002
In the same manner as in Example 1, the title compound (10.5 mg, yield 34%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 2- (pyrrolidin-2-yl) pyridine (18 mg) . HPLC purity 93%. MS m/z 594 (MH-H+) .
Example 152 N-.(2-ethoxyethyl) -N- [2- (5-{ [methyl (pyridin-3- ylmethyl) amino]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000250_0001
In the same manner as in Example 1, the title compound (10.6 rag, yield 35%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol~7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and N-methyl-1- (pyridin-3-yl)methanamine hydrochloride (19 mg) . HPLC purity 97%. MS m/z 568 (M+H+) .
Example 153 N- (2-ethoxyethyl) -N- [2- (5-{ [3- (methylsulfonyl)pyrrolidin-l-yl]methyl}-l, 3-thiazol-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide trifluoroacetate H3
Figure imgf000250_0002
In the same manner as in Example 1, the title compound (8.2 mg, yield 30%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 3- (methylsulfonyl) pyrrolidine (18 mg) . HPLC purity 100%. MS m/z 595(M+H+) . Example 154 N- (2-ethoxyethyl) -N- { 2- [5- ( {methyl [2-
(methylsulfonyl ) ethyl] amino }methyl) -1 , 3-thiazol-2-yl] -IH- indol- 7 -yl } thiophene-2- sulfonamide trifluoroacetate
Figure imgf000251_0001
In the same manner as in Example 1, the title compound (6.6 mg, yield 25%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-ylJ-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and N-methyl-2- (methylsulfonyl) ethanamine (16 mg) . HPLC purity 100%. MS m/z 583 (M+H+) .
Example 155 N- (2-ethoxyethyl) -N- [2- (5- { [4- (pyrimidin-2- yloxy) piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000251_0002
In the same manner as in Example 1, the title compound (10.3 mg, yield 37%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 2- (piperidin-4-yloxy)pyrimidine dihydrochloride (30 mg) . HPLC purity 93%. MS m/z 625 (M+H+) .
Example 156 N- (2-ethoxyethyl) -N- [2- (5-{ [4- (pyrazin-2- yloxy) piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000252_0001
In the same manner as in Example 1, the title compound (11.1 mg, yield 39%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 2- (piperidin-4-yloxy)pyrazine dihydrochloride (30 mg) . HPLC purity 100%. MS m/z 625 (M+H+) .
Example 157 N- (2-ethoxyethyl) -N- [2- (5-{ [4- (tetrahydrofuran-2- ylmethyl)piperazin-l-yl]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide ditrifluoroacetate
Figure imgf000252_0002
In the same manner as in Example 1, the title compound
(12.9 mg, yield 40%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 1- (tetrahydrofuran-2-ylmethyl)piperazine
(20 mg) .
HPLC purity 94%.
MS m/z 616(M+H+) . Example 158 2- { 4- [ (2- {7- [ (2-ethoxyethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l, 3-thiazol-5- yl) methyl] piperazin-1-yl}-N,N-dimethylacetamide ditrifluoroacetate
Figure imgf000253_0001
In the same manner as in Example 1, the title compound (10.1 mg, yield 31%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and N,N-dimethyl-2-piperazin-l-ylacetamide (20 mg) .
HPLC purity 97%. MS m/z 617 (M+H+) .
Example 159 N- (2-ethoxyethyl) -N- [2- (5-{ [4- (6-methylpyridin-2- yl)piperazin-l-yl]methyl}-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide tritrifluoroacetate
Figure imgf000253_0002
In the same manner as in Example 1, the title compound
(17.3 mg, yield 47%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 1- (6-methylpyridin-2-yl)piperazine (21 mg) .
HPLC purity 100%.
MS m/z 623 (M+H+) . Example 160 N- (2-ethoxyethyl) -N- (2-{5- [ (3- (pyrimidin-2- yl) pyrrolidin-1-yl)methyl] -1, 3-thiazol-2-yl} -lH-indol-7- yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000254_0001
In the same manner as in Example 1, the title compound (10.8 mg, yield 40%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 2- (pyrrolidin-3-yl)pyrimidine trihydrochloride (31 mg) . HPLC purity 100%. MS m/z 595(M+H+) .
Example 161 N- (2-ethoxyethyl) -N- (2- {5- [ (3- (pyridin-2- yl)piperidino)methyl]-l,3-thiazol~2~yl}-lH-indol-7-yl) thiophene- 2-sulfonamide ditrifluoroacetate
Figure imgf000254_0002
In the same manner as in Example 1, the title compound
(14.2 mg, yield 45%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 2- (piperidin-3-yl) pyridine (19 mg) .
HPLC purity 100%.
MS m/z 608 (M+H+) .
Example 162 N- (2-ethoxyethyl) -N- (2- {5- [ (4- (pyridin-2- yl) piperidino)methyl] -1, 3-thiazol-27yl} -lH-indol-7-yl) thiophene-
2-sulfonamide ditrifluoroacetate
Figure imgf000255_0001
In the same manner as in Example 1, the title compound (14.5 mg, yield 45%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 2- (piperidin-4-yl) pyridine (19 mg) . HPLC purity 97%. MS m/z 608 (M+H+) .
Example 163 N- (2-ethoxyethyl) -N- (2- {5- [ (5-methyl-4, 6- dioxohexahydropyrrolo [3, 4-c]pyrrol-2 (IH) -yl) methyl] -1, 3-thiazol- 2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000255_0002
In the same manner as in Example 1, the title compound
(5.9 mg, yield 22%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 2-methyltetrahydropyrrolo [3, 4-c]pyrrole-
1,3 (2H, 3aH)-dione hydrochloride (23 mg) .
HPLC purity 100%.
MS m/z 600 (M+H+) .
Example 164 N- (2-ethoxyethyl) -N- (2-{5- [ (4-hydroxy-4- methylpiperidino)methyl] -1, 3-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide trifluorqacetate
Figure imgf000256_0001
In the same manner as in Example 1, the title compound (11.7 mg, yield 46%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 4-methylpiperidin-4-ol hydrochloride (18 mg) .
HPLC purity 100%. MS m/z 561 (M+H+) .
Example 165 N- [2- (5-{ [cyclopropyl (isobutyl) amino]methyl }~1, 3- ' thiazol-2-yl) -lH-indol-7-yl] -N- (2-ethoxyethyl) thiophene-2- sulfonamide trifluoroacetate
Figure imgf000256_0002
In the same manner as in Example 1, the title compound
(3.9 mg, yield 15%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and N-isobutyl-cyclopropanamine hydrochloride (18' mg) .
HPLC purity 97%.
MS m/z 559 (M+H+) . Example 166 N- (2- { 5- [ ( 4-tert-butylpiperidino) methyl] -1, 3- thiazol-2-yl} -lH-indol-7-yl) -N- (2-ethoxyethyl) thiophene-2- sulfonamide trifluoroacetate
Figure imgf000257_0001
In the same manner as in Example 1, the title compound (10.6 ing, yield 40%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 4-tert-butylpiperidine hydrochloride (21 mg) .
HPLC purity 100%. MS m/z 587 (M+H+) .
Example 167 N- (2-ethoxyethyl) -N- [2- (5-{ [3- (pyrrolidin-1- ylcarbonyl) piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000257_0002
In the same manner as in Example 1, the title compound
(17.1 mg, yield 61%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 3- (pyrrolidin-l-ylcarbonyl)piperidine
(22 mg) .
HPLC purity 96%.
MS m/z 628 (M+H+) . Example 168 N- (2-ethoxyethyl) -N- {2- [5- (pyrrolidin-1-ylmethyl) -
1, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide trifluoroacetate
Figure imgf000258_0001
In the same manner as in Example 1, the title compound (8.9 mg, yield 37%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and pyrrolidine (9 mg) . HPLC purity 100%. MS m/z 517 (M+H+) .
Example 169 N- (2- {5- [ (diethylamino)methyl] -1, 3-thiazol-2-yl}-lH- indol-7-yl) -N- (2-ethoxyethyl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000258_0002
In the same manner as in Example 1, the title compound (6.4 mg, yield 27%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- ' sulfonamide (18 mg) and diethylamine (9 mg) . HPLC purity 100%. MS m/z 519 (M+H+) .
1H-NMR (400 MHz, CDCl3) δ:1.14 (3 H, t, J=7.0 Hz), 1.42 (6 H, t, J=7.3 Hz), 3.15 (4 H, d, J=7.3 Hz) , .3.32 - 3.57 (4 H, m) , 3.90 (2 H, brs), 4.55 (2 H, s) , 6.68 (1 H, d, J=8.0 Hz), 7.01 (1 H, t, J=8.0 Hz), 7.04 (1 H, d, J=2.1 Hz), 7.08 (1 H, dd, J=5.1, 3.8 Hz), 7.44 (1 H, dd, J=3.8, 1.3 Hz), 7.59 - 7.63 (2 H, m) , 7.81 (1 H, s) , 9.87 (1 H, brs) . Example 170 N- (2-ethoxyethyl) -N- { 2- [5- (piperidinomethyl) -I 1 3- thiazol-2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide tri f luoroacetat e
Figure imgf000259_0001
In the same manner as in Example 1, the title compound (9.5 mg, yield 39%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and piperidine (10 mg) . HPLC purity 100%. MS m/z 531 (M+H+) .
Example 171 N- (2-ethoxyethyl) -N- (2- {5- [ (4- hydroxypiperidino) methyl] -1, 3-thiazol-2~yl}-lH-indol-7- yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000259_0002
In the same manner as in Example 1, the title compound (11.3 mg, yield 45%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 4-hydroxypiperidine (12 mg) . HPLC purity 100%. MS m/z 547 (M+H+) .
Example 172 N- (2-ethoxyethyl) -N- (2- {5- [ (3- hydroxypiperidino)methyl] -1, 3-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide trifluoroacetate
Figure imgf000260_0001
In the same manner as in Example 1, the title compound (13.5 mg, yield 54%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 3-hydroxypiperidine (12 mg) . HPLC purity 100%. MS m/z 547 (M+H+) .
Example 173 N- (2-ethoxyethyl) -N- [2- (5-{ [ (2- methoxyethyl) (methyl) amino] methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000260_0002
In the same manner as in Example 1, the title compound (7.4 mg, yield 30%) was obtained from N-{2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and N- (2-methoxyethyl)methylamine (11 mg) . HPLC purity 100%. MS m/z 535(M+H+) .
Example 174 N- (2-ethoxyethyl) -N- [2-.(5-{ [ (2S) -2- (methoxymethyl) pyrrolidin-1-yl]methyl }-1, 3-thiazol-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000261_0001
In the same manner as in Example 1, the title compound (9.2 mg, yield 36%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and (S) -2- (methoxymethyl) pyrrolidine (14 ing) HPLC purity 100%. MS m/z 561 (M+H+) .
Example 175 N- {1- [ (2-{7- [ (2-ethoxyethyl) (2- thienylsulfonyl) amino] -lH-indol-2~yl}-l, 3-thiazol-5- yl) methyl]pyrrolidin-3-yl}acetamide trifluoroacetate
Figure imgf000261_0002
In the same manner as in Example 1, the title compound (9.6 mg, yield 37%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 3-acetamidopyrrolidine (15 mg) . HPLC purity 100%. MS m/z 574 (M+H+) .
Example 176 1- [ (2-{7- [ (2-ethoxyethyl) (2-thienylsulfonyl) amino] - lH-indol-2-yl}-l,3-thiazol-5-yl) methyl] piperidine-4-carboxamide trifluoroacetate
Figure imgf000262_0001
In the same manner as in Example 1, the title compound (9.1 mg, yield 35%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and isonipecotamide (15 mg) . HPLC purity 96%. MS m/z 574 (M+H+) .
Example 177 N- (2-ethoxyethyl) -N- [2- (5- { [4- (2- hydroxyethyl)piperidino]methyl }-l, 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000262_0002
In the same manner as in Example 1, the title compound (10.7 mg, yield 41%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 2- (piperidin-4-yl) ethanol (16 mg) . HPLC purity 100%. MS m/z 575(M+H+) .
Example 178 N- [2- (5-{ [bis (2-methoxyethyl) amino]methyl }-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N- (2-ethoxyethyl) thiophene-2- sulfonamide trifluoroacetate
Figure imgf000263_0001
In the same manner as in Example 1, the title compound (5.8 mg, yield 22%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and bis (2-methoxyethyl) amine (16 mg) . HPLC purity 100%. MS m/z 579 (M+H+) .
Example 179 ethyl 1- [ (2- {7- [ (2-ethoxyethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl } -1, 3-thiazol-5- yl) methyl] piperidine-4-carboxylate trifluoroacetate
Figure imgf000263_0002
In the same manner as in Example 1, the title compound (10.9 mg, yield 40%) was obtained from N- {2- [5- (chloromethyl) - 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and ethyl isonipecotate (19 mg) . HPLC purity 100%. MS m/z 603 (M+H+) .
Example 180 ethyl 1- [ (2- {7- [ (2-ethoxyethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl} -1, 3-thiazol-5- yl) methyl] piperidine-3-carboxylate trifluoroacetate
Figure imgf000264_0001
In the same manner as in Example 1, the title compound (13.3 rag, yield 49%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and ethyl nipecotate (19 mg) . HPLC purity 91%. MS m/z 603 (M+H+) .
Example 181 N- (2-ethoxyethyl) -N- (2- {5- [ (3-hydroxypyrrolidin-l- yl)methyl]-l,3-thiazol-2-yl}-lH-indol-7-yl) thiophene-2- sulfonamide trifluoroacetate
Figure imgf000264_0002
In the same manner as in Example 1, the title compound (10.4 mg, yield 42%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl] -IH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and DL-3-pyrrolidinol (10 mg) . HPLC purity 95%. MS m/z 533 (M+H+) .
Example 182 N- (2-ethoxyethyl) -N- [2- (5-{ [2- (hydroxymethyl) piperidino]methyl }-!,_ 3-thiazol-2-yl) -lH-indol-7- yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000265_0001
In the same manner as in Example 1, the title compound (7.3 mg, yield 28%) was obtained from N-{2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and piperidin-2-ylmethanol (14 mg) . HPLC purity 100%. MS m/z 561 (M+H+) .
Example 183 N- [ (2-{7- [ (2-ethoxyethyl) (2-thienylsulfonyl) amino] - lH-indol-2-yl}-l, 3-thiazol-5-yl) methyl] -N-methy1glycine ethyl ester trifluoroacetate
Figure imgf000265_0002
In the same manner as in Example 1, the title compound
(14.0 mg, yield 54%) was obtained from N- {2- [5- (chloromethyl) -
1, 3-thiazol-2-yl] -lH-indol-7-yl } -N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and sarcosine ethyl ester hydrochloride (18 mg) .
HPLC purity 100%.
MS m/z 563 (M+H+) .
Example 184 ethyl 4- [ (2- { 7- [ (2-ethoxyethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl} -l/3-thiazol-5- yl) methyl] piperazine-1-carboxylate trifluoroacetate
Figure imgf000266_0001
In the same manner as in Example 1, the title compound ( 9. 0 mg, yield 33%) was obtained from N- {2- [5- (chloromethyl) - l, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide ( 18 mg) and 1-ethoxycarbonylpiperazine (19 mg) . HPLC purity 100% . MS m/z 604 (MH-H+) .
Example 185 N- (2-ethoxyethyl) -N- [2- (5- { [A- ( ethyl sulfonyl) piperazin-l-yl] methyl } -l, 3-thiazol-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide trifluoroacetate
Figure imgf000266_0002
In the same manner as in Example 1, the title compound (8.0 mg, yield 28%) was obtained from N- {2- [5- (chloromethyl) - l,3-thiazol-2-yl]-lH-indol-7-yl}-N- (2-ethoxyethyl) thiophene-2- sulfonamide (18 mg) and 1-ethylsulfonylpiperazine (21 mg) . HPLC purity 100%. MS m/z 624 (M+H+) .
Example 186 N- (2- {5- [ (4-acetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2-sulfonamide
Figure imgf000266_0003
A mixture of N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -IH- indol-7-yl}-N-methylthiophene-2-sulfonamide (0.40 g) , 1- acetylpiperazine (0.24 g) , triethylamine (0.26 ml) and N,N- dimethylformamide (15 ml) was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.33 g, yield 68%) as colorless crystals from a fraction eluted with ethyl acetate, melting point 177-178°C.
Example 187 N-methyl-N-{2- [5- (thiomorpholinomethyl) -1, 3-thiazol-
2-yl] -lH-indol-7-yl} thiophene-2-sulfonamide
Figure imgf000267_0001
In the same manner as in Example 186, the title compound (0.51 g, yield 43%) was obtained as yellow crystals from N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- methylthiophene-2-sulfonamide (0.96 g) and thiomorpholine (0.58 g) . melting point 177-178°C. Example 188 N- (2-{5- [ (1, 1-dioxidothiomorpholino) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2-sulfonamide
Figure imgf000267_0002
A mixture of N-methyl-N- {2- [5- (thiomorpholinomethyl) -1, 3- thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide (0.35 g) , sodium percarbonate (0.33 g) , acetonitrile (6 ml) and water (2 ml) was stirred at 40°C for 30 min. Sodium percarbonate (0.15 g) was added, and the mixture was further stirred at 40°C for 1 hr. Water was added to the reaction mixture, and the resulting crystals were collected by filtration, washed with water, and dried. The obtained crystals were subjected to silica gel short column to give the title compound (0.28 g, yield 76%) as colorless crystals from a fraction eluted with tetrahydrofuran- hexane (3:1, volume ratio), melting point 225-226°C. Example 189 methyl {4- [ (2-{7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-l, 3-thiazol-5-yl)methyl] -2-oxopiperazin-l- yl} acetate
Figure imgf000268_0001
In the same manner as in Example 186, the title compound (0.32 g, yield 66%) was obtained as yellow crystals from N-{2- [5-(chloromethyl)-l,3-thiazol-2-yl]-lH-indol-7-yl}-N- methylthiophene-2-sulfonamide (0.37 g) and methyl (2- oxopiperazin-1-yl) acetate hydrochloride (0.27 g) . melting point
182-183°C.
Example 190 N- (2- {5- [ (4-acetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) -N-isopropylthiophene-2-sulfonamide
Figure imgf000268_0002
In the same manner as in Example 186, the title compound (0.15 g, yield 64%) was obtained as colorless crystals from N- {2-[5-(chloromethyl)-l,3-thiazol-2-yl]-lH-indol-7-yl}-N- isopropylthiophene-2-sulfonamide (0.20 g) and 1-acetylpiperazine (0.11 g) . melting point 145-146°C. Example 191 N- (2-{5- [ (4-acetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl}-4-chloro-lH-indol-7-yl)-N-methylthiophene-2- sulfonamide
Figure imgf000269_0001
To a mixture of N-{4-chloro-2- [5- (hydroxymethyl) -1, 3- thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (0.26 g) and tetrahydrofuran (10 ml) was added thionyl chloride
(0.08 ml) at 0°C, and the mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. A mixture of the obtained residue, 1- acetylpiperazine (0.15 g) , triethylamine (0.17 ml) and N,N- dimethylformamide (10 ml) was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed with saturated brine, dried (MgSU4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.08 g, yield 25'%) as colorless crystals from a fraction eluted with ethyl acetate, melting point 224-225°C.
Example 192 N- (2- {5- [ (4-acetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide
Figure imgf000269_0002
In the same manner as in Example 191, the title compound (0.37 g, yield 41%) was obtained as colorless crystals from N- 007/070772
{2- [5- (hydroxymethyl) -1, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene-
2-sulfonarαide (0.63 g) . melting point 221-222°C.
Example 193 N-.(2-{5-[ (4-acetyl-2-oxopiperazin-l-yl)methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2-sulfonamide
Figure imgf000270_0001
To a mixture of N- (2-{[ (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l, 3-thiazol-5- yl)methyl] amino}ethyl) acetamide (0.33 g) and N,N- dimethylacetamide (6 ml) was added chloroacetyl chloride (0.06 ml) at 0°C, and the mixture was stirred at 0°C for 30 min. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated.
To a mixture of the obtained residue and N,N- dimethylformamide (6 ml) was added sodium hydride (60%, in oil,
0.06 g) at 00C, and the mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.07 g, yield 19%) as a colorless amorphous solid from a fraction eluted with ethyl acetate-methanol (3:2, volume ratio) . MS:MH+=530. Example 194 N- (2- {5- [ (4-acetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl}-6-chloro-lH-indol-7-yl) thiophene-2-sulfonamide
Figure imgf000270_0002
In the same manner as in Example 191, the title compound ( 0. 18 g, yield 34%) was obtained as colorless crystals from N- { β-chloro-2- [5- (hydroxymethyl) -1, 3-thiazol-2-yl] -lH-indol-7- yl } thiophene~2-sulfonamide ( 0. 42 g) . melting point 200-201°C . Example 195 N- (2- { 5- [ ( 4-acetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl } -6-chloro-lH-indol-7-yl) -N-methylthiophene-2- sulfonamide
Figure imgf000271_0001
In the same manner as in Example 191, the title compound (0.14 g, yield 34%) was obtained as colorless crystals from N- {6-chloro-2-[5- (hydroxymethyl) -1, 3-thiazol-2-yl] -IH-indol-7-yl}- N-methylthiophene-2-sulfonamide (0.32 g) . melting point 193-
194°C.
Example 196 N- { (3R) -1- [ (2-{7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-l, 3-thiazol-5-yl) methyl] pyrrolidin-3-yl}acetamide
Figure imgf000271_0002
In the same manner as in Example 186, the title compound
(0.10 g, yield 41%) was obtained as yellow crystals from N-{2- [5- (chloromethyl)-l, 3-thiazol-2-yl] -IH-indol-7-yl}-N- methylthiophene-2-sulfonamide (0.20 g) and N- [ (3R) -pyrrolidin-3- yl]acetamide (0.10 g) . melting point 129-130°C.
Example 197 N- { (3S) -1- [ (2-{7- [methyl (2-thienylsulfonyl) amino]- lH-indol-2-yl }-1, 3-thiazol-5-yl) methyl] pyrrolidin-3-yl } acetamide
Figure imgf000272_0001
In the same manner as in Example 186, the title compound (0.12 g, yield 47%) was obtained as yellow crystals from N- {2- [5-(chloromethyl)-l,3-thiazol-2-yl]-lH-indol-7-yl}-N- methylthiophene-2-sulfonamide (0.20 g) and N- [ (3S) -pyrrolidin-3- yl]acetamide (0.10 g) . melting point 130-1310C. Example 198 N- (2-{5- [ (4-acetylpiperazin-l-yl) methyl] -1, 3, 4- thiadiazol-2-yl}-lH-indol-7-yl)-N-methylthiophene-2-sulfonamide
Figure imgf000272_0002
A mixture of N-{2- [5- (hydroxymethyl) -1, 3, 4-thiadiazol-2- yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (0.50 g) , thionyl chloride (0.13 ml) and tetrahydrofuran (25 ml) was stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate, washed twice with saturated brine, dried (MgSO4) , and concentrated to give a residue.
A mixture of the obtained residue, 1-acetylpiperazine (0.31 g) , sodium hydrogencarbonate (0.21 g) and N,N- dimethylformamide (15 ml) was stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.32 g, yield 50%) as pale-yellow crystals from a fraction eluted with ethyl acetate, melting point 194-195°C.
Example 199 N-{2- [5- (2-hydroxyethyl) -5-methyl-4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000273_0001
To a solution of triphenylphosphine oxide (1.28 g) in acetonitrile (25 ml) was slowly added trifluoromethanesulfonic anhydride (0.39 ml) at 0°C, and the mixture was stirred for 10 min. N- [2- (Benzylthio) -4-hydroxy-2-methylbutyl] -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide (0.50 g) was added, and the reaction mixture was stirred at O0C for 30 min. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCi) / and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.17 g, yield 42%) as colorless crystals from a fraction eluted with ethyl acetate- hexane (2:1, volume ratio), melting point 149-150°C. Example 200 N-methyl-N- {2- [5-methyl-5- (2- (morpholino) ethyl) -4, 5- dihydro-l,3-thiazol-2-yl] -lH~indol-7-yl}thiophene-2-sulfonamide
Figure imgf000273_0002
To a solution of triphenylphosphine oxide (1.90 g) in acetonitrile (25 ml) was slowly added trifluoromethanesulfonic anhydride (0.57 ml) at 00C, and the mixture was stirred for 10 min. N- [2- (Benzylthio) -2-methyl-4- (morpholino) butyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (1.39 g) was added, and the reaction mixture was stirred at 0°C for 30 min. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.80 g, yield 70%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (5:1, volume ratio), melting point 154-155°C. Example 201 N-methyl-N-{2- [5-methyl-5~ (morpholinomethyl) -4,5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000274_0001
To a solution of triphenylphosphine oxide (1.00 g) in acetonitrile (20 ml) was slowly added trifluoromethanesulfonic anhydride (0.30 ml) at 0°C, and the mixture was stirred for 10 min. N- [2- (Benzylthio) -2-methyl-3- (morpholino) propyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (0.43 g) was added, and the reaction mixture was stirred at 0°C for 30 min. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed with saturated brine, dried (MgSC^) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.20 g, yield 57%) as colorless crystals from a fraction eluted with ethyl acetate- hexane (2:1, volume ratio), melting point 146-147°C. Example 202 N-methyl-N- {2- [5-methyl-5- (piperazine-1-ylmethyl) - 4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000274_0002
To a solution of triphenylphosphine oxide (3.09 g) in acetonitrile (20 ml) was slowly added trifluoromethanesulfonic anhydride (0.93 ml) at 0°C, and the mixture was stirred for 10 min. tert-Butyl 4-{2- (benzylthio) -2-methyl-3- [ ({7- [methyl (2- thienylsulfonyl) amino] -IH-indol-2-yl}carbonyl) amino]propyl} piperazine-1-carboxylate (1.55 g) was added, and the reaction 5 mixture was stirred at 0°C for 30 min. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, and dried (MgSCi) • 4N Hydrogen chloride-ethyl acetate solution was added to the ethyl acetate layer, and the io precipitated solid was collected by filtration, and washed with ethyl acetate. The obtained solid was suspended in saturated aqueous sodium hydrogencarbonate, and the mixture was stirred for 30 min. The solid was collected by filtration, washed with water and ethyl acetate, and dried to give the title compound
15 (0.49 g, yield 45%) as colorless crystals, melting point 178-
180°C.
Example 203 N- (2-{5- [ (4-acetylpiperazin-l-yl) methyl] -5-methyl- 4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene- 2-sulfonamide
Figure imgf000275_0001
A mixture of N-methyl-N-{2- [5-methyl-5- (piperazine-1- ylmethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene- 2-sulfonamide (0.21 g) , acetic anhydride (0.30 ml) and pyridine
(6 ml) was stirred at 0°C for 1 hr, and concentrated. Water was 25 added to the residue, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.19 g, yield 84%) as a colorless amorphous solid from a 30 fraction eluted with ethyl acetate-methanol (6:1, volume ratio) . MS: 532 (MH+) . Example 204 N-methyl-N- [2- (5-methyl-5- { [4- (methylsulfonyl) piperazin-l-yl] methyl } -4, 5-dihydro-l, 3-thiazol-
2-yl) -lH-indol-7-yl] thiophene-2-sulfonamide
Figure imgf000276_0001
To a mixture of N-methyl-N- {2- [5-methyl-5- (piperazine-1- ylmethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene- 2-sulfonamide (0.28 g) , triethylamine (0.17 ml) and tetrahydrofuran (6 ml) was added methanesulfonyl chloride (0.06 ml) at 0°C, and the reaction mixture was stirred overnight at room temperature, and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.26 g, yield 81%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (4:1, volume ratio) . melting point 209-210°C. Example 205 N- {2- [5- (dimethoxymethyl) -5-methyl-4, 5-dihydro-l, 3- thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000276_0002
To a solution of triphenylphosphine oxide (1.02 g) in dichloromethane (10 ml) was slowly added trifluoromethanesulfonic anhydride (0.31 ml) at 0°C, and the mixture was stirred for 10 min. N- [2- (Benzylthio) -3, 3-dimethoxy- 2-methylpropyl] -7- [methyl (2-thienylsulfonyl) amino] -IH-indole-2- carboxamide (0.70 g) was added, and the reaction mixture was stirred at 0°C for 30 min. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.28 g, yield 50%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (2:3, volume ratio). melting point 153-154°C.
Example 206 N- [2- (5-cyano-5-methyl-4, 5-dihydro-l, 3-thiazol-2- yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide
Figure imgf000277_0001
To a solution of triphenylphosphine oxide (0.68 g) in acetonitrile (10 ml) was slowly added trifluoromethanesulfonic anhydride (0.21 ml) at 0°C, and the mixture was stirred for 10 min. N- [2- (Benzylthio) -2-cyanopropyl] -7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (0.43 g) was added, and the reaction mixture was stirred at 0°C for 30 min. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.27 g, yield 79%) as colorless crystals from a fraction eluted with ethyl acetate- hexane (2:3, volume ratio), melting point 178-179°C. Example 207 5-methyl-2-{7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazole-5-carboxylic acid
Figure imgf000277_0002
A mixture of N- [2- (5-cyano-5-methyl-4, 5-dihydro-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide (0.15 g) , 2N aqueous sodium hydroxide solution (0.36 ml), tetrahydrofuran (3 ml) and ethanol (3 ml) was heated under reflux for 4 hr. 10% Aqueous citric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.11 g, yield 69%) as yellow crystals from a fraction eluted with tetrahydrofuran. melting point >232°C (decomposition) . Example 208 ethyl {4- [ (2-{7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-1, 3-thiazol-5-yl)methyl]piperazin-1-yl} acetate
Figure imgf000278_0001
To a solution of N- {2- [5- (chloromethyl) -I13-thiazol-2-yl]- lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (0.700 g) in N,N- dimethylformamide (16 ml) were- added ethyl piperazin-1-ylacetate (0'.568 g) and triethylamine (0.46 ml), and the mixture was stirred at room temperature for 5 hr. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (ethyl acetate :hexane = 50:50 - 100:0), and recrystallized from ethyl acetate-hexane to give the title compound (0.531 g, yield 57%) as colorless crystals. melting point 167-169°C.
Example 209 {4- [ (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol- 2-yl}-l, 3-thiazol-5-yl) methyl] piperazin-1-yl}acetic acid
Figure imgf000279_0001
To a solution of ethyl {4- [ (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l, 3-thiazol-5- yl) methyl]piperazin-1-yl} acetate (0.490 g) in a mixed solvent of tetrahydrofuran (10 ml) and methanol (5 ml) was added 8N aqueous sodium hydroxide solution (1.5 ml), and the mixture was stirred at room temperature for 16 hr. Saturated aqueous ammonium chloride solution was added to the reaction solution, and the precipitated crystals were collected by filtration, washed with ethyl acetate and water, and dried to give the title compound (0.360 g, yield 57%) as colorless crystals. melting point 171-173°C.
Example 210 N-methyl-2-{4- [ (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-!, 3-thiazol-5- yl) methyl] piperazin-1-yl} acetamide
Figure imgf000279_0002
To a solution of {4- [ (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l, 3-thiazol-5~ yl) methyl] piperazin-1-yl} acetic acid (0.200 g) in N,N- dimethylformamide (10 ml) were added IH-I, 2, 3-benzotriazol-l-ol (0.061 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.087 g) and 2.0 mol/L solution of N-methylamine in THF (0.25 ml), and the mixture was stirred at room temperature for 15 hr. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol) , and recrystallized from ethyl acetate-hexane to give the title compound (0.150 g, yield 67%) as colorless crystals. melting point 190-192°C.
Example 211 N/N-dimethyl-2-{4- [ (2-{7-[ (2-thienylsulfonyl) amino] - lH-indol-2-yl}-l, 3-thiazol-5-yl)methyl]piperazin-l-yl}acetamide
Figure imgf000280_0001
To a solution of N-{2- [5- (chloromethyl) -1, 3-thiazol-2-yl] - lH-indol-7-yl}thiophene-2-sulfonamide (0.250 g) in N,N- dimethylformamide (6 ml) were added N,N-dimethyl-2-piperazin-l- ylacetamide (0.208 g) and triethylamine (0.17 ml), and the mixture was stirred at room temperature for 15 hr. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol) , and recrystallized from ethyl acetate-hexane to give the title compound (0.230 g, yield 69%) as colorless crystals. MS m/z 545 (M+H+) .
Example 212 ethyl {4- [ (2- {7- [ (2-thienylsulfonyl) amino] -lH-indol- 2-yl}-l, 3-thiazol-5-yl) methyl]piperazin-l-yl}acetate
Figure imgf000280_0002
To a solution of N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] - lH-indol-7-yl}thiophene-2-sulfonamide (0.460 g) in N,N- dimethylformamide (12 ml) were added ethyl piperazin-1-ylacetate (0.385 g) and triethylamine (0.31 ml), and the mixture was stirred at room temperature for 15 hr. Saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was recrystallized from tetrahydrofuran- hexane to give the title compound (0.507 g, yield 83%) as colorless crystals. MS m/z 54β(M+H+) .
Example 213 {4-[ (2-{7-[ (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 1, 3-thiazol-5-yl) methyl]piperazin-1-yl} acetic acid
Figure imgf000281_0001
To a solution of ethyl {4-[ (2-{7-[ (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l, 3-thiazol-5- yl) methyl] piperazin-1-yl} acetate (0.500 g) in a mixed solvent of tetrahydrofuran (15 ml) and methanol (5 ml) was added 2N aqueous sodium hydroxide solution (1.5 ml), and the mixture was stirred at 50°C for 2 hr. 10% Aqueous citric acid solution, ethyl acetate, sodium chloride and tetrahydrofuran were successively added to the reaction solution, and the precipitated crystals were collected by filtration, washed with ethyl acetate, and dried to give the title compound (0.360 g, yield 76%) as colorless crystals. MS m/z 518 (M+H+) .
Example 214 N-methyl-2- { 4- [ (2-{7- [ (2-thienylsulfonyl) amino] -IH- indol-2-yl }-1, 3-thiazol-5-yl)methyl]piperazin-1-yl } acetamide
Figure imgf000282_0001
To a solution of {4- [ (2-{7- [ (2-thienylsulfonyl) amino] -IH- indol-2-yl }-1, 3-thiazol-5-yl) methyl] piperazin-1-yl } acetic acid (0.230 g) in N,N-dimethylformamide (4 ml) were added IH-I, 2, 3- benzotriazol-1-ol (0.066 g) and N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (0.093 g) , and the mixture was stirred at 50°C for 1 hr. A 2.0 mol/L solution of N-methylamine in THF (0.60 ml) was added to the reaction solution, and the mixture was stirred at 50°C for 1 hr. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol) , and recrystallized from tetrahydrofuran-hexane to give the title compound (0.100 g, yield 42%) as colorless crystals. MS m/z 531 (M+H+) .
Example 215 N- [2- (8-benzyl-l-thia-3, 8-diazaspiro [4.5] dec-2-en-2- yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide
Figure imgf000282_0002
To a solution of N- [ (l-benzyl-4-hydroxypiperidin-4- yl) methyl] -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carboxamide (1.30 g) in a mixed solvent of toluene (60 ml) and tetrahydrofuran (30 ml) was added Lawesson's reagent (.1.94 g) , and the mixture was heated under reflux for 3 hr. The reaction solution was concentrated under reduced pressure, and the residue was purified by basic silica gel column chromatography (ethyl acetate:hexane = 5:95 - 40:60), and recrystallized from ethyl acetate-hexane to give the title compound (0.063 g, yield 5%) as colorless crystals. melting point 197-199°C. "
Example 216 N- {2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3-thiazol-2- yl] -lH-indol-7-yl}-N-methylthiophene~2-sulfonaird.de
Figure imgf000283_0001
In the same manner as in Example 200, the title compound (0.240 g, 49%) was obtained as colorless crystals from N- [2- (benzylthio) -3, 3-dimethoxypropyl] -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide (0.628 g) . melting point 138-140°C. Example 217 N-methyl-N-{2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide dihydrochloride
Figure imgf000283_0002
To a solution of triphenylphosphine oxide (0.409 g) in acetonitrile (3.6 ml) was added dropwise trifluoromethanesulfonic anhydride (0.124 ml) under ice-cooling, and the mixture was stirred at 0°C for 10 min. A solution of N- [2- (benzylthio) -3- (morpholino) propyl] -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide (0.215 g) in acetonitrile (3.6 ml) was added to the reaction solution, and the mixture was stirred at 0°C for 10 min. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction, solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (ethyl acetate rhexane = 30:70 - 100:0). The obtained product was dissolved in ethyl acetate, 4N hydrogen chloride-ethyl acetate solution was added to give the title compound (0.092 g, yield 45%) as pale-yellow crystals. melting point 218-221°C.
Example 218 N- (2-{5- [ (4-acetylpiperazin-l-yl) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2- sulfonamide
Figure imgf000284_0001
In the same manners as in Example 202 and Example 203, the title compound (0.026 g, yield 11% in two steps) was obtained as colorless crystals from tert-butyl 4-{2- (benzylthio) -3- [ ({7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2- yl} carbony1) amino] propyl}piperazine-l-carboxylate (0.330 g) . melting point 177-180°C.
Example 219 N- (2- {5- [ (3, 3-difluoropiperidino) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2- sulfonamide
Figure imgf000284_0002
In the same manner as in Example 200, the title compound (0.013 g, yield 10%) was obtained as colorless crystals from N- [2- (benzyl thio) -3- (2 , 2-difluoromorpholino) propyl] -7- [methyl (2- thienylsulfonyl ) amino] -lH-indole-2-carboxamide (0 .155 g) . melting point 205-2080C .
Example 220 N- [2- (5-cyano-4, 5-dihydro-l, 3-thiazol-2-yl) -IH- indol-7-yl] -N-methylthiophene-2- sulfonamide
Figure imgf000285_0001
In the same manner as in Example 206, the title compound (2. 32 g, 82%) was obtained as colorless crystals from N- [2- (benzylthio) -2-cyanoethyl] -7- [methyl (2-thienylsulfonyl) amino] - IH- indole- 2 -carboxamide ( 3. 60 g) . melting point 188-189°C .
Example 221 2- { 7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2- yl } — 4, 5-dihydro-l, 3-thiazole-5-carboxylic acid
Figure imgf000285_0002
In the same manner as in Example 207, the title compound (0.259 g, 88%) was obtained as colorless crystals from N- [2- (5- cyano-4, 5-dihydro-l, 3-thiazol-2-yl) -IH-indol-7-yl] -N- methylthiophene-2-sulfonamide (0.280 g) . melting point 235-238°C. Example 222 N- {2- [5- (aminomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] IH-indol-7-yl }-N-methylthiophene-2-sulfonamide
Figure imgf000285_0003
To a suspension of lithium aluminum hydride (0.015 g) in tetrahydrofuran (2 ml) was added dropwise a solution of N- [2- (5- cyano-4, 5-dihydro-l, 3-thiazol~2-yl) -lH-indol-7-yl] -N- methylthiophene-2-sulfonamide (0.080 g) in tetrahydrofuran (3 ml) under ice-cooling, and the reaction mixture was stirred at
0°C for 2 hr. IN Aqueous ' sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (ethyl acetate : hexane = 80:20 - 100:0), and recrystallized from hexane-ethyl acetate to give the title compound (0.029 g, yield 36%) as colorless crystals. melting point 185-187°C. Example 223 2- {7- [methyl (2-thienylsulfonyl) amino] -IH-indol-2- yl}-4, 5-dihydro-l, 3-thiazole-5-carboxamide
Figure imgf000286_0001
To a solution of 2- {7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazole-5-carboxylic acid (0.090 g) in N,N-dimethylformamide (6 ml) were added IH-I, 2,3- benzotriazol-1-ol (0.034 g) and N- [3- (dimethylamino) propyl] -Nf - ethylcarbodiimide hydrochloride (0.049 g) , and the mixture was stirred at 50°C for 45 min. 28% Aqueous ammonia (2 ml) was added to the reaction, and the mixture was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (ethyl acetate:methanol = 100:0 - 90:10), and recrystallized from hexane-ethyl acetate to give the title compound (0.010 g, yield 11%) as colorless crystals. melting point 230-232°C.
Example 224 N-methyl-N-{2- [5- (pyrrolidin-1-ylcarbonyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000287_0001
In the same manner as in Example 223, the title compound ( 0. 034 g, yield 47%) was obtained as colorless crystals from 2- { 7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl }— 4, 5-dihydro- l , 3-thiazole-5-carboxylic acid ( 0.065 g) and pyrrolidine ( 0 .025 ml) . melting point 202-204°C .
Example 225 methyl 2- { 7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl } -4 , 5-dihydro-l, 3-thiazole-5-carboxylate
Figure imgf000287_0002
To a solution of 2-{7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4,5~dihydro-l,3-thiazole-5-carboxylic acid (1.48 g) in N,N-dimethylformamide (30 ml) were added IH-I, 2,3- benzotriazol-1-ol (0.716 g) , N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (1.02 g) , N, N-dimethyl-4- aminopyridine (0.043 g) and methanol (0.215 ml), and the mixture was stirred at room temperature for 3 days. 10% Aqueous citric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate :hexane = 50:50 - 100:0), and recrystallized from hexane-ethyl acetate to give the title compound (1.00 g, yield 65%) as colorless crystals. melting point 175-176°C.
Example 226 N-{2- [5- (1-hydroxy-l-methylethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000288_0001
To a solution of methyl 2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazole- 5-carboxylate (0.181 g) in tetrahydrofuran (10 ml) was added 1.0 mol/L methylmagnesium bromide (1.04 ml), and the mixture was stirred at 50°C for 5 hr. Saturated aqueous sodium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate :hexane = 20:80 - 80:20), and recrystallized from hexane-ethyl acetate to give the title compound (0.054 g, yield 30%) as pale-yellow crystals. melting point 174-175°C.
Example 227 N- {2- [5- (hydroxymethyl) -4, 5-dihydro-l, 3-thiazol-2- yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000288_0002
To a solution of methyl 2- {7- [methyl (2- thienylsulfonyl) amino] -IH-indol-2-yl}-4, 5-dihydro-l, 3-thiazole- 5-carboxγlate (0.126 g) in tetrahydrofuran (5 ml) were successively added lithium borohydride (0.035 g) and methanol (1 ml), and the mixture was stirred at room temperature for 2 hr.- Saturated aqueous sodium chloride solution was added to the 5 reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate :hexane = 20:80 - 10 100:0), and recrystallized from hexane-ethyl acetate to give the title compound (0.105 g, yield 89%) as colorless crystals. melting point 207-208°C.
Example 228 N-methyl-N- (2-{5- [ (4-oxohexahydropyrazino [2, 1- c] [l,4]oxazin-8 (IH) -yl) methyl] -l,'3-thiazol-2-yl}-lH-indol-7- 15 yl) thiophene-2-sulfonamide
Figure imgf000289_0001
A mixture of N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -lH- indol-V-ylJ-N-methylthiophene^-sulfonamide (150 mg) , triethylamine (150 μL) , hexahydropyrazino [2, 1-c] [1, 4] oxazin- 20 4 (3H) -one hydrochloride (135 mg) and N,N-dimethylformamide (2 ml) was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was 25 subjected to silica gel column chromatography to give the title compound (85 mg, yield 45%) as a colorless amorphous form from a fraction eluted with ethyl acetate. MS 544. (M+1) . Example 229 N-methyl-N- (2-{5- [ (3-oxotetrahydro [1,3] oxazolo [3,4- a]pyrazin-7 (IH) -yl) methyl]-l, 3-thiazol-2-yl}-lH-indol-7- 30 yl) thiophene-2-sulfonamide
Figure imgf000290_0001
A mixture of N- {2- [5- (chloromethyl) -I13-thiazol-2-yl] -IH- indol-7-yl}-N-methylthiophene-2-sulfonamide (150 mg) , triethylamine (150 μL) , hexahydro [1, 3]oxazolo [3, 4-a]pyrazin-3- one hydrochloride (125 mg) and N,N-dimethylformamide (2 ml) was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title' compound (103 mg, yield 56%) as a colorless amorphous form from a fraction eluted with ethyl acetate. MS 530 (M+l). Example 230 N-methyl-N- (2-{5- [ (2-oxo-l-oxa-3, 8- diazaspiro [4.5] dec-8-yl)methyl] -1, 3-thiazol-2-yl }-lH-indol-7- yl) thiophene-2-sulfonamide
Figure imgf000290_0002
A mixture of N-{2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -IH- indol-7-yl}-N-methylthiophene-2-sulfonamide (150 mg) , triethylamine (150 μL) , l-oxa-3, 8-diazaspiro [4.5]decan-2-one (110 mg) and N,N-dimethylformamide (2 ml) was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSU4), and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (82 mg, yield 43%) as colorless crystals from a fraction eluted with ethyl acetate, melting point 224°C. Example 231 N- (2-{5- [ (4-acetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) -N- (cyclopropylmethyl) thiophene-2- sulfonamide
Figure imgf000291_0001
A mixture of N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -IH- indol-7-yl}-N- (cyclopropylmethyl) thiophene-2-sulfonamide (100 mg) / triethylamine (60 μL) , 1-acetylpiperazine (55 mg) and N,N- dimethylformamide (3 ml) was stirred at room temperature for 16 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (91 mg, yield 76%) as colorless crystals from a fraction eluted with ethyl acetate. MS 556 (M+1) .
Example 232 N- (2-{5- [ (4-acetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) -N-ethylthiophene-2-sulfonamide
Figure imgf000291_0002
In the same manner as in Example 186, the title compound (180 mg, yield 50%) was obtained as colorless crystals from N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- ethylthiophene-2-sulfonamide (300 mg) and 1-acetylpiperazine (176 mg) . MS 530 (M+l) . Example 233 N- (2- { 5- [ ( 4-acetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl } -lH-indol-7-yl) -N- ( ethoxyethyl ) thiophene-2- sulfonamide
Figure imgf000292_0001
In the same manner as in Example 186, the title compound
( 48 mg, yield 50%) was obtained as colorless crystals from N- {2- [ 5- (chloromethyl) -1, 3-thiazol-2-yl] -lH-indol-7-yl }-N- ( ethoxyethyl) thiophene-2-sulfonamide ( 82 mg) and 1- acetylpiperazine (176 mg) . MS 574 (M+l) . Example 234 N-methyl-N- (2- { 5- [ (2-oxopyrrolidin-l-yl) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide
Figure imgf000292_0002
A mixture of N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -IH- indol-7-yl}-N-methylthiophene-2-sulfonamide (424 mg) , triethylamine (693 μL) , ethyl 4-aminobutanoate dihydrochloride (335 mg) and N,N-dimethylforrαamide (5 ml) was stirred at room temperature for 16 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give ethyl 4-{ [ (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-1, 3-thiazol-5- yl) methyl] amino}butanoate as a crude product from a fraction eluted with ethyl acetate. A mixture of this product, methanol (2 ml), IN aqueous sodium hydroxide solution (4 ml) and tetrahydrofuran (4 ml) was stirred at 450C for 20 hr. The mixture was neutralized with IN aqueous hydrochloric acid solution, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (49 mg, yield 10%) as colorless crystals from a fraction eluted with ethyl acetate. MS 473 (M+l).
Example 235 N-ethyl-N- (2-{5- [ (3-oxopiperazin-l-yl) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide
Figure imgf000293_0001
In the same manner as in Example 186, the title compound (176 mg, yield 52%) was obtained as colorless crystals from N-
{2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -lH~indol-7-yl}-N- ethylthiophene-2-sulfonamide (300 mg) and piperazin-2-one (137 mg) . MS 502 (M+l) .
Example 236 N- { 2- [5- ( 5, 6-dihydro [ 1 , 2 , 4 ] triazolo [ 4, 3-a] pyrazin- 7 ( 8H) -ylmethyl) -l , 3-thiazol-2-yl ] -lH-indol-7-yl } -N- ethylthiophene-2-sulfonamide
Figure imgf000293_0002
In the same manner as in Example 228, the title compound (280 mg, yield 53%) was obtained as colorless crystals from 5, 6,7, 8-tetrahydro [1,2,4] triazolo [4, 3-a]pyrazine monohydrochloride (360 mg) prepared according to J. Med. Chem. 2005, 48, 141-151 and N-{2- [5- (chloromethyl) -1, 3-thiazol-2-yl] - lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (438 mg) . MS 526 (M+l) .
Example 237 N-ethyl-N- (2-{5- [ (4-methyl-3-oxopiperazin-l- yl)methyl] -1, 3-thiazol-2-yl}-lH-indol-7-yl) thiophene-2- sulfonaiαide
Figure imgf000294_0001
In the same manner as in Example 186, the title compound (280 mg, yield 80%) was obtained as colorless crystals from N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- ethylthiophene-2-sulfonamide (300 mg) and l-methylpiperazin-2- one (300 mg) . MS 516 (M+l) .
Example 238 N-ethyl-N- [2- (5-{ [3- (trifluoromethyl) -5, 6- dihydro [1, 2, 4] triazolo [4, 3-a]pyrazin-7 (8H) -yl] methyl }-l, 3- thiazol-2-yl) -lH-indol-7-yl] thiophene-2-sulfonamide
Figure imgf000294_0002
In the same manner as in Example 228, the title compound (220 mg, yield 54%) was obtained as colorless crystals from 3- (trifluoromethyl) -5, 6,7, 8-tetrahydro [1, 2, 4] triazolo [4, 3- a]pyrazine monohydrochloride (300 mg) prepared according to J. Med. Chem. 2005, 48, 141-151 and N- {2- [5- (chloromethyl) -1, 3- thiazol-2-yl]-lH-indol-7-yl}-N-ethylthiophene-2-sulfonamide (280 mg) . MS 594 (M+l) . Example 239 N- ethyl -N- (2- { 5- [ (3-methyl-5, 6- dihydro [ 1, 2, 4 ] triazolo [4, 3-a] pyrazin-7 ( 8H) -yl) methyl] -1, 3- thiazol-2-yl } -lH-indol-7-yl ) thiophene-2-sulf onamide
Figure imgf000295_0001
A mixture of 3-methyl [1,2,4] triazolo [4, 3-a]pyrazine (81 mg) prepared according to Heterocycles, 1989, 28, 239-248, methanol (10 ml) and 10% palladium carbon (30 mg) was stirred for 3 days under hydrogen atmosphere. The mixture was filtrated through celite, and the filtrate was concentrated to give an oil. In the same manner as in Example 186, the title compound (31 mg, yield 7%) was obtained as colorless crystals from this oil and N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- ethylthiophene-2-sulfonamide (300 mg) . MS 540 (M+1) . Example 240 N- {2- [5- (5, 6-dihydro [1, 2, 4] triazolo [4, 3-a]pyrazin- 7 (8H) -ylmethyl) -1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- methylthiophene-2-sulfonamide •
Figure imgf000295_0002
In the same manner as in Example 228, the title compound (49 mg, yield 21%) was obtained as colorless crystals from 5, 6,7, 8-tetrahydro [1,2, 4] triazolo [4,.3-a]pyrazine monohydrochloride (240 mg) prepared according to J. Med. Chem. 2005, 48, 141-151 and N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] - IH-indol-7-yl}-N-methylthiophene-2-sulfonamide (200 mg) . MS 512 (M+1) . Example 241 N-methyl-N- (2- {5- [(4-methyl-3-oxopiperazin-l- yl)methyl]-l,3-thiazol-2-yl}-lH-indol-7-yl)thiophene-2- sulfonamide
Figure imgf000296_0001
In the same manner as in Example 186, the title compound (50 mg, yield 21%) was obtained as colorless crystals from N-{2- [5- (chloromethyl)-l,3-thiazol-2-yl]-lH-indol-7-yl}-N- methylthiophene-2-sulfonamide (200 mg) and l-methylpiperazin-2- one (200 mg) . MS 502 (M+l). Example 242 N-methyl-N- (2- {5- [ (3-methyl-5, 6- dihydro [1, 2, 4] triazolo [4, 3-a]pyrazin-7 (8H) -yl) methyl] -1, 3- thiazol-2-yl}-lH-indol-7-yl) thiophene-2-sulfonamide
Figure imgf000296_0002
A mixture of 3-methyl [1,2, 4] triazolo [4, 3-a]pyrazine (81 mg) prepared according to Heterocycles, 1989, 28, 239-248, methanol (10 ml) and 10% palladium carbon (30 mg) was stirred for 3 days under hydrogen atmosphere. The mixture was filtrated through celite, and the filtrate was concentrated to give an oil. In the same manner as in Example 186, the title compound (50 mg, yield 19%) was obtained as colorless crystals from this oil and N-{2-[5-(chloromethyl)-l,3-thiazol-2-yl]-lH-indol-7-yl}-N- methylthiophene-2-sulfonamide (216 mg) . MS 526 (M+l). Example 243 N-methyl-N- [2- (8-oxa-l-thia-3-azaspiro [4.5] dec-2-en- 2-yl) -lH-indol-7-yl] thiophene-2-sulfonamide
Figure imgf000297_0001
To a solution of triphenylphosphine oxide (1.15 g) in acetonitrile (20 ml) was slowly added trifluoromethanesulfonic anhydride (0.35 ml) at 0°C, and the mixture was stirred for 10 min. N- { [4- (Benzylthio) tetrahydro-2H-pyran-4-yl]methyl}-7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (0.76 g) was added, and the reaction mixture was stirred at 10°C for 1 hr. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.22 g, yield 36%) as colorless crystals from a fraction eluted with ethyl acetate- hexane (1:1, volume ratio), melting point 189-191°C. Example 244 N-methyl-N- [2- (l-thia-3, 8-diazaspiro [4.5] dec-2-en-2- yl) -lH-indol-7-yl] thiophene-2-sulfonamide hydrochloride HCI
Figure imgf000297_0002
In the same manner as in Example 243, N-methyl-N- [2- (1- thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl) -IH-indol-7-yl] thiophene- 2-sulfonamide (515 mg, 63%) was obtained as colorless crystals from tert-butyl 4- (benzylthio) -4-{ [ ({7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2- yl}carbonyl) amino]methyl}piperidine-l-carboxylate (1.20 g) .
To a mixture of the obtained crystals (100 mg) and methanol (5 ml) was added 10% hydrogen chloride-methanol solution (0.5 ml) at 0°C. The reaction solution was concentrated, and the resulting crystals were washed with methanol, and dried to give the title compound (53 rag, yield 50%) as yellow crystals. melting point 248-25O0C (decomposition) . Example 245 N- [2- (8-acetyl-l-thia-3, 8-diazaspiro [4.5] dec-2-en-2- yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonarαide
Figure imgf000298_0001
To a solution of N-methyl-N- [2- (l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide (100 mg) , pyridine (0.022 ml), tetrahydrofuran (2 ml) and acetonitrile (1 ml) was slowly added acetic anhydride
(0.022 ml) at 0°C, and the mixture was stirred for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed successively with IN hydrochloric acid, saturated aqueous sodium hydrogencarbonate and saturated brine, dried (Na2SO4) , and concentrated. The obtained crystals were recrystallized from tetrahydrofuran-heptane to give the title compound (88 mg, yield
82%) as colorless crystals, melting point 216-218°C. Example 246 N, N-dimethyl-2-{7- [methyl (2-thienylsulfonyl) amino] - IH-indol-2-yl}-l-thia-3, 8-diazaspiro [4.5] dec-2-ene-8-carboxamide
Figure imgf000298_0002
To a solution of N-methyl-N- [2- (l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide (82 mg) and dimethylcarbamoyl chloride (100 μL) in tetrahydrofuran (3 ml) was added triethylamine (100 μL) , and the mixture was stirred at room temperature for 30 min. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (43 mg, yield 46%) as colorless crystals from a fraction eluted with ethyl acetate, melting point 245°C. Example 247 N-methyl-N- (2-{8- [( 1-methyl-lH-imidazol-2- yl) methyl] -l-thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide
Figure imgf000299_0001
To a solution of N-methyl-N- [2- (l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide (100 mg) and l-methyl-lH-imidazole-2-carbaldehyde (33 mg) in tetrahydrofuran (3 ml) was added sodium triacetoxyborohydride (125 mg) , and the mixture was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (14 mg, yield 12%) as colorless crystals from a fraction eluted with ethyl acetate, melting point 103°C. Example 248 N-methyl-N-{2- [8- (methylsulfonyl) -l-thia-3, 8- diazaspiro[4.5]dec-2-en-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000300_0001
To a solution of N-methyl-N- [2- (l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide (82 mg) and methanesulfonyl chloride (100 μL) in tetrahydrofuran (3 ml) was added triethylamine (100 μL) , and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, and water was added. The precipitated crystals were collected by filtration, and washed with water. The obtained crystals were recrystallized from tetrahydrofuran to give the title compound (42 mg, yield 36%) as colorless crystals, melting point 251°C. Example 249 N- [2- (8-ethyl-l-thia-3, 8-diazaspiro [4.5] dec-2-en-2- yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide
Figure imgf000300_0002
To a solution of N-methyl-N- [2- (l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide (100 mg) and acetaldehyde (90%) (100 μL) in tetrahydrofuran (3 ml) was added sodium triacetoxyborohydride (125 mg) , and the mixture was stirred at room temperature for 30 min. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography .to give the title compound (83 ing, yield 80%) as colorless crystals from a fraction eluted with ethyl acetate. melting point 215°C.
Example 250 N- (2- {5- [ (4-iacetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl}-4-methyl-lH-indol-7-yl)-N-methylthiophene-2- sulfonaitiide
Figure imgf000301_0001
To a solution of N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] - 4-methyl-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (0.15 g) and N-acetylpiperazine (90 mg) in N,N-dimethylformamide (10 ml) was added potassium carbonate (120 mg) under ice-cooling, and the mixture was stirred at room temperature for 18 hr. The reaction solution was poured into water, and the mixture was extracted with ethyl acetate. 'The extract was washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate : hexane=l : 1 - 7:3), and the obtained pale-yellow oil was crystallized from ethyl acetate-hexane to give the title compound (95 mg, yield 52%) as colorless crystals, melting point
171-1720C.
Example 251 N- (2-{5- [ (3-hydroxypyrrolidin-l-yl) methyl] -1, 3- thiazol-2-yl}-4-methyl~lH-indol-7-yl) -N-methylthiophene-2- sulfonamide
Figure imgf000302_0001
To a solution of N- {2- [5- (chloromethyl) -1, 3-thiazol-2-yl] - 4-methyl-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (0.13 g) and 3-pyrrolidinol (60 mg) in N, N-dimethylformamide (8 ml) was added potassium carbonate (110 mg) under ice-cooling, and the mixture was stirred at room temperature for 18 hr. The reaction solution was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate:hexane=l : 1 - 7:3), and the obtained pale-yellow crystals were washed with ethyl acetate-hexane to give the title compound (85 mg, yield 59%) as pale-yellow prism crystals, melting point 190-1910C. MSMSg(MH+) Example 252 N- (2-{5- [ (4-acetylpiperazin-l-yl) methyl] -1, 3- thiazol-2-yl}-4-methyl-lH-indol-7-yl)-N-ethylthiophene-2- sulfonamide
Figure imgf000302_0002
To a solution of N-methyl-N- {2- [5- (chloromethyl) -1,3- thiazol-2-yl] -4-methyl-lH-indol-7-yl}thiophene-2-sulfonamide (0.20 g) and N-acetylpiperazine (0.11 g) in N, N- dimethylformamide (10 ml) was added potassium carbonate (0.14 g) under ice-cooling, and the mixture was stirred at room temperature for 18 hr. The reaction solution was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to basic silica gel column chromatography (ethyl acetate:hexane=3: 7 - 6:4), and the obtained colorless crystals was recrystallized from ethyl acetate-hexane to give the title compound (112 ing, yield 47%) as colorless crystals, melting point 157-158°C.
Reference Example 94 optically active form of N- [2- (benzylthio) -3-morpholinopropyl] -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000303_0001
N- [2- (Benzylthio) -3-morpholinopropyl] -7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (2.0 g) was subjected to an optical resolution using chiral column [Column; CHIRALPAK AD 50 mmIDχ500mmL, Mobile phase;
Hexane/EtOH=50/50, Flow rate; 60 mL/min, Temperature; 40°C,
Detection; UV 220 nm, Injection; 120 mg in mobile phase (25 mL) /load] to give an optically active form (retention time: longer, 980 mg) and (retention time: shorter, 984 mg) . retention time: longer, MS m/z 585(M+H+). retention time: shorter, MS m/z 585(M+H+).
Reference Example 95 N- [2- (benzylthio) -3- (1, 4-dioxa-8- azaspiro[4.5]dec-8-yl) -2-methylpropyl] -7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide
Figure imgf000304_0001
In the same manner as in Reference Example 41, the title compound (0.72 g, yield 53%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -2-methyl-3-oxopropyl] - 7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (1.00 g) and 1, 4-dioxa-8-azaspiro [4.5] decane (0.54 g) . MS: 655 (MH+) .
Reference Example 96 8- (benzylthio) -8- (nitromethyl) -1, 4- dioxaspiro [4.5] decane
Figure imgf000304_0002
A mixture of 1, 4-dioxaspiro [4.5] decan-8-one (6.0O g), benzylmercaptan (5.00 iriL) , nitromethane (20 mL) , ethylenediamine (2.83 mL) and acetonitrile (25 mL) was heated under reflux for 3 hr. The reaction mixture was concentrated, and the obtained residue was subjected to silica gel column chromatography to give the' title compound (8.96 g, yield 72%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (2:3, volume ratio), melting point 121-122°C. Reference Example 97 N- { [8- (benzylthio) -1, 4- dioxaspiro [4.5]dec-8-yl]methyl}-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000305_0001
To a mixture of lithium aluminum . hydride (2.63 g) and tetrahydrofuran (50 mL) was added. a solution of 8- (benzylthio) -8- (nitromethyl) -1, 4-dioxaspiro [4.5] decane (8.96 g) in tetrahydrofuran (80 mL) over 1 hr at room temperature, and the reaction mixture was stirred at room temperature for 30 min. Ethanol (15 mL) and water (10 mL) was successively added, and the resulting inorganic salt was removed by filtration. The filtrate was concentrated, and the residue was dissolved in ethyl acetate. The solution was dried (MgSO4), and concentrated to give 1- [8- (benzylthio) -1, 4- dioxaspiro [4.5] dec-8-yl]iαethanamine (10.02 g) as a crude oil.
To a mixture of the above-mentioned crude oil (1.30 g) , 7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxylic acid (1.00 g) , lH-l,2,3-benzotriazol-l-ol (0.48 g) and N, N- dimethylformamide (10 mL) was- added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.68 g) at room temperature, and the mixture was stirred at
50°C for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (1.45 g, yield 80%) as colorless crystals from a fraction eluted with ethyl acetate, melting point 211-2.12°C.
Reference Example 98 N- { [1- (benzylthio) -4- oxocyclohexyl] methyl}-7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxamide
Figure imgf000306_0001
A mixture of N- { [8- (benzylthio) -1, 4-dioxaspiro [4.5] dec- 8-yl]methyl}-7- [methyl (2-thienylsulfonyl) amino] -IH-indole-2- carboxamide (1.21 g) and acetic acid (15 πiL) was added at 80°C for 24 hr, water was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.79 g, yield 71%) as a colorless amorphous solid from a fraction eluted with tetrahydrofuran- methanol (1:1, volume ratio). MS:568(MH+).
Reference Example 99 ethyl 7- [ [ (2-chloropyridin-3- yl) sulfonyl] (methyl) amino] -4-methyl-lH-indole-2-carboxylate
Figure imgf000306_0002
To a solution of ethyl 7-amino-4-methyl-lH-indole-2- carboxylate (1.00 g) in pyridine (10 mL) was added 2- chloropyridine-3-sulfonyl chloride (1.99 g) at 0°C, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated, ,10% aqueous citric acid solution was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with 10% aqueous citric acid solution and saturated brine, dried (MgSO4), and concentrated to give ethyl 7-{ [ (2-chloropyridin-3- yl) sulfonyl] amino} -4-methyl-lH-indole-2-carboxylate (1.32 g) as a crude oil .
A mixture of the above-mentioned crude oil (1.32 g) , methyl iodide (0.20 mL) , potassium carbonate (0.46 g) and N, N- dimethylformamide (8 mL) was stirred at room temperature for 4 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.86 g, yield 63%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (1:2, volume ratio), melting point 158-159°C. Reference Example 100 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 7- [ [ (2-chloropyridin-3-yl) sulfonyl] (methyl) amino] -4-methyl-lH- indole-2-carboxamide
Figure imgf000307_0001
A mixture of ethyl 7- [ [ (2-chloropyridin-3- yl) sulfonyl] (methyl) amino] -4-methyl-lH-indole-2-carboxylate (0.86 g) , IN aqueous sodium hydroxide solution (4.2 mL) , methanol (6 mL) and tetrahydrofuran (6 mL) was stirred at 50°C0 for 1 hr. 10% Aqueous citric acid solution was added to the reaction mixture, and the mixture was concentrated. The resulting crystals were collected by filtration, washed with water, dried, and concentrated to give 7- [ [ (2-chloropyridin-3- yl) sulfonyl] (methyl) amino] -4-methyl-lH-indole-2-carboxylic5 acid as crude crystals.
To a mixture of the above-mentioned crude crystals, 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (0.82 g) , IH-I, 2,3- benzotriazol-1-ol (0.85 g) and N,N-dimethylformamide (10 mL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimideo hydrochloride (1.21 g) at room temperature, and the mixture was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (1.07 g, yield 85%) as a pale-yellow oil from a fraction eluted with ethyl acetate-hexane (1:1, volume ratio) .
1H-NMR (CDCl3) δ: 2.50 (3H, s) , 2.94 (IH, q, J=5.β Hz), 3.40 (3H, S)- , 3.47 (3H, s), 3.50-3.62 (4H, m) , 3.80-3.92 (3H, m) , 4.36 (IH, d, J=4.8 Hz), 6.66-6.78 (4H, m) , 7.14-7.37 (6H, m) , 8.04 (IH, dd, J=2.1, 8.1 Hz), 8.50 (IH, dd, J=2.1, 4.8 Hz), 9.54 (IH, brs) .
Reference Example 101 N- [2- (benzylthio) -3-oxopropyl] -7- [ [ (2- chloropyridin-3-yl) sulfonyl] (methyl) amino] -4-methy1-lH-indoIe- 2-carboxamide
Figure imgf000308_0001
In the same manner as in Reference Example 40, the title compound (1.00 g, quantitative) was obtained as a yellow oil from N- [2- (benzylthio) -3, 3-dimethoxypropyl] -7- [ [ (2- chloropyridin-3-yl) sulfonyl] (methyl) amino] -4-methyl-lH-indole- 2-carboxamide (1.07 g) . MS:557(MH+).
Reference Example 102 N- [2- (benzylthio) -3-morpholinopropyl] -7- [ [ (2-chloropyridin-3-yl) sulfonyl] (methyl) amino] -4-methyl-lH- indoIe-2-carboxamide
Figure imgf000309_0001
In the same manner as in Reference Example 41, the title compound (1.10 g, yield 98%) was obtained as a yellow amorphous solid from N- [2- (benzylthio) -3-oxopropyl] -7- [ [ (2- chloropyridin-3-yl) sulfonyl] (methyl) amino] -4-methyl-lH-indole- 2-carboxamide (1.00 g) and morpholine (0.31 g) . MS:628(MH+). Reference Example 103 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 4-methyl-7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carboxamide
Figure imgf000309_0002
A solution of 4-methyl-7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxylic acid (3.0 g) , 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (2.4 g) , N- ethyldiisopropylamine (3.7 mL) and 0- (7-azabenzotriazol-l-yl) - N, N, N' ,N' -tetramethyluronium hexafluorophosphate (4.2 g) in N,N-dimethylformamide (40 mL) was stirred at room temperature for 8 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate:hexane=2:3-3:2) to give the title compound (4.75 g, yield: 97%) as a pale-yellow oil. MS:542(MH+). Reference Example 104 N- [2- (benzylthio) -3-oxopropyl] -4-methyl- 1- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000310_0001
A mixture of N- [2- (benzylthio) -3, 3-dimethoxypropyl] -4- methyl-7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carboxamide (4.75 g) , Amberlyst (registered trade mark) 15 ion exchange resin (1.0 g) , acetone (100 mL) and water (0.4 mL) was stirred at room temperature for 20 hr. Amberlyst (registered trade mark) 15 ion exchange resin was filtered off, and washed with ethyl acetate. The filtrate was concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=2: 3- 3:2) to give the title compound (4.4 g, yield: 100%) as a colorless amorphous solid. MS: 528 (MH+).
Reference Example 105 N- [2- (benzylthio) -3-morpholinopropyl] -4- methyl-7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carboxamide
Figure imgf000310_0002
In the same manner as in Reference Example 41, the title compound (1.01 g, yield 85%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3-oxopropyl] -4-methyl- 7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (1.05 g) and morpholine (0.35 g) . MS:599(MH+). Reference Example 106 N- [2- (benzylthio) -2-cyanoethyl] -4- methyl-7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carboxamide
Figure imgf000311_0001
In the same manner as in Reference Example 43, N- [2- (Benzylthio) -3- (hydroxyimino) propyl] -4-methyl-7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (1.20 g) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3-oxopropyl] -4-methyl-7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (1.78 g) . In the same manner as in Reference Example 44, the title compound (1.10 g, yield 95%) was obtained as a yellow amorphous solid from the amorphous solid (1.20 g) . MS:525(MH+).
Reference Example 107 7- [methyl (pyridin-3-ylsulfonyl) amino] - lH-indole-2-carboxylic acid
Figure imgf000311_0002
A mixture of pyridine-3-sulfonyl chloride (10.0 g) , ethyl 7-amino-1- (methoxymethyl) -lH-indole-2-carboxylate (10.0 g) and pyridine (30 mL) was stirred at 50°C for 2 hr. The reaction mixture was concentrated, and the residue was diluted with ethyl acetate (500 mL) and IN hydrochloric acid (500 mL) . The organic layer was washed with saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (ethyl acetate-hexane=3: 7, volume ratio) to give a pale-yellow solid. The obtained solid was dissolved in N, N-dimethylformamide (100 mL) , and potassium carbonate (11.6 g) and methyl iodide (8.0 g) were added. The reaction mixture was stirred at room temperature for 1 hr, and diluted with ethyl acetate (500 itiL) and saturated brine (500 mL) . The organic layer was washed with saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The obtained residue was dissolved in a mixture of 6N hydrochloric acid (80 mL) , tetrahydrofuran (100 mL) and ethanol (100 mL) , and the mixture was stirred at 100°C for 3 hr, and diluted with ethyl acetate (500 mL) and saturated brine (500 mL) . The organic layer was dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The residue was dissolved in a mixture of 2N aqueous sodium hydroxide solution (100 mL) , tetrahydrofuran (100 mL) and ethanol (100 mL) , and the mixture was stirred at 80°C for 1 hr, and diluted with ethyl acetate (500 mL) and IN hydrochloric acid (500 mL) . The organic layer was washed with saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The obtained crude solid was washed with ethyl acetate and hexane to give the title compound (4.92 g, yield 37%) as a pale-yellow solid. LC-MS: 332 (MH+) . Reference Example 108 N- [2- (benzylthio) -3-morpholinopropyl] -7- [methyl (pyridin-3-ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000312_0001
A mixture of 7- [methyl (pyridin-3-ylsulfonyl) amino] -IH- indole-2-carboxylic acid (658 mg) , 2- (benzylthio) -3, 3- dimethoxypropan-1-amine (576 mg) , Q- (7-azabenzotriazol-l-yl) - N, N,N' ,N'-tetramethyluronium hexafluorophosphate (1021 mg) , N, N-diisopropylethylamine (0.86 mL) and N,N-dimethylformamide (10 mL) was stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate (100 mL) and IN hydrochloric acid (100 mL) . The organic layer was washed successively with saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The obtained residue was purified by silica gel column chromatography (ethyl acetate : hexane=4 : 6, volume ratio) to give a pale-yellow solid. A mixture of this solid, Amberlyst (registered trade mark) 15 ion exchange resin (176 mg) , water (88 μL) and acetone (20 mL) was stirred overnight at room temperature. The reaction mixture was filtrated, and the filtrate was concentrated. The obtained residue was purified by silica gel column chromatography (ethyl acetate :hexane=4: 6, volume ratio) to give a pale-yellow oil (790 mg) . A mixture of the obtained oil, morpholine (280 mg) , sodium triacetoxyborohydride (1.02 g) and 1, 2-dichloroethane (5 mL) was stirred at room temperature for 16 hr. The reaction mixture was diluted with ethyl acetate (100 mL) and saturated aqueous sodium hydrogencarbonate (100 mL) . The organic layer was washed with saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The obtained residue was purified by silica gel column chromatography (ethyl acetate :hexane=l : 1, volume ratio) to give the title compound (410 mg, yield 39%) as a white solid. LC-MS: 580 (MH+) . Reference Example 109 7- [methyl (pyridin-3-ylsulfonyl) amino] - lH-indole-2-carbothioamide
Figure imgf000313_0001
A mixture of 7- [methyl (pyridin-3-ylsulfonyl) amino] -IH- indole-2-carboxylic acid (1.99 g) , IH-I, 2, 3-benzotriazol-l-ol (1.22 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (1.73 g) and N,N-dimethylformamide (50 mL) was stirred at 60°C for 30 min. The mixture was cooled to 0°C, 28% aqueous ammonia (912 μL) was added, and the mixture was stirred for 30 rain. The reaction mixture was diluted with ethyl acetate (200 inL) and water (200 ruL) . The organic layer was washed with saturated brine (200 mL) , dried over sodium sulfate, and filtrated, and the filtrate was concentrated. A mixture of the obtained residue (780 mg) , Lawesson's reagent (573 mg) and tetrahydrofuran (10 mL) was stirred at 70°C for 2 hr . Toluene was added to the reaction mixture, and the precipitated solid was collected by filtration to give the title compound (450 mg, yield 55%) as a pale-yellow solid. 1H-NMR(DMSO-d6)δ:3.29 (3H, s) , 6.59 (IH, d, J=7.2 Hz), 6.96 (IH, t, J=7.8 Hz), 7.36 (IH, d, J=2.3 Hz), 7.67 (2H, t, J=7.6 Hz), 8.01 (IH, dd, J=6.3, 2.1 Hz), 8.73 (IH, d, J=I .9 Hz), 8.91 (IH, d, J=3.0 Hz), 9.61 (IH, s) , 9.80 (IH, s) , 10.63 (IH, s) . Reference Example 110 1, 3-thiazole-2-sulfonyl chloride
Figure imgf000314_0001
A mixture of 1, 3-thiazole~2-thiol (5.0 g) , acetic acid (150 mL) and water (50 mL) was cooled to 0°C, and chlorine gas was blown into the reaction mixture at less than 20°C. When the reaction temperature ceased to rise, blowing of the chlorine gas was stopped, and nitrogen gas was blown thereinto. The reaction mixture was diluted with diethyl ether (100 mL) and saturated brine (100 mL) . The organic layer was washed successively with 10% aqueous sodium sulfite solution (100 mL) , aqueous sodium hydrogencarbonate (300 mL) and saturated brine (300 mL) , dried over sodium sulfate, and filtrated, the filtrate was concentrated to give the title compound (6.61 g, yield 84%) as a red oil.
1H-NMR(CDCl3)S: 7.91 (IH, d, J=3.2 Hz), 8.14 (IH, d, J=3.2 Hz). IR (KBr) cm"1 : 1391, 1196. Reference Example 111 7- [methyl (1, 3-thiazol-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid
Figure imgf000315_0001
A mixture of 1, 3-thiazole-2-sulfonyl chloride (2.5 g) , ethyl 7-amino-l- (methoxymethyl) -lH-indole-2-carboxylate (2.47 g) and pyridine (5 itiL) was stirred at room temperature for 16 hr. The reaction mixture was diluted with ethyl acetate (100 itiL) and IN hydrochloric acid (100 itiL) . The organic layer was washed with aqueous sodium hydrogencarbonate and saturated, dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (ethyl acetate :hexane=3 : 7, volume ratio) to give a pale-yellow solid (2.50 g) . This solid was dissolved in N,N-dimethylformamide (50 mL) , potassium carbonate (2.61 g) and methyl iodide (1.79 g) were added, and the reaction mixture was stirred overnight, and diluted with ethyl acetate (200 mL) and saturated brine (200 mL) . The organic layer was washed with saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated to give a pale- yellow oil. The solid was dissolved in a mixture of 6N hydrochloric acid (30 mL) , tetrahydrofuran (30 mL) and ethanol (30 mL) , and the mixture was stirred at 100°C for 3 hr, and diluted with ethyl acetate (100 mL) and saturated brine (100 mL) . The organic layer was dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The residue was dissolved in a mixture of 2N aqueous sodium hydroxide solution (36 mL) , tetrahydrofuran (30 mL) and ethanol (30 mL) , and the mixture was stirred at room temperature for 4 hr, and diluted with ethyl acetate (200 mL) and IN hydrochloric acid (100 mL) . The organic layer was washed with saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The crude solid was washed with ethyl .acetate and hexane to give the title compound (1.65 g, yield 80%) as a pale-yellow solid.
1H-NMR(DMSO-d6)δ:3.40 (3H, s) , 6.74 (IH, d, J=7.6 Hz), 6.98 (IH, t, J=7.4 Hz), 7.18 (IH, s) , 8.24 (2H, s) , 12.2 (IH, s) , 13.1 (IH, brs) . Reference Example 112 7- [methyl (1, 3-thiazol-2- ylsulfonyl) amino] -lH-indble-2-carboxamide
Figure imgf000316_0001
A mixture of 7- [methyl (1, 3-thiazol-2-ylsulfonyl) amino] - lH-indole-2-carboxylic acid (1.65 g) , IH-I, 2, 3-benzotriazol-l- ol (991 mg) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide' hydrochloride (1.41 g) and N,N-dimethylformamide (10 mL) was stirred at 60°C for 30 min. The mixture was cooled to 0°C, 28% aqueous ammonia (600 μL) was added, and the mixture was stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate (200 mL) and water (200 mL) . The organic layer was washed with saturated brine (200 mL) , dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The obtained residue was purified by silica gel column chromatography with 50% ethyl acetate-hexane mixture as an eluate to give the title compound (1.30 g, yield 79%) as a white solid, melting point 220-221°C.
Reference Example 113 ethyl 1- (methoxymethyl) -7- [ (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000316_0002
In the same manner as in Reference Example 3, the title compound (1.33 g, yield 73%) was obtained as a colorless amorphous solid from ethyl 7-amino-l- (methoxymethyl) -IH- indole-2-carboxylate (1.28 g) and pyridine-2-sulfonyl chloride monohydrochloride (1.00 g) .
1H-NMR (DMSO-de) δ:1.35 (3H, t) , 3.10 (3H, s) , 4.34 (2H, q, J=7.1 Hz), 6.31 (2H, s), 6.58-6.67 (IH, m) , 6.93 (IH, t, J=7.7 Hz), 7.37-7.42 (IH, m) , 7.59 (IH, d, J=7.9 Hz), 7.67-7.74 (IH, m) , 7.79 (IH, d, J=7.9 Hz), 7.99-8.07 (IH, m) , 8.83 (IH, d, J=3.8 Hz) , 10.26 (IH, s) .
Reference Example 114 ethyl 1- (methoxymethyl ) -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000317_0001
In the same manner as in Reference Example 4, the title compound (1.25 g, yield 91%) was obtained as a colorless amorphous solid from ethyl 1- (methoxymethyl) -7- [ (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylate (1.33 g) . 1H-NMR (DMSO-de) δ:1.35 (3H, t, J=7.1 Hz), 3.15 (3H, s) , 3.47 3H, s), 4.30-4.42 (2H, m) , 6.26 (2H, d, ■ J=I .1 Hz), 6.66 (IH, dd, J=7.6, 1.0 Hz), 7.01 (IH, t, J=7.7 Hz), 7.43-7.46 (IH, m) , 7.68-7.83 (3H, m) , 8.04-8.12 (IH, m) , 8.89-8.93 (IH, m) . Reference Example 115 ethyl 7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000317_0002
In the same manner as in Reference Example 5, the title compound (800 mg, yield 72%) was obtained as a colorless amorphous solid from ethyl 1- (methoxymethyl) -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxylate (1.25 g) . MS: 360 (MH+) . Reference Example 116 7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indole-2-carboxylic acid
Figure imgf000318_0001
In the same manner as in Reference Example 6, the title compound (658 mg, yield 89%) was obtained as a white solid from ethyl 7- [methyl (pyridin-2-ylsulfonyl) amino] -IH-indole-2- carboxylate (800 mg) . MS:332 (MH+).
Reference Example 117 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000318_0002
In the same manner as in Reference Example 48, the title compound (1050 mg, yield 95%) was obtained as a colorless amorphous solid from 7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid (658 mg) and 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (576 mg) . • 1H-NMR (CDCl3) 6:2.80-3.04 (IH, m) , 3.32 (3H, s) , 3.39 (3H, s) ,
3.48 (3H, s), 3.55-3.73 (IH, m) , 3.78-3.92 (3H, m) , 4.36 (IH, d, J=4.5 Hz), 6.73 (IH, d, J=2.1 Hz), 6.82 (IH, s) , 7.11 (IH, t, J=7.7 Hz), 7.16-7.22 (IH, m) , 7.23-7.30 (3H, m) , 7.32-7.38
(2H, m) , 7.57-7.69 (2H, m) , 7.90-8.03 (IH, m) , 8.07-8.15 (IH, m) , 9.18-9.32 (IH, m) , 12.33 (IH, brs) .
Reference Example 118 N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000318_0003
In the same manner as in Reference Example 40, the title compound (800 mg, yield 83%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3, 3-dimethoxypropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxamide (1050 mg) .
1H-NMR(CDCI3)OIS^I (3H, S) , 3.55-3.62 (IH, m) , 3.66-3.92 (4H, m) , 6.43 (IH, t, J=6.1 Hz), 6.77 (IH, dΛ J=2.3 Hz), 7.11 (IH, t, J=7.7 Hz), 7.21-7.25 (IH, m) , 7.26-7.39 (5H, m) , 7.58-7.68 (2H, m) , 7.93-8.05 (IH, m) , 8.12 (IH, d, J=7.9 Hz), 9.19-9.25 IH, m) , 9.43 (IH, d, J=I.9 Hz), 12.42 (IH, brs) .
Reference Example 119 N- [2- (benzylthio) -3-morpholinopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000319_0001
In the same manner as in Reference Example 41, the title compound (80 mg, yield 26%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxamide (275 mg) and morpholine (47.1 mg). MS:580(MH+). Reference Example 120 7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indole-2-carboxamide
Figure imgf000319_0002
In the same manner as in Reference Example 7, the title compound (1.13 g, yield 100%) was obtained as a colorless amorphous solid from 7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carboxylic acid (1.14 g) . MS:331(MH+).
Reference Example 121 7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indole-2-carbothioamide
Figure imgf000320_0001
In the same manner as in Reference Example 14, the title compound (1.19 g, yield 100%) was obtained as a yellow amorphous solid from 7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carboxamide (1.13 g) . MS:347(MH+).
Reference Example 122 ethyl 7- [ (2-furylsulfonyl) amino] -1- (methoxymethyl) -lH-indole-2-carboxylate
Figure imgf000320_0002
In the same manner as in Reference Example 3, the title compound (4.00 g, yield 70%) was obtained as a colorless amorphous solid from ethyl 7-amino-l- (methoxymethyl) -IH- indole-2-carboxylate (4.10 g) and furan-2-sulfonyl chloride (2.50 g) .
1H-NMR (DMSO-de)δ: 1.34 (3H, t),'3.08 (3H, s) , 4.34 (2H, q, J=7.2 Hz), 6.24 (2H, s), 6.57 (IH, dd, J=7.5, 1.1 Hz), 6.68 (IH, dd,
J=3.6, 1.7 Hz), 6.97 (IH, dd, J=3.5, 0.8 Hz), 7.04 (IH, t,
J=7.7 Hz), 7.38-7.43 (IH, m) , 7.67 (IH, d, J=7.3 Hz), 8.07 (IH, d, J=O.9 Hz), 10.32 (IH, s) .
Reference Example 123 ethyl 7-[(2- furylsulfonyl) (methyl) amino] -1- (methoxymethyl) -IH-indole-2- carboxylate
Figure imgf000320_0003
In the same manner as in Reference Example 4, .the title compound (3.90 g, yield 94%) was obtained as a colorless amorphous solid from ethyl 7- [ (2-furylsulfonyl) amino] -1- (methoxymethyl) -lH-indole-2-carboxylate (4.00 g) .
1H-NMR(CDCl3)O:.1.41 (3H, t, J=7.0 Hz), 3.31 (3H, s) , 3.44 (3H, s), 4.32-4.45 (2H, m) , 6.24-6.46 (2H, m) , 6.57 (IH, dd, J=3.4, 1.9 Hz), 6.65 (IH, d, J=6.8 Hz), 6.94 (IH, d, J=3.0 Hz), 7.03 (IH, t, J=7.8 Hz), 7.38 (IH, s) , 7.60-7.72 (2H, m) . Reference Example 124 ethyl 7-[(2- furylsulfonyl) (methyl) amino] -lH-indole-2-carboxylate
Figure imgf000321_0001
In the same manner as in Reference Example 5, the title compound (2.58 g, yield 100%) was obtained as a colorless amorphous solid from ethyl 7- [ (2-furylsulfonyl) (methyl) amino] - 1- (methoxymethyl) -lH-indole-2-carboxylate (2.90 g) . MS: 349 (MH+) . Reference Example 125 7- [ (2-furylsulfonyl) (methyl) amino] -IH- indole-2-carboxylic acid
Figure imgf000321_0002
In the same manner as in Reference Example 6, the title compound (2.76 g, yield iθθ%) was obtained as a white solid from ethyl 7- [ (2-furylsulfonyl) (methyl) amino] -lH-indole-2- carboxylate (3.00 g) . MS:321(MH+).
Reference Example 126 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 7- [ (2-furylsulfonyl) (methyl) amino] -lH-indole-2-carboxamide
Figure imgf000322_0001
In the same manner as in Reference Example 48, the title compound (2.04 g, yield 100%) was -obtained' as a colorless amorphous solid from 7-[(2- furylsulfonyl) (methyl) amino] -lH-indole-2-carboxylic acid (1.20 g) and 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (1.09 g) . 1H-NMR (CDCl3) 6:2.87-2.99 (IH, m) , 3.37-3.39 (3H, m) , 3.47 (3H, s), 3.52-3.68 (IH, m) , 3.77-3.90 (3H, m) , 4.34 (IH, d, J=4.5 Hz), 6.51 (IH, dd, J=3.5, 1.8 Hz), 6.72 (IH, d, J=2.3 Hz), 6.81 (IH, dd, J=7.6, 0.8 Hz), 6.92 (IH, dd, J=3.5, 0.8 Hz), 7.04 (IH, t, J=7.7 Hz), 7.15-7.25 (2H, m) , 7.27-7.40 (4H, m) , 7.56-7.63 (IH, m) , 7.67 (IH, dd, J=I.8, 0.8 Hz), 9.42 (IH, d, J=I.1 Hz) . Reference Example 127 N- [2- (benzylthio) -3-oxopropyl] -7- [ (2- furylsulfonyl) (methyl) amino] -lH-indole-2-carboxamide
Figure imgf000322_0002
In the same manner as in Reference Example 40, the title compound (830 mg, yield 44%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3, 3-dimethoxypropyl] -7- [ (2-furylsulfonyl) (methyl) amino] -IH-indole-2-carboxamide (2.04 g) •
1H-NMR (CDCl3) δ: 3.40 (3H, s) , 3.53-3,63 (IH, m) , 3.67-3.85 (4H, m) , 6.41 (IH, s), 6.51 (IH, dd, J=3.6, 1.9 Hz), 6.73-6.83 (2H, m) , 6.91 (IH, dd, J=3.5, 0.8 Hz), 7.03 (IH, t, J=7.8 Hz), 7.28-7.32 (IH, m) , 7.33-7.40 (4H, m) , 7.58 (IH, d, J=8.1 Hz), 7.66 (IH, dd, J=I.8, 0.8 Hz), 9.35-9.53 (2H, m) . Reference Example 128 N- [2- (benzylthio) -3-morpholinopropyl] -7- [ (2-furylsulfonyl) (methyl) amino] -lH-indole-2-carboxamide
Figure imgf000323_0001
In the same manner as in Reference Example 41, the title compound (860 mg, yield 91%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3-oxopropyl] -7- [ (2- furylsulfonyl) (methyl) amino] -lH-indole-2-carboxamide (830 mg) and morpholine (292 mg) . MS: 569 (MH+).
Reference Example 129 7- [ (2-furylsulfonyl) (methyl) amino] -IH- indole-2-carboxamide
Figure imgf000323_0002
In the same manner as in Reference Example 7, the title compound (1495 mg, yield 100%) was obtained as a colorless amorphous solid from 7- [ (2-furylsulfonyl) (methyl) amino] -IH- indole-2-carboxylic acid (1500 mg) . MS:320(MH+). Reference Example 130 7- [ (2-furylsulfonyl) (methyl) amino] -IH- indole-2-carbothioamide
Figure imgf000323_0003
In the same manner as in Reference Example 14, the title compound (1280 mg, yield 80%) was obtained as a yellow amorphous solid from 7- [ (2-furylsulfonyl) (methyl) amino] -IH- indole-2-carboxamide (1520 mg) . MS:336(MH+).
Reference Example 131 N- [2- (benzylthio) -3, 3-dimethoxypropyl] 7- [ (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000324_0001
In the same manner as in Reference Example 48, the title compound (7.00 g, yield 83%) was obtained as a colorless amorphous solid from 7- [ (2-thienylsulfonyl) amino] -lH-indole-2- carboxylic acid (5.00 g) and 2- (benzylthio) -3, 3- dimethoxypropan-1-amine (4.5 g) .
1H-NMR (CDCl3) 5:3.00-3.09 (IH-, m) , 3.42 (3H, s), 3.48 (3H, s) , 3.84 (2H, d, J=I.3 Hz), 4.02-4.17 (2H, m) , 4.40 (IH, d, J=3.8 Hz), 6.62-6.67 (IH, m) , 6.75 (IH, d, J=2.1 Hz), 7.10-7.24 (6H, m) , 7.27-7.36 (3H, m) , 7.46-7.54' (2H, m) , 9.40 (IH, s) , 11.15' (IH, s) .
Reference Example 132 N- [2- (benzylthio) -3-oxopropyl] -7- [ (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000324_0002
In the same manner as in Reference Example 40, the title compound (3.00 g, yield 47%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3, 3-dimethoxypropyl] -7- [ (2-thienylsulfonyl) amino] -IH-indole-2-carboxamide (7.00 g) . MS :500(MH+). Reference Example 133 N- [2- (benzylthio) -3-morpholinopropyl] -7- [ (2-thienylsulfonyl) amino] -IH-indole-2-carboxamide
Figure imgf000324_0003
In the same manner as in Reference Example 41, the title compound (2.74 g, yield 80%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3-oxopropyl] -7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (3.00 g) and morpholine (1.06 g). MS:571(MH+). Reference Example 134 1- (methoxymethyl) -7- [ (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid
Figure imgf000325_0001
Ethyl 1- (methoxymethyl) -7- [ (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylate (7.0 g) was dissolved in a mixed solvent of tetrahydrofuran (30 mL)- methanol (20 mL) . Aqueous potassium hydroxide solution (prepared by dissolving potassium hydroxide (3.0 g) in water (10 mL) ) was added to this solution, and the mixture was stirred at room temperature for 15 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained pale-pink crystals were washed with ethyl acetate-hexane to give the title compound (5.94 g, yield: 91%) as colorless crystals.
MS:332 (MH+). melting point :199-200°C.
Reference Example 135 7- [ (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carboxamide
Figure imgf000325_0002
In the same manner as in Reference Example 7, 1-
(methoxymethyl) -7- [ (pyridin-2-ylsulfonyl) amino] -lH-indole-2- carboxamide (4.99 g) was obtained as a colorless amorphous solid from 1- (methoxymethyl) -7- [ (pyridin-2-ylsulfonyl) amino] - lH-indole-2-carboxylic acid (5.00 g) . In the same manner as in Reference Example 5, the title compound (3.10 g, yield 71%) was obtained as a colorless amorphous solid from 1- (methoxymethyl) -7- [ (pyridin-2-ylsulfonyl) amino] -lH-indole-2- carboxamide. MS : 317 (MH+)'.
Reference Example 136 7- [ (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carbothioamide
Figure imgf000326_0001
In the same manner as in Reference Example 14, the title compound (3.20 g, yield 98%) was obtained as a yellow amorphous solid from 7- [ (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carboxamide (3.10 g) . MS:333(MH+). Reference Example 137 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 1- (methoxymethyl) -7- [ (pyridin-2-ylsulfonyl) amino] -lH-indole-2- carboxamide
Figure imgf000326_0002
A solution of 1- (methoxymethyl) -7- [ (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid (0.94 g) , 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (0.70 g) , N- ethyldiisopropylamine (1.0 mL) and O- (7-azabenzotriazol-l-yl) - N, N, N' , N'-tetramethyluronium hexafluorophosphate (1.2 g) in N,N-dimethylformamide (20 mL) was stirred at room temperature for 20 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous citric acid solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=4: 6-6:4) to give the title compound (1.6 g, yield: 100%) as a pale-yellow oil. MS:553(MH+). Reference Example 138 N- [2- (benzylthio) -3, 3~dimethoxypropyl] - 1- (methoxymethyl) -7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carboxamide
Figure imgf000327_0001
To a solution of N- [2- (benzylthio) -3, 3- dimethoxypropyl] -1- (methoxymethyl) -7- [ (pyridin-2- ylsulfonyl) amino] -IH-indole-2-carboxamide (1.52 g) and potassium carbonate (0.54 g) in N,N-dimethylformamide (14 mL) was added methyl iodide (0.16 mL) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 18 hr. The reaction solution was ice-cooled, potassium carbonate (0.30 g) and methyl iodide (0.16 mL) were added again, and the mixture was further stirred from under ice- cooling to room temperature for 15 hr. The reaction solution was diluted with ethyl acetate, washed with aqueous- citric acid solution, water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate: hexane=4: 6-6: 4) to give the title compound (1.6 q, yield: 100%) as a colorless oil. MS :599(MH+) . Reference Example 139 N- [2- (benzylthio) -3- thiomorpholinopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indole-2-carboxamide
Figure imgf000328_0001
To a mixture of N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxamide (0.60 g) , thiomorpholine (0.21 inL) and 1,2-dichloroethane (25 mL) was added sodium triacetoxyborohydride (0.65 g) , and the mixture was stirred at room temperature for 15 hr. The reaction solution was acidified with diluted hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with aqueous sodium hydrogencarbonate solution and saturated ' brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=35: 65-55 : 45) to give the title compound (0.67 g, yield: 95%) as a colorless oil. MS:596(MH+). Reference Example 140 ethyl 1- (methoxymethyl) -7-{ [ (2- methoxyphenyl) sulfonyl] amino}-IH-indole-2-carboxylate
Figure imgf000328_0002
To a mixture of ethyl 7-amino-l- (methoxymethyl) -IH- indole-2-carboxylate (12.0 g) and pyridine (100 mL) was added 2-methoxybenzenesulfonyl chloride (10.0 g) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 20 hr. The reaction mixture was concentrated, and the residue was diluted with ethyl acetate. The solution was washed with aqueous citric acid solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained crystals were washed with ethyl acetate-hexane to give the title compound (16.58 g, yield 89%) as pale-gray crystals, melting point :106-107°C.
Reference Example 141 ethyl 1- (methoxymethyl) -7- [ [ (2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indole-2-carboxylate
Figure imgf000329_0001
To a solution of ethyl 1- (methoxymethyl) -7- {[ (2- methoxyphenyl) sulfonyl] amino}-IH-indole-2-carboxylate (11.0 g) and potassium carbonate (5.9 g) in N,N-dimethylformamide (80 mL) was added methyl iodide (2.7 mL) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 18 hr. The reaction solution was diluted with ethyl acetate, washed with aqueous citric acid solution, water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=3 : 2-4 : 1) , and the obtained crystals were washed with ethyl acetate-hexane to give the title compound (10.9 g, yield: 89%) as colorless needle crystals, melting point :124-
125°C. Reference Example 142 7-[[(2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indole-2-carboxylic acid
Figure imgf000329_0002
A mixture of ethyl 1- (methoxymethyl) -7- [[ (2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indole-2-carboxylate (10.9 g) , 6N-hydrochloric acid (50 mL) , tetrahydrofuran (50 mL) and methanol (50 mL) was stirred at 90°C for 24 hr. The organic solvent of the reaction solution was evaporated under reduced pressure, and the residue was diluted with ethyl acetate. The solution was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was dissolved in a mixed solvent of tetrahydrofuran (50 iuL)- methanol (50 mL) , aqueous potassium hydroxide solution
(prepared by dissolving potassium hydroxide (4.2 g) in water (30 mL) ) was added to this solution, and the mixture was stirred at room temperature for 15 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained pale-brown crystals were filtered off, and washed, with ethyl acetate- hexane. The filtrate was concentrated under reduced pressure, and the obtained crystals were washed with ethyl acetate- hexane to give the title compound (6.47g, crude yield: 71%) as pale-yellow crystals. MS: 361 (MH+).
Reference Example 143 7-[[(2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indole-2-carboxamide
Figure imgf000330_0001
To a mixture of 7- [[(2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indole-2-carboxylic acid (3.0 g) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (1.65 g) and N,N-dimethylformamide (30 mL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (2.1 g) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 18 hr. The reaction solution was diluted with ethyl acetate, washed with aqueous sodium hydrogencarbonate solution, water and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained crystals were washed with ethyl acetate-hexane to give the title compound (2.82 g, crude yield 94%) as pale-pink crystals. MS:360(MH+).
Reference Example 144 7-[[(2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indole-2- carbothioamide
Figure imgf000331_0001
A mixture of 7-[ [ (2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indole-2-carboxamide (2.82 g) , Lawesson' s reagent (1.6 g) and tetrahydrofuran (250 mL) was stirred at 70°C for 3 hr. The reaction solution was concentrated under reduced pressure, and the obtained oil was crystallized from ethyl acetate-hexane to give the title compound (2.3 g, yield: 78%) as pale-yeliow crystals.
MS: 376 (MH+) .
Reference Example 145 ethyl 7-({[2- (trifluoromethyl) phenyl] sulfonyl} amino) -lH-indole-2- carboxylate
Figure imgf000331_0002
To a mixture of ethyl 7-amino-lH-indole-2-carboxylate (4.1 g) and pyridine (60 mL) was added 2- trifluoromethylbenzenesulfonyl chloride (5.0 g) under ice- cooling, and the mixture was stirred from under ice-cooling to room temperature for 18 hr. The reaction mixture was concentrated, and the residue was diluted with ethyl acetate. The solution was washed with aqueous citric acid solution and saturated brine, and filtrated through silica gel. The eluate was concentrated under reduced pressure, and the obtained pale-brown oil was crystallized from ethyl acetate-hexane to give the title compound (7.3 g, yield 88%) as pale-brown crystals. MS:413(MH+). melting point :138-139°C. Reference Example 146 ethyl 7- (methyl { [2-
( tr if luoromethyl ) phenyl ] sulfonyl } amino) -lH-indole-2- carboxylate
Figure imgf000332_0001
To a solution of ethyl 7-({[2-
(trifluoromethyl) phenyl] sulfonyl} amino) -lH-indole-2- carboxylate (5.0 g) and potassium carbonate (2.0 g) in N, N- dimethylformamide (50 mL) was added methyl iodide (0.75 mL) under ice-cooling, and the mixture was stirred from under ice- cooling to room temperature for 18 hr. The reaction solution was ice-cooled, methyl iodide (0.75 mL) was added again, and the mixture was stirred from under ice-cooling to room temperature for 18 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous citric acid solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to basic silica gel column chromatography (ethyl acetate :hexane=20 : 80-35 : 65) , and the obtained crude product was subjected three times to silica gel column chromatography (ethyl acetate :hexane=5 : 95-10 : 90) to give the title compound (3.7 g, yield: 72%) as a pale-yellow oil. MS:427 (MH+). Reference Example 147 7- (methyl{ [2-
(trifluoromethyl) phenyl] sulfonyl} amino) -lH-indole-2-carboxylic acid
Figure imgf000332_0002
Ethyl 7- (methyl { [2-
(trifluoromethyl) phenyl] sulfonyl} amino) -lH-indole-2- carboxylate (3.7 g) was dissolved in a mixed solvent of tetrahydrofuran (25 mL) -methanol (25 mL) . Aqueous potassium hydroxide solution (prepared by dissolving potassium hydroxide (1.5 g) in water (20 mL) ) was added to this solution, and the mixture was stirred at room temperature for 2 days. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained colorless crystals were washed with ethyl acetate-hexane to give the title compound (2.7 g, yield: 63%) as colorless crystals. MS:399(MH+). melting point :211-212°C. Reference Example 148 7- (methyl { [2- (trifluoromethyl) phenyl] sulfonyl }amino) -lH-indole-2- carboxamide
Figure imgf000333_0001
To a mixture of 7- (methyl { [2-
(trifluoromethyl) phenyl] sulfonyl}amino) -lH-indole-2-carboxylic acid (2.65 g) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (1.3 g) and N,N-dimethylformamide (30 mL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (1.7 g) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 18 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained colorless crystals were washed with ethyl acetate-hexane to give the title compound (2.6 g, yield 98%) as colorless crystals. MS:398 (MH+). melting point
:223-224°C.
Reference Example 149 7- (methyl { [2- (trifluoromethyl) phenyl] sulfonyl} amino) -lH-indole-2- carbothioamide
Figure imgf000334_0001
A mixture of 7- (methyl { [2-
(trifluoromethyl) phenyl] sulfonyl} amino) -lH-indole-2- carboxamide (2.6 g) , Lawesson' s reagent- (1.3 g) and tetrahydrofuran (50 mL) was stirred at 60°C for 3 hr. The reaction solution was concentrated under reduced pressure, and the obtained oil was crystallized from toluene to give the title compound (2.65 g, yield: 100%) as pale-yellow crystals. MS: 414 (MH+) . Reference Example 150 N- [2- (benzylthio) -3- (1, 1- dioxidothiomorpholino) propyl] -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000334_0002
To a mixture of N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxamide (0.30 g) , thiomorpholine 1,1-dioxide (0.15 g) and 1,2- dichloroethane (12 mL) was' added sodium triacetoxyborohydride (0.25 g) , and the mixture was stirred at room temperature for 2 days. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=25: 75-40: 60) to give the title compound (0.37 g, yield: 100%) as a colorless oil. MS: 628 (MH+). Reference Example 151 ethyl 7- {methyl [ (l-methyl-lH-imidazol-2- yl) sulfonyl] amino} -IH-indole-2-carboxylate
Figure imgf000335_0001
To a solution of ethyl 7-amino-lH-indole-2-carboxylate (3 g) in pyridine (30 rαL) was added l~methyl-lH-imidazole~2- sulfonyl chloride (3.6 g) under ice-cooling, and the mixture was stirred for 1 hr. The reaction mixture was concentrated, and the residue was dissolved in ethyl acetate. The solution was washed with water. The ethyl acetate layer was washed with IN hydrochloric acid, saturated brine and saturated aqueous sodium hydrogencarbonate solution, dried (MgSO4) , and concentrated. The obtained residue was dissolved in DMF (30 πiL) , potassium carbonate (2.1 g) and methyl iodide (2.1 g) were added at room temperature, and the mixture was stirred . for 3 hr at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with IN hydrochloric acid, saturated brine and saturated aqueous sodium hydrogencarbonate solution, dried (MgSCU), and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (3.0 g, yield 59%) as white crystals from a fraction eluted with ethyl acetate :hexane=50: 50. melting point 120°C.
Reference Example 152 7- {methyl [ (l-methyl-lH-imidazol-2- yl) sulfonyl] amino} -IH-indole-2-carboxylic acid
Figure imgf000335_0002
Ethyl 7- {methyl [ (l-methyl-lH-imidazol-2- yl) sulfonyl] amino} -IH-indole-2-carboxylate (2.87 g) was dissolved in a mixed solvent of tetrahydrofuran (30 mL)- methanol (20 mL) . Aqueous potassium hydroxide solution (prepared by dissolving potassium hydroxide (2.0 g) in water (20 mL) ) was added to this solution, and the mixture was stirred at room temperature for 16 hr, and concentrated under reduced pressure to evaporate methanol. The obtained residue was acidified with aqueous citric acid solution, and the mixture .was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound (2.65 g, yield: 100%) as colorless crystals. MS:335(MH+). melting point :241-242°C.
Reference Example 153 N- [2- (benzylthio) -3, 3-dimethoxypropyl] -
7- {methyl [ (l-methyl-lH-imidazol-2-yl) sulfonyl] amino} -IH- indole-2-carboxamide
Figure imgf000336_0001
A solution of 7- {methyl [ (l-methyl-lH-imidazol-2- yl) sulfonyl] amino} -IH-indole-2-carboxylic acid (2.64 g) , 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (2.10 g) , N- ethyldiisopropylamine (3.2 mL) and 0- (7-azabenzotriazol-l-yl) - N, N,N' , N'-tetramethyluronium hexafluorophosphate (3.6 g) in N,N-dimethylformamide (40 mL) was stirred at room temperature for 16 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=35: 65-50 : 50) to give the title compound (4.5 g, yield: 100%) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 2.92 (IH, td, J=IO.5, 6.3 Hz), 3.38 (3H, s) , 3.46 (3H, s), 3.53 (3H, s) , 3.54-3.68 (IH, m) , 3.80-3.90 (IH, m) , 3.83 (3H, s), 4.34 (IH, d, J=4.5 Hz), 6.72 (IH, d, J=2.1 Hz ) , 6 . 78 ( IH, brt, J=5. 4 Hz) , 6 . 97 ( IH, d, J=O . 9 Hz ) , 7 . 08- 7 . 40 ( 8H, m) , 7. 65 (IH, d, J=8 .1 Hz) , 12 .46 ( IH, brs ) . Reference Example 154 ethyl 2- { [2-nitro-4-
(trifluoromethoxy) phenyl] hydrazono }propanoate
Figure imgf000337_0001
To a mixture of 2-nitro-4- (trifluoromethoxy) aniline (56.0 g) and 6N hydrochloric acid (210 mL) was added dropwise an aqueous solution (100 mL) of sodium nitrite (18.6 g) at 4 to 10°C. After the completion of the dropwise addition, the mixture was stirred at 5°C for 1 hr. The insoluble substance was removed by filtration, and the filtrate was added dropwise to a mixture of ethyl 2-methylacetoacetate (40.4 g) , potassium hydroxide (85%, 99.0 g) , ethanol (200 mL) and water (500 mL) at 0°C. After the completion of the dropwise addition, the mixture was stirred for 30 min. Water was added to the reaction mixture, the mixture was stirred at room temperature, and the precipitated crystals were collected by filtration. The obtained crystals were dissolved in ethyl acetate, and the ethyl acetate layer was washed with saturated brine, dried (MgSCu) i and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (7.41 g, yield 8.8%) as yellow crystals from a fraction eluted with hexane-ethyl acetate (4:1, volume ratio).
1H-NMR (CDCl3) δ: 1.40 (3H, t, J=7.06 Hz), 2.25, (3H, s) , 4.36 (2H, q, J=7.16 Hz), 7.50 (IH, dd, J=9.42, 2.64 Hz), 8.02-8.15 (2H, m) , 10.90 (IH, s) .
Reference Example 155 ethyl 7-nitro-5- (trifluoromethoxy) -IH- indole-2-carboxylate
Figure imgf000337_0002
A mixture of ethyl 2-{ [2-nitro-4-
(trifluoromethoxy) phenyl] hydrazono}propanoate (6.30 g) and polyphosphoric. acid (60 g) was stirred at 95°C for 1 hr. The reaction mixture was added to ice water, and the obtained mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate (98:2 to 4:1, volume ratio) , and the obtained crystals were washed with hexane to give the title compound (3.06 g, yield 51%) as yellow crystals.
1H-NMR(CDCl3)O=I^S (3H, t, J=7.19 Hz), 4.48 (2H, q, J=7.19 Hz), 7.38 (IH, d, J=2.27 Hz), 7.93 (IH, s) , 8.19 (IH, s) , 10.36 (IH, brs) .
Reference Example 156 ethyl 7-amino-5- (trifluoromethoxy) -IH- indole-2-carboxylate
Figure imgf000338_0001
A mixture of ethyl 7-nitro-5- (trifluoromethoxy) -IH- indole-2-carboxylate (3.06 g) , 10% palladium-carbon (50% containing water, 600 mg) and tetrahydrofuran (150 mL) was subjected to catalytic reduction under hydrogen atmosphere at' normal pressure. The palladium-carbon was removed by filtration, and the filtrate was concentrated. The obtained crystals were washed with hexane to give the title compound (2.63 g, yield 95%) as colorless crystals. The crystals were recrystallized from ethyl acetate-hexane to give colorless prism crystals, melting point 190-1910C.
Reference Example 157 ethyl 7- [ (2-thiehylsulfonyl) amino] -5- (trifluoromethoxy) -IH-indole-2-carboxylate
Figure imgf000339_0001
To a mixture of ethyl 7-amino-5- (trifluoromethoxy) -IH- indole-2-carboxylate (2.53 g) and pyridine (50 rriL) was added thiophene-2-sulfonyl chloride (1.94 g) at 0°C, and the mixture was stirred at room temperature for 4 hr, and concentrated. IN Hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained crystals were washed with diisopropyl ether to give the title compound (3.40 g, yield 89%) as colorless crystals. The crystals were recrystallized from ethyl acetate-hexane to give colorless prism crystals, melting point 196-197°C. Reference Example 158 ethyl 7- [methyl (2- thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indole-2- carboxylate
Figure imgf000339_0002
A mixture of ethyl 7- [ (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -IH-indole-2-carboxylate (3.30 g) , potassium carbonate (1.05 g) and N, N-dimethylformamide (50 mL) was stirred at 0°C for 30 min. Methyl iodide (1.08 g) was added to the reaction mixture at 0°C, and the mixture was stirred at room temperature for 15 hr. Aqueous citric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried over magnesium sulfate, and concentrated. The obtained residue was' subjected to silica gel column chromatography, and eluted with ethyl acetate-hexane (9:1-3:1, volume ratio) to give the title compound (2.26 g, yield 66%) as colorless crystals. The crystals were recrystallized from ethyl acetate-hexane to give colorless prism crystals, melting point 149-150°C.
Reference Example 159 7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indole-2-carboxylic acid
Figure imgf000340_0001
A mixture of ethyl 7- [methyl (2-thienylsulfonyl) amino] - 5- (trifluoromethoxy)-lH-indole-2-carboxylate (2.19 g) , IN aqueous sodium hydroxide solution (10 mL) , tetrahydrofuran (10 itiL) and ethanol (10 inL) was stirred at room temperature for 15 hr. The reaction mixture was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO,}) , and concentrated. The residue was washed with hexane to give the title compound (2.05 g, yield 100%) as colorless crystals. 1H-NMR(DMSO-d6)δ:3.27 (3H, s) , 6.50 (IH, d, J=I.51 Hz), 7.23 (IH, d, J=2.07 Hz), 7.28 (IH, dd, J=5.09, 3.77 Hz), 7.56 (IH, dd, J=3.77, 1.32 Hz), 7.71 (IH, s) , 8.08 (IH, dd, J=5.09, 1.32 Hz), 12.29 (IH, d, J=I.13 Hz), 13.23 (IH, brs) . Reference Example 160 7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -IH-indole-2-carboxamide
Figure imgf000340_0002
A mixture of 7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indole-2-carboxylic acid (1.60 g) , IH- 1, 2, 3-benzotriazol-l-ol (0.77 g) , N- [3- (dimethylamino) propyl] - N' -ethylcarbodiimide hydrochloride (1.09 g) and N,N- dimethylformamide (50 mL) was stirred at room temperature for 15 hr. 28% Aqueous ammonia (320 mg) was added to the reaction mixture, and the mixture was further stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was "extracted with ethyl acetate. The ethyl acetate layer was washed successively with aqueous citric acid solution, saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4), and concentrated. The residue was washed with hexane to give the title compound (1.25 g, yield 79%) as pale-brown' crystals. The crystals were recrystallized from ethyl acetate-hexane to give pale-yellow prism crystals, melting point 228-2290C.
Reference Example 161 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -IH- indole-2-carboxamide
Figure imgf000341_0001
To a mixture of 7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indole-2-carboxylic acid (600 mg) , 2- (benzylthio) -3, 3-dimethoxyproρan-l-amine (410 mg) , diisopropylethylamine (450 mg) and N,N-dimethylformamide (10 mL) was added O- (7-azabenzotriazol-l-yl) -N,N,N' , N' - tetramethyluronium hexafluorophosphate (HATU, 720 mg) at room temperature, and the mixture was stirred for 2.5 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSθ4), and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-2:1, volume ratio) to give the title compound (600 mg, yield 67%) as a colorless amorphous solid.
1H-NMR (CDCl3) δ: 2.89-2.94 (IH, m) , 3.32 (3H, s) , 3.38 (3H, s) ,
3.48 (3H, s), 3.56-3.65 (IH, m) , 3.79-3.88 (3H, m) , 4.34 (IH, d, J=4.5 Hz), 6.44 (IH, d, J=I.2 Hz), 6.72 (IH, d, J=2.4 Hz), 6.80-6.84 (IH, m) , 7.11-7.36 (6H, m) , 7.41-7.47 (2H, m) , 7.64- 7.67 (IH, m), 9.89 (IH, brs) . Reference Example 162 N- [2- (benzylthio) -3-oxopropyl] -7- tmethyl (2-thienylsulfonyl) amino] -5- (trif luoromethoxy) -IH- indole-2-carboxamide
Figure imgf000342_0001
A mixture of N- [2- (benzylthio) -3, 3-dimethoxypropyl] -7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -IH- indole-2-carboxamide (600 mg) , Amberlyst (registered trade mark) 15 ion exchange resin (120 mg) , water (0.05 itiL) and acetone (15 πiL) was stirred at room temperature for 15 hr. The insoluble substance was removed by filtration, and the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-3:1, volume ratio) to give the title compound (560 mg, yield 100%) as a colorless amorphous solid. 1H-NMR (CDCl3) δ: 3.30 (3H, s) , 3.55-3.68 (IH, rα) , 3.73-3.85 (4H, m) , 6.38-6.56 (2H, m) , 6.75 (IH, d, J=2.27 Hz), 7.05-7.19 (IH, m) , 7.23-7.48 (7H, m) , 7.64-7.71 (IH, m) , 9.43 (IH, d, J=I.51 Hz) , 9.67 (IH, brs) . Reference Example 163 N- [2- (benzylthio) -3-morpholinopropyl] -7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -IH- indole-2-carboxamide
Figure imgf000342_0002
To a mixture of N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -IH- indole-2-carboxamide (560 mg) and 1, 2-dichloroethane (15 mL) was added morpholine (170 mg) at room temperature, and the reaction mixture was stirred at room temperature for 30 min. Sodium triacetoxyborohydride (590 mg) was added at room temperature, and the mixture was further stirred at room temperature for 15 hr. Morpholine (170 mg) was added to the reaction mixture at room temperature, and the mixture was stirred at room temperature for 30 min. Sodium triacetoxyborohydride (590 mg) was added at room temperature, and the mixture was further stirred at room temperature for 3 hr. Water was added to the reaction' mixture, and the mixture ■ was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-2:1, volume ratio) to give the title compound (400 mg, yield 63%) as colorless crystals. 1H-NMR (CDCl3) 5:2.28-2.63 (6H, m) , 2.80-3.00 (IH, m) , 3.31 (3H, s), 3.50-3.94 (8H, m) , 6.44 (IH, d, J=I.13 Hz), 6.80 (IH, d, J=2.26 Hz), 7.14 (IH, dd, J=4.99, 3.86 Hz), 7.19-7.43 (5H, m) , 7.48 (IH, d, J=O.94 Hz), 7.61 (IH, brs) , 7.67 (IH, dd, J=5.09, 1.32 Hz) , 9.62 (IH, brs) . Reference Example 164 7- [ (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indole-2-carboxylic acid
Figure imgf000343_0001
A mixture of ethyl 7- [ (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indole-2-carboxylate (3.0 g) , IN aqueous sodium hydroxide solution (20 mL) , tetrahydrofuran (10 mL) and ethanol (10 mL) was stirred at 60°C for 1 hr. The reaction mixture was acidified with IN hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was washed with hexane to give the title compound (2.60 g, yield 93%) as pale-yellow crystals. The crystals were recrystallized from ethyl acetate-hexane to give pale-yellow prism crystals, melting point 288-290°C (decomposition). Reference Example 165 7- [ (2-thienylsulfonyl) amino] -5-
(trifluoromethoxy) -lH-indole-2-carboxamide
Figure imgf000344_0001
A mixture of 7- [ (2-thienylsulfonyl) amino] -5-
(trifluoromethoxy) -lH-indole-2-carboxylic acid (2.50 g) , IH- 1, 2, 3-benzotriazol-l-ol-ammonia complex (1.89 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (2.38 g) and N,N-dimethylformamide (20 iriL) was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSCu) i and concentrated. The residue was washed with hexane to give the title compound (2.23 g, yield 89%) as pale-yellow crystals. The crystals were recrystallized from ethyl acetate-hexane to give colorless prism crystals, melting point >300°C. Reference Example 166 4- (2-methoxyethoxy) -2-nitroaniline
Figure imgf000344_0002
To a mixture of 4-hydroxy-2-nitroaniline (25.0 g) , 2- methoxyethanol (21.0 g) , tributylphosphine (49.2 g) and tetrahydrofuran (700 mL) was added 1,1'-
(azodicarbonyl) dipiperidine (61.3 g) at room temperature, and the mixture was stirred at room temperature for 2.5 days . The precipitate was filtered off, and the filtrate was concentrated. Diisopropyl ether was added to the residue, and the insoluble substance was filtered off. The filtrate was concentrated, and the residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate (2:1, volume ratio). The obtained crude product was further subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-2:1, volume ratio) to give the title, compound (30.9 g, yield 90%) as orange crystals The crystals were recrystallized from hexane-ethyl acetate to
5 give orange prism crystals, melting point 89-90°C.
Reference Example 167 ethyl 2-{ [4- (2-methoxyethoxy) -2- nitrophenyl] hydrazono}propanoate
Figure imgf000345_0001
To a mixture of 4- (2-methoxyethoxy) -2-nitroaniline io (15.0 g) , 6N hydrochloric acid (59 itiL) and acetonitrile (50 HiL) was added dropwise an agueous solution (50 mL) of sodium nitrite (4.88 g) at 5-100C. The reaction mixture was stirred at 5-10°C for 1.5 hr. This mixture was added to a mixture of ethyl 2-methylacetoacetate (11.2 g) , 85% potassium hydroxide
,25 (23.8 g) , ethanol (50 mL) and water (50 mL) at 10-200C. The reaction mixture was stirred at 100C for 10 min, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed with saturated brine, dried (MgSO,)) , and concentrated. The obtained
20 residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-2:1, volume ratio) to give the title compound (1.39 g, yield 6%) as orange crystals.
1H-NMR (CDCl3) δ: 1.40 (3H, t, J=I .19 Hz) , 2.22 (3H, s) , 3.47 (3H, s) , 3.74-3.82 (2H, m) , 4.12-4.20 (2H, m) , 4.35 (2H, q, J=6.94 25 Hz), 7.33 (IH, dd, J=9.47, 3.03 Hz), 7.65 (IH, d, J=3.03 Hz), 7.99 (IH, d, J=9.47 Hz), 10.84 (IH, brs) . ■
Reference Example 168 ethyl 5- (2-methoxyethoxy) -7-nitro-lH- indole-2-carboxylate
Figure imgf000345_0002
30 A mixture of ethyl 2- { [4- (2-methoxyethoxy) -2- nitrophenyl]hydrazono}propanoate (250 mg) and polyphosphoric acid (2.0 g) was stirred at 1100C for 1 hr. After cooling, water and ethyl acetate were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSC>4) , and concentrated. The obtained residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-2:1, volume ratio) to give the title compound (40 mg, yield 17%) as yellow crystals.- The crystals were recrystallized from ethyl acetate-hexane to give yellow prism crystals, melting point 90-91°C.
Reference Example 169 ethyl 7-amino-5- (2-methoxyethoxy) -IH- indole-2-carboxylate
Figure imgf000346_0001
A mixture of ethyl 5- (2-methoxyethoxy) -7-nitro-lH- indole-2-carboxylate (2.30 g) , 10% palladium carbon (50% containing water, 500 mg) and tetrahydrofuran (100 mL) was subjected to catalytic reduction at room temperature under hydrogen atmosphere at normal pressure. The catalyst was removed by filtration, and the filtrate was concentrated. The residue was washed with hexane to give the title compound
(2.07 g, yield 99%) as pale-brown crystals. The crystals were recrystallized from ethyl acetate-hexane to give pale-brown prism crystals, melting point 162-163°C. Reference Example 170 ethyl 5- (2-methoxyethoxy) -7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxylate
Figure imgf000346_0002
To a mixture of ethyl 7~amino-5- (2-methoxyethoxy) -IH- indole-2-carboxylate (2.00 g) and pyridine (30 mL) was added thiophene-2-sulfonyl chloride (1.57 g) at 0°C, and the mixture was stirred at room temperature for 15 hr. The reaction mixture was concentrated, aqueous citric acid solution was added to the residue, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-1:1, volume ratio) to give the title compound (1.62 g, yield 53%) as colorless crystals. The crystals were recrystallized from ethyl acetate-hexane to give colorless prism crystals, melting point 106-107°C. Reference Example 171 ethyl 5- (2-methoxyethoxy) -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000347_0001
A mixture of ethyl 5- (2-methoxyethoxy) -7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxylate (1.50 g) , potassium carbonate (480 mg) and N,N-dimethylforiuamide (20 mL) was stirred at 00C for 30 min. Methyl iodide (550 mg) was added at 0°C to the reaction mixture, and the mixture was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried over magnesium sulfate, and concentrated. The obtained residue was subjected to basic silica gel column chromatography, and eluted with ethyl acetate-hexane (4:1-2:1) to give the title compound (1.30 g, yield 85%) as a colorless oil.
1H-NMR (CDCl3) δ: 1.42 (3H, t, J=7.00 Hz), 3.29 (3H, s) , 3.43 (3H, s) , 3.64-3.79 (2H, m) , 3.96-4.10 (2H, m) , 4.42 (2H, q, J=7.19 Hz), 6.41 (IH, d, J=I.89 Hz), 7.05 (IH, d, J=I.89 Hz), 7.09- 7.20 (2H, m) , 7.35-7.45 (IH, m) , 7.55-7.69 (IH, m) , 9.22 (IH, brs) .
Reference Example 172 5- (2-methoxyethoxy) -7- [methyl (.2- thienylsulfonyl) amino] -lH-indole-2-carboxylic acid
Figure imgf000348_0001
A mixture of ethyl 5- (2-methoxyethoxy) -7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxylate (1.30 g) , IN aqueous sodium hydroxide solution (10 mL) , tetrahydrofuran (10 mL) and ethanol (10 mL) was stirred at room temperature for 15 hr. The reaction mixture was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and saturated brine, dried (MgSCu) / and concentrated to give the title compound (1.15 g, yield 93%) as colorless crystals. The crystals were recrystallized from ethyl acetate-hexane to give colorless prism crystals, melting point 198-199°C. Reference Example 173 5- (2-methoxyethoxy) -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000348_0002
A mixture of 5- (2-methoxyethoxy) -7- [methyl {2- thienylsulfonyl) amino] -IH-indole-2-carboxylic acid (1.05 g) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (590 mg) , N-[3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (750 mg) and N,N-dimethylformamide (5 mL) was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with aqueous citric acid solution, saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated to give the title compound (1.00 g, yield 94%) as colorless crystals. The crystals were recrystallized from acetone-hexane to give colorless prism crystals, melting point 214-2150C. Reference Example 174 ethyl 2- [ (4-hydroxy-2- ni trophenyl ) hydrazono ] propanoate
Figure imgf000349_0001
To a mixture of 4-hydroxy-2-nitroaniline (5.0 g) , IN hydrochloric acid (65 mL) and acetonitrile (20 mL) was added dropwise an aqueous solution (10 mL) of sodium nitrite (2.44 g) at 0-5°C, and the reaction mixture was stirred at 0°C for 10 min. This mixture was added dropwise to a mixture of ethyl 2- methylacetoacetate (5.61 g) , 85% potassium hydroxide (4.37 g) , ethanol (50 mL) and water (50 mL) at 0-5°C. After the completion of the dropwise addition, IN hydrochloric acid (13 mL) and water were added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried (MgSCU) i and concentrated. The obtained residue was washed with hexane to give the title compound (4.94 g, yield 57%) as brown crystals.
1H-NMR(DMSO-d6)δ:1.29 (3H, t, J=7.06 Hz), 2.13 (3H, s) , 4.24 (2H, q, J=7.03 Hz), 7.30 (IH, dd, J=9.14, 2.73 Hz), 7.46-7.52 (IH, m) , 7.74 (IH, d, J=9.23 Hz), 9.95 (IH, s) , 10.44 (IH, s) .
Reference Example 175 ethyl 5-hydroxy-7-nitro-lH-indole-2- carboxylate
Figure imgf000349_0002
A mixture of Eaton's reagent (1.0 g) and methanesulfonic acid (1.0 g) was stirred at 100°C for 10 min. A mixture of ethyl 2- [ (4-hydroxy-2- nitrophenyl) hydrazono] propanoate (1.0 g) and toluene (10 mL) was added to the mixture, and the mixture was further stirred at 100°C for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography, and eluted with ethyl acetate- methanol (98:2-95:5, volume ratio) to give the title compound (250 mg, yield 27%) as orange crystals.
1H-NMR (DMSO-de) 5: 1.35 (3H, t, J=7.00 Hz), 4.37 (2H, q, J=7.07 Hz), 7.30 (IH, s), 7.56 (IH, d, J=2.27 Hz), 7.74 (IH, d, J=2.27 Hz), 9.93 (IH, brs) , 11.05 (IH, brs) .
Reference Example 176 ethyl 5- [3- (methylsulfonyl) propoxy] -7- nitro-lH-indole-2-carboxylate
Figure imgf000350_0001
A mixture of ethyl 5-hydroxy-7-nitro-lH-indole-2- carboxylate (300 mg) , 3- (methylsulfonyl) propyl 4- methylbenzenesulfonate (410 mg) , potassium carbonate (170 mg) and N, N-dimethylformamide (10 mL) was stirred at room temperature for 15 hr. Ethyl 5-hydroxy-7-nitro-lH-indole-2- carboxylate (100 mg) was added to the reaction mixture, and the mixture was further stirred at 50°C for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSC^) , and concentrated. The obtained residue was washed with diisopropyl ether to give the title compound (400 mg, yield 77%) as yellow crystals. The crystals were recrystallized from acetone-hexane to give yellow prism crystals, melting point 162-163°C. Reference Example 177 ethyl 7-amino-5- [3- (methylsulfonyl) propoxy] -lH-indole-2-carboxylate
Figure imgf000350_0002
A mixture of ethyl 5- [3- (methylsulfonyl) propoxy] -7- nitro-lH-indole-2-carboxylate (200 mg) , 10% palladium-carbon (50% containing water, 100 mg) and tetrahydrofuran (20 mL) was subjected to catalytic reduction at room temperature under hydrogen atmosphere at normal pressure. The catalyst was filtered off, and the filtrate was concentrated. The obtained crystals were washed with hexane to give the title compound (140 mg, yield 78%) as pale-yellow crystals. The crystals were recrystallized. from ethyl acetate-hexane to give pale-yellow prism crystals, melting point 187-188°C. Reference Example 178 ethyl 5- [3- (methylsulfonyl)propoxy] -7- [ (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000351_0001
To a mixture of ethyl 7-amino-5- [3-
(methylsulfonyl)propoxy]-lH-indole-2-carboxylate (4.8 g) and pyridine (50 iαL) was added pyridine-2-sulfonyl chloride (3.0 g) at O0C, and the mixture was stirred at 0°C for 1 hr. The reaction mixture was concentrated, aqueous citric acid solution was added to the residue, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and saturated brine, dried
(MgSO4) , and concentrated. The obtained crystals were washed with diisopropyl ether, and recrystallized from acetone-hexane to give the title compound (4.68 g, yield 69%) as pale-brown prism crystals, melting point 194-195°C. Reference Example 179 ethyl 7- [methyl (pyridin-2- ylsulfonyl) amino] -5- [3- (methylsulfonyl)propoxy] -lH-indole-2- carboxylate
To a mixture of ethyl 5- [3- (methylsulfonyl)propoxy] -7- [ (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxylate (3.50 g) , potassium carbonate (1.01 g) and N, N-dimethylformamide (50 mL) was added methyl iodide (1.14 g) at 0°C, and the reaction mixture was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with a mixed solvent of ethyl acetate—tetrahydrofuran. The organic layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate (1:1-1:4, volume ratio) to give the title compound (2.70 g, yield 75%) as colorless crystals. The crystals were recrystallized from ethyl acetate-hexane to give colorless prism crystals, melting point 176-177°C.
Reference Example 180 7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3- (methylsulfonyl)propoxy]-lH-indole-2-carboxylic acid
Figure imgf000352_0001
A mixture of ethyl 7- [methyl (pyridin-2- ylsulfonyl) amino] -5- [3- (methylsulfonyl)propoxy] -lH-indole-2- carboxylate (2.50 g) , IN aqueous sodium hydroxide solution (10 mL), ethanol (10 itiL) and tetrahydrofuran (10 mL) was stirred at 60°C for 1.5 hr. IN Hydrochloric acid (10 mL) and water were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated to give the title compound (2.30 g, yield 98%) as colorless crystals. The crystals were recrystallized from acetone-hexane to give colorless prism crystals, melting point 207-208°C. Reference Example 181 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3- (methylsulfonyl)propoxy]-lH-indole-2-carboxarαide
Figure imgf000352_0002
A mixture of 7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3- (methylsulfonyl)propoxy]-lH-indole-2-carboxylic acid (2.10 g) , 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (1.30 g) , IH- 1,2,3-benzotriazol-l-ol (730 mg) , N- [3- (dimethylamino) propyl] - N' -ethylcarbodiimide hydrochloride (1.04 g) and N, N- dimethylformamide (50 mL) was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (1:4-1:9, volume ratio) to give the title compound (2.70 g, yield 87%) as a colorless amorphous solid.
1H-NMR (CDCl3) 5:2.29-2.43 (2H, m) , 2.86-3.01 (IH, m) , 2.96 (3H, s), 3.22-3.33 (5H, m) , 3.39 (3H, s) , 3.48 (3H, s) , 3.56-3.71 ' (IH, m) , 3.76-3.93 (3H, m) , 4.04-4.19 (2H, m) , 4.31-4.40 (IH, m) , 6.62-6.68 (IH, m) , 6.80 (IH, t, J=5.68 Hz), 6.93-7.01 (IH, m) , 7.07 (IH, d, J=I.89 Hz), 7.14-7.31 (3H, m) , 7.31-7.40 (2H, m) , 7.63 (IH, dd, J=7.57, 4.92 Hz), 7.99 (IH, t, J=7.00 Hz), 8.13 (IH, d, J=7.95 Hz), 9.24 (IH, d, J=4.54 Hz), 12.31 (IH, brs) .
Reference Example 182 N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3- (methylsulfonyl) propoxy] -lH-indole-2-carboxamide
Figure imgf000353_0001
A mixture of N- [2- (benzylthio) -3, 3-dimethoxypropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino].-5- [3- (methylsulfonyl) propoxy] -lH-indole-2-carboxamide (1.5 g)-, Amberlyst (registered trade mark) 15 ion exchange resin (0.35 g) , acetone (30 mL) and water (0.15 mL) was stirred at room temperature for 18 hr. Amberlyst (registered trade mark) 15 ion exchange resin was filtered off, and washed with ethyl acetate . The filtrate was concentrated under reduced pressure to give the title compound ( 1 . 4 g, yield : 100%) as a pale- yellow amorphous solid . MS : 645 (MH+) .
Reference Example 183 N- [2- (benzylthio) -3-morpholinopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3-
(methylsulfonyl) propoxy] -lH-indole-2-carboxamide
Figure imgf000354_0001
A solution of N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3- (methylsulfonyl) propoxy] -lH-indole-2-carboxamide (0.90 g) and morpholine (0.15 mL) in tetrahydrofuran (20 πiL) was stirred at room temperature for 30 min, and ice-cooled. Sodium triacetoxyborohydride (0.39 g) was added to this solution, and the mixture was stirred from under ice-cooling to room temperature for 16 hr. The reaction solution .was acidified with aqueous citric acid solution, basified with aqueous sodium hydrogencarbonate solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained• residue was subjected to silica gel column chromatography (ethyl acetate :hexane=6: 4-10: 0) to give the title compound (0.89 g, yield: 89%) as a colorless amorphous solid. MS:716(MH+). Reference Example 184 N- [2- (benzylthio) -3- thiomorpholinopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3- (methylsulfonyl) propoxy] -IH-indole-2-carboxamide
Figure imgf000355_0001
A mixture of N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3-
(methylsulfonyl)propoxy] -lH-indole-2-carboxamide (0.75 g) , thiomorpholine (0.24 mL) and 1, 2-dichloroethane (20 itiL) was stirred at room temperature for 15 min. Sodium triacetoxyborohydride (0.74 g) was added to the reaction solution, and the mixture was stirred at room temperature for 5 hr. The reaction solution was acidified with aqueous citric acid solution, basified with aqueous sodium hydrogencarbonate solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=5: 5-10 : 0). to give the title compound (0.76 g, yield: 89%) as a colorless amorphous solid. MS: 733 (MH+) .
Reference Example 185 N- [3- (4-acetylpiperazin-l-yl) -2- (benzylthio) propyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3- (methylsulfonyl)propoxy] -lH-indole-2-carboxamide
Figure imgf000355_0002
A mixture of N- [2- (benzylthio) -3-oxopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3- (methylsulfonyl) propoxy] -lH-indole-2-carboxamide ( 0.35 g) , N- acetylpiperazine (0.14 g) and 1, 2-dichloroethane (8 rtiL) was stirred at room temperature for 10 min. Sodium triacetoxyborohydride (345 mg) was added to the reaction solution, and the mixture was stirred at room temperature for 16 hr. The reaction solution was acidified with aqueous citric acid solution, basified with aqueous sodium hydrogencarbonate solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :methanol=10 : 0-9 : 1) to give the title compound (0.35 g, yield: 85%) as a colorless amorphous solid. MS: 756 (MH+) . Reference Example 186 N- {2- (benzylthio) -3- [4- (methylsulfonyl) piperazin-1-yl] propyl} -7- [methyl (pyridin-2- ylsulfonyl) amino] -5- [3- (methylsulfonyl)propoxy] -lH-indole-2- carboxamide
Figure imgf000356_0001
A mixture of N- [2- (benzylthio) -3-oxopropyl] -7- [m-βthyl (ρyridin-2-ylsulfonyl) amino] -5- [3-
(methylsulfonyl)propoxy]-lH-indole-2-carboxamide (0.35 g) , N- methylsulfonylpiperazine (0.18 g) and 1, 2-dichloroethane (8 iriL) was stirred at room temperature for 20 min. Sodium triacetoxyborohydride (345 mg) was .added to the reaction solution, and the mixture was stirred at room temperature for 16 hr. The reaction solution was acidified with aqueous citric acid solution, and basified with aqueous sodium hydrogencarbonate solution. The precipitated crystals were collected by filtration, washed with water and ethyl acetate, and dried to give the title compound (341 mg, yield: 43%) as colorless crystals. MS: 794 (MH+). melting point :195-196°C. Reference Example 187 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 5- (2-methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carboxaruide
Figure imgf000357_0001
To a mixture of 5- (2-methoxyethoxy) -7- [methyl (pyridin- 2-ylsulfonyl) amino] -IH-indole-2-carboxylic acid (2.50 g) , 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (1.79 g) , diisopropylethylamine (2.00 g) and N,N-dimethylformamide (30 mL) was added 0- (7-azabenzotriazol-l-yl) -N, N, N' ,W - tetramethyluronium hexafluorophosphate (HATU, 3.19 g) at room temperature, and the mixture was stirred at room temperature for 2.5 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with aqueous citric acid solution, saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4)', and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (1:1-1:4, volume ratio) to give the title compound (3.11 g, yield 80%) as a colorless amorphous solid.
1H-NMR (CDCl3) 5:2.85-2.99 (IH, m) , 3.29 (3H, s) , 3.39 (3H, s) , 3.47 (6H, s), 3.55-3.69 (IH, m) , 3.72-3.93 (5H, m) , 4.10-4.21 (2H, m) , 4.35 (IH, d, J=4.54 Hz), 6.64 (IH, d, J=2.27 Hz),
6.78 (IH, t, J=5.49 Hz), 7.00 (IH, d, J=2.27 Hz), 7.09 (IH, d, J=I.89 Hz), 7.14-7.22 (IH, m) , 7.22-7.38 (4H, m) , 7.61 (IH, dd, J=7.00, 3.98 Hz), 7.92-8.03 (IH, m) , 8.10 (IH, d, J=7.95 Hz), 9.21 (IH, d, J=4.17 Hz), 12.15 (IH, brs) . Reference Example 188 5- (2-methoxyethoxy) -7- [ (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid
Figure imgf000358_0001
To a mixture of ethyl 5- (2-methoxyethoxy) -7- [ (pyridin- 2-ylsulfonyl) amino] -lH-indole-2-carboxylate (5.40 g) , tetrahydrofuran (50 mL) and methanol (50 mL) was " added a 85% aqueous solution (30 mL) of potassium hydroxide (3.0 g) , and the mixture was stirred at room temperature for 15 hr. The reaction mixture was concentrated, aqueous citric acid solution was added to the residue, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with water, and concentrated to give a white solid. The obtained solid was washed with a mixed solvent of ethyl acetate-hexane to give the title compound (4.24 g, yield 84%) as colorless crystals, melting point 230-232°C. Reference Example 189 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 5- (2-methoxyethoxy) -7- [ (pyridin-2-ylsulfonyl) amino] -IH-indole- 2-carboxamide
Figure imgf000358_0002
A mixture of 5- (2-methoxyethoxy) -7- [ (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid (4.24 g) , 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (2.88 g) , IH-I, 2,3- benzotriazol-1-ol (1.80 g) , N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (2.70 g) and N, N- dimethylformamide (40 mL) was stirred at room temperature for 3 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCU) r and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (2:3-1:4, volume ratio) to give the title compound (6.03 g, yield 91%) as a colorless amorphous solid.
1H-NMR (CDCl3) 5:2.95-3.06 (IH, m) , 3.12-3.36 (IH, m) , 3.38 (3H, s) , 3.45 (3H, s), 3.46 (3H, s) , 3.72-3.80 (3H, m) , 3.83 (2H, s), 4.06-4.16 (2H, m) , 4.37 (IH, d, J=4.16 Hz), 6.59 (IH, d, J=I.89 Hz), 6.87 (IH, d, J=I.89 Hz), 7.07-7.23 (5H, m) , 7.28- 7.34 (2H, m) , 7.37-7.45 (IH, m) , 7.56-7.67 (IH, m) , 7.83 (IH, d, J=7.57 Hz), 8.27 (IH, d, J=4.17 Hz), 9.18 (IH, brs) , 11.30 (IH, brs) . Reference Example 190 N- [2- (benzylthio) -3-oxopropyl] -5- (2- methoxyethoxy) -7- [ (pyridin-2-ylsulfonyl) amino] -lH-indole-2- carboxamide
Figure imgf000359_0001
A mixture of N- [2- (benzylthio) -3, 3-dimethoxypropyl] -5- (2-methoxyethoxy) -7- [ (pyridin-2-ylsulfonyl) amino] -IH-indole-2- carboxamide (3.0 g) , Amberlyst (registered trade mark) 15 ion exchange resin (600 mg) , acetone (80 mL) and water (260 ifcig) was stirred at room temperature for 15 hr. The insoluble substance was removed by filtration, and the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (2:3-1:9, volume ratio) to give the title compound (2.09 g, yield 75%) as colorless crystals.
Figure imgf000359_0002
(3H, s) , 3.70-3.79 (5H, m) , 3.86-4.01 (2H, m) , 4.05-4.13 (2H, m) , 6.67 (IH, d, J=2.07 Hz), 6.71-6.80 (IH, m), 6.84 (IH, d, J=I.88 Hz), 7.10 (IH, d, J=I.88 Hz), 7.16- 7.37 (5H, m) , 7.57-7.69 (IH, m) , 7.83 (IH, d, J=I .12 Hz),' 8.25 (IH, d, J=3.01 Hz), 8.86 (IH, brs), 9.39 (IH, d, J=I .32 Hz), 11.21 (IH, brs) . Reference Example 191 N- [2- (benzylthio) -3- (1, 1- dioxidothiomorpholino) propyl] -5- (2-methoxyethoxy) -7- [ (pyridin- 2-ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000360_0001
A mixture of N- [2- (benzylthio) -3-oxopropγl] -5- (2- methoxyethoxy) -7- [ (pyridin-2-ylsulfo'nyl) amino] -IH-indole-2- carboxamide (500 mg) , thiomorpholine 1,1-dioxide (240 mg) and tetrahydrofuran (10 mL) was stirred at room temperature for 30 min. Sodium triacetoxyborohydride (280 mg) was added at room temperature, and the mixture was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate . The ethyl acetate ■ layer was washed with saturated brine, dried (MgSCM / and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (3:7-1:9, volume ratio) to give the title compound (210 mg, yield 35%) as a colorless amorphous solid. 1H-NMR(CDCl3)O^.65 (2H, d, J=7.19 Hz), 2.79-3.14 (8H, m) , 3.47 (3H, s), 3.49-3.63 (IH, m) , 3,68-3.85 (4H, m) , 4.03-4.20 (3H, m) , 6.64 (IH, d, J=I.51 Hz), 6.88 (IH, d, J=I.51 Hz), 6.95- 7.08 (IH, m) , 7.08-7.36 (8H, m) , 7.53-7.70 (IH, m) , 7.84 (IH, d, J=7.95 Hz), 8.05 (IH, d, J=4.17 Hz), 9.10 (IH, brs) , 11.44 (IH, brs) .
Reference Example 192 N- [2- (benzylthio) -3- thiomorpholinopropyl] -5- (2-methoxyethoxy) -7- [ (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxamide .
Figure imgf000360_0002
A mixture of N- [2- (benzylthio) -3-oxopropyl] -5- (2- methoxyethoxy) -7- [ (pyridin-2-ylsulfonyl) amino] -lH-indole-2- carboxamide (800 ing) , thiomorpholine (290 mg) and tetrahydrofuran (30 mL) was stirred at room temperature for 30 min. Sodium triacetoxyborohydride (450 mg) was added at room temperature, and the mixture was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCu) / and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (3:2-1:4, volume ratio) to give the title compound (590 mg, yield 64%) as colorless crystals. The crystals were recrystallized from acetone-hexane to give colorless prism crystals, melting point 160-1610C. Reference Example 193 ethyl 2-{ [4- (3-methoxypropoxy) -2- nitrophenyl]hydrazono}propanoate
Figure imgf000361_0001
To a mixture of ethyl 2- [ (4-hydroxy-2- nitrophenyl) hydrazono] propanoate (6.81 g) , potassium carbonate (3.52 g) and N,N-dimethylformamide (100 mL) was added 1-bromo- 3-methoxypropane (3.90 g) at 600C, and the mixture was stirred at 600C for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with- hexane-ethyl acetate (4:1-1:1, volume ratio) to give the title compound (3.67 g, yield 42%) as orange crystals. 1H-NMR(CDCl3)SlLSg (3H, t, J=7.19 Hz), 2.01-2.14 (2H, ,m)-, 2.22 (3H, s), 3.37 (3H, s) , 3.56 (2H, t, J=6.06 Hz), 4.09 (2H, t, J=6.25 Hz), 4.35 (2H, q, J=7.07 Hz), 7.23-7.31 (IH, m) , 7.64 (IH, d, J=2.65 Hz), 7.98 (IH, d, J=9.09 Hz), 10.82 (IH, s) . Reference Example 194 ethyl 5- (3-methoxypropoxy) -7-nitro-lH- indole-2-carboxylate
Figure imgf000362_0001
Methanesulfonic acid (15 g) was added to Eaton's reagent (15 g) at 90°C, and the mixture was stirred at 90°C for 30 min. A toluene solution (150 πiL) of ethyl 2-{[4-(3- methoxypropoxy) -2-nitrophenyl] hydrazono}propanoate (16.17 g) was added dropwise to the mixture, and the reaction mixture was stirred at 9O0C for 30 min. Ice water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with water, saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-2:1, volume ratio) to give the title compound (6.51 g, yield 42%) as orange crystals. The crystals were recrystallized from ethyl acetate-hexane to give orange prism crystals, melting point 94-95°C.
Reference Example 195 ethyl 7-amino-5- (3-methoxypropoxy) -IH- indole-2-carboxylate
Figure imgf000362_0002
A mixture of ethyl 5- (3-methoxypropoxy) -7-nitro-lH- indole-2-carboxylate (6.15 g) , 10% palladium-carbon (50% containing water, 1.0 g) and tetrahydrofuran (150 inL) was subjected to catalytic reduction at room temperature under hydrogen atmosphere at normal pressure. The catalyst was filtered off, and the filtrate was concentrated. The obtained crystals were washed with diisopropyl ether to give the title compound (5.41 g, yield 97%) as yellow crystals. The crystals were recrystallized from ethyl acetate-diisopropyl ether to give pale-yellow prism crystals, melting point 139-140°C.
Reference Example 196 ethyl 5- (3-methoxypropoxy) -7- [ (pyridin- 2-ylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000363_0001
To a mixture of ethyl 7-amino-5- (3-methoxypropoxy) -IH- indole-2-carboxylate (3.00 g) and pyridine (50 mL) was added pyridine-2-sulfonyl chloride (2.0 g) at 0°C, and the mixture was stirred at room temperature for 15 hr. The reaction mixture was concentrated, IN hydrochloric acid and ethyl acetate were added to the residue, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and saturated brine, dried
(MgSC>4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane- ethyl acetate (2:1-1:1, volume ratio) to give the title compound (4.02 g, yield 90%) as colorless crystals. The crystals were recrystallized from ethyl acetate-hexane to give colorless prism crystals, melting point 126-127°C. Reference Example 197 ethyl 5- (3-methoxypropoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000363_0002
To a mixture of ethyl 5- (3-methoxypropoxy) -7- [ (pyridin- 2-ylsulfonyl) amino] -lH-indole-2-carboxylate (3.97 g) , potassium carbonate (1.27 g) and N,N-dimethylformamide (30 mL) was added methyl iodide (1.56 g) at room temperature, and the reaction mixture was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was crystallized from ethyl acetate- hexane, and the crystals were washed with hexane to give the title compound (3.63 g, yield 88%) as colorless crystals. The crystals were recrystallized from ethyl acetate-hexane to give colorless prism crystals, melting point 98-99°C. Reference Example 198 5- (3-methoxypropoxy) -7- [methyl (pyridin- 2-ylsulfonyl) amino] -IH-indole-2-carboxylic acid
Figure imgf000364_0001
A mixture of ethyl 5- (3-methoxypropoxy) -7-
[methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxylate (3.50 g) , IN aqueous sodium hydroxide solution (10 mL) , ethanol (10 mL) and tetrahydrofuran (10 mL) was stirred at 50°C for 1 hr. IN Hydrochloric acid (10 mL) and water were added to the reaction mixture, and the mixture was extracted with a mixed solvent of tetrahydrofuran-ethyl acetate. The organic layer was washed with saturated brine, dried (MgSCM , and concentrated. The obtained crystals were washed with hexane to give the title compound (3.26g, 100%) as colorless crystals. MS: 420 (MH+) .
Reference Example 199 N- [2- (benzylthio) -3- thiomorpholinopropyl] -5- (3-methoxypropoxy) -7- [methyl (pyridin- 2-ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000364_0002
A mixture of 5- (3-methoxypropoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid (330 mg) , 2- (benzylthio) -3-thiomorpholinopropan-l-amine (200 mg) , IH- 1,2, 3-benzotriazol-l-ol (120 mg) , N- [3- (dimethylamino) propyl]- N' -ethylcarbodiimide hydrochloride (180 mg) and N,N- dimethylformamide (5 mL) was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated. .The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (1:1-1:2, volume ratio) to give the title compound (380 nag, yield 78%) as a pale-yellow amorphous solid.
1H-NMR (CDCl3) 5:2.00-2.12 (2H, m) , 2.43-2.82 (1OH, m) , 2.91 (IH, dd, J=Il.55, 4.73 Hz), 3.29 (3H, s), 3.38 (3H, s), 3.50-3.63 (3H, m) , 3.76-3.91 (3H, m) , 4.08 (2H, t, J=6.25 Hz), 6.69 (IH, d, J=I.89 Hz), 6.96 (IH, d, J=I.89 Hz), 7.09 (IH, d, J=I.89 Hz), 7.16-7.41 (5H, m) , 7.51 (IH, t, J=5.11 Hz), 7.62 (IH, dd, J=I.16, 4.73 Hz), 7.98 (IH, t, J=7.76 Hz), 8.11 (IH, d, J=7.95 Hz), 9.22 (IH, d, J=4.54 Hz), 12.23 (IH, brs) . Reference Example 200 3-fluoro-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carbothioamide
Figure imgf000365_0001
To a solution of 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxamide (5.60 g) in 1, 2-dichloroethane' (170 mL) was added N-fluoropyridinium triflate (8.23 g) , and the mixture was heated under reflux for 4- hr. Saturated aqueous sodium hydrogen solution and IN aqueous sodium thiosulfate solution were added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous- magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate :hexane = 50:50-100:0) to give the title compound (1.43 g, crude product) as a pale-yellow solid. To a solution of this solid in tetrahydrofuran (40 mL) was added Lawesson' s reagent (1.56 g) , and the mixture was stirred at 60°C for 5 hr, and concentrated under reduced pressure. The precipitated solid was washed with toluene to give the title compound (494 rag, yield 8%) as pale-yellow crystals. MS:370(MH+). Reference Example 201 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 5-hydroxy-7-nitro-lH-indole-2-carboxamide
Figure imgf000366_0001
To a solution of ethyl 5-hydroxy-7-nitro-lH-indole-2- carboxylate (5.11 g) in tetrahydrofuran (80 itiL) and ethanol (80 mL) was added IN aqueous sodium hydroxide solution (45 mL) , and the mixture was stirred at room temperature for 3 hr. The organic solvent was evaporated under reduced pressure, ethyl acetate was added, and the mixture was acidified with 6N hydrochloric acid. The organic layer was dried (MgSO4) , and concentrated to give a pale-yellow solid (5.2 g) . To a solution of this solid and 2- (benzylthio) -3, 3-dimethoxypropan- 1-amine (5.2 g) in tetrahydrofuran (100 mL) and acetonitrile (100 mL) were added l-ethyl-3- (3- dimethylaminopropyl) carbodiimide hydrochloride (4.95 g) and 1- hydroxybenzotriazole monohydrate (3.96 g) , and the mixture was stirred overnight at room temperature. The mixture was diluted with ethyl acetate, washed' with saturated aqueous sodium hydrogencarbonate, water and saturated brine, dried over anhydrous magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane: ethyl acetate=10 : 1-0 : 1) , and the obtained solid was recrystallized (ethyl acetate-diisopropyl ether) to give the title compound (4.77 g, yield 50%) as a colorless solid. melting point 134-
135°C.
Reference Example 202 2- ({ [2- (benzylthio) -3, 3- dimethoxypropyl] amino }carbonyl) -7-nitro-lH-indol-5-yl pivalate
Figure imgf000367_0001
To a solution of N- [2- (benzylthio) -3, 3- dimethoxypropy1] -5-hydroxy-7-nitro-lH-indole-2-carboxamide (1.0 g) in tetrahydrofuran (10 mL) were added dropwise triethylamine (0.38 mL) and pivaloyl chloride (0.30 rαL) under ice-cooling. The mixture was stirred overnight at room temperature, diluted with ethyl acetate, washed with water, IN hydrochloric acid and saturated brine, dried (MgSO4) , and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate=l:l) to give the ■ title compound (1.18 g, yield 99%) as a pale-yellow amorphous powder .
1H-NMR (DMSO-d6) δ: 1.36 (9H, s) , 3.02-3.12 (IH, m) , 3.31 (3H, s), 3.32-3.35 (3H, m) , 3.36-3.46 (IH, m) , 3.61-3.76 (IH, m) , 3.83 (2H, s), 4.38 (IH, d, J=4.3 Hz), 7.08-7.17 (IH, m) , 7.17-7.25 (2H, m) , 7.26-7.33 (2H7 m) , 7.39 (IH, s) , 7.87-8.21 (2H, m) , 9.14 (IH, t, J=5.7 Hz), 11.44 (IH, brs) .
Reference Example 203 2- [5- (dimethoxymethyl) -4, 5-dihydro-l , 3- thiazol-2-yl] -7-nitro-lH-indol-5-yl pivalate
Figure imgf000367_0002
To a solution of triphenylphosphine oxide (14.8 g) in dichloromethane (50 mL) was added dropwise trifluoromethanesulfonic anhydride (3.0 mL) under ice-cooling, and the mixture was stirred for 30 min. A solution of 2-({[2- (benzylthio) -3, 3-dimethoxypropyl] amino}carbonyl) -7-nitro-lH- indol-5-yl pivalate (9.38 g) and thioanisole (10.4 mL) in dichloromethane (100 mL) was added dropwise to this solution at -78°C, and the reaction mixture was stirred at -78°C for 1 hr, and then at 00C for 1 hr. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with water and saturated brine, dried (MgSO4) , and concentrated. The residue was purified by basic silica gel column chromatography (hexane : ethyl acetate=l : 0-4: 6) to give the title compound (4.32 g, yield 58%) as a pale-yellow amorphous powder. MS: 422 (MH+) .
Reference Example 204 7-amino~2- [5- (dimethoxymethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-5-yl pivalate
Figure imgf000368_0001
To a solution of 2- [5- (dimethoxymethyl) -4, 5-dihydro- l,3-thiazol-2-yl]-7-nitro-lH-indol-5-yl pivalate (4.32 g) in ethanol (100 mL) were added water (10 ml>) , calcium chloride (1.13 g) and iron (3.42 g) , and the mixture was stirred at 900C for 2 hr. The mixture was allowed to cool, and basified with saturated aqueous sodium hydrogencarbonate, and the insoluble substance was filtered off. The filtrate was extracted with ethyl acetate, and the combined organic layers were washed with water and saturated brine, dried (MgSO4) , and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate=4: 1-1 : 3) to give the title compound (2.55 g, yield 64%) as a pale-yellow amorphous powder. MS: 392 (MH+). Reference Example 205 2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indol- 5-yl pivalate
Figure imgf000368_0002
To a solution of 7-amino-2- [5- (dimethoxymethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-5-yl pivalate (2.55 g) in pyridine (50 mL) was added dropwise a pyridine solution (10 mL) of pyridine-2-sulfonyl chloride (1.27 g) under ice-cooling, and the mixture was stirred at room temperature for 30 min. The reaction solution was diluted with ethyl acetate and diethyl ether, washed with water and saturated brine, dried (MgSC>4) , and concentrated. The residue was dissolved in N, N- dimethylformamide (50 mL) , and potassium carbonate (1.1 g) and methyl iodide (0.45 mL) were added under ice-cooling. The mixture was stirred at room temperature for 30 min, diluted with ethyl acetate, washed with water and saturated brine, dried (MgSO4), and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate=95: 5-4 : 6) to give the title compound (3.1 g, yield 87%) as a pale-yellow amorphous powder. MS: 547 (MH+) .
Reference Example 206 N-{5-hydroxy-2- [5-
(thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol- 7-yl}-N-methylpyridine-2-sulfonamide
Figure imgf000369_0001
To a solution of 2- [5- (dimethoxymethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indol-5-yl pivalate (273 mg) in trifluoroacetic acid (2 mL) were added water (4 mL) and concentrated sulfuric acid (2 mL) , and the mixture was stirred at 80°C for 5 hr, basified with saturated aqueous sodium hydrogencarbonate, and extracted with ethyl acetate. The organic layer was diluted with ethyl, acetate, washed with water and saturated brine, dried (MgSO4), and concentrated under reduced pressure. To a tetrahydrofuran solution (5 mL) of the residue were added thiomorpholine (0.041 mL) and sodium triacetoxyborohydride (215 mg) , and the mixture was stirred overnight at room temperature. Saturated aqueous sodium hydrogencarbonate and ethyl acetate were added to the reaction solution, and the organic layer was washed with water and saturated brine, dried (MgSO4) , and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (h'exane: ethyl acetate=5: 1-1:2) to give the title compound (145 mg, yield 85%) as a colorless amorphous powder. MS: 504 (MH+).
Reference Example 207 5- (2-methoxyethoxy) -7-nitro-lH-indole-2- carboxylic acid
Figure imgf000370_0001
Ethyl 5- (2-methoxyethoxy) -7-nitro-lH-indole-2- carboxylate (7.7 g) was dissolved in a mixed solvent of ethanol (75 mL) and tetrahydrofuran (75 mL) , IN aqueous sodium hydroxide solution (75 mL) was added to this solution, and the mixture was stirred at 50°C for 1.5 hr. Aqueous citric acid solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained crude product was crystallized from ethyl acetate-hexane to give the title compound (6.8 g, yield 97%) as yellow crystals, melting point 192-1930C. Reference Example 208 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 5- (2-methoxyethoxy) -7-nitro-lH-indole-2-carboxamide
Figure imgf000370_0002
A mixture of 5- (2-methoxyethoxy) -7-nitro-lH-indole-2- carboxylic acid (4.7 g) , 2- (benzylthio) -3, 3-dimethoxypropan-l- amine (4.9 g) , 1H-1,2, 3-benzotriazol-l-ol (3.4 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiirαide hydrochloride (4.9 g) and N,N-dimethylformamide (150 mL) 'was stirred at room temperature for 15 hr. The reaction solution was concentrated under reduced pressure, ethyl acetate and water were added, and the mixture was extracted with ethyl acetate. The obtained organic .layer was washed successively with aqueous citric acid solution, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (ethyl acetate :hexane=20 : 80-80 : 20) to give the title compound (6.8 g, yield 97%) as a orange oil.
1H-NMR (CDCl3) 6:2.85-2.99 (IH, m) , 3.39 (3H, s) , 3.48 (6H, s) , 3.52-3.65 (IH, m) , 3.76-3.94 (5H, m) , 4.18-4.29 (2H, m) , 4.35
(IH, d, J=4.2 Hz), 6.73 (IH, d, J=2.3 Hz), 6.80 (IH, brs) ,
7.09-7.45 (5H, m) , 7.55 (IH, d, J=2.3 Hz), 7.94 (IH, d, J=2.3
Hz) , 10.27 (IH, s) .
Reference Example 209 2- [5- (dimethoxymethyl) -4 , 5-dihydro-l , 3- thiazol-2-yl] -5- (2-methoxyethoxy) -7-nitro-lH-indole
Figure imgf000371_0001
Triphenylphosphine oxide (3 g) was dissolved in dichloromethane (30 mL) , trifluoroacetic anhydride (3.1 g) was added under ice-cooling, and the mixture was stirred for 10 min. A solution of N- [2- (benzylthio) -3, 3-dimethoxypropyl] -5- (2-methoxyethoxy) -7-nitro-lH-indole-2-carboxamide (5.0 g) and thioanisole (2.5 g) in dichloromethane (20 mL) was added dropwise to this suspension under ice-cooling. The reaction solution was allowed to warm to room temperature, and stirred for 10 min. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained crude product was subjected to silica gel column chromatography. (ethyl acetate : hexane=10 : 90-40: 60) , and the obtained solid was washed with ethyl acetate-hexane to give the title compound (6.8 g, yield 97%) as yellow crystals. melting point 100-1010C. '
Reference Example 210 2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -5- (2-methoxyethoxy) -lH-indol-7-amine
Figure imgf000372_0001
2- [5- (Dimethoxymethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -5- (2-methoxyethoxy) -7-nitro-lH-indole (100 mg) was suspended in' ethanol, and 10% palladium-carbon (50% containing water, 50 mg) was added under nitrogen atmosphere. Hydrazine monohydrate (0.07 HiL) was added to the mixture, and the mixture was stirred at 90°C for 2 hr. Hydrazine monohydrate (0.07 ruL) was added again, and the mixture was further stirred at 90°C for 1 hr. The reaction solution was allowed to cool to room temperature, the catalyst was filtered off, and the filtrate was concentrated under reduced pressure. The obtained crude product was subjected to silica gel column chromatography
(ethyl acetate :hexane=30: 70-80 : 20) to give the title compound (27 mg, yield 29%) as a orange oil.
1H-NMR(CDCl3)0: 3.38 (3H, s) , 3.41 (3H, s) , 3.43 (3H, s) , 4.07- 4.16 (3H, m) , 4.30-4.48 (3H, m) , 6.29 (IH, brs) , 6.52 (IH, brs), 6.77 (IH, s) , 10.28 (IH, s) .
Reference Example 211 ethyl 5- ( 2-methoxyethoxy) -7- { [ ( 1-methyl- lH-imidazol-2-yl ) sulfonyl] amino } -IH- indole-2-carboxylate
Figure imgf000372_0002
Ethyl 7-amino-5- (2-methoxyethoxy) -lH-indole-2- carboxylate (1 g) was dissolved in tetrahydrofuran (10 itiL) , then 2,6-lutidine (2.5 mL) and l-methyl-lH-imidazole-2- sulfonyl chloride (0.98 g) were added under ice-cooling, and the mixture was stirred' at room temperature for 2 hr. IN Hydrochloric acid was added to the reaction solution under ice-cooling, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (ethyl acetate :hexane=10: 90-100: 0) to give the title compound (780 mg, yield 51%) as a white solid. MS: 566 (MH+). Reference Example 212 ethyl 5- (2-methoxyethoxy) -7-{methyl [ (I-1 methyl-lH-imidazol-2-yl) sulfonyl] amino}-lH-indole-2- carboxylate
Figure imgf000373_0001
Ethyl 5- (2-methoxyethoxy) -7-{ [ (l-methyl-lH-imidazol-2- yl) sulfonyl] amino}-lH-indole-2-carboxylate (780 mg) was dissolved in N,N-dimethylformamide (10 mL) , potassium carbonate (256 mg) and methyl iodide (0.15 mL) were added, and the mixture was stirred at room temperature for 15.5 hr. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with aqueous sodium thiosulfate solution and saturated brine, dried over magnesium sulfate, and filtrated, and the -filtrate was concentrated under reduced pressure. The obtained crude product was subjected to basic silica gel column chromatography (ethyl acetate :hexane=10: 90-40: 60) to give the title compound (740 mg, yield 92%) as a colorless oil. MS: 437 (MH+) . Reference Example 213 5- (2-methoxyethoxy) -7- {methyl [ (1-methyl- lH-imidazol-2-yl ) sulfonyl ] amino } -lH-indole-2-carboxylic acid
Figure imgf000374_0001
Ethyl 5- (2-methoxyethoxy) -7- {methyl [ (1-methyl-lH- imidazol-2-yl) sulfonyl] amino}-IH-indole-2-carboxylate (2.8 g) was dissolved in a mixed solvent of tetrahydrofuran (12 iuL) and ethanol (12 rαL) , IN aqueous sodium hydroxide solution (12 mL) was added, and the mixture was stirred at 60°C for 1.5 hr. The reaction solution was acidified with IN hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained crude product was recrystallized from ethyl acetate-hexane to give the title compound (2.5 g, yield 95%) as a white solid. melting point 174-175°C.
Reference Example 214 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 5- (2-methoxyethoxy) -7- {methyl [ (l-methyl-lH-imidazol-2- yl) sulfonyl] amino}-IH-indole-2-carboxamide
Figure imgf000374_0002
A mixture of 5- (2-methoxyethoxy) -7- {methyl [ (1-methyl- lH-imidazol-2-yl) sulfonyl] amino}-IH-indole-2-carboxylic acid (2.3 g) , 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (1.7 g) , lH-l,2,3-benzotriazol-l-ol (1.2 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (1.6 g) and N,N-dimethylformamide (70 mL) was stirred at room temperature for 14 hr. The reaction solution was concentrated under reduced pressure, ethyl acetate and water were added, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water, aqueous citric acid solution, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over magnesium sulfate, and filtrated, and. the filtrate was concentrated under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (ethyl acetate :hexane=20: 80-80 : 20) to give the title compound (3.2 g, yield 89%) as a colorless oil.
1H-NMR (CDCl3) 5:2.87-2.96 (IH, m) , 3.37 (3H, s) , 3.46 (3H, s) , 3.47 (3H, s), 3.50 (3H, s) , 3.54-3.66 (IH, m) , 3.74-3.80 (2H, m) , 3.80-3.89 (6H, m) , 4.12-4.19 (2H, m) , 4.34 (IH, d, J = 4.5 Hz), 6.63 (IH, d, J = 2.3 Hz), 6.74 (IH, t, J = 5.5 Hz), 6.97 (IH, s), 7.05 (IH, d, J = 2.3 Hz), 7.13 (IH, d, J = 2.3 Hz), 7.14-7.21 (IH, m) , 7.22-7.29 (IH, m) , 7.30-7.38 (3H, rα) , 12.24 (IH, s) . Reference Example 215 N-{ [4- (benzylthio) tetrahydro-2H-pyran-4- yl] methyl} -5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000375_0001
A mixture of 5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid (1.0 g) , l-[4- (benzylthio) tetrahydro-2H-pyran-4-yl]methanamine (0.65 g) , IH- 1, 2,3-benzotriazol-l-ol (0.44 g) , N- [3- (dimethylamino) propyl] - N' -ethylcarbodiimide hydrochloride (0.62 g) and N, N- dimethylformamide (15 mL) was stirred at room temperature for 18 hr. The reaction solution was concentrated under reduced pressure, ethyl acetate and water were added, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water, aqueous citric acid solution, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained crude, product was subjected to silica gel column chromatography (ethyl acetate :hexane=20: 80-80:20) to give the title compound (1.4 g, yield 90%) as a white solid. MS: 625 (MH+) .
Reference Example 216 N- [2- (benzylthio) -3, 3-dimethoxy-2- methylpropyl] -5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000376_0001
To a mixture of 5- (2-methoxyethoxy) -7- [methyl (pyridin- 2-ylsulfonyl) amino] -lH-indole-2-carboxylic acid (1.62 g) , IH- 1,2,3-benzotriazol-l-ol (919 mg) , 2- (benzylthio) -3, 3- dimethoxy-2-methylpropan-l-amine (1.02 g) and N, N- dimethylformamide (30 mL) was added- N- [3-
(dimethylamino) propyl] -Nf -ethylcarbodiimide hydrochloride (1.53 g) at room temperature, and the mixture was added overnight at room temperature, and concentrated under reduced pressure. The residue was diluted with ethyl acetate and water. The organic layer was washed with saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to give the title compound (1.96 g, yield 76%) as a colorless amorphous solid from a fraction eluted with ethyl acetate-hexane (4:1). 1H-NMR(CDCl3)OlLSe (3H, s) , 3.29 (3H, s) , 3.47 (3H, s) , 3.60 (6H, s), 3.66-3.83 (4H, in), 3.89 (2H, s) , 4.04-4.17 (2H, m) , 4.25 (IH, s), 6.66 (IH, d, J=2.3 Hz), 6.91 (IH, t, J=5.3 Hz), 7.01 (IH, d, J=2.3 Hz), 7.09 (IH, d, J=2.3 Hz), 7.20-7.37 (4H, m) , 7.60 (IH, dd, J=6.6, 4.7 Hz), 7.96 (IH, td, J=7.8, 1.9 Hz), 8.03-8.17 (IH, m) , 9.22 (IH, d, J=4.9 Hz), 12.21 (IH, brs) . Reference Example 217 N- [2- (benzylthio) -2-methyl-3-oxopropyl] - 5- (2-methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carboxamide
Figure imgf000377_0001
To a mixture of N- [2- (benzylthio) -3, 3-dimethoxy-2- methylpropyl] -5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxamide (1.95 g) , water (0.16 mL) and acetone (30 mL) was added Amberlyst (registered1 trade mark) 15 ion exchange resin (500 mg) at room temperature, and the mixture was added overnight at room temperature. The insoluble substance was filtered off. The filtrate was concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography to give the title compound (1.56 g, yield 87%) as a colorless amorphous solid from a fraction eluted with ethyl acetate-hexane (9:1).
1H-NMR(CDCl3)0: 1.41 (3H, s) , 3.26 (3H, s) , 3.47 (3H/ s) , 3.62 (2H, s), 3.74-3.84 (4H, m) , 4.09-4.19 (2H, m) , 6.28 (IH, t, J=6.3 Hz), 6.66 (IH, d, J=2.1 Hz), 7.01 (IH, d, J=2.3 Hz), 7.06 (IH, d, J=2.1 Hz), 7.22-7.38 (3H, m) , 7.61 (IH, ddd,
J=7.7, 4.7, 1.1 Hz), 7.97 (IH, td, J=7.7, 1.8 Hz), 8.10 (IH, d, J=7.9 Hz), 9.12-9.22 (IH, m) , 9.24 (IH, s) , 12.27 (IH, brs). Reference Example 218 N- [2- (benzylthio) -2-methyl-3- thiomorpholinopropyl] -5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000378_0001
To a mixture of N- [2- (benzylthio) -2-methyl-3- oxopropyl] -5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxamide (1.56 g) and 1,2- dichloroethane (50 mL) was added thiomorpholine (1.31 mL) at room temperature, and the mixture was stirred at room temperature for 30 min. Sodium triacetoxyborohydride (1.66 g) was added, and the reaction mixture was stirred overnight at room temperature. Aqueous sodium bicarbonate was added, and ' the mixture was extracted with 1, 2-dichloroethane. The extract was washed with saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to give the title compound (998 mg, yield 56%) as a colorless amorphous solid from a fraction eluted with ethyl acetate-hexane (9:1) .
1H-NMR (CDCl3) δ: 1.35 (3H, s) , 2.49-2.78 (6H, m) , 2.80-3.01 (4H, m) , 3.29 (3H, s) , 3.47 (3H, s) , 3.58-3.71 (IH, m) , 3.72-3.87 (4H, m) , 4.08-4.24 (2H, m) , 6.75 (IH, s) , 7.02 (IH, d, J=2.3 Hz), 7.11 (IH, d, J=I.9 Hz), 7.19-7.36 (4H, m) , 7.45-7.56 (IH, m) , 7.54-7.71 (IH, m) , 7.94-8.04 (IH, m) , 8.11 (IH, d, J=7.9 Hz), 9.22 (IH, d, J=O.8 Hz), 12.28 (IH, brs) . Reference Example 219 tert-butyl [2- (benzylthio) -3, 3- dimethoxypropyl] carbamate
Figure imgf000378_0002
2- (Benzylthio) -3, 3-dimethoxypropan-l-amine (Ig) was dissolved in tetrahydrofuran (7 mL) , and IN aqueous sodium hydroxide solution (10 mL) was added. A solution of t-butyl bicarbonate (993 mg) in tetrahydrofuran (3 xαL) was added dropwise to the reaction solution under ice-cooling, and the mixture was stirred overnight at room temperature. The reaction mixture was extracted with ethyl acetate, and the organic layer was washed with saturated brine, and dried over sodium sulfate. The obtained solution was filtrated through basic silica gel, and concentrated to give the title compound (1.39 g, yield 99%) as a pale-yellow' oil.
1H-ISlMR(CDCl3)0: 1.44 (9H, s) , 2.80 (IH, q, J=5.8 Hz), 3.15-3.30 (IH, m) , 3.32 (3H, s) , 3.37 (3H, s) , 3.40-3.55 (IH, m) , 3.81 (2H, d, J=I.5 Hz), 4.25 (IH, d, J=4.9 Hz), 5.00 (IH, brs) , 7.20-7.37 (5H, m) .
Reference Example 220 tert-butyl [2- (benzylthio) -3- oxopropyl] carbamate
Figure imgf000379_0001
tert-Butyl [2- (benzylthio) -3, 3- dimethoxypropyl] carbamate (9.4 g) was dissolved in tetrahydrofuran (50 rαL) and water (50 itiL) , and acetic acid (100 mL) was added. The reaction mixture was stirred overnight at 5O0C, and concentrated, and the residue was partitioned between ethyl acetate and saturated aqueous sodium hydrogencarbonate solution. The organic layer was washed with saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel chromatography to give the title compound (5.35 g, yield 66%) as a pale-yellow oil from a fraction eluted with ethyl acetate-hexane (1:19) .
1H-NMR (CDCl3) δ: 1.42 (9H, s) , 3.31-3,44 (3H, m) , 3.59-3.75 (2H, m) , 4.83 (IH, brs), 7.20-7.37 (5H, m) , 9.35 (IH, d, J=2.3 Hz). Reference Example 221 tert-butyl [2- (benzylthio) -3- thiomorpholinopropyl] carbamate
Figure imgf000380_0001
To a solution of tert-butyl [2- (benzylthio) -3- oxopropyl] carbamate (820 mg) in tetrahydrofuran (30 itiL) was added thiomorpholine (0.42 mL) , and the mixture was stirred at room temperature for 1 hr. Sodium triacetoxyborohydride (1.76 g) was added to the reaction mixture' under ice-cooling, and the mixture was stirred overnight at room temperature. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture under ice-cooling, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography to give the title compound (936 mg, yield 91%) as a colorless oil from a fraction eluted with ethyl acetate-hexane (3:7).
1H-NMR(CDCI3)OII^S (9H, s) , 2.29-2.85 (HH, m) , 3.09-3.56 (2H, m) , 3.78 (2H, s) , 7.20-7.37 (5H, m) .
Reference Example 222 2- (benzylthio) -3-thiomorpholinopropan-l- amine
Figure imgf000380_0002
To a solution of tert-butyl [2- (benzylthio) -3- thiomorpholinopropyl] carbamate (21.46 g) in a mixed solvent of ethyl acetate (60 mL) and methanol (60 mL) was added hydrogen chloride-ethyl acetate solution (120 mL) at 0°C, and the mixture was stirred at room temperature for 4 hr. The reaction solution was concentrated, and the .residue was partitioned between ethyl acetate and saturated aqueous potassium carbonate solution. The organic layer was washed with saturated brine, and dried over sodium sulfate, and the solvent was evaporated to give the title compound (14.41 g, yield 91%) as a yellow oil. 1H-NMR(CDCl3)0: 1.41 (2H, brs) , 2.21-2.80 (12H, m) , 2.91 (IH, d, J=8.7 Hz), 3.76 (2H, s) , 7.19-7.36 (5H, m) . Reference Example 223 4- (benzylthio) -4- (ni tromethyl ) tetrahydro-2H-thiopyran
Figure imgf000381_0001
In the same manner as in Reference Example 58, the title compound (10.4 g, yield 74%) was obtained as colorless crystals from 4-oxothiane (5.81 g) .
1H-NMR (CDCl3) 6:2.03-2.18 (4H, m) , 2.42 (2H, d, J=13.9 Hz), 3.13-3.30 (2H, m) , 3.68 (2H, s) , 4.49 (2H, s) , 7.22-7.39 (5H, m) .
Reference Example 224 1- [4- (benzylthio) tetrahydro-2H- thiopyran-4-yl]methanamine
Figure imgf000381_0002
In the same manner as in Reference Example 60, the title compound (2.57 g, yield >99%) • was obtained as a yellow oil from 4- (benzylthio) -4- (nitromethyl) tetrahydro-2H-thiopyran (2.83 g) .
1H-NMR(CDCl3)OiLSe (2H, brs), 1.62-1.76 (2H, m) , 1.97-2.11 (2H, us), 2.33-2.48 (2H, m) , 2.66 (2H, s) , 3.02-3.18 (2H, m) , 3.57 (2H, s) , 7.21-7.38 (5H, m) .
Reference Example 225 N- { [4- (benzylthio) tetrahydro-2H- thiopyran-4-yl]methyl} -5- (2-methoxyethoxy) -7- [methyl (pyridin- 2-ylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000381_0003
A mixture of 5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid (1.60 g) , l-[4- (benzylthio) tetrahydro-2H-thiopyran-4-γl]methanamine (1.00 g) , lH-l,2,3-benzotriazol-l-ol (0.90 g) , N- [ 3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (1.12 g) and N,N-dimethylformamide (20 mL) was stirred at room temperature for 15 hr. The reaction mixture was concentrated, water was added, and the' mixture was extracted with ethyl acetate. The organic layer was washed with IN hydrochloric acid, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-1:1, volume ratio) to give the title compound (1.92 g, yield 77%) as a colorless amorphous solid.
1H-NMR (CDCl3) 5:1.85-1.97 (2H, m) , 2.05-2.16 (2H, m) , 2.44-2.55' (2H, m) , 3.00-3.14 (2H, m) , 3.27 (3H, s) , 3.43-3.57 (2H, m) , 3.47 (3H, s), 3.70 (2H, s) , 3.73-3.82 (2 H, m) , 4.07-4.22 (2H, m) , 6.52-6.62 (IH, m) , 6.71 (IH, d, J=2.3 Hz), 7.02 (IH, d, J=2.3 Hz), 7.09 (IH, d, J=2.1 Hz), 7.20-7.29 (IH, m) , 7.29- 7.42 (4H, m) , 7.60-7.68 (IH, m) , 7.98 (IH, td, J=7.7, 1.7 Hz), 8.11 (IH, d, J=7.7 Hz), 9.17-9.30 (IH, m) , 12.31 (IH, brs) . Reference Example 226 S-benzyl-N- ( {5- (2-methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl}carbonyl) -L- cysteine methyl ester
Figure imgf000382_0001
■ A mixture of 5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid (3.00 g) , S- benzyl-L-cysteine methyl ester hydrochloride (1.90 g) , IH- 1, 2,3-benzotriazol-l-ol (1.70 g) , N- [3- (dimethylamino) propyl] N' -ethylcarbodiimide hydrochloride (2.10 g) , triethylamine (1.50 mL) and N,N-dimethylformamide (40 mL) was stirred at room temperature for 18 hr. The reaction mixture was concentrated, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with IN hydrochloric acid, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was' subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (1:1-1:2, volume ratio) to give the title compound (4.30 g, yield 94%) as a colorless amorphous solid. 1H-NMR (CDCl3) δ: 3.04 (2H, t, J=5.2 Hz), 3.29 (3H, s) , 3.47 (3H, s), 3.75 (2H, s), 3.76-3.79 (2H, m) , 3.80 (3H, s), 4.07-4.22 (2H, m) , 4.95-5.12 (IH, m) , 6.87 (IH, d, J=2.3 Hz), 6.87-6.96 (IH, m) , 7.02 (IH, d, J=2.3 Hz), 7.09 (IH, d, J=2.1 Hz), 7.16- 7.33 (5H, m) , 7.52-7.68 (IH, m) ,' 7.97 (IH, td, J=7.8, 1.6 Hz), 8.10 (IH, d, J=7.7 Hz), 9.17 (IH, d, J=4.7 Hz), 12.23 (IH, brs) .
Reference Example 227 S-trityl-D-cysteine methyl ester hydrochloride
Figure imgf000383_0001
D-Cysteine methyl ester hydrochloride (2.0 g) was suspended in N,N-dimethylformamide (12 mL) , 4N hydrochloric acid/ethyl acetate solution (0.5 mL) was added, and the mixture was stirred at room temperature for 20 min. Trityl chloride (3.2 g) was added, and the mixture was stirred at 50°C for 18 hr, diluted with diethyl ether, and poured into ice water. The mixture was neutralized with saturated aqueous sodium hydrogencarbonate solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was diluted with ethyl acetate, and 4N hydrochloric acid/ethyl acetate solution (5 mL) was added. The precipitated solid was collected by filtration to give the title compound (3.0 g, yield 64%) as a colorless amorphous solid. 1H-NMR (DMSCHd6) 5:2.52-2.68 (2H, m) , 3.71 (3H, s) , 3.85 (IH, t, J=5.5 Hz), 7.25-7.41 (15H, m) , 8.47 (3H, brs) . Reference Example 228 N- ( {5- (2-methoxyethoxy) -7- [inethyl (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl}carbonyl) -S- trityl-D-cysteine methyl ester
Figure imgf000384_0001
A mixture of 5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid (0.45 g) , S- trityl-D-cysteine methyl ester hydrochloride (0.46 g) , IH- 1, 2,3-benzotriazol-l-ol (0.26 g) , N- [3- (dimethylamino) propyl]- N' -ethylcarbodiimide hydrochloride (0.32 g) , triethylamine
(0.19 mL) and N,N-dimethylformamide (5 mL) was stirred at room temperature for 64 hr. The reaction mixture was concentrated, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with IN hydrochloric acid, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-1:4, volume ratio) to give the title compound (0.60 g, yield 72%) as a colorless amorphous solid.
1H-NMR(CDCl3)O^.67-2.90 (2H, m) , 3.29 (3H, s) , 3.47 (3H, s) , 3.72-3.84 (2H, m) , 3.77 (3H, s) , 4.12-4.25 (2H, m) , 4.80-4.94 (IH, m) , 6.71 (IH, d, J=7.9 Hz), 6.84 (IH, d, J=2.1 Hz), 7.02 (IH, d, J=2.1 Hz), 7.10 (IH, d, J=2.1 Hz), 7.13-7.29 (1OH, m) , 7.37 (5H, d, J=7.9 Hz) , 7.53-7.67 (IH, m) , 7.91-8.01 (IH, m) ,
8.09 (IH, d, J=O.9 Hz) , 9.13 (IH, dd, J=3.9, 0.8 Hz) , 12.18 (IH, brs) .
Reference Example 229 ethyl 2- [ (4-methyl-2- nitrophenyl)hydrazono]propanoate
Figure imgf000385_0001
In the same manner as in Reference Example 154, the title compound (42 g, yield 32%) was obtained as brown crystals from 4-methyl-2-nitroaniline (75 g) . MS:266(MH+). Reference Example 230 ethyl 5-methyl-7-nitro-lH-indole-2- carboxylate
Figure imgf000385_0002
In the same manner as in Reference Example 155, the title compound (23 g, yield 58%) was obtained as brown crystals from ethyl 2- [ (4-methyl-2-- nitrophenyl)hydrazono]propanoate (42 g) . MS:249(MH+). Reference Example 231 ethyl 7-amino-5-methyl-lH-indole-2- carboxylate
Figure imgf000385_0003
In the same manner as in Reference Example 156, the title compound (11.4 g, yield 56%) was obtained as yellow crystals from ethyl 5-methyl-7-nitro-lH-indole-2-carboxylate (23 g) . MS: 219 (MH+) . Reference Example 232 ethyl 5-methyl-7- [ (2- thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000386_0001
In the same manner as in Reference Example 157, the title compound (14.4 g, yield 93%) was obtained as pale-yellow crystals from ethyl 7-amino-5-methyl-lH-indole-2-carboxylate (9.6 g) and thiophene-2-sulfonyl chloride (9.1 g) . MS:351(MH+) Reference Example 233 ethyl 5-methyl-7- [methyl (2~ thienylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000386_0002
In the same manner as in Reference Example 158, the title compound (10.7 g, yield 95%) was obtained as pale-yellow crystals from ethyl 5-methyl-7- [ (2-thienylsulfonyl) amino] -IH- indole-2-carboxylate (11.4 g) . MS:379(MH+). Reference Example 234 5-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxylic acid
Figure imgf000386_0003
In the same manner as in Reference Example 159, the title compound (9.0 g, yield 83%) was obtained as pale-yellow crystals from ethyl 5-methyl-7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxylate (10.7 g) . MS: 351 (MH+) .
Reference Example 235 5-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000386_0004
In the same manner as in Reference Example 160, the title compound (2.25 g, yield 56%) was obtained as pale-yellow crystals from 5-methyl-7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxylic acid (4 g) . MS:350 (MH+). Reference Example 236 5-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carbothioamide
Figure imgf000387_0001
In the same manner as in Reference Example 13, the title compound (2.15 g, yield 92%) was obtained as yellow crystals from 5-methyl-7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carboxamide (2.25 g). MS:366(MH+).
Reference Example 237 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 5-methyl-7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carboxamide
Figure imgf000387_0002
In the same manner as in Reference Example 48, the title compound (8.2 g, yield 99%) was obtained as a pale- yellow oil from 5-methyl-7- [methyl (2-thienylsulfonyl) amino] - lH-indole-2-carboxylic acid (5g) and 2- (benzylthio) -3, 3- dimethoxypropan-1-amine (4.1 g) . MS:574 (MH+).
Reference Example 238 N- [2- (benzylthio) -3-oxopropyl] -5-methyl- 7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000387_0003
In the same manner as in Reference Example 40, the title compound (7.5 g, yield 99%) was obtained as a pale- yellow amorphous solid from N- [2- (benzylthio) -3, 3- dimethoxypropyl] -5-methyl-7- [methyl ( 2-thienylsulfonyl) amino] - lH-indole-2-carboxamide ( 8 .2 g) . MS : 528 (MH+) .
Reference Example 239 N- [2- (benzylthio) -3-morpholinopropyl] -5- me thy 1-7- [methyl (2-thienylsulfonyl ) amino] -IH- indole-2- carboxamide
Figure imgf000388_0001
In the same manner as in Reference Example 41, the title compound (926 mg, yield 82%) was obtained as white crystals from N- [2- (benzylthio) -3-oxopropyl] -5-methyl-7- [methyl (2-thienylsulfonyl) amino] -IH-indole-2-carboxamide (1 g) and morpholine (175 mg) . melting point 163°C. Reference Example 240 N- [ (3E) -2- (benzylthio) -3- (hydroxyimino) propyl] -5-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide
Figure imgf000388_0002
In the same manner as in Reference Example 43, the title compound (2.03 g, yield 66%) was obtained as a white amorphous solid from N- [2- (benzylthio) -3-oxopropyl] -5-methy1- 7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (3 g) . MS: 543 (MH+) .
Reference Example 241 N- [2- (benzylthio) -2-cyanoethyl] -5- methyl-7- [methyl (2-thienylsulfonyl) amino] -IH-indole-2- carboxamide
Figure imgf000388_0003
To a solution of N- [ (3E) -2- (benzylthio) -3- (hydroxyimino) propyl] -5-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide (2.03 g) in N,N-dimethylformamide (10 mL) was added cyanuric chloride (700 mg) under ice-cooling, and the mixture was stirred for 1 hr. IN Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried (MgSCu) , and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to give the title compound (1.7 g, yield 88%) as a white amorphous solid from a fraction eluted with ethyl acetate. MS: 525 (MH+). Reference Example 242 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 7-nitro-lH-indole-2-carboxamide
Figure imgf000389_0001
In the same manner as in Reference Example 48, the title compound (53.6 g, yield 87%) was obtained as yellow crystals from 7-nitro-lH-ind_ole-2-carboxylic acid (30 g) and 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (36 g) . melting point 78°C. Reference Example 243 2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -7-nitro-lH-indole
Figure imgf000389_0002
In the same manner as in Example 205, the title compound (16.5 g, yield 48%) was obtained as yellow crystals from N- [2- (benzylthio) -3, 3-dimethoxypropyl] -7-nitro-lH-indole-
2-carboxamide (46 g) . melting point 90°C.
Reference Example 244 2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -lH-indol-7-amine
Figure imgf000390_0001
To a solution of 2- [5- (dirαethoxymethyl) -4, 5-dihydro- l,3-thiazol-2-yl]-7-nitro-lH-indole (16.25 g) in ethanol (200 mL) and tetrahydrofuran (100 mL) was' added 10% palladium carbon (50% containing water, 2g) under nitrogen atmosphere, and hydrazine monohydrate (14.5 mL) was added dropwise at room temperature. The reaction mixture was stirred at 80°C for 20 min, and allowed to cool to room temperature . The palladium carbon was removed by the filtration, and the filtrate was concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (11.2 g, yield 76%) as yellow crystals from a fraction eluted with ethyl acetate-hexane (50:50, volume ratio). MS:292(MH+). Reference Example 245 ethyl 2- [ (4-methoxy-2- nitrophenyl) hydrazono] propanoate
Figure imgf000390_0002
A mixture of ethyl 2- [ (4-hydroxy-2- nitrophenyl) hydrazono] propanoate (30 g) , methyl iodide (21.3 g) , potassium carbonate (21 g) and N,N-dimethylformamide (300 mL) was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with IN hydrochloric acid and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was crystallized from diethyl ether to give the title compound (28 g, yield 89%) as orange crystals. MS: 282 (MH+). Reference Example 246 ethyl 5-methoxy-7-nitro-lH-indole-2- carboxylate
Figure imgf000391_0001
In the same manner as in Reference Example 155, the title compound (8.7 g, yield 38%) was obtained as orange crystals from ethyl 2- [ (4-methoxy-2- nitrophenyl) hydrazono]propanoate (24.5 g) . MS:265(MH+). Reference Example 247 ethyl 7-amino-5-methoxy-lH-indole-2- carboxylate
Figure imgf000391_0002
In the same manner as in Reference Example 156, the title compound (2.5 g, yield 96%) was obtained as pale-yellow crystals from ethyl 5-methoxy-7-nitro-lH-indole-2-carboxylate (3 g) . MS: 235 (MH+) . Reference Example 248 ethyl 5-methoxy-7- [methyl (pyridin-2- ylsulfonyl) amino] ~lH-indole-2-carboxylate
Figure imgf000391_0003
To a solution of ethyl 7-amino-5-methoxy-lH-indole-2- carboxylate (2.5 g) in pyridine (20 mL) was added 2- pyridinesulfonyl chloride (2.1 g) under ice-cooling, and the mixture was stirred for 2 hr. The .reaction mixture was concentrated, water was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was dissolved in N,N-dimethylformaruide (20 mL) , methyl iodide (1.5 g) and potassium carbonate (2 g) were added, and the mixture was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with . ethyl acetate. The organic layer was washed with IN hydrochloric acid and saturated brine, dried (MgSO4) , and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to give the title compound (2.7 g, yield 68%) as pale-yellow crystals from a fraction eluted with ethyl acetate-hexane (50:50, volume ratio) . MS: 390 (MH+) . Reference Example 249 5-methoxy-7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid
Figure imgf000392_0001
In the same manner as in Reference Example 159, the title compound (2.4 g, yield 99%) was obtained as pale-yellow crystals from ethyl 5-methoxy-7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylate (2.6 g) . MS:362(MH+) Reference Example 250 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 5-methoxy-7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2- carboxamide
Figure imgf000392_0002
In the same manner as in Reference Example 48, the title compound (3.9 g, yield 99%) w.as obtained as a yellow oil from 5-methoxy-7- [methyl (pyridin-2-ylsulfonyl) amino] -IH-- indole-2-carboxylic acid (2.4 g) and 2- (benzylthio) -3, 3- dimethoxypropan-1-amine (1.7 g) . MS: 585 (MH+). Reference Example 251 ethyl 2- [ (4-bromo-2- nitrophenyl) hydrazono] propanoate
Figure imgf000393_0001
In the same manner as in Reference Example 154, the title compound (74 g, yield 49%) was obtained as brown crystals from 4-bromo-2-nitroaniline (100 g) . MS: 331 (MH+). Reference Example 252 ethyl 5-bromo-7-nitro-lH-indole-2- carboxylate
Figure imgf000393_0002
In the same manner as in Reference Example 155, the title compound (14 g, yield 20%) was obtained as. brown crystals from ethyl 2- [ (4-bromo-2- nitrophenyl)hydrazono]propanoate (74 g) . MS: 331 (MH+). Reference Example 253 5-bromo-7-nitro~lH-indole-2-carboxylic acid
Figure imgf000393_0003
In the same manner as in Reference Example 159, the title compound (12.8 g, yield 95%) was obtained as pale-yellow crystals from ethyl 5-bromo-7-nitro-lH-indole-2-carboxylate (14g) . MS: 286 (MH+) . Reference Example 254 N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 5-bromo-7-nitro-lH-indole-2-carboxamide
Figure imgf000393_0004
In the same manner as in Reference Example 48, the title compound (10.1 g, yield 46%) was obtained as a yellow oil from 5-bromo-7-nitro-lH-indole-2-carboxylic acid (12.2 g) and 2- (benzylthio) -3, 3-dimethoxypropan-l-amine (12 g) . MS : 509 (MH+ ) .
Reference Example 255 N- [2- (benzylthio) -3-morpholinopropyl] -5- bromo-7-nitro-lH-indole-2-carboxamide
Figure imgf000394_0001
In the same manners as in Reference Example 40 and Reference Example 41, the title compound (8.86 g, yield 83%) was obtained as yellow crystals from N- [2- (benzylthio) -3, 3- dimethoxypropyl] -5-bromo-7-nitro-lH-indole-2-carboxamide (10.1 g) and morpholine (3.5 g) . MS: 534 (MH+). Reference Example 256 5-bromo-2- [5- (morpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -7-nitro-lH-indole
Figure imgf000394_0002
In the same manner as in Example 205, the title compound (2.4 g, yield 34%) was obtained as yellow crystals from N- [2- (benzylthio) -3-morpholinopropyl] -5-bromo-7-nitro-lH- indole-2-carboxamide (8.86 g) . MS:426(MH+). Reference Example 257 5-bromo-2- [5- (morpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-amine
Figure imgf000394_0003
A mixture of 5-bromo-2- [5- (morpholinomethyl) -4, 5- dihydro-l,3-thiazol~2-yl]-7-nitro-lH-indole (2.4 g) , iron (1.7 g) , calcium chloride (310 mg) , ethanol (50 mL) , tetrahydrofuran (25 mL) and water (5 mL) was stirred under heating at 80°C for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried (MgSO4) , and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to give the title compound. (500 mg, yield 22%) as yellow crystals from a fraction eluted with ethyl acetate : hexane=50 : 50. MS: 396 (MH+). Reference Example 258 ethyl 5- (2-methoxyethoxy) -7- [ (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000395_0001
To a solution of ethyl 7-amino-5- (2-methoxyethoxy) -IH- indole-2-carboxylate (5.80 g) in pyridine (100 mL) was added pyridine-2-sulfonyl chloride monohydrochloride (14.0 g) , and ■ the mixture was stirred overnight at room temperature. The solvent was evaporated under reduced pressure, and the residue was dissolved in ethyl acetate. The ethyl acetate layer was washed with IM hydrochloric acid, saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSCu) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (5.70 g, yield 65%) as a colorless amorphous solid from a fraction eluted with ethyl acetate-hexane (1:1, volume ratio). MS:420 (MH+). Reference Example 259 ethyl 5- (2-methoxyethoxy) -7-
[methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxylate
Figure imgf000395_0002
To a solution of ethyl 5- (2-methoxyethoxy) -7- [ (pyridin- 2-ylsulfonyl) amino] -lH-indole-2-carboxylate (5.70 g) in N, N- dimethylformamide (50 mL) were added potassium carbonate (2.85 g) and methyl iodide (930 μL) , and the mixture was stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate, and washed with water and saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (5.67 g, yield 96%) as a colorless amorphous solid from a fraction eluted with ethyl acetate- hexane (1:1, volume ratio). MS:434(MH+).
Reference Example 260 5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxylic acid
Figure imgf000396_0001
To a solution of ethyl 5- (2-methoxyethoxy) -7-
[methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxylate (5.67 g) in tetrahydrofuran (50 mL) and methanol (25 itiL) was added 2M aqueous sodium hydroxide solution, and the mixture was stirred at 500C for 4 hr. The reaction mixture was allowed to cool to room temperature, diluted with ethyl acetate, and neutralized with IM hydrochloric acid. The ethyl acetate layer was washed with saturated brine, dried (MgSC^) , and concentrated. The residue was recrystallized from a mixed solvent of ethyl acetate-hexane to give the title compound (5.30 g, yield 100%) as a white solid. MS:406(MH+).
Reference Example 261 ethyl 7- [ (cyclopropylmethyl) (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylate
Figure imgf000396_0002
A mixture of ethyl 5- ( 2-methoxyethoxy) -7- [ (pyridin-2- ylsulfonyl ) amino] -lH-indole-2-carboxylate ( 937 mg) ,
(bromomethyl) cyclopropane ( 0.22 mL) , potassium carbonate ( 401 mg) and N, N-dimethylformamide (20 mL) was stirred at 50°C for 15 hr. The reaction mixture was diluted with ethyl acetate and saturated brine. The organic layer was washed with aqueous sodium bicarbonate solution and saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The residue was subjected to basic silica gel column chromatography to give the title compound (673 mg, yield 64%) as a pale-yellow amorphous solid from a fraction eluted with ethyl acetate. IH-NMR (CDCl3) δ: -0.16 - -0.04 (2H, m) , 0.19-0.34 (2H, m) , 0.73- 0.89 (IH, m) , 1.43 (3H, t, J=7.2 Hz), 3.47 (3H, s) , 3.54 (2H, d, J=7.0 Hz), 3.77 (2H, dd, J=5.6, 3.9 Hz), 4.14 (2H, dd, J=5.5, 4.0 Hz), 4.43 (2H, q, J=7.2 Hz), 7.05 (IH, d, J=2.3 Hz), 7.13 (2H, d, J=2.3 Hz), 7.61 (IH, ddd, J=7.5, 4.7, 1.1 Hz), 7.97 (IH, td, J=I.1, 1.7 Hz), 8.10 (IH, d, J=7.9 Hz), 9.10 (IH, dd, J=4.8, 0.8 Hz) .
Reference Example 262 7- [ (cyclopropylmethyl) (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylic acid
Figure imgf000397_0001
To a mixture of ethyl 7- [ (cyclopropylmethyl) (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylate (650 mg) , ethanol (10 mL) and tetrahydrfuran (10 mL) was added 2N aqueous sodium hydroxide solution (3.43 mL) at room temperature, and the mixture was stirred at 50°C for 5 hr. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl .acetate and IN aqueous hydrochloric acid. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure to give the title compound (630 mg, yield 99%) as a colorless amorphous solid. IH-NMR (DMSOd6) δ: -0.28 0.14 (2H, m) , 0.04-0.21 (2H, m) ,
0.67-0.87 (IH, m) , 3.30 (3H, s) , 3.57 (2H, d, J=7.2 Hz), 3.63 (2H, dd, J=5.4, 3.7 Hz), 4.04 (2H, dd, J=5.3, 3.8 Hz), 6.75 (IH, d, J=2.1 Hz), 7.06 (IH, d, J=I.9 Hz), 7.18 (IH, d, J=2.3 Hz), 7.85 (IH, dd, J=6.8, 4.7 Hz), 8.04 (IH, d, J=7.9 Hz), 8.12-8.25 (IH, m) , 8.96 (IH, d, J=4.5 Hz), 12.39 (IH, s) , 13.08 (IH, brs) .
Reference Example 263 N- [2- (benzylthio) -3- thiomorpholinopropyl] -7- [ (cyclopropylmethyl) (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxamide
Figure imgf000398_0001
In the same manner as in Reference Example 216, the title compound (537 mg, yield 76%) was obtained as a colorless amorphous solid from 7- [ (cyclopropylmethyl) (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylic acid (445 mg) and 2- (benzylthio) -3-thiomorpholinopropan-l- amine (339 mg) .
IH-NMR (CDCl3) δ: -0.19- -0.07 (2H, m) , 0.25-0.32 (IH, m) , 0.76- 0.91 (IH, m) , 2.59-2.75 (9H, m) , 2.84-2.97 (IH, m) , 3.47 (3H, s), 3.51 (2H, d, J=7.2 Hz), 3.73-3.88 (5H, m) , 4.08-4.24 (2H, m) , 6.69 (IH, s) , 7.06 (IH, d, J=2.1 Hz), 7.14 (IH, d, J=2.3 Hz), 7.22-7.38 (6H, m) , 7.41-7.54 (IH, m) , 7.61 (IH, ddd, J=I.6, 4.8, 1.1 Hz), 7.96 (IH, td, J=7.7, 1.7 Hz), 8.11 (IH, d, J=7.9 Hz), 9.22 (IH, d, J=O.9 Hz), 12.24 (IH, brs). Reference Example 264 ethyl 7- [ (2,2-difluoroethyl) (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylate
Figure imgf000399_0001
To a mixture of ethyl 5- (2-methoxyethoxγ) -7- [ (pyridin- 2-ylsulfonyl) amino] -lH-indole-2-carboxylate (500 mg) , 2,2- difluoroethanol (0.09 iriL) , tributylphophine (0.59 rαL) and toluene (30 inL) was added 1, V - (azodicarbonyl) dipiperidine (600 mg) , and the mixture was stirred at room temperature overnight. The insoluble substance was filtered off, and the filtrate was diluted with ethyl acetate and IN aqueous hydrochloric acid solution. The organic layer was washed with aqueous sodium bicarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The residue was subjected to basic silica gel column chromatography to give the title compound (211 mg, yield 37%) as a colorless amorphous solid from a fraction eluted with ethyl acetate- hexane (1:4, volume ratio) .
IH-NMR (CDCl3) δ: 1.43 (3H, t, J=7.2 Hz), 3.45 (3H, s) , 3.70-3.83 • (2H, m) , 4.06-4.20 (4H, m) , 4.43 (2H, q, J=7.2 Hz), 5.85 (IH, tt, J=55.6, 4.3 Hz), 6.95 (IH, d, J=2.3 Hz), 7.12 (2H, d, J=2.1 Hz), 7.62 (IH, ddd, J=7.3, 4.7, 1.5 Hz), 7.97 (2H, dddd, J=14.9, 7.9, 7.6, 1.5 Hz), 9.06 (IH, dd, J=4.1, 0.8 Hz). Reference Example 265 7- [ (2, 2-difluoroethyl) (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylic acid
Figure imgf000399_0002
In the same manner as in Reference Example 262, the title compound (277 mg, yield 92%) was obtained as a colorless amorphous solid from ethyl 7- [ (2,2-difluoroethyl) (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylate (320 mg) .
IH-NMR (DMSO-ds)δ: 3.27 (3H, s) , 3.50-3.64 (2H7 m) , 3.89-4.02 (2H, m) , 4.19-4.35 (2 H, m) , 6.11-6.68 (IH, m) , 6.45 (IH, d, J=2.1 Hz), 7.05 (IH, d, J=2.1 Hz), 7.15 (IH, d, J=2.1 Hz), 7.70-7.95 (2H, m) , 7.99-8.28 (IH, m) , 8.93 (IH, d, J=4.0 Hz), 12.10 (IH, s), 13.00 (IH, brs) . . ' Reference Example 266 N- [2- (benzylthio) -3- thiomorpholinopropyl] -7- [ (2, 2-difluoroethyl) (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxamide
Figure imgf000400_0001
In the same manner as in Reference Example 216, the title compound (294 mg, yield 69%) was obtained as a colorless amorphous solid from 7- [ (2, 2-difluoroethyl) (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylic acid (270 mg) and 2- (benzylthio) -3-thiomorpholinopropan-l- amine (201 mg) .
IH-NMR (CDCl3) δ: 2.62-2.98 (1OH, m) , 3.00-3.15 (IH, m) , 3.45 (3H, s), 3.49-3.62 (IH, m) , 3..69-3.87 (5H, m) , 4.01-4.20 (3H, m) ,
5.63-6.19 (2H, m) , 6.89 (2H, dd, J=8.8, 2.2 Hz), 7.07 (IH, d,
J=2.1 Hz), 7.19-7.35 (6H, m) , 7.55-7.70 (2H, m) , 7.72-7.82 (IH, m) , 7.89-8.06 (2H, m) .
Reference Example 267 1-tert-butyl 2-ethyl 5-(2- methoxyethoxy) -7-nitro-lH-indole-lΛ2-dicarboxylate
Figure imgf000400_0002
To a mixture of ethyl 5- (2-methoxyethoxy) -7-nitro-lH- indole-2-carboxylate (3.08 g) , t-butyl bicarbonate (4.37 g) and tetrahydrofuran (100 ruL) was added N,N-dimethyl-4- aminopyridine (122 mg) , and the mixture was stirred at 50°C for 4 hr. The reaction mixture was diluted with ethyl acetate and water, and the organic layer was washed successively with 10% aqueous citric acid solution, aqueous sodium bicarbonate solution and saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The residue was subjected to basic silica gel column chromatography to give the title compound (3.93 g, yield 96%) as a yellow oil from a fraction eluted with ethyl acetate-hexane (2:3, volume ratio).
IH-NMR (CDCl3) δ: 1.40 (3H, t, J=7.2 Hz), 1.62 (9H, s) , 3.72-3.86 (2H, m) , 4.11-4.26 (2H, m) , 4.40 (2H, q, J=7.2 Hz), 7.11 (IH,' s), 7.37 (IH, d, J=2.4 Hz), 7.64 (IH, d, J=2.4 Hz).
Reference Example 268 1-tert-butyl 2-ethyl 7-amino-5- (2- methoxyethoxy) indoline-1, 2-dicarboxylate
Figure imgf000401_0001
A mixture of 1-tert-butyl 2-ethyl 5- (2-methoxyethoxy) - 7-nitro-lH-indole-l, 2-dicarboxylate (3.9 g) , 10% palladium- carbon (50% containing water, 400 mg) and tetrahydrofuran (80 mL) was stirred at room temperature under hydrogen atmosphere at normal pressure for 6 hr. The catalyst was filtered off, and the filtrate was concentrated. The residue was subjected to silica gel column chromatography to give the title compound (3.22 g, yield 89%) as a colorless solid from a fraction eluted with ethyl acetate-hexane (9:1, volume ratio). IH-NMR (CDCl3) δ: 1.25 (3H, t, J=7.2 Hz), 1.50 (9H, s) , 2.99 (IH, dd, J=16.4, 2.8 Hz), 3.35-3.51 (IH, m) , 3.42 (3H, s) , 3.69 (2 H, dd, J=5.6, 4.1 Hz), 4.02 (2H, dd, J=5.2, 4.1 Hz), 4.08-4.25 (2H, m) , 4.87-5.04 (3H, m) , 6.12 (IH, d, J=2.4 Hz), 6.16 (IH, d, J=2.4 Hz) . Reference Example 269 1-tert-butyl 2-ethyl 7-
(cyclopropyl amino) -5- (2-methoxyethoxy) indoline-1 , 2- dicarboxylate
Figure imgf000402_0001
To a mixture of 1-tert-butyl 2-ethyl 7-amino-5- (2- methoxyethoxy) indoline-1, 2-dicarboxylate (2.76 g) , [ (1- ethoxycyclopropyl) oxy] (trimethyl) silane (7.29 mL) , acetic acid (4.19 rαL) and ethanol (70 mL) was added sodium cyanoborohydride (122 mg) , and the mixture was refluxed for 3 hr. The reaction mixture was concentrated unde reduced pressure, and the residue was diluted with ethyl acetate and water. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to give the title compound (2.30 g, yield 75%) as a pale-yellow oil from a fraction eluted with ethyl acetate-hexane (4:1, volume ratio).
IH-NMR (CDCl3) δ: 0.44-0.60 (2H," m) , 0.62-0.76 (2H, m) , 1.24 (3H, t, J=7.0 Hz), 1.49 (9H, s) , 2.35-2.46 (IH, m) , 2.97 (IH, dd, J=16.3, 2.7 Hz), 3.44 (3H, s) , 3.37-3.54 (IH, m) , 3.64-3.78
(2H, m) , 4.01-4.25 (4H, m, J=IO.6, 7.1, 7.1, 3.6 Hz), 4.93 (IH, dd, J=IO.6, 3.0 Hz), 6.10 (IH, d, J=2.3 Hz), 6.58 (IH, d,
J=2.3 Hz), 6.80 (IH, brs) .
Reference Example 270 1-tert-butyl 2-ethyl 7- [cyclopropyl (pyridin-2-ylsulfonyl) amino] -5- (2- methoxyethoxy) indoline-1, 2-dicarboxylate
Figure imgf000402_0002
To a mixture of 1-tert-butyl 2-ethyl 7- (cyclopropylamino) -5- ( 2-methoxyethoxy) indoline-1 , 2- dicarboxylate (1.9 g) and pyridine (3 mL) was added a mixture of 2-pyridylsulfonyl chloride (1.2 g) and pyridine (2 mL) at
0°C, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated unde reduced pressure, and the residue was diluted with ethyl acetate and water. The organic layer was washed with aqueous 10% aqueous citric acid solution, aqueous sodium bicarbonate solution and saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to give the title compound (1.70 g, yield 67%) as a pale-yellow oil from a fraction eluted with ethyl acetate-hexane (9:1, volume ratio). MS: 562 (MH+). Reference Example 271 ethyl 7- [cyclopropyl (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) indoline-2-carboxylate
Figure imgf000403_0001
1-tert-Butyl 2-ethyl 7- [cyclopropyl (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) indoline-1, 2- dicarboxylate (1.70 g) was added to 4N hydogen chloride-ethyl acetate solution (50 mL) , and the mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate and aqueous sodium bicarbonate solution. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure to give the title compound (1.34 g, yield 96%) as a pale-yellow amorphous solid.
IH-NMR (CDCl3) δ: 0.49-0.97 (4H, m) , 1.19-1.36 (4H, m) , 3.08-3.23 (IH, m) , 3.23-3.37 (2H, m) , 3.40 (3H, s) , 3.63 (2H, t, J=4.8 Hz), 3.77-3.93 (2H, m) , 4.20 (2H, q, J=7.2 Hz), 4.30-4.46 (IH, m) , 6.27 (IH, d, J=I.7 Hz), 6.67 (IH, d, J=2.4 Hz), 7.52 (IH, ddd, J=7.3, 4.8, 1.3 Hz), 7.81-7.97 (2H, m) , 8.80 (IH, d, J=4 . 3 Hz ) .
Reference Example 272 ethyl 7- [cyclopropyl (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylate
Figure imgf000404_0001
To a mixture of ethyl 7- [cyclopropyl (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) indoline-2-carboxylate (1.31 g) and toluene (30 mL) was added manganese (IV) oxide (0.99 g) at room temperature, and the mixture was refluxed for 3 hr. The catalyst was filtered off, and the filtrate was concentrated. The residue was subjected to silica gel column chromatography to give the title compound (1.23 g, yield 94%) as a colorless solid from a fraction eluted with ethyl acetate-hexane (4:1, volume ratio).
IH-NMR (CDCl3) δ: 0.33 (2H, brs) , 0.52-0.68 (2H, m) , 1.43 (3H, t, 3=1.1 Hz), 3.19-3.30 (IH, m) , 3.47 (3H, s) , 3.73-3.82 (2H, m) ,
4.12-4.21 (2H, m) , 4.42 (2H, q, J=7.1 Hz), 7.08 (2H, s) , 7.12
(IH, d, J=2.1 Hz), 7.64 (IH, ddd, J=7.7, 4.7, 0.9 Hz), 8.01
(IH, td, J=7.8, 1.7 Hz), 8.20- (IH, d, J=7.9 Hz), 9.13 (IH, d,
J=4.0 Hz), 12.38 (IH, brs). Reference Example 273 7- [cyclopropyl (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylic acid
Figure imgf000404_0002
In the same manner as in Reference Example 262, the title compound (1.08 g, yield 95%) was obtained as a colorless amorphous solid from ethyl 7- [cyclopropyl (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylate (1.21 g) . IH-NMR (DMSO-dβ)δ: 0.40 (2H, brs), 0.61 (2H, brs), 3.31 (3H, s) , 3 . 32-3 . 42 ( IH, m) , 3 . 61-3 . 68 ( 2H, in) , 4 . 00-4 . 10 ( 2H, m) , 6 . 79
(IH, d, J=2.3 Hz), 7.06 (IH, d, J=2.1 Hz), 7.14 (IH, d, J=2.1 Hz), 7.82-7.93. (IH, m) , 8.09 (IH, d, J=7.9 Hz), 8.18-8.26 (IH, m) , 8.97 (IH, d, J=4.1 Hz), 12.48 (IH, s) . Reference Example 274 N- [2- (benzylthio) -3- thiomorpholinopropyl] -7-[cyclopropyl (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxamide
Figure imgf000405_0001
In the same manner as in Reference Example 216, the title compound (451 mg, yield 65%) was obtained as a colorless amorphous solid from 7- [cyclopropyl (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxylic acid (231 mg) and 2- (benzylthio) -3-thiomorpholinopropan-l- amine (339 mg) . IH-NMR (CDCl3) δ: 0.34 (2H, brs) , 0.5-0.64 (2H, m) , 2.59-2.75 (1OH, m) , 2.84-3.00 (IH, m) , 3.19-3.30 (IH, m) , 3.48 (3H, s) , 3.50-3.63 (IH, m) , 3.73-3.88 (5H, m) , 4.18 (2H, t, J=4.6 Hz), 6.69 (IH, d, J=I.7 Hz), 7.03-7.11 (2H, m) , 7.22-7.37 (5H, m) , 7.43-7.56 (IH, m) , 7.64 (IH, ddd,' J=7.6, 4.7, 1.0 Hz), 8.01 (IH, td, J=I.1, 1.7 Hz), 8.20 (IH, d, J=7.9 Hz), 9.26 (IH, dd, J=4.6, 0.8 Hz), 12.60 (IH, brs).
Example 253 N- [2- [ (4R) -4- (hydroxymethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -5- (2-methoxyethoxy) -lH-indol-7-yl] -N- methylpyridine-2-sulfonamide
Figure imgf000405_0002
To a solution of triphenylphosphine oxide (2.7 g) in dichlororαethane (6 mL) was added dropwise trifluoromethanesulfonic anhydride (1.2 mL) at 0°C, and the mixture was stirred at 0°C for 15 min. The obtained suspension was diluted with dichloromethane (19 mL) , and a solution of S- benzyl-N- ( {5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}carbonyl) -L-cysteine methyl ester (1.0 g) and thioanisole (1.5 mL) in dichloromethane (25 mL) was added. The reaction mixture was stirred at 0°C for 1 hr, saturated aqueous sodium hydrogencarbonate solution was added, and the mixture was concentrated. The residue was extracted with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, . dried (MgSO4) , and concentrated. The obtained residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate (1:1, volume ratio) to give a mixture of methyl (4R)- 2- {5- (2-methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazole-4-carboxylate and triphenylphosphine oxide. The obtained mixture of the ester and triphenylphosphine oxide was dissolved in tetrahydrofuran (5 mL) , sodium borohydride (0.053 mg) was added at 00C, and methanol (2.5 mL) was added dropwise at 0°C. The reaction mixture was stirred at 0°C for 1 hr, and then at room temperature for 3 hr. Water was added, the mixture was concentrated, and the residue was extracted with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-0:1, volume ratio) to give the title compound (0.27 g, yield 36%) .as a colorless amorphous solid. MS: 477 (MH+) .
1H-NMR (CDCl3) 5:1.97-2.03 (IH, m) , 3.30-3.39 (IH, m) , 3.33 (3H, s), 3.46 (3H, s), 3.47-3.58 (IH, m) , 3.68-3.79 (2H, m) , 3.79-
3.95 (IH, m) , 3.98-4.09 (IH, m) , 4.08-4.14 (2H, m) , 4.77-4.96 (IH, m) , 6.86 (IH, d, J=2.1 Hz), 6.88 (IH, d, J=2.1 Hz), 7.06 ( IH, d, J=2 . 1 Hz ) , 7. 57-7 . 68 ( IH, m) , 7 . 90-7 . 99 (IH, m) , 8 . 00- 8 . 06 ( IH, m) , 9 . 04 ( IH, d, J=4 . 0 Hz ) , 11 . 53 ( IH, d, J=2 . 6 Hz ) . Example 254 N- [2- [ (4S) -4- (hydroxymethyl) -4 , 5-dihydro-l , 3- thiazol-2-yl ] -5- ( 2-methoxyethoxy) -lH-indol-7-yl] -N- methylpyridine-2-sulfonarαide
Figure imgf000407_0001
To a solution of triphenylphosphine oxide (1.3 g) in dichloromethane (3 mL) was added dropwise trifluoromethanesulfonic anhydride (0.59 mL) at 0°C, and the mixture was stirred at 0°C for 15 min. The obtained suspension was diluted with dichloromethane (5 mL) , and a solution of N- ( {5- (2-methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indol-2-yl}carbonyl) -S-trityl-D-cysteine methyl ester (0.60 g) and thioanisole (0.74 mL) in dichloromethane (8 mL) was added. The reaction mixture was stirred at 00C for 2 hr, and saturated aqueous sodium hydrogencarbonate solution was added. The mixture was concentrated, ■ and the residue was extracted with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, dried (MgSCu) i and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted' with hexane-ethyl acetate (4:1-1:1, volume ratio) to give a mixture (0.39 g) of methyl (4S)-2-{5- (2-methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazole-4-carboxylate and triphenylphosphine oxide. The obtained mixture of the ester and triphenylphosphine oxide was dissolved in tetrahydrofuran (3 mL) , sodium borohydride (0.010 mg) was added at 0°C, and methanol (1.5 mL) was added dropwise at 0°C. The reaction mixture was stirred at 0°C for 30 min, and then at room temperature for 2 hr. Water was added, the mixture was concentrated, and the residue was extracted with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate-methanol (4:1:0-0:10:1, volume ratio) to give the title compound (0.076 g, yield 20%) as colorless crystals, melting point 146.6-146.7°C. 1H-NMR (CDCl3) δ: 2.22 (IH, brs) , 3.27-3.39 (IH, m) , 3.34 (3H, s) , 3.45 (3H, s), 3.46-3.56 (IH, m) , 3.70-3.77 (2H, m) , 3.78-3.93 (IH, m) , 4.01-4.07 (IH, m) , 4.07-4.15 (2H, m) , 4.79-4.91 (IH, in.), 6.81-6.93 (2H, m) , 7.05 (IH, d, J=2.3 Hz), 7.53-7.63 (IH, m) , 7.89-7.98 (IH, m) , 7.98-8.07 (IH, m) , 9.03 (IH, d, J=4.5 Hz) , 11.54 (IH, brs) .
Example 255 ( (4R) -2-{5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-4- yl) methyl methanesulfonate
Figure imgf000408_0001
A solution of N- [2- [ (4R) -4- (hydroxymethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] -5- (2-methoxyethoxy) -lH-indol-7-yl] -N- methylpyridine-2-sulfonamide (0.28 g) , methanesulfonyl chloride (0.10 g) and triethylamine (0.16 roL) in tetrahydrofuran (5.0 mL) was stirred at room temperature for 2 hr, and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried (MgSU4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-1:4, volume ratio) to give the title compound (0.25 g, yield 77%) as a colorless oil.
1H-NMR(CDCl3)O^OS (3H, s) , 3.28 (3H, s) , 3.31-3.41 (IH, m) , 3.46 (3H, s), 3.52-3.64 (IH, m) , 3.69-3.81 (2H, m) , 4.06-4.18 (2H, m) , 4.49-4.59 (2H, m) , 4.97-5.08 (IH, m) , 6.88 (IH, d,
J=I.9 Hz), 6.96 (IH, d, J=I .9 Hz), 7.07 (IH, s) , 7.64-7.74 (IH, m) , 7 . 98 ( IH, t, J=7 . 8 Hz) , 8 . 04-8 . 11 ( IH, m) , 9 . 13 ( IH, d, J=4 . 0 Hz) , 12 . 04 ( IH, brs) .
Example 256 N- [2- (1, 8-dithia-3-azaspiro [4.5] dec-2-en-2-yl) -5- (2-methoxyethoxy) -lH-indol-7-yl] -N-methylpyridine-2- sulfonamide
Figure imgf000409_0001
To a solution of triphenylphosphine oxide (2.0 g) in acetonitrile (14 mL) was added dropwise trifluoromethanesulfonic anhydride (1.0 mL) at 00C, and the mixture was stirred at 0°C for 30 min. The obtained suspension was diluted with acetonitrile (36 mL) , and a solution of N- { [4- (benzylthio) tetrahydro-2H~thiopyran-4-yl]methyl} -5- (2- methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carboxamide (1.9 g) and thioanisole (0.70 mL) in acetonitrile (50 mL) was added. The reaction mixture was stirred at 00C for 2 hr, saturated aqueous sodium hydrogencarbonate solution was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (9:1-3:7, volume ratio) to give the title compound (0.26 g, yield 17%) as colorless crystals.
1H-NMR (CDCl3) 5:1.90-2.20 (2H, m) , 2.35 (2H, d, J=13.9 Hz), 2.61-2.76 (2H, m) , 2.78-2.94 (2H, m) , 3.30 (3H, s) , 3.46 (3H, s), 3.64-3.80 (2H, m) , 4.05-4.15 (2H, m) , 4.18 (2H, s) , 6.81 (IH, d, J=2.1 Hz), 6.90 (IH, d, J=2.3 Hz), 7.06 (IH, d, J=2.1 Hz), 7.56-7.64 (IH, m) , 7.88-7.99 (IH, m) , 8.01-8.10 (IH, m) , 9.00-9.07 (IH, m) , 11.71 (IH, brs). Example 257 N-methyl-N-{2- [5- (morpholinomethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene-2-sulfonamide
Figure imgf000410_0001
In the same manner as in Example 201, the title compound (0.125 g, yield 60%) was obtained as colorless crystals from N- [2- (benzylthio) -3-morpholinopropyl] -7-
[methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (an optically active form: retention time: longer) (0.255 g) obtained in Reference Example 94. melting point 137-138°C. Example 258 N-methyl-N-{2- [5- (morpholinomethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] ~lH-indol-7-yl} thiophene-2-sulfonamide
Figure imgf000410_0002
To a suspension of N-methyl-N- {2- [5- (morpholinomethyl) - 4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl } thiophene-2- sulfonamide dihydrochloride (0.010 g) in ethyl acetate (50 lαL) was added 2N aqueous sodium hydroxide solution (20 inL) , and the mixture was stirred at room temperature for 15 min. The organic layer was separated, and washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was recrystallized from hexane- ethyl acetate to give the title compound (0.004 g, yield 46%) as colorless crystals, melting point 199-201°C.
Example 259 N- {2- [5- (2-hydroxy-2-methylpropyl) -4, 5-dihydro- l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2- sulfonamide
Figure imgf000411_0001
To a solution of ethyl (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetate (0.204 g) in absolute tetrahydrofuran (10 mL) was added a 1.0M tetrahydrofuran solution (4.4 mL) of methylmagnesium bromide, and the mixture was stirred at room temperature for 2 hr. Saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and ■ concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate :hexane = 30:70-80:20), and recrystallized from hexane-ethyl acetate to give the title compound (0.142 g, yield 72%) as colorless crystals, melting point 15β-158°C.
Example 260 N-methyl-N- {2- [5- (2-morpholino-2-oxoethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000411_0002
To a solution of (2- { 7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl }-4, 5-dihydro-l, 3-thiazol- 5-yl) acetic acid (0.150 g) in N,N-dimethylformamide (6 mL) were added 1H-1,2, 3-benzotriazol-l-ol (0.063 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.079 g) , N-ethyldiisopropylamine (0.12 mL) and morpholine
(0.06 mL) , and the mixture was stirred at room temperature for 20 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (ethyl acetate:methanol = 50:50-0:100), and recrystallized from hexane-ethyl acetate to give the title compound (0.099 g, yield 57%) as colorless crystals, melting point 173-174°C. Example 261 N- (2-{ 5- [2- (3, 3-difluoropyrrolidin-1-yl) -2- oxoethyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) -N- methylthiophene-2-sulfonamide
Figure imgf000412_0001
In the same manner as in Example 260, the title compound (0.030 g, yield 16%) was obtained as colorless crystals from (2- {7- [methyl (2-i-thienylsulfonyl) amino] -lH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (0.150 g) and
3,3-difluoropyrrolidine (0.099 mg) . melting point 172-173°C. Example 262 N-cyclopropyl-2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-Indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000412_0002
In the same manner as in Example 260, the title compound (0.085 g, yield 52%) was obtained as colorless crystals from (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (0.150 g) and 2 cyclopropylamine (0.099 mg) . melting point 179-181°C. Example 263 2- (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) -N- (tetrahydro-2H-pyran-4- yl) acetamide
Figure imgf000413_0001
In the same manner as in Example 260, the title compound (0.155 g, yield 87%) was obtained as colorless crystals from (2- {7- [methyl (2-thienylsulfonyl) amino] -IH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (0.150 g) and tetrahydro-2H-pyran-4-amine (0.069 mg) . melting point 190-
192°C.
Example 264 N-methyl-N-{2- [5- (2-oxo-2- (pyrrolidin-1-yl) ethyl) -
4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000413_0002
In the same manner as in Example 260, the title compound (0.131 g, yield 78%) was obtained as colorless crystals from (2- {7- [methyl (2-thienylsulfonyl) amino] -IH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (0.150 g) and pyrrolidine (0.057 πiL) . melting point 175-176°C. Example 265 N,N-diethyl-2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000414_0001
In the same manner as in Example 260, the title compound (0.108 g, yield 64%) was obtained as colorless crystals from (2- {7- [methyl (2-thienylsulfonyl) amino] -IH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (0.150 g) and diethylamine (0.071 mL) . melting point 144-148°C.
Example 266 N- {2- [5- (2-aminoethyl) -4, 5-dihydro-l, 3-thiazol-2- yl] -lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000414_0002
To a solution of N- {2- [5- (2-hydroxyethyl) -4, 5-dihydro- l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2- sulfonamide (0.242 g) in tetrahydrofuran (5 mL) were added triphenylphosphine (0.301 g) , a 40% toluene solution (0.500 g) of diethyl azodicarboxylate and diphenylphosphorylazide (0.247 mL) , and the mixture was stirred at room temperature for 2 hr. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate rhexane = 5:95-60:40) to give a yellow oil. To a solution of the obtained oil in tetrahydrofuran (5 mL) were added water (0.1 mL) and triphenylphosphine (0.226 g) , and the mixture was stirred at room temperature for 24 hr. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (ethyl acetate:methanol = 100:0-80:20), and recrystallized from hexane-ethyl acetate to give the title compound (0.100g, yield in two steps 41%) as pale-yellow crystals, melting point 172- 174°C.
Example 267 N- {2- [5- (1, 4-dioxa-8-azaspiro [4.5] dec-8-ylmethyl) -
5-methyl-4,5-dihydro-l,3-thiazol-2-yl]~lH-indol-7-yl}-N- methylthiophene-2-sulfonamide
Figure imgf000415_0001
To a solution of triphenylphosphine oxide (0.83 g) in ' dichloromethane (6 mL) was slowly added trifluoromethanesulfonic anhydride (0.25 mL) at 00C, and the mixture was added for 10 min. N- [2- (benzylthio) -3- (1, 4-dioxa- 8-azaspiro [4.5]dec-8-yl) -2-methylpropyl] -7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (0.72 g) and dimethylsulfide (0.22 mL) were added, and the reaction mixture was stirred at 00C for 20 min. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCu) , and concentrated. The residue was subjected to silica gel column chromatography from a fraction eluted with ethyl acetate-hexane (2:3, volume ratio) to give the title compound (0.28 g, yield 50%) as colorless crystals, melting point 172-173°C. Example 268 N- [2- (9, 12-dioxa-l-thia-3- azadispiro [4.2.4.2] tetradec-2-en-2-yl) -lH-indol-7-yl] -limethylthiophene-2-sulfonamide
Figure imgf000416_0001
To a solution of triphenylphosphine oxide' (1.98 g) in acetonitrile (30 mL) was slowly added trifluoromethanesulfonic anhydride (0.60 mL) at 0°C, and the mixture was stirred for 10 rain. N- { [8- (Benzylthio) -1, 4-dioxaspiro [4.5] dec-8-yl] methyl}-7- [methyl (2-thienylsulfonyl) amino] -IH-indole-2-carboxamide (1.45 g) and dimethylsulfide (0.52 mL) were added, and the reaction mixture was stirred at 0°C for 30 min. Saturated aqueous sodium hydrogencarbonate was added, and the precipitated solid was collected by filtration, and washed with water. The obtained solid was washed with ethyl acetate, and dried to give the title compound (0.75 g, yield 63%) as colorless crystals, melting point 224-225°C.
Example 269 2- (5-methyl-2-{ 7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl } -4, 5-dihydro-l, 3-thiazol-5-yl) ethyl methanesulfonate
Figure imgf000416_0002
To a solution of N- {2- [5- (2-hydroxyethyl) -5-rαethyl-4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2- sulfonamide (0.75 g) and triethylamine (0.50 mL) in tetrahydrofuran (10 mL) was slowly,added methanesulfonyl chloride (0.20 mL) at 00C, and the mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.56 g, yield 65%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (3:1, volume ratio), melting point 149-
150°C. Example 270 N-methyl-N-{2- [5-methyl-5- (piperazine-1-ylmethyl) - 4,5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene-2- sulfonamide
Figure imgf000417_0001
To a mixture of triphenylphosphine oxide (3.09 g) and acetonitrile (20 iriL) was slowly added trifluoromethanesulfonic anhydride (0.93 mL) at 0°C, and the mixture was stirred for 10 min. tert-Butyl 4- {2- (benzylthio) -2-methyl-3- [ ( {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2- yl}carbonyl) amino] propyl }piperazine-l-carboxylate (1.55 g) and dimethylsulfide (0.24 mL) were added, and the reaction mixture was stirred at 0°C for 30 min. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was added to 4N hydrogen chloride-ethyl acetate solution, and the resulting crystals were collected by filtration, and washed with ethyl acetate. The obtained crystals were added to saturated aqueous sodium hydrogencarbonate, and the mixture was stirred for 30 min. The crystals were- collected by filtration, washed with water and ethyl acetate, and dried to give the title compound (0.49 g, yield 45%) as colorless crystals, melting point 178-180°C.
Example 271 N-methyl-N- [2- (8-oxo-l-thia-3-azaspiro [4.5] dec-2- en-2-yl) -lH-indol-7-yl] thiophene-2-sulfonamide
Figure imgf000418_0001
In the same manner as in Example 267, the title compound (0.34 g, yield 53%) was obtained as colorless crystals from N- { [1- (benzylthio) -4-oxocyclohexyl]methyl} -7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (0.79 g) . melting point 207-2080C.
Example 272 N-methyl-N-{2- [5- (morpholinocarbonyl) -4, 5-dihydro-
1, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000418_0002
To a mixture of 2- {7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazole-5-carboxylic acid (0.25 g) , morpholine (0.10 g) , 1H-1> 2, 3-benzotriazol-l-ol (0.10 g) and N,N-dimethylformamide (4 itiL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.14 g) at room temperature, and the mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and the precipitated solid was collected by filtration, washed with water, and dried. The obtained solid was subjected to basic silica gel column chromatography to give the title compound (0.25 g, yield 86%) as pale-yellow crystals from a fraction eluted with tetrahydrofuran. melting point 238-239°C.
Example 273 N-methyl-N- (2-{5- [ (4-methylpiperazin-l- yl) carbonyl] -4 , 5-dihydro-l, 3-thiazol-2-yl } -lH-indol-7- yl) thiophene-2-sulfonamide
Figure imgf000419_0001
In the same manner as in Example 272, the title compound (0.21 g, yield 71%) was obtained as pale-yellow crystals from 2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazole-5-carboxylic acid (0.25 g) and
N-methylpiperazine (0.12 g) . melting point 198-199°C. Example 274 N-methyl-N-{2- [5- (morpholinomethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000419_0002
To a mixture of triphenylphosphine oxide (1.72 g) and acetonitrile (15 mL) was slowly added trifluoromethanesulfonic anhydride (0.52 mL) at 0°C, and the 'mixture was stirred for 10 min. N- [2- (benzylthio) -3-morpholinopropyl] -7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carboxamide (an optically active form: retention time: shorter) (0.91 g) obtained in
Reference Example 94 and dimethylsulfide (0.33 mL) were added.
The reaction mixture was stirred at 0°C for 15 min, saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give an oil containing the title compound and triphenylphosphine oxide from a fraction eluted with ethyl acetate-hexane (4:1, volume ratio). The obtained oil was added to 4N hydrogen chloride-ethyl acetate solution, and the resulting crystals were collected by filtration, and washed with ethyl acetate. The obtained crystals were added to saturated aqueous sodium hydrogencarbonate, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCU) i and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.62 g, yield 81%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (4:1, volume ratio), melting point 139-140°C. Example 275 N, N-diethyl-2-{ 7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazole-5-carboxamide
Figure imgf000420_0001
n the same manner as in Example 272, the title compound (0.24 g, yield 85%) was obtained as pale-yellow crystals from 2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazole-5-carboxylic acid (0.25 g) and diethylamine (0.12 rriL) . melting point 218-219°C.
Example 276 N- [ (2- {7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl)methyl] acetamide
Figure imgf000420_0002
To a solution of N- {2- [5- (aminomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (0.27 g) in N, N-dimethylacetamide (6 inL) was added acetic anhydride (0.10 mL) at 0°C, and the. mixture was stirred for 30 min. Water was added to the reaction mixture, and the precipitated solid was collected by filtration, washed with water, and dried. The obtained solid was subjected to silica gel column chromatography to give the title compound (0.20 g, yield 68%) as pale-yellow crystals from a fraction eluted with ethyl acetate-hexane (95:5, volume ratio) . melting point 212-
213°C.
Example 277 N- {2- [5- (aminomethy1) -5-methyl-4, 5~dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000421_0001
To a mixture of lithium aluminum hydride (0.05 g) and tetrahydrofuran (6 mL) was added N- [2- (5-cyano-5-methyl-4, 5- dihydro-1, 3-thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2- sulfonamide (0.40 g) at 0°C, and the mixture was stirred for 15 min. Ethanol (2 mL) and IN aqueous sodium hydroxide solution (0.2 mL) were successively added, and the resulting inorganic salt was removed by filtration. The filtrate was concentrated, and the residue was subjected to basic silica gel column chromatography to give the title compound (0.23 g, yield 57%) as colorless crystals from a fraction eluted with ethyl acetate, melting point 164-165°C.
Example 278 5-methyl-2- {7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazole-5-carboxamide
Figure imgf000421_0002
A mixture of N- [2- (5-cyano-5-methyl-4, 5-dihydro-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide (0.38 g) , 2N aqueous sodium hydroxide solution (0.90 mL) , tetrahydrofuran (4 mL) and ethanol (4 mL) was heated under reflux for 4 hr. 10% Aqueous citric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. A mixture of the obtained residue, IH-I, 2, 3-benzotriazol-l-ol (0.15 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.21 g) and N,N-dimethylformamide (6 mL) was added at room temperature for 1 hr, and 28% aqueous ammonia (0.22 mL) was added. The mixture was stirred overnight at room temperature, water was added to the reaction mixture, and the precipitated solid was collected by filtration, washed with water, and dried. The obtained solid was suspended in ethanol, and the mixture was stirred for 15 min. The crystals were collected by filtration,, washed with ethanol and ethyl acetate, and dried to give the title compound (0.29 g, yield 74%) as colorless crystals, melting point 248-249°C. Example 279 2-chloro-N-methyl-N-{4-methyl-2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7- yl}pyridine-3-sulfonamide
Figure imgf000422_0001
To a mixture of triphenylphosphine oxide (1.95 g) and acetonitrile (20 mL) was slowly added trifluoromethanesulfonic anhydride (0.59 mL) at 0°C, and the mixture was stirred for 10 min. N- [2- (Benzylthio) -3-morpholinopropyl] -7- [ [ (2- chloropyridin-3-yl) sulfonyl] (methyl) amino] -4-methyl-lH-indole- 2-carboxamide (1.10 g) and dimethylsulfide (0.20 mL) were added. The reaction mixture was stirred at 0°C for 15 min. Saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSθ4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (0.69 g, yield 76%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (3:1, volume ratio), melting point 151- 153°C .
Example 280 N-methyl-N-{4-methyl-2- [5- (morpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl]-lH-indol-7-yl} thiophene-2- sulfonamide
Figure imgf000423_0001
In the same manner as in Example 274, the title compound (0.45 g, yield 54%) was obtained as colorless crystals from N- [2- (benzylthio) -3-morpholinopropyl] -4-methyl- 7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (1.01 g) . melting point 192-193°C.
Example 281 N- [2- (5-cyano-4, 5-dihydro-l, 3-thiazol-2-yl) -4- methyl-lH-indol-7-yl]-N-methylthiophene-2-sulfonamide
Figure imgf000423_0002
To a mixture of triphenylphosphine oxide (2.35 g) and acetonitrile (20 mL) was slowly added trifluoromethanesulfonic anhydride (0.71 mL) at O0C, and the mixture was stirred for 10 min. N- [2- (Benzylthio) -2-cyanoethyl] -4-methyl-7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (1.10 g) and dimethylsulfide (0.46 mL) were added. The reaction mixture was stirred at 0°C for 30 min, saturated aqueous sodium hydrogencarbonate was added, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed with saturated brine, dried (MgSd) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (0.58 g, yield 67%) as colorless crystals from a fraction eluted with ethyl acetate-hexane (3:2, volume ratio) . melting point 173-174°C. Example 282 N- {2- [5- (aminomethyl) -4, 5-dihydro-l, 3-thiazol-2- yl] -4-methyl~lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000424_0001
In the same manner as in Example 277, the title compound (0.58 g, yield 67%) was obtained as colorless crystals from N- [2- (5-cyano-4, 5-dihydro-l, 3-thiazol-2-yl) -4- methyl-lH-indol-7-yl]-N-methylthiophene-2-sulfonamide (1.10 g) . melting point 146-147°C.
Example 283 ethyl (2- {7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate
Figure imgf000424_0002
A solution of 7- [methyl (2-thienylsulfonyl) amino] -IH- indole-2-carbothioamide (0.50 g) , ethyl but-2-ynoate (0.40 mL) and tributylphosphine (0.40 mL) in a mixed solvent of tetrahydrofuran (16 mL) -toluene (8 mL) was stirred at 50°C for 3 hr. The reaction solution was concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=l : 4-1 :1) to give the title compound (0.33 g, yield: 50%) as a pale-yellow oil. A part of the oil was crystallized from ethyl acetate-hexane to give pale-yellow crystals. MS:464 (MH+) .• melting point 101- 102°C.
Example 284 (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2- yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000424_0003
Ethyl (2- {7- [methyl (2-thienylsulfonyl) amino] -IH-indol- 2-yl}-4,5-dihydro-l,3-thiazol-5-yl) acetate (0.52 g) was dissolved in a mixed solvent of tetrahydrofuran (6 mL) - methanol (6 mL) , and the mixture was ice-cooled. Aqueous potassium hydroxide solution (prepared by dissolving potassium hydroxide (0.25 g) in water (5 mL) ) was added to this solution, and the mixture was stirred from under ice-cooling to room temperature for 7 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained amorphous solid was crystallized from ethyl acetate-hexane to give the title compound (407 mg, yield: 83%) as pale-yellow prism crystals. MS:436(MH+). melting point 232-234°C.
Example 285 N- {2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl] -lH-indol-7~yl}-N-methylthiophene-2-sulfonamide
Figure imgf000425_0001
To a mixture of ethyl (2- { 7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl)acetate (0.21 g) , lithium borohydride (20 mg) and tetrahydrofuran (10 mL) was added methanol (2 mL) , and the mixture was stirred at room temperature for 3 hr. Aqueous citric acid solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound (182 mg, yield: 96%) as pale-yellow crystals. A part of the crystals was recrystallized from ethyl acetate-hexane to give pale-yellow crystals. MS: 422 (MH+). melting point 174-175°C. Example 286 N-methyl-N- (2-{ 5- [2- (4-methylpiperazin-l-yl) -2- oxoethyl] -4, 5-dihydro-l, 3-thiazol-2-yl }~lH-indol-7- yl ) thiophene-2-sulfonamide
Figure imgf000426_0001
To a mixture of (2- {7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4,5-dihydro-l/3-thiazol-5-yl) acetic acid (80 mg) , N-methylpiperazine (25 μL) , IH-1, 2, 3-benzotriazol-l-ol (35 mg) and N, N-dimethylformamide (8 mL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (50 mg) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 18 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained pale-yellow crystals were recrystallized from ethyl acetate-hexane to give the title compound (59 mg, yield: 62%) as colorless crystals.
MS: 518 (MH+). melting point 151-1530C.
Example 287 2- (2- {7- [methyl (2-thienylsulfonyl) amino] -IH-indol-
2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000426_0002
To a mixture of (2- {7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (100 mg) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (42 mg) and N, N-dimethylformamide (6 mL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (53 mg) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 18 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate : hexane=9 : 1-ethyl acetate) , and the obtained pale-yellow oil was crystallized from ethyl acetate-hexane to give the title compound (82 mg, yield: 82%) as pale-yellow prism crystals. MS:435(MH+). melting point 193-194°C.
Example 288 N- (2-{5- [2- (2, 5-dioxopyrrolidin-l-yl) ethyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2- sulfonamide
Figure imgf000427_0001
A solution (1O mL) of N- {2- [5- (2-hydroxyethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH~indol-7-yl}-N-methylthiophene-2- sulfonamide (100 mg) , succinimide (29 mg) and triphenylphosphine (93 mg) in tetrahydrofuran was added a 40% toluene solution (0.155 mL) of diethyl azodicarboxylate, and the mixture was stirred at room temperature for 18 hr. A 40% toluene solution (0.155 mL) of diethyl azodicarboxylate was added again to the reaction solution, and the mixture was further stirred at room temperature for 5 days. The reaction solution was concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (ethyl acetate : hexane=2 : 8-10: 0) , and the obtained colorless oil was crystallized from ethyl acetate- hexane to give the title compound (36 mg, yield: 30%) as colorless prism crystals. MS:503(MH+). melting point 189-191°C. Example 289 methyl [2- (2-{7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) ethyl] carbamate
Figure imgf000428_0001
A mixture of (2-{7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl }-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid, (40 mg) , triethylamine (0.038 mL) , diphenylphosphorylazide (0.024 itiL) and N,N-dimethylformamide (3 iαL) was' stirred at room temperature for 1 hr. Methanol (3 itiL) was added to the reaction solution, and the mixture was heated at 50°C for 3 hr. The reaction solution was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=l : 3-7 : 3) , and the obtained pale-yellow oil was crystallized from ethyl acetate-hexane to give the title compound (11.7 mg, yield: 28%) as pale-yellow crystals. MS:465(MH+). melting point 201-203°C.
Example 290 ethyl (2-{4-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-
5-yl) acetate
Figure imgf000428_0002
A solution of 4-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indole-2-carbothioamide (1.62 g) , ethyl but-2-ynoate' (1.2 itiL) and tributylphosphine (1.1 itiL) in a mixed solvent of tetrahydrofuran _ (30 mL) -toluene (20 mL) was stirred at room temperature for 4 hr. The reaction solution was concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=10: 90-35: 65) . The obtained crystals were crystallized from ethyl acetate-hexane to give the title compound ( 1 . 35 g, yield: 64%) as pale-yellow crystals . MS : 478 (MH+) . melting point 109-1100C .
Example 291 N- { 2- [ 5- (2-hydroxyethyl ) -4 , 5-dihydro-l , 3-thiazol- 2-yl] -4-methyl-lH-indol-7-yl } -N-methylthiophene-2-sulfonamide
Figure imgf000429_0001
To a mixture of ethyl (2-{4-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl }~4, 5-dihydro-l, 3-thiazol- 5-yl) acetate (0.12 g) , lithium borohydride (20 mg) and tetrahydrofuran (10 mL) was added methanol (2 mL) , and the mixture was stirred at room temperature for 3 hr. Aqueous citric acid solution was added to the reaction solution^ and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained crystals were washed with ethyl acetate-hexane to give the title compound (103 mg, yield: 94%) as pale-yellow crystals. MS:436(MH+). melting point 168-169°C. Example 292 (2-{4-methyl-7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000429_0002
Ethyl (2- {4-methyl-7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (0.99 g) was dissolved in a- mixed solvent of tetrahydrofuran (12 mL) - methanol (12 mL) , and the mixture was ice-cooled. Aqueous potassium hydroxide solution (prepared by dissolving potassium hydroxide (0.35 g) in water (5 mL) ) was added to this solution, and the mixture was stirred from under ice-cooling to room temperature for 15 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained pale-yellow crystals were washed with ethyl acetate-hexane to give the title compound (1.00 g, yield: 95%) as pale-yellow crystals. MS:450(MH+). melting point 269-270°C.
Example 293 2- (2- {4~methyl-7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000430_0001
To a mixture of (2- {4-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetic acid (0.25 g) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (0.11 g) and N,N-dimethylformamide (15 rriL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.14 g) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 2 days . The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=9: 1-10: 0) , and the obtained colorless oil was crystallized from ethyl acetate-hexane to give the title compound (228 mg, yield: 92%) as colorless crystals. MS : 449 (MH+) .. melting point 120-1210C. Example 294 N,N-dimethyl-2- (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000431_0001
A mixture of (2-{7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (70 mg) , lH-l,2,3-benzotriazol-l-ol (33 ing), N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (46 mg) and N,N-dimethylforrαamide (4 mL) was stirred at room temperature for 2 hr. 2M tetrahydrofuran solution (0.25 mL) of dimethylamine was added to this solution, and the mixture was stirred at room temperature for 15 hr. The reaction solution was diluted with ethyl acetate, washed, with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate) , and the obtained colorless crystals were washed with ethyl acetate-hexane to give the title compound (53 mg, yield: 30%) as colorless crystals. MS:463(MH+). melting point 153-154°C.
Example 295 N- {2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3-thiazol-
2-yl] -lH-indol-7-yl} thiophene-2-sulfonamide
Figure imgf000431_0002
To a mixture of ethyl (2- { 7- [ (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3~thiazol-5-yl) acetate (0.27 g) , lithium borohydride (70 mg) and tetrahydrofuran (10 mL) was added methanol (2 mL) , and the mixture was stirred at room temperature for 5 hr. Diluted hydrochloric acid was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=l: 1-7:3) , and the obtained colorless oil was crystallized from ethyl acetate-hexane to give the title compound (46 mg, yield: 19%) as colorless plate crystals. MS: 408 (MH+). melting point 156-1580C.
Example 296 (2-{7- [ (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000432_0001
Ethyl (2-{7-[ (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetate (0.49 g) was dissolved in a mixed solvent of tetrahydrofuran (8 mL) -methanol (8 mL) . Aqueous potassium hydroxide solution (prepared by dissolving potassium hydroxide (0.25 g) in water (4 mL) ) was added to this solution, and the mixture was stirred at room temperature for 15 hr. The reaction solution was acidified with diluted hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained amorphous solid was crystallized from ethyl acetate-hexane to give the title compound (256 mg, yield: 56%) as pale-yellow crystals. MS:422(MH+). melting point >240°C (decomposition) .
Example 297 2- (2-{7- [ (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000432_0002
To a mixture of (2- { 7- [ (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (153 mg) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (72 mg) and N, N- dimethylformamide (8 mL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiiiαide hydrochloride (91 mg) under ice-cooling, and the mixture was stirred from under ice-cooling to. room temperature for 15 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced .pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate-ethyl acetate :methanol=95: 5) , and the obtained pale-yellow oil was crystallized from ethyl acetate-hexane to give the title compound (118 mg, yield: 77%) as pale-yellow crystals.
MS:421(MH+). melting point 130-1310C.
Example 298-A N- {2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -lH-indol-7-ylJ-N-methylthioph.ene-2-sulfonam.ide
Figure imgf000433_0001
N- {2- [5- (2-Hydroxyethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] - lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (510 mg) was dissolved in hexane-ethanol (50:50, volume ratio) to prepare a 0.5 mg/mL solution. This solution was subjected to HPLC using CHIRALCEL OD (50mmIDχ500mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with hexane-ethanol (50:50, volume ratio) as a mobile phase at 30°C at flow rate of 60 mL/min. A fraction with the retention time of 22 min was separated, and concentrated. The obtained solid was dissolved in ethyl acetate, the insoluble substance was removed by filtration, and the filtrate was concentrated. The obtained oil was crystallized from ethyl acetate-hexane to give the title compound (217 mg) as pale-yellow crystals, melting point 173-174°C. Example 298-B N-{2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000434_0001
N- {2- [5- (2-Hydroxyethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] - lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (510 mg) was dissolved in hexane-ethanol (50:50, volume ratio) to prepare a 0.5 mg/mL solution. This solution was subjected to HPLC using CHIRALCEL OD (50mmID><500mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with hexane-ethanol (50:50, volume ratio) as a mobile phase at 300C at flow rate of 60 mL/min. A fraction with the retention time of 36 min was separated, and concentrated. The obtained solid was dissolved in ethyl acetate, the insoluble substance was removed by filtration, and the filtrate was concentrated. The obtained oil was crystallized from ethyl acetate-hexane to give the title compound (229 mg) as pale-yellow crystals, melting point 168-169°C.
Example 299 N-methoxy-N-methyl-2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000434_0002
To a solution of N, O-dimethylhydroxylamine hydrochloride (0.28 g) in N,N-dimethylformamide (20 mL) was added triethylamine (0.43 mL) under ice-cooling, and the mixture was stirred for 10 min under ice-cooling. (2-{7- [Methyl (2-thienylsulfonyl) amino] -IH-indol-2-yl}-4, 5-dihydro- 1, 3-thiazol-5-yl) acetic acid (1.03 g) , IH-I, 2, 3-benzotriazol- l-ol (0.42 g) and N-[3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (0.59 g) were added to the mixture, and the mixture was stirred from under ice-cooling to room temperature for 24 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=7 : 3-10: 0) , and the obtained pale-yellow crystals were washed with ethyl acetate- hexane to give the title compound ■ (911 mg, yield: 81%) as pale-yellow crystals. MS:479(MH+). melting point 153-154°C. Example 300 N-methyl-N-{2- [5- (2-oxopropyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000435_0001
N-Methoxy-N-methyl-2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide (0.20 g) was dissolved in absolute tetrahydrofuran (20 irtL) , and a 12% methylmagnesium bromide tetrahydrofuran solution (1.4 mL) was added under ice-cooling.
The mixture was stirred at 10°C for 5 hr under ice-cooling, acidified with aqueous citric acid solution, and extracted with ethyl acetate . The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=35: 65-50:50) , and the obtained colorless oil was crystallized from ethyl acetate-hexane • to give the title compound (121 mg, yield: 67%) as colorless crystals.
MS:434 (MH+). melting point 123-124°C.
Example 301 N-methyl-N-{2- [5- (2-oxobut-3-en-l-yl) -4, 5-dihydro-
1, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000436_0001
N-Methoxγ-N-methyl-2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide (589 mg) was dissolved in absolute tetrahydrofuran (20 mL) , and IM vinylmagnesium bromide tetrahydrofuran solution (3.7 mL) was added under ice-cooling. The mixture was stirred for 5 hr under ice-cooling, IM vinylmagnesium bromide tetrahydrofuran solution (2.0 mL) was added again, and the mixture was further stirred under ice- cooling for 2 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate, The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate) , and the obtained pale-yellow crystals were washed with ethyl acetate-hexane to give the title compound (210 mg, yield: 38%) as pale-yellow crystals. MS:446(MH+). melting point 157-158°C. Example 302 N-methyl-N- (2-{5- [ (l-methyl-4, 5-dihydro-lH- pyrazol-3-yl) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide
Figure imgf000436_0002
A mixture of at N-methyl-N- {2- [5- (2-oxobut-3-en-l-yl) -
4, 5-dihydro-l, 3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide (250 mg) , methylhydrazine (0.050 mL) and tetrahydrofuran (20 mL) was stirred at room temperature for 3 hr. The reaction solution was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. Ethyl acetate was added to the obtained residue, the insoluble substance was filtered off, and the filtrate was concentrated. The obtained residue was subjected to basic silica gel column chromatography (ethyl acetate :hexane=3: 7-5: 5) , and the obtained colorless oil was crystallized from ethyl acetate- hexane to give the title compound (156 mg, yield: 59%) as colorless needle crystals. MS: 474 (MH+). melting point 149-
150°C.
Example 303 N-methyl-N-{2- [5- (thiomorpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}pyridine-2-sulfonamide
Figure imgf000437_0001
To a solution of triphenylphosphine oxide (0.79 g) in dichloromethane (5 mL) was slowly added trifluoromethanesulfonic anhydride (0.38 mL) under ice-cooling, and the mixture was stirred for 20 min. A solution of N- [2- (benzylthio) -3-thiomorpholinopropyl] -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxamide (0.67 g) in dichloromethane (5 mL) was added dropwise, and the mixture was stirred for 1 hr under ice-cooling. The reaction solution was diluted with ethyl acetate, washed with aqueous citric acid solution, water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained solid was filtered off, and washed with ethyl acetate. The filtrate was concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=4 : 6-6: 4) . The obtained colorless oil was crystallized from ethyl acetate-hexane to give the title compound (29 mg, yield: 5%) as colorless crystals. MS:488 (MH+). melting point 142-144°C. Example 304 N-methyl-N- (2-{ 5- [ (1-oxidothiomorpholino) methyl] - 4, 5-dihydro-l, 3-thiazol-2-yl }-lH-indol-7-yl) pyridines- sulfonamide
Figure imgf000438_0001
To a solution of N-methyl-N-{2- [5-
(thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -IH-indol- 7-yl}pyridine-2-sulfonamide (180 mg) in dichloromethane (8 mL) was added m-chloroperbenzoic acid (7'5 mL) under ice-cooling, and the mixture was stirred for 3 hr under ice-cooling. The reaction solution was diluted with ethyl acetate, washed with aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to basic silica gel column chromatography (ethyl acetate :hexane=6: 4- 9:1), and the obtained colorless oil was crystallized from ethyl acetate-hexane to give the title compound (39 mg, yield: 21%) as colorless needle crystals. MS : 504 (MH+).. melting point 193-194°C.
Example 305 ethyl (2-{7-[[(2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol-5-yl) acetate
Figure imgf000438_0002
A mixture of 7-[[(2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indole-2- carbothioamide (2.3 g) , ethyl but-2-ynoate (1.5 mL) , tributylphosphine (1.5 mL) , toluene (25 mL) and tetrahydrofuran (25 mL) was stirred for 3 hr at room temperature. The reaction solution was concentrated, and the obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=3: 7-5: 5) to give the title compound (1.23 g, yield: 41%) as a pale-brown amorphous solid. 1H-ISIMR(CDCl3)S:!^ (3H, t, J=I .2 Hz), 2.72 (2H, d, J=7.5 Hz), 3.40 (3H, s), 3.95 (3H, s) , 4.19 (2H, q, J=7.2 Hz), 4.22-4.48 (3H, m) , 6.86-6.98 (4H, m) , 7.03 (IH, d, J=8.7 Hz), 7.48-7.56 (2H, m) , 7.72 (IH, dd, J=7.8, 1.8 Hz), 9.61 (IH, brs) . Example 306 N- {2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl] -lH-indol-7-yl}-2~methoxy-N-methylbenzenesulfonamide
Figure imgf000439_0001
To a mixture of ethyl (2-{7-[[(2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol-5-yl) acetate (140 mg) , lithium borohydride (40 mg) and tetrahydrofuran (5 mL) was added methanol (1 mL),' and the mixture was stirred at room temperature for 2 hr. Aqueous citric acid solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=6: 4-10: 0) , and the obtained pale-yellow oil was crystallized from ethyl acetate- hexane to give the title compound (87 mg, yield: 69%) as colorless needle crystals. MS:446(MH+). melting point 154-
155°C.
Example 307 (2- { 7- [[ (2-methoxyphenyl) sulfonyl] (methyl) amino] -
IH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000439_0002
Ethyl (2-{7- [ [ (2-methoxyphenyl) sulfonyl] (methyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (1.0 g) was dissolved in a mixed solvent of tetrahydrofuran (10 mL) - methanol (10 mL) . Aqueous potassium hydroxide solution (prepared by dissolving potassium hydroxide (0.50 g) in water (5 πiL) ) was added to this solution, and the mixture was stirred at room temperature for 7 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained pale-brown oil was crystallized from ethyl acetate-hexane to give the title compound (730 mg, yield: 78%) as pale-yellow crystals. MS:460(MH+). melting point 197-198°C. Example 308 2- (2-{7- [ [ (2- methoxyphenyl) sulfonyl] (methyl) amino] -IH-indol-2-yl} -4, 5- dihydro-1, 3-thiazol-5-yl) acetamide
Figure imgf000440_0001
To a mixture of (2-{7-[[(2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indol-2-yl}-4, 5- dihydro-l,3-thiazol-5-yl) acetic acid (0.25 g) , IH-I, 2, 3-' benzotriazol-1-ol-ammonia complex (0.13 g) and N, N- dimethylformamide (10 nxL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride
(0.16 g) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 15 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :methanol=10 : 0-8 : 2) , and the obtained pale-brown solid was washed with ethyl . acetate-hexane to give the title compound (143 mg, yield 57%) as pale-brown crystals. MS:459(MH+). melting point 227-228°C. Example 309 N-methoxy-2- (2- {7- [ [ (2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol-5-yl) -N-methylacetamide
Figure imgf000441_0001
To a solution of N, O-dimethylhydroxylamine hydrochloride (48 mg) in N,N-dimethylformamide (10 inL) was added triethylamine (85uL) under ice-cooling, and the mixture was stirred for 10 min under ice-cooling. (2-{7-[[(2- Methoxyphenyl) sulfonyl] (methyl) amino] -lH-indol-2-yl} -4, 5- dihydro-l,3-thiazol-5-yl) acetic acid (200 mg) , IH-I, 2,3- benzotriazol-1-ol (90 mg) and N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (130 mg) were added to the mixture, and the mixture was stirred from under ice-cooling to room temperature for 15 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :methanol=100 : 0-95: 5) to give the title compound (180 mg, yield: 85%) as a pale-yellow amorphous solid. MS:489(MH+). Example 310 2- (2-{7- [ [ (2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol-5-yl) -N-4H-1, 2, 4-triazol-3-ylacetamide
Figure imgf000441_0002
To a mixture of (2-{7-[[(2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol-5-yl) acetic acid (150 mg) , 2-amino-l, 2, 4- triazole (36 mg) , IH-I, 2, 3-benzotriazol-l-ol (67 mg) and N,N- dimethylformamide (8 mL) was added N- [3-
(dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (94 mg). under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 15 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate rmethano1=100: 0-95:5) , and the obtained colorless oil was crystallized from ethyl acetate-hexane to give the title compound (118 mg, yield 69%) as colorless prism crystals. MS:526(MH+). melting point 208-
209°C.
Example 311 N- (2- { 5- [2- ( 4-hydroxypiperidino) -2-oxoethyl] -4 , 5- dihydro-1, 3-thiazol-2-yl }-lH-indol-7-yl) -2-methoxy-N- methylbenzenesulfonamide
Figure imgf000442_0001
To a mixture of (2- { 7- [ [ (2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indol-2-yl} -4, 5- dihydro-1, 3-thiazol-5-yl) acetic acid (150 mg) , 4- hydroxypiperidine (43 mg),' IH-I, 2, 3-benzotriazol-l-ol (67 mg) and N, N-dimethylformamide (8 mL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (94 mg) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 15 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :methanol=100: 0-90: 10) , and the obtained colorless oil was crystallized from ethyl acetate-hexane to give the title compound (131 mg, yield 74%) as colorless prism crystals. MS: 543 (MH+) . melting point 166-
167°C.
Example 312 2- (2-{ 7- [ [ (2- methoxyphenyl) sulfonyl] (methyl) amino] -IH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol-5-yl) -N-lH-tetrazol-5-ylacetamide
Figure imgf000443_0001
To a mixture of (2-{7-[[(2- methoxyphenyl) sulfonyl] (methyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol-5-yl) acetic acid (165 mg) , 5-amino- tetrazole (37 mg) , IH-I, 2, 3-benzotriazol-l-ol (68 mg) and N, N- dimethylformamide (8 mL) was added N- [3-
(dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (96 mg) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 2 days. The reaction solution was diluted with ethyl acetate, washed with water, aqueous citric acid solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by preparative HPLC to give the title compound (107 mg, yield 56%) as a pale- yellow amorphous solid. MS: 527 (MH+). Example 313 ethyl {2- [7- (methyl { [2-
(trifluoromethyl) phenyl] sulfonyl} amino) -lH-indol-2-yl] -4, 5- dihydro-1, 3-thiazol-5-yl }acetate
Figure imgf000443_0002
A mixture of 7- (methyl { [2-
(trifluoromethyl) phenyl] sulfonyl} amino) -lH-indole-2- carbothioamide (2.65 g) , ethyl but-2-ynoate (1.5 mL) , tributylphosphine (1.6 mL) , toluene (30 itiL) and tetrahydrofuran (20 mL) was stirred for 2.5 hr at room temperature. The reaction solution was concentrated, and the obtained residue was subjected to silica gel column chromatography (ethyl acetate : hexane=2 : 8-4 : 6) to give the title compound (1.92 g, yield: 57%) as a pale-yellow oil. MS: 526 (MH+) .
Example 314 {2- [7- (methyl { [2-
(trifluoromethyl) phenyl] sulfonyl} amino) -lH-indol-2-yl] -4, 5- dihydro-1, 3-thiazol-5-yl} acetic acid
Figure imgf000444_0001
Ethyl {2- [7- (methyl { [2-
(trifluoromethyl) phenyl] sulfonyl} amino) -lH-indol-2-yl] -4, 5- dihydro-1, 3-thiazol-5-yl}acetate (0.55 g) was dissolved in a mixed solvent of tetrahydrofuran (6 mL) -methanol (6 mL) .
Aqueous potassium hydroxide solution (prepared by dissolving potassium hydroxide (0.30 g) in water (5 mL) ) was added to this solution, and the mixture was stirred at room temperature for 6 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained pale-yellow oil was crystallized from ethyl acetate-hexane to give the title compound (372 mg, yield: 72%) as pale-yellow crystals. MS:498 (MH+). melting point 170-172°C.
Example 315 N- {2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3-thiazol-
2-yl]-lH-indol-7-yl}-N-methyl-2-
(trifluoromethyl)benzenesulfonamide
Figure imgf000445_0001
To a mixture of ethyl {2- [7- (methyl { [2-
(trifluoromethyl) phenyl] sulfonyl}amino) -lH-indol-2-yl] -4, 5- dihydro-1, 3-thiazol-5-yl}acetate (1.4 g) , lithium borohydride (0.30 g) and tetrahydrofuran (20 mL) was added methanol (3 mL) , and the mixture was stirred at room temperature for 3 hr . Aqueous citric acid solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=5: 5-7: 3) , and the obtained pale-yellow oil was crystallized from ethyl acetate- hexane to give the title compound (0.79 g, yield: 61%) as colorless needle crystals. MS:484 (MH+). melting point 153-
154°C.
Example 316 1- ( {2- [7- (methyl { [2-
(trifluoromethyl) phenyl] sulfonyl} amino) -lH-indol-2-yl] -4, 5- dihydro-1, 3-thiazol-5-yl}acetyl) -L-proline
Figure imgf000445_0002
To a mixture of {2- [7- (methyl { [2-
(trifluoromethyl) phenyl] sulfonyl} amino) -lH-indol-2-yl] -4, 5- dihydro-1, 3-thiazol-5-yl}acetic acid (150 mg) , L-proline methyl ester hydrochloride (60 mg) , triethylamine (50 μL) , IH- 1, 2, 3-benzotriazol-l-ol (53 mg) and N,N-dimethylformamide (8 mL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (75 mg) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 15 hr. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate) to give pale-yellow crystals (180 mg) . The obtained crystals were dissolved in a mixed solvent of tetrahydrofuran (5 mL) - methanol (5 mL) . Aqueous potassium hydroxide solution (prepared by dissolving potassium hydroxide (0.10 g) in water (3 mL) ) was added to this solution, and the mixture was stirred at room temperature for 15 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and ■ concentrated under reduced pressure. The obtained pale-yellow crystals were washed with ethyl acetate-hexane to give the title compound (139 mg, yield: 77%) as pale-yellow crystals.
MS:595(MH+). melting point 132-135°C. Example 317 [ (2-{2- [7- (methyl{ [2- (trifluoromethyl) phenyl] sulfonyl} amino) -lH-indol-2-yl] -4, 5- dihydro-1, 3-thiazol-5-yl} ethyl) thio] acetic acid
A solution (15 mL) of N- {2- [5- (2-hydroxyethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methyl-2- (trifluoromethyl) benzenesulfonamide (710 mg) and thionyl chloride (0.32 mL) in tetrahydrofuran was stirred at 60°C for 2 hr. The reaction solution was diluted with ethyl acetate, washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained pale-yellow oil was crystallized from diethyl ether to give pale-yellow crystals (667 mg) . To a mixture of the obtained pale-yellow crystals, methyl mercaptoacetate (0.18 mL) , tetrabutylammonium iodide (147 mg) and N,N~dimethylformamide (8 itiL) was added potassium carbonate (140 mg) , and the mixture was stirred 70°C for 3 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate: hexane=2 : 8-4 : 6) to give a pale-yellow oil (165 mg) . The obtained oil was dissolved in a mixed solvent of tetrahydrofuran (5 mL) -methanol (5 mL) .
Aqueous potassium hydroxide solution (prepared by dissolving potassium hydroxide (90 mg) in water (3 mL) ) was added to this solution, and the mixture was stirred at room temperature for 15 hr. The reaction solution was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate-ethyl acetate : methanol=9: 1) to give the title compound (80 mg, yield: 50%) as a pale-yellow amorphous solid. MS: 558 (MH+) .•
Example 318 N- (2-{ 5- [ (1, 1-dioxidothiomorpholino) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylpyridine-2- sulfonamide
Figure imgf000447_0001
To a solution of triphenylphosphine oxide (0.50 g) in dichloromethane (5 mL) was slowly added trifluoromethanesulfonic anhydride (0.25 mL) under ice-cooling, and the mixture was stirred for 20 min; A solution of N- [2- (benzylthio) -3- (1, 1-dioxidothiomorpholino) propyl] -7-
[methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxamide (0.37 g) in dichloromethane (5 mL) was added dropwise, and the mixture was stirred for 30 min under ice-cooling. The reaction solution was diluted with ethyl acetate, washed with aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=3: 7-10 : 0) . The obtained colorless oil was crystallized from ethyl acetate- hexane to give the title compound (87 mg, yield: 28%) as colorless prism crystals. MS:520(MH+). melting point 188-189°C. Example 319 N- {2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl] -lH-indol-7-yl}-N, l-dimethyl-lH-imidazole-2-sulfonamide
Figure imgf000448_0001
To a solution of triphenylphosphine oxide (2.41 g) in dichloromethane (15 mL) was slowly added trifluoromethanesulfonic anhydride (1.46 mL) under ice-cooling, and the mixture was stirred for 20 min. A solution of N- [2- (benzylthio) -3, 3-dimethoxypropyl] -7- {methyl [ (1-methyl-lH- imidazol-2-yl) sulfonyl] amino }-lH-indole-2-carboxamide (4.4 g) and thioanisole (1.4 mL) in dichloromethane (20 mL) was added dropwise, and the mixture was stirred under ice-cooling for 1 hr. The reaction solution was diluted with ethyl acetate, washed with aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=3: 7-4: 6) to give the title compound (1.7 g, yield: 48%) as a pale-yellow oil. MS:450(MH+).
Example 320 N, 1-dimethyl-N- (2-{ 5- [ (1- oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl} -IH- indol-7-yl) -lH-imidazole-2-sulfonamide
Figure imgf000449_0001
A mixture of N- {2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}-N, l-dimethyl-lH-imidazole-2- sulfonamide (0.32 g) , trifluoroacetic acid (2 itiL) , concentrated sulfuric acid (2 mL) and water (5 mL) was stirred at 65°C for 3 hr. The reaction solution was neutralized with aqueous sodium hydrogencarbonate solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained pale-pink crystals and thiomorpholine 1-oxide hydrochloride (222 mg) were dissolved in tetrahydrofuran (25 mL) , triethylamine (0.30 mL) was added to this solution, and the mixture was stirred at room temperature for 30 min. Sodium triacetoxyborohydride (0.46 g) was added, and the mixture was stirred at room temperature for 1 hr. The reaction solution was acidified with diluted hydrochloric acid, basified with aqueous sodium hydrogencarbonate solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to basic silica gel column chromatography (ethyl acetate :hexane=50: 50-90 : 10) , and the obtained pale-yellow oil was crystallized from ethyl acetate-hexane to give the title compound (137 mg, yield: 38%) as pale-yellow crystals. MS:507 (MH+). melting point 161-162°C. Example 321 N-methyl-N- { 5- [3- (methylsulfonyl)propoxy] -2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7- yl }pyridine-2-sulfonamide
Figure imgf000449_0002
To a solution of triphenylphosphine oxide (1.0 g) in dichloromethane (4 mL) was slowly added trifluoromethanesulfonic anhydride (0.46 mL) under ice-cooling, and the mixture was stirred for 30 min. A solution of N- [2- (benzylthio) -3-morpholinopropyl] -7- [methyl (pyridin-2- ylsulfonyl) amino] -5- [3- (methylsulfonyl) propoxy] -lH-indole-2- carboxamide (0.88 g) and thioanisole (0.61 mL) in dichloromethane (25 mL) was added dropwise, and the mixture was stirred for 90 min under ice-cooling. The reaction solution was diluted with ethyl acetate, washed with aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=50: 50-85: 15) / and the obtained colorless oil was crystallized from ethyl acetate-hexane to give the title compound (174 rag, yield: 23%) as colorless prism crystals. MS: 608 (MH+) . melting point 168-
169°C.
Example 322 N-methyl-N- { 5- [ 3- (methylsulfonyl ) propoxy] -2- [5- (thiomorpholinorαethyl) -4, 5-dihydro-l , 3-thiazol-2-yl] -lH-indol- 7-yl }pyridine-2-sulfonamide
Figure imgf000450_0001
To a solution of triphenylphosphine oxide (0.70 g) in dichloromethane (3 mL) was slowly added trifluoromethanesulfonic anhydride (0.41 mL) under ice-cooling, and the mixture was stirred for 30 min. A, solution of N- [2- (benzylthio) -3-thiomorpholinopropyl] -7- [methyl (pyridin-2- ylsulfonyl) amino] -5- [3- (methylsulfonyl) propoxy] -lH-indole-2- carboxamide (0.75 g) and thioanisole (0.30 mL) in dichloromethane (10 mL) was added dropwise, and the mixture was stirred for 30 min under ice-cooling. The reaction solution was diluted with ethyl acetate, washed with aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=50: 50-90: 10) to give the title compound (350 iαg, yield: 54%) as a colorless amorphous solid. MS: 625(MH+) .
Example 323 N-methyl-N- (5- [3- (methylsulfonyl) prόpoxy] -2- {5- [ (1-oxidothiomorpholino)methyl] -4, 5-dihydro-l, 3-thiazol-2-yl}- lH-indol-7-yl)pyridine-2-sulfonamide
Figure imgf000451_0001
To a mixture of N-methyl-N- {5- [3-
(methylsulfonyl) propoxy] -2- [5- (thiomorpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}pyridine-2-sulfonamide (0.35 g) , ethanol (60 inL) , water (30 itiL) and tetrahydrofuran (30 mli) was added OXONE (registered trade mark, 0.19 g) , and the mixture was stirred at room temperature for 3 hr. Aqueous sodium sulfite solution was added to the reaction mixture, the mixture was stirred for 30 min, and the organic solvent was evaporated under reduced pressure. The residue was diluted with water, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained colorless crystals were recrystallized from ethyl acetate-hexane to give the title compound (193 mg, yield: 54%) as colorless crystals. MS:641 (MH+). melting point
107-1100C.
Example 324 N- { 2- { 5- [ ( 4-acetylpiperazin-l-yl ) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl }-5- [3- (methylsulf onyl) propoxy] -IH- indol-7-yl } -N-methylpyridine-2-sulf onamide
Figure imgf000452_0001
To a solution of triphenylphosphine oxide (0.38 g) in dichloromethane (3 mL) was slowly added trifluoromethanesulfonic anhydride (0.23 mL) under ice-cooling, and the mixture was stirred for 30 min. A solution of N- [3- (4- acetylpiperazin-1-yl) -2- (benzylthio) propyl] -7- [methyl (pyridin- 2-ylsulfonyl) amino] -5- [3- (methylsulfonyl) propoxy] -lH-indole-2- carboxamide (0.34 g) and thioanisole (0.17 mL) in dichloromethane (5 mL) was added dropwise, and the mixture was stirred for 1 hr under ice-cooling. The reaction solution was diluted with ethyl acetate, washed with aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to basic silica gel column chromatography (ethyl acetate) , and the obtained colorless oil was crystallized from ethyl acetate-hexane to give the title compound (109 mg, yield: 37%) as colorless crystals. MS:650(MH+). melting point 165-167°C. Example 325 N-methyl-N- {2- (5- { [4- (methylsulfonyl) piperazin-1- yl]methyl}-4, 5-dihydro-l, 3-thiazol-2-yl) -5- [3-
(methylsulfonyl) propoxy] -lH-indol-7-yl}pyridine-2-sulfonamide
Figure imgf000452_0002
To a solution of triphenylphosphine oxide (0.48 g) in - dichloromethane (3 mL) was slowly added trifluoromethanesulfonic anhydride (0.29 mL) under ice-cooling, and the mixture was stirred for 20 min. A solution of N- {2- (benzylthio) -3- [4- (methylsulfonyl)piperazin-l-yl]propyl}-7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3- (methylsulfonyl) propoxy] -lH-indole-2-carboxamide (0.34 g) in 0772 dichloromethane (15 inL) was added dropwise, and the mixture was stirred for 1 hr under ice-cooling. The reaction solution was diluted with ethyl acetate, washed with aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=7 : 3-10 : 0-ethyl acetate :methanol=9 : 1) , and the obtained colorless oil was crystallized from ethyl acetate-diethyl ether to give the title compound (142 mg, yield: 48%) as colorless crystals.
MS:686(MH+). melting point 151-153°C.
Example 326 N-methyl-N-{2- [5- (morpholinomethyl) -4, 5-dihydro-
1, 3-thiazol-2-yl] -lH-indol-7-yl}pyridine-3-sulfonamide
Figure imgf000453_0001
To a mixture of triphenylphosphine oxide (790 mg) and acetonitrile (15 mL) was added trifluoromethanesulfonic anhydride (238 μL) , and the mixture was stirred at 0°C for 10 min. A solution of N- [2- (benzylthio) -3-morpholinopropyl] -7- [methyl (pyridin-3-ylsulfonyl) amino] -lH-indole-2-carboxamide (410 mg) and dimethylsulfide (52 μL) in acetonitrile (15 mL) and dichloromethane (15 mL) was added to the mixture, and the mixture was stirred at 0°C for 2 hr. The reaction mixture was diluted with ethyl acetate (100 mL) and saturated brine (100 mL) . The organic layer was dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The obtained residue was purified by preparative HPLC to give the title compound (38.3 mg, yield 11%) as a white solid, melting point
234-236°C.
Example 327 ethyl (2-{7- [methyl (1, 3-thiazol-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetate
Figure imgf000454_0001
A mixture of 7- [methyl (1, 3-thiazol-2-ylsulfonyl) amino] - lH-indole-2-carboxamide (1.30 g) , Lawesson' s reagent (937 mg) and tetrahydrofuran (10 mL) was stirred 80°C for 30 min. The reaction mixture was concentrated, toluene was added, and the precipitated solid was collected by filtration. A mixture of the obtained solid, ethyl but-2-ynoate (388 mg) , tributylphosphine (63 μL) , tetrahydrofuran (10 mL) and toluene (5 mL) was stirred at 500C for 2 hr. The reaction mixture was diluted with ethyl acetate (200 mL) and saturated brine (100 ' mL) . The organic layer was dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The obtained residue was purified by silica gel column chromatography (ethyl acetate : hexane=l : 1, volume ratio) to give the title compound (780 mg, yield 44%) as a pale-yellow solid. MS: 465 (MH+) .
Example 328 (2- {7- [methyl (1, 3-thiazol-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000454_0002
A mixture of ethyl (2-{7- [methyl (1, 3-thiazol-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetate (300 mg) , tetrahydrofuran (5 mL) , ethanol (5 mL) and 2N aqueous sodium hydroxide solution (4 mL) was stirred at room temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (100 mL) and IN hydrochloric acid (50 mL) . The organic layer was dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The obtained solid was washed with ethyl acetate to give the title compound (278 mg, yield 98%) as a white solid, melting point 121-123°C.
Example 329 N- {2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3-thiazol-
2-yl] -lH-indol-7-yl}-N-methyl-l, 3-thiazole-2-sulfonamide
Figure imgf000455_0001
Ethyl (2- {7- [methyl (1, 3-thiazol-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (200 mg) was dissolved in a mixed solvent of tetrahydrofuran (5 mL) and methanol (5 ml), and the mixture was cooled to 0°C. Lithium borohydride (20 mg) was added, and the mixture was stirred at' room temperature for 2 hr. The reaction mixture was diluted with ethyl acetate (100 mL) and IN hydrochloric acid (50 mL) . The organic layer was dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The obtained residue was purified by silica gel column chromatography (ethyl acetate) to give the title compound (25 mg, yield 14%) as a pale-yellow solid. MS: 423 (MH+) .
Example 330 2- (2-{7- [methyl (1, 3-thiazol-2-ylsulfonyl) amino] - lH-indol-2-yl } -4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000455_0002
A mixture of (2-{7- [methyl (1, 3-thiazol-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetic acid (250 mg) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (114 mg) , N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (144 mg) and N, N- dimethylformamide (10 mL) was stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate (100 mL) and water (100 mL) , and the organic layer was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained solid was washed with ethyl acetate to give the title compound (166 mg, yield 67%) as a white solid, melting point 216-218°C.
Example 331 N-methyl-N-{2- [5- (morpholinomethyl) -4, 5-dihydro-
1, 3-thiazol-2-yl] -lH-indol-7-yl}pyridine-2-sulfonamide
Figure imgf000456_0001
.
In the same manner as in Example 201, the title compound (63 mg, yield 47%) was obtained as a colorless amorphous solid from N- [2- (benzylthio) -3-morpholinopropyl] -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxamide (165 mg) . MS:472(MH+).
Example 332 ethyl (2-{ 7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate
Figure imgf000456_0002
In the same manner as in Example 283, the title compound (670 mg, yield 42%) was obtained as a pale-yellow amorphous solid from 7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carbothioamide (1190 mg) and ethyl but-2-ynoate
(0.922 mL). MS:459(MH+).
Example 333 (2-{7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000457_0001
To a solution of ethyl (2-{7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetate (470 mg) in tetrahydrofuran (6 itiL) and methanol (6 mL) was added a solution of potassium hydroxide (85% purity,
170 mg) in water (2.5 mL) , and the mixture was stirred at 0°C for 1 hr, and then at room temperature for 3 hr. The reaction mixture was diluted with ethyl acetate, and neutralized with IM hydrochloric acid. The ethyl acetate layer was washed with saturated brine, dried (MgSCu) / and concentrated. The residue was recrystallized from a mixed solvent of ethyl acetate- hexane to give the title compound (400 mg, yield 91%) as white crystals. MS:431(MH+). melting point 231-233°C. Example 334 2- (2-{ 7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000457_0002
To a mixture of (2-{7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}—4, 5-dihydro-l, 3-thiazol-5- yl) acetic acid (200 mg) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (92 mg) and N,N-dimethylformamide (10 mL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (120 mg) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 4 days. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was crystallized from ethyl acetate-hexane to give the title compound (166 rag, yield: 83%) as pale-yellow prism crystals. MS: 430(MH+) . melting point 206-2070C.
Example 335 (2-{7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000458_0001
(2-{7- [Methyl (pyridin-2-ylsulfonyl) amino] -IH-indol-2- yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (180 mg) was dissolved in ethanol-acetic acid (1000:1, volume ratio, 360 TdL) . This solution was subjected to HPLC using CHIRALCEL OJ ' (50mmIDχ500mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with ethanol-acetic acid (1000:1, volume ratio) as a mobile phase at 30°C at flow rate of 40 nxL/min. A fraction with the retention time of 39.9 min was separated, and concentrated. The obtained solid was dissolved in ethyl acetate, the insoluble substance was removed by filtration, and the filtrate was concentrated to give the title compound (64.2 mg) as a colorless solid. MS:431(MH+). Example 336 (2- {7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000458_0002
(2- {7- [Methyl (pyridin-2-ylsulfonyl) amino] -lH-indol-2- yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (180 mg) was dissolved in ethanol-acetic acid (1000:1, volume ratio, 360 ml,) . This solution was subjected to HPLC using CHIRALCEL OJ (50mmIDx500mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with ethanol-acetic acid (1000:1, volume ratio) as a mobile phase at 30°C at flow rate of 40 itiL/rαin. A fraction with the retention time of 53.1 min was separated, and concentrated. The obtained solid was dissolved in ethyl acetate, the insoluble substance was removed by filtration, and the filtrate was concentrated to give the title compound (71.8 mg) as a white solid. MS:431 (MH+).
Example 337 2- (2-{7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000459_0001
To a mixture of 2-{7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2~yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetic acid (64 mg) obtained in Example 335, IH-I, 2,3- benzotriazol-1-ol-ammonia complex (35 mg) and N, N- dimethylformamide (3 mL) was added N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (45 mg) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 18 hours. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was crystallized from ethyl acetate-hexane to give the title compound (54 mg, yield: 85%) as pale-yellow prism crystals. MS: 430 (MH+). melting point 149-150°C. Example 338 2- (2-{7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000459_0002
To a mixture of 2- {7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetic acid (72 mg) obtained in Example 336, IH-I, 2,3- benzotriazol-1-ol-ammonia complex (40 mg) and N, N- dimethylformamide (3 mL) was added N- [3-
(dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (50 mg) under ice-cooling, and the mixture was stirred from under ice-cooling to room temperature for 18 hours. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was crystallized from ethyl acetate-hexane to give the title compound (57 mg, yield: 79%) as pale-yellow prism crystals. MS: 430 (MH+). melting point 148-149°C.
Example 339 N-{2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl]-lH-indol-7-yl}-N-methylpyridine-2-sulfonamide
Figure imgf000460_0001
In the same manner as in Example 285, the title compound (141 mg, yield 78%) was obtained as a colorless amorphous solid from ethyl (2-{7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl)acetate (200 mg) . MS:417 (MH+) .
Example 340 N-methyl-N-{2- [5- (morpholinomethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] -lH-indol-7-yl}furan-2-sulfonamide
Figure imgf000460_0002
In the same manner as in Example 201, the title compound (200 mg, yield 29%) was obtained as white crystals from N- [2- (benzylthio) -3-morpholinopropyl] -7- [ (2- furylsulfonyl) (methyl) amino] -lH-indoϊe-2-carboxamide (840 mg) . MS: 461 (MH+) . Example 341 ethyl (2-{ 7- [ (2-furylsulfonyl) (methyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate
Figure imgf000461_0001
In the same manner as in Example 283, the title compound (605 mg, yield 35%) was obtained as a pale-yellow amorphous solid from 7- [ (2-furylsulfonyl) (methyl) amino] -IH- indole-2-carbothioamide (1280 mg) and ethyl but-2-ynoate (1.025 mL). MS: 448 (MH+).
Example 342 (2- { 7- [ (2-furylsulfonyl) (methyl) amino] -IH-indol-2- yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000461_0002
In the same manner as in Example 284, the title compound (250 mg, yield 67%) was obtained as white crystals from ethyl (2- {7- [ (2-furylsulfonyl) (methyl) amino] -lH-indol-2- yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (400 mg) . MS:420(MH+) Example 343 2- (2- {7- [ (2-furylsulfonyl) (methyl) amino] -IH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000461_0003
In the same manner as in Example 287, the title compound (120 mg, yield 60%) was obtained as white crystals from (2-{7-[ (2-furylsulfonyl) (methyl) amino] -lH-indol-2-yl }- 4, 5-dihydro-l,.3-thiazol-5-yl) acetic acid (150 mg) . MS:419(MH+) Example 344 N- {2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl] -lH-indol-7-yl}-N-methylfuran-2-sulfonamide
Figure imgf000462_0001
In the same manner as in Example 285, the title compound (150 mg, yield 83%) was obtained as white crystals from ethyl (2- {7- [ (2-furylsulfonyl) (methyl) amino] -IH-indol-2- yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (200 mg) . MS:406(MH+) Example 345 N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000462_0002
In the same manner as in Example 201, the title compound (330 mg, yield 41%) was obtained as white crystals from N- [2- (benzylthio) -3-morpholinopropyl] -7- [ (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (1000 mg) .
MS: 463 (MH+).
Example 346 N- (difluoromethyl) -N-{2- [5- (morpholinomethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000462_0003
To a solution of N- {2- [5- (morpholinomethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide (200 iαg) in N,N-dimethylformamide (3 mL) were added potassium carbonate (90.0 iαg) and difluoroiodomethane (77.0 mg) , and the mixture was stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography to give the title compound (60 mg, yield 27%) as white crystals from a fraction eluted with ethyl acetate-hexane (1:1, volume ratio). MS:513(MH+). melting point 185-1860C.
Example 347 N- (difluoromethyl) -N- {2- [5- (morpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene-2- sulfonamide
Figure imgf000463_0001
(N- (Difluoromethyl) -N- {2- [5—(morpholinomethyl) -4,5- dihydro-l,3-thiazol-2-yl]-LH-indol-7-yl}thiophene-2- sulfonamide (93 mg) obtained in Example 346 was dissolved in hexane-ethanol (700:300, volume ratio, 190 mL) . This solution was subjected to HPLC using CHIRALCEL OD (50mmIDχ500mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with hexane-ethanol (700:300, volume ratio) as a mobile phase at 30°C at flow rate of 60 mL/min. A fraction with the retention time of 18.2 min was separated, and concentrated. The obtained solid was dissolved in ethyl acetate, the insoluble substance was removed by filtration, and the filtrate was concentrated to give the title compound (43.0 mg) as a colorless solid. MS: 513 (MH+).
Example 348 N- (difluoromethyl) -N- {2- [5- (morpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene-2- sulfonamide
Figure imgf000464_0001
(N- (Difluoromethyl) -N- {2- [5- (morpholinomethyl) -4,5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene-2- sulfonamide (93 mg) obtained in Example 346 was dissolved in hexane-ethanol (700:300, volume ratio, 190 mL) . This solution was subjected to HPLC using CHIRALCEL OD (50mmIDχ500mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with hexane-ethanol (700:300, volume ratio) as a mobile phase at 30°C at flow rate of 60 mL/min. A fraction with the retention time of 26.2 min was separated, and concentrated.
The obtained solid was dissolved in ethyl acetate, the insoluble substance was removed by filtration, and the filtrate was concentrated to give the title compound (45.0 mg) as a colorless solid. MS: 513 (MH+). Example 349 N- (2, 2-difluoroethyl) -N- {2- [5- (morpholinomethyl) -
4,5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene-2- sulfonamide
Figure imgf000464_0002
In the same manner as in Example 346, the title compound (80.0 mg, yield 35%) was obtained as white crystals from N-{2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] - lH-indol-7-yl}thiophene-2-sulfonaruide (200 mg) and 1,1- difluoro-2-iodoethane (91.0 mg). MS:527 (MH+).
Example 350 N- (2-fluoroethyl) -N- {2- [5- (morpholinomethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000465_0001
In the same manner as in Example 346, the title compound (200 mg, yield 91%) was obtained as white crystals from N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl]- lH~indol-7-yl}thiophene-2-sulfonamide (200 mg) and l-fluoro-2- iodoethane (90.0 mg). MS:509(MH+).
Example 351 N- (cyanomethyl) -N- {2- [5- (morpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene-2- sulfonamide
Figure imgf000465_0002
In Nthe same manner as in Example 346, the title compound (85.0 mg, yield 26%) was obtained as white crystals from N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] lH-indol-7-yl}thiophene-2-sulfonamide (300 mg) and iodoacetonitrile (120 mg) . MS:502 (MH+).
Example 352 N-ethyl-N- {2- [5- (morpholinomethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene-2-sulfonamide
Figure imgf000465_0003
In the same manner as in Example 346, the title compound (63.4 rag, yield 60%) was obtained as white crystals from N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] - lH-indol-7-yl} thiophene-2-sulfonamide (100 mg) and iodoethane (34.0 mg) . MS: 491 (MH+) . Example 353 N- { 2- [ 5- (morpholinomethyl) -4 , 5-dihydro-l , 3- thiazol-2-yl] -lH-indol-7-yl} -N- (2-thienylsulfonyl) glycine ethyl ester
Figure imgf000466_0001
In the same manner as in Example 346, the title compound (400 mg, yield 67%) was obtained as white crystals from N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] - lH-indol-7-yl} thiophene-2-sulfonamide (500 mg) and ethyl iodoacetate (255 mg) . MS:549(MH+). Example 354 N- (2-hydroxyethyl) -N- {2- [5- (morpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000466_0002
To a solution of N- {2- [5- (morpholinomethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}-N-(2- thienylsulfonyl) glycine ethyl ester (100 mg) in tetrahydrofuran (10 mL) and methanol (2 mL) was added lithium borohydride (18.0 mg) , and the mixture was stirred at room temperature for 4 hr. IM Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was recrystallized from a mixed solvent of ethyl acetate-hexane to give the title compound (70 mg, yield 76%) as white crystals. MS: 507 (MH+) .
Example 355 N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}-N- (2-thienylsulfonyl) glycine
Figure imgf000467_0001
To a solution of N- {2- [5- (morpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-ylJ-N- (2- thienylsulfonyl) glycine ethyl ester (120 mg) in tetrahydrofuran (3 mL) and methanol (3 itiL) was added, under ice-cooling, a solution prepared by dissolving potassium hydroxide (purity 85%, 30 mg) in water (1 mL) , and the mixture was stirred for 30 min, and then at room temperature for 1 hr. IM Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was recrystallized from a mixed solvent of ethyl acetate-hexane to give the title compound (106 mg, yield 93%) as white crystals. MS:521(MH+).
Example 356 N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}-N- (2-thienylsulfonyl) glycinamide
Figure imgf000467_0002
To a solution of N- {2- [5- (morpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}-N- (2- thienylsulfonyl) glycine (60 mg) in N,N-dimethylformamide (5 mL) were added IH-1, 2, 3-benzotriazol-l-ol-ammonia complex (30 mg) and N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (35 mg) under ice-cooling, and the mixture was stirred overnight at room temperature. Saturated aqueous sodium hydrogencarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, dried (MgSO4) , and concentrated. The residue was recrystallized from a mixed solvent of ethyl acetate-hexane to give the title compound (43 mg, yield 71%) as white crystals. MS:520(MH+). Example 357 N- (2-hydroxy-2-methylpropyl) -N- {2- [5-
(morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7- yl } thiophene-2-sulfonamide
Figure imgf000468_0001
To a solution of N- {2- [5- (morpholinomethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}-N-(2- thienylsulfonyl) glycine ethyl ester (110 mg) in tetrahydrofuran (5 mL) was added methylmagnesium bromide (1.0M tetrahydrofuran solution, ImL) , and the mixture was stirred overnight at 50°C. IM Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4), and concentrated. The residue was purified by preparative HPLC to give the title compound (30 mg, yield 28%) as white crystals. MS: 535 (MH+).
Example 358 2- (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) ethyl methanesulfonate and N- {2- [5- (2-chloroethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -IH- indol-7-yl }-N-methylthiophene-2-sulfonamide
Figure imgf000468_0002
To a solution of N- { 2- [5- ( 2-hydroxyethyl ) -4 , 5-dihydro- 1 , 3-thiazol-2-yl] -lH-indol-7-yl } -N-methyl thiophene-2- sulfonamide (200 mg) and triethylamine (70 μL) in tetrahydrofuran (5 inL) was added methanesulfonyl chloride (60 mg) at room temperature, and the mixture was stirred for 3 hr.
Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCU) , and concentrated.
The obtained residue was' subjected to silica gel column chromatography to give 2- (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indo'l-2-yl}-4, 5-dihydro-l, 3-thiazol-
5-yl) ethyl methanesulfonate (126 mg, yield 54%, MS:500(MH+)) and N-{2-[5- (2-chloroethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -IH- indol-7-yl}-N-methylthiophene-2-sulfonamide (16 mg, yield 8%,
MS : 440 (MH+) ), as a white amorphous solid from a fraction eluted with ethyl acetate, respectively .
Example 359 2- (2-{7- [ (difluoromethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl }-4, 5-dihydro-l, 3-thiazol-
5-yl) acetamide
Figure imgf000469_0001
In the same manner as in Example 346, the title compound (50 mg, yield 22%) was obtained as a colorless solid from 2- (2-{7-[ (2-thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol-5-yl) acetamide (200 mg) and difluoroiodomethane (102 mg) . MS: 471 (MH+) .
Example 360 ethyl (2- { 7- [ (difluoromethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetate
Figure imgf000470_0001
In the same manner as in Example 346, the 'title compound (150 mg, yield 27%) was obtained as a colorless amorphous solid from ethyl (2-{7- [ (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4,5-dihydro-l,3-thiazol-5-yl) acetate (500 mg) and difluoroiodomethane (238 mg) . MS: 500 (MH+). Example 361 N- (difluoromethyl) -N- {2- [5- (2-hydroxyethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000470_0002
In the same manner as in Example 285, the title compound (120 mg, yield 88%) was obtained as a colorless solid from ethyl (2-{7- [ (difluoromethyl) (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4,5-dihydro-l,3-thiazol-5-yl) acetate (150 mg) . MS: 458 (MH+) .
Example 362 ethyl (2-{7- [ (2-fluoroethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl }-4, 5-dihydro-l, 3-thiazol-
5-yl) acetate
Figure imgf000470_0003
In the same manner as in Example 346, the title compound (400 mg, yield 61%) was obtained as a colorless amorphous solid from ethyl (2-{7- [ (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4,5-dihydro-l,3-thiazol-5-yl) acetate (600 mg) and l-fluoro-2-iodoethane (280 mg) . MS: 496 (MH+). Example 363 N- (2-fluoroethyl) -N-{2- [5- (2-hydroxyethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000471_0001
In the same manner as in Example 285, the title compound (90 mg, yield 66%) was obtained as a colorless solid from ethyl (2-{7- [ (2-fluoroethyl) (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (150 mg) . MS: 454 (MH+) .
Example 364 (2-{7- [ (2-fluoroethyl) (2-thienylsulfonyl) amino] - lH-indol-2-yl } -4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000471_0002
In the same manner as in Example 284, the title compound (140 mg, yield 98%) was obtained as a colorless solid from ethyl (2- { 7- [ (2-fluoroethyl) (2-thienylsulfonyl) amino] -IH- indol-2-yl }-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (150 mg) . MS: 468 (MH+).
Example 365 2- (2- { 7- [ (2-fluoroethyl) (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetamide -
Figure imgf000472_0001
In the same manner as in Example 287, the title compound (100 mg, yield 72%) was obtained as a colorless solid from (2-{7-[ (2-fluoroethyl) (2-thienylsulfonyl) amino] -IH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (140 mg) . MS: 467 (MH+) .
Example 366 ethyl (2- { 7- [ethyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate
Figure imgf000472_0002
In the same manner as in Example 346, the title compound (300 mg, yield 69%) was obtained as a colorless amorphous solid from ethyl (2- {7- [ (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (410 mg) and iodoethane (75 μL) . MS: 478 (MH+). Example 367 N-ethyl-N- {2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000472_0003
In the same manner as in Example 285, the title compound (70 mg, yield 77%) was obtained as a colorless amorphous solid from ethyl (2-{7- [ethyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4/ 5-dihydro-l, 3-thiazol- 5-yl)acetate (100 mg) . MS:436(MH+).
Example 368 (2- {7- [ethyl (2-thienylsulfonyl) amino] -lH-indol-2- yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000473_0001
In the same manner as in Example 284, the title compound (140 mg, yield 89%) was obtained as a colorless solid from ethyl (2- {7- [ethyl (2-thienylsulfonyl) amino] -IH-indol-2- yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (167 mg) . MS:450(MH+) Example 369 2- (2-{7- [ethyl (2-thienylsulfonyl) amino] -IH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000473_0002
In the same manner as in Example 287, the title compound (70 mg, yield 58%) was obtained as a colorless solid from (2- {7- [ethyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5- dihydro-l,3-thiazol-5-yl) acetic acid (120 mg) . MS:449(MH+). Example 370 ethyl (2- {7- [ (cyanomethyl) (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetate
Figure imgf000474_0001
In the same manner as in Example 346, the title compound (400 mg, yield 62%) was obtained as a colorless solid from ethyl (2-{7- [ (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetate (600 mg) and iodoacetonitrile (245 mg) . MS: 489 (MH+).
Example 371 ethyl (2-{ 7- [ (pyridin-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate
Figure imgf000474_0002
In the same manner as in Example 283, the title compound (920 mg, yield 21%) was obtained as a pale-yellow amorphous solid from 7- [ (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carbothioamide (3200 mg) and ethyl but-2-ynoate (2.6 inL) . MS: 445 (MH+) . Example 372 (2-{7- [ (pyridin-2-ylsulfonyl) amino] -lH-indol-2- yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000474_0003
In the same manner as in Example 284, the title compound (650 mg, yield 76%) was obtained as a white solid from ethyl (2-{7- [ (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetate (920 mg) . MS:417 (MH+). Example 373 2- (2-{7- [ (pyridin-2-γlsulfonyl) amino] -lH-indol-2- yl}-4, 5-dihydro-l,3-thiazol-5-yl) acetamide
Figure imgf000475_0001
In the same manner as in Example 287, the title compound (310 mg, yield 50%) was obtained as a white solid from (2-{7-[ (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl}-4, 5- dihydro-l,3-thiazol-5-yl) acetic acid (620 mg) . MS:416(MH+). Example 374 2- (2-{7- [ (2-fluoroethyl) (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetamide
Figure imgf000475_0002
In the same manner as in Example 346, the title compound (100 mg, yield 90%) was obtained as a white solid from 2-(2-{7-[ (pyridin-2-ylsulfonyl) amino] -IH-indol-2-yl} -4, 5- dihydro-1, 3-thiazol-5-yl) acetamide (100 mg) and l-fluoro-2- iodoethane (55 mg) . MS: 462 (MH+) .
Example 375 ethyl { [2- (2-{7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) ethyl] thio}acetate
Figure imgf000475_0003
To a solution of N-{2- [5- (2-chloroethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-methylthiophene-2- sulfonamide (100 mg) in N,N-dimethylformamide (3 iriL) were added potassium carbonate (65 mg) and ethyl mercaptoacetate
(50 μL) , and the mixture was stirred overnight at 50°C. Potassium carbonate (20 mg) was added to the reaction mixture, and the mixture was stirred at 50°C for 3 hr, and cooled to room temperature. The reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried (MgSO4), and concentrated. The residue was subjected to silica gel column chromatography to give the . title compound (60 mg, yield 50%) as a colorless amorphous solid from a fraction eluted with ethyl acetate-hexane (1:1, volume ratio). MS:524 (MH+). Example 376 { [2- (2-{7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4,5-dihydro-l,3-thiazol-5-yl) ethyl] thio}acetic acid
Figure imgf000476_0001
To a solution of ethyl { [2- (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl }-4, 5-dihydro-l, 3-thiazol- 5-yl) ethyl] thio}acetate (60 mg) in tetrahydrofuran (2 itiL) and methanol (2 mL) was added, under ice-cooling, a solution prepared by dissolving potassium hydroxide (purity 85%, 20 mg) in water (0.5 mL) . The reaction mixture was allowed to warm to room temperature, and stirred for 1 hr. IM Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, dried (MgSO4) , and concentrated. The residue was recrystallized from a mixed solvent of ethyl acetate-hexane to give the title compound (35 mg, yield 61%) as white crystals. MS: 496 (MH+). Example 377 N- [2- (5- {2- [ (2-hydroxyethyl) amino] ethyl} -4, 5- dihydro-1, 3-thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2- sulfonamide
Figure imgf000477_0001
To a solution of N-methyl-N-{2- [5- (2-oxoethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide (300 mg) in methanol (5 inL) was added 2- aminoethanol (70 μL) , and the mixture was stirred with heating under reflux for 4 hr. The reaction mixture was allowed to cool to room temperature, sodium borohydride (55 mg) was added, and the mixture was stirred for 30 min. The reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (220 mg, yield 67%) as a colorless amorphous solid from a fraction eluted with ethyl acetate-methanol (10:1, volume ratio) . MS: 465 (MH+). Example 378 N-methyl-N- (2-{ 5- [2- (3-oxomorpholino) ethyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) thiophene-2- sulfonamide
Figure imgf000477_0002
To a solution of N- [2- (5-{2- [ (2- hydroxyethyl) amino] ethyl} -4, 5-dihydro-l, 3-thiazol-2-yl) -IH- indol-7-yl]-N-methylthiophene-2-sulfonamide (220 mg) in ethanol (2 mL) and water (1 inL) were added chloroacetyl chloride (95 μL) and 8M aqueous sodium hydroxide solution (310 μL) , and the mixture was stirred at the inside temperature of 20°C or less for 3 hr. IM Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography to give the title compound (100 mg, yield 41%) as a colorless amorphous solid from a fraction eluted with ethyl acetate-methanol (10:1, volume ratio). MS: 505 (MH+) . Example 379 N- {5- (2-methoxyethoxy) -2- [ (4R) -4-
(morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7- yl } -N-methylpyridine-2-sulfonamide
Figure imgf000478_0001
A solution of ( (4R) -2- {5- (2-methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol-4-yl) methyl methanesulfonate (0.1 g) , morpholine (0.032 mL) and potassium carbonate (0.050 g) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 18 hr, and the mixture was stirred at 50°C for 6 hr. The same amount of morpholine (0.032 mL) and potassium carbonate
(0.050 g) were added, and the mixture was stirred at 80°C for 18 hr. The reaction mixture was concentrated, and the residue was extracted with ethyl ' acetate. The ethyl acetate layer was washed with IN hydrochloric acid, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried (MgSU4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate-methanol (4:1:0-0:10:1, volume ratio) to give the title compound (0.002 g, yield 2%) as a colorless amorphous solid.
1H-NMR (CDCl3) 6:2.53-2.69 (4H, m) , 2.75-2.89 (IH, m) , 3.08-3.68 (4H, m) , 3.27-3.37 (3H, m) , 3.42-3.52 (3H, m) , 3.72-3.84 (4H, iα), 3.96-4.09 (IH, m) , 4.06-4.21 (2H, m) , 4.75-4.99 (IH, m) , 6.84 (IH, d, J=2.1 Hz), 6.87 (IH, d, J=2.1 Hz), 7.06 (IH, d, J=2.3 Hz), 7.55-7.66 (IH, m) , 7.95 (IH, td, J=7.6, 1.7 Hz), 7.98-8.06 (IH, m) , 9.02-9.16 (IH, m) , 11.57 (IH, brs)
Example 380 N-methyl-N- [2- [5- (morpholinomethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] -5- (trifluoromethoxy) -lH-indol-7- yl] thiophene-2-sulfonamide
Figure imgf000479_0001
To a solution of triphenylphosphine oxide (670 mg) in dichloromethane (15 mL) was added trifluoromethanesulfonic anhydride (340 mg) under ice-cooling, and the mixture was stirred for 10 min. A solution of N- [2- (benzylthio) -3- morpholinopropyl] -7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indole-2-carboxamide (400 mg) and dimethylsulfide (40 mg) in dichloromethane (15 mL) was added dropwise to the reaction mixture under ice-cooling, and the mixture was stirred for 2 hr under ice-cooling. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed with saturated brine, dried (MgSθ4) , and concentrated. The obtained residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-2:1, volume ratio) . The obtained compound was further purified by preparative HPLC to give the title compound (150 mg, yield
44%) as white crystals. The crystals were recrystallized from ethyl acetate-hexane to give colorless prism crystals, melting point 165-166°C.
Example 381 ethyl {2- [7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yl} acetate
Figure imgf000480_0001
A mixture of 7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-iridole-2-carboxamide (1.15 g) , Lawesson's reagent (1.09 g) and tetrahydrofuran (20 mL) was stirred at 50°C for 30 min. The reaction mixture was concentrated, and the residue was washed with diisopropyl ether to give pale-yellow crystals. A mixture of the obtained crystals, ethyl but-2-ynoate (710 mg) , tributylphosphine (510 mg) , toluene (30 mL) and tetrahydrofuran (15 mL) was stirred at 50°C for 2 hr. ethyl but-2-ynoate (710 mg) and tributylphosphine (510 mg) were added to the mixture, and the' mixture was further stirred at room temperature for 2.5 days . The reaction mixture was concentrated, and the residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-3:1, volume ratio) . The obtained crystals were washed with hexane to give the title compound (600 mg, yield 41%) as pale-yellow crystals, melting point 93-
94°C.
Example 382 {2- [7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yl} acetic acid
Figure imgf000480_0002
A mixture of ethyl {2- [7- [methyl (2- thienylsulfonyl) amino] -5- (trifluoro.methoxy) -lH-indol-2-yl] - 4, 5-dihydro-l, 3-thiazol-5-yl} acetate (300 mg) , IN aqueous sodium hydroxide solution (5 mL) , tetrahydrofuran (5 mL) and ethanol (5 mL) was stirred at room temperature for 15 hr. The reaction mixture was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was crystallized from ethyl acetate- hexane to give the title compound (270 mg, yield 93%) as pale- yellow crystals. The crystals were purified by preparative HPLC, and recrystallized from ethyl acetate-hexane to give pale-yellow prism crystals, melting point 225-227°C. Example 383 N- [2- [5- (2-hydroxyethyl) -4, 5-dihydrό-l, 3-thiazol- 2-yl] -5- (trifluoromethoxy) -lH-indol-7-yl] -N-methylthiophene-2- sulfonamide
Figure imgf000481_0001
To a mixture of ethyl {2- [7- [methyl (2- thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] - 4, 5-dihydro-l, 3-thiazol-5-yl}acetate (350 mg) , tetrahydrofuran (15 mL) and methanol (3 itiL) was added lithium borohydride (30 mg) , and the mixture was stirred at room temperature for 2 hr. Lithium borohydride (15 mg) was added to the mixture, and the mixture was further stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (2:1-1:4, volume ratio) to give the title compound (110 mg, yield 34%) as colorless crystals. The crystals were recrystallized from ethyl acetate- hexane to give colorless prism crystals, melting point 152-
153°C.
Example 384 2- {2- [7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yl } acetamide
Figure imgf000482_0001
A mixture of {2- [7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yl}acetic acid (210 mg) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (90 mg) , N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (120 mg) and N,N- dimethylformamide (10 inL) was stirred at room temperature for 15 hr. 1H~1,2, 3-Benzotriazol-l-ol-ammonia complex (150 mg) and N- [3- (dimethylamino) propyl] -W -ethylcarbodiimide hydrochloride (190 mg) were added to the reaction mixture, and the mixture was further stirred at room temperature for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with aqueous citric acid solution, saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated. The residue was purified by preparative HPLC to give the title compound (90 mg, yield 43%) as pale-yellow crystals. The crystals were recrystallized from ethyl acetate-hexane to give pale-yellow prism crystals. melting point 186-187°C. MS: 519 (MH+).
Example 385 ethyl (2- {7- [methyl (pyridin-3-ylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate
Figure imgf000482_0002
A mixture of 7- [methyl (pyridin-3-ylsulfonyl) amino] -IH- • indole-2-carbothioamide (150 mg) , ethyl but-2-ynoate (120 mg) , tributylphosphine (90 mg) , dichloromethane (20 mL) and tetrahydrofuran (40 mL) was stirred at room temperature for 15 hr, and the mixture was stirred at 5O0C for 3 hr. The reaction mixture was concentrated, and the residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-1:4, volume ratio). The obtained crystals were further subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-1:4, volume ratio) to give pale-yellow crystals. The crystals were s recrystallized from ethyl acetate-hexane to give the title compound (60 mg, yield 30%) as pale-yellow prism crystals. melting point 146-147°C.
Example 386 2- (2-{7- [methyl (pyridin-3-ylsulfonyl) amino] -IH- indol-2-yl } -4 , 5-dihydro-l , 3-thiazol-5-yl ) acetamide
Figure imgf000483_0001
thyl (2-{7- [methyl (pyridin-3- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetate (330 mg) , IN aqueous sodium hydroxide solution (5 mL) , tetrahydrofuran (5 mL) and ethanol (5 mL) was stirred at5 50°C for 30 min. The reaction mixture was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSθ4), and concentrated to give pale-yellow crystals. A mixture of the obtained crystals, IH-I, 2, 3-benzotriazol-l-ol-0 ammonia complex (1.10 g) , N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (1.38 g) and N, N- dimethylformamide (10 mL) was stirred at room temperature for 2.5 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate5 layer was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSθ4) , and concentrated. The residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-methanol (100:0- 85:15, volume ratio) to give the title compound (130 mg, yield0 42%) as colorless crystals. The crystals were recrystallized from- ethyl acetate-hexane to give colorless prism crystals. melting point 185-186°C.
Example 387 2-{2- [7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yl }acetamide
2- {2- [7- [Methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4,'5-dihydro-l, 3-thiazol-5- yl}acetamide (140 mg) was dissolved in hexane-ethanol (850:150, volume ratio, 700 itiL) . This solution was subjected to HPLC using CHIRALPAK AD (50mmIDχ500mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with hexane-ethanol (850:150, volume ratio) as a mobile phase at 350C at flow rate of 75 mL/min. A fraction with the retention time of 1 hr and' 13 min was separated, and concentrated. The obtained solid was crystallized from ethyl acetate-hexane to give the title compound (62 mg) as colorless prism crystals, melting point 205-206°C.
Example 388 {2- [7- [ (2-thienylsulfonyl) amino] -5-
(trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yl} acetic acid
Figure imgf000484_0002
A mixture of ethyl {2- [7- [ (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yl}acetate (780 mg) , IN aqueous sodium hydroxide solution (5 inL) , tetrahydrofuran (5 mL) and ethanol (5 mL) was stirred at
50°C for 30 min. The reaction mixtμre was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCM) i and concentrated. The residue was crystallized from ethyl acetate-diisopropyl ether to give the title compound (490 mg, yield 64%) as brown crystals. The crystals were recrystallized from ethyl acetate-hexane to give brown prism crystals, melting point 247-248°C (decomposition) . Example 389 2- {2- [7- [ (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol~5- yl }acetamide
Figure imgf000485_0001
A mixture of {2- [7- [ (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yl}acetic acid (410 mg) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (240 mg) , N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (310 mg) and N, N- dimethylformamide (5 mL) was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed successively with IN hydrochloric acid, saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO,}) , and concentrated. The residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-methanol (100:0-90:10, volume ratio), and the obtained solid was washed with hexane to give the title compound (260 mg, yield 63%) as brown crystals. The crystals were recrystallized from acetone-hexane to give pale-yellow prism • crystals, melting point 239-2400C. Example 390 (2-{5- (2-methoxyethoxy) -7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4/ 5-dihydro-l, 3-thiazol- 5-yl) acetic acid
Figure imgf000485_0002
A mixture of ethyl (2- {5- (2-methoxyethoxy) -7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetate (300 mg) , IN aqueous sodium hydroxide solution (2 it\L) , tetrahydrofuran (2 mL) and ethanol (2 mL) was stirred at room temperature for 15 hr. The reaction mixture was acidified with aqueous citric acid solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSθ4) , and concentrated to give the title compound (280 mg, yield 97%) as yellow crystals." The crystals were recrystallized from ethyl acetate-hexane to give yellow prism crystals, melting point 113-114°C. Example 391 N- [2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl] -5- (2-methoxyethoxy) -lH-indol-7-yl] -N-methylthiophene-2- sulfonamide
Figure imgf000486_0001
To a mixture of ethyl (2- {5- (2-methoxyethoxy) -7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro- 1, 3-thiazol-5-yl) acetate (200 mg) , tetrahydrofuran (5 mL) and methanol (1 mL) was added lithium borohydride (16 mg) , and the mixture was stirred at room temperature for 1 hr. Lithium borohydride (16 mg) was added to the mixture, and the mixture was further stirred at room temperature for 1 hr. Lithium borohydride (16 mg) was added to the mixture, and the mixture was further stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (1:1-1:9, volume ratio) to give yellow crystals. The crystals were recrystallized from ethyl acetate-hexane to give the title compound (100 mg, yield 56%) as a pale-yellow powder, melting point 122-123°C. Example 392 2- (2-{5- (2-methoxyethoxy) -7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000487_0001
A mixture of (2-{5- (2-methoxyethoxγ) -7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetic acid (220 mg) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (100 mg) , N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (120 mg) and N,N- dimethylformamide (3 mL) was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with aqueous citric acid solution, saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-methanol (97:3-90:10, volume ratio) to give pale-yellow crystals. The crystals were recrystallized from acetone-hexane to give the title compound (110 mg, yield 50%) as pale-yellow prism crystals, melting point 189-190°C. Example 393 N- (5- (2-methoxyethoxy) -2- {5- [ (1- oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl }-lH- indol-7-yl) -N-methylpyridine-2-sulfonamide
Figure imgf000487_0002
A mixture of trifluoromethanesulfonic anhydride (1.44 g) , triphenylphosphine oxide (1.42 g) and dichloromethane (100 mL) was stirred at 0°C for 10 min. .A solution of N- [2- (benzylthio) -3, 3-dimethoxypropyl] -5- (2-methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indole-2-carboxamide (2.92 g) and thioanisole (1.14 g) in dichloromethane (50 mL) was added dropwise to the reaction mixture under ice-cooling, and the mixture was stirred for 10 min under ice-cooling. Water was added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined, washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate (2:1-1:4, volume ratio) to give a yellow oil. The obtained oil was crystallized from ethyl acetate-diisopropyl ether, and recrystallized from ethyl acetate-diisopropyl ether to give colorless crystals (1.03 g) . To a mixture of the obtained crystals (400 mg) , trifluoroacetic acid (5 mL) and water (15 itiL) was added concentrated sulfuric acid (5 mL) at room temperature, and the mixture was stirred at 60°C for 4 hr. Water was added to the reaction mixture, and trifluoroacetic acid was evaporated under reduced pressure. The residue was ice-cooled, and 8N aqueous sodium hydroxide solution (20 mL) was added. The mixture was basified with saturated aqueous sodium hydrogencarbonate, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The residue was dissolved in tetrahydrofuran (10 mL) , and triethylamine (120 mg) and thiomorpholine 1-oxide hydrochloride (150 mg) were added to the obtained solution, and the mixture was stirred at room temperature for 15 min. Sodium triacetoxyborohydride (320 mg) was added to the reaction mixture at room temperature, and the mixture was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-methanol (100:0-70:30, volume ratio), and the obtained compound was further purified by preparative HPLC to give colorless crystals. The crystals were recrystallized from acetone-hexane to give the title compound (110 mg, yield 11%) as colorless prism crystals, melting point 182-183°C . MS : 578 (MH+) .
Example 394 (2- { 5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl }-4, 5-dihydro-l, 3-thiazol-5- yl ) acetic acid
Figure imgf000489_0001
A mixture of ethyl (2- {5- (2-methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol~5-yl) acetate (960 mg) , IN aqueous sodium hydroxide solution (5 mL) , tetrahydrofuran (5 mL) and ethanol (5 mL) was stirred for 500C for 1 hr. IN Hydrochloric acid (5 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCu) , and concentrated to give the title compound (800 mg, yield 88%) as a yellow amorphous solid. The solid was crystallized from ethyl acetate-hexane, and recrystallized from ethyl acetate-hexane to give pale-yellow powder, melting point 107-109°C. Example 395 2- (2- {5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl)acetamide
Figure imgf000489_0002
A mixture of (2- {5- (2-methoxyethoxy) -7- [methyl (pyridin- 2-ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetic acid (200 mg) , IH-I, 2, 3-benzotriazol-l-ol-ammonia complex (90 mg) , N- [3- (dimethylamino) propyl] -N' - ethylcarbodiimide hydrochloride (120 mg) and N, N- dimethylformamide (5 mL) was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-methanol (100:0- 90:10, volume ratio) to give colorless crystals. The crystals were recrystallized from acetone-hexane to give the title compound (80 mg, yield 55%) as a colorless powder, melting point 100-102°C.
Example 396 N- (2-hydroxyethyl) -2- (2- {5- (2-methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazol-5-yl) -N-methylacetamide
Figure imgf000490_0001
A mixture of (2- {5- (2-methoxyethoxy) -7- [methyl (pyridin- 2-ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetic acid (250 mg) , IH-I, 2, 3-benzotriazol-l-ol (100 mg) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (140 mg) , 2- (methylamino) ethanol (60 mg) and N, N- dimethylformamide (5 mL) was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-methanol (100:0- 95:5, volume ratio) to give colorless crystals. The crystals were recrystallized from ethyl acetate-hexane to give the title compound (140 mg, yield 50%) as colorless crystals. melting point 94-96°C.
Example 397 N- (5- (2-methoxyethoxy) -2- {5- [ (1- oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH- indol-7-yl) -N-methylpyridine-2-sulfonamide
Figure imgf000491_0001
N- (5- (2-Methoxyethoxy) -2- { 5- [ ( 1- oxidothiomorpholino)methyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH- indol-7-yl) -N-methylpyridine-2-sulfonamide (20 mg) was dissolved in hexane-ethanol (500:500', volume ratio, 200 mL) . This solution was subjected to HPLC using CHIRZHJCEL OD (50mmIDx500mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with hexane-ethanol (500:500, volume ratio) as a mobile phase at 30°C at flow rate of 60 mL/min. A fraction with the retention time of 45.6 min was separated, and concentrated. The obtained solid was dissolved in methanol, the insoluble substance was removed by filtration, and the filtrate was concentrated to give the title compound (10.9 mg) as a pale-yellow amorphous solid. MS: 578 (MH+). Example 398 N- (5- (2-methoxyethoxy) -2- {5- [ (1- oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH- indol-7-yl) -N-methylpyridine-2-sulfonamide
Figure imgf000491_0002
N- (5-(2-methoxyethoxy)-2-{5-[ (1- oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH- indol-7-yl) -N-methylpyridine-2-sulfonamide (20 mg) was dissolved in hexane-ethanol (500:500, volume ratio, 200 mL) . This solution was subjected to HPLC using CHIRALCEL OD (50mmIDx500mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with hexane-ethanol (500:500, volume ratio) as a mobile phase at 30°C at flow rate of 60 mL/min. A fraction with the retention time of 60.9 min was separated, and concentrated. The obtained crystals were dissolved in methanol, the insoluble substance was removed by filtration, and the filtrate was concentrated to give the title compound (11 mg) as colorless crystals. MS:578(MH+).
Example 399 N- [2- {5- [2- (3-hydroxyazetidin-l-yl) -2-oxoethyl] - 4, 5-dihydro-l, 3-thiazol-2-yl}-5- (2-methoxyethoxy) -lH-indol-7- yl] -N-methylpyridine-2-sulfonamide
Figure imgf000492_0001
A mixture of azetidin-3-ol hydrochloride (80 mg) , triethylamine (75 mg) and N,N-dimethylformamide (5 mL) was stirred at room temperature for 15 min. (2-{5-(2- Methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -IH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (250 mg) , IH- ' 1, 2, 3-benzotriazol-l-ol (100 mg) and N- [3-
(dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (140 mg) were added to the reaction mixture, and the mixture was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried (MgSCU), and concentrated. The residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-methanol (100:0-95:5, volume ratio) to give the title compound (80 mg, yield 29%) as a colorless amorphous solid.
1H-NMR(CDCl3)0: 2.46 (3H, d, J=6.06 Hz), 3.29 (3H, s) , 3.46 (3H, s) , 3.75 (2H, t, J=4.16 Hz), 3.80-4.04 (2H, m) , 4.06-4.16 (2H, m) , 4.18-4.47 (5H, m) , 4.54-4.74 (IH, m), 6.84 (IH, dd, J=5.49, 2.08 Hz), 6.91 (IH, dd, J=3.98, 2.08 Hz), 7.06 (IH, d, J=I.89 Hz), 7.61 (IH, t, J=6.06 Hz), 7.95 (IH, t, J=7.76 Hz), 8.01- 8.14 (IH, m) , 8.98-9.15 (IH, m) , 11.71-11.97 (IH, m) . Example 400 N-methyl-N- {2- [5- (IH-I, 2, 4-triazol-l-ylmethyl) - 4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl}pyridine-2- sulfonamide and N-methyl-N- {2- [5- (4H-1, 2, 4-triazol-4- ylmethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7- yl }pyridine-2-sulf onamide
Figure imgf000493_0001
A mixture of (2-{7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) methyl methanesulfonate (1.0 g) , 1H-1,2, 4-triazole (290 mg) , potassium carbonate (580 mg) and N,N-dimethylformamide (10 mL) was stirred at 60°C for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate-methanol (50:50:0-0:100:0-0:95:5, volume ratio) to give N-methyl-N- {2- [5- (IH-I, 2, 4-triazol-l-ylmethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}pyridine-2-sulfonamide (560 mg, yield 59%) as a pale-yellow amorphous solid.
1H-NMR(CDCl3)0: 3.32 (3H, s) , 4.20-4.62 (5H, m) , 6.95 (IH, d, J=2.27 Hz), 7.09 (IH, t, J=7.76 Hz), 7.19 (IH, d, J=7.57 Hz), 7.54-7.68 (2H, m) , 7.90-7.99 (IH, m) , 8.01 (IH, s) , 8.06-8.12 (IH, m) , 8.13 (IH, s) , 9.07 (IH, d, J=3.79 Hz), 12.13 (IH, brs) .
N-Methyl-N-{2- [5- (4H-1, 2, 4-triazol-4-ylmethyl) -4,5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}pyridine-2-sulfonamide (10 mg, yield 1%) was obtained as brown . crystals from the fraction eluted sequentially. 1H-NMR(CDCl3)0: 3.32 (3H, s) , 4.12-4.25 (3H, m) , 4.30-4.53 (2H, m) , 6.96 (IH, d, J=2.27 Hz), 7.09 (IH, t, J=7.57 Hz), 7.17- 7.22 (IH, m) , 7.59-7.68 (2H, m) , 7.94-8.03 (IH, m) , 8.06-8.13 (IH, m) , 8.25 (2H, s) , 9.04 (IH, d,, J=3.79 Hz), 12.13 (IH, brs) . Example 401 N- [2- {5- [ (1, 1-dioxidothiomorpholino) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-5- (2-methoxyethoxy) -lH-indol-7- yl ] pyridine-2-sulfonamide
Figure imgf000494_0001
A mixture of trifluoromethanesulfonic anhydride (100 mg) , triphenylphosphine oxide (95 rag) and dichloromethane (5 mL) was stirred at 0°C for 10 min. A solution of N-[2- (benzylthio) -3- (1, 1-dioxidothiortiorpholino) propyl] -5- (2- rαethoxyethoxy) -7- [ (pyridin-2-ylsulfonyl) amino] -IH-indole-2- carboxamide (210 mg) and thioanisole (80 mg) in dichloromethane (40 mL) was added dropwise to the reaction mixture under ice-cooling, and the mixture was stirred for 2 hr under ice-cooling. The reaction mixture was added dropwise to a mixture of trifluoromethanesulfonic anhydride (100 mg) , triphenylphosphine oxide (95 mg) and dichloromethane (2 mL) under ice-cooling, and the mixture was stirred at room temperature for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSU4) , and concentrated. The residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (2:3-5:95, volume ratio) to give the title compound (80 mg, yield 44%) as colorless crystals. The crystals were recrystallized from acetone-hexane to give colorless prism crystals, melting point 218-219°C. Example 402 N- (5- (2-methoxyethoxy) -2-{5- [ (1- oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH- indol-7-yl ) pyridine-2-sulfonamide
Figure imgf000494_0002
To a solution of triphenylphosphine oxide (470 mg) in dichloromethane (3 mL) was added trifluoromethanesulfonic anhydride (480 mg) under ice-cooling, and the mixture was stirred for 30 min. - A solution of N- [2- (benzylthio) -3- thiomorpholinopropyl] -5- (2-methoxyethoxy) -7- [ (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxamide (570 mg) and thioanisole (210 mg) in dichloromethane (20 mL) was added dropwise to the reaction mixture under ice-cooling, and the mixture was stirred for 3 hr under ice-cooling. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO,)) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (1:1-1:9, volume ratio) to give colorless crystals. To a mixture of the obtained crystals, ethanol (20 mL) , water (10 mL) and tetrahydrofuran (10 mL) was added OXONE (registered trade mark, 43 mg) at room temperature, and the mixture was stirred at room temperature for 2 hr. Aqueous sodium sulfite solution was added to the reaction mixture, the mixture was stirred for 30 min, and the organic solvent was evaporated under reduced pressure. The residue was extracted with a mixed solvent of ethyl acetate- tetrahydrofuran. The organic layer was washed with saturated brine, dried (MgSO,]) , and concentrated. The residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-methanol (100:0-90:10, volume ratio) to give colorless crystals. The obtained crystals was further purified by preparative HPLC, and recrystallized from acetone-methanol to give the title compound (30 mg, yield 6.1%) as colorless prism crystals, melting point 235-236°C. Example 403 N, N-dimethyl-2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l-thia-3, 8- diazaspiro [4.5] dec-2-ene-8-carboxamide
Figure imgf000496_0001
To a solution of N-methyl-N- [2- (l-thia-3, 8- diazaspiro [4.5]dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide (82 mg) and dimethylcarbamoyl chloride (100 μL) in tetrahydrofuran (3 itiL) was added triethylamine (100 μL) , and the mixture was stirred at room temperature for 30 min. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (43 mg, yield 46%) as white crystals from a fraction eluted with ethyl acetate. melting point 245°C.
Example 404 N-methyl-N- (2- { 8- [ (l-methyl-lH-imidazol-2- ' yl) methyl] -l-thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl}-lH-indol- 7-yl) thiophene-2-sulfonamide
Figure imgf000496_0002
To a solution of N-methyl-N-; [2- (l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide (100 mg) and l-methyl-lH-imidazole-2-carbaldehyde (33 mg) in tetrahydrofuran (3 πiL) was added sodium triacetoxyborohydride (125 mg) , and the mixture was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (14 mg, yield 12%) as white crystals from a fraction eluted with ethyl acetate, melting point 103°C.
Example 405 N-methyl-N- {2- [8- (methylsulfonyl) -l-thia-3, 8- diazaspiro [4.5] dec-2-en~2-yl] -lH-indbl-7-yl} thiophene-2- sulfonamide
Figure imgf000497_0001
To a solution of N-methyl-N- [2- (l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide (82 mg) and methanesulfonyl chloride (100 μL) in tetrahydrofuran (3 mL) was added triethylamine (100 μL) , and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, and water was added. The precipitated crystals were collected by filtration, and washed with water. The obtained crystals were recrystallized from tetrahydrofuran to give the title compound (42 mg, yield 36%) as white crystals, melting point 251°C.
Example 406 N- [2- (8-ethyl-l-thia-3, 8-diazaspiro [4.5] dec-2-en- 2-yl) -lH-indol-7-yl] -N-methylthiophene-2-sulfonamide
Figure imgf000497_0002
To a solution of N-methyl-N- [2- (l-thia-3, diazaspiro [4.5]dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide (100 mg) and acetaldehyde (90%, 100 μL) in tetrahydrofuran (3 itiL) was added sodium triacetoxyborohydride (125 rag) , and the mixture was stirred at room temperature for 30 min. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (83 mg, yield 80%) as white crystals from a fraction eluted with ethyl acetate, melting point 215°C.
Example 407 N- {2- [8- (cyanomethyl) -l-thia-3, 8- diazaspiro[4.5]dec-2-en-2-yl]-lH-indol-7-yl}-N- methylthiophene-2-sulfonamide ■ •
Figure imgf000498_0001
A mixture of N-Methyl-N- [2- (l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonarαide (100 mg) , 3- (chloromethyl) -1, 2, 4-oxadiazole (35 mg) , potassium carbonate (44 mg) and N,N-dimethylformamide (5 itiL) was stirred at 50°C for 16 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCU) , and concentrated. The obtained residue was purified by preparative HPLC to give the title compound (55 mg, yield 47%) as white crystals, melting point 211°C. Example 408 N- {2- [8- (2-furylmethyl) -l-thia-3, 8- diazaspiro[4.5]dec-2-en-2-yl]-lH-indol-7-yl}-N- methylthiophene-2-sulfonamide
Figure imgf000499_0001
In the same manner as in Example 404, the' title compound (92 mg, yield 79%) was obtained as white crystals from N-methyl-N- [2- (l-thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl) - lH-indol-7-yl] thiophene-2-sulfonamide (100 mg) and 2- furaldehyde (30 mg) . melting point 196°C.
Example 409 N-methyl-N- {2- [8- (pyridin-2-ylmethyl) -l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl] -lH-indol-7-yl} thiophene-2- sulfonamide
Figure imgf000499_0002
In the same manner as in Example 404, the title compound (88 mg, yield 74%) was obtained as white crystals from N-methyl-N- [2- (l-thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl) - lH-indol-7-yl] thiophene-2-sulfonamide (100 mg) and pyridine-2- carbaldehyde (33 mg) . melting point 177°C. Example 410 N,N-diethyl-2- (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-l-thia-3, 8- diazaspiro [4.5]dec-2-en-8-yl) acetamide
Figure imgf000499_0003
In the same manner as in Example 407, the title compound (74 mg, yield 60%) was obtained as white crystals from N-methyl-N- [2- (l-thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl) - lH-indol-7-yl] thiophene-2-sulfonamide (100 mg) and 2-chloro- N, N-diethylacetamide (45 mg) . melting point 171°C.
Example 411 N-methyl-N- {2- [8- (2-oxopropyl) -l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl] -lH-indol-7-yl} thiophene-2- sulfonamide
Figure imgf000500_0001
In the same manner as in Example 407, the title compound (58 mg, yield 53%) was obtained as white crystals from N-methyl-N- [2- (l-thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl) - lH-indol-7-yl] thiophene-2-sulfonamide (100 mg) and chloroacetone (30 mg) . melting point 168°C. Example 412 methyl (2- {7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl} -l-thia-3, 8-diazaspiro [4.5] dec-2-en-8-yl) acetate
Figure imgf000500_0002
In the same manner as in Example 407, the title compound (165 mg, yield 72%) was obtained as white crystals from N-methyl-N- [2- (l-thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl) - lH-indol-7-yl] thiophene-2-sulfonamide (200 mg) and methyl bromoacetate (180 mg) . melting point 156°C.
Example 413 (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2- yl} -l-thia-3, 8-diazaspiro [4.5] dec-2-en-8-yl) acetic acid
Figure imgf000501_0001
In the same manner as in Example 382, the title compound (98 mg, yield 99%) was obtained as white crystals from methyl (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2- yl}-l-thia-3, 8-diazaspiro [4.5] dec-2-en-8-yl) acetate (103 mg) . melting point 236°C.
Example 414 2- (2- {7- [methyl (2-thienylsulfonyl) amino] -IH-indol- 2-yl}-l-thia-3, 8-diazaspiro [4.5] dec-2-en-8-yl) acetamide
Figure imgf000501_0002
A mixture of N-methyl-N- [2- (l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl) -lH-indol-7-yl] thiophene-2- sulfonamide (100 mg) , chloroacetamide (30 mg) , potassium carbonate (40 mg) and N,N-dimethylformamide (3 mL) was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSOJ, and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with ethyl acetate : hexane=l : 1 from a fraction to give the title compound
(62 mg, yield 56%) as white crystals, melting point 226°C. MS: 504 (MH+) .
Example 415 N-{2- [8- (2-methoxyethyl) -l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl] -lH-indol-7-yl} -limethylthiophene-2-sulfonamide
Figure imgf000502_0001
In the same manner as in Example -407, the title compound (84 mg, yield 76%) was obtained as white crystals from N-methyl-N- [2- (l-thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl) - lH-indol-7-yl] thiophene-2-sulfonamide (100 mg) and 2- bromoethyl methyl ether (35 mg) . melting point 177°C. Example 416 N-methyl-N- {2- [8- (tetrahydro-2H-pyran-4-yl) -1- thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl] -lH-indol-7- yl } thiophene-2-sulfonamide
Figure imgf000502_0002
In the same manner as in Example 404, the title compound (92 mg, yield 79%) was obtained as white crystals from N-methyl-N- [2- (l-thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl) - lH-indol-7-yl] thiophene-2-sulfonamide (100 mg) and tetrahydro- 4H-pyran-4-one (30 mg) . melting point 225°C.
Example 417 N-methyl-N- {2- [8- (pyridin-3-ylmethyl) -l-thia-3, 8- diazaspiro [4.5]dec-2-en-2-yl] -lH-indol-7-yl} thiophene-2- sulfonamide
Figure imgf000502_0003
In the same manner as in Example 404, the title compound (91 mg, yield 77%) was obtained as white crystals from N-methyl-N-[2- (l-thia-3, 8-diazaspiro [4.5] dec-2-en-2-yl) - lH-indol-7-yl] thiophene-2-sulfonamide (100 mg) and pyridine-3- carbaldehyde (33 mg) . melting point 210°C.
Example 418 N- {2- [ 8- (2-hydroxyethyl) -l-thia-3, 8- diazaspiro[4.5]dec-2-en-2-yl]-lH-indol-7-yl}-N- methylthiophene-2-sulfonamide
Figure imgf000503_0001
In the same manner as in Example 285, the title compound (62 mg, yield 31%) was obtained as white crystals from methyl (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2- yl} -l-thia-3, 8-diazaspiro [4.5] dec-2-en-8-yl) acetate, melting point 214°C. Example 419 N- {2- [8- (2-hydroxy-2-methylpropyl) -l-thia-3, 8- diazaspiro [4.5] dec-2-en-2-yl] -lH-indol-7-yl}-N- methylthiophene-2-sulfonamide
Figure imgf000503_0002
To a solution of methyl (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl }-l-thia-3, 8- diazaspiro [4.5] dec-2-en-8-yl) acetate (211 mg) in tetrahydrofuran (3 πiL) was added 1.5M methyllithium-diethyl ether solution (2 mL) at room temperature, and the mixture was stirred for 30 min. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (92 mg, yield 44%) as white crystals from a fraction eluted with ethyl acetate :hexane=l:3. melting point 191°C. Example 420 ethyl (2-{5-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetate
Figure imgf000504_0001
In the same manner as in Example 283, the title compound (1.59 g, yield 56%) was obtained as white crystals from 5-methyl-7- [methyl (2-thienylsulfonyl) amino] -lH-indole-2- carbothioamide (2.15 g) and ethyl but-2-ynoate (1.54 g) . melting point 83°C.
Example 421 (2- {5-methyl-7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl} -4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000504_0002
In the same manner as in Example 382, the title compound (0.49 g, yield 99%) was obtained as white crystals from ethyl (2- {5-methyl-7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (0.5 g) . melting point 209°C.
Example 422 2- (2- { 5-methyl-7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl} -4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000504_0003
In the same manner as in Example 287, the title compound (104 mg, yield 56%) was obtained as white crystals from (2-{5-methyl-7- [methyl (2-thienylsulfonyl) amino] -lH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (180 mg) . melting point 179°C.
Example 423 N- {2- [5- (2-hydroxyethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl] -5-methyl-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide
Figure imgf000505_0001
In the same manner as in Example 285, the title compound (180 mg, yield 66%) was obtained as white crystals from ethyl (2- {5-methyl-7- [methyl (2-thienylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate (300 mg) . melting point 161°C.
Example 424 N-methyl-N-{5-methyl-2- [5- (morpholinomethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000505_0002
In the same manner as in Example 201, the title compound (544 mg, yield 72%) was obtained as white crystals from N- [2- (benzylthio) -3-morpholinopropyl] -5-methyl-7-
[methyl (2-thienylsulfonyl) amino] -lH-indole-2-carboxamide (812 mg) . melting point 189°C.
Example 425 benzyl [ (2-{5-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) methyl] carbamate
Figure imgf000506_0001
To a solution of (2-{5-methyl-7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl'}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetic acid (500 mg) , benzyl alcohol (570 μL) and triethylamine (185 μL) in N,N~dimethylformamide (10 mL) was added diphenylphosphorylazide (287 μL) at room temperature, and the mixture was stirred under heating at 100°C for 30 min. The reaction mixture was allowed to cool to room temperature, water was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (112 mg, yield 18%) as pale-ye.llow crystals from a fraction eluted with ethyl acetate :hexane=25: 75. melting point 160°C.
Example 426 N- [2- (5-cyano-4, 5-dihydro-l, 3-thiazol-2-yl) -5- methyl-lH-indol-7-yl] -N-methylthiophene-2-sulfonamide
Figure imgf000506_0002
In the same manner as in Example 201, the title compound (406 mg, yield 30%) was obtained as white crystals from N- [2- (benzylthio) -2-cyanoethyl] -5-methyl-7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (1.7 g) . melting point 203°C.
Example 427 N- {2- [5- (aminomethyl) -4, 5-dihydro-l, 3-thiazol-2- yl] -5-methyl-lH-indol-7-yll-N-methylthiophene-2-sulfonanu.de
Figure imgf000507_0001
In the same manner as in Example 277, the title compound (140 mg, yield 44%) was obtained as white crystals from N- [2- (5-cyano-4, 5-dihydro-l, 3-thiazol-2-yl) -5-methyl-lH- indol-7-yl] -N-methylthiophene-2-sulfonamide (314 mg) . melting point 168°C.
Example 428 N- (2-hydroxyethyl) -2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000507_0002
To a solution of (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl }-4, 5-dihydro-l, 3-thiazol- 5-yl) acetic acid (200 mg) , IH-I, 2, 3-benzotriazol-l-ol (150 mg) and N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (190 mg) in tetrahydrofuran (3 mL) and acetonitrile (3 mL) was added 2-aminoethanol (100 mg) , and the mixture was stirred at room temperature for 3 hr. The reaction mixture was concentrated, water was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (124 mg, yield 56%) as white crystals from a fraction eluted with ethyl acetate :hexane=50: 50. melting point 214°C. Example 429 N- (2-hydroxyethyl) -N-methyl-2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000508_0001
In the same manner as in Example 428, the' title compound (49 mg, yield 22%) was obtained as white crystals from (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (200 mg) and 2-
(methylamino) ethanol (150 mg) . melting point 1120C. Example 430 N,N-bis (2-hydroxyethyl) -2- (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000508_0002
In the same manner as in Example 428, the title compound (14.5 mg, yield 6%) was obtained as white crystals from (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (200 mg) and 2,2'- iminodiethanol (200 mg) . ' melting point 104°C.
Example 431 N- (2-methoxyethyl) -2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000509_0001
In the same manner as in Example 428, the' title compound (134 mg, yield 59%) was obtained as white crystals from (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (200 mg) and 2- methoxyethaneamine (150 mg) . melting point 140°C. Example 432 N- (2-methoxyethyl) -N-methyl-2- (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000509_0002
In the same manner as in Example 428, the title compound (167 mg, yield 72%) was obtained as white crystals from (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (200 mg) and 2- methoxy-N-methylethaneamine (180 mg) . melting point 103°C. Example 433 N- [2- (methylsulfonyl) ethyl] -2- (2-{7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000509_0003
In the same manner as in Example 428, the title compound (109 mg, yield 44%) was obtained as white crystals from (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (200 mg) and 2-
(methylsulfonyl) ethaneamine (300 mg) . melting point 146°C. Example 434 N-methyl-N- [2- (methylsulfonyl) ethyl] -2- (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro- 1, 3-thiazol-5-yl) acetamide
Figure imgf000510_0001
In the same manner as in Example 428, the title compound (95 mg, yield 37%) was obtained as white crystals from (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (200 mg) and N- methyl-2- (methylsulfonyl) ethaneamine (350 mg) . melting point 96°C. Example 435 N- (2-{5- [2- (3-hydroxypyrrolidin-l-yl) -2-oxoethyl] 4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) -N- methylthiophene-2-sulfonamide
Figure imgf000510_0002
In the same manner as in Example 428, the title compound (206 mg, yield 89%) was obtained as white crystals from (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (200 mg) and 3- hydroxypyrrolidine (60 mg) . melting point 208°C. Example 436 N- (2-{ 5- [2- (4-hydroxypiperidino) -2-oxoethyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2- sulfonamide
Figure imgf000511_0001
In the same manner as in Example 428, the title compound (210 mg, yield 88%) was obtained as white crystals from (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl }- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (200 mg) and 4- hydroxypiperidine (60 mg) . melting point 121°C. Example 437 N- (methylsulfonyl) -2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl }-4, 5-dihydro-l, 3-thiazol- 5-yl) acetamide
Figure imgf000511_0002
A solution of (2- {7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (200 mg) , 2-methyl-β-nitrobenzoic acid anhydride (190 mg) , 4- dimethylaminopyridine (56 mg) , triethylamine (200 μL) and methanesulfonamide (46 mg) in acetonitrile (5 mL) was stirred at room temperature for 18 hr. IN Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (76 mg, yield 33%) as white crystals from a fraction eluted with ethyl acetate, melting point 141°C. Example 438 N- [2- ( 5- { 2- [ (2-hydroxyethyl ) amino] ethyl } -4 , 5- dihydro-1, 3-thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2- sulfonamide hydrochloride
Figure imgf000512_0001
To a solution of 2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) ethyl methanesulfonate (124 mg) in N, N-dimethylformamide (3 mL) was added 2-aminoethanol (60 mg) , and the mixture was stirred under heating at 80°C for 4 hr. The reaction mixture was allowed to cool to room temperature, saturated aqueous sodium hydrogencarbonate solution was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give colorless oil from a fraction eluted with ethyl acetate. To a solution of the obtained colorless oil in ethyl acetate (1 mL) was added 4N hydrogen chloride- ethyl acetate solution (1 mL) . The precipitated crystals were collected by filtration, washed with diethyl ether, and dried to give the title compound (27 mg, yield 22%) as yellow crystals, melting point 196°C.
Example 439 N- [2- (5-{2- [4- (2-hydroxyethyl) piperidino] -2- oxoethyl}-4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7-yl] -N- methylthiophene-2-sulfonamide
Figure imgf000513_0001
In the same manner as in Example 428, the title compound (102 mg, yield 41%) was obtained as white crystals from (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (200 mg) and 2-
(piperidin-4-yl) ethanol (100 mg) . melting point 106°C. Example 440 N-methyl-N-{2- [5- (2-oxo-2-thiomorpholinoethyl) - 4, 5-dihydro-l, 3-thiazol-2~yl]-lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000513_0002
In the same manner as in Example 428, the title compound (624 mg, yield 52%) was Obtained as white crystals from (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (1.0 g) and thiomorpholine (300 mg) . melting point 182°C.
Example 441 N- (2-{5- [2- (1, 1-dioxidothiomorpholino) -2- oxoethyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) -N- methylthiophene-2-sulfonamide
Figure imgf000514_0001
To a solution of N-methyl-N-{2- [5- (2-oxo-2- thiomorpholinoethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7- yl} thiophene-2-sulfonamide (560 mg) in tetrahydrofuran (15 mL) , ethanol (5 mL) and water (5 mL) was added OXONE (registered trade mark, 986 mg) at room temperature, and the mixture was stirred for 1 hr. Sodium sulfite (3 g) was added to the reaction mixture, and the mixture was stirred for 10 min. Water was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO,)) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (242 mg, yield 44%) as white crystals from a fraction eluted with ethyl acetate, melting point 158°C. Example 442 N-methyl-N- (2-{5- [2- (1-oxidothiomorpholino) -2- oxoethyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide
Figure imgf000514_0002
The title compound (92 mg, yield 17%) was obtained as white crystals from a fraction eluted after the elution of the compound of Example 441 with ethyl acetate in the silica gel column chromatography. melting point 149°C.
Example 443 2- (2-{7- [methyl (2-thienylsulfonyl) amino] -IH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) ethyl (cis) -2,6- dimethylmorpholine-4-carboxylate hydrochloride
Figure imgf000515_0001
To a solution of 2- (2- {7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) ethyl methanesulfonate (180 mg) in N,N-dimethylformamide (5 mL) were added potassium carbonate (60 mg) and cis-2,6- dimethylmorpholine (60 mg) , and the mixture was stirred under heating at 50°C for 3 days. The reaction mixture was allowed to cool to room temperature, water was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give colorless oil from a fraction eluted with ethyl acetate. The obtained colorless oil was dissolved in ethyl acetate (1 mL) , and 4N hydrogen chloride-ethyl acetate solution (1 mL) was added. The precipitated crystals were collected by filtration, washed with diethyl ether, and dried to give the title compound (71 mg, yield 36%) as yellow crystals, melting point 154°C.
Example 444 N- [2- (5-{2- [ (cis) -2, 6-dimethylmorpholino] ethyl}- 4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7-yl] -limethylthiophene-2-sulfonamide hydrochloride
Figure imgf000515_0002
A colorless oil was obtained from a fraction eluted after the elution of the compound of Example 443 with ethyl acetate in the silica gel column chromatography. The obtained colorless oil was dissolved in ethyl acetate (1 mL) , and 4N hydrogen chloride-ethyl acetate solution (1 mL) was added. The precipitated crystals were collected by filtration, washed with diethyl ether, and dried to give the title compound (37 mg, yield 21%) as yellow crystals, melting point 196°C. Example 445 2- (2- {7- [methyl (2-thienylsulfonyl) amino] -IH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) -N-4H-1, 2, 4-triazol-3- ylacetamide
Figure imgf000516_0001
In the same manner as in Example 428, the title compound (164 mg, yield 71%) was obtained as white crystals from (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (1.0 g) and 4H-1,2,4- triazol-3-amine (50 mg) . melting point 194°C.
Example 446 2- (2- {7- [methyl (2-thienylsulfonyl) amino] -IH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) -N-lH-tetrazol-5- ylacetamide
Figure imgf000516_0002
In the same manner as in Example 428, the title compound (69 mg, yield 30%) was obtained as white crystals from (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (1.0 g) and IH- tetrazol-5-amine (50 mg) . melting point 1540C. Example 447 N- (2-{5- [2- (3-hydroxyazetidin-l-yl) -2-oxoethyl] - 4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) -N- methylthiophene-2-sulfonamide
Figure imgf000517_0001
In the same manner as in Example 428, the title compound (190 mg, yield 84%) was obtained as white crystals from (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (1.0 g) and 3- hydroxyazetidine (60 mg) . melting point 187°C. Example 448 N- [2- (5-{2- [ (cis) -2, 6-dimethylmorpholino] -2- oxoethyl}-4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7-yl] -rimethylthiophene-2-sulfonamide
Figure imgf000517_0002
In the same manner as in Example 428, the title compound (206 mg, yield 84%) was obtained as white crystals from (2- {7- [methyl (2-thienylsulfonyl) amino.] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (1.0 g) and cis-2,6- dimethylmorpholine (60 mg) . melting point 170°C.
Example 449 N-methyl-N-{2- [5- (2-oxoethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide
Figure imgf000518_0001
To a solution of N-{2- [5- (2-hydroxyethyl) -4, 5-dihydro- l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2- sulfonamide (2.78 g) in acetonitrile (150 mL) was added Dess- Martin reagent (3 g) , and the mixture was stirred under heating at 70°C for 30 min. The reaction mixture was allowed to cool to room temperature, water was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCU) / and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (27 mg, yield 22%) as a brown amorphous solid from a fraction eluted with ethyl acetate :hexane=25: 75. MS: 420(MH+) . Example 450 N-methyl-2- (2- { 7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000518_0002
In the same manner as in Example 428, the title compound (56 mg, yield 27%) was obtained as white crystals from (2-{7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (1.0 g) and 2M methylamine tetrahydrofuran solution (2 mL) . melting point
192°C.
Example 451 N- (2-{5- [2- (4-hydroxypiperidino) ethyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2- sulfonamide
Figure imgf000519_0001
In the same manner as in Example 404, the title compound (248 mg, yield 77%) was obtained as white crystals from N-methyl-N-{2- [5- (2-oxoethyl) -4, 5-dihydro-l, 3-thiazol-2- yl]-lH-indol-7-yl}thiophene-2-sulfonamide (270 mg) and 4- hydroxypiperidine (100 mg) . melting point 176°C.
Example 452 N- (2-{ 5- [2- (3-hydroxyazetidin-l-yl) ethyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2- sulfonamide
Figure imgf000519_0002
In the same manner as in Example 404, the title compound (195 mg, yield 64%) was obtained as white crystals from N-methyl-N-{2- [5- (2-oxoethyl) -4, 5-dihydro-l, 3-thiazol-2- yl]-lH-indol-7-yl}thiophene-2-sulfonamide (270 mg) and 3- hydroxyazetidine (110 mg) . melting point 149°C.
Example 453 N- (2-{5- [2- (1, 1-dioxidothiomorpholino) ethyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2- sulfonamide
Figure imgf000520_0001
In the same manner as in Example 404, the title compound (145 mg, yield 56%) was obtained as white crystals from N-methyl-N-{2-[5- (2-oxoethyl) -4, 5-dihydro-l, 3-thiazol-2- yl]-lH-indol-7-yl}thiophene-2-sulfonamide (200 mg) and thiomorpholine 1,1-dioxide (95 mg) . melting point lβl°C. Example 454 N-methyl-N- {2- [5- (2-thiomorpholinoethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide
Figure imgf000520_0002
In the same manner as in Example 404, the title compound (606 mg, yield 84%) was Obtained as white crystals from N-methyl-N- {2- [5- (2-oxoethyl) -4, 5-dihydro-l, 3-thiazol-2- yl] -lH-indol-7-yl}thiophene-2-sulfonamide (600 mg) and thiomorpholine (300 mg) . melting point 164°C.
Example 455 N-methyl-N- (2-{5- [2- (1-oxidothiomorpholino) ethyl] 4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) thiophene-2- sulfonamide
Figure imgf000521_0001
In the same manner as in Example 323, the title compound (87 mg, yield 15%) was obtained as white crystals from N-methyl-N-{2- [5- (2-thiomorpholinoethyl) -A15-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide (559 mg) . melting point 146°C.
Example 456 N- [2- (5-{2- [ (cis) -3, 5-dimethylpiperazin-l- yl] ethyl}-4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7-yl] -N- methylthiophene-2-sulfonamide dihydrochloride
Figure imgf000521_0002
To a solution of N-methyl-N-{2- [5- (2-oxoethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}thiophene-2- sulfonamide (200 mg) and 2, 6-dimethylpiperazine (58 mg) in tetrahydrofuran (5 mL) was' added sodium triacetoxyborohydride (200 mg) at room temperature, and the mixture was stirred for 10 min. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the. mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCU) / and concentrated. The obtained residue was subjected to basic silica gel column chromatography to give a colorless oil from a fraction eluted with ethyl acetate. The obtained colorless oil was dissolved in ethyl acetate (2 mL) , and 4N hydrogen chloride-ethyl acetate solution (1 mL) was added. The precipitated crystals were collected by filtration, washed with diethyl ether, and dried to give the title compound (130 mg, yield 46%) as yellow crystals, melting point 217°C. Example 457 N-methyl-N- [2- (5- {2- [ (cis) -3, 4, 5- trimethylpiperazin-1-yl] ethyl}-4, 5-dihydro-l, 3-thiazol-2-yl) - lH-indol-7-yl] thiophene-2-sulfonamide
Figure imgf000522_0001
In the same manner as in Example 404, the title compound (138 mg, yield 99%) was obtained as white crystals from N- [2- (5-{2- [ (cis) -3, 5-dimethylpiperazin-l-yl] ethyl}-4, 5- dihydro-1, 3-thiazol-2-yl) -lH-indol-7-yl] -N-methylthiophene-2- sulfonamide dihydrochloride (135 mg) and 37% aqueous formaldehyde solution (1 mL) . melting point 138°C. Example 458 N- [2- (5-{2- [ (cis) -3, 5-dimethylpiperazin-l-yl] -2- oxoethyl}-4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7-yl] -N- methylthiophene-2-sulfonamide-
Figure imgf000522_0002
In the same manner as in Example 428, the title compound (421 mg, yield 86%) was obtained as white crystals from (2- {7- [methyl (2-thienylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid (400 mg) and cis-2, 6- dimethylpiperazine (114 mg) . melting point 158°C. Example 459 N-methyl-N- [2- (5-{2-oxo-2- [ (cis) -3, 4, 5- trimethylpiperazin-1-yl] ethyl}-4, 5-dihydro-l, 3-thiazol-2-yl) - lH-indol-7-yl] thiophene-2-sulfonamide
Figure imgf000523_0001
In the same manner as in Example 404, the' title compound (286 mg, yield 99%) was obtained as white crystals from N- [2- (5-{2- [ (cis) -3, 5-dimethylpiperazin-l-yl] -2- oxoethyl}-4, 5-dihydro-l, 3-thiazol-2-yl)-lH-indol-7-yl] -N- methylthiophene-2-sulfonamide (277 mg) and 37% aqueous formaldehyde solution (0.5 mL) . melting point 134°C. Example 460 N- [2- (5-{ [1- (2-hydroxyethyl) -4, 5-dihydro-lH- pyrazol-3-yl] methyl} --4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7- yl] -N-methylthiophene-2-sulfonamide
Figure imgf000523_0002
A solution of N-methyl-N-{2- [5- (2-oxobut-3-en-l-yl) - 4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl} thiophene-2- sulfonamide (223 mg) and 2-hydroxyethylhydrazine (60 mg) in tetrahydrofuran (5 mL) was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (146 mg, yield 58%) as a white amorphous solid from a fraction eluted with ethyl acetate. MS: 504 (MH+) .
Example 461 N- [2- (5-{2- [ (2-hydroxyethyl) (methyl) amino] ethyl}- 4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7-yl] -N- methylthiophene-2-sulfonamide
Figure imgf000524_0001
In the same manner as in Example 404, the title compound (110 mg, yield 48%) was obtained as white crystals from N-methyl-N-{2- [5- (2-oxoethyl) -4, 5-dihydro-l, 3-thiazol-2- yl]-lH-indol-7-yl}thiophene-2-sulfonamide (200 mg) and 2-
(methylamino) ethanol (57 mg) . melting point 1160C. Example 462 N-methyl-N-{2- [5- (2- {methyl [2-
(methylsulfonyl) ethyl] amino}ethyl) -4, 5-dihydro-l, 3-thiazol-2- yl]-lH-indol-7-yl}thiophene-2-sulfonamide hydrochloride
Figure imgf000524_0002
In the same manner as in Example 456, the title compound (190 mg, yield 68%) was obtained as yellow crystals from N-methyl-N-{2- [5- (2-oxoethyl) -4, 5-dihydro-l, 3-thiazol-2- yl]-lH-indol-7-yl}thiophene-2-sulfonamide (200 mg) and N- methyl-2- (methylsulfonyl) ethaneamine (100 mg) . MS:541(MH+). Example 463 N-methyl-N- (2-{ 5- [2- (4H-1, 2, 4-triazol-3- ylamino) ethyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide
Figure imgf000524_0003
To a solution of N-methyl-N- {2- [5- (2-oxoethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2- sulfonamide (200 mg) and 4H-1, 2, 4-triazol-3-amine (80 mg) in acetic acid (3 rαL) was added sodium triacetoxyborohydride (200 mg) at room temperature, and the mixture was stirred for 10 min. The reaction mixture was neutralized with saturated aqueous sodium hydrogencarbonate solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (120 mg, yield 50%) as white crystals from a fraction eluted with ethyl acetate, melting point 195°C. Example 464 N- [2- (5-{2- [ (trans-4-hydroxy-4- methylcyclohexyl) amino] ethyl}-4, 5-dihydro-l, 3-thiazol-2-yl) - lH-indol-7-yl] -N-methylthiophene-2-sulfonamide hydrochloride
Figure imgf000525_0001
A mixture of N-methyl-N-{2- [5- (2-oxoethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl]-lH-indol-7-yl}thiophene-2-sulfonamide (200 mg) and trans-4-amino-l-methylcyclohexanol (80 mg) in methanol
(5 mL) was stirred at 50°C for 1 hr. The reaction mixture was allowed to cool to room temperature, sodium borohydride (38 mg) was added, and the mixture was stirred for 10 min.
Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCU) i and concentrated. The obtained residue was subjected to silica gel column chromatography to give a yellow oil from a fraction eluted with ethyl acetate. The obtained yellow oil was dissolved in ethyl acetate (3 mL) , and 4N hydrogen chloride-ethyl acetate solution (2 mL) was added. The precipitated crystals were collected by filtration, washed with diethyl ether, and dried to give the title compound (148 mg, yield 54%) as yellow crystals, melting point 161°C.
Example 465 N- [2- (5-{2- [ (2-hydroxy-2- methylpropyl) amino] ethyl}-4, 5-dihydro-l, 3-thiazol-2-yl) -IH- indol-7-yl] -N-methylthiophene-2-sulfonamide hydrochloride
Figure imgf000526_0001
In the same manner as in Example 464, the title compound (116 mg, yield 46%) was obtained as yellow crystals from N-methyl-N-{2- [5- (2-oxoethyl) -4, 5-dihydro-l, 3-thiazol-2- yl]-lH-indol-7-yl}thiophene-2-sulfonamide (200 mg) and 1- amino-2-methylpropan-2-ol (50 mg) . melting point 1560C.
Example 466 N-methyl-N- (2- {5- [2- (tetrahydro-2H-thiopyran-4- ylamino) ethyl] -4, 5-dihydro-l, 3-thiazol-2-yl} -IH-indol-7- yl) thiophene-2-sulfonamide
Figure imgf000526_0002
In the same manner as in Example 377, the title compound (403 mg, yield 55%) was obtained as white crystals from N-methyl-N- {2- [5- (2-oxoethyl) -4, 5-dihydro-l, 3-thiazol-2- yl]-lH-indol-7-yl} thiophene-2-sulfonamide (600 mg) and tetrahydro-2H-thiopyran-4-aiuine (300 mg) . melting point 132°C. Example 467 N-methyl-N- [2- (5- {2- [ (l-oxidetetrahydro-2H- thiopyran-4-yl) amino] ethyl}-4, 5-dihydro-l, 3-thiazol-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide
Figure imgf000527_0001
In the same manner as in Example 323, the title compound (55 mg, yield 16%) was obtained as yellow crystals from N-methyl-N- (2- {5- [2- (tetrahydro-2H-thiopyran-4- ylamino) ethyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7- yl) thiophene-2-sulfonamide (330 mg) . melting point 172°C. Example 468 N- [2- (5-{2- [ (1, l-dioxidetetrahydro-2H-thiopyran-4- yl) amino] ethyl}-4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7-yl] - N-methylthiophene-2-sulfonamide hydrochloride
Figure imgf000527_0002
In the same manner as in Example 464, the title compound (108 mg, yield 38%) was obtained as yellow crystals from N-methyl-N- {2- [5- (2-oxoethyl) -4, 5-dihydro-l, 3-thiazol-2- yl] -lH-indol-7-yl}thiophene-2-sulfonamide (200 mg) and tetrahydro-2H-thiopyran-4-amine 1,1-dioxide (100 mg) . melting point 195°C.
Example 469 N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -IH- indol-7-yl] -N-methylthiophene-2-sulfonamide
Figure imgf000527_0003
A mixture of N- {2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}-N-methylthiophene-2-sulfonamide (1.18 g) , trifluoroacetic acid (3 mL) , concentrated sulfuric acid (3 mL) and water (10 mL) was stirred at 50°C for 2 hr. The reaction mixture was a-llowed to cool to room temperature, neutralized with saturated aqueous sodium hydrogencarbonate solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4)-, and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (1.1 g, yield 99%) as a brown amorphous solid from a fraction eluted with ethyl acetate :hexane=50: 50. MS -.406(MH+). Example 470 N-methyl-N-{2- [5- (thiomorpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl]-lH-indol-7-yl} thiophene-2- sulfonamide
Figure imgf000528_0001
In the same manner as in Example 404, the title compound (18 mg, yield 17%) was obtained as white crystals from N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7- yl] -N-methylthiophene-2-sulfonamide (88 mg) and thiomorpholine
(30 mg) . melting point 178°C.
Example 471 N-methyl-N- (2-{ 5- [ (1-oxidothiomorpholino) methyl] - 4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol~7-yl) thiophene-2- sulfonamide
Figure imgf000528_0002
To a mixture of N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol- 2-yl) -lH-indol-7-yl] -N-iαethylthiophene-2-sulfonamide (550 mg) , thiomorpholine 1-oxide hydrochloride (310 mg) , triethylamine
(200 μL) and tetrahydrofuran (15 mL) was added sodium triacetoxyborohydride (420 mg) at room temperature, and the mixture was stirred for 10 min. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate . The ethyl acetate layer was washed with saturated brine, dried (MgSCM) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give a colorless oil from a fraction eluted with ethyl acetate :methanol=90: 10. The obtained colorless oil was purified by preparative HPLC to give the title compound (230 mg, yield 35%) as white crystals. melting point 204°C.
Example 472 N- (2-{5- [ (1, 1-dioxidothiomorpholino) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylthiophene-2- sulfonamide
Figure imgf000529_0001
To a mixture of N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol- 2-yl) -lH-indol-7-yl]-N-methylthiophene-2-sulfonamide (550 mg) , thiomorpholine 1,1-dioxide (270 mg) and tetrahydrofuran (15 mL) was added sodium triacetoxyborohydride (420 mg) at room temperature, and the mixture was stirred for 10 min. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give pale-pink crystals from a fraction eluted with ethyl acetate :hexane=50: 50. The obtained pale-pink crystals were purified by preparative HPLC to give the title compound (140 mg, yield 20%) as white crystals, melting point 242°C. Example 473 N- {2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl] -lH-indol-7-yl }pyridine-2-sulfonamide
Figure imgf000530_0001
To a solution of triphenylphosphine oxide (849 mg) in dichloromethane (10 πiL) was added tr'ifluoromethanesulfonic anhydride (515 μL) under ice-cooling, and the mixture was stirred for 10 min. A solution of N- [2- (benzylthio) -3, 3- dimethoxypropyl] -7- [ (pyridin-2-ylsulfonyl) amino] -lH-indole-2- carboxamide (1.5 g) and thioanisole (690 mg) in dichloromethane (10 mL) was added dropwise to the reaction mixture under ice-cooling , and the mixture was stirred for 10 min. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give white crystals from a fraction- eluted with ethyl acetate :hexane=50: 50. The white crystals were purified by preparative HPLC to give the title compound (487 mg, yield
40%) as white crystals, melting point 153°C. Example 474 N- (2-{ 5- [ (1-oxidothiomorpholino) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) pyridine-2-sulfonamide
Figure imgf000530_0002
A mixture of N-{2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}pyridine-2-sulfonamide (240 mg) , trifluoroacetic acid (4 mL) , concentrated sulfuric acid (4 mL) and water (10 mL) was stirred at 50°C for 4 hr. The reaction mixture was allowed to cool to room temperature, neutralized with saturated aqueous sodium hydrogencarbonate solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was dissolved in tetrahydrofuran (5 itiL) , and then thiomorpholine 1-oxide (110 mg) , triethylamine (140 μL) and sodium triacetoxyborohydride (235 mg) were added at room temperature. The mixture was stirred for 10 min. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (37.3 mg, yield 14%) as white crystals from a fraction eluted with ethyl acetate :methanol=90: 10. melting point 270°C.
Example 475 N- (2-{5- [ (1, 1-dioxidothiomorpholino) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) pyridine-2-sulfonamide
Figure imgf000531_0001
In the same manner as in Example 474, the title compound (10.1 mg, yield 1.8%) was obtained as white crystals from N- {2- [5- (dimethoxymethy1) -4, 5-dihydro-l, 3-thiazol-2-yl] - lH-indol-7-yl}pyridine-2-sulfonamide (500 mg) and thiomorpholine 1,1-dioxide (190 mg) . melting point 252°C. Example 476 N- {2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl]-lH-indol-7-yl}-N-methylpyridine-2-sulfonamide
Figure imgf000531_0002
In the same manner as in Reference Example 197, the title compound (6.66 g, yield 92%) was obtained as white crystals from N- {2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-7-yl}pyridine-2-sulfonamide (7 g) . melting point 131°C. Example 477 N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -IH- indol-7-yl] -N-methylpyridine-2-sulfonamide
Figure imgf000532_0001
In the same manner as in Example 469, the title compound (4.3 g, yield 91%) was obtained as a pink amorphous solid from N- {2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl]-lH-indol-7-yl}-N-methylpyridine-2-sulfonamide (5.3 g) . ■ MS: 401 (MH+) .
Example 478 N- [2- (5- {[ (2-hydroxyethyl) (methyl) amino] methyl }- 4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7-yl] -N-methylpyridine- 2-sulfonamide hydrochloride
Figure imgf000532_0002
In the same manner as in Example 456, the title compound (40 mg, yield 16%) was obtained as white crystals from N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7- yl] -N-methylpyridine-2-sulfonamide (200 mg) and 2-
(methylamino) ethanol (56 mg) . melting point 185°C. Example 479 N- (2-{5- [ (3-hydroxyazetidin-l-yl) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylpyridine-2- sulfonamide hydrochloride
Figure imgf000532_0003
In the same manner as in Example 456, the title compound ( 166 nag, yield 67%) was obtained as white crystals from N- [2- ( 5-formyl-4 , 5-dihydro-l , 3-thiazol-2-yl ) -lH-indol-7- yl] -N-methylpyridine-2-sulfonamide (200 mg) and 3- hydroxyazetidine ( 82 mg) . melting point 139°C . Example 480 N- (2- { 5- [ (4-hydroxypiperidino) methyl] -4, 5-dihydro- 1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylpyridine-2- sulfonamide
Figure imgf000533_0001
In the same manner as in Example 404, the title compound (184 mg, yield 74%) was obtained as white crystals from N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7- ' yl] -N-methylpyridine-2-sulfonamide (200 mg)^and 4- hydroxypiperidine (75 mg) . melting point 160°C. Example 481 N- {2- [5- (hydroxymethyl) -4, 5-dihydro-l, 3-thiazol-2- yl]-lH-indol-7-yl} -N-methylpyridine-2-sulfonamide
Figure imgf000533_0002
To a solution of N- [2- (5-formyl-4, 5-dihydro-l, 3- thiazol-2-yl) -lH-indol-7-yl] -N-methylpyridine-2-sulfonamide (200 mg) in tetrahydrofuraή (2 itiL) and ethanol (2 itiL) was added sodium tetrahydroborate (38 mg) , and the mixture was stirred at room temperature for 30 min. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCU) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (160 mg, yield 80%) as a white amorphous solid from a fraction eluted with ethyl acetate. MS: 403 (MH+). Example 482 (2- {7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indol-2-yl}-4, 5-dihydro-l, 3-thiazol~5-yl) methyl methanesulfonate
Figure imgf000534_0001
To a solution of N-{2- [5- (hydroxymethyl) -4, 5-dihydro- l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylpyridine-2- sulfonamide (2.0 g) and triethylamine (1.4 mL) in tetrahydrofuran (50 mL) was added methanesulfonyl chloride (860 mg) , and the mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSCU) / and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (1.85 g, yield 77%) as a white amorphous solid from a fraction eluted with ethyl acetate. MS:48l(MH+).
Example 483 N- [2- (5-{ [ (2-hydroxyethyl) amino] methyl} -4, 5- dihydro-1, 3-thiazol-2-yl) -lH-indol-7-yl] -N-methylpyridine-2- sulfonamide dihydrochloride
Figure imgf000534_0002
A mixture of (2- {7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indol-2-yl}-4,5-dihydro-l,3-thiazol-5-yl) methyl methanesulfonate (240 mg) , 2-aminoethanol (61 mg) , potassium carbonate (138 mg) and N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give a colorless oil from a fraction eluted with ethyl acetate :methanol=90: 10. The colorless oil was dissolved in ethyl acetate (3 πiL) , and 4N hydrogen chloride-ethyl acetate solution (I mL) was added. The precipitated crystals were collected by filtration, washed with diethyl ether, and dried to give the title compound (110 mg, yield 42%) as a white amorphous solid. MS: 446 (MH+).
Example 484 N- [2- (5-{ [ (2-hydroxy-2-methylpropyl) amino] methyl }- 4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7-yl] -N-methylpyridine- 2-sulfonamide dihydrochloride
Figure imgf000535_0001
In the same manner as in Example 483, the title compound (75 mg, yield 27%) was obtained as a white amorphous solid from (2- {7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indol- 2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) methyl methanesulfonate
(240 mg) and l-amino-2-methylpropan-2-ol (89 mg) . MS:474 (MH+). Example 485 N- (2-{ 5- [ (2, 5-dioxopyrrolidin-l-yl) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylpyridine-2- sulfonamide hydrochloride
Figure imgf000535_0002
A mixture of (2-{7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indol-2-yl } -4, 5-dihydro-l, 3-thiazol-5-yl) methyl methanesulfonate (200 mg) , succinimide (100 mg) , potassium carbonate (200 mg) and N,N-dimethylformamide (5 mL) was stirred at 50°C for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The obtained residue was subjected to silica gel column chromatography to give a colorless oil from a fraction eluted with ethyl acetate :methanol=90: 10. The colorless oil was dissolved in ethyl acetate (3 inL) , and 4N hydrogen chloride-ethyl acetate solution (1 inL) was added. The precipitated crystals were collected by filtration, washed with diethyl ether, and dried to give the title compound (192 mg, yield 89%) as white crystals, melting point '1810C. Example 486 N- {2- [5- (lH-imidazol-1-ylmethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -lH-indol-7-yl}-N-methylpyridine-2-sulfonamide dihydrochloride
Figure imgf000536_0001
In the same manner as in Example 483, the title compound (138 mg, yield 66%) was obtained as yellow crystals from (2- {7- [methyl (pyridin-2-ylsulfonyl) amino] -IH-indol-2-yl }- 4, 5-dihydro-l, 3-thiazol-5-yl) methyl methanesulfonate (195 mg) and imidazole (70 mg) . melting point 142°C.
Example 487 N-methyl-N- (2-{5- [ (3-oxopyrazolidin-l-yl)methyl] -
4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) pyridine-2- sulfonamide
Figure imgf000536_0002
n the same manner as in Example 404, the title compound (86 mg, yield 36%) was obtained as a white amorphous solid from N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -IH- indol-7-yl]-N-methylpyridine-2-sulfonamide (200 mg) and pyrazolidin-3-one (123 mg) . MS:471 (MH+).
Example 488 N- {2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl]-5-methoxy-lH-indol-7-yl}-N-methylpyridine-2-sul-fonamide
Figure imgf000537_0001
In the same manner as in Example 473, the title compound (910 mg, yield 28%) was obtained as a white amorphous solid from N- [2- (benzylthio) -3, 3-dimethoxypropyl] -5-methoxy-7- [methyl (pyridin-2-ylsulfonyl) amino] -IH-indole-2-carboxamide (3.9 g) . MS: 477 (MH+) .
Example 489 N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -5- methoxy-lH-indol-7-yl] -N-methylpyridine-2-sulfonamide
Figure imgf000537_0002
In the same manner as in Example 469, the title compound (495 mg, yield 61%) was obtained as a yellow amorphous solid from N- {2- [5- (dimethoxymethyl) -4, 5-dihydro- l,3-thiazol-2-yl]-5-methoxy-lH-indol-7-yl}-N-methylpyridine-2- sulfonamide (910 mg)'. MS: 431 (MH+) . Example 490 N- (5-methoxy-2-{5- [ (1-oxidothiomorpholino) methyl] - 4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylpyridine- 2-sulfonamide
Figure imgf000537_0003
In the same manner as in Example 404, the title compound (101 mg, yield 50%) was obtained as white crystals from N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -5-methoxy- lH-indol-7-yl] -N-methylpyridine-2-sulfonamide (165 mg) and thiomorpholine 1-oxide hydrochloride (156 mg) . melting point
228°C. Example 491 N- (2-{5- [ (3-hydroxyazetidin-l-yl) methyl] -4, 5- dihydro-1 , 3-thiazol-2-yl } -5-methoxy- lH-indol-7-yl ) -N- methylpyridine-2-sulfonaitιide dihydrochloride
Figure imgf000538_0001
In the same manner as in Example 456, the title compound ( 106 mg, yield 50%) was obtained as yellow crystals from N- [2- ( 5-formyl-4 , 5-dihydro-l , 3-thiazol-2-yl ) -5-methoxy- lH-indol-7-yl] -N-methylpyridine-2-sulfonamide ( 165 mg) and 3- hydroxyazetidine ( 110 mg) . melting point 146°C . Example 492 N- ( 5-methoxy-2- { 5- [ ( 3-oxopyrazolidin-l-yl ) methyl ] - 4 , 5-dihydro-l, 3-thiazol-2-yl } -lH-indol-7-yl ) -N-methylpyridine- 2-sulfonamide dihydrochloride
Figure imgf000538_0002
In the same manner as in Example 456, the title compound (77 mg, yield 35%) was obtained as yellow crystals from N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -5-methoxy- lH-indol-7-yl] -N-methylpyridine-2-sulfonamide (165 mg) and pyrazolidin-3-one (123 mg) . melting point 168°C. Example 493 N- {5- (2-itιethoxyethoxy) -2- [5-
(thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol- 7-yl}-N-methylpyridine-2-sulfonamide
Figure imgf000538_0003
In the same manner as in Example 404, the title compound (52 mg, yield 33%) was obtained as white crystals from N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -5- (2- methoxyethoxy) -lH-indol-7-yl] -N-methylpyridine-2-sulfonamide (200 mg) and thiomorpholine (62 mg) . melting point 138°C. Example 494 (2-{3-fluoro-7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetic acid
Figure imgf000539_0001
To a solution of ethyl (2-{3-fluoro-7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl'}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetate (0.1 g) in tetrahydrofuran (1 mL) and ethanol (1 mL) was added 2N aqueous sodium hydroxide solution (0.15 mL) , and the mixture was stirred at room temperature for 1 hr, and then at 50°C for 1 hr. The mixture was acidified with IN hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried (MgSO,)) , and concentrated. The obtained residue was recrystallized from ethyl acetate to give the title compound (0.080 g, yield 85%) as colorless crystals, melting point 213- 214°C.
Example 495 2- (2- { 3-fluoro-7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetamide
Figure imgf000539_0002
To a solution of (2- {3-fluoro-7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl }-4, 5-dihydro-l, 3-thiazol- 5-yl) acetic acid (97.2 mg) in tetrahydrofuran (2 mL) and acetonitrile (2 mL) were added l-ethyl-3- (3- dimethylaminopropyl) carbodiimide hydrochloride (48 mg) and 1- hydroxybenzotriazole monohydrate (39 mg) , and the mixture was stirred at room temperature for 1 hr. Aqueous ammonia (28%, 2 mL) was added, and the mixture was stirred at room temperature for 30 min, and diluted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogencarbonate, water and saturated brine, dried over anhydrous magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (eluate : ethyl acetate), and the obtained solid was recrystallized (ethyl acetate-diisopropyl ether) to give the title compound (50.1 mg, yield 53%) as a colorless solid. melting point 204-205°C.
Example 496 N- (5- [ (IS) -2-methoxy-l-methylethoxyJ-2-{5- [ (1- oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol~2-yl}-lH- indol-7-yl ) -N-methylpyridine-2-sulfonamide
Figure imgf000540_0001
To a solution of N- {5- [ (IS) -2-methoxy-l-methylethoxy] - 2- [5- (thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -IH- indol-7-yl}-N-methylpyridine-2-sulfonamide (80 mg) in dichloromethane (2 mL) was added m-chloroperbenzoic acid (16 mg) under ice-cooling, and the mixture was stirred for 30 min. Aqueous sodium thiosulfate solution was added, and the mixture was diluted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was recrystallized (acetone-hexane-diisopropyl ether) to give the title compound (37.5 mg, yield 46%) as a colorless solid. melting point 175-176°C.
Example 497 N- {5- (2-hydroxyethoxy) -2- [5-
(thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol- 7-yl} -N-methylpyridine-2-sulfonamide
Figure imgf000540_0002
To a solution of ethyl ( {7- [methyl (pyridin-2- ylsulfonyl) amino] -2- [5- (thiomorpholinomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-5-yl}oxy) acetate (400 mg) in tetrahydrofuran (5 inL) was added lithium borohydride (18 mg) under ice-cooling, and the mixture was stirred at room temperature for 3 days . IN Hydrochloric acid was added under ice-cooling, and the mixture was basified with saturated aqueous sodium hydrogencarbonate, and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.' The residue was crystallized from ethyl acetate to give the title compound (205 mg, yield 55%) as a colorless solid. melting point 160-
162°C.
Example 498 N- ( 5- (2-hydroxyethoxy) -2- { 5- [ ( 1- oxidothiomorpholino) methyl ] -4 , 5-dihydro-l , 3-thiazol-2-yl } -lH- indol-7-yl ) -N-methylpyridine-2-sulfonamide
Figure imgf000541_0001
In the same manner as in Example 496, the title compound (59 mg, yield 45%) was obtained as yellow crystals from N- {5- (2-hydroxyethoxy) -2- [5- (thiomorpholinomethyl) -4, 5- dihydro-l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylpyridine-2- sulfonamide (102 mg) . melting point 160-162°C.
Example 499 N-methyl-N- [2-{ 5- [ (1-oxidothiomorpholino) methyl] - 4, 5-dihydro-l, 3-thiazol-2-yl}-5- (2-oxopropoxy) -lH-indol-7- yl ] pyridine-2-sulfonamide
Figure imgf000541_0002
In the same manner as in Example 496, the title compound (81 mg, yield 62%) was obtained as yellow crystals from N-methyl-N- {5- (2-oxopropoxy) -2- [5- (thiomorpholinomethyl) - 4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl }pyridine-2- sulfonamide (127 mg) . melting point 110-1120C. Example 500 ethyl ({ 7- [methyl (pyridin-2-ylsulfonyl) amino] -2- [5- (thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -IH- indol-5-yl}oxy) acetate
Figure imgf000542_0001
To a solution of N-{5-hydroxy'-2- [5-
( thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol- 7-yl}-N-methylpyridine-2-sulfonamide (800 mg) in N, N- dimethylformamide (10 mL) were added potassium carbonate (264 mg) and ethyl bromoacetate (0.18 mL) , and the mixture was stirred at 50°C for 6 hr. The mixture was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane: ethyl acetate=85: 15-0 : 1) to give the title compound (724 mg, yield 76%) as a pale-yellow powder. MS: 590 (MH+) .
Example 501 N-methyl-N- {5- (2-oxopropoxy) -2- [5- ( thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -IH-indol- 7-yl }pyridine-2-sulf onamide
Figure imgf000542_0002
In the same manner as in Example 500, the title compound (456 mg, yield 79%) was obtained as a pale-yellow powder from N- {5-hydroxy-2- [5- (thiomorpholinomethyl) -4, 5- dihydro-1, 3-thiazol-2-yl] -lH-indol-7-yl}-N-methylpyridine-2- sulfonamide (517 mg) and bromoacetone (205 mg) . MS: 560 (MH+). Example 502 ({ 7- [methyl (pyridin-2-ylsulfonyl) amino] -2- [5- (thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol- 5-yl}oxy) acetic acid
Figure imgf000543_0001
To a solution of ethyl ( {7- [methyl (pyridin-2- ylsulfonyl) amino] -2- [5- (thiomorpholinomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl]-lH-indol-5-yl}oxy) acetate (275 mg) in tetrahydrofuran (2 πiL) and ethanol (2 πiL) was added IN aqueous sodium hydroxide solution (0.70 mL) , and the mixture was stirred overnight at room temperature. The organic solvent was evaporated under reduced pressure, and the residue was neutralized with IN hydrochloric acid. The mixture was extracted with a mixed solvent of tetrahydrofuran-ethyl acetate, and the combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was crystallized from ethyl acetate to give the title compound (137 mg, yield 53%) as colorless crystals, melting point 132-
134°C.
Example 503 2- ( { 7- [methyl (pyridin-2-ylsulfonyl ) amino ] -2- [ 5- (thiomorpholinomethyl) -4 , 5-dihydro-l , 3-thiazol-2-yl ] -lH-indol- 5-yl } oxy) acetamide
Figure imgf000543_0002
In the same manner as in Example 495, the title compound (31.7 mg, yield 30%) was obtained as colorless crystals from ( {7- [methyl (pyridin-2-ylsulfonyl) amino] -2- [5- (thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol- 5-yl}oxy) acetic acid (100 mg) . melting point 192-193°C.
Example 504 2- [ (7- [methyl (pyridin-2-ylsulfonyl) amino] -2- { 5- [ (1-oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl }- lH-indol-5-yl) oxy] acetamide
Figure imgf000544_0001
To a solution of 2- ( {7- [methyl (pyridin-2- ylsulfonyl) amino] -2- [5- (thiomorpholinomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -lH-indol-5-yl}oxy) acetamide (31.7 mg) in tetrahydrofuran (1 mL) and ethanol (1 mL) were added water (1 πiL) and OXONE (registered trade mark, 20 mg) , and the mixture was stirred at room temperature for 3 hr. Aqueous sodium thiosulfate solution was added, and the mixture diluted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was crystallized from ethyl acetate-diisopropyl ether to give the title compound (15.7 mg, yield 48%) as colorless crystals. melting point 160-1610C.
Example 505 N- {5- [ (IS) -2-methoxy-l-methylethoxy] -2- [5- (thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -IH-indol- 7-yl}-N-methylpyridine-2-sulfonamide
Figure imgf000544_0002
To a solution of N-{5-hydroxy-2- [5-
(thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -IH-indol- 7-yl}-N-methylpyridine-2-sulfonamide (145 mg) in toluene (2 mL) and tetrahydrofuran (1 mL) were, added tributylphosphine (0.22 mL) , (2R) -l-methoxypropan-2-ol (0.057 mL) and 1,1'- (azodicarbonyl) dipiperidine (220 mg) , and the mixture was stirred at 80°C for 3 hr, and concentrated. The residue was diluted with ethyl acetate, and subjected to basic silica gel column chromatography (eluate : ethyl acetate), and the obtained crude product was purified by silica gel column chromatography (hexane : ethyl acetate=3: 1-1 :2) to give the title compound (80 mg, yield 48%) as a colorless powder. MS: 576 (MH+) . Example 506 ethyl 1- [ (2-{7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) methyl] -lH-imidazole-2-carboxylate
Figure imgf000545_0001
A mixture of (2- {7- [methyl (pyridin-2-ylsulfonyl) amino] - lH-indol-2-yl}-4/ 5-dihydro-l, 3-thiazol-5-yl) methyl methanesulfonate (250 mg) , ethyl lH-imidazole-2-carboxylate (146 mg) , potassium carbonate (144 mg) and N, N- dimethylformamide (5 πiL) was stirred at 60°C for 4.5 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The residue was silica gel column chromatography (ethyl acetate :hexane=15: 85-100: 0) to give the title compound (227 mg, yield 83%) as a orange oil MS: 525 (MH+) .
Figure imgf000545_0002
(3H, t, J=7.2 Hz), 3.33 (3H, s) , 4.25-4.39 (2H, m) , 4.38-4.52 (4H, m) , 4.64 (IH, dd, J=13.1 Hz, 5.9 Hz), 6.96 (IH, d, J=2.3 Hz), 7.08 (IH, t, J=7.8 Hz), 7.12-7.23 (3H, m) , 7.56-7.67 (2H, m) , 7.92-8.03 (IH, m) , 8.04-8.13 (IH, m) , 9.08 (IH, d, J=4.2 Hz), 12.07 (IH, brs) .
Example 507 N- [2- [5- (dimethoxymethyl) -4, 5-dihydro-l, 3-thiazol- 2-yl] -5- (2-methoxyethoxy) -lH-indol-7-yl] -N, 1-dimethyl-lH- imidazole-2-sulfonamide
Figure imgf000546_0001
Triphenylphosphine oxide (0.9 g) was dissolved in dichloromethane (10 πiL) ,' trifluoromethanesulfonic anhydride (0.55 inL) was added under ice-cooling, and the mixture was stirred for 10 min. A solution of N- [2- (benzylthio) -3, 3- diitιethoxypropyl]-5- (2-methoxyethoxy) -7- {methyl [ (1-methyl-lH- imidazol-2-yl) sulfonyl] amino} -IH-indole-2-carboxamide (1.9 g) and thioanisole (0.7 mL) in dichloromethane (10 inL) was added dropwise under ice-cooling, and the mixture was stirred for 25 min, and then at room temperature for 1 hr. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The residue was silica gel column chromatography (ethyl acetate :hexane=10: 90-80:20) to give the title compound (620 mg, yield 39%) as a colorless oil.
1H-NMR(CDCI3)OIS^I (3H, s) , 3.43 (3H, s) , 3.46 (3H, s) , 3.48 (3H, s), 3.74-3.77 (2H, m) , 3.80 (3H, s) , 4.10-4.15 (3H, m) , 4.32-4.40 (2H, m) , 4.50-4.57 (IH, m) , 6.82 (IH, d, J=2.1 Hz), 6.95 (IH, s), 6.99 (IH, d, J=2.1 Hz), 7.10 (IH, d, J=2.1 Hz), 7.23 (IH, d, J=O.9 Hz), 12.1 (IH, brs) .
Example 508 N- [2- (5-{ [2- (hydroxymethyl) -lH-imidazol-1- yl]methyl} -4, 5-dihydro-l, 3-thiazol-2-yl) -lH-indol-7-yl] -N- methylpyridine-2-sulfonamide
Figure imgf000546_0002
Ethyl l-[ (2- {7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indol-2-yl }-4, 5-dihydro-l, 3-thiazol-5-yl) methyl] -lH-imidazole- 2-carboxylate (220 mg) was dissolved in a mixed solvent of tetrahydrofuran (8 mL) and methanol (4 πiL) , lithium borohydride (27 mg) was added, and the mixture was stirred at room temperature for 1 hr. Lithium borohydride (20 mg) was added, and the mixture was stirred at room temperature for 24 hr. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The residue was silica gel column chromatography (methanol : ethyl acetate=0 : 100-15: 85) to give the title compound (38 mg, yield 19%) as a white solid. MS:482(MH+).
1H-NMR (CDCl3) δ: 3.33 (3H, s) , 4.13 (2H, t, J=6.6 Hz), 4.22-4.44
(2H, m) , 4.52 (IH, d, J=15.1 Hz), 4.74 (2H, s) , 6.90-7.04 (3H, m) , 7.09 (IH, t, J=7.8 Hz), 7.14-7.22 (IH, m) , 7.62 (2H, d,
J=8.3 Hz), 7.91-8.03 (IH, m) , 8.04-8.14 (IH, m) , 9.07 (IH, d,
J=4.2 Hz) , 12.10 (IH, s) .
Example 509 N- (5- (2-methoxyethoxy) -2- {5- [ (1- oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl }-lH- indol-7-yl) -N, l-dimethyl-lH-imidazole-2-sulfonamide
Figure imgf000547_0001
To a mixture of N- [2- [5- (dimethoxymethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] -5- (2-methoxyethoxy) -lH-indol-7-yl] -N, 1- dimethyl-lH-imidazole-2-sulfonamide (280 mg) , trifluoroacetic acid (3.5 mL) and water (10.5 mL) was added concentrated sulfuric acid (3.5 mL) , and the mixture was stirred at 60°C for 3.5 hr. The excess trifluoroacetic acid was evaporated under reduced pressure, and the residue was neutralized with sodium hydrogencarbonate. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained crude product was dissolved in tetrahydrofuran (10 mL) , thiomorpholine 1-oxide hydrochloride (103 mg) and triethylamine (0.1 mL) were added, and the mixture was stirred at room temperature for 15 min. Sodium triacetoxyborohydride (233 mg) was added, and the mixture was stirred at room temperature for 16 hr. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The residue was silica gel column chromatography (methanol : ethyl acetate=0: 100-10: 90) , and the obtained crude product was further purified by preparative HPLC to give the title compound (56 mg, yield 18%) as a white solid. MS: 581 (MH+). 1H-NMR (CDCl3) 5:2.62-2.65 (2H, m) , 2.71-2.94 (6H, m) , 3.10-3.22 (2H, m), 3.46 (3H, s) , 3.48 (3H, s) , 3.52-3.77 (2H, m) , 3.80 (3H, s), 4.06-4.15 (3H, m) , 4.29-4.46 (2H, m) , 6.82 (IH, d, J=2.1 Hz), 6.96 (IH, d, J=O.9 Hz), 6.99 (IH, d, J=2.1 Hz), 7.10 (IH, d, J=2.4 Hz), 7.23 (IH, d, J=O .9 Hz), 12.10 (IH, s). Example 510 N- [2- [ 5- (hydroxymethyl ) -4 , 5-dihydro-l , 3-thiazol-2- yl ] -5- (2-methoxyethoxy) -lH-indol-7-yl ] -N, 1-dimethyl-lH- imidazole- 2 -sulfonamide
Figure imgf000548_0001
To a mixture of N- [2- [5- (dimethoxymethy1) -4, 5-dihydro- 1, 3-thiazol-2-yl] -5- (2-methoxyethoxy) -lH-indol-7-yl] -N, 1- dimethyl-lH-imidazole-2-sulfonamide (335 mg) , trifluoroacetic acid (4 mL) and water (12 mL) was added concentrated sulfuric acid (4 mL) , and the mixture was stirred at 60°C for 2 hr. The excess trifluoroacetic acid was evaporated under reduced pressure, and the residue was neutralized with sodium hydrogencarbonate. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained, crude product was dissolved in a mixed solvent of tetrahydrofuran (3 iαL) and ethanol (2 mL) , and sodium borohydride (26.5 mg) was added under ice-cooling. The reaction solution was stirred at room temperature for 2 hr, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with IN hydrochloric acid, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The residue was silica gel column chromatography (ethyl acetate :hexane=20: 80-90:10) , and the obtained crude product was further purified by preparative HPLC to give the title compound (30.8 mg, yield 10%) as a white solid. MS: 480 (MH+) .
1H-NMR (CDCl3) δ: 3.47 (3H, s) , 3.49 (3H, s) , 3.61-3.73 (2H, m) , 3.74-3.80 (2H, m) , 3.81 (3H, s) , 4.11-4.18 (3H, m) , 4.32-4.43 (IH, m), 4.49-4.58 (IH, m) , 6.84 (IH, d, J=2.1 Hz), 6.97 (IH, s), 7.01 (IH, d, J=2.3 Hz), 7.12 (IH, d, J=2.3 Hz), 7.24 (IH, s) , 12.19 (IH, s) .
Example 511 N- {5- (2-methoxyethoxy) -2- [5- (morpholinomethyl) - 4,5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7-yl}-N, 1-dimethyl-lH- imidazole-2-sulfonamide
Figure imgf000549_0001
To a mixture of N- [2- [5- (dimethoxymethyl) -4, 5-dihydro- 1, 3-thiazol-2-yl] -5- (2-methoxyethoxy) -lH-indol-7-yl] -N, 1- dimethyl-lH-imidazole-2-sulfonamide (580 mg) , trifluoroacetic acid (7 mL) and water (14 mL) was added concentrated sulfuric acid (7 mL) , and the mixture was stirred at 60°C for 3 hr. The excess trifluoroacetic acid was evaporated under reduced pressure, and the residue was neutralized with sodium hydrogencarbonate. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The obtained crude product was dissolved in tetrahydrofuran (15 mL) , morpholine (0.1 mL) was added, and the mixture was stirred at room temperature for 15 min. Sodium triacetoxyborohydride (466 mg) was added, and the mixture was stirred for 1 hr. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate . The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The residue was subjected to basic silica gel column chromatography (ethyl acetate :hexane=10: 90-80:20) to give the title compound (183.5 mg, yield 30%) as a white solid. 1H-NMR (CDCl3) 5:2.47-2.54 (4H, m) , 2.54-2.59 (2H, m) , 3.46 (3H, s), 3.49 (3H, s), 3.68-3.79 (6H, m) , 3.80 (3H, s) , 4.08-4.17 (3H, m) , 4.29-4.50 (2H, m) , 6.83 (IH, d, J=I .9 Hz), 6.96 (IH, s), 6.99 (IH, d, J=2.3 Hz), 7.11 (IH, d, J=2.3 Hz), 7.24-7.26 (IH, m) . Example 512 N- [5- (2-methoxyethoxy) -2- ( 8-oxa-l-thia-3- azaspiro [4 . 5] dec-2-en-2-yl ) -lH-indol-7-yl] -N-methylpyridine-2- sulfonamide
Figure imgf000550_0001
Triphenylphosphine oxide (0.63 g) was dissolved in dichloromethane (2 mL) , trifluoromethanesulfonic anhydride (0.38 mL) was added under ice-cooling, and the mixture was stirred for 10 min. A solution of N- { [4- (benzylthio) tetrahydro-2H-pyran-4-yl]methyl} -5- (2- methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carboxamide (0.71 g) and thioanisole (0.27 mL) in dichloromethane (8 mL) was added dropwise, and the mixture was stirred for 1 hr under ice-cooling. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure. The residue was subjected to basic silica gel column chromatography (ethyl acetate:hexane=10: 90-80:20) , and the obtained crude product was purified by preparative HPLC to give a white' solid (108.6 mg) as a crude product. The white solid was dissolved in a small amount of ethyl acetate, and an excess amount of 4N hydrogen chloride-ethyl acetate solution was added. The mixture was concentrated under reduced pressure, and the obtained white solid was washed with a small amount of ethyl acetate, and collected by filtration. The obtained solid was suspended in ethyl acetate, and the mixture was neutralized with saturated aqueous sodium hydrogencarbonate solution. The aqueous layer was extracted with ethyl acetate, and the combined organic layer was dried over magnesium sulfate, and filtrated, and the filtrate was concentrated under reduced pressure to give the title compound (85 mg, yield 15%) as a white solid. MS: 517 (MH+).
1H-NMR (CDCl3) 5:1.94-2.04 (4H, m) , 3.30-3.32 (3H, m) , 3.45-3.47 (3H, m), 3.55-3.68 (2H, m) , 3.72-3.79 (2H, m) , 3.94-4.05 (2H, m) , 4.09-4.14 (2H, m) , 4.22-4.23 (2H, m) , 6.82 (IH, d, J=2.1 Hz), 6.90 (IH, d, J=2.3 Hz), 7.06 (IH, d, J=2.1 Hz), 7.57-7.63 (IH, m) , 7.89-8.00 (IH, m) , 8.00-8.08 (IH, m) , 9.02-9.09 (IH, m) , 11.72 (IH, brs) .
Example 513 N- [5- (2-methoxyethoxy) -2- (8-oxido-l, 8-dithia-3- azaspiro [4.5] dec-2-en-2-yl) -lH-indol-7-yl] -N-methylpyridine-2- sulfonamide
Figure imgf000551_0001
To a solution of N- [2- (1, 8-dithia-3-azaspiro [4.5]dec-2- en-2-yl) -5- (2-methoxyethoxy) -lH-indol-7-yl] -N-methylpyridine- 2-sulfonamide (50.7 mg) in methanol (2 mL) , water (1 mL) and dichloromethane (1 mL) was added OXONE (registered trade mark, 29 mg) at room temperature, and the mixture was stirred for 18 hr. Aqueous sodium sulfite solution was added to the reaction mixture, and the mixture was stirred for 30 min.' The organic solvent was evaporated under reduced pressure. The residue was extracted with ethyl acetate, and the organic layer was washed with water and saturated brine, dried (MgSO4) , and concentrated. The residue was subjected to basic silica gel column chromatography, and eluted with ethyl acetate to give two steric isomer (10.3 mg, yield 20% (retention time: shorter), and 1.7 mg, yield 3% (retention time: longer)) of the title compound as a colorless amorphous solid, respectively.
(retention time: shorter) 1H-NMR(CDCl3) δ: 2.08-2.17 (2H, m) , 2.68-2.81 (4H, m) , 3.05-3.21 (2H, m) , 3.28 (3H, s) , 3.46 (3H, s), 3.65-3.82 (2H, m) , 4.06-4.18 (2H, m) , 4.28 (2H, s) , 6.79 ' (IH, d, J=I.9 Hz), 6.95 (IH, d, J=2.3 Hz), 7.07 (IH, d, J=I .9 Hz), 7.60-7.65 (IH, m) , 7.98 (IH, td, J=7.8, 1.9 Hz), 8.06- 8.11 (IH, m) , 9.06 (IH, d, J=4.9 Hz), 11.98 (IH, d, J=I .5 Hz).
(retention time: longer) 1H-NMR(CDCl3) δ: 1.98-2.25 (2H, m) , 2.53-2.64 (2H, m) , 2.96 (2H, t, J=IO.6 Hz), 3.14-3.28 (2H, m) , 3.31 (3H, s), 3.46 (3H, s) , 3.74-3.78 (2H, m) , 4.06-4.16 (2H, m) , 4.26 (2H, s) , 6.84 (IH, d, J=I .9 Hz), 6.90 (IH, d, J=2.3 Hz), 7.07 (IH, d, J=2.3 Hz), 7.60 (IH, dd, J=8.3, 5.3 Hz), 7.95 (IH, t, J=6.8 Hz), 8.00-8.17 (IH, m) , 9.02 (IH, d, J=3.8 Hz) , 11.66 (IH, brs) . Example 514 N- [2-{5- [ (1, 1-dioxidothiomorpholino) methyl] -4, 5- dihydro-l,3-thiazol-2-yl} -5- (2-methoxyethoxy) -lH-indol-7-yl] - N-methylpyridine-2-sulfonamide
Figure imgf000552_0001
To a solution of N- [2- (5-formyl-4, 5-dihydro-l, 3- thiazol-2-yl) -5- (2-methoxyethoxy) -lH-indol-7-yl] -N- methylpyridine-2-sulfonamide (200 mg) and thiomorpholine 1,1- oxide (81 mg) in acetic acid (5 πiL) was added sodium triacetoxyborohydride (212 mg) at room temperature, and the mixture was stirred for 10 min. The reaction mixture was neutralized with saturated aqueous sodium hydrogencarbonate solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to basic silica gel column chromatography to give the title compound (128 mg, yield 50%) as white crystals from a fraction eluted with ethyl acetate, melting point 115°C. MS:594 (MH+). Example 515 N- {5- (2-methoxyethoxy) -2- [5- (morpholinomethyl) - 4, 5-dihydro-l, 3-thiazol-2-yl]-lH-indol-7-yl}-N-methylpyridine- 2-sulfonamide dihydrochloride
Figure imgf000553_0001
In the same manner as in Example 456, the title compound (130 mg, yield 50%) was obtained as yellow crystals from N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -5- (2- methoxyethoxy) -lH-indol-7-yl] -N-methylpyridine-2-sulfonamide
(200 mg) and morpholine (80 mg) . melting point 165°C. Example 516 N- [2-{5- [ (3-hydroxyazetidin-l-yl) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-5- (2-methoxyethoxy) -lH-indol-7-yl] - N-methylpyridine-2-sulfonamide dihydrochloride
Figure imgf000553_0002
In the same manner as in Example 456, the title compound (60 mg, yield 28%) was obtained as yellow crystals from N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol-2-yl) -5- (2- methoxyethoxy) -lH-indol-7-yl] -N-methylpyridine-2-sulfonamide
(200 mg) and 3-hydroxyazetidine (100 mg) . melting point 16O0C. Example 517 N- [2- (5-{ [ (2-hydroxyethyl) (methyl) amino] methyl }- 4, 5-dihydro-l, 3-thiazol-2-yl) -5- (2-methoxyethoxy) -lH-indol-7- yl] -N-methylpyridine-2-sulfonamide dihydrochloride
Figure imgf000554_0001
In the same manner as in Example 438, the title compound (110 mg, yield 28%) was obtained as yellow crystals from (2- {5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) methyl methanesulfonate (200 mg) and 2- (methylamino) ethanol (60 mg) . MS: 534 (MH+) .
Example 518 N-methyl-N- (2-{ 5- [ (3-oxopyrrolidin-l-yl) methyl] - 4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) pyridine-2- sulfonamide dihydrochloride
Figure imgf000554_0002
To a mixture of N- [2- (5-formyl-4, 5-dihydro-l, 3-thiazol- 2-yl)-lH-indol-7-yl] -N-methylpyridine-2-sulfonamide (200 mg) , pyrrolidin-3-one hydrochloride (120 mg) , triethylamine (150 μL) and tetrahydrofuran (5 inL) was added sodium triacetoxyborohydride (210 mg) , and the mixture was stirred at room temperature for 10 min. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography to give a colorless oil from a fraction eluted with ethyl acetate. The colorless oil was dissolved in ethyl acetate (3 mL) , and 4N hydrogen chloride-ethyl acetate solution (1 mL) was added. The precipitated solid was collected by filtration, washed with diethyl ether, and dried to give the title compound (110 mg, yield 40%) as a yellow amorphous solid. MS: 470 (MH+). Example 519 N- { 5-bromo-2- [5- (morpholinomethyl) -4, 5-dihydro- l,3-thiazol-2-yl]-lH-indol-7-yl}-N-methylpyridine-2- sulfonamide
Figure imgf000555_0001
In the same manners as in Reference Example 178 and Reference Example 179, the title compound (128 mg, yield 46%) was obtained as white crystals from 5-bromo-2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol-7- amine (200 mg) . melting point 232°C.
Example 520 2- {2- [7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yljacetamide
Figure imgf000555_0002
2- {2- [7- [Methyl (2-thienylsulfonyl) amino] -5-
(trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yljacetamide (140 mg) was dissolved in hexane-ethanol (850:150, volume ratio, 700 mL) . This solution was subjected to HPLC using CHIRALPAK AD (50mmIDx500mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with hexane-ethanol
(850:150, volume ratio) as a mobile phase at 35°C at flow rate of 75 mL/min. A fraction with the retention time of 1 hr and 39 min was separated, and concentrated. The obtained solid was crystallized from ethyl acetate-hexane to give the title compound (67 mg) as colorless crystals, melting point 202- 203°C. Example 521 ethyl {2- [7- [ (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5- yl } acetate
Figure imgf000556_0001
A mixture of 7- [ (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) -lH-indole-2-carboxamide (2.14 g) , Lawesson' s reagent (2.14 g) and tetrahydrofuran (50 inL) was stirred at 50°C for 1.5 hr, and heated under reflux for 1.5 hr. The reaction mixture was concentrated, and the residue was washed with diisopropyl ether to give pale-yellow crystals. The obtained crystals were subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-1:2, volume ratio) to give yellow crystals. A mixture of the obtained crystals, ethyl but-2-ynoate (1.49 g) , tributylphosphine (1.07 g) , toluene (30 mL) and tetrahydrofuran (10 mL) was stirred at 700C for 5 hr. ethyl but-2-ynoate (900 mg) and tributylphosphine (1.07 g) were added to the mixture, and the- mixture was further stirred at room temperature for 2.5 days . The reaction mixture was concentrated, and the residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-1:3, volume ratio) to give the title compound (780 mg, yield 28%) as a brown oil. 1H-NMR(CDCl3)0: 1.28 (3H, t, J=6.44 Hz), 2.73 (2H, d, J=6.82 Hz), 4.15-4.26 (2H, m) , 4.27-4.49 (3H, m) , 6.68 (IH, s) , 6.89 (IH, s), 6.91-6.99 (IH, m) , 7.32-7.43 (2H, m) , 7.52 (IH, d, J=4.92 Hz) , 10.05 (IH, brs) .
Example 522 ethyl (2-{5- (2-methoxyethoxy) -7- [methyl (2- thienylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol- 5-yl) acetate
Figure imgf000557_0001
A mixture of 5- (2-methoxyethoxy) -7- [methyl (2- thienylsulfonyl) amino] -IH-indole-2-carboxamide (920 mg) , Lawesson' s reagent (690 mg) and tetrahydrofuran (20 mL) was stirred at 50°C for 2 hr. The reaction mixture was concentrated, and the residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (2:1-1:9, volume ratio) to give a yellow amorphous solid. A mixture of the obtained amorphous solid, ethyl but-2-ynoate (620 mg) , tributylphosphine (450 mg) , toluene (30 mL) and tetrahydrofuran (15 mL) was stirred at 50°C for 1 hr. The reaction mixture was concentrated, and the residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-1:1, volume ratio). The obtained compound was further subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (1:1, volume ratio) to give the title compound (500 mg, yield 42%) as a yellow oil .
1H-NMR(CDCl3)O:!^ (3H, t, J=7.16 Hz), 2.65-2.77 (2H, m) , 3.27 (3H, s), 3.43 (3H, s) , 3.66-3.74 (2H, m) , 4.01-4.09 (2H, m) ,
4.14-4.49 (5H, m) , 6.35 (IH, d, J=2.26 Hz), 6.81 (IH, d,
J=2.07 Hz), 7.03 (IH, d, J=2.07 Hz), 7.11 (IH, dd, J=4.99,
3.86 Hz), 7.40 (IH, dd, J=3.77, 1.13 Hz), 7.62 (IH, dd, J=5.09,
1.32 Hz) , 9.39 (IH, brs) . Example 523 ethyl (2- { 5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazol-5- yl) acetate
Figure imgf000557_0002
A mixture of 5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indole-2-carboxamide (2.28 g) , Lawesson's reagent (1.70 g) and tetrahydrofuran (50 mL) was stirred at 50°C for 2 hr. The reaction mixture was concentrated, the residue was crystallized from diisopropyl ether-toluene, and the crystals were collected by filtration. A mixture of the obtained crystals, ethyl but-2-ynoate (1.57 g) , tributylphosphine (1.13 g) , toluene (100 mL) and tetrahydrofuran (100 mL)' was stirred at 50°C for 4 hr. The reaction mixture was concentrated, and the residue was subjected to basic silica gel column' chromatography, and eluted with hexane-ethyl acetate (1:1-1:9, volume ratio). The obtained compound was further subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (1:1-1:9, volume ratio) to give the title compound (1.57 g, yield 53%) as a brown oil.
1H-NMR (CDCl3) δ: 1.28 (3H, t, J=7.16 Hz), 2.67-2.77 (2H, m) , 3.31 (3H, s), 3.46 (3H, s) , 3.71-3.78 (2H, m) , 4.04-4.24 (4H, m) ,
4.27-4.55 (3H, m) , 6.83 (IH, d, J=2.07 Hz), 6.91 (IH, d,
J=2.07 Hz), 7.06 (IH, d, J=2.07 Hz), 7.54-7.66 (IH, m) , 7.86-
8.00 (IH, m) , 8.01-8.09 (IH, m) , 9.00-9.09 (IH, m) , 11.75 (IH, brs) . Example 524 N- { 2- [ 5- (dimethoxymethyl ) -4, 5-dihydro-l, 3-thiazol-
2-yl] -5- [3- (methylsulfonyl ) propoxy] -lH-indol-7-yl } -N- methylpyridine-2-sulfonamide
Figure imgf000558_0001
A mixture of triphenylphosphine oxide (1.17 g) , trifluoromethanesulfonic anhydride (1.18 g) and dichloromethane (30 mL) was stirred for 15 min under ice- cooling. A solution of N- [2- (benzylthio) -3, 3-dimethoxypropyl] - 7- [methyl (pyridin-2-ylsulfonyl) amino] -5- [3-
(methylsulfonyl)propoxy]-lH-indole-2-carboxamide (2.65 g) and thioanisole (940 mg) in dichloromethane (10 mL) was added dropwise to the reaction mixture under ice-cooling, and the mixture was stirred for 30 min under ice-cooling. The reaction mixture was diluted with ethyl acetate, and extracted with 3N hydrochloric acid. The aqueous layer was alkalified with 2N aqueous sodium hydroxide solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (2:8-1:9, volume ratio) to give the title compound (840 mg, yield 38%) as a colorless amorphous solid. 1H-NMR (CDCl3) 6:2.25-2.44 (2H, m) , 2.96 (3H, s) , 3.18-3.33 (2H, m) , 3.29 (3H, s), 3.43 (3H, s) , 3.45 (3H, s) , 4.07-4.22 (3H, m) , 4.33-4.46 (2H, m) , 4.52-4.64 (IH, m) , 6.83 (IH, d, J=I.89 Hz), 6.89 (IH, d, J=2.27 Hz), 7.05 (IH, d, J=2.27 Hz), 7.62 (IH, dd, J=6.44, 4.92 Hz), 7.93-8.03 (IH, m) , 8.06-8.13 (IH, • m) , 9.09 (IH, d, J=3.79 Hz), 11.98 (IH, brs) . Example 525 N- {5- (3-methoxypropoxy) -2- [5-
(thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol- 7-yl} -N-methylpyridine-2-sulfonamide
Figure imgf000559_0001
To a mixture of triphenylphosphine oxide (610 mg) and acetonitrile (10 mL) was added trifluoromethanesulfonic anhydride (310 mg) at 2°C, and the mixture was stirred at 0-50C for 30 min. A solution of• N- [2- (benzylthio) -3- thiomorpholinopropyl] -5- (3-methoxypropoxy) -7- [methyl (pyridin- 2-ylsulfonyl) amino] -lH-indole-2-carboxamide (380 mg) and thioanisole (140 mg) in acetonitrile (10 mL) was added dropwise to the reaction mixture at 0-5°C, and the mixture was stirred at 0-50C for 30 min. The reaction mixture was poured into saturated aqueous sodium hydrogencarbonate, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was extracted with concentrated hydrochloric acid (10 mL
X3), and the hydrochloric acid layers were combined, and washed with ethyl acetate. The aqueous layer was basified with potassium carbonate/ and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSOJ, and concentrated. The obtained residue was subjected to basic silica gel column chromatography, and eluted with hexane-ethyl acetate (9:1-1:2, volume ratio) to give the title compound (110 mg, yield 34%) as a colorless oil. 1H-My[R (CJDCl3) δ: 1.96-2.12 (2H, m) , 2.50-2.86 (1OH, m) , 3.31 (3H, s), 3.36 (3H, s), 3.56 (2H, t, J=6.25 Hz), 3.97-4.18 (3H, m) , 4.27-4.50 (2H, m) , 6.83 (2H, dd, J=I .16, 2.08 Hz), 7.06 (IH, d, J=I.89 Hz), 7.54-7.64 (IH, m) , 7.89-7.99 (IH, m) , 8.01-8.09 (IH, in), 9.07 (IH, d, J=4.16 Hz), 11.72 (IH, brs) . Example 526 N- (5- (3-methoxypropoxy) -2-{5- [ (1- oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl}-lH- indol-7-yl) -N-methylpyridine-2-sulfonamide
Figure imgf000560_0001
To a mixture of N- {5- (3-methoxypropoxy) -2- [5-
(thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol- 7-yl} -N-methylpyridine-2-sulfonamide (110 mg) , methanol (3 mL) , water (3 mL) and tetrahydrofuran (3 mL) was added OXONE (registered trade mark, 60 mg) at room temperature, and the mixture was stirred at room temperature for 1 hr. Aqueous sodium sulfite solution was added to the reaction mixture, and the mixture was stirred for 30 min, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO<i), and concentrated. The residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-methanol (100:0-90:10, volume ratio). The obtained crystals were washed with diisopropyl ether to give the title compound (35 mg, yield 32%) as colorless crystals. The crystals were recrystallized from acetone-hexane to give colorless prism crystals, melting point 176-177°C.
Example 527 N- [2- {5- [ (1, 1-dioxidothiomorpholino) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-5- (2-methoxyethoxy) -lH-indol-7-yl] - N-methylpyridine-2-sulfonamide
Figure imgf000561_0001
N- [2- { 5- [ ( 1, 1-Dioxidothiomorpholino) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-5- (2-methoxyethoxy) -lH-indol-7-yl] - N-methylpyridine-2-sulfonamide (48 mg) was dissolved in methanol (48 mL) . This solution was subjected to supercritical fluid chromatography using CHIRiYLPAK AS-H (manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with carbon dioxide-methanol (550:450, volume ratio) as a mobile phase at 100 bar at 35°C at flow rate of 50 mL/min. A fraction with the retention time of 7.5 min was separated, and concentrated. The obtained solid was crystallized from ethyl acetate-hexane, and the obtained crystals were washed with hexane to give the title compound (13 mg) as pale-yellow crystals, melting point 113-116°C.
Example 528 N- [2-{ 5- [ (1, 1-dioxidothiomorpholino) methyl] -4, 5- dihydro-1, 3-thiazol-2-yl}-5- (2-methoxyethoxy) -lH-indol-7-yl] - N-methylpyridine-2-sulfonamide
Figure imgf000561_0002
N- [2-{5-[ (1, 1-Dioxidothiomorpholino) methyl] -4,5- dihydro-1, 3-thiazol-2-yl}-5- (2-methoxyethoxy) -lH-indol-7-yl] - N-methylpyridine-2-sulfonamide (48 mg) was dissolved in methanol (48 mL) . This solution was subjected to supercritical fluid chromatography using CHIRALPAK AS-H (manufactured by DAICEL CHEMICAL INDUSTRIES, LTD.), and eluted with carbon dioxide-methanol (550:450, volume ratio) as a mobile phase at
100 bar at 350C at flow rate of 50 mL/min. A fraction with the retention time of 8.5 min was separated, and concentrated. The obtained solid was crystallized from diethyl ether-ethyl acetate to give the title compound (15.7 mg) as colorless crystals, melting point 164.6-166.7°C. Example 529 N- {5- (2-methoxyethoxy) -2- [5-methyl-5- (thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol- 7-yl } -N-methylpyridine-2-sulfonamide
Figure imgf000562_0001
To a mixture of triphenylphosphine oxide (178 mg) and dichloromethane (8 mL) was added trifluoromethanesulfonic anhydride (0.11 mL) at 0°C, the mixture was stirred at 0°C for 15 min, and dichloromethane (4 mL) was added. A mixture of N- [2- (benzylthio) -2-methyl-3-thiomorpholinopropyl] -5- (2- methoxyethoxy) -7- [methyl (pyridin-2-ylsulfonyl) amino] -IH- indole-2-carboxamide (220 mg) , thioanisole (0.075 mL) and dichloromethane (3 mL) was added to the reaction solution at -
78°C, and the mixture was stirred at -78°C for 10 min. Aqueous sodium bicarbonate was added, and the mixture was extracted with dichloromethane. The extract was washed with saturated brine, dried over sodium sulfate, and filtrated, and the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and eluted with ethyl acetate. The obtained amorphous solid was purified1 by preparative HPLC to give the title compound (28 mg, yield 15%) as a colorless amorphous solid.
IH-NMR (CDCl3) δ: 1.56 (3H, s) , 2.60-2.75 (6H, m) , 2.82-2.98 (4H, m) , 3.32 (3H, s) , 3.45 (3H, s) , 3.73-3.80 (2H, m) , 4.01 (IH, d, J=15.9 Hz), 4.07-4.15 (2H, m) , 4.19 (IH, d, J=15.9 Hz), 6.78 (IH, d, J=I .9 Hz) , 6.86 (IH, d, J=2 . 3 Hz ) , 7 .05 (IH, d, J=2 .3 Hz ) , 7 .58 ( IH, dd, J=6.2, 4 .7 Hz ) , 7 . 85-7. 98 ( IH, m) , 7. 98- 8 . 07 ( IH, m) , 9. 03 ( IH, d, J=4 .2 Hz) , 11 .54 ( IH, brs ) . Example 530 N- [5- (2-methoxyethoxy) -2- { 5-methyl-5- [ (1- oxidothiomorpholino) methyl ] -4, 5-dihydro-l, 3-thiazol-2-yl }-lH- indol-7-yl ] -N-methylpyridine-2-sulf onamide
Figure imgf000563_0001
To a mixture of N- {5- (2-methoxyethoxy) -2- [5-methyl-5- (thiomorpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -lH-indol- 7-yl}-N-methylpyridine-2-sulfonamide (253 mg) , tetrahydrofuran (5 mL) , ethanol (5 mL) and water (5 mL) was added OXONE
(registered trade mark, 160 mg) at room temperature, and the mixture was added at room temperature for 2 hr. 10% Aqueous sodium sulfite solution was added, and the mixture was concentrated to dryness. The residue was diluted with ethyl acetate, tetrahydrofuran and water, and the organic layer was washed with saturated brine, dried over sodium sulfate, and filtrated. The filtrate was concentrated, and the residue was purified by preparative HPLC to give the title compound (605 mg, yield 99%) as a colorless amorphous solid. IH-NMR (CDCl3) δ: 1.59 (3H, s) , 2.62-2.98 (8H, m) , 3.24-3.41 (5H, m) , 3.45 (3H, s) , 3.68-3.79 (2H, m) , 4.00-4.17 (3H, m) , 4.17- 4.27 (IH, m) , 6.78 (IH, d, J=I .9 Hz), 6.87 (IH, d, J=2.3 Hz), 7.05 (IH, d, J=2.1 Hz), 7.59 (IH, ddd, J=7.5, 4.7, 1.1 Hz), 7.87-7.99 (IH, m) , 7.98-8.08 (IH, m) , 9.02 (IH, d, J=4.5 Hz), 11.57 (IH, brs) .
Example 531 ethyl (2-{7- [ (2-thienylsulfonyl) amino] -lH-indol-2- yl}-4, 5-dihydro-l, 3-thiazol-5-yl) acetate
Figure imgf000563_0002
A solution of 7- [ (2-thienylsulfonyl) amino] -lH-indole-2- carbothioamide (4.3 g) , ethyl but-2-ynoate (3.2 mL) and tributylphosphine (3.2 mL) in tetrahydrofuran (40 mL) -toluene (40 mL) was stirred at room temperature for 2 days, ethyl but- 2-ynoate (1.6 mL) was added to the reaction solution. again, and the mixture was stirred at 60°C for 2 hr. The reaction solution was concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (ethyl acetate :hexane=2: 8-4 : 6) to give the title compound (1.6 g, yield: 28%) as a pale-brown oil. MS .-450(MH+) .
Example 532 (4R) -2-{5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazole-4- carboxylic acid
Figure imgf000564_0001
To a solution of triphenylphosphine oxide (8.9 g) in dichloromethane (12 inL) was added dropwise trifluoromethanesulfonic anhydride (3.9 itiL) at 0°C, and the mixture was stirred for 30 min at 0°C. The obtained suspension was diluted with dichloromethane (38 mL) , and a solution of S- benzyl-N- ( {5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}carbonyl) -L-cysteine methyl ester (3.2 g) and thioanisole (5.0 mL) in dichloromethane (50 mL) was added. The reaction mixture was stirred at '00C for 2 hr, and saturated aqueous sodium hydrogencarbonate solution was added. The mixture was concentrated, and the residue was extracted with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, dried (MgSO,}) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with hexane-ethyl acetate (4:1-1:1, volume ratio) to give a mixture (2.3 g) of methyl (4R) -2- {5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazole-4- carboxylate and triphenylphosphine oxide. A mixture of the obtained mixture (1.3 g) , 2N aqueous sodium hydroxide solution (2.0 mL) , tetrahydrofuran (2.0 mL) and methanol (2.0 mL) was stirred at room temperature for 2 hr. Diethyl ether was added to the reaction mixture, and the aqueous layer was separated, and acidified with IN hydrochloric acid. The mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, dried (MgSO^) , and concentrated to give the title compound (1.1 g, yield 43%) .
1H-NMR(CDCI3)SJS^I (3H, s) , 3.46 (3H, s) , 3.68-3.85 (4H, m) , 4.05-4.17 (2H, m) , 5.38 (IH, t, J=9.3 Hz), 6.92 (IH, d, J=2.1 Hz), 6.94 (IH, d, J=2.3 Hz), 7.05 (IH, d, J=2.3 Hz), 7.50-7.64 (IH, m), 7.83-7.97 (IH, m) , 7.96-8.06 (IH, m) , 9.10 (IH, d, J=4.0 Hz), 11.90 (IH, brs) .
Example 533 (4R) -2-{5- (2-methoxyethoxy) -7- [methyl (pyridin-2- ylsulfonyl) amino] -lH-indol-2-yl}-4, 5-dihydro-l, 3-thiazole-4- carboxamide
Figure imgf000565_0001
A solution of (4R) -2- {5- (2-methoxyethoxy) -7-
[methyl (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl}-4, 5- dihydro-1, 3-thiazole-4-carboxylic acid (0.15 g) , IH-I, 2, 3- benzotriazol-1-ol ammonium salt (0.072 g) , N- [3- (dimethylamino) propyl] -N' -ethylcarbodiimide hydrochloride (0.090 g) and triethylamine (0.086 mL) in N, N- dimethylformamide (5 mL) was stirred at room temperature for 3 hr. The reaction mixture was concentrated, water was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with IN hydrochloric acid, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried (MgSO4) , and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with ethyl acetate to give the title compound (0.056 g, yield 37%) as colorless crystals. 1H-NMR(CDCl3)OrS^S (3H, s) , 3.45 (3H, s) , 3.70-3.86 (4H, m) , 4.05-4.17 (2H, m) , 5.25 (IH, t, J=9.1 Hz), 5.50 (IH, brs), 6.75 (IH, brs), 6.86 (IH, d, J=2.3 Hz), 6.93 (IH, d, J=2.1 Hz),
7.06 (IH, d, J=2.1 Hz), 7.53- 7.70 (IH, m) , 7.91-8.00 (IH, m) , 8.01-8.07 (IH, m) , 8.99 (IH, dd, J=4.7, 0.8 Hz), 11.43 (IH, brs) .
5 Example 534 N- (cyclopropylmethyl) -N- (5- (2-methoxyethoxy) -2- {5- [ (1-oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl}- lH-indol-7-yl) pyridine-2-sulfonamide
Figure imgf000566_0001
To a mixture of triphenylphosphine oxide (557 mg) and io dichloromethane (1 πiL) was added trifluoromethanesulfonic anhydride (0.17 mL) at O0C, and the mixture was stirred at 0°C for 15 min, followed by an addition of dichloromethane (3 mL) . A mixture of N- [2- (benzylthio) -3-thiomorpholinopropyl] -7- [ (cyclopropylmethyl) (pyridin-2-ylsulfonyl) amino] -5- (2-
15 methoxyethoxy) -lH-indole-2-carboxamide (355 mg) , thioanisole (0.12 mL) and dichloromethane (3 mL) was added thereto at 0°C, and the mixture was stirring at 00C for 10 min. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the organic layer was separated. The organic layer was
20 extracted with concentrated hydrochloric acid, and after basified with the aqueous layer with potassium carbonate, the whole mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under
25 reduced pressure. The residue was subjected to silica gel column chromatography to give the amorphous solid from a fraction eluted with ethyl acetate. To the mixture of the obtained amorphous solid, tetrahydrofurane (5 mL) , ethanol (5 mL) and water (5 mL) was added OXONE (registered trade mark,
30 369 mg) at room temperature, and the mixture was stirred at room temperature for 1 hr. To the resulting mixture was added 10% aqueous sodium sulfite solution, and the mixture was extracted with a mixed sonvent of ethyl acetate and tetrahydrofuran. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC to give amorphous solid, which was crystallized from diisopropyl ether to give the title compound (146 mg, yield 47%) as colorless crystals.
IH-NMR (CDCl3) δ: -0.07 (2H, q, J=4.8 Hz), 0.27 (2H, d, J=7.0 Hz), 0.76-0.91 (IH, m) , 2.56-2.69 (2H, m) , 2.71-2.99 (6H, m) , 3.10- 3.26 (2H, m) , 3.46 (3H, s) , 3.55 (2H, d, J=7.2 Hz), 3.74-3.86 (2H, m) , 4.00-4.22 (3H, m) , 4.34-4.48 (2H, m) , 6.83 (IH, d, J=2.1 Hz), 6.94 (IH, d, J=2.1 Hz), 7.10 (IH, d, J=2.1 Hz), 7.59 (IH, dd, J=4.8, 1.0 Hz), 7.93 (IH, td, J=7.8, 1.6 Hz), 7.99-8.13 (IH, m) , 9.05 (IH, d, J=4.0 Hz), 11.70 (IH, brs) .
Example 535 N- (2, 2-difluoroethyl) -N- (5- (2-methoxyethoxy) -2-{ 5- [ (1-oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl}- lH-indol-7-yl) pyridine-2-sulfonamide
Figure imgf000567_0001
In the same manner as in Example 534, the title compound (45 mg, yield 14%) was obtained as colorless crystals from N- [2- (benzylthio) -3- (thiomorpholino) propyl] -7- [ (2,2- difluoroethyl) (pyridin-2-ylsulfonyl) amino] -5- (2- methoxyethoxy) -lH-indole-2-carboxamide (360 mg) . IH-NMR (CDCl3) δ: 2.59-2.69 (2H, m) , 2.71-2.98 (6H, m) , 3.08-3.25 (2H, m), 3.45 (3H, s) , 3.67-3.82 (3H, m) , 4.05-4.22 (4H, m) , 4.31-4.44 (2H, m) , 5.60-6.10 (IH, m) , 6.77-6.87 (2 H, m) , 7.09 (IH, d, J=I.9 Hz), 7.59 (IH, ddd, J=6.8, 4.8, 1.8 Hz), 7.86- 8.02 (2H, m) , 9.01 (IH, d, J=4.5 Hz), 11.01 (IH, brs). Example 536 N-cyclopropyl-N- (5- (2-methoxyethoxy) -2- { 5- [ (1- oxidothiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl } -IH- indol-7-γl)pyridine-2-sulfonamide
Figure imgf000568_0001
In the same manner as in Example 534, the title compound (140 mg, yield 46%) was obtained as colorless crystals from N- [2- (benzylthio) -3-thiomorpholinopropyl]-7- [cyclopropyl (pyridin-2- ylsulfonyl) amino] -5- (2-methoxyethoxy) -lH-indole-2-carboxamide (350 mg) .
IH-NMR (CDCl3) δ: 0.34 (2H, brs) , 0.61 (2H, d, J=6.0 Hz), 2.64 (2H, dd, J=7.6, 1.6 Hz), 2.71-2.96 (6H, m) , 3.12-3.28 (3H, m) , 3.47 (3H, s), 3.68-3.85 (2H, m) , 4.05-4.21 (3H, m) , 4.33-4.49 (2H, m), 6.82 (IH, d, J=2.1 Hz)/ 6.97-7.12 (2H, m) , 7.63 (IH,' ddd, J=I.6, 4.7, 1.0 Hz), 8.00 (IH, td, J=7.8, 1.8 Hz), 8.16 (IH, d, J=7.9 Hz), 9.09 (IH, dd, J=4.7, 0.9 Hz), 12.18 (IH, brs) .
Reference Example IA Construction of glucokinase (GK) expression vector
Plasmid DNA to be used for the expression of a protein (GST-hLGKl) containing GST (Glutathione S-transferase) added to the amino terminal of human liver GK in Escherichia coli was prepared as follows.
First, PCR was performed using human liver cDNA (Marathon Ready cDNA, Clontech Laboratories, Inc.) as a template and two kinds of synthetic DNAs (5'-CAGCTCTCCATCCAAGCAGCCGTTGCT-S' (SEQ ID NO: 1) and 5'-GGCGGCCTGGGTCCTGACAAG-S' (SEQ ID NO: 2)), and the obtained DNA fragment was closed using a TOPO TA Cloning Kit (Invitrogen Corporation) . PCR was performed using the obtained plasmid DNA as a template and a synthetic DNA (5'- GGATCCATGCCCAGACCAAGATCCCAACTCCCACAACCCAACTCCCAGGTAGAGCAGATCCTGG CAGAG-3' (SEQ ID NO: 3) ) with a BamHI site added to immediately before the initiation codon, and a synthetic DNA (5'- GAATTCCTGGCCCAGCATACAGGC-3' (SEQ ID NO: 4)) with an EcoRI site added to immediately after the stop codon. The obtained DNA fragment was subcloned to pGEX6P-2 (Amersham Biosciences K.K.) cleaved with BamHI and EcoRI to give a plasmid (pGEX6P-2/hLGKl) for expression of human liver GK. Reference Example 2A Expression and purification of GST-hLGKl BL21 strain (Stratagene) transformed with pGEX6P-2/hLGKl obtained in Reference Example IA was cultured with shaking at 37°C for 14 hr in a 200 ml Erlenmeyer' flask containing 50 ml of 100 μg/ml ampicillin-containing LB medium. The culture medium (25 ml) was diluted with 225 ml of 100 μg/ml ampicillin- containing LB medium, and further cultured with shaking at 37°C for 1 hr in a 1 L Erlenmeyer flask. After culture, the
Erlenmeyer flask was cooled on ice, 125 μL of 100 mM isopropyl- thio-β-D-galactopyranoside (IPTG) was added (final concentration 50 μM) , and cultured at 17°C for 20 hr. The culture medium was centrifuged, and the obtained fungus was disrupted by ultrasonication. The object protein (GST-hLGKl) was purified from the supernatant using Glutathione Sepharose 4B (Amersham Biosciences K.K.). Experimental Example 1: Determination of GK activity value
A solution (5 μL) of test compound in 50% dimethyl sulfoxide was added to each well of 384 well black plate (Nalge
Nunc International K.K.). Then, a solution (35 μL) obtained by diluting GST-hLGKl obtained in Reference Example 2A with measurement buffer (containing 5.0 mM HEPES (pH 7.4), 200 mM KCl,
5 mM MgCl2, 2.5 mM DTT and 50 μM 2' - (or-3' ) -0- (N- methylanthraniloyl) adenosine 5' -triphosphate (Mant-ATP) (Jena
Bioscience GmbH)) to 6 μg/mL was added to each well.
Each well was stood at 37°C for 10 min, and 25 mM D-glucose solution (10 μL) was added to start,the reaction.
Each well after the reaction was stood at 37°C for 60 min, and the reaction was quenched by adding 25 μL of a quenching solution (containing 200 mM HEPES (pH 7.4), 20 mM MgCl2, 200 mM EDTA, 0.03% Triton-X 100, 0.3% Coating 3 reagent (Caliper Life Sciences, Inc.)). 2' - (or-3' ) -O- (N-methylanthraniloyl) adenosine 5' - triphosphate (Mant-ATP, substrate) and Mant-ADP (reaction resultant product) were separated from each well after the reaction by a microchip type capillary electrophoresis apparatus 250 HTS (Caliper Life Sciences, Inc.). The reaction rate
[ (reaction resultant product peak height) / (reaction resultant product peak height + substrate peak height) xlOO (%)] was calculated from the ratio of the substrate peak height and reaction resultant product peak height obtained by fluorescence detection (excitation wavelength 355 nm, measurement wavelength 460 nm) and used as the index of GK activity.
As a control group, the reaction rate was calculated in the same manner as above except that "solution in 50% dimethyl sulfoxide (without test compound) " was used instead of "solution of test compound in 50% dimethyl sulfoxide".
A concentration dependency curve of the test compound was drawn with the percentage obtained by dividing the reaction rate of the well added with the test compound (test compound addition group) by the reaction rate of the control group was taken as the GK activity value of the test compound, and the concentration of the test compound at the midpoint between the maximum activity value of the test compound addition group and the control group activity value is shown as EC50 value. The results are shown in Table 1.
Table 1
Test compound EC50 value (μM) (Example No. )
10 0.21
191 0.031
198 • 0.53
200 0.061
218 0.18
226 0.053
229 0.12
236 0.25
243 0.024
253 0.21
254 0.20
274 0.081
337 0.082
348 0.044
398 0.21
414 0.037
520 0,19
528 0.26
As is clear from Table 1, the compound of the present invention has a superior glucokinase activation action.
Formulation Example 1 (production of capsule)
1) compound of Example 1 30 mg
2) finely divided powder cellulose 10 mg 3) lactose 19 mg
4) magnesium stearate 1 mg total 60 mg 1), 2), 3) and- 4) are mixed and filled in a gelatin capsule. Formulation Example 2 (production of tablet)
1) compound of Example 1 3O g
2) lactose ■ 50 g
3) cornstarch 15 g
4) calcium carboxymethylcellulose ' 44 g
5) magnesium stearate 1 g 1000 tablets total 140 g
The total amount of 1), 2) and 3), and 30 g of 4) are kneaded with water, vacuum dried and sized. The sized powder is mixed with 14 g of 4) and 1 g of 5) , and the mixture is punched by a tabletting machine. In this way, 1000 tablets containing 30 mg of the compound of Example 1 per tablet are obtained.
Industrial Applicability
The compound of the present invention has a superior glucokinase activating action, and is useful as a pharmaceutical agent such as an agent for the- prophylaxis or treatment of diabetes, obesity and the like, and the like.
This application is based on patent application No. 2006- 285551 filed in Japan, the contents of which are incorporated in full herein by this reference.

Claims

1. A compound represented by the formula (I) :
Figure imgf000573_0001
wherein
R1 is a hydrogen atom or a halogen atom; R2 is a group represented by
Figure imgf000573_0002
wherein A is CH or N;
R4 and R5 are each independently an optionally substituted QL-6 alkyl group or an optionally substituted C3-I0 cycloalkyl group, or R4 and R5 in combination form an optionally substituted ring wherein the ring should not be morpholine; and
R6, R7, R21 and R22 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, a cyano group or an acyl group, or R6 and R7 in combination form an optionally substituted ring/ W is O or NR8 wherein R8 is a hydrogen atom, an optionally substituted Ci_6 alkyl group or an optionally substituted C3-10 cycloalkyl group;
R3 is an optionally substituted heterocyclic group or an optionally substituted Ce-u aryl group; and R9, R10 and R11 are each independently a hydrogen atom, a halogen atom, an optionally substituted Cχ-6 alkyl group or an optionally substituted Cχ-6 alkoxy group, provided that a compound wherein R21 is a hydrogen atom or a Ci_6 alkoxy- carbonyl group, R22 is a hydrogen atom, and R6 and R7 are both hydrogen atoms, and a compound wherein R21 is a hydrogen atom or a Ci-6 alkoxy- carbonyl groug, R22 is a hydrogen atom, and R6 and R7 are both methyl groups are excluded, or a salt thereof.
2. The compound of claim 1 which is a compound represented by the formula (I) :
Figure imgf000574_0001
wherein
R1 is a hydrogen atom or a halogen atom;
R2 is a group represented by
Figure imgf000574_0002
wherein
A is CH or N;
R4 and R5 are each independently an optionally substituted
Ci-6 alkyl group or an optionally substituted C3-10 cycloalkyl group, or R4 and R5 in combination form an optionally substituted ring wherein the ring should not be morpholine; and
R6 and R7 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, a cyano group or an acyl group, or R6 and R7 in combination form an optionally substituted ring;
W is 0 or NR8 wherein R8 is a hydrogen atom or an optionally substituted Ci_6 alkyl group;
R3 is an optionally substituted heterocyclic group; and R9, R10 and R11 are each independently a hydrogen atom, a halogen atom, an optionally substituted Ci-e alkyl group or an optionally substituted Ci_6 alkoxy group, provided that a compound wherein R6 and R7 are both hydrogen atoms, and a compound wherein R6 and R7 are both methyl groups are excluded, or a salt thereof.
3. The compound of, claim 1, wherein R2 is a group represented by
Figure imgf000575_0001
wherein R6 and R7 are as defined in claim 1.
4. The compound of claim 3, wherein R6 is a Ci-β alkyl group substituted by an optionally substituted heterocyclic group.
5. The compound of claim 3, wherein R7 is a hydrogen atom.
6. The compound of claim 3, wherein R6 and R7 in combination form an optionally substituted ring.
7. The compound of claim 3, wherein W is NR8 wherein R8 is as defined in claim 1.
8. The compound of claim 3, wherein R3 is a 5- or 6-membered monocyclic aromatic heterocyclic group.
9. The compound of claim 3, wherein R9 is a hydrogen atom or a halogen atom.
10. The compound of claim 3, wherein R10 is a hydrogen atom, a halogen atom, a Ci_6 alkyl group or an optionally substituted Ci-6 alkoxy group.
11. The compound of claim 3, wherein R11 is a hydrogen atom, a halogen atom or a Ci_6 alkyl group.
12. N,N-dimethyl-2-{4-[ (2- {7- [methyl (2-thienylsulfonyl) amino] - lH-indol-2-yl } -1, 3-thiazol-5-yl) methyl] piperazin-1- yl} acetamide;
N-methyl-N-[2- (8-oxa-l-thia-3-azaspiro [4.5]dec-2-en-2-yl) -IH- indol-7-yl] thiophene-2-sulfonamide; N- [2- [4- (hydroxymethyl) -4, 5-dihydro-l, 3-thiazol-2-yl] -5- (2- methoxyethoxy) -lH-indol-7-yl]-N-methylpyridine-2-sulfonamide;
N-methyl-N-{2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3-thiazol-2- yl ] -lH-indol-7-yl }thiophene-2-sulfonamide;
2- (2- {7- [methyl (pyridin-2-ylsulfonyl) amino] -lH-indol-2-yl}- 4, 5-dihydro-l, 3-thiazol-5-yl) acetamide;
N- (difluoromethyl) -N- {2- [5- (morpholinomethyl) -4, 5-dihydro-l, 3- thiazol-2-yl] -lH-indol-7-ylJthiophene-2-sulfonanu.de;
2- {2- [7- [methyl (2-thienylsulfonyl) amino] -5- (trifluoromethoxy) - lH-indol-2-yl] -4, 5-dihydro-l, 3-thiazol-5-yl} acetamide; N- (5- (2-methoxyethoxy) -2- {5- [ (1-oxidothiomorpholino) methyl] -
4, 5-dihydro-l, 3-thiazol-2-yl}-lH-indol-7-yl) -N-methylpyridine-
2-sulfonamide;
2- (2-{7- [methyl (2-thienylsulfonyl) amino] -IH-indol-2-yl}-l- thia-3, 8-diazaspiro [4.5] dec-2-en-8-yl) acetamide; or N- [2- {5- [ (1, 1-dioxidothiomorpholino) methyl] -4, 5-dihydro-l, 3- thiazol-2-yl}-5- (2-methoxyethoxy) -lH-indol-7-yl] -N- methylpyridine-2-sulfonamide; or a salt thereof.
13. A prodrug of the compound of claim 1.
14. A glucokinase activator comprising the compound of claim 1 or a prodrug thereof.
15. A pharmaceutical agent comprising the compound of claim 1 or a prodrug thereof.
16. The pharmaceutical agent of claim 15, which is an agent for the prophylaxis or treatment of diabetes or obesity.
17. A method of activating a glucokinase in a mammal, which comprises administering the compound of claim 1 or a prodrug thereof to the mammal.
18. A method for the prophylaxis or treatment of diabetes or obesity in a mammal, which comprises administering the compound of claim 1 or a prodrug thereof to the mammal.
19. Use of the compound of claim 1 or a prodrug thereof for the production of a glucokinase activator.
20. Use of the compound of claim 1 or a prodrug thereof for the production of an agent for the prophylaxis or treatment of diabetes or obesity.
PCT/JP2007/070772 2006-10-19 2007-10-18 Indole compound WO2008050821A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
RU2009118602/04A RU2454415C9 (en) 2006-10-19 2007-10-18 Indole derivative
US12/311,893 US8410087B2 (en) 2006-10-19 2007-10-18 Indole compound
CA2666973A CA2666973C (en) 2006-10-19 2007-10-18 Indole compound having a glucokinase activating action
MEP-118/09A MEP11809A (en) 2006-10-19 2007-10-18 Indole compound
CN2007800470664A CN101573357B (en) 2006-10-19 2007-10-18 Indole compound
GEAP200711259A GEP20115241B (en) 2006-10-19 2007-10-18 Indole compound
NZ576570A NZ576570A (en) 2006-10-19 2007-10-18 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
JP2009515658A JP5260507B2 (en) 2006-10-19 2007-10-18 Indole compounds
EP07830506A EP2074119A1 (en) 2006-10-19 2007-10-18 Indole compound
BRPI0717722-4A BRPI0717722A2 (en) 2006-10-19 2007-10-18 COMPOUND OR A SALT OF THE SAME, PRODUCT, GLYCOKINASE ACTIVATOR, PHARMACEUTICAL AGENT, METHODS TO ACTIVATE A GLYCHOKINASE IN A MAMMAL AND FOR PROPHYLAXIS OR TREATMENT OF DIABETES OR OBESITY, OR USE OF THE MAMMAL DRUG THIS
MX2009003972A MX2009003972A (en) 2006-10-19 2007-10-18 Indole compound.
UAA200904957A UA97257C2 (en) 2006-10-19 2007-10-18 Indole derivatives
AU2007310064A AU2007310064B2 (en) 2006-10-19 2007-10-18 Indole compound
KR1020097010151A KR101444486B1 (en) 2006-10-19 2007-10-18 Indole compound
CL2008001017A CL2008001017A1 (en) 2006-10-19 2008-04-10 Indole derived compounds, glucokinase activators; pharmaceutical composition comprising them; and its use for the prevention or treatment of diabetes or obesity.
ARP080101557A AR080058A1 (en) 2007-10-18 2008-04-16 DERIVATIVES OF TIAZOL-THIOPHEN INDOL GLUCOKINASE ACTIVATORS, PHARMACEUTICAL AGENTS CONTAINING THEM AND USES OF THE SAME TO PREVENT AND / OR TREAT DIABETES OR OBESITY
PE2008000659A PE20090884A1 (en) 2006-10-19 2008-04-16 INDOL COMPOUNDS AS GLUCOKINASE ACTIVATORS
TNP2009000129A TN2009000129A1 (en) 2006-10-19 2009-04-08 Indole compound
IL198154A IL198154A (en) 2006-10-19 2009-04-16 Indole compound
NO20091948A NO20091948L (en) 2006-10-19 2009-05-19 Indole compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006285551 2006-10-19
JP2006-285551 2006-10-19

Publications (1)

Publication Number Publication Date
WO2008050821A1 true WO2008050821A1 (en) 2008-05-02

Family

ID=39010108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/070772 WO2008050821A1 (en) 2006-10-19 2007-10-18 Indole compound

Country Status (26)

Country Link
US (4) US7652133B2 (en)
EP (2) EP2074119A1 (en)
JP (1) JP5260507B2 (en)
KR (1) KR101444486B1 (en)
CN (1) CN101573357B (en)
AU (1) AU2007310064B2 (en)
BR (1) BRPI0717722A2 (en)
CA (1) CA2666973C (en)
CL (1) CL2008001017A1 (en)
CR (1) CR10748A (en)
EC (1) ECSP099330A (en)
GE (1) GEP20115241B (en)
IL (1) IL198154A (en)
MA (1) MA30890B1 (en)
ME (1) MEP11809A (en)
MX (1) MX2009003972A (en)
MY (1) MY158052A (en)
NO (1) NO20091948L (en)
NZ (1) NZ576570A (en)
PE (1) PE20090884A1 (en)
RU (1) RU2454415C9 (en)
TN (1) TN2009000129A1 (en)
TW (1) TWI460176B (en)
UA (1) UA97257C2 (en)
WO (1) WO2008050821A1 (en)
ZA (1) ZA200902585B (en)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010035806A1 (en) 2008-09-25 2010-04-01 武田薬品工業株式会社 Solid pharmaceutical composition
EP2178869A1 (en) * 2007-08-17 2010-04-28 LG Life Sciences Ltd. Indole compounds as an inhibitor of cellular necrosis
WO2010050445A1 (en) 2008-10-27 2010-05-06 武田薬品工業株式会社 Bicyclic compound
WO2010076884A1 (en) 2008-12-29 2010-07-08 武田薬品工業株式会社 Novel fused ring compound and use thereof
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
WO2011013639A1 (en) 2009-07-28 2011-02-03 武田薬品工業株式会社 Tablet
JP2011507833A (en) * 2007-12-20 2011-03-10 エルジー・ライフ・サイエンシーズ・リミテッド Glucokinase activator and pharmaceutical composition containing it as an active ingredient
WO2011136385A1 (en) 2010-04-27 2011-11-03 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as acc inhibitors.
WO2011158880A1 (en) 2010-06-16 2011-12-22 武田薬品工業株式会社 Crystal of amide compound
WO2012036293A1 (en) 2010-09-17 2012-03-22 武田薬品工業株式会社 Diabetes therapeutic agent
WO2012074126A1 (en) 2010-11-30 2012-06-07 Takeda Pharmaceutical Company Limited Bicyclic compound
WO2012111849A1 (en) 2011-02-17 2012-08-23 Takeda Pharmaceutical Company Limited Production method of optically active dihydrobenzofuran derivative
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
US8349886B2 (en) 2008-04-16 2013-01-08 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
WO2013061962A1 (en) 2011-10-24 2013-05-02 武田薬品工業株式会社 Bicyclic compound
WO2013105676A1 (en) 2012-01-12 2013-07-18 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
WO2013122028A1 (en) 2012-02-13 2013-08-22 武田薬品工業株式会社 Aromatic ring compound
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
WO2013122029A1 (en) 2012-02-13 2013-08-22 武田薬品工業株式会社 Aromatic ring compound
WO2013125732A1 (en) 2012-02-24 2013-08-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013147026A1 (en) 2012-03-29 2013-10-03 武田薬品工業株式会社 Aromatic ring compound
WO2013168760A1 (en) 2012-05-10 2013-11-14 武田薬品工業株式会社 Aromatic ring compound
WO2013168759A1 (en) 2012-05-10 2013-11-14 武田薬品工業株式会社 Aromatic ring compound
WO2013183784A1 (en) 2012-06-05 2013-12-12 Takeda Pharmaceutical Company Limited Solid preparation
WO2014014129A1 (en) 2012-07-19 2014-01-23 Takeda Pharmaceutical Company Limited Solid preparation
US8673942B2 (en) 2008-04-10 2014-03-18 Takeda Pharmaceutical Company Limited Fused ring compounds and use thereof
WO2014142363A1 (en) 2013-03-14 2014-09-18 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
WO2015005489A1 (en) 2013-07-09 2015-01-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015020184A1 (en) 2013-08-09 2015-02-12 武田薬品工業株式会社 Aromatic compound
WO2015052910A1 (en) 2013-10-07 2015-04-16 Takeda Pharmaceutical Company Limited Antagonists of somatostatin receptor subtype 5 (sstr5)
WO2015122187A1 (en) 2014-02-13 2015-08-20 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2015122188A1 (en) 2014-02-13 2015-08-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
WO2018182050A1 (en) 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders
WO2018182051A1 (en) 2017-03-30 2018-10-04 Takeda Pharmaceutical Company Limited Ip6k inhibitors
WO2018181847A1 (en) 2017-03-31 2018-10-04 武田薬品工業株式会社 Aromatic compound
WO2018181864A1 (en) 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Gip receptor activating peptide
WO2020045326A1 (en) 2018-08-27 2020-03-05 株式会社スコヒアファーマ Benzoic ester compound
WO2020067557A2 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2020067575A1 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2021193983A2 (en) 2020-03-25 2021-09-30 Takeda Pharmaceutical Company Limited Qw dosing of gip receptor agonist peptide compounds and uses thereof
WO2021193984A2 (en) 2020-03-25 2021-09-30 Takeda Pharmaceutical Company Limited Qd dosing of gip receptor agonist peptide compounds and uses thereof
WO2022241287A2 (en) 2021-05-13 2022-11-17 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors
US11535660B1 (en) 2018-03-23 2022-12-27 Cannot Therapeutics, Inc. Modulators of G-protein coupled receptors
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US11891402B2 (en) * 2012-04-10 2024-02-06 The Regents Of The University Of California Compositions and methods for treating cancer
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024138048A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008242983B2 (en) * 2007-04-16 2013-07-11 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
US20100291533A1 (en) * 2008-01-04 2010-11-18 Soon Ha Kim Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect
WO2009097995A1 (en) * 2008-02-07 2009-08-13 Sanofi-Aventis Novel phenyl-substituted imidazolidines, method for the production thereof, medicaments containing said compounds and use thereof
AR072297A1 (en) * 2008-06-27 2010-08-18 Novartis Ag DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
US8288559B2 (en) * 2008-08-18 2012-10-16 Promega Corporation Luminogenic compounds and methods to detect cytochrome P450 3A enzymes
EP2448921A4 (en) * 2009-04-09 2013-01-23 Msd Kk Aryl indole derivatives
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011159781A2 (en) * 2010-06-17 2011-12-22 Senomyx, Inc. Bitter taste modulators
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2781521A4 (en) * 2011-10-19 2015-03-04 Kowa Co Novel spiroindoline compound, and medicinal agent comprising same
WO2015026172A1 (en) * 2013-08-22 2015-02-26 주식회사 엘지생명과학 Indole amide compound as inhibitor of necrosis
CN104098498A (en) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 Indazole-type compound and preparation method thereof
CN109250963B (en) * 2018-09-29 2021-07-16 福建省昊立建设工程有限公司 Composite toughened concrete and preparation method thereof
CN113563306B (en) * 2020-04-28 2022-07-01 新发药业有限公司 Preparation method of 2- (4-phenoxyphenyl) -6- (piperidine-4-) nicotinamide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0673937A1 (en) * 1993-09-10 1995-09-27 Eisai Co., Ltd. Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
WO2005049019A1 (en) * 2003-11-24 2005-06-02 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
WO2006112549A1 (en) * 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656610B1 (en) * 1989-12-29 1992-05-07 Sanofi Sa DERIVATIVES OF 2-AMINO PHENYL-4 THIAZOLE, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION.
JP3545461B2 (en) * 1993-09-10 2004-07-21 エーザイ株式会社 Bicyclic heterocycle-containing sulfonamide derivatives
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
WO1999043654A2 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
JP4007743B2 (en) 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Angiogenesis inhibitor
AR035016A1 (en) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST.
GB0003636D0 (en) * 2000-02-16 2000-04-05 Smithkline Beecham Plc Novel compounds
ATE479429T1 (en) 2000-04-28 2010-09-15 Takeda Pharmaceutical ANTAGONISTS OF THE MELANIN CONCENTRATING HORMONE
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
ATE374768T1 (en) * 2002-10-03 2007-10-15 Hoffmann La Roche INDOLE-3-CARBONIC ACID AMIDES AS GLUCOKINASE (GK) ACTIVATORS
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
WO2007037543A1 (en) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. Biarylamide derivative
AU2006295645B2 (en) 2005-09-30 2011-09-29 Msd K.K. 2-heteroaryl-substituted indole derivative
CL2008002398A1 (en) * 2007-08-14 2009-07-31 Bayer Ip Gmbh Compounds derived from 6- (phenyl piperidine) pyrimidines fused with imidazole, triazole or pyrozole, inhibitors of the pi3k / akt pathway; pharmaceutical composition; pharmaceutical combination; and use of the compounds for the treatment of benign and / or malignant neoplasia and for cancer.
US8592591B2 (en) * 2007-08-14 2013-11-26 Bayer Intellectual Property Gmbh Fused bicyclic imidazoles
MX2010004177A (en) * 2007-10-18 2010-05-03 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles.
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 1,3,5-trisubstitued triazole derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0673937A1 (en) * 1993-09-10 1995-09-27 Eisai Co., Ltd. Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
WO2005049019A1 (en) * 2003-11-24 2005-06-02 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
WO2006112549A1 (en) * 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP1873144A1 (en) * 2005-04-20 2008-01-02 Takeda Pharmaceutical Company Limited Fused heterocyclic compound

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
JP2010536845A (en) * 2007-08-17 2010-12-02 エルジー・ライフ・サイエンシーズ・リミテッド Indole compounds as cell necrosis inhibitors
EP2178869A1 (en) * 2007-08-17 2010-04-28 LG Life Sciences Ltd. Indole compounds as an inhibitor of cellular necrosis
EP2178869A4 (en) * 2007-08-17 2012-03-21 Lg Life Sciences Ltd Indole compounds as an inhibitor of cellular necrosis
JP2011507833A (en) * 2007-12-20 2011-03-10 エルジー・ライフ・サイエンシーズ・リミテッド Glucokinase activator and pharmaceutical composition containing it as an active ingredient
US8673942B2 (en) 2008-04-10 2014-03-18 Takeda Pharmaceutical Company Limited Fused ring compounds and use thereof
US8349886B2 (en) 2008-04-16 2013-01-08 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
WO2010035806A1 (en) 2008-09-25 2010-04-01 武田薬品工業株式会社 Solid pharmaceutical composition
WO2010050445A1 (en) 2008-10-27 2010-05-06 武田薬品工業株式会社 Bicyclic compound
WO2010076884A1 (en) 2008-12-29 2010-07-08 武田薬品工業株式会社 Novel fused ring compound and use thereof
US8557805B2 (en) 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
WO2011013639A1 (en) 2009-07-28 2011-02-03 武田薬品工業株式会社 Tablet
WO2011136385A1 (en) 2010-04-27 2011-11-03 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as acc inhibitors.
WO2011158880A1 (en) 2010-06-16 2011-12-22 武田薬品工業株式会社 Crystal of amide compound
WO2012036293A1 (en) 2010-09-17 2012-03-22 武田薬品工業株式会社 Diabetes therapeutic agent
WO2012074126A1 (en) 2010-11-30 2012-06-07 Takeda Pharmaceutical Company Limited Bicyclic compound
WO2012111849A1 (en) 2011-02-17 2012-08-23 Takeda Pharmaceutical Company Limited Production method of optically active dihydrobenzofuran derivative
WO2013061962A1 (en) 2011-10-24 2013-05-02 武田薬品工業株式会社 Bicyclic compound
WO2013105676A1 (en) 2012-01-12 2013-07-18 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
WO2013122028A1 (en) 2012-02-13 2013-08-22 武田薬品工業株式会社 Aromatic ring compound
WO2013122029A1 (en) 2012-02-13 2013-08-22 武田薬品工業株式会社 Aromatic ring compound
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
WO2013125732A1 (en) 2012-02-24 2013-08-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013147026A1 (en) 2012-03-29 2013-10-03 武田薬品工業株式会社 Aromatic ring compound
US11891402B2 (en) * 2012-04-10 2024-02-06 The Regents Of The University Of California Compositions and methods for treating cancer
US12116375B2 (en) 2012-04-10 2024-10-15 The Regents Of The University Of California Compositions and methods for treating cancer
WO2013168759A1 (en) 2012-05-10 2013-11-14 武田薬品工業株式会社 Aromatic ring compound
WO2013168760A1 (en) 2012-05-10 2013-11-14 武田薬品工業株式会社 Aromatic ring compound
WO2013183784A1 (en) 2012-06-05 2013-12-12 Takeda Pharmaceutical Company Limited Solid preparation
WO2014014129A1 (en) 2012-07-19 2014-01-23 Takeda Pharmaceutical Company Limited Solid preparation
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
WO2014142363A1 (en) 2013-03-14 2014-09-18 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
WO2015005489A1 (en) 2013-07-09 2015-01-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015020184A1 (en) 2013-08-09 2015-02-12 武田薬品工業株式会社 Aromatic compound
WO2015052910A1 (en) 2013-10-07 2015-04-16 Takeda Pharmaceutical Company Limited Antagonists of somatostatin receptor subtype 5 (sstr5)
WO2015122187A1 (en) 2014-02-13 2015-08-20 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2015122188A1 (en) 2014-02-13 2015-08-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2018182051A1 (en) 2017-03-30 2018-10-04 Takeda Pharmaceutical Company Limited Ip6k inhibitors
WO2018182050A1 (en) 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders
WO2018181864A1 (en) 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Gip receptor activating peptide
WO2018181847A1 (en) 2017-03-31 2018-10-04 武田薬品工業株式会社 Aromatic compound
US11535660B1 (en) 2018-03-23 2022-12-27 Cannot Therapeutics, Inc. Modulators of G-protein coupled receptors
WO2020045326A1 (en) 2018-08-27 2020-03-05 株式会社スコヒアファーマ Benzoic ester compound
WO2020067575A1 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2020067557A2 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2021193984A2 (en) 2020-03-25 2021-09-30 Takeda Pharmaceutical Company Limited Qd dosing of gip receptor agonist peptide compounds and uses thereof
WO2021193983A2 (en) 2020-03-25 2021-09-30 Takeda Pharmaceutical Company Limited Qw dosing of gip receptor agonist peptide compounds and uses thereof
WO2022241287A2 (en) 2021-05-13 2022-11-17 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024138048A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Also Published As

Publication number Publication date
AU2007310064A2 (en) 2009-06-04
CN101573357A (en) 2009-11-04
MA30890B1 (en) 2009-11-02
IL198154A (en) 2014-08-31
US20090286975A1 (en) 2009-11-19
CA2666973C (en) 2015-03-31
IL198154A0 (en) 2009-12-24
GEP20115241B (en) 2011-06-10
KR101444486B1 (en) 2014-09-24
RU2009118602A (en) 2010-11-27
AU2007310064A1 (en) 2008-05-02
NZ576570A (en) 2010-11-26
JP5260507B2 (en) 2013-08-14
KR20090068292A (en) 2009-06-25
MY158052A (en) 2016-08-30
NO20091948L (en) 2009-07-13
EP2074119A1 (en) 2009-07-01
TN2009000129A1 (en) 2010-10-18
AU2007310064B2 (en) 2013-03-28
CL2008001017A1 (en) 2009-04-24
RU2454415C9 (en) 2013-02-27
JP2010506825A (en) 2010-03-04
UA97257C2 (en) 2012-01-25
RU2454415C2 (en) 2012-06-27
BRPI0717722A2 (en) 2013-10-29
CR10748A (en) 2009-05-20
ME00681B (en) 2011-12-20
US20100137610A1 (en) 2010-06-03
US20080096877A1 (en) 2008-04-24
TW200825071A (en) 2008-06-16
US7777047B2 (en) 2010-08-17
EP2508524A2 (en) 2012-10-10
ZA200902585B (en) 2010-09-29
CN101573357B (en) 2013-01-23
US7718798B2 (en) 2010-05-18
MEP11809A (en) 2011-12-20
US20100144702A1 (en) 2010-06-10
MX2009003972A (en) 2009-04-27
TWI460176B (en) 2014-11-11
US7652133B2 (en) 2010-01-26
PE20090884A1 (en) 2009-08-05
ECSP099330A (en) 2009-06-30
CA2666973A1 (en) 2008-05-02
EP2508524A3 (en) 2012-10-24
US8410087B2 (en) 2013-04-02

Similar Documents

Publication Publication Date Title
US7652133B2 (en) Indole compound
US8957070B2 (en) Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
AU2009234666B2 (en) Fused ring compounds and use thereof
EP2157859A1 (en) Indazole compounds for activating glucokinase
EP2077267A1 (en) Fused heterocyclic compound
AU2013358112A1 (en) Heterocyclic compound

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780047066.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07830506

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007830506

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009040447

Country of ref document: EG

ENP Entry into the national phase

Ref document number: 2009515658

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/003972

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 198154

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 0900894

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2666973

Country of ref document: CA

Ref document number: 12311893

Country of ref document: US

Ref document number: 12009500742

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2009-010748

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2007310064

Country of ref document: AU

Ref document number: 576570

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: DZP2009000285

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 09049919A

Country of ref document: CO

Ref document number: 09049919

Country of ref document: CO

Ref document number: 1819/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020097010151

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009118602

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11259

Country of ref document: GE

Ref document number: A20090722

Country of ref document: BY

ENP Entry into the national phase

Ref document number: 2007310064

Country of ref document: AU

Date of ref document: 20071018

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0717722

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090417